

# Curriculum Vitae

**Geoffrey Liu**  
**M.D., M.Sc., F.R.C.P.C.**

**A. Date Curriculum Vitae is Prepared: 2025 January 11**

## **B. Biographical Information**

Primary Office	Princess Margaret Cancer Research Tower 101 College Street 11th floor, Room 11-704 Toronto, Ontario, Canada M5G 1L7
Telephone	416-946-4501 ext. 3428
Fax	416-946-6546
Email	geoffrey.liu@uhn.ca

## **1. EDUCATION**

### **Degrees**

2002	MSc, Clinical Epidemiology, University of Toronto, Canada
1993	MD, Dept of Medicine, University of Toronto, Canada
1991	BSc, Biochemistry/Human Biology, University of Toronto, Canada

### **Postgraduate, Research and Specialty Training**

2001 - 2003	Clinical/Research Fellow, Harvard School of Public Health, Boston, Massachusetts, United States
2001 - 2002	Clinical/Research Fellow, Harvard Medical School, Boston, Massachusetts, United States
2000 - 2002	Charles A. King Research Fellowship, Medical Foundation, Boston, Massachusetts, United States
2000 - 2001	Noah T. Herndon Fellowship in Gastrointestinal Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts, United States
1999 - 2000	Amgen Oncology Research Fellowship, Amgen Corporation, Thousand Oaks, California, United States
1998 - 2001	Clinical Fellow, Hematology-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States
1998 - 2001	Clinical Fellow in Medicine, Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States
1998 - 2001	Clinical Fellow in Medicine, Hematology-Oncology, Brigham and Women's Hospital, Boston, Massachusetts, United States
1997 - 1998	University of Toronto Medicine Research Fellowship, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
1997 - 1998	William S. Fenwick Research Fellowship, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

	Ontario, Canada
1996 - 1997	Chief Medical Resident, Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada
1995 - 1996	Senior Resident, Internal Medicine, The Toronto Hospital, Toronto, Ontario, Canada
1994 - 1995	Junior Resident, Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada
1993 - 1994	Intern, Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada

## Qualifications, Certifications and Licenses

1998 - present	Massachusetts Medical License (Inactive), United States
1997 - present	Independent Practice License, The College of Physicians and Surgeons of Ontario, Ontario, Canada
1997 - present	Royal College of Physicians and Surgeons of Canada, Canada
1995 - present	Licentiate, Medical Council of Canada, Canada
2002 - 2012	Medical Oncology Board Certification, American Board of Internal Medicine, United States
1996 - 2006	American Board of Internal Medicine, United States

## 2. EMPLOYMENT

### Current Appointments

2024 - present	The M. Qasim Choksi Chair in Lung Cancer Translational Research, Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
2019 - present	Professor, Pharmacology & Toxicology, University of Toronto
2017 Dec - present	Professor, Institute of Medical Science, University of Toronto
2017 - present	Professor, Medicine, Medical Biophysics, University of Toronto
2017 - present	Professor, Epidemiology, Dalla Lana School of Public Health, University of Toronto
2012 - present	Senior Scientist, Research, Ontario Cancer Institute, Toronto, Ontario, Canada
2010 - present	Research Lead, Medicine, University of Toronto <i>Medical Oncology and Hematology Executive, University of Toronto</i>
2006 - present	Associate Staff Physician, Mount Sinai Hospital, Toronto, Ontario, Canada
2006 - present	Active Staff Physician, University Health Network, Toronto, Ontario, Canada 2014- 1. Two half days of clinic (lung & thoracic cancers) 2. Two to three weeks on call for solid tumour

### Previous Appointments

#### HOSPITAL

2004 - 2006	Physician, Internal Medicine, North Shore Medical Center, Salem, Massachusetts, United States
2003 - 2006	Physician, Internal Medicine, Northeast Health Systems, Beverly, Massachusetts, United States
2002 - 2007	Assistant in Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States
2001 - 2002	Graduate Assistant in Medicine, MGPO, Massachusetts General Hospital, Boston, Massachusetts, United States
1998 - 2004	Clinical Associate, Medicine, Toronto East General Hospital, Toronto, Ontario, Canada
1997 - 2004	Clinical Associate, Medicine, St. Joseph's Hospital, Toronto, Ontario, Canada
1997 - 1998	Clinical Associate, The Toronto Hospital, Toronto, Ontario, Canada

Geoffrey LIU

1997 - 1998 Clinical Associate, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada  
1997 - 1998 Clinical Associate, Medicine, North York General Hospital, Toronto, Ontario, Canada

## RESEARCH

2011 - 2019 Co-Director, On-PROST Applied Clinical Research Unit, Ontario Cancer Institute, Toronto, Ontario, Canada  
2009 - 2014 Research Chair in Experimental Therapeutics and Population Studies, Cancer Care Ontario, Ontario, Canada  
2009 - 2013 Visiting Scientist, Biostatistics, Harvard School of Public Health, United States  
2006 - 2012 Scientist, Division of Applied Molecular Oncology, Ontario Cancer Institute, Toronto, Ontario, Canada

## UNIVERSITY

2019 Jul 1 - 2021 Jun 30 Visiting Professor, West China School of Medicine/West China Hospital, Sichuan University, Sichuan, China  
2006 - 2023 Alan B. Brown Chair in Molecular Genomics, Princess Margaret Hospital and Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada  
2003 - 2004 Research Associate, Harvard School of Public Health, United States

## UNIVERSITY - CROSS APPOINTMENT

2011 Jul 1 - 2017 Jun 30 Associate Professor, Medicine, Medical Biophysics and Epidemiology, University of Toronto, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada  
2008 - 2011 Assistant Professor, Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

## UNIVERSITY - RANK

2007 - 2011 Assistant Professor, Division of Applied Molecular Oncology, Medical Biophysics, Ontario Cancer Institute, Toronto, Ontario, Canada  
2006 - 2011 Assistant Professor, Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, Ontario, Canada  
2005 - 2007 Assistant Professor, Department of Medicine, Harvard Medical School, United States  
2004 - 2009 Instructor, Graduate School, Environmental Health, Harvard School of Public Health, United States  
2002 - 2006 Instructor, Department of Medicine, Harvard Medical School, United States  
1997 - 1998 Instructor, Medicine, University of Toronto, Toronto, Ontario, Canada

## 3. HONOURS AND CAREER AWARDS

### Distinctions and Research Awards

#### INTERNATIONAL

##### Received

2017 Jul - present **Fellow (Elected)**, International Society for Pharmacoepidemiology (ISPE). (Distinction)  
2003 **Scholar-in-Training Award**, 1st American Association of Cancer Research SNP, Haplotypes, and Cancer Conference, United States.  
2003 **Scholar-in-Training Award**, 94th American Association of Cancer Research Annual Meeting, United States.  
2003 **Young Investigator's Award**, International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer

Geoffrey LIU

2001	<b>Doris Duke Clinician Scientist Award</b>
2000	<b>Young Investigator Award</b> , American Society of Clinical Oncology, United States.
1999	<b>Amgen Oncology Research Fellowship</b> , Amgen Corporation, Thousand Oaks, California, United States.
1996	<b>Research Award</b> , Physician Services Inc.

#### NATIONAL

##### Received

2023 Jan - 2023 Dec	<b>Ranking of Best Scientists in the field of Medicine by Research.com. Top 500 in Canada.</b> , Medicine by Research.com
2008	<b>William E. Rawls Award</b> , National Cancer Institute of Canada, Canada. <i>"The [formerly NCI-Canada, now Canadian Cancer Society Research Institute] William E. Rawls Prize is given to a young investigator whose work has led to important advances in cancer control within the past decade". "Cancer control [is] defined to include clinical, epidemiological, behavioural, psychosocial, population-based research or similarly-applied research." A single annual prize is given to an investigator in Canada.</i>

#### PROVINCIAL / REGIONAL

##### Received

2009 - 2014	<b>Research Chair in Experimental Therapeutics and Population Studies</b> , Cancer Care Ontario, Canada. <i>"The Cancer Care Ontario (CCO) Research Chairs program, funded by the Ministry of Health and Long-Term Care, is designed to attract leading new scientists to Ontario and support outstanding scientists already working in the province." Dr. Liu is the first to receive such a chair that bridges between population studies and experimental therapeutics. There are a total of thirteen such research chairs across Ontario as of March, 2010.</i>
1989	<b>Ivan H. Smith Scholarship in Radiation Oncology</b> , Province of Ontario, Ontario, Canada.
1986	<b>Province of Ontario Scholar</b> , Brebeuf College Secondary School, Canada.

#### LOCAL

##### Received

2022 May - 2022 Dec	<b>2022 Institute of Medical Science Faculty Recognition Award for Exceptional Teaching</b> , University of Toronto <i>This Faculty Teaching Recognition Award is presented to IMS faculty members for their exceptional contributions in teaching IMS graduate courses within an appointment term.</i>
2020 Aug	<b>Princess Margaret Innovation in Education Award</b> , Princess Margaret Cancer Centre. (Research Award) <i>This program, open to students from high school through visiting scientist level, provides education on cross-disciplinary cancer research, through the use of innovative and creative strategies, fostering a supportive environment, while stimulating trainees to think critically and problem-solve.</i>
2020 May	<b>Department of Medicine Citizenship Award; Medical Oncology</b> , University Health Network/Sinai Health System. (Research Award)
2017 Jun	<b>2017 Medical Oncology Divisional Research Award</b> , University of Toronto. (Research Award)
2016	<b>Department of Medicine Goldie Award and Travel Prize for Research.</b> , University of Toronto. (Research Award) <i>The William Goldie Prize and Travel Award was established in 1945 by an anonymous donor</i>

*to honor the late Dr. William Goldie, who held a faculty appointment in the Department of Medicine. The prize is awarded annually to a member of the Department who is within ten years of appointment to the Department and who has made a contribution of notable merit to the advancement of sound knowledge in Internal Medicine through research contributions and one for teaching contributions.*

- 2009 **Young Investigator Award (Research), Department of Medicine, Division of Medical Oncology and Hematology**, University of Toronto, Toronto, Ontario, Canada.
- 2008 **Junior Staff Award (Research), Medical Oncology and Hematology**, Princess Margaret Hospital, Toronto, Ontario, Canada.
- 2007 **Junior Investigator Award (Research), Clinical Trials Studies Unit**, Princess Margaret Hospital, Toronto, Ontario, Canada.
- 1997 **Medicine Research Fellowship**, University of Toronto, Toronto, Ontario, Canada.
- 1997 **William S. Fenwick Research Fellowship, Faculty of Medicine**, University of Toronto, Toronto, Ontario, Canada.
- 1996 **Ontario Graduate Scholarship**, Province of Ontario, Ontario, Canada.
- 1995 **Consultant Resident Award**, St. Michael's Hospital, Toronto, Ontario, Canada.
- 1995 **Resident Research Award**, St. Michael's Hospital, Toronto, Ontario, Canada.
- 1993 **Cody Silver Medal, Faculty of Medicine**, University of Toronto, Toronto, Ontario, Canada.
- 1993 **K.J.R. Wightman Award (Internal Medicine)**, University of Toronto, Toronto, Ontario, Canada.
- 1992 **Medical Alumni Association Scholarship**, University of Toronto, Toronto, Ontario, Canada.
- 1991 **(summa cum laude)/Gold Medal Science, St. Michael's College**, University of Toronto, Toronto, Ontario, Canada.
- 1991 **Governor General of Canada Medal (Undergraduate)**, University of Toronto, Toronto, Ontario, Canada.
- 1991 **University of Toronto Medical Journal Award (Medical Society)**, University of Toronto, Toronto, Ontario, Canada.
- 1990 **Dr. F.J. Colling, OBE Memorial Scholarship**, University of Toronto, Toronto, Ontario, Canada.
- 1989 **J. Zoberman Scholarship**, University of Toronto, Toronto, Ontario, Canada.
- 1988 **Genevieve Khoury Award**, University of Toronto, Toronto, Ontario, Canada.
- 1988 **J. Melody Scholarship**, University of Toronto, Toronto, Ontario, Canada.
- 1987 **Alexander T. Fulton Scholarship**, Canada.
- 1986 - 1990 **J.W. Billes Scholarship**, University of Toronto, Toronto, Ontario, Canada.
- 1986 **Governor General of Canada Medal, Secondary School Level**, Canada.

#### Nominated

- 2022 Jun - 2022 Dec **2021-2022 University of Toronto MOTP Outstanding Teaching Award Nomination**, University of Toronto  
*The success of the Medical Oncology Training Program is attributed to the dedication of our faculty teachers (nominations).*
- 2022 - 2022 Jun **2022 Gerald Kirsh Humanitarian Award Nomination**, The Princess Margaret Cancer Foundation  
*The awards were established by the Kirsh family along with The Princess Margaret Cancer Foundation to honour Princess Margaret Cancer Centre employees who demonstrate outstanding commitment to compassionate care. They are designed to help grateful cancer patients and their families express their thanks to the dedicated employees who are so integral to their treatment as well as allow Princess Margaret Cancer Centre staff recognize the outstanding work of their colleagues.*

## Student/Trainee Awards

### INTERNATIONAL

#### Received

2020 Jun	<b>Merit Award</b> , Supervisor, Awardee Name: Aline Fares. American Society of Clinical Oncology (ASCO), Chicago, Illinois, United States <i>Award for meritorious research in the form of high quality abstracts submitted to ASCO Annual and Thematic meetings; primarily awarded to senior residents and fellows.</i>
2020 Jun	<b>Merit Award</b> , Supervisor, Awardee Name: Lawson Eng. American Society of Clinical Oncology (ASCO), Chicago, Illinois, United States <i>Award for meritorious research in the form of high quality abstracts submitted to ASCO Annual and Thematic meetings; primarily awarded to senior residents and fellows.</i>
2018 Jul	<b>Travel Scholarship</b> , Awardee Name: Jianjun Ren. Asian Conference on Pharmacoepidemiology (ACPE)
2018 Jun	<b>Annual Meeting Travel Scholarships</b> , Supervisor, Awardee Name: Lawson Eng. Multinational Association for Supportive Care in Cancer (MASCC), Vienna, Austria <i>MASCC offers a limited number of travel scholarships to attend the MASCC/ISOO Annual Meeting.</i>
2018 May	<b>Committee of 100 Leadership Scholarship</b> , Supervisor, Awardee Name: Jianjun Ren. Committee of 100, Silicon Valley, California, United States <i>Scholarship.</i>
2018	<b>Scholarship</b> , Supervisor, Awardee Name: Lidija Latifovic. The Asian Conference on Pharmacoepidemiology (ACPE) <i>Scholarship to attend the 11th ISPE ACPE conference.</i>
2017 Jun	<b>Merit Award</b> , Supervisor, Awardee Name: Daniel Shepshelovich. American Society of Clinical Oncology (ASCO), Chicago, Illinois, United States
2017	<b>National Scholarship Award</b> , Supervisor, Awardee Name: Jianjun Ren. China Scholarship Council, Beijing, China <i>Scholarship.</i>
2017	<b>State Scholarship</b> , Supervisor, Awardee Name: Jianjun Ren. China Scholarship Council, Beijing, China <i>Scholarship.</i>
2016	<b>Merit Award</b> , Main Supervisor, Awardee Name: Dr. Lawson Eng. American Society of Clinical Oncology (ASCO)/United States <i>Award for meritorious research in the form of high quality abstracts submitted to ASCO Annual and Thematic meetings; primarily awarded to senior residents and fellows.</i>
2015	<b>Merit Award</b> , Main Supervisor, Awardee Name: Dr. Lawson Eng. American Society of Clinical Oncology (ASCO), United States <i>"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The awards are given to oncology fellows who are first authors on selected abstracts." 25-35 awards are given annually worldwide.</i>
2015	<b>Merit Award</b> , Main Supervisor, Awardee Name: Hiten Naik. American Society of Clinical Oncology (ASCO), United States <i>"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The awards are given to oncology fellows who are first authors on selected abstracts." 25-35 awards are given annually worldwide.</i>
2015	<b>Travel Award</b> , Main Supervisor, Awardee Name: Dr. Lawson Eng. International Society for

Pharmacoepidemiology (ISPE), United States  
*Awarded for meritorious research to be presented as an abstract at the ISPE 2015 Annual Conference.*

- 2014 **ASCO Young Investigator Award**, Secondary Supervisor, Awardee Name: Dr. Kit Man Wong. American Society of Clinical Oncology (ASCO), United States  
*The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting.*
- 2014 **Merit Award**, Awardee Name: Hiten Haik. American Society of Clinical Oncology (ASCO), United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The awards are given to oncology fellows who are first authors on selected abstracts." 25-35 awards are given annually worldwide.*
- 2014 **Merit Award**, Main Supervisor, Awardee Name: Dr. Lawson Eng. American Society of Clinical Oncology (ASCO), United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The awards are given to oncology fellows who are first authors on selected abstracts." 25-35 awards are given annually worldwide.*
- 2014 **Merit Award**, Main Supervisor, Awardee Name: Dr. Eric Morgen. American Society of Clinical Oncology (ASCO), United States  
*ASCO GI Merit Award.*
- 2014 **National Science Foundation Award of China**, Main Supervisor, Awardee Name: Dr. Ying Nanjiao. National Science Foundation, China
- 2014 **Resident Poster Viewing Award-Biology Section**, Main Supervisor, Awardee Name: Kate Barrett. American Society for Radiation Oncology (ASTRO), United States  
*2nd Place trophy in the Resident Poster Viewing Award-Biology section.*
- 2014 **SSO 2014 Poster Contest**, Main Supervisor, Awardee Name: Maja Segedi. Society of Surgical Oncology, United States  
*One of five finalists for the SSO 2014 Poster Contest in the Best Basic/Transitional Research Poster category.*
- 2013 **Conquer Cancer Foundation Merit Award**, Main Supervisor, Awardee Name: Dr. Olusola Faluyi. American Society of Clinical Oncology (ASCO), United States  
*Merit Award.*
- 2013 **Conquer Cancer Foundation of ASCO**, Main Supervisor, Awardee Name: Dr. Lawson Eng. American Society of Clinical Oncology (ASCO), United States  
*Merit Award.*
- 2013 **Conquer Cancer Foundation of ASCO**, Main Supervisor, Awardee Name: Kit Man Wong. American Society of Clinical Oncology (ASCO), United States  
*Merit Award.*
- 2013 **Conquer Cancer Foundation of ASCO**, Main Supervisor, Awardee Name: Sinead Cuffe. American Society of Clinical Oncology (ASCO), United States  
*Merit Award.*
- 2013 **International Society for Pharmacoepidemiology Student Travel Scholarship**, Main Supervisor, Awardee Name: Dr. Lawson Eng. International Society for Pharmacoepidemiology, United States  
*Travel Award.*
- 2013 **International Society for Pharmacoepidemiology Student Travel Scholarship**, Main

- Supervisor, Awardee Name: Eric Morgen. International Society for Pharmacoepidemiology, United States  
*Travel Award.*
- 2012 **Conquer Cancer Foundation Merit Award**, Main Supervisor, Awardee Name: Petra Martin. American Society of Clinical Oncology (ASCO), United States  
*Merit Award.*
- 2012 **Conquer Cancer Foundation of (ASCO)**, Main Supervisor, Awardee Name: Sinead Cuffe. American Society of Clinical Oncology (ASCO), United States  
*Merit Award.*
- 2012 **Gary J. Miller Undergraduate Student Prizes for Cancer and Cancer-Related Biomedical Research**, Main Supervisor, Awardee Name: Kangping Cui. American Association of Cancer Research, United States  
*2nd place.*
- 2012 **Genetic Analysis Workshop (GAW) 18**, Co-supervisor, Awardee Name: Xiaowei Shen. BioMed Central Ltd, United States  
*Student travel Award.*
- 2012 **Genetic Analysis Workshop (GAW) 18**, Co-supervisor, Awardee Name: Osvaldo Espin-Garcia. BioMed Central Ltd, United States  
*Student Travel Award.*
- 2012 **International Society for Pharmacoepidemiology Student Travel Scholarship**, Main Supervisor, Awardee Name: Lawson Eng. International Society for Pharmacoepidemiology, United States  
*Travel Award.*
- 2012 **Merit Award**, Main Supervisor, Awardee Name: Kitman Wong. American Society of Clinical Oncology (ASCO), United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The awards are given to oncology fellows who are first authors on selected abstracts." 25-35 awards are given annually worldwide.*
- 2011 **International Society for Pharmacoepidemiology Student Travel Scholarship**, Main Supervisor, Awardee Name: Abdul Kalam Azad. International Society for Pharmacoepidemiology, United States  
*Travel Award.*
- 2011 **Merit Award**, Main Supervisor, Awardee Name: Daniel Renouf. American Society of Clinical Oncology (ASCO), United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The awards are given to oncology fellows who are first authors on selected abstracts." 25-35 awards are given annually worldwide.*
- 2009 **Merit Award winner**, main supervisor, Awardee Name: Winson Cheung. American Society of Clinical Oncology, United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting.*
- 2008 **(A.A.C.R.)-Glaxo Smith Kline Outstanding Clinical Scholar**, main supervisor, Awardee Name: David Cescon. American Association of Cancer Research, United States  
*"AACR-GlaxoSmithKline Outstanding Clinical Scholar Awards are presented to promising young cancer researchers who are the first authors and presenters of highly meritorious abstracts related to clinical cancer research." 12-16 awards are presented annually*



worldwide.

- 2008 **Merit Award winner**, main supervisor, Awardee Name: Winson Cheung. American Society of Clinical Oncology, United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting."*
- 2008 **Merit Award winner**, main supervisor, Awardee Name: David Cescon. American Society of Clinical Oncology, United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting."*
- 2007 **Merit Award winner**, main supervisor, Awardee Name: Penny Bradbury. American Society of Clinical Oncology, United States  
*"The ASCO Cancer Foundation Merit Awards are designed to further promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting."*
- NATIONAL  
Received
- 2023 Sep **Poster First Prize**, Awardee Name: Salahaldin Alamleh. Canadian Society of Otolaryngology and Head and Neck Surgery (CSOHN), Toronto, Ontario, Canada
- 2020 Jun **NOYCIA Award**, Supervisor, Awardee Name: Aline Fares. Novartis Oncology Young Canadian Investigator Awards
- 2019 Jun **Annual Meeting Merit Award**, Co-Supervisor, Awardee Name: Lawson Eng. ASCO American Society for Clinical Oncology  
*Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.*
- 2019 Jun **Novartis Oncology Young Canadian Investigators Award**, Co-Supervisor, Awardee Name: Lawson Eng. Novartis  
*Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.*
- 2018 Sep - 2021 Aug **Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award**, Supervisor, Awardee Name: Lidija Latifovic. Canadian Institutes of Health Research (CIHR).  
*The CIHR Doctoral Research Awards provide special recognition and funding to students who are pursuing a doctoral degree, allowing them an opportunity to gain research experience.*
- 2018 Jun **Novartis Oncology Young Canadian Investigator Awards (NOYCIA)**, Supervisor, Awardee Name: Mary Mahler. Novartis, Chicago, Illinois, United States  
*The program provides funding and recognition to 10 Canadian oncology researchers every year who demonstrate excellence in their area of study.*
- 2018 Apr - 2019 Mar **Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program**, Supervisor, Awardee Name: Lidija Latifovic. Canadian Institutes of Health Research  
*A training initiative funded by the Canadian Institutes of Health Research through the Drug*

*and Safety & Effectiveness Network (DSEN).*

- 2017 Jul **Summer Studentship Grant**, Main Supervisor, Awardee Name: Judy Chen. Lung Cancer Canada  
*Summer studentship provides support for highly qualified applicants in all areas of lung cancer health research at all post-secondary staged to add to their experience by engaging in health research in Canada. Total Amount: 5,000 CAD*
- 2017 Jun **Novartis Oncology Young Canadian Investigator Awards (NOYCIA)**, Supervisor, Awardee Name: Grainne O'Kane. Novartis, Chicago, Illinois, United States  
*The program provides funding and recognition to 10 Canadian oncology researchers every year who demonstrate excellence in their area of study.*
- 2016 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.)**, Main Supervisor, Awardee Name: Lawson Eng. Novartis Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the ASCO Meeting, be present at ASCO and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2015 Sep - 2018 Aug **Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award**, Main Supervisor, Awardee Name: Erin Stewart. Canadian Institutes of Health Research (CIHR), Canada  
*The CIHR Doctoral Research Awards provide special recognition and funding to students who are pursuing a doctoral degree, allowing them an opportunity to gain research experience.*
- 2014 **Best Student Poster Presentation Award**, Main Supervisor, Awardee Name: Hiten Haik. Canadian Association for Population Therapeutics (CAPT), Canada
- 2014 **Fellowship**, Main Supervisor, Awardee Name: Dr. Kit Man Wong. The Canadian Association of Medical Oncologists (CAMO), Canada
- 2014 **Institute of Cancer Research (ICR) Publication Prize**, Main Supervisor, Awardee Name: Dr. Lawson Eng. Canadian Institutes of Health Research (CIHR), Canada  
*Awarded for significant contributions by trainees in the field of cancer research and awards meritorious authors of outstanding published scientific articles that focus on cancer research. Total Amount: 1,000 CAD*
- 2014 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.)**, Main Supervisor, Awardee Name: Dr. Lawson Eng. Novartis Canada, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the ASCO Meeting, be present at ASCO and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2014 **Trainee Travel Award**, Main Supervisor, Awardee Name: Erin Stewart. Terry Fox Research Institute, Canada  
*Travel Award.*
- 2013 **Excellence in Radiation Research of the 21st Century Award**, Main Supervisor, Awardee Name: Erin Stewart. Canadian Institutes of Health Research (CIHR) - Terry Fox Foundation, Canada
- 2013 **Strategic Training Program in Advanced Genetic Epidemiology (STAGE)**, Main Supervisor, Awardee Name: Dr. Lizhen Xu. Canadian Institutes of Health Research (CIHR), Canada  
*Postdoctoral Award.*
- 2013 **Travel Award**, Main Supervisor, Awardee Name: Dr. Kit Man Wong. Canadian Cancer Society, Canada  
*Travel Award.*
- 2012 **Frederick Banting and Charles Best Graduate Scholarship Master's Award**, Main Supervisor, Awardee Name: Lawson Eng. Canadian Institutes for Health Research (CIHR), Canada  
*Fellowship Award.*

- 2012 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.)**, Main Supervisor, Awardee Name: Sinead Cuffe. Novartis Canada, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the ASCO Meeting, be present at ASCO and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2012 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.)**, Main Supervisor, Awardee Name: Kitman Wong. Novartis Canada, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the ASCO Meeting, be present at ASCO and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2009 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.) Award**, Main Supervisor, Awardee Name: Winson Cheung. Novartis, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the 2010 ASCO Meeting, be present at ASCO 2010 and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2009 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.) Award**, Main Supervisor, Awardee Name: Paul Wheatley-Price. Novartis, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the 2010 ASCO Meeting, be present at ASCO 2010 and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2008 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.) Award**, Main Supervisor, Awardee Name: David Cescon. Novartis, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the 2010 ASCO Meeting, be present at ASCO 2010 and be affiliated with a Canadian institution." Ten awards are given annually.*
- 2007 **Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.) Award**, Main Supervisor, Awardee Name: Penny Bradbury. Novartis, Canada  
*"NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. Eligible candidates must be first author of an abstract accepted for the 2010 ASCO Meeting, be present at ASCO 2010 and be affiliated with a Canadian institution." Ten awards are given annually.*

#### PROVINCIAL / REGIONAL

##### Received

- 2016 **Ontario Graduate Scholarship (OGS)**, Main Supervisor, Awardee Name: Lidija Latifovic. Government of Ontario
- 2014 **Ontario Graduate Scholarship (OGS)**, Main Supervisor, Awardee Name: Erin Stewart. Government of Ontario, Canada
- 2013 **Ontario Research Trainees Travel Award**, Main Supervisor, Awardee Name: Dr. Qi Wang. Government of Ontario, Canada  
*Travel Award.*

##### Nominated

- 2015 **Peterborough K.M. Hunter Charitable Foundation Graduate Award**, Faculty of Medicine, Main Supervisor, Awardee Name: Erin Stewart. University of Toronto, Canada  
*The K.M. Hunter graduate Studentships are to be awarded to Ph.D. students studying in the Faculty of Medicine with research interests in the following areas: Alzheimer's disease,*

*arthritis, cancer, heart and stroke, schizophrenia, glaucoma, cerebral palsy or lung disease. A cumulative grade point average of A- is required for eligibility. The K.M. Hunter Post-Doctoral Fellowships are to be awarded to post-doctoral fellows holding an M.D. or Ph.D. degree, with research interests in urban health.*

LOCAL

Received

2020 Dec	<b>Ankle Award</b> , Supervisor, Awardee Name: Lawson Eng. University of Toronto <i>This award recognizes a student who has completed a project that represents innovative, 'outside-the-box' thinking with an outcome or outcomes related to improved health systems, patient care, research results or new ways of completing tasks that enhance medical practice.</i>
2020 Jun	<b>Medical Oncology Division Research Trainee Award</b> , Supervisor, Awardee Name: Aline Fares. University of Toronto
2020 Jun	<b>Medical Oncology Division Research Trainee Award</b> , Supervisor, Awardee Name: Mary Mahler. University of Toronto
2020 Jun	<b>Medical Oncology Division Research Trainee Award</b> , Supervisor, Awardee Name: Andrew Lam. University of Toronto
2019 Aug	<b>Summer Student Best Presentation Award</b> , Supervisor, Awardee Name: Joelle Soriano. Institute of Medical Science (University of Toronto)
2019 Jun	<b>Best Trainee Poster Presentation Award</b> , Supervisor, Awardee Name: Daniel Davies. Medical Oncology Annual Research Day (University of Toronto)
2018 Mar	<b>MACK Foundation Bursary</b> , Supervisor, Awardee Name: Sophia Liu. Toronto Global Cancer Control Conference <i>Rapid Fire Presentation. Total Amount: 1,000</i>
2015 Sep - 2016 Aug	<b>The Frank Fletcher Memorial Fund</b> , Faculty of Medicine, Main Supervisor, Awardee Name: Erin Stewart. University of Toronto, Canada <i>To be awarded to a graduate student on the basis of financial need who is pursuing study and research of the cause and cure of cancer.</i>
2015	<b>Department of Medicine: UHN/MSH Charles Hollenberg Competition, 3rd Place</b> , Main Supervisor, Awardee Name: Dr. Lawson Eng. University of Toronto, Toronto, Ontario, Canada <i>Awarded to residents and fellows supervised by a member of the Department of Medicine UHN/MSH for meritorious clinical epidemiology or clinical investigative projects. Total Amount: 250 CAD</i>
2015	<b>Division of Medical Oncology, Research Day - Oral Presentation Prize</b> , Main Supervisor, Awardee Name: Dr. Lawson Eng. University of Toronto, Toronto, Ontario, Canada <i>Awarded to outstanding research conducted by trainees (medical students, residents, fellows) working with members of the Division of Medical Oncology presented at the Annual Divisional Research Day.</i>
2015	<b>Postgraduate Medical Education: Joseph M. West Family Memorial Fund</b> , Main Supervisor, Awardee Name: Dr. Lawson Eng. University of Toronto, Toronto, Ontario, Canada <i>Awarded to post-graduate trainees completing residency research projects in the Faculty of Medicine at the University of Toronto. Total Amount: 9,000 CAD</i>
2015	<b>School of Graduate Studies Conference Grant (European Lung Cancer Conference)</b> , Main Supervisor, Awardee Name: Erin Stewart. University of Toronto, Canada <i>Travel grant.</i>
2014	<b>Clinician Investigator Program</b> , Main Supervisor, Awardee Name: Dr. Jennifer Wang. University of Toronto, Canada
2014	<b>Joseph M. West Family</b> , Main Supervisor, Awardee Name: Dr. Jennifer Wang. University of

Toronto, Canada

- 2014 **Medical Biophysics 50th Anniversary Travel Award**, Main Supervisor, Awardee Name: Erin Stewart. University of Toronto, Canada  
*Travel Award.*
- 2014 **Ontario Student Opportunity Trust Funds**, Main Supervisor, Awardee Name: Erin Stewart. University of Toronto, Canada  
*The "OSOTF awards" refer to a class of awards, which have resulted from Ontario government's "matching" program. Under the program every dollar of donation received for student assistance has been matched by the government as well as the university on a dollar-for-dollar basis. There are two major conditions for all OSOTF awards. Recipients must be Ontario residents and demonstrate financial need.*
- 2014 **William S. Fenwick Research Fellowship**, Main Supervisor, Awardee Name: Dr. Jennifer Wang. University of Toronto, Canada  
*University of Toronto Post Graduate Medical Research Award.*
- 2013 **Chisholm Memorial Fellowship**, Main supervisor, Awardee Name: Dr. Kit Man Wong. University of Toronto, Canada  
*University of Toronto Post Graduate Medical Research Award.*
- 2013 **Heidi Sternbach Scholarship**, Main Supervisor, Awardee Name: Dr. Kit Man Wong. University of Toronto, Canada  
*University of Toronto Post Graduate Medical Research Award.*
- 2013 **Joseph M. West Family Memorial Fellowship**, Main Supervisor, Awardee Name: Dr. Kit Man Wong. University of Toronto, Canada  
*University of Toronto Post Graduate Medical Research Award.*
- 2013 **Medical Biophysics Excellence Ontario Student Opportunity Trust Funds Scholarship**, Main Supervisor, Awardee Name: Erin Stewart. University of Toronto, Canada
- 2013 **Starr Medal**, Main supervisor, Awardee Name: Dr. Kit Man Wong. University of Toronto, Canada  
*University of Toronto Post Graduate Medical Research Award.*
- 2012 **Best Paper Category 1: Work Undertaken by PGY2 residents during clinical rotation.**, Main Supervisor, Awardee Name: Jennifer Wang. University Health Network, Department of Otolaryngology-Head and Neck Surgery, Canada  
*Best Paper.*
- 2012 **University of Toronto McLaughlin Centre**, Co-supervisor, Awardee Name: Xiaowei Shen. University of Toronto, Canada  
*Training Award.*
- 2012 **University of Toronto McLaughlin Centre**, Co-supervisor, Awardee Name: Osvaldo Espin-Garcia. University of Toronto, Canada  
*Training Award.*
- 2008 **Second prize, Charles H. Hollenberg Prize in Research, Department of Medicine, Resident category**, main supervisor, Awardee Name: David Cescon. University of Toronto, Canada  
*The University of Toronto Department of Medicine provides annual research prizes for trainees at the medical student, resident, and fellow level, named after Dr. Hollenberg, prior Chair of Medicine at the University of Toronto.*
- 2007 **Charles H. Hollenberg First Prize in Research, Fellow category, Department of Medicine**, main supervisor, Awardee Name: Penny Bradbury. University of Toronto, Canada  
*The University of Toronto Department of Medicine provides annual research prizes for trainees at the medical student, resident, and fellow level, named after Dr. Hollenberg, prior Chair of Medicine at the University of Toronto.*

## 4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

### Professional Associations

2009 - present	<b>Member</b> , Canadian Society of Epidemiology and Biostatistics
2008 - present	<b>Affiliate Member</b> , Pharmacogenetics Research Network
2006 - present	<b>Member</b> , Barrett's Esophagus and Adenocarcinoma Consortium (BEACON)
2005 - present	<b>Member</b> , International Society for Pharmacoepidemiology
2004 - present	<b>Lifetime Member</b> , National Lung Cancer Partnership (formerly Women Against Lung Cancer)
2003 - present	<b>Member</b> , International Association for the Study of Lung Cancer
2000 - present	<b>Member</b> , American Association of Cancer Research
1999 - present	<b>Member</b> , American Society of Clinical Oncology
1993 - present	<b>Lifetime Member</b> , Alpha Omega Alpha Honor Medical Society
1993 - present	<b>Member</b> , College of Physicians and Surgeons of Ontario
1993 - present	<b>Member</b> , Ontario Medical Association
1998 - 2005	<b>Member</b> , Massachusetts Medical Society
1994 - 1998	<b>Member</b> , American College of Physicians

### Administrative Activities

#### INTERNATIONAL

##### Other Organizations

2018 - present	Brigatinib vs Alectinib Post-crizotinib Trial Steering Committee
----------------	--

##### American Association of Cancer Research

2001 - present	<b>Member</b> , Molecular Epidemiology Group
----------------	--

##### International Lung Cancer Consortium

2018 - present	<b>Chair</b> , Survival Analysis Working Group
2018 - 2021	Steering Committee Member
2017 Jun 15 - 2018	<b>Co-Chair</b> , Annual Meeting Toronto

##### International Society for Pharmacoepidemiology

2020 - present	<b>Member</b> , Real-World Evidence Working Group
2014 - present	<b>Member</b> , Publications and Communications Committee
2009 - present	<b>Member</b> , Education Committee
2023	<b>Member</b> , Asian Conference for Pharmacoepidemiology 2024 Program Committee
2017 Mar 1 - 2017 Mar	<b>Co-Chair</b> , Mid-year Meeting (Toronto)
2016 - 2018	<b>Member</b> , Curriculum Planning Committee
2015 - 2017	<b>Member</b> , ad hoc President's Committees
2013 - 2014	<b>Member</b> , Curriculum Planning Committee
2012 - 2013	<b>Member</b> , Host Committee

##### International Society of Pharmacoepidemiology

Geoffrey LIU

2017 - present	<b>Founding Member, Oncology Interest Group</b> , Pharmacogenetics and Molecular Epidemiology Working Group
2010 - present	<b>Secretary</b> , Pharmacogenetics and Molecular Epidemiology Working Group
2008 - present	<b>Member</b> , Special Interest Group Executive
2008 - 2009	<b>Chair</b> , Pharmacogenetics and Molecular Epidemiology Working Group

Main Correlative Science Committees

2007 - present	<b>Member</b> , NCIC-CTG Lung Cancer, GI
----------------	--

National Cancer Institute/National Institute of Health

2009 - 2018	<b>Member</b> , The Esophago-Gastric Task Force of the Gastrointestinal Steering Committee
-------------	--

Novartis

2016 - 2019	<b>Member</b> , Novartis Global Advisory Board for Ceritinib Development, Sole Canadian Representative
-------------	--

Ovarian Gynecologic Cancer InterGroup (GCIC)

2010 - 2014	<b>Member</b> , Pharmacogenetics Steering Committee
-------------	---

Pfizer

2016 - present	<b>Member</b> , Pfizer Lorlatinib Phase III ALK+ Treatment Naïve Trial Steering Committee, Sole Canadian Representative
----------------	---

2024 May 22 - 2024 May 23	<b>Organizer</b> , PMH-Pfizer Lung Cancer Virtual Preceptorship, India.
---------------------------	---

2023 Dec 7 - 2023 Dec 8	<b>Organizer</b> , PMH-Pfizer Lung Cancer Virtual Preceptorship, India.
-------------------------	---

Radiation Therapy Oncology Group

2012 - 2017	<b>Member</b> , Lung Translational Research Program
-------------	---

2010 - 2015	<b>Member</b> , Radiation Therapy Oncology Group, GI Translational Research Program
-------------	---

Takeda

2018 - present	<b>Member</b> , Takeda 2002 Trial Steering Committee
----------------	--

Takeda 2002 Trial Steering Committee

**Member**

**Member**

The Cancer Genome Atlas

2015 - 2018	<b>Member</b> , Gastroesophageal and Gastric Cancer Working Group
-------------	---

2011 - 2017	<b>Member</b> , Head and Neck Cancer Working Group
-------------	--

2011 - 2015	<b>Member</b> , Esophageal Cancer Working Group
-------------	---

The German Cancer Research Center (DKFZ)

2023 Jun 28 - 2023 Jul 4	<b>Global Partnership</b> , DKFZ Fact-finding trip/ DKFZ-PM collaboration, Germany.
--------------------------	---

Thoracic Oncology

2023 Dec 7 - 2023 Dec 8	<b>Organizer</b> , Cross-India virtual thoracic Oncology preceptorship for 48 medical oncologists
-------------------------	---

Geoffrey LIU

throughout India (5 hours total), India.

2023 Oct 22 - 2023 Oct 24 **Organizer**, Thoracic Oncology Preceptorship for five medical oncology residents across Ireland (2.5 hours), Ireland.

## NATIONAL

### Applied Research in Cancer Centre (CC-ARCC)

2011 - present **Associate Member**, CC-ARCC, Canada.

### Canadian Pharmacogenetics Network for Drug Safety (CPNDS)

2011 - present **Member**, CPNDS, Ontario, Canada.

### CCTG

2012 - present **Member**, Clinical Trials Group, Lung Correlative Science Tissue Working Group

2011 - present **Member**, GI Correlative Science Tissue Committee, Canada.

2007 - present **Member**, Correlative Sciences Working Group

2010 - 2015 **Member**, Head & Neck Cancer Correlative Science Working Group, Canada.

### Lung Cancer Expert

2018 - 2019 **Member**, pCODR, Canada.

2018 - 2019 **Member**, Health Canada NDS, Canada.

### National Cancer Institute of Canada/Clinical Trials Group

2007 - 2009 **Member**, Lung Cancer Committee

### Novartis

2016 - 2017 **Member**, Global Advisory Board for Ceritinib Development, Sole Canadian Representative

### pCODR Lung Cancer Expert

**Member**, Canada.

## PROVINCIAL / REGIONAL

### Government of Ontario

2010 - 2013 **Member**, Ontario Cancer Study Working group for Clinic-based Recruitment, Ontario, Canada.

2010 - 2013 **Member**, Ontario Cancer Study Committee on Cancer Epidemiology and Biospecimens, Ontario, Canada.

2010 - 2011 **Member**, Provincial Expert Panel on Pharmacogenetics, Ontario, Canada.

### Ministry of Health and Long Term Care, Ontario

2010 - 2011 **Member**, Ontario Pharmacogenomics Provincial Panel, Ontario, Canada.

## LOCAL

### Other Organizations

2012 - present **Director**, Lung cancer Clinical And Liquid biopsy, Informatics, Breathomics, Radiomics for Early detection (Lung CALIBRE)



Geoffrey LIU

2007 - present                    **Director**, AMPPEL, Applied Molecular Profiling Pharmacogenetic Epidemiology Laboratory  
2007 - present                    **Co-Director**, AMPL, Applied Molecular Profiling, Laboratory

Applied Clinical Research Unit, Cancer Care Ontario

2011 - 2020                    **Co-Director**, Ontario Patient Reported Outcomes of Symptoms and Toxicity, Ontario, Canada.

Ontario Institute for Cancer Research

2011 - 2014                    **Member**, Program Management Committee High Impact Clinical Trials, Toronto, Ontario, Canada.

Ontario Institute of Cancer Research

2009 - 2012                    **Member**, Planning Committee, Biomarkers Workshop

Princess Margaret Cancer Centre, University Health Network

2023 Mar - present            **Member**, Global Partnership Committee, Toronto, Ontario, Canada.  
2023 Jan - present            **Chair**, External partnerships in Cancer / EPIC  
2020 - 2021                    **Member**, COVID Executive Committee  
2012 - 2015                    **PMH Lead**, TCGA, Esophageal Cancer: The Cancer Genome Atlas  
2009                              **Co-Director**, Applied Molecular Oncology Division Retreat, Toronto, Ontario.

Princess Margaret Hospital/Ontario Cancer Institute

2011 - present                **Co-Director**, COMBIEL, Cancer Outcomes, Medicine, Biostatistics, Epidemiology and Laboratory Training Program, Toronto, Ontario, Canada.  
2009 - present                **Member**, Head and Neck Cancer Tissue Sub-Committee  
2008 - present                **Member**, Head and Neck Cancer Translational Research Committee  
2008 - present                **Member**, Head and Neck Cancer Research Executive Committee  
2011 - 2021                    **Member**, Gastro-Esophageal Cancer Tissue Sub-committee, Ontario, Canada.

University Health Network

2022 - present                **Member**, Senior Promotions Mentor, Toronto, Ontario, Canada.  
2014 - 2017                    **Co-Chair**, Pharmacogenetics, Clinical Genomics Group, Toronto, Ontario, Canada.  
2008 - 2012                    **Member**, Tumour Bank Committee  
2008 - 2012                    **Member**, Tissue Committee of the Research Ethics Board, Toronto, Ontario, Canada.

University of Toronto

2016 - present                **Co-Chair**, Medical Oncology Research Executive  
2012 - 2016                    **Chair**, Medical Oncology Research Sub-Committee, Toronto, Ontario, Canada.

University of Toronto, Department of Medicine

2018 - present                **Member**, Senior Promotions Committee, Toronto, Ontario, Canada.  
2010 - present                **Member**, Division of Medical Oncology and Hematology Executive Committee, Toronto, Ontario, Canada.

## Peer Review Activities

### EDITORIAL BOARDS

#### Member

2012 - 2022 Cancer Medicine (Clinical Cancer Research Stream)

### GRANT REVIEWS

#### External Grant Reviewer

2016 NIH U01, Barretts Esophagus Translational Network Review Committee  
2015 Canadian Institutes of Health Research, Live Pilot-Foundation Grant Second Stage  
2008 - 2011 Canadian Institutes of Health Research, Cancer, Progression and Therapeutics Panel (CPT)  
2008 Alberta Cancer Board  
2008 Hong Kong Research Council

#### Member

2012 - 2014 High Impact Clinical Trials Group Grant review panels  
2011 NIH U01, Barrett's Esophagus Program Project Grant  
2007 - 2008 Canadian Institutes of Health Research, Genomics Panel (GMX)  
2007 National Cancer Institute of Canada, Epidemiology Panel  
2006 - 2007 Canadian Institutes of Health Research, Cancer Biology and Therapeutics Panel (CBT)

#### Reviewer

2023 Netherlands Cancer Institute  
2014 Netherlands Cancer Institute, Research Council

### MANUSCRIPT REVIEWS

#### Ad hoc Reviewer

2014 - present The Pharmacogenetics Journal  
2013 - present New England Journal of Medicine  
2011 - present Disease of the Esophagus  
2010 - present PLOS ONE  
2009 - present Journal of Thoracic Oncology  
2009 - present Lancet Oncology  
2009 - present Oncogene  
2008 - present Pharmacogenetics & Genomics  
2007 - present Cancer Detection and Prevention  
2007 - present Disease Markers  
2007 - present Pharmacogenomics  
2006 - present Lancet  
2006 - present The Oncologist  
2005 - present Carcinogenesis  
2004 - present Journal of Clinical Oncology  
2004 - present Journal of the National Cancer Institute  
2003 - present Annals of Human Genetics  
2003 - present Cancer Research  
2003 - present Lung Cancer  
2002 - present Cancer, Epidemiology, Biomarkers, and Prevention

## C. Academic Profile

### 1. RESEARCH STATEMENTS

2019 - present

Geoffrey Liu Laboratory Overall Research Strategy.

The Geoffrey Liu laboratory is a multidisciplinary, collaborative translational laboratory that seeks to improve outcomes in cancer. The laboratory has four main programs and a multi-level training program (COMBIEL; Cancer Outcomes Medicine, Biostatistics, Informatics, Epidemiology, and Laboratory Training Program). The four main programs are:

(A) - AMP PEL Program

(B) - CALIBRE Program

(C) - ON-PROST Program

(D) - HANG-OUT Program.

(A) The AMP-PEL program: stands for Applied Molecular, Pharmacoepidemiologic, Pharmacogenomic, and Epidemiologic Laboratory, and focuses on identifying and validating cancer biomarkers. There are four translational projects

- Project 1: using mouse (REAL-PDX: Resistance modeling in EGFR and ALK Lung cancer Patient-Derived Xenografts for personalized post-progression therapy) models

- Project 2: using organoid cell culture models OPTIMAL (CIHR, PI) and POLOR (AstraZeneca, NPI) to study drug resistance mechanisms

- Project 3: large scale human population studies (COS-ILCCO: Clinical Outcomes Studies of the International Lung Cancer Consortium Studies of Clinical Outcomes) to study genetic and environmental components of risk and outcomes of cancers

- Project 4: developing improved methods of clinical outcomes and patient phenotyping of symptoms and toxicities: 2BLAST (PM Data Science Catalyst Project); Machine Learning, Biostatistical and Bioinformatic Longitudinal Assessment of Symptoms and Toxicities using innovative methods

(B) The CALIBRE program: stands for Clinical And Liquid biopsy, Informatics, Breathomics, and Radiomics for Early detection of cancer. This first phase focuses on lung cancer screening (LUNG-CALIBRE)

- Project 1: Clinical and Implementation Studies in Lung Cancer Screening (Lusi Wong Early Detection Program funding)

- Project 2: Radiomics in Lung Cancer Screening funded by a US U01 mechanism (co-investigator)

- Project 3: Liquid Biopsies in Lung Cancer in Early Detection (funded by CIHR grant (co-PI) and industry collaborations (Adela Bio, Toronto, ON, Canada; Oxford Cancer Analytics, Oxford, UK)

- Project 4: Breathomics in Lung Cancer Early Detection (funded by CCSRI Innovation grant and Industry Partners (Breathomix, Rotterdam, Netherlands, Breath Biomedical, Moncton, NB, Canada)

- Project 5: CALIBRE Integrative Analysis for Lung Cancer Screening (funded by Lusi Wong Early Detection Program)

In addition to these projects, there are administrative, biostatistics/bioinformatic, and

pathology/tissue cores (funded by Lusi Wong Early Detection Program).

(C) The ON-PROST program: stands for ONtario Patient Reported Outcomes of Symptoms and Toxicity

- Project 1: CARMA BROS is the CANadian Rare Molecular Alterations Basket Real-world Observational Study (funded by Takeda, AstraZeneca, and Amgen)
- Project 2: CLINTA stands for CLInic-based New Technology Applications
- Project 3: CHUQoLS(pronounced Chuckles) which stands for Cancer Health Utilities and Quality of Life Studies (funded by Takeda and Lusi Wong Fund)

(D) The HANG-OUT program: stands for Head And Neck cancer Genetics, Observational Outcomes, and Toxicities: A combined AMP-PEL and ON-PROST initiative

- Project 1: GENE-SMOKE: Genetics of Smoking Outcomes and Knowledge Effects (supported in-kind by the Head and Neck Translational Program)
- Project 2: GENE-LAST: Genetics of Long and Short-term Toxicities (supported in-kind by the Head and Neck Translational Program and the West China School of Medicine/West China Hospital, Sichuan University, Sichuan, China)

COMBIEL training program: stands for Cancer Outcomes, Medicine, Biostatistics, Informatics, Epidemiology and Laboratory, a multi-level training program in multidisciplinary clinico-translational cancer research. This multi-level training program ([www.UHNCOMBIEL.com](http://www.UHNCOMBIEL.com)) has trained over 220 individuals from the secondary school level through to Visiting Scientists on research methodology and collaborative translational/clinical research, co-led by Drs. Liu and Wei Xu (Staff Scientist, head of Biostatistics, Princess Margaret Cancer Centre).

2011 Jul - 2020 Dec

TITLE: Applied Molecular Pharmacogenomic and Pharmacoepidemiologic Laboratory (AMP-PEL).

DESCRIPTION:

The overarching hypothesis in my pharmacoepidemiologic and pharmacogenomics laboratory, AMP-PEL, is that clinically meaningful integration of personalized cancer care is unlikely to be derived from single biomarkers, but instead will likely involve multiple biomarkers, especially those that are multi-modal, i.e., a combination of biomarkers derived from both clinico-epidemiologic and bio-molecular sources.

Specifically, my laboratory has two areas of overlapping interest: (i) biomarkers that affect how drugs move through the body (pharmacokinetics) or affect their target tissues (pharmacodynamics); and (ii) biomarkers related to the aerodigestive tract and thoracic tumours, including lung cancer, gastroesophageal cancer, head and neck cancer, pancreatic, colorectal cancers and mesotheliomas.

Examples of the diverse types of biomarkers evaluated in my laboratory include:

(i) Tumour Pharmacogenomic Biomarkers: My laboratory generated dozens of primary derived xenografts of the upper aerodigestive tract (mainly esophageal and some lung cancer models) focusing on the utility of these PDXs as models to test response to targeted therapy, chemotherapy, radiation, and combination therapy;

(ii) Germline Pharmacogenetic Biomarkers: Pharmacogenomic epidemiology utilizes epidemiologic methodologies to interrogate genomic questions involving drug therapy. My laboratory focuses on the use of observational datasets or secondary analyses of clinical trials to evaluate the impact of genetic variation and tumour genomics within pharmacodynamic and pharmacokinetic pathways of therapies on important patient outcomes, such as treatment response, survival or toxicity. My laboratory also serves as the

primary pharmacogenomic laboratory of both the Princess Margaret Drug Development Program and the Canadian Clinical Trials Group (CCTG, Kingston);

(iii) Germline biomarkers of risk and prognosis are another area of strong interest of my laboratory, where we have been awarded six peer-reviewed grants to evaluate such markers. My laboratory is also the major Canadian centre involved in three NCI US/IARC-based international consortia.

(iv) Serologic biomarkers has led to multiple studies of such markers in mesothelioma, a rare tumour type;

and (v) Clinical biomarkers including various clinic-demographic and epidemiologic factors affecting prognosis have been extensively studied, in order to improve prediction models that involve molecular and blood-based biomarkers.

#### IMPACT OF RESEARCH

My laboratory follows a rigorous biomarker development pipeline that uses the acronym, ACCE: Analytical validity, Clinical validity, Clinical Utility, and Ethics/legal/societal implications. All different modalities of biomarkers are included for analysis. The underlying hypothesis of my laboratory's work is that the best (i.e., most discriminatory, best calibrated) biomarker prediction models will utilize all different types of biomarkers combined in a single model, rather than multiple competing models each involving a single biomarker.

Various biomarkers studied in my laboratory have had important impact at different levels of clinical patient management:

(i) In in vivo mouse models, my laboratory demonstrated proof of principle that primary derived xenografts of the aerodigestive tract recapitulate the primary patient's tumour molecularly and in their therapeutic responses. My laboratory is utilizing these xenografts, funded by a Canadian Cancer Society Research Institute IMPACT grant, to test drugs, drug combinations, and chemoradiation, in a manner that will allow clinicians to select potentially optimal therapies for the corresponding patients who carry these tumours;

(ii) In germline pharmacogenetics markers, my research has identified and/or validated series of biomarkers across over a half-dozen publications involving the platinum, EGFR, and VEGF targeting pathways. These markers are being validated in additional large scale clinical trial datasets. For example, the FCGR2A polymorphism is being considered for prospective evaluation as a marker of lack of cetuximab response in colorectal cancer.

(iii) For germline markers of cancer risk and cancer prognosis, our laboratory has published over 15 manuscripts of germline prognostic markers in head and neck cancer, esophageal cancer, and lung cancer, in addition to participation in over ten consortia-based cancer risk analyses publications. These manuscripts are the basis of the development of multimodal biomarker prediction models that will incorporate multiple biomarkers. On an additional note, my laboratory has led the first germline polymorphism analysis of the chromatin remodeling gene, BRM, and its association with the risk of various aerodigestive cancers.

(iv) For serologic markers of mesothelioma, we have identified mesothelin as an excellent marker of tracking therapeutic responses, fibulin-3 as a high sensitivity/high specificity serologic biomarker of mesothelioma diagnostics, and plasma osteopontin as a serologic biomarker of mesothelioma prognosis. Such markers are now being studied prospectively in the clinical and clinical trial setting;

(v) In addition we have identified and validated a number of important clinical prognostic factors, such as smoking and alcohol intake, body mass index, and comorbidity, what we have demonstrated to be important and must be taken into account whenever biomarker analyses are performed in aerodigestive tract cancers.

## 2. TEACHING PHILOSOPHY

(A) 2011- pres.

COMBIEL Cancer Outcomes, Medicine, Biostatistics, Bioinformatics, Epidemiology, and Laboratory Medicine. Research Training Program, Multilevel Education, Faculty of Medicine, Department of Medicine, Oncology (Medical), University of Toronto

Developed an innovative research training program with Associated Professor, Dr. Wei Xu (Biostatistics), which involves basic research training for individuals without a strong translational research background to perform multidisciplinary research. Trainees have been accepted from the Clinician-Scientist programs at the University of Toronto, graduate students from Epidemiology and Biostatistics, post-doctoral and clinical fellows in oncology, interns and residents in their research blocks, visiting scientists and scholars internationally, medical undergraduates, and undergraduates. A select number of high school students through the Toronto District School Board Clinician-Scientist program and several private secondary schools with summer-work programs are also selected. The focus of the training is in basic research question development and hypothesis generation, development of skills associated with identifying gaps of knowledge in science, operationalizing the research question into proper study design and methods, biostatistical and analytical skills, and presentation and communication skills. Teaching methods include an innovative lecture series, seminars, and workshops. See [www.uhncombiel.com](http://www.uhncombiel.com) for additional details. The lecture series runs twice weekly from May through August, and monthly sessions run the rest of the year. Trainees from different disciplines (epidemiology, medicine, biostatistics, informatics, laboratory, etc.) work on the same research projects to foster better inter-disciplinary understanding and communication. A major criterion of success is the number of abstracts/publications with different trainees of various disciplines. Another criterion is the number of individuals who remain in translational academics. IMPACT: Increased multidisciplinary translational oncology training, interest in translational oncology research. Over 30 publications and 150 presentations/abstracts have followed the multidisciplinary trainee exposure model. At least 120 past-trainees have continued to stay in academics/research fields.

(B) 2009-pres.

Introduction to Pharmacogenetics/Advanced Topics in Pharmacogenetics, Continuing Education, International Conference for Pharmacoepidemiology (ICPE), Medicine/Pharmaceutical Sciences, International Society for Pharmacoepidemiology (ISPE).

Since 2009, this has been an annual pre-conference course for the International Conference for Pharmacoepidemiology, focused on training epidemiologists to understand the role of genetics and how to perform genetic analyses in pharmacoepidemiology datasets. Innovative aspects: (i) first pre-conference course to have round-table sessions, 2009; (ii) first pre-conference course to be full day (double session), 2009; (iii) first pre-conference course to have basic and advanced topic streams (2012); (iv) first pre-conference course to collect formal feedback from attendees (2009); (v) first course to use debate as a didactic tool (2012); (vi) first pre-conference course to have pre-conference video-teaching (2014).<sup>[SEP]</sup> IMPACT: Increased awareness and interest in pharmacogenetics by pharmacoepidemiologists; advancement of innovative pedagogy within the professional society.

(C) 2017 - present

Oncology for Pharmacoepidemiologists. Continuing Education, International Conference for Pharmacoepidemiology (ISPE), Medicine/Pharmaceutical Sciences, International Society for Pharmacoepidemiology (ISPE).

This course focuses on the unique aspects of data and analytical elements when it comes to cancer databases and analysis, including incorporation of biomarker data, genetic and genomic elements, diagnostic and staging dilemmas, and use of cancer registries. IMPACT: Increased knowledge within the pharmacoepidemiology community of cancer-specific issues in pharmacoepidemiology.

(D) 2017 - present

Non-Database Pharmacoepidemiology: Learning through examples from Resource-Limited and Resource-Rich Countries. Continuing Education, Asian Conference for Pharmacoepidemiology (ACPE), Medicine/Pharmaceutical Sciences, International Society for Pharmacoepidemiology (ISPE).

This course focuses on the basics of pharmacoepidemiology when not using available databases (commonly not available in developing countries and in countries without an established universal health care system), with examples from Non-European countries and the non-Americas. IMPACT: Increased pharmacoepidemiology footprint in Asian countries, Australia, Africa and Middle East, where most of the attendees come from.

## D. Research Funding

### 1. GRANTS, CONTRACTS AND CLINICAL TRIALS

#### PEER-REVIEWED GRANTS

##### FUNDED

2024 Dec - 2025 Nov	<b>Principal Investigator.</b> Canadian Cancers of the Lung in Light and Never Smokers (CLANS) Network Website. Lung Cancer Canada. 2024 Geoffrey Ogram Memorial Research Grant. 25,000 CAD <i>Winner of the 2024 Geoffrey Ogram Memorial Research Grant.</i>
2024 Feb - 2029 Jan	<b>Principal Investigator.</b> Choksi lung cancer research program. Princess Margaret Cancer Foundation. M. Qasim Choksi Chair in Lung Cancer Research. 450,000 CAD
2023 Apr - 2028 Mar	<b>Co-investigator/ Site Principal Investigator.</b> Integrative analysis of lung cancer etiology and risk (Project 3) (INTEGRAL). National Institutes of Health (NIH) (USA). US U01 (Project 3). 429,000 USD. [Grants]
2023 Jan - 2027 Dec	<b>Co-Investigator.</b> Improving Detection of Early Lung cancer in a diverse population (IDEAL). Canadian Cancer Society (CSS). PI: Hung, Rayjean. 312,000 CAD. [Grants]
2023 Jan - 2025 Dec	<b>Co-Investigator.</b> Symptom screening with Targeted Early Palliative care (STEP) for patients with advanced cancer: a pilot trial. Innovation Fund Provincial Oversight Committee. Innovation Fund. PI: Zimmermann, Camilla. Collaborator(s): Hannon, Breffni; Krzyzanowska, Monika; Rodin, Dr. Gary; Li, Madeline; Howell, Doris; Knox, Jennifer; Leighl, Natasha; Sridhar, Srikala; Oza, Amit; Prince, Rebecca; Lheureux, Stephanie; Hansen, Aaron; Rydall, Ann; Booth, Christopher M; Leonie.Herx; Deborah Dudgeon; Dhani, Neesha; Bedard, Philippe; Mathews, Jean; Swami, Nadia; Le, Lisa; Chow, Brittany. 250,000 CAD <i>To determine feasibility of screening symptoms in palliative patients.</i>
2023 Jan - 2023 Dec	<b>Principal Investigator.</b> Progression In Patients with EGFR-mutations after Osimertinib and NGS analysis. EMD Serono Canada. Medical Education Awards. 13,563 CAD <i>To identify genomic charges in patients after they fail osimertinib.</i>
2022 May - 2024 Apr	<b>Co-Principal Investigator.</b> Development of a pharmacoeconomic modeling framework to evaluate the cost effectiveness of novel therapeutics for advanced lung cancer. University of Toronto Division of Medical Oncology Strategic Innovation Fund. PI: Parmar, Ambika. 30,000 CAD. [Grants] <i>To develop a pharmacoeconomic modeling framework in lung cancer.</i>
2021 Jan - 2023 Jan	<b>Principal Investigator.</b> LUNG cancer Earlier Detection to Intercept Cancerous-relapsing Tumors (Lung EDICT). Princess Margaret Cancer Foundation. 100,000 CAD. [Grants] <i>To study the role of hydroxymethylation in cfDNA analysis of lung cancer samples.</i>
2021 Jan - 2021 Dec	<b>Co-Investigator.</b> Integrated use of wearable diagnostics in lung cancer. University of Toronto. Internal Seed Grant Competition Fall 2020. PI: Raman, Srinivas. Collaborator(s): Co-Investigators: Tatiana Conrad, Philip Wong, Patrick Cheung, Jennifer Croke, Frederick Yoon, Anthony Brade, Andrew Hope, Alexander Louie. 50,000 CAD. [Grants]

- 2020 Oct - 2025 Sep **Principal Investigator.** Organoids to guide Post-resistance Therapy In driver Mutated Lung cancers (OPTIMAL). Canadian Institutes of Health Research (CIHR). Collaborator(s): Co-Investigators: Dr. Ming-Sound Tsao, Dr. Trevor John Pugh, Dr. Mathieu Lupien, Dr. Michael Francis Moran. 1,147,500 CAD. [Grants]  
*To evaluate the role of organoids in non small cell lung cancer.*
- 2020 Oct - 2025 Mar **Co-Investigator.** Metabolomics for Prediction of Cisplatin Mediated Acute Kidney Injury: A Canadian Multi-Centre Adult and Pediatric Study (Protocol). Canadian Institutes of Health Research (CIHR). 36,700 CAD. [Grants]  
*To study novel biomarkers of cisplatin toxicity.*
- 2020 Apr - 2021 Mar **Principal Investigator.** IASLC 9th Edition Lung Cancer Staging Project. International Association for the Study of Lung Cancer (IASLC). Staging Project. 20,000 USD. [Grants]
- 2019 Dec - 2021 Feb **Nominated Principal Investigator.** 2BLAST Data Science Catalyst Grant. Princess Margaret Data Science Program. Collaborator(s): Co-PI: Xu W. Collaborators: B. Haibe-Kains, A. Oza, A. Hope. 50,000 CAD. [Grants]
- 2019 Oct - 2025 Sep **Co-Applicant.** Electronic Patient Reported Outcome Measures to Improve Patient Centered Solid Organ Transplant Care. CIHR. Canadian Donation and Transplantation Research Program. PI: Bartlett, S. Collaborator(s): Alba, A.C., Fortin, M-C., Howell, D., Li, M., **Liu, G.**, MacIver, J., Mitsakakis, N., Nissim, R., Novak, M., Singer, L., Truong, T., Veillette, C. 918,000 CAD. [Grants]  
*Development and application of patient reported tools for chronic disease and solid organ transplant.*
- 2019 Oct - 2024 Sep **Co-Principal Applicant.** Lung cancer early detection and classification using methylome analysis of plasma cell free DNA. Canadian Institutes of Health Research (CIHR). PI: NPI: Scott Bratman. Collaborator(s): Michael Hoffman, Xu Wei, Frances Shepherd, Rayjean Hung, Daniel De Carvalho, Philip Awadalla, Stephen Lam. 995,264 CAD  
*Use of plasma cell free methylome analysis for early detection of lung cancer. This study as a similar overall goal as our current grant application; however, this CIHR grant uses different samples and different molecular profiling techniques so no major overlap with our current grant application  
(Co-Principal Investigator: Scott Bratman).*
- 2019 Aug - 2021 Jul **Co-Investigator.** ONCO-GEMINI: ONcology Continuum GEneral Medicine INpatient Initiative; comparing cancer patients admitted to oncology vs non-oncology services. Canadian Cancer Society Research Institute (CCSRI). Innovation Grant. PI: Razak, Fahad. 198,919 CAD. [Grants]
- 2019 Aug - 2021 Jul **Principal Investigator.** Breathomics as a noninvasive, inexpensive, point-of-care predictive test for immune checkpoint inhibitor efficacy. Canadian Cancer Society Research Institute (CCSRI). Innovation Grants. Collaborator(s): Adrian Sacher, Marcus Butler, Pamela Ohashi, Ming-Sound Tsao, Wei Xu. 200,000 CAD. [Grants]
- 2019 Jul - 2021 Jun **Co-Investigator.** ONCO-GEMINI: ONcology Continuum GEneral Medicine INpatient Initiative. University of Toronto Medical Oncology Strategic Innovation Fund. PI: PI: Razak, Fahad; Krzyzanowski, Monika. [Grants]
- 2018 Apr - 2023 May **Co-Investigator.** Integrative analysis of lung cancer etiology and risk (Project 3) ("Integral"). National Institutes of Health (NIH). U19CA203654. 55,114 USD. [Grants]  
*To study the role of biomarkers in lung cancer screening.*



2017 Nov - 2019 Oct	<b>Co-Principal Applicant.</b> Implementing lung cancer screening for those living with low income. Canadian Cancer Society Research Institute (CCSRI). Knowledge to action grant. PI: Lofters, Aisha. 99,925 CAD. [Grants]
2017 Aug - 2020 Dec	<b>Co-applicant.</b> Integrative analysis of Lung Cancer Risk & Etiology. National Cancer Institute (USA). 13,636,352. [Grants] <i>To identify and validate the genomic predictors of smoking and lung cancer risk; (2) To identify and validate nongenomic biomarkers of lung cancer risk; (3) To translate the molecular and clinical data to population lung cancer risk assessment.</i>
2017 Feb - 2019 Jan	<b>Co-Principal Investigator.</b> Invest in Research - Lung Cancer. Princess Margaret Hospital Foundation (The). Invest in Research. PI: DeCarvalho, Daniel. 100,000 CAD. [Grants]
2017 Feb - 2019 Jan	<b>Co-Applicant.</b> Adaptation, feasibility and acceptability study of the advanced symptom monitoring and management system (ASyMS) mobile health intervention to reduce chemotherapy toxicities in Canadian cancer patients. Canadian Cancer Society Research Institute (CCSRI). Innovation Grant 1 - 2017. PI: Howell, Doris. Collaborator(s): Krzyzanowska MK, Maguire R, Kukreti V, <b>Liu G</b> , Cafazzo JA, Morita P, Moradian S, Bender J, Le LW, Husain A, Puts MM, Amir E. 196,000 USD. [Grants]
2017 Jan - 2021 Dec	<b>Co-Investigator.</b> The role of germline and somatic DNA mutations in oral and oropharyngeal cancers (Voyager). National Institutes of Health (NIH). 24,000 USD. [Grants]
2016 Nov - 2021 Oct	<b>Co-Investigator.</b> The role of germline and somatic DNA mutations in oral and oropharyngeal cancers. 1R01DE025712-01A1. US National Institute of Health. National Institute of Dental and Craniofacial Research. PI: Brennan, Paul. Collaborator(s): Rayjean Hung, John Fields, <b>Geoffrey Liu</b> . 3,045,630 USD. [Grants]
2016 Jul - 2018 Jun	<b>Co-Principal Investigator.</b> Expanding an online tool to multiple University of Toronto hospitals, CEASE, to aid smoking cessation referral in cancer patients: A feasibility study. University of Toronto. Medical Oncology Strategic Planning Innovation Fund. 212374. Collaborator(s): Co-PIs: L. EngC. Brezden-Masley, J. Jones, M. Giuliani, A. Eisen. 30,000 CAD. [Grants]
2016 Apr - 2020 Mar	<b>Co-Applicant.</b> Evaluation of myocardial changes during breast adenocarcinoma therapy to detect cardiotoxicity earlier with MRI-The EMBRAE-MRI Study. Canadian Institutes of Health Research (CIHR). PI: Thavendiranathan Paaladinesh. Collaborator(s): <b>Liu, Geoffrey</b> . 641,160 CAD. [Grants]
2016 Apr - 2018 Mar	<b>Co-Principal Investigator.</b> X-chromosomes wide genetic association on cancer prognostic and pharmacogenetic analysis of clinical trials: methodological development and analysis. Canadian Institutes of Health Research (CIHR). Catalyst Grant. 145546. PI: Xu, Wei, <b>Liu, Geoffrey</b> . Collaborator(s): Chen BE, Hung R, MacKay H, O'Callaghan C, Tu D. 150,000 CAD. [Grants] <i>Catalyst grant: Integrating sex as a variable in biomedical or translational research.</i>
2015 Sep - 2019 Jun	<b>Co-Applicant.</b> Evaluation of myocardial changes during breast adenocarcinoma therapy to detect cardiotoxicity earlier with MRI-The EMBRAE-MRI Study. Canadian Institutes of Health Research (CIHR). The EMBRAE-MRI Study. PI: Thavendiranathan, Paaladinesh. 641,160 CAD. [Grants]
2015 Jul - 2016 Jun	<b>Co-Investigator.</b> Genome-Wise Association Study (GWAS) in Hepatocellular Carcinoma (HCC). National Institutes of Health (NIH) (USA). R01CA186566. PI: Hassan, Manal. Collaborator(s): Amos C, Li D, Roberts, L. 165,134 USD. [Grants]

- 2015 Feb - 2020 Jan **Principal Applicant.** REAL-PDX: Resistance modeling in EGFR and ALK Lung cancer patient-derived xenografts for personalized post-progression therapy. Canadian Cancer Society Research Institute (CCSRI). Impact Grants - 2015. PI: **Liu, Geoffrey**. Collaborator(s): M-S Tsao, FA Shepherd, NB Leighl, K Yasufuku, M Pintilie, M Lupien, B Haibe-Kains, P Bradbury, S Shah. 1,249,999 CAD. [Grants]
- 2014 Jul - 2015 Jun **Co-Applicant.** CEASE: A novel electronic patient directed knowledge translation tool to improve smoking cessation in cancer patients. Cancer Care Ontario/Ontario Institute for Cancer Research. PI: Jones, Jennifer & Giuliani, Meredith. Collaborator(s): **Liu, G.**; Selby, P; Goldstein, D.; Abdelmutti, N.; Eng, L. 86,181.5 CAD. [Grants]  
*Design & Analysis.*
- 2014 May - 2016 Sep **Principal Applicant.** Early detection of lung cancer using next generation sequencing technology. McLaughlin Centre. 50,000 CAD. [Grants]  
*Accelerator Grant Competition.*
- 2014 Apr - 2019 May **Co-Applicant.** DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PRVENT). Canadian Institutes of Health Research (CIHR). Collaborator(s): Kim, R, Carleton, B. 2,000,000 CAD. [Grants]  
*Analysis.*
- 2014 Apr - 2019 Feb **Co-Applicant.** CA 13-006-NCI Experimental Therapeutics-Clinical Network with Phase I Emphasis (ET-CTN) UM1). Princess Margaret Phase I Consortium. PI: Siu, L L. Collaborator(s): Affiliated Organizations P.Is: Sullivan D, Hotte S, Chi K. 1,756,985 CAD. [Grants]  
*Princess Margaret Phase I Consortium  
Design, Conduct Analysis, Correlative Science Co-Lead.*
- 2013 Jul - 2015 Jun **Co-Investigator.** Cell free DNA whole-genome methylation profiles for pancreatic cancer for early detection and clinical outcome. Canadian Cancer Society Research Institute (CCSRI). Analysis. PI: Hung Rayjean. Collaborator(s): **Geoffrey Liu** and Gord Fehringer. 199,000 CAD. [Grants]
- 2013 Jul - 2014 Jun **Principal Investigator.** Pharmacokinetic and pharmacogenetic analysis of NCIC CTG CO.20 and CO.17 Clinical Trials. Ontario Institute for Cancer Research. Collaborator(s): Eric Morgen, Lillian L Siu, Wei Xu, Xueyu(Eric) Chen, Christopher John O'Callaghan, Andrew Brown, Derek Jonker, Dongsheng Tu. 128,945 CAD. [Grants]
- 2012 Oct - 2015 Sep **Principal Investigator.** The pharmacogenetics of bevacizumab: A companion correlative study of the ovarian cancer clinical trial ICON7. Canadian Institutes of Health Research (CIHR). MOP - 123227. Collaborator(s): R. Kim, H. MacKay, S. Marsh, A. Oza, W. Xu. 390,342 CAD. [Grants]
- 2012 Apr - 2019 Mar **Co-Investigator.** A Randomized Phase III Trial of Preoperative Chemotherapy vs Preoperative Chemotherapy for Resectable Gastric Cancer. Canadian Institutes of Health Research (CIHR). PI: O'Callaghan, Christopher J., & Kwok Sum, Rebecca. 1,700,000 CAD. [Grants]  
*Correlative Science Lead.*
- 2011 Jul - 2017 Mar **Co-Principal Investigator.** And Administrative PI. On-PROST: Ontario Patient Reported Outcomes of Symptoms and Toxicity. CCO - Cancer Care Ontario. PI: **Liu, Geoffrey** and Doris, Howell. Collaborator(s): Barbera, Lisa; Bradbury, Penny; Brundage, Michael; Hope, Andrew; Hung, Rayjean; Kim Richard; Leighl, Natasha; Li, Madeline; Mittman, Nicole; Rodin, Gary; Waldron, John; Wong, Rebecca; Zimmerman, Camilla. 1,497,912 CAD. [Grants]

2011 Jul - 2013 Jun	<b>Co-Principal Investigator.</b> And Administrative PI. Pharmacogenetic Study of Gemcitabine in Pancreatic Cancer: Analysis of Clinical and Observational Trials. OICR - Ontario Institute for Cancer Research. 10-NOV-415. PI: <b>Liu, Geoffrey</b> ; Cleary, Sean and Renouf, Daniel. Collaborator(s): Moore, Malcolm; Xu, Wei; Cotterchio, Michelle; Hung, Rayjean; Gallinger, Steven. 239,475.6 CAD. [Grants]
2011 Jul - 2012 Jun	<b>Principal Investigator.</b> Companion Pharmacogenetic Study in the Ovarian Cancer ICON7 Trial. OICR, Ontario Institute for Cancer Research. Collaborator(s): Oza, Amit; Marsh, Sharon. 99,749.6 CAD. [Grants]
2010 Dec - 2011 Mar	<b>Principal Investigator.</b> Companion Pharmacogenetic Study of BR.24. Ontario Institute for Cancer Research (On TRECT Small Project Submission#: HICT-SPS2010-05. ON TRECT Small Project Submission #: HICT-SPS2010-05. 88,140 CAD. [Grants]
2010 Jul - 2011 Jun	<b>Principal Investigator.</b> And Administrative PI. Genetic Polymorphisms as Predictors of Erlotinib Outcome in NCIC-CTG BR.24 Study. International Association for the Study of Lung Cancer (IASLC-LCFA). 39,437 USD. [Grants]
2010 Feb - 2016 Jan	<b>Co-Applicant.</b> STAGE (Strategic Training for Advanced Genetic Epidemiology): An integrated program in statistical & epidemiological training for genetics with a population health impact. Canadian Institutes of Health Research (CIHR). Research Training Grant. Collaborator(s): co-PIs: Bull SB, Gagnon F, Narod SA, Paterson AD, Sun L. 1,774,814 CAD. [Grants]
2009 Jul - 2017 Jun	<b>Co-Investigator.</b> Integrated molecular pathology of targeted cancer therapy in lung cancer. ORF-RE. PI: Tsao, Ming. 4,675,545 CAD. [Grants] <i>Supervisor, Analysis and Clinical Interpretation.</i>
2009 Jul - 2014 Jun	<b>Principal Investigator.</b> Pharmacogenetic epidemiologic and molecular epidemiologic methodologic development and application in cancer studies within Ontario. Cancer Care Ontario. 500,000 CAD. [Grants] <i>Cancer Care Ontario Research Chair in Experimental Therapeutics and Population Studies.</i>
2009 - 2014	<b>Co-Investigator.</b> Molecular Epidemiology of Lung Cancer Prognosis (GWAS). National Institutes of Health (NIH) (USA). NIH R01. PI: Christiani, David. 2,340,242 USD. [Grants] <i>Analysis.</i>
2009 - 2014	<b>Co-Applicant.</b> Post-genomewide association study of lung cancer in Ontario. Canadian Cancer Society. PI: Hung, Rayjean J. 877,735 CAD. [Grants] <i>Analysis.</i>
2009 - 2013	<b>Co-Investigator.</b> BEAGESS Genome Wide Association Study of Barrett's Esophagus And Esophageal Adenocarcinoma. National Institutes of Health (NIH) (USA). NIH R01. PI: Vaughan, Thomas; Whiteman, David. 4,703,890 USD. [Grants] <i>Design, Conduct Analysis.</i>
2009 - 2011	<b>Co-Principal Investigator.</b> Vitamin D Pharmacogenetic Epidemiology and Head and Neck Cancer Survivorship. National Institutes of Health (NIH) (USA). NIH R03. PI: Tsao, Ming. 100,000 USD. [Grants]
2009 - 2011	<b>Principal Investigator.</b> Pharmacogenetic Companion Study of NCIC CTG BR.19 study. Ontario Institute of Cancer Research. Operating Grant. 78,760 CAD. [Grants]

- 2008 Jul - 2017 Jun **Co-Investigator.** Pan Canadian Early Detection of Lung Cancer Study. Terry Fox Research Institute (TFRI). PI: Tsao, M and Lam S. 8,428,851 CAD. [Grants]  
*Correlative Science lead.*
- 2008 Apr - 2015 Mar **Co-Principal Investigator.** Excellence in radiation research for the 21st century (EIRR21). Canadian Institutes of Health Research (CIHR). Research Training Grant. PI: Liu, Fei-Fei. Collaborator(s): Bezjak A, Bristow RGlen, Catton P, Cheung P, Czarnota GJ, Dawson LA, Derry WB, Durocher D, Earle CC, Fyles AW, Gospodarowicz M, Hill RP, Hodgson DC, Hudson TJ, Jaffray DA, Jurisica I, Kelley SO, Koch A, **Liu G**, Milosevic M, Penn LZ, Podgorsak EB, Reilly RM, Rowlands JA, Schimmer AD, Seuntjens JP, Siewerdsen JH, Stambolic V, Wong S, Wouters B. 952,500 CAD. [Grants]  
*Mentor, Executive Member.*
- 2008 - 2013 **Co-Applicant.** Clinician-Scientists in Molecular Oncologic Pathology. Canadian Institutes of Health Research (CIHR). Research Training Grant. PI: Tsao, Ming. 1,950,000 CAD. [Grants]  
*Canadian Institutes of Health Research and Terry Fox Research Institute.*  
*Mentor, Supervisor.*
- 2008 - 2013 **Co-Investigator.** Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01). National Cancer Institute (USA). PI: Siu, Lillian. 3,141,916 USD. [Grants]  
*Correlative Science Co-Lead.*
- 2008 - 2011 **Co-Investigator.** Improved radiation induced lung toxicity prediction with linked pre-clinical/clinical models and biomarkers. National Cancer Institute of Canada (NCIC). Operating Grant/New Investigator. PI: Hope, Andrew. 381,099 CAD. [Grants]  
*Analysis.*
- 2008 - 2011 **Co-Principal Investigator.** Genetic Polymorphisms and Head and Neck Cancer Outcomes. National Cancer Institute of Canada (NCIC). Operating Grant. Collaborator(s): Co-PIs – **Geoffrey Liu** and Francois Meyer (Laval/CHUQ). 567,850 CAD. [Grants]  
*NCIC National Cancer Institute of Canada.*
- 2008 - 2010 **Principal Investigator.** Evaluation of Genetic Polymorphisms as Predictors of Erlotinib Outcome in the BR.21 Study. Ontario Institute of Cancer Research. Operating Grant. 135,000 CAD. [Grants]
- 2008 - 2010 **Principal Investigator.** Molecular Epidemiology of Lung Cancer Prognosis. University of Toronto. Connaught New Staff Matching Grants. 30,000 CAD. [Grants]
- 2007 - 2012 **Principal Investigator.** Molecular Epidemiology of Esophageal Cancer Survival. Canadian Institutes of Health Research (CIHR). Operating Grant. 689,220 CAD. [Grants]
- 2007 - 2010 **Co-Applicant.** Pharmacokinetic and Pharmacogenetic Determinants of Erlotinib Toxicity and Response. Ontario Cancer Research Network. Operating Grant. PI: Chen, Eric. 114,482 CAD. [Grants]
- 2007 - 2009 **Co-Investigator.** Second Hand Smoke and Risk of Esophageal Cancer (Boston). Flight Attendants Medical Research Institute. Young Investigator Award. PI: Zhai, Rihong. 370,000 USD. [Grants]
- 2004 - 2011 **Principal Investigator.** Molecular Epidemiology of Esophageal Cancer Prognosis. National Cancer Institute (USA). R01. 1,702,082 USD. [Grants]
- 2004 - 2007 **Principal Investigator.** H. pylori, Genes and esophageal adenocarcinoma. National Cancer

Institute (USA). R03. 115,008 USD. [Grants]

- 2003 - 2008 **Co-Investigator.** Genetic Susceptibility to Lung Cancer. National Cancer Institute (USA). R01. PI: Christiani, David. 1,920,405 USD. [Grants]
- 2003 - 2005 **Principal Investigator.** Gender and Genetic Factors in Lung Cancer Susceptibility. National Institutes of Health (NIH) (USA). SPORE Career Development Award, Harvard (US). 50,000 USD. [Grants]
- 2002 - 2007 **Consultant.** Molecular and Genetic Analysis of Lung Cancer Survival. National Cancer Institute (USA). R01. PI: Christiani, David. 61,600 USD. [Grants]
- 2001 - 2007 **Principal Investigator.** Molecular Epidemiology of Barrett's Adenocarcinoma. Doris Duke Clinician Scientist (US). Doris Duke Clinician Scientist (US). 460,000 USD. [Grants]
- 2000 - 2002 **Principal Investigator.** Charles A. King Research Fellowship. The Medical Foundation. 64,000 USD. [Research Fellowships]  
*Mentor: Robert Mayer, Dana Farber Cancer Institute.*
- 2000 - 2001 **Principal Investigator.** Molecular Epidemiology of Barrett's Esophagus. American Society of Clinical Oncology. Young Investigator's Award. 35,000 USD. [Research Fellowships]  
*Mentor: David Christiani, Harvard School of Public Health.*
- 2000 - 2001 **Principal Investigator.** Dana Farber Cancer Institute. Dana Farber Cancer Institute. 18,400 USD. [Research Fellowships]  
*Mentor: Robert Mayer, Dana Farber Cancer Institute.*
- 1999 - 2000 **Co-Investigator.** Helicobacter pylori infection and Barrett's esophagus. National Institute of Environmental Health Science. Pilot grant project. ES00002. PI: Christiani, David. 15,000 USD. [Grants]  
*Mentor: David Christiani, Harvard School of Public Health.*
- 1998 - 2000 **Additional Author.** Molecular Epidemiology of Pancreatic Cancer. National Cancer Institute of Canada (NCIC). Collaborator(s): Co-Principal Investigators: Steven Gallinger/Steven Narod. 356,409 CAD. [Grants]

## NON-PEER-REVIEWED GRANTS

### FUNDED

- 2006 Apr - present **Principal Investigator.** Lusi Wong Early Detection of Lung Cancer Program. PMH Foundation. 2,500,000 CAD. [Grants]  
*To develop the infrastructure to support early detection work.*
- 2024 Jun - 2025 Jun **Co-Investigator.** TRACES: Thoracic Radiotherapy After Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer. AstraZeneca Canada Inc. PI: Sun, Alex. 15,000 CAD
- 2024 Apr - 2026 Mar **Principal Investigator.** Early Detection Lung Screening in high risk population. Astra Zeneca Canada Inc. 216,086 USD
- 2024 Apr - 2025 Dec **Principal Investigator.** Early Detection of Lung Cancer A Pan-Canadian Study. Oxford Cancer Analytics Ltd. Collaborator(s): Ming Tsao. 72,000 CAD

2024 Mar - 2030 Feb	<b>Site Principal Investigator.</b> Randomized, Open-Label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3). Bristol-Myers Squibb Company. Clinical Trial. 288,457.85 CAD
2024 Feb - 2033 Apr	<b>Site Principal Investigator.</b> A Phase I-II, Multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with locally advanced, unresectable, stage III non-small cell lung cancer. Roche. 1,238,820 CAD. [Clinical Trials]
2024 Jan - 2026 Dec	<b>Principal Investigator.</b> CANadian Cancers with Rare Molecular Alternations - Basket Real-world Observational Study - ROS1 (CARMA-BROS-ROS1). AnHeart Therapeutics Inc. 327,060 USD
2023 Dec - 2028 Nov	<b>Site Principal Investigator.</b> A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial). PharmaMar. 165,000 USD
2023 Dec - 2025 Jan	<b>Principal Investigator.</b> Geospatial Analysis of Patients, Treatments, and Outcomes of Lung Cancer in Ontario. Astra Zeneca Canada Inc. 59,960 CAD
2023 Nov - 2028 Oct	<b>Site Principal Investigator.</b> Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations MOMENT (Met nOn sMall cEll caNcer regisTry). EMD Serono Research & Development Institute, Inc. 110,933 CAD. [Clinical Trials]
2023 Nov - 2025 Jan	<b>Principal Investigator.</b> Sub-optimal Outcomes in Lung cancer with ALK-translocations (SOLA): A Canada-Wide Quality Improvement Project. Pfizer Canada Inc. Research Grant. 52,172.8 CAD. [Grants]
2023 Apr - 2024 Mar	<b>Site Principal Investigator [Investigator-Initiated Study].</b> Pan Canadian Lung Cancer Observational Study (PALEOS). Pulse Infoframe Inc. Collaborator(s): Cheema, Parneet; Kuruvilla, Sara. 130,000 CAD. [Clinical Trials] <i>To study the real world data of NSCLC lung cancer patients.</i>
2023 Mar - 2024 Mar	<b>Principal Investigator.</b> Mobile Lung Cancer Screening & Search - Solution Based Whitepaper. Multiple Industry Partners: Amgen, Takeda, AstraZeneca, Gilead, Pfizer, Novartis. Educational Grant. 145,000 CAD. [Grants] <i>The goal of this study is to identify methods of improving equity of lung cancer screening, possibly through a traveling mobile screening unit.</i>
2022 Nov - 2027 Nov	<b>Site Principal Investigator.</b> Protocol # JZP 712 – 402 _EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca. Jazz Pharmaceuticals Inc. 40,000 CAD. [Clinical Trials]
2022 Nov - 2027 Nov	<b>Site Principal Investigator.</b> (VICTORIA) Comparative effectiveness study of real world control of TRK fusion positive cancer with patients from larotrectinib (Vitrakvi) clinical trials. Bayer Canada Inc. 21,000 CAD. [Clinical Trials]
2022 Nov - 2027 Nov	<b>Site Principal Investigator.</b> Patterns of care and clinical outcomes of patients with

advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.  
Takeda Canada Inc. 34,000 CAD. [Clinical Trials]

- 2022 Nov - 2024 Jul **Overall National Chair and Principal Investigator (Arm E) [Investigator Initiated Study].** Canadian Cancers with Rare Molecular Alterations Basket Real-World Observational Study (CARMA BROS). EMD Serono, Canada. 34,259 CAD. [Clinical Trials]  
*To study the real-world evidence associated with secondary rare molecular alternations of non-small cell lung cancer with EGFR mutations after failing 1L therapy.*
- 2022 Oct - 2026 Jul **Overall National Chair and Principal Investigator (Arm D) [Investigator Initiated Study].** Canadian Cancers with Rare Molecular Alterations Basket Real-World Observational Study (CARMA BROS). Bayer, Canada. 225,534 CAD. [Clinical Trials]  
*To study the real-world evidence associated with rare molecular alternations of non-small cell lung cancer with NTRK fusions.*
- 2022 Aug - 2025 Jun **Principal Investigator [Investigator Initiated Study].** Multi-Cancer Early Detection of cfMeDIP-seq for Head and Neck Cancer. Adela Canada, Inc. Collaborator(s): Anne-Renee Hartman. 136,733 CAD. [Grants]  
*The goal of this Research Project is to develop classifiers using the cfMeDIP platform that can discriminate between head and neck cancer and non-cancer plasma samples across all stages. Additionally, the classifier will be trained to discriminate between different histologic and phenotypic subtypes.*
- 2022 May - 2024 Jan **Overall Principal Investigator.** Canadian Cancers with Rare Molecular Alterations - Basket Real-world Observational Study (CARMA-BROS). Amgen Canada Inc. 259,879.26 CAD. [Grants]  
*ARM C: KRAS G12C mutations. The goal of this study is to determine the current treatment and outcome landscape of patients with KRAS G12C mutations across Canada.*
- 2022 Jan - 2024 Jun **Principal Investigator.** Testing for Resistance Mechanism in EGFR-mutated Osimertinib-treated patients (TRiMEO). AstraZeneca Canada Inc. 22,000 CAD. [Grants]  
*To study the resistance mechanisms of EGFR-mutated osimertinib treated patients.*
- 2022 Jan - 2024 Jun **Principal Investigator.** Durvalumab and Radiation in Extensive Stage Small cell lung cancer (DRESS). AstraZeneca Canada Inc. 16,500 CAD. [Grants]  
*To study the clinical interaction of durvalumab and radiation in small cell lung cancer.*
- 2021 Dec - 2024 Jun **Principal Investigator [Investigator Initiated Study].** Multi-Cancer Early Detection of cfMeDIP-seq for Lung Cancer. Adela Canada, Inc. Collaborator(s): Anne-Renee Hartman. 142,423.2 CAD. [Grants]  
*The goal of this Research Project is to develop classifiers using the cfMeDIP platform that can discriminate between lung cancer and non-cancer plasma samples across all stages. Additionally, the classifier will be trained to discriminate between different histologic and phenotypic subtypes.*
- 2021 Nov - 2026 Dec **Site Principal Investigator.** Study of DS-1062a versus Docetaxel in previously treated advanced or metastatic non-small cell lung cancer without actionable genomic alternations (TROPION 1). Daiichi Sankyo. [Clinical Trials]  
*The goal of this research if to evaluate whether DS-1062a is more efficacious than docetaxel in the second line setting for non-targetable NSCLC.*
- 2021 Sep - 2025 Feb **Site Principal Investigator.** Trastuzumab Deruxtecan in Participants with HER2-mutated Metastatic Non-Small Cell Lung Cancer (DESTINY-LUNG02). Daiichi Sankyo/Astra Zeneca. 60,000 CAD. [Clinical Trials]  
*To determine the benefit of trastuzumab deruxtecan in participants with HER2-mutated*

NSCLC.

2021 Jun - 2026 May	<b>Site Principal Investigator.</b> Osimertinib then Chemotherapy in EGFR mutated Lung cancer with Osimertinib Third-line rechallenge (OCELOT). Lawson Health Research Institute. 74,405 CAD. [Clinical Trials] <i>To determine benefit of third line osimertinib rechallenge after first line use followed by chemotherapy outline of Methodology: Single Arm Clinical Trial.</i>
2021 Apr - 2026 Jun	<b>Site Principal Investigator.</b> A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety Talrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors. IQVIA RDS Canada ULC. 60,000 CAD. [Grants]
2021 Apr - 2024 Dec	<b>Principal Investigator.</b> Diagnostic NTRK Gene Fusion Testing. Bayer Canada Inc. 389,156 CAD. [Grants] <i>To study the implementation of NTRK testing at Princess Margaret Cancer Centre.</i>
2021 Apr - 2024 Mar	<b>Co-Principal Investigator [Investigator Initiated Study].</b> Patient-derived Organoids of Lung cancer to understand Osimertinib Resistance (POLOR). AstraZeneca Partners of Choice. Collaborator(s): Co-PI: Tsao, Mindy-Sound. 830,000 CAD. [Grants] <i>To study the role of organoids post-osimertinib.</i>
2021 Feb - 2025 Apr	<b>Site Principal Investigator.</b> A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer. AstraZeneca Canada Inc. 60,000 CAD. [Clinical Trials] <i>To study different novel combinations in lung cancer.</i>
2021 Feb - 2025 Jan	<b>Principal Investigator [Investigator-Initiated Study].</b> Breath analysis of patients diagnosed with lung cancer compared with healthy controls using infrared spectroscopy. Breathe Biomedical. 396,738 <i>To study the role of breathomics in lung cancer screening.</i>
2020 Oct - 2025 Jul	<b>Overall National Chair and Principal Investigator (Arm B) [Investigator Initiated Study].</b> Canadian Cancers with Rare Molecular Alternations Basket Real-World Observational Study (CARMA BROS). AstraZeneca Canada Inc. Collaborator(s): Co-Investigators: Iqra Syed, Karen Pope, Mary-Kate Shanahan, Mehdi Belgnaoui. 558,894 CAD. [Grants] <i>To study the real-world evidence associated with rare molecular alternations of non-small cell lung cancer.</i>
2020 Oct - 2022 Oct	<b>Site Principal Investigator.</b> ON-TRK Prospective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with Larotrectinib. Bayer Canada Inc. 5,000 CAD. [Clinical Trials] <i>Collection of observational data for NTRK+ NSCLC patients.</i>
2020 Aug - 2025 Jul	<b>Site Principal Investigator.</b> A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations. Takeda Pharmaceutical Inc. 60,000. [Clinical Trials] <i>Comparing Mobobertinib to chemotherapy.</i>
2020 Aug - 2020 Dec	<b>Principal Investigator.</b> Real-World Treatment Patterns and Outcomes in KRAS-Positive Advanced Lung Cancer Patients. Amgen Canada Inc. 39,416.34 CAD. [Clinical Trials]



2019 Dec - 2027 Dec	<b>Site Principal Investigator.</b> A study of repotrectinib (TPX-0005) in patients with advanced solid tumors harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT). Turning point therapeutics, Inc. 142,000 <i>To study the role of repotrectinib in the Phase II setting for patients with NSCLC with ROS1 and NTRK fusions.</i>
2019 Nov - 2024 Jan	<b>Site Principal Investigator.</b> Brigatinib 3001 - Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®). ARIAD Pharmaceuticals, Inc. 35,105
2019 Nov - 2023 Mar	<b>Principal Investigator [Investigator Initiated Study].</b> Assessment of a combined lung cancer-COPD-smoking cessation tool in the primary care setting using a tablet-based screening platform. Boehringer Ingelheim Canada Ltd. (BICL). 62,040 CAD <i>To study the role of improved tracking of lung cancer screening patients.</i>
2019 Oct - 2021 Sep	<b>Site Principal Investigator.</b> Clinical Trial # 01AT1B & 02AT18 Treatment Patterns, Mechanisms of Resistance and Outcomes among patients with EGFR, ALK and ROS1 Translocated Non-Small Cell Lung Cancer: An ATOMIC Consortium Analysis. Academic Thoracic Oncology Medical Investigators Consortium. 50,000. [Clinical Trials]
2019 Aug - 2023 Jan	<b>Site Principal Investigator.</b> Brigatinib 2002 - Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib. ARIAD Pharmaceuticals Inc. 48,207 <i>To study efficacy of brigatinib post-ceritinib or alectinib.</i>
2019 - 2024 Mar	<b>Overall National Study Chair and Principal Investigator (Arm A) [Investigator Initiated Study].</b> Canadian Cancers with Rare Molecular Alteration (CARMA) Basket Real-World Observational Study (BROS). Takeda Canada, Inc. Observational Study. 2,370,787 CAD. [Grants] <i>Observational study of rare molecular alterations in NSCLC patients.</i>
2018 Jun - 2020 Feb	<b>Principal Investigator [Investigator Initiated Study].</b> EGFR positive Lung Cancer and Health Utility Scores. AstraZeneca. AstraZeneca Sponsored Epidemiology Grant. 36,000 CAD. [Grants]
2018 - 2024 Apr	<b>Site Principal Investigator.</b> An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Participants Who Have Progressed on Crizotinib. Takeda Pharmaceuticals Inc. 43,000. [Clinical Trials] <i>Comparing brigatinib vs alectinib post crizotinib.</i>
2018 - 2024 Feb	<b>Site Principal Investigator.</b> Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671). Merck. 67,306. [Clinical Trials] <i>To study role of neoadjuvant and adjuvant pembrolizumab in resectable lung cancer.</i>
2018 - 2019	<b>National Principal Investigator.</b> Real World Evidence for Small Cell Lung Cancer Clinical Outcomes. Abvie Pharma. Observational Study. [Clinical Trials]
2017 - 2020	<b>National Principal Investigator.</b> Prospective Toxicity and Health Utility Assessment of EGFR-targeting agents in a Real World Observational Study. AstraZeneca Canada Inc. Observational Study. [Clinical Trials]

2016 - 2024 Dec	<b>Site Principal Investigator.</b> Phase III Trial of Brigatinib versus Crizotinib in treatment naïve ALK positive Non-Small Cell Lung Cancer: ALTA-1L. Takeda Pharmaceuticals Inc. 52,346. [Clinical Trials] <i>To compare brigatinib vs crizotinib in ALK+ patients.</i>
2016 - 2020	<b>Site Principal Investigator.</b> Food Effects Trial of LDK378 in ALK-positive Non-Small Cell Lung Cancer. Novartis Pharma, Inc. 35,252. [Clinical Trials]
2016 - 2019	<b>Site Principal Investigator.</b> ASTRIS Real World Evidence Trial of Osimertinib in T790M EGFR mutated Non-Small Cell Lung Cancer. AstraZeneca Canada Inc. 25,242. [Clinical Trials]
2015 Nov - 2023 Jun	<b>Site Principal Investigator.</b> Atomic Retrospective Study 01-02AT18 [Investigator-Initiated Study]. The Academic Thoracic Oncology Medical Investigators Consortium. 26,854. [Grants] <i>To study real world data in ALK patients.</i>
2015 Jul - 2025 Mar	<b>Site Principal Investigator.</b> Phase III CROWN Trial of Lorlatinib vs Crizotinib in Firstline ALK Positive Lung Cancer. Pfizer Canada Inc. 47,343. [Clinical Trials] <i>To compare lorlatinib vs crizotinib in ALK + metastatic NSCLC.</i>
2015 Jul - 2023 Jan	<b>Site Principal Investigator.</b> Phase II Study of Frontline Atezolizumab in Patients with Non Small Cell Lung Cancer who do not Tolerate Platinum Chemotherapy. Hoffmann-la Roche Limited, Canada. 63,252. [Clinical Trials] <i>To study role of atezolizumab in PS2 patients.</i>
2015 - 2024 Dec	<b>Site Principal Investigator.</b> Phase Ib/II study of Lorlatinib in ALK-positive Non-Small Cell Lung Cancer. Pfizer, Inc. 46,353. [Clinical Trials] <i>To study the role of lorlatinib in ALK+ patients.</i>
2015 - 2023 Feb	<b>Site Principal Investigator.</b> A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib. Takeda Pharmaceuticals Inc. 55,736. [Clinical Trials] <i>To study role of brigatinib in ALK+ patients.</i>
2015 - 2020	<b>Principal Site Investigator.</b> LDK378 for ALK-activated Non-Small Cell Lung Cancer with Brain Cancer. Novartis Pharma Canada Inc. 52,780. [Clinical Trials]
2015 - 2019	<b>Principal Site Investigator.</b> LDK378 and Nivolumab for ALK-activated Non-Small Cell Lung Cancer. Novartis Pharma Canada Inc. [Clinical Trials]
2014 - 2016	<b>Principal Site Investigator.</b> LDK378 in Crizotinib naïve Adult Patients with ALK-activated Non-small Cell Lung Cancer: Phase III. Novartis Pharma Canada Inc. [Clinical Trials]
2014 - 2016	<b>Principal Site Investigator.</b> Denosumab (AMGEN) with Chemotherapy in first line NSCLC patients: Phase II trial. Amgen Canada Inc (Mississauga, ON). Clinical Trials Group. [Clinical Trials]
2014 - 2016	<b>Principal Site Investigator.</b> ASTEX trial in NSCLC patients: Phase II trial. Astex Therapeutics Ltd. [Clinical Trials]
2014 - 2015	<b>Principal Site Investigator.</b> Novel agent in squamous cell (ABBVIE) lung cancer. Abbvie Pharmaceutical. Clinical Trials Group. [Clinical Trials]

2013 - 2015	<b>Principal Site Investigator.</b> LDK378 in Adult patients with ALK-activated NSCLC previously treated with chemotherapy and crizotinib: Phase II. Novartis Pharma Canada Inc. [Clinical Trials]
2013 - 2015	<b>Principal Site Investigator.</b> LDK378 in Crizotinib and Chemotherapy treated patients with ALK-activated NSCLC: Phase II. Novartis Pharma Canada Inc. [Clinical Trials]
2011 Jul - 2013 Jun	<b>Principal Investigator.</b> Somalogic Mesothelioma Biomarkers Study. Somalogic, Inc. 63,000 CAD. [Industrial Grants]
2011 - 2014	<b>Principal Site Investigator.</b> A Phase I, multicenter, open label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK). Novartis Pharma Canada Inc. Clinical Trials Group. [Clinical Trials]
2009 Dec - 2014	<b>Principal Site Investigator.</b> A Double Blind Placebo Controlled Randomized Trial of PF-00299804 (PF-804) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease (BR.26). National Cancer Institute of Canada (NCIC). Clinical Trials Group. [Clinical Trials]
2009 - 2020 Dec	<b>Principal Investigator.</b> Posluns Family Fund. PMH Foundation. 105,000 CAD. [Grants]
2008 Mar - 2009 Nov	<b>Principal Investigator.</b> A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib (NCIC Clinical Trials Group PI) MARVEL study or NCIC CTG BRC.4. National Cancer Institute of Canada (NCIC). [Clinical Trials] <i>Overall Canadian and Correlative Studies PI.</i>
2007 - 2009	<b>Principal Site Investigator.</b> Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing erlotinib or gefitinib (1200.23). Boehringer Ingelheim Canada Ltd./Ltée. [Clinical Trials]
2007 - 2009	<b>Principal Site Investigator.</b> A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin-based chemotherapy (gemcitabine or paclitaxel) (BO21015). F. Hoffmann-LA Roche Ltd. [Clinical Trials]
2006 Sep - 2008 Apr	<b>Principal Site Investigator.</b> A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Amgen. [Clinical Trials]
2006 - 2020 Dec	<b>Principal Investigator.</b> Personalized Medicine in Lung Cancer. Alan B. Brown Chair. PMH Foundation. 840,000 CAD. [Grants] <i>To support the Clinical Outcomes Studies of the International Lung Cancer Consortium.</i>

## E. Publications

### 1. MOST SIGNIFICANT PUBLICATIONS

1. Aline F Fares, Yao Li, Mei Jiang, M Catherine Brown, Andrew C L Lam, Reenika Aggarwal, Sabine Schmid, Natasha B Leighl, Frances A Shepherd, Zhichao Wang, Nancy Diao, Angela S Wenzlaff, Juntao Xie, Takashi Kohno, Neil E Caporaso, Curtis Harris, Hongxia Ma, Matthew J Barnett, Leticia Ferro Leal, G Fernandez-Tardon, Mónica Pérez-Ríos, Michael P A Davies, Fiona Taylor, Ben Schöttker, Paul Brennan, David Zaridze, Ivana Holcatova, Jolanta Lissowska, Beata Świątkowska, Dana Mates, Milan Savic, Hermann Brenner, Angeline Andrew, Angela Cox, John K Field, Alberto Ruano-Ravina, Sanjay S Shete, Adonina Tardon, Ying Wang, Loic Le Marchand, Rui Manuel Reis, Matthew B Schabath, Chu Chen, Hongbing Shen, Brid M Ryan, Maria Teresa Landi, Kouya Shiraishi, Jie Zhang, Ann G Schwartz, Ming S Tsao, David C Christiani, Ping Yang, Rayjean J Hung, Wei Xu, **Geoffrey Liu**. Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies. The Lancet Public Health. 2023 Sep;8(9):e691-e700. Impact Factor 50. **Senior Responsible Author. Supervising AFF, YL, MCB, ACCLL, RA, SS.**

*This study demonstrated that quitting smoking can improve lung cancer survival, across all stages, if lung cancer were to be discovered one year later at the next lung cancer screening timepoint. These results have clinical impact on the messaging to active smokers receiving lung cancer screening.*

2. García-Pardo M, Chang A, Schmid S, Dong M, Brown MC, Christiani D, Tindel HA, Brennan P, Chen C, Zhang J, Ryan BM, Zaridze D, Schabath MB, Leal LF, Reis RM, Tardon A, Fernández-Tardon G, Shete SS, Andrew A, Brenner H, Xu W, Hung RJ, **Liu G**. Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium. J Thorac Oncol. 2023 Mar;18(3):313-323. Impact Factor 20.4. **Senior Responsible Author. Supervising M G-P, AC, SS, MD, CMB.**

*This study demonstrated the comorbidities impact on lung cancer survival in different ways: respiratory comorbidities affect lung cancer mortality, while cardiovascular comorbidities affect non-lung cancer related mortality. An editorial accompanied the publication of this manuscript.*

3. Lee JJW, Kunaratnam V, Kim CJH, Pienkowski M, Hueniken K, Sahoalier A, Lam ACL, Davies JC, Brown CM, De Almeida JR, Huang SH, Waldron JN, Spreafico A, Hung RJ, Xu W, Goldstein DP, **Liu G**. Cigarette smoking cessation, duration of smoking abstinence, and head and neck squamous cell carcinoma prognosis. Cancer. 2023 Mar;129(6):897-877. Epub 2023 Jan 18. Impact Factor 6.921. **Senior Responsible Author. Supervising MP, KH, ACLL, CMB.**

*We demonstrated that quitting smoking improves survival of head and neck cancer patients, especially the longer the period of smoking cessation. This has clinical implications of smoking cessation counselling.*

4. Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, **Liu G**. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer. 2022 Dec;174:146-156. Impact Factor 5.3. **Senior Responsible Author.**

*This is the first analysis of quality of life in the treatment changing CROWN trial of lorlatinib versus crizotinib for first line treatment of metastatic ALK-positive non-small cell lung cancer.*

5. Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, **Liu G**. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. Lung Cancer. 2020 Aug;146:78-85. Impact Factor 5.3. **Co-Senior Responsible Author. Supervising RS, SNMF, AF.**

*This study identified specific resistance pathways for ALK mutated lung cancer after pharmacologic treatment using tyrosine kinase inhibitors, utilizing a patient derived xenograft model.*

6. Lam AC, Aggarwal R, Huang J, Varadi R, Davis L, Tsao MS, Shepherd FA, Lam S, Kavanagh J, **Liu G**. Point-Of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening. *Am J Respir Crit Care Med*. 2020 Jul 16;202(10):1473-1477. Impact Factor 30.528. **Senior Responsible Author. Supervised ACL, RA.**

*This publication provides data to support point-of-care spirometry to improve the selection of patients for lung cancer screening.*

7. Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, Leighl NB, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, **Liu G**. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. *Lung Cancer*. 2020 Jul;145:144-151. Impact Factor 5.3. **Co-Senior Responsible Author. Supervising SNMF, AF, ELS, DP.**

*This study identified primary derived xenograft factors of engraftment in EGFR-mutated lung cancer post-treatment models.*

8. Ren J, Xu W, Su J, Ren X, Cheng D, Chen Z, Bender N, Mirshams M, Habbous S, de Almeida JR, Perez-Ordenez B, Goldstein DP, Wang JR, Bratman SV, Huang SH, Jang R, Zhao Y, Waterboer T, Hung RJ, **Liu G**. Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. *Int J Cancer*. 2020 Apr 15;146(8):2166-2174. Impact Factor 7.316. **Senior Responsible Author. Supervising JR, DC, ZC, MM, SH.**

*This study utilized multiple imputation models to predict missing HPV status in older epidemiological studies.*

9. Ren J, Yang W, Su J, Ren X, Fazelzad R, Albert T, Habbous S, Goldstein DP, de Almeida JR, Hansen A, Jang R, Bratman SV, Hope A, Chen R, Wang J, Xu Y, Cheng D, Zhao Y, Xu W, **Liu G**. Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. *Int J Cancer*. 2019 Sep 15;145(6):1465-1474. Impact Factor 7.316. **Senior Responsible Author. Supervising JR, WY, RF, SH, DC.**

*This study utilized our Princess Margaret Head and Neck Translational Study data, demonstrating the importance of HPV p16 staining in unknown primary cancers in the head and neck cancer region.*

10. Shepshelovich D, Xu W, Lu L, Fares A, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz AG, Tardon A, Schabath MB, Teare MD, Le Marchand L, Zhang ZF, Field JK, Brenner H, Diao N, Xie J, Kohno T, Harris CC, Wenzlaff AS, Fernandez-Tardon G, Ye Y, Taylor F, Wilkens LR, Davies M, Liu Y, Barnett MJ, Goodman GE, Morgenstern H, Holleczeck B, Brown MC, **Liu G**, Hung RJ. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. *J Thorac Oncol*. 2019 Sep;14(9):1594-1607. Impact Factor 20.4. **Co-Senior Responsible Author. Supervising DS, LL, AF, MCB.**

*This is the first publication of the Clinical Outcomes Studies of the International Lung Cancer Consortium (COS-ILCCO), where the coordinating centre is at Princess Margaret Cancer Centre (G Liu is the lead coordinator and data management group). The consortium now has over 35,000 patients across 24 studies harmonized in its database, and at the time of publication of this manuscript, ~25,000 cases had been harmonized over 16 studies for this particular analysis. Additional analyses are also listed as part of the most significant publications.*

11. Aggarwal R, Lam ACL, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, **Liu G**, Kavanagh J. Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts. *J Thorac Oncol*. 2019 Jun;14(6):1003-1011. Epub 2019 Feb 13. Impact Factor 20.4. **Co-Senior Responsible Author. Supervising RA, ACLL, KH, HT.**

*This manuscript demonstrates that lung cancer screening by low dose CT scan can be stratified by the underlying risk stratification process into different risk cohorts. The clinical impact is to demonstrate that continued screening after 4-5.5 years is still relevant, especially when using a risk stratification model.*

12. Kavanagh J, **Liu G**, Menezes R, O'Kane GM, McGregor M, Tsao M, Shepherd FA, Schmidt H. Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening. Radiology. 2018 Oct;289(1):218-224. Epub 2018 Jul 10. Impact Factor 29.146. **Co-Principal Author supervising GMO'K and MG.**

*1. The only long-term follow-up study of lung cancer screening by CT scan after a gap in screening of over 5 years that shows the importance of continued longitudinal screening. The NELSON and NLST randomized trials had screening periods of only 3-4 years. 2. Demonstrates the impact of Lung-CALIBRE. Impact on discipline: Currently the Canadian recommendations for screening are for only three annual screens in participants who are between the ages of 50 and 74 years of age. These data has re-opened the (Canadian) national discussion to consider screening over additional years.*

## 2. PEER-REVIEWED PUBLICATIONS

### Journal Articles

1. Bhavsar Amit, **Liu Geoffrey**, et al. TLR4 Downregulation Protects Against Cisplatin-Induced Ototoxicity in Adult and Pediatric Cancer Patients. Journal of Pharmacology and Experimental Therapeutics. 2025 Feb;392(2):100057. In Press. **Coauthor or Collaborator.**
2. Li Y, Law J, Le LW, Li JJN, Pettengell C, Demarco P, Duong M, Merritt D, Davidson S, Sung M, Li Q, Lau SC, Zahir S, Chu R, Ryan M, Karim K, Morganstein J, Sacher A, Eng L, Shepherd FA, Bradbury P, **Liu G**, Leighl NB. Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients. Lung Cancer. 2025 Jan;199:108080. In Press. **Coauthor or Collaborator.**
3. Melosky B, Juergens RA, Banerji S, Sacher A, Wheatley-Price P, Snow S, Tsao MS, Leighl NB, Martins I, Cheema P, **Liu G**, Chu QSC. The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer. Ther Adv Med Oncol. 2025 Jan. In Press. **Coauthor or Collaborator.**
4. **G. Liu**, S. Huang, L. Ailles, K. Rey-McIntyre, C. Melton, S. Shen, J. Burgener, B. Brown, J. Zhang, J. Min, Y. Wang, O. Hall, J.T. Jones, K. Budhreja, J. Provance, E. Sosa, A. Licon, A. Williams, S. Bratman, B. Allen, J. Zhang, A.-R. Hartman, D. De Carvalho. Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies. Annals of Oncology. 2025 Jan;36(1):108-117. **First Listed Author.**
5. Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, **Liu G**, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70049. In Press. **Coauthor or Collaborator.**
6. Ghazali N, Feng J, Hueniken K, Khan K, Balaratnam K, Waddell TK, Yasufuku K, Pierre A, Donahoe L, Wakeam E, Cypel M, Yeung J, Keshavjee S, de Perrot M, Leighl NB, **Liu G**, Bradbury PA, Sacher A, Eng L, Stockley T, Tsao MS, Shepherd FA. Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations. Ther Adv Med Oncol. 2024 Dec;16:17588359241308466. **Coauthor or Collaborator.**
7. Abdulrahman Alghabban, Lucy Corke, Hans Katzberg, Vera Bril, Carolina Barnett-Tapia, Warren Mason, Raed Alothman, Abdul Razak Albiruni Ryan, David Hogg, Srikala Sridhar, Neesha Dhani, Anna Spreafico, Lawson Eng, Adrian Sacher, Penelope Bradbury, **Geoffrey Liu**, Natasha Leighl, Frances A. Shepherd. Myasthenia gravis in patients treated with immune checkpoint inhibitors. JTO Clinical and Research Reports. 2024 Nov. In Press. **Coauthor or Collaborator.**

8. Blechter B, Wang X, Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, Kim YT, Choudhury PP, Williams J, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Li S, Zhang T, Breeze C, Wang Z, Bassig BA, Kim JH, Albanes D, Wong JY, Shin MH, Chung LP, Yang Y, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Man Ho JC, Kubo M, Daigo Y, Song M, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood HD, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Ohe Y, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Dai H, Machiela MJ, Su J, Kim YH, Oh IJ, Fun Lee VH, Chang GC, Tsai YH, Che KY, Huang MS, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Chen KC, Gao YT, Qian B, Wu C, Lu D, Liu J, et. al. Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers. medRxiv. 2024 Nov. In Press. **Coauthor or Collaborator**.
9. Murison KR, Warkentin MT, Khodayari Moez E, Brhane Y, **Liu G**, Hung RJ. Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations. Ann Am Thorac Soc. 2024 Nov. In Press. **Coauthor or Collaborator**.
10. Samir Barghout, Nicholas Meti, Simren Chotai, Christina Kim, Devalben Patel, M. Brown, Katrina Hueniken, Luna Zhan, Stavroula Raptis, Faisal Al-Agha, Christopher Deutschman, Benjamin Grant, Martha Pienkowski, Patrick Moriarty, John de Almeida, David Goldstein, Scott Bratman, Frances Shepherd, Ming-Sound Tsao, Andrew Freedman, Wei Xu, and **Geoffrey Liu**. Adaptive Universal Principles for Real-world Observational Studies (AUPROS): An approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology research. British Journal of Cancer. 2024 Nov. In Press. **Senior Responsible Author**.
11. Stalker M, Grady CB, Watts A, Hwang WT, Chandrasekhara K, Sun F, **Liu G**, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Bravo Montenegro GL, Tompkins W, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Sun L, Marmarelis ME. Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis. JTO Clin Res Rep. 2024 Nov;6(1):100765. **Coauthor or Collaborator**.
12. Pastorino R, Pires Marafon D, Lentini N, Hoxhaj I, Grossi A, Giraldi L, Rondinò A, Cadoni G, Polesel J, Serraino D, La Vecchia C, Garavello W, Canova C, Richiardi L, Lissowska J, Pandics T, Dudding T, Ness A, Thomas S, Pring M, Kelsey K, McClean M, Bradshaw P, Zhang ZF, Morgenstern H, Rozek L, Wolf G, Olshan A, **Liu G**, Hung R, Vilensky M, Brasilino de Carvalho M, Mendonza López RV, Wunsch-Filho V, Boffetta P, Hashibe M, Amy Lee YC, Boccia S. The effect of body mass index at diagnosis on survival of patients with squamous cell head and neck carcinoma. Am J Cancer Res. 2024 Nov;14(11):5411-5426. **Coauthor or Collaborator**.
13. Bauman JR, **Liu G**, Preeshagul I, Liu SV, Melosky B, Abrahami D, Li B, Thomaidou D, Duncan K, Krulewicz S, Rupp M, Lin JJ. Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. Lung Cancer. 2024 Nov;197:108000. **Coauthor or Collaborator**.
14. Sabine Schmid; Luna Zhan; Miguel Garcia; Kristen Dietrich; Khaleeq Khan; Maisha Chowdhury; Michael Herman; Devalben Patel; Fatemeh Zaeimi; Natasha B. Leighl; Adrian Sacher; Ronald Feld; Frances A. Shepherd; Laura Donahoe; Marc de Perrot; B.C. John Cho; **Geoffrey Liu**; Penelope A. Bradbury. Immediate versus deferred systemic therapy in patients with mesothelioma. Clinical Lung Cancer. 2024 Nov;25(7):e277-e285. **Coauthor or Collaborator**.
15. Solomon BJ, **Liu G**, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer. Future Oncol. 2024 Oct. In Press. **Coauthor or Collaborator**.
16. Solomon BJ, **Liu G**, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024 Oct;42(29):3400-3409. **Coauthor or Collaborator**.

17. Toffalorio, Francesca; Solomon Ben; **Liu, Geoffrey**; Enriqueta Felip; MOK Shu Kam, Tony; Soo, Ross; Mazieres, Julien; Shaw, Alice; De Marinis, Filippo; Yasushi, Goto; Wu, Yi-Long; Martini, Jean-Francois; Messina, Rossella; Paolini, Iolanda; Polli, Anna; Thomaidou, Despina; Todd, Bauer. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. *Journal of Clinical Oncology*. 2024 Oct;42(29):3400-3409. **Coauthor or Collaborator**.
18. **Liu G**, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM. A pragmatic guide for management of adverse events associated with lorlatinib. *Lung Cancer*. 2024 Oct;191:107535. **Coauthor or Collaborator**.
19. Cheema PK, Syed I, Gwadry-Sridhar F, Rakibuz-Zaman M, Sachdeva R, Pencz A, Zhan L, Hueniken K, Patel D, Balaratnam K, Khan K, Grant B, Sheffield BS, Locke MEO, Moldaver D, Shanahan MK, **Liu G**, Kuruvilla MS. Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study. *Curr Oncol*. 2024 Oct;31(11):6735-6748. **Coauthor or Collaborator**.
20. Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. *J Clin Oncol*. 2024 Sep. In Press. **Coauthor or Collaborator**.
21. John Lee, Abhinav Thakral, Tianzhichao Hou, Katrina Hueniken, Tom Dudding, Mark Gormley, Shama Virani, Andrew Olshan, Brenda Diergaarde, Andrew Ness, Tim Waterboer, Karl Smith-Byrne, Paul Brennan, D Hayes, Eleanor Sanderson, M. Catherine Brown, Sophie Huang, Scott Bratman, Anna Spreafico, John de Almeida, Joel Davies, Laura Bierut, Gary Macfarlane, Pagona Lagiou, Areti Lagiou, Jerry Polesel, Antonio Agudo, Laia Alemany, Wolfgang Ahrens, Claire Healy, David Conway, Mari Nygård, Cristina Canova, Ivana Holcatova, Lorenzo Richiardi, Ariana Znaor, David Goldstein, Rayjean Hung, Wei Xu, **Geoffrey Liu**, and Osvaldo Espin-Garcia. Smoking and Alcohol by HPV Status in Head and Neck Cancer A Mendelian Randomization Study. *Nature Communications*. 2024 Sep;15(1):7835. **Senior Responsible Author**.
22. Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooks C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaff JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2024 Sep;404(10459):1240-1252. **Coauthor or Collaborator**.
23. Bauman JR, **Liu G**, Preeshagul I, Liu SV, Melosky B, Abrahami D, Li B, Thomaidou D, Duncan K, Krulwicz S, Rupp M, Lin JJ. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer. *Lung Cancer*. 2024 Sep;195:107919. **Coauthor or Collaborator**.
24. Gill RR, Nowak AK, Giroux DJ, Eisele M, Rosenthal A, Kindler H, Wolf A, Ripley RT, Billé A, Rice D, Opitz I, Rimner A, dePerrot M, Pass HI, Rusch VW; IASLC Staging and Prognostic Factors Committee; Advisory Boards and Participating Institution. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. *J Thorac Oncol*. 2024 Sep;19(24):1310-1325. **Coauthor or Collaborator**.
25. Kuang S, Chen K, Sayal S, Prabahan G, Rabey MR, Le LW, Seto A, Shepherd FA, **Liu G**, Bradbury P, Sacher AG, Law JH, Sabatini P, Stockley TL, Tsao MS, Leighl NB. Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience. *Curr Oncol*. 2024 Aug;31(8):4476-4485. In Press. **Coauthor or Collaborator**.



26. William Tompkins, Connor B. Grady, Wei-Ting Hwang, Krishna Chandrasekhara, Caroline McCoach, Fangdi Sun, **Geoffrey Liu**, Devalben Patel, Jorge Nieva, Amanda Herrmann, Kristen Marrone, Vincent K. Lam, Vamsi Velcheti, Stephen V. Liu, Gabriela Liliana Bravo Montenegro, Tejas Patil, Jared Weiss, Kelsey Leigh Miller, William Schwartzman, Jonathan E. Dowell, Khvaramze Shaverdashvili, Liza Villaruz, Amanda Cass, PharmD, Wade Iams, Dara Aisner, Charu Aggarwal, D. Ross Camidge, Melina E. Marmarelis, Lova Sun. Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC. JTO Clinical and Research Reports. 2024 Aug;5(8):100669. **Coauthor or Collaborator.**
27. Rosenberger A, Bickeböllner H, Christiani DC, **Liu G**, Schabath MB, Duarte LF, Le Marchand L, Haiman C, Landi T, Consonni D, Field JK, Davies MPA, Albanes D, Tardón A, Fernández-Tardón G, Rennert G, Amos CI, Hung RJ. On the informative value of community-based indoor radon values in relation to lung cancer. Cancer Med. 2024 Aug;13(16):e70126. **Coauthor or Collaborator.**
28. Torres S, Bayoumi AM, Abrahao ABK, Trudeau M, Pritchard KI, Li CN, Mitsakakis N, **Liu G**, Krahn M. Implementing routine collection of EQ-5D-5L in a breast cancer outpatient clinic. PLoS One. 2024 Aug;19(8):e0307225. **Coauthor or Collaborator.**
29. Duinkerken CW, Chiodo S, Hueniken K, Hauptmann M, Jóźwiak K, Cheng D, Hope A, **Liu G**, Zuur CL. The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy. Cancer Med. 2024 Aug;13(16):e7465. **Coauthor or Collaborator.**
30. Barghout SH, Zhan LJ, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, Kasymjanova G, Proulx-Rocray F, Chan SWS, Richardson M, Brown MC, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Goldshtein D, Cleary-Gosine J, Gibson AJ, Hubley L, Balaratnam K, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd FA, Leigh N, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, **Liu G**, Snow S. Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study. Lung Cancer. 2024 Aug;194:107898. **Senior Responsible Author.**
31. Schmid S, Garcia M, Zhan L, Cheng S, Khan K, Chowdhury M, Sabouhanian A, Herman J, Walia P, Strom E, Brown MC, Patel D, Xu W, Shepherd FA, Sacher AG, Leigh NB, Bradbury PA, **Liu G**, Shultz D. Outcomes with non-small cell lung cancer and brain-only metastasis. Heliyon. 2024 Aug;10(7):e37082. **Senior Responsible Author.**
32. Ul-Haq S, Downs G, Zhan LJ, Schmid S, Patel D, Sacdalan D, Li JJN, Cheng D, Meti N, Philip V, Kim RH, **Liu G**, Bratman SV, Sabatini PJB, Lok BH. Identifying Novel Germline Mutations and Copy Number Variations in Patients With SCLC. JTO Clin Res Rep. 2024 Jul;5(12):100702. **Coauthor or Collaborator.**
33. Frank C Detterbeck, Marcin Ostrowski, Hans Hoffmann, Ramón Rami-Porta, Ray U Osarogiagbon, Jessica Donnington, Maurizio Infante, Mirella Marino, Edith M Marom, Jun Nakajima, Andrew G Nicholson, Paul van Schil, William D Travis, Ming S Tsao, John G Edwards, Hisao Asamura; Members of the Staging and Prognostic Factors Committee and Advisory Boards. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2024 Jul;19(7):1052-1072. **Coauthor or Collaborator.**
34. Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, **Liu G**, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 Jul;80(1):87-101. **Coauthor or Collaborator.**
35. Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ; Princess Margaret Lung Group; Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, **Liu G**, Aldrich MC, Schoenfeld AJ, Ziv E. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. medRxiv. 2024 Jun. In Press. **Coauthor or Collaborator.**

36. Seung SJ, Moldaver D, Hassan S, Syed I, Shanahan M, **Liu G**. Correction: Real-World Treatment Patterns and Survival Among Patients with Stage I-III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment. *Oncol Ther*. 2024 Jun;12(2):311-326. **Senior Responsible Author**.
37. Gray C, Ralphs E, Fox MP, Lash TL, **Liu G**, Kou TD, Rivera DR, Bosco J, Braun KVN, Grimson F, Layton D. Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls. *Pharmacoepidemiol Drug Saf*. 2024 May;33(5):e5796. **Coauthor or Collaborator**.
38. Detterbeck FC, Ostrowski M, Hoffmann H, Rami-Porta R, Osarogiagbon RU, Donnington J, Infante M, Marino M, Marom EM, Nakajima J, Nicholson AG, van Schil P, Travis WD, Tsao MS, Edwards JG, Asamura H; Members of the Staging and Prognostic Factors Committee and Advisory Boards. The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9th) Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol*. 2024 Apr;S1556-0864(24):00129-1. In Press. **Coauthor or Collaborator**.
39. Rao Y, Qiu K, Song Y, Mao M, Feng L, Cheng D, Li J, Zhang Z, Zhang Y, Shao X, Pang W, Wang Y, Chen X, Jiang C, Wu S, Yu S, Liu J, Wang H, Peng X, Yang L, Chen L, Mu X, Zheng Y, Xu W, **Liu G**, Chen F, Yu H, Zhao Y, Ren J. The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma. *iScience*. 2024 Apr;27(5):109668. **Coauthor or Collaborator**.
40. Moulson R, Law J, Sacher A, **Liu G**, Shepherd FA, Bradbury P, Eng L, Iczkovitz S, Abbie E, Elia-Pacitti J, Ewara EM, Mokriak V, Weiss J, Pettengell C, Leighl NB. Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence. *Curr Oncol*. 2024 Apr;31(4):1947-1960. **Coauthor or Collaborator**.
41. David J Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel SB Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, **Geoffrey Liu**, Alan Kaplan, Silvana Spadafora, Shaun Goodman, Rebecca Craufurd Auer, Gerald Batist. New anticancer drugs: reliably assessing “value” while addressing high prices. *Current Oncology*. 2024 Apr;31(5):2453-2480. **Coauthor or Collaborator**.
42. Pooja Middha, Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A. Bejan, Eduardo Cardenas, Christina J. Falcon, David M. Faleck, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Douglas B. Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M. Lovly, Megan H. Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M. Balko, **Geoffrey Liu**, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. *Nat Commun*. 2024 Mar;15(1):2568. **Coauthor or Collaborator**.
43. Zhao X, Yang M, Fan J, Wang M, Wang Y, Qin N, Zhu M, Jiang Y, Gorlova OY, Gorlov IP, Albanes D, Lam S, Tardón A, Chen C, Goodman GE, Bojesen SE, Landi MT, Johansson M, Risch A, Wichmann HE, Bickeböllner H, Christiani DC, Rennert G, Arnold SM, Brennan P, Field JK, Shete S, Le Marchand L, **Liu G**, Hung RJ, Andrew AS, Kiemeny LA, Zienolddiny S, Grankvist K, Johansson M, Caporaso NE, Woll PJ, Lazarus P, Schabath MB, Aldrich MC, Patel AV, Davies MPA, Ma H, Jin G, Hu Z, Amos CI, Shen H, Dai J. Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls. *Cancer*. 2024 Mar;130(6):913-926. **Coauthor or Collaborator**.
44. Li Y, Xiao X, Li J, Han Y, Cheng C, Fernandes GF, Slewitzke SE, Rosenberg SM, Zhu M, Byun J, Bossé Y, McKay JD, Albanes D, Lam S, Tardón A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböllner H, Wichmann HE, Christiani DC, Rennert G, Arnold SM, Goodman GE, Field JK, Davies MPA, Shete S, Le Marchand L, **Liu G**, Hung RJ, Andrew AS, Kiemeny LA, Sun R, Zienolddiny S, Grankvist K, Johansson M, Caporaso NE, Cox A, Hong YC, Lazarus P, Schabath MB, Aldrich MC, Schwartz AG, Gorlov I, Purrington KS, Yang P, Liu Y, Bailey-Wilson JE, Pinney SM, Mandal D, Willey JC, Gaba C, Brennan P, Xia J, Shen H, Amos CI. Lung cancer in ever- and never-smokers: findings from multi-population GWAS studies. *Cancer Epidemiol Biomarkers Prev*. 2024 Mar;33(3):389-399. **Coauthor or Collaborator**.
45. Warkentin MT, Al-Sawaihey H, Lam S, **Liu G**, Diergaarde B, Yuan JM, Wilson DO, Atkar-Khattra S, Grant B, Brhane Y, Khodayari-Moez E, Murison KR, Tammemagi MC, Campbell KR, Hung RJ. Radiomics analysis to predict pulmonary nodule malignancy using machine learning approaches. *Thorax*. 2024 Mar;79(4):307-315. **Coauthor or Collaborator**.

46. Stewart DJ, Ramsay T, Navani V, **Liu G**, Jiang DM, Batist G. Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies. *J Clin Oncol*. 2024 Mar;42(8):973-974. **Coauthor or Collaborator**.
47. Du M, Xin J, Zheng R, Yuan Q, Wang Z, Liu H, Liu H, Cai G, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböllér H, Wichmann HE, Rennert G, Arnold S, Brennan P, Field JK, Shete SS, Le Marchand L, **Liu G**, Andrew AS, Kiemeny LA, Zienolddiny S, Grankvist K, Johansson M, Caporaso NE, Cox A, Hong YC, Yuan JM, Schabath MB, Aldrich MC, Wang M, Shen H, Chen F, Zhang Z, Hung RJ, Amos CI, Wei Q, Lazarus P, Christiani DC. CYP2A6 activity and cigarette consumption interact in smoking-related lung cancer susceptibility. *Cancer Res*. 2024 Feb;84(4):616-625. **Coauthor or Collaborator**.
48. Xinan Wang, Ziwei Zhang, Yi Ding, Tony Chen, Lorelei Mucci, Demetrios Albanes, Maria Teresa Landi, Neil E. Caporaso, Stephen Lam, Adonina Tardon, Chu Chen, Stig E. Bojesen, Mattias Johansson, Angela Risch, Heike Bickeböllér, H-Erich Wichmann, Gadi Rennert, Susanne Arnold, Paul Brennan, James D. McKay, John K. Field, Sanjay S. Shete, Loic Le Marchand, **Geoffrey Liu**, Angeline S. Andrew, Lambertus A. Kiemeny, Shan Zienolddiny-Narui, Annelie Behndig, Mikael Johansson, Angie Cox, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Rayjean J. Hung, Christopher I. Amos, Xihong Lin & David C. Christiani. Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification. *Genome Medicine*. 2024 Feb;16(1):22. **Coauthor or Collaborator**.
49. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfield C, Nagasaka M, Filip E, Yang N, Velcheti V, Lu S, Kao S, Doms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2024 Jan;390(2):118-131. **Coauthor or Collaborator**.
50. Kusters JMA, Diergaarde B, Ness A, Schim van der Loeff MF, Heijne JCM, Schroeder L, Hueniken K, McKay JD, Macfarlane GJ, Lagiou P, Lagiou A, Polesel J, Agudo A, Alemany L, Ahrens W, Healy CM, Conway DI, Robinson M, Canova C, Holcátová I, Richiardi L, Znaor A, Pring M, Thomas S, Hayes DN, **Liu G**, Hung RJ, Brennan P, Olshan AF, Virani S, Waterboer T. Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex. *Int J Cancer*. 2024 Jan;154(2):389-402. **Coauthor or Collaborator**.
51. Zhang Y, Li J, Feng L, Luo Y, Pang W, Qiu K, Mao M, Song Y, Cheng D, Rao Y, Wang X, Hu Y, Ying Z, Pu X, Lin S, Huang S, **Liu G**, Zhang W, Xu W, Zhao Y, Ren J. A Population-Based Outcome-Wide Association Study of the Comorbidities and Sequelae Following COVID-19 Infection. *J Epidemiol Glob Health*. 2023 Dec;13(4):870-885. **Coauthor or Collaborator**.
52. Di Maria Jiang, Shruti Parshad, Luna Zhan, Hao-Wen Sim, Lillian L. Siu, **Geoffrey Liu**, Jeremy D. Shapiro, Timothy J. Price, Derek J. Jonker, Christos S. Karapetis, Andrew H. Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe Sabesan, Jenny Shannon, Amanda Townsend, Chris J. O'Callaghan, Eric X. Chen. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. *Clinical Colorectal Cancer*. 2023 Dec;22(4):457-463. **Coauthor or Collaborator**.
53. Chen KH, Barnes TA, Laskin J, Cheema P, **Liu G**, Iqbal M, Rothenstein J, Burkes R, Tsao MS, Leighl NB. The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing-Patient's Willingness-to-Pay: A Brief Report. *JTO Clin Res Rep*. 2023 Nov;5(1):100615. **Coauthor or Collaborator**.
54. Esfahanian N, Chan SWS, Zhan LJ, Brown MC, Khan K, Lee J, Balaratnam K, Yan E, Parker J, Garcia-Pardo M, Barghout SH, Eng L, Bradbury PA, Shepherd FA, Leighl NB, Sacher AG, Snow S, Juergens R, **Liu G**. Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. *Cancer Treat Res Commun*. 2023 Nov;37:100774. **Senior Responsible Author**.
55. Herman M, Lok BH, Gallinger S, Dawson L, Kim R, Cheng D, Paton T, Bucur R, Patel D, Fazelzad R, Hueniken K, **Liu G**. Analysis of prognostic germline polymorphisms in patients with advanced hepatocellular carcinoma. *Transl Gastroenterol Hepatol*. 2023 Oct;8:32. **Senior Responsible Author**.

56. Naderi E, Aguado-Barrera ME, Schack LMH, Dorling L, Rattay T, Fachal L, Summersgill H, Martínez-Calvo L, Welsh C, Dudding T, Odding Y, Varela-Pazos A, Jena R, Thomson DJ, Steenbakkers RJHM, Dennis J, Lobato-Busto R, Alsner J, Ness A, Nutting C, Gómez-Caamaño A, Eriksen JG, Thomas SJ, Bates AM, Webb AJ, Choudhury A, Rosenstein BS, Taboada-Valladares B, Herskind C, Azria D, Dearnaley DP, de Ruyscher D, Sperk E, Hall E, Stobart H, Chang-Claude J, De Ruyck K, Veldeman L, Altabas M, De Santis MC, Farcy-Jacquet MP, Veldwijk MR, Sydes MR, Parliament M, Usmani N, Burnet NG, Seibold P, Symonds RP, Elliott RM, Bultijnck R, Gutiérrez-Enríquez S, Mollà M, Gulliford SL, Green S, Rancati T, Reyes V, Carballo A, Peleteiro P, Sosa-Fajardo P, Parker C, Fonteyne V, Johnson K, Lambrecht M, Vanneste B, Valdagni R, Giraldo A, Ramos M, Diergaarde B, **Liu G**, Leal SM, Chua MLK, Pring M, Overgaard J, Cascallar-Caneda LM, Duprez F, Talbot CJ, Barnett GC, Dunning AM, Vega A, Andreassen CN, Langendijk JA, et al. Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. *JNCI Cancer Spectr.* 2023 Oct;7(6):pkad088. **Coauthor or Collaborator.**
57. Pooja Middha, Rohit Thummalapalli , Michael J Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A Bejan , Eduardo Cardenas, Christina J Falcon, David M Faleck; Princess Margaret Lung Group; Matthew A Gubens, Scott Huntsman, Douglas B Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M Lovly, Megan H Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M Balko, **Geoffrey Liu**, Melinda C Aldrich, Adam J Schoenfeld, Elad Ziv. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. *medRxiv.* 2023 Sep. In Press. **Coauthor or Collaborator.**
58. Nafees A, Khan M, Chow R, Fazelzad R, Hope A, **Liu G**, Letourneau D, Raman S. Evaluation of clinical decision support systems in oncology: An updated systematic review. *Crit Rev Oncol Hematol.* 2023 Sep;192:104143. **Coauthor or Collaborator.**
59. Xu J, Xu W, Choi J, Brhane Y, Christiani DC, Kothari J, McKay J, Field JK, Davies MPA, **Liu G**, Amos CI, Hung RJ, Briollais L. Large-scale whole exome sequencing studies identify two genes, CTSL and APOE, associated with lung cancer. *PLoS Genet.* 2023 Sep;19(2):e1010902. **Coauthor or Collaborator.**
60. Luyapan J, Bossé Y, Li Z, Xiao X, Rosenberger A, Hung RJ, Lam S, Zienolddiny S, **Liu G**, Kiemeny LA, Chen C, McKay J, Johansson M, Johansson M, Tardon A, Fernandez-Tardon G, Brennan P, Field JK, Davies MP, Woll PJ, Cox A, Taylor F, Arnold SM, Lazarus P, Grankvist K, Landi MT, Christiani DC, MacKenzie TA, Amos CI. Candidate pathway analysis of surfactant proteins identifies CTSH and SFTA2 that influences lung cancer risk. *Hum Mol Genet.* 2023 Sep;32(18):2842-2855. **Coauthor or Collaborator.**
61. Aline F Fares, Yao Li, Mei Jiang, M Catherine Brown, Andrew C L Lam, Reenika Aggarwal, Sabine Schmid, Natasha B Leighl, Frances A Shepherd, Zhichao Wang, Nancy Diao, Angela S Wenzlaff, Juntao Xie, Takashi Kohno, Neil E Caporaso, Curtis Harris, Hongxia Ma, Matthew J Barnett, Leticia Ferro Leal, G Fernandez-Tardon, Mónica Pérez-Ríos, Michael P A Davies, Fiona Taylor, Ben Schöttker, Paul Brennan, David Zaridze, Ivana Holcatova, Jolanta Lissowska, Beata Świątkowska, Dana Mates, Milan Savic, Hermann Brenner, Angeline Andrew, Angela Cox, John K Field, Alberto Ruano-Ravina, Sanjay S Shete, Adonina Tardon, Ying Wang, Loic Le Marchand, Rui Manuel Reis, Matthew B Schabath, Chu Chen, Hongbing Shen, Brid M Ryan, Maria Teresa Landi, Kouya Shiraishi, Jie Zhang, Ann G Schwartz, Ming S Tsao, David C Christiani, Ping Yang, Rayjean J Hung, Wei Xu, **Geoffrey Liu**. Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies. *The Lancet Public Health.* 2023 Sep;8(9):e691-e700. Impact Factor 50. **Senior Responsible Author. Supervising AFF, YL, MCB, ACCLL, RA, SS.**
62. Deng Y, Tu D, O'Callaghan CJ, **Liu G**, Xu W. Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions. *Stat Methods Med Res.* 2023 Aug;32(8):1543-1558. **Coauthor or Collaborator.**
63. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. *N Engl J Med.* 2023 Aug;389(6):491-503. **Coauthor or Collaborator.**
64. Chih-Hsin Yang J, **Liu G**, Lu S, He J, Burotto M, Ahn MJ, Kim DW, Liu X, Zhao Y, Vincent S, Yin J, Ma X, Lin HM, Popat S. Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. *J Thorac Oncol.* 2023 Aug;S1556-0864(23):00730-X. **Coauthor or Collaborator.**

65. Lau SCM, Perdrizet K, Fung AS, Mata DGMM, Weiss J, Holzapfel N, **Liu G**, Bradbury PA, Shepherd FA, Sacher AG, Feilotter H, Sheffield B, Hwang D, Tsao MS, Cheng S, Cheema P, Leighl NB. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies. *JTO Clin Res Rep*. 2023 Aug;4(10):100562. **Coauthor or Collaborator**.
66. Cheng C, Hong W, Li Y, Xiao X, McKay J, Han Y, Byun J, Peng B, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböllner H, Wichmann HE, Christiani DC, Rennert G, Arnold S, Goodman G, Field JK, Davies MP, Shete SS, Le Marchand L, **Liu G**, Hung RJ, Andrew AS, Kiemeny LA, Zhu M, Shen H, Zienoldiny S, Grankvist K, Johansson M, Cox A, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Brennan P, Li Y, Gorlova O, Gorlov I, Amos CI; INTEGRAL-ILCCO lung cancer consortium. Mosaic Chromosomal Alterations Are Associated With Increased Lung Cancer Risk: Insight From the INTEGRAL-ILCCO Cohort Analysis. *J Thorac Oncol*. 2023 Aug;18(8):1003-1016. **Coauthor or Collaborator**.
67. Siow Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz Kowalski, Aleksandra Szczesna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano, Diego Cortinovis, Anh Tuan Le, Dingzhi Huang, **Geoffrey Liu**, Federico Cappuzzo, Jessica Reyes Contreras, Martin Reck, Ramon Palmero, Milena Perez Mak, Youyou Hu, Stefanie Morris, Elen Högländer, Mary Connors, Alice M Biggane, Hans Kristian Volla, Solange Peters. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. *The Lancet*. 2023 Aug;402(10400):451-463. **Coauthor or Collaborator**.
68. Duncan, Kirsten; Lam, Vincent; **Liu, Geoffrey**; Pfizer Lung CS Team CT; Whann, Beth; Kelton, John Mark; Sidrah Qureshi. Podcast on Lorlatinib as a First-Line Treatment Option for Patients With ALK-Positive Metastatic NSCLC With Brain Metastasis. *Advances in Therapy*. 2023 Aug;40(10):4117-4126. Review Article. **Coauthor or Collaborator**.
69. Zeuge U, Fares AF, Soriano J, Hueniken K, Bajwa J, Wang W, Schmid S, Rudolph-Naiberg S, Brown MC, Yeung J, Chen EX, Jang RW, Xu W, Elimova E, **Liu G**, Rozenberg D, McInnis MC. Differential prognostic significance of sarcopenia in metastatic esophageal squamous and adenocarcinoma. *Esophagus*. 2023 Jul;20(3):557-566. **Co-Senior Responsible Author supervising UZ, ATF, KH, SS and MCB**.
70. Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, **Liu G**. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. *Curr Oncol*. 2023 Jul;30(7):6559-6574. **Senior Responsible Author**.
71. García-Pardo M, Czarnicka-Kujawa K, Law JH, Salvarrey AM, Fernandes R, Fan ZJ, Waddell TK, Yasufuku K, **Liu G**, Donahoe LL, Pierre A, Le LW, Gunasegaran T, Ghuman N, Shepherd FA, Bradbury PA, Sacher AG, Schmid S, Corke L, Feng J, Stockley T, Pal P, Rogalla P, Pipinikas C, Howarth K, Ambasager B, Mezquita L, Tsao MS, Leighl NB. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial. *JAMA Netw Open*. 2023 Jul;6(7):e2325332. **Coauthor or Collaborator**.
72. Alnajjar S, Idiaquez Rios JF, Fathi D, **Liu G**, Bril V. Gastrointestinal Dysmotility as the First Manifestation of Myasthenia Gravis. *Can J Neurol Sci*. 2023 Jul;50(4):640-641. **Coauthor or Collaborator**.
73. Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, Powis ML, **Liu G**, Peppercorn JM, Bedard PL, Krzyzanowska MK. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. *J Clin Oncol*. 2023 Jun;41(17):3122-3134. **Coauthor or Collaborator**.
74. Elham Khodayari Moez, Yonathan Brhane, Matthew Warkentin, Stephen Lam, John K Field, **Geoffrey Liu**, Luis M Montuenga, Javier J Zulueta, Karmele Valencia, Miguel Mesa-Guzman, Sukhinder Atkar-Khattra, Michael PA Davies, Benjamin Grant, Andrea Pasquier Niolet, Christopher I Amos, Hilary A Robbins, Mattias Johansson, Rayjean J Hung. Circulating Proteome for Pulmonary Nodule Malignancy. *Journal of the National Cancer Institute*. 2023 Jun;115(9):1060–1070. **Coauthor or Collaborator**.

75. Zimmermann C, Pope A, Hannon B, Bedard PL, Rodin G, Dhani N, Li M, Herx L, Krzyzanowska MK, Howell D, Knox JJ, Leigh NB, Sridhar S, Oza AM, Lheureux S, Booth CM, **Liu G**, Castro JA, Swami N, Sue-A-Quan R, Rydall A, Le LW. Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study. *Support Care Cancer*. 2023 Jun;31(7):404. **Coauthor or Collaborator**.
76. Lindström S, Wang L, Feng H, Majumdar A, Huo S, Macdonald J, Harrison T, Turman C, Chen H, Mancuso N, Bammler T; Breast Cancer Association Consortium (BCAC); Gallinger S, Gruber SB, Gunter MJ, Le Marchand L, Moreno V, Offit K; Colorectal Transdisciplinary Study (CORECT), Colon Cancer Family Registry Study (CCFR), Genetics And Epidemiology Of Colorectal Cancer Consortium (GECCO); de Vivo I, O'Mara TA, Spurdle AB, Tomlinson I; Endometrial Cancer Association Consortium (ECAC); Fitzgerald R, Gharahkhani P, Gockel I, Jankowski J, Macgregor S, Schumacher J, Barnholtz-Sloan J, Bondy ML, Houlston RS, Jenkins RB, Melin B, Wrensch M, Brennan P, Christiani D, Johansson M, McKay J, Aldrich MC, Amos CI, Landi MT, Tardon A; International Lung Cancer Consortium (ILCCO); Bishop DT, Demenais F, Goldstein AM, Iles MM, Kanetsky PA, Law MH; Ovarian Cancer Association Consortium (OCAC); Amundadottir LT, Stolzenberg-Solomon R, Wolpin BM; Pancreatic Cancer Cohort Consortium (Pancscan); Klein A, Petersen G, R. Genome-Wide Analyses Characterize Shared Heritability Among Cancers and Identify Novel Cancer Susceptibility Regions. *J Natl Cancer Inst*. 2023 Jun;115(6):712-732. **Coauthor or Collaborator**.
77. Sun A, Abdulkarim B, Blais N, Greenland J, Louie AV, Melosky B, Schellenberg D, Snow S, **Liu G**. Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations. *Lung Cancer*. 2023 May;179:107166. **Senior Responsible Author**.
78. Middha P, Thummalapalli R, Betti MJ, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Faleck DM; Princess Margaret Lung Group; Gubens MA, Huntsman S, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Zhan LJ, **Liu G**, Aldrich MC, Schoenfeld AJ, Ziv E. Genetic prediction of colitis in non-small cell lung cancer patients on immune checkpoint inhibitor therapy. *medRxiv*. 2023 May. In Press. **Coauthor or Collaborator**.
79. Solomon BJ, Bauer TM, K Mok TS, **Liu G**, Mazieres J, Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer. *Future Oncol*. 2023 May;19(14):961-973. Review Article. **Coauthor or Collaborator**.
80. de Oliveira Faria S, Hueniken K, Kunaratnam V, Hui Huang S, Goldstein D, Ringash J, Pun J, Hope A, Spreafico A, Xu W, Howell D, **Liu G**. Associations between Human Papillomavirus Status, Weight Change, and Survival of Oropharyngeal Cancer Patients. *Nutr Cancer*. 2023 May;75(7):1541-1550. **Senior Responsible Author**.
81. Budhathoki S, Diergaarde B, **Liu G**, Olshan A, Ness A, Waterboer T, Virani S, Basta P, Bender N, Brenner N, Dudding T, Hayes N, Hope A, Huang SH, Hueniken K, Kanterewicz B, McKay JD, Pring M, Thomas S, Wisniewski K, Thomas S, Brhane Y, Agudo A, Alemany L, Lagiou A, Barzan L, Canova C, Conway DI, Healy CM, Holcatova I, Lagiou P, Macfarlane GJ, Macfarlane TV, Polesel J, Richiardi L, Robinson M, Znaor A, Brennan P, Hung RJ. A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers. *Int J Cancer*. 2023 May;152(10):2069-2080. **Coauthor or Collaborator**.
82. Jianxin S, Kouya S, Jiyeon C, Keitaro M, Tzu-Yu C, Juncheng D, Rayjean H, Kexin C, Xiao-Ou S, Young T, Maria T, Dongxin L, Wei Z, Zhihua Y, Baosen Zhou, Bao Song, Jiucun Wang, Wei Jie Seow, Lei Song, I-Shou Chang, Wei Hu, Li-Hsin Chien, Qiuyin Cai, Yun-Chul Hong, Hee Nam Kim, Yi-Long Wu, Maria Wong, Brian Douglas Richardson, Karen Funderburk, Shilan Li, Tongwu Zhang, Charles Breeze, Zhaoming Wang, Batel Blechter, Bryan Bassig, Jin Hee Kim, Demetrius Albanes, Jason Wong, Min-Ho Shin, Lap Ping Chung, Yang Yang, Shejuan AN, Hong Zheng, Yasushi Yatabe, Xuchao Zhang, Young-Chul Kim, Neil Caporaso, Jiang Chang, James Chung Man Ho, Michiaki Kubo, Yataro Daigo, Minsun Song, Yukihide Momozawa, Yoichiro Kamatani, Masashi Kobayashi, Kenichi Ohkubo, Takayuki Honda, **Geoffrey Liu**, et al. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. *Nature Communications*. 2023 May;14(1):3043. **Coauthor or Collaborator**.
83. Chow R, Midroni J, Kaur J, Boldt G, **Liu G**, Eng L, Liu FF, Haibe-Kains B, Lock M, Raman S. Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2023 Apr;115(4):365-374. **Coauthor or Collaborator**.

84. Benjamin J Solomon, Todd M Bauer, Tony S K Mok, **Geoffrey Liu**, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylán López López, Ross A Soo, Alice T Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. *The Lancet Respiratory Medicine*. 2023 Apr;11(4):354-366. **Coauthor or Collaborator**.
85. Andreas Halner, Luke Hankey, Zhu Liang, Francesco Pozzetti, Daniel Szulc, Ella Mi, **Geoffrey Liu**, Benedikt Kessler, Junetha Syed, Peter Jianrui Liu. DEcancer: Machine Learning Framework Tailored to Liquid Biopsy Based Cancer Detection and Biomarker Signature Selection. *iScience*. 2023 Apr;26(5):106610. **Coauthor or Collaborator**.
86. Moghal N, Li Q, Stewart EL, Navab R, Mikubo M, D'Arcangelo E, Martins-Filho SN, Raghavan V, Pham NA, Li M, Shepherd FA, **Liu G**, Tsao MS. Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model. *J Thorac Oncol*. 2023 Apr;18(4):499-515. **Coauthor or Collaborator**.
87. García-Pardo M, Chang A, Schmid S, Dong M, Brown MC, Christiani D, Tindel HA, Brennan P, Chen C, Zhang J, Ryan BM, Zaridze D, Schabath MB, Leal LF, Reis RM, Tardon A, Fernández-Tardon G, Shete SS, Andrew A, Brenner H, Xu W, Hung RJ, **Liu G**. Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium. *J Thorac Oncol*. 2023 Mar;18(3):313-323. Impact Factor 20.4. **Senior Responsible Author. Supervising M G-P, AC, SS, MD, CMB**.
88. Zhang Y, Grant BMM, Hope AJ, Hung RJ, Warkentin MT, Lam ACL, Aggawal R, Xu M, Shepherd FA, Tsao MS, Xu W, Pakkal M, **Liu G**, McInnis MC. Using Recurrent Neural Networks to Extract High-Quality Information From Lung Cancer Screening Computerized Tomography Reports for Inter-Radiologist Audit and Feedback Quality Improvement. *JCO Clin Cancer Inform*. 2023 Mar;7:e2200153. **Co-Senior Responsible Author supervising YZ, BMMG, ACLL, and RA**.
89. Deng Y, Tu D, O'Callaghan CJ, Jonker DJ, Karapetis CS, Shapiro J, **Liu G**, Xu W. A Bayesian approach for two-stage multivariate Mendelian randomization with mixed outcomes. *Stat Med*. 2023 Mar;42(13):2241-2256. **Coauthor or Collaborator**.
90. Song Y, Cheng D, Yi X, Rao Y, Qiu K, Mao M, Pang W, Li J, Zheng Y, Feng R, Song X, Huang S, **Liu G**, Xu W, Zhao Y, Ren J. The role of HPV status in patients with overlapping grey zone cancer in oral cavity and oropharynx. *Eur Arch Otorhinolaryngol*. 2023 Mar;280(3):1455-1465. **Coauthor or Collaborator**.
91. Zhang J, Kong W, Hu P, Jonker D, Moore M, Ringash J, Shapiro J, Zalcberg J, Simes J, Tu D, O'Callaghan CJ, **Liu G**, Xu W. Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial. *Cancer Med*. 2023 Mar;12(5):6117-6128. **Coauthor or Collaborator**.
92. Lee JJW, Kunaratnam V, Kim CJH, Pienkowski M, Hueniken K, Sahovaler A, Lam ACL, Davies JC, Brown CM, De Almeida JR, Huang SH, Waldron JN, Spreafico A, Hung RJ, Xu W, Goldstein DP, **Liu G**. Cigarette smoking cessation, duration of smoking abstinence, and head and neck squamous cell carcinoma prognosis. *Cancer*. 2023 Mar;129(6):897-877. Epub 2023 Jan 18. Impact Factor 6.921. **Senior Responsible Author. Supervising MP, KH, ACLL, CMB**.
93. Moradian S, Maguire R, **Liu G**, Krzyzanowska MK, Butler M, Cheung C, Signorile M, Gregorio N, Ghasemi S, Howell D. Promoting Self-management and Patient Activation Through eHealth: Protocol for a Systematic Literature Review and Meta-analysis. *JMIR Res Protoc*. 2023 Mar;12:e38758. **Coauthor or Collaborator**.
94. Cheng D, Qiu K, Rao Y, Mao M, Li L, Wang Y, Song Y, Chen J, Yi X, Shao X, Huang SH, Zhang Y, Chen X, Wu S, Yu S, Liu J, Wang H, Peng X, Li D, Yang L, Chen L, Ying Z, Zheng Y, Zheng M, Ying B, Zeng X, Zhang W, Xu W, **Liu G**, Chen F, Yu H, Zhao Y, Ren J. Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma. *Elife*. 2023 Feb;12:e82705. **Coauthor or Collaborator**.
95. Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, **Liu G**, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. *Future Oncol*. 2023 Jan;19(2):123-135. Review Article. **Coauthor or Collaborator**.

96. Mirhadi S, Zhang W, Pham NA, Karimzadeh F, Pintilie M, Tong J, Taylor P, Krieger J, Pitcher B, Sykes J, Wybenga-Groot L, Fladd C, Xu J, Wang T, Cabanero M, Li M, Weiss J, Sakashita S, Zaslaver O, Yu M, Caudy AA, St-Pierre J, Hawkins C, Kislinger T, **Liu G**, Shepherd FA, Tsao MS, Moran MF. Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer. *Mol Cancer Res*. 2023 Jan;21(1):36-50. **Coauthor or Collaborator**.
97. Schmid S, Cheng S, Chotai S, Garcia M, Zhan L, Hueniken K, Balaratnam K, Khan K, Patel D, Grant B, Raptis R, Brown MC, Xu W, Moriarty P, Shepherd FA, Sacher AG, Leighl NB, Bradbury PA, **Liu G**. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2023 Jan;24(1):40-50. **Senior Responsible Author**.
98. Robbins HA, Alcala K, Moez EK, Guida F, Thomas S, Zahed H, Warkentin MT, Smith-Byrne K, Brhane Y, Muller D, Feng X, Albanes D, Aldrich MC, Arslan AA, Bassett J, Berg CD, Cai Q, Chen C, Davies MPA, Diergaarde B, Field JK, Freedman ND, Huang WY, Johansson M, Jones M, Koh WP, Lam S, Lan Q, Langhammer A, Liao LM, **Liu G**, Malekzadeh R, Milne RL, Montuenga LM, Rohan T, Sesso HD, Severi G, Sheikh M, Sinha R, Shu XO, Stevens VL, Tammemägi MC, Tinker LF, Visvanathan K, Wang Y, Wang R, Weinstein SJ, White E, Wilson D, Yuan JM, Zhang X, Zheng W, Amos CI, Brennan P, Johansson M, Hung RJ. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program. *Ann Epidemiol*. 2023 Jan;77:1-12. **Coauthor or Collaborator**.
99. Noel CW, Hueniken K, Forner D, **Liu G**, Eng L, Hosni A, Hahn E, Irish JC, Gilbert R, Yao CMKL, Monteiro E, O'Sullivan B, Waldron J, Huang SH, Goldstein DP, de Almeida JR. Association of Household Income at Diagnosis With Financial Toxicity, Health Utility, and Survival in Patients With Head and Neck Cancer. *JAMA Otolaryngology – Head and Neck Surgery*. 2023 Jan;179(1):63-70. **Coauthor or Collaborator**.
100. Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, Tony Mok, Fabrice Barlesi, Caicun Zhou, Enriqueta Felip, Filippo de Marinis, Sang-We Kim, Maurice Pérol, **Geoffrey Liu**, Maria Rita Migliorino, Dong-Wan Kim, Silvia Novello, Alessandra Bearz, Pilar Garrido, Julien Mazieres, Alessandro Morabito, Huamao M. Lin, Hui Yang, Huifeng Niu, Pingkuan Zhang, Edward S. Kim. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigatinib-2 (ALTA-2). *Journal of Thoracic Oncology*. 2022 Dec;17(12):1404-1414. **Coauthor or Collaborator**.
101. Warkentin MT, Tammemägi MC, Espin-Garcia O, Budhathoki S, **Liu G**, Hung RJ. Lung Cancer Absolute Risk Models for Mortality in an Asian Population using the China Kadoorie Biobank. *J Natl Cancer Inst*. 2022 Dec;114(12):1665-1673. **Coauthor or Collaborator**.
102. Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, **Liu G**. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. *Lung Cancer*. 2022 Dec;174:146-156. Impact Factor 5.3. **Senior Responsible Author**.
103. Eng, L; Brual, J; Nagee, A; Mok, S; Fazelzad, R; Chaiton, M; Saunders, D P; Mittmann, N; Truscott, R; **Liu, G**; Bradbury, P A; Evans, W K; Papadakos, J; Giuliani, M E. Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. *ESMO Open*. 2022 Dec;7(6):100605. Review Article. **Coauthor or Collaborator**.
104. Danielle Lilly Nicholls, Maria Xu, Lanujan Kaneswaran, Benjamin Grant, M. Catherine Brown, Jeremy Shapiro, Christos S. Karapetis, John Simes, Derek Jonker, Dongsheng Tu, Christopher O'Callaghan, **Geoffrey Liu**. Assessment of Successful Randomization Through a Machine Learning and Visualization Tool for Pre-treatment Symptoms: Examples from CCTG/AGITG CO.17 and CO.20 Trials. *International Information and Engineering Technology Association*. 2022 Dec;36(6):913-918. **Senior Responsible Author**.
105. Weiss J, Pham NA, Pintilie M, Li M, **Liu G**, Shepherd FA, Tsao MS, Xu W. Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts. *Cancer Inform*. 2022 Nov;21:11769351221136056. **Coauthor or Collaborator**.
106. UI Haq S, Schmid S, Aparnathi MK, Hueniken K, Zhan LJ, Sacdalan D, Li JJN, Meti N, Patel D, Cheng D, Philip V, Tsao MS, Cabanero M, de Carvalho D, **Liu G**, Bratman SV, Lok BH. Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction. *iScience*. 2022 Nov;25(12):105487. **Coauthor or Collaborator**.



107. Sara Kuruvilla M\*, **Liu G\***, Syed I, Gwadry-Sridhar F, Sheffield BS, Sachdeva R, Pencz A, Zhan L, Hueniken K, Patel D, Balarathnam K, Khan K, Grant B, Noy S, Singh K, Liu L, Rakibuz-Zaman M, Moldaver D, Kate Shanahan M, Cheema PK. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. *Lung Cancer*. 2022 Nov;173:58-66. **Co-Principal Author**.
108. Haddad G, Hueniken K, Xu MC, Bratman S, de Almeida J, Goldstein D, Huang SH, Hansen A, Hope A, Spreafico A, Xu W, **Liu G**. Association of post-treatment longitudinal symptom severity clusters with subsequent survival in oropharyngeal cancer. *Head Neck*. 2022 Oct;44(10):2181-2196. **Senior Responsible Author**.
109. Garcia-Pardo M, Czarnecka K, Law JH, Salvarrey A, Fernandes R, Fan J, Corke L, Waddell TK, Yasufuku K, Donahoe LL, Pierre A, Le LW, Ghumman N, **Liu G**, Shepherd FA, Bradbury P, Sacher A, Stockley T, Pal P, Rogalla P, Tsao MS, Leighl NB. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. *Ther Adv Med Oncol*. 2022 Sep;14:17588359221126151. **Coauthor or Collaborator**.
110. Lau SCM, Rabindranath M, Weiss J, Li JJN, Fung AS, Mullen D, Alshamlan N, Ruff HM, Tong LCB, Pal P, Cabanero MR, Hsu YR, Sacher AG, Shepherd FA, **Liu G**, Bradbury PA, Yasufuku K, Czarnecka-Kujawa K, Mi Ko H, Tsao MS, Leighl NB, Schwock J. PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC. *Lung Cancer*. 2022 Sep;171:42-46. **Coauthor or Collaborator**.
111. **Liu G**, Cheung WY, Feilotter H, Manthorne J, Stockley T, Yeung M, Renouf DJ. Precision Oncology in Canada: Converting Vision to Reality with Lessons from International Programs. *Curr Oncol*. 2022 Sep;29(10):7257-7271. Review Article. **Primary Author**.
112. Wang X, Gharahkhani P, Levine DM, Fitzgerald RC, Gockel I, Corley DA, Risch HA, Bernstein L, Chow WH, Onstad L, Shaheen NJ, Lagergren J, Hardie LJ, Wu AH, Pharoah PDP, **Liu G**, Anderson LA, Iyer PG, Gammon MD, Caldas C, Ye W, Barr H, Moayyedi P, Harrison R, Watson RGP, Attwood S, Chegwiddden L, Love SB, MacDonald D, deCaestecker J, Prenen H, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weismüller J, Reeh M, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Tomlinson I, Palles C, Jankowski JA, Whiteman DC, MacGregor S, Schumacher J, Vaughan TL, Buas MF, Dai JY. eQTL Set-Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma. *Cancer Epidemiol Biomarkers Prev*. 2022 Sep;31(9):1735-1745. **Coauthor or Collaborator**.
113. Byun J, Han Y, Li Y, Xia J, Long E, Choi J, Xiao X, Zhu M, Zhou W, Sun R, Bossé Y, Song Z, Schwartz A, Lusk C, Rafnar T, Stefansson K, Zhang T, Zhao W, Pettit RW, Liu Y, Li X, Zhou H, Walsh KM, Gorlov I, Gorlova O, Zhu D, Rosenberg SM, Pinney S, Bailey-Wilson JE, Mandal D, de Andrade M, Gaba C, Willey JC, You M, Anderson M, Wiencke JK, Albanes D, Lam S, Tardon A, Chen C, Goodman G, Bojeson S, Brenner H, Landi MT, Chanock SJ, Johansson M, Muley T, Risch A, Wichmann HE, Bickeböllner H, Christiani DC, Rennert G, Arnold S, Field JK, Shete S, Le Marchand L, Melander O, Brunnstrom H, **Liu G**, Andrew AS, Kiemeny LA, Shen H, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Cox A, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Patel A, Lan Q, Rothman N, Taylor F, Kachuri L, Witte JS, Sakoda LC, Spitz M, Brennan P, Lin X, McKay J, Hung RJ, Amos CI. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. *Nat Genet*. 2022 Aug;54(8):1167-1177. **Coauthor or Collaborator**.
114. Li Y, Xiao X, Li J, Byun J, Cheng C, Bossé Y, McKay J, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböllner H, Wichmann HE, Christiani DC, Rennert G, Arnold S, Goodman G, Field JK, Davies MPA, Shete SS, Le Marchand L, Melander O, Brunnström H, **Liu G**, Hung RJ, Andrew AS, Kiemeny LA, Shen H, Sun R, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Teare DM, Hong YC, Lazarus P, Schabath MB, Aldrich MC, Schwartz AG, Gorlov I, Purrington K, Yang P, Liu Y, Han Y, Bailey-Wilson JE, Pinney SM, Mandal D, Willey JC, Gaba C, Brennan P, Amos CI; INTEGRAL-ILCCO lung cancer consortium. Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. *Hum Mol Genet*. 2022 Aug;31(16):2831-2843. **Coauthor or Collaborator**.
115. Soo RA, Huat Tan E, Hayashi H, Seto T, Lin CC, Ignatius Ou SH, Kim DW, **Liu G**, Abbattista A, Martini JF, Hooi Wong C, Toffalorio F, Solomon BJ. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. *Lung Cancer*. 2022 Jul;169:67-76. **Coauthor or Collaborator**.

116. Solomon BJ, Bauer TM, Ignatius Ou SH, **Liu G**, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. *J Clin Oncol*. 2022 Jul;40(31):3593-3602. **Coauthor or Collaborator**.
117. Khan MN, Hueniken K, Manojlovic-Kolarski M, Eng L, Mirshams M, Khan K, Simpson C, Au M, **Liu G**, Xu W, Longo CJ, Goldstein DP, Ringash J, Martino R, Hansen AR, de Almeida JR. Out-of-pocket costs associated with head and neck cancer treatment. *Cancer Rep (Hoboken)*. 2022 Jul;5(7):e1528. **Coauthor or Collaborator**.
118. Kuang S, Fung AS, Perdrizet KA, Chen K, Li JJN, Le LW, Cabanero M, Karsaneh OAA, Tsao MS, Morganstein J, Ranich L, Smith AC, Wei C, Cheung C, Shepherd FA, **Liu G**, Bradbury P, Pal P, Schwock J, Sacher AG, Law JH, Stockley TL, Leighl NB. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. *Curr Oncol*. 2022 Jun;29(7):4428-4437. **Coauthor or Collaborator**.
119. Gauthier MP, Law JH, Le LW, Li JJN, Zahir S, Nirmalakumar S, Sung M, Pettengell C, Aviv S, Chu R, Sacher A, **Liu G**, Bradbury P, Shepherd FA, Leighl NB. Automating Access to Real-World Evidence. *JTO Clin Res Rep*. 2022 May;3(6):100340. **Coauthor or Collaborator**.
120. Zhang R, Shen S, Wei Y, Zhu Y, Li Y, Chen J, Guan J, Pan Z, Wang Y, Zhu M, Xie J, Xiao X, Zhu D, Li Y, Albanes D, Landi MT, Caporaso N, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeboller H, Wichmann HE, Rennert G, Arnold S, Brennan P, McKay J, Field JK, Shete SS, Le Marchand L, **Liu G**, Andrew A, Kiemeny LA, Zienolddiny-Narui S, Behndig A, Johansson M, Cox A, Lazarus P, Schabath MB, Aldrich MC, Dai J, Ma H, Zhao Y, Hu Z, Hung RJ, Amos CI, Shen H, Chen F, Christiani DC. A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians. *J Thorac Oncol*. 2022 Apr;17(8):974-990. **Coauthor or Collaborator**.
121. Mirhadi S, Tam S, Li Q, Moghal N, Pham NA, Tong J, Golbourn BJ, Krieger JR, Taylor P, Li M, Weiss J, Martins-Filho SN, Raghavan V, Mamatjan Y, Khan AA, Cabanero M, Sakashita S, Huo K, Agnihotri S, Ishizawa K, Waddell TK, Zadeh G, Yasufuku K, **Liu G**, Shepherd FA, Moran MF, Tsao MS. Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. *Nat Commun*. 2022 Apr;13(1):1811. **Coauthor or Collaborator**.
122. Zimmermann C, Pope A, Hannon B, Krzyzanowska MK, Rodin G, Li M, Howell D, Knox JJ, Leighl NB, Sridhar S, Oza AM, Prince R, Lheureux S, Hansen AR, Rydall A, Chow B, Herx L, Booth CM, Dudgeon D, Dhani N, **Liu G**, Bedard PL, Mathews J, Swami N, Le LW. Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer. *J Natl Compr Canc Netw*. 2022 Apr;20(4):361-370. **Coauthor or Collaborator**.
123. Qin N, Li Y, Wang C, Zhu M, Dai J, Hong T, Albanes D, Lam S, Tardon A, Chen C, Goodman G, Bojesen SE, Landi MT, Johansson M, Risch A, Wichmann HE, Bickeboller H, Rennert G, Arnold S, Brennan P, Field JK, Shete S, Le Marchand L, Melander O, Brunnstrom H, **Liu G**, Hung RJ, Andrew A, Kiemeny LA, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Woll P, Lazarus P, Schabath MB, Aldrich MC, Stevens VL, Jin G, Christiani DC, Hu Z, Amos CI, Ma H, Shen H. Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. *Front Med*. 2022 Apr;15(2):275-291. **Coauthor or Collaborator**.
124. Schmid S, Jiang M, Brown MC, Fares A, Garcia M, Soriano J, Dong M, Thomas S, Kohno T, Ferro Leal L, Diao N, Xie J, Wang Z, Zaridze D, Holcatova I, Lissowska J, Świątkowska B, Mates D, Savic M, Wenzlaff AS, Harris CC, Caporaso NE, Ma H, Fernandez-Tardon G, Barnett MJ, Goodman GE, Davies MPA, Pérez-Ríos M, Taylor F, Duell EJ, Schoettker B, Brenner H, Andrew A, Cox A, Ruano-Ravina A, Field JK, Le Marchand L, Wang Y, Chen C, Tardon A, Shete S, Schabath MB, Shen H, Landi MT, Ryan BM, Schwartz AG, Qi L, Sakoda LC, Brennan P, Yang P, Zhang J, Christiani DC, Reis RM, Shiraishi K, Hung RJ, Xu W, **Liu G**. Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data. *Cancer Epidemiol Biomarkers Prev*. 2022 Mar;31(3):679-687. **Senior Responsible Author**.
125. Schmid S, Garcia M, Cheng S, Zhan L, Chotai S, Balaratnam K, Khan K, Patel D, Catherine Brown M, Sachdeva R, Xu W, Shepherd FA, Sacher A, Leighl NB, Bradbury P, Moriarty P, Sara Kuruvilla M, **Liu G**. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. *Lung Cancer*. 2022 Feb;166:58-62. **Senior Responsible Author**.

126. Perdrizet K, Stockley TL, Law JH, Smith A, Zhang T, Fernandes R, Shabir M, Sabatini P, Youssef NA, Ishu C, Li JJ, Tsao MS, Pal P, Cabanero M, Schwock J, Ko HM, Boerner S, Ruff H, Shepherd FA, Bradbury PA, **Liu G**, Sacher AG, Leighl NB. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. *Cancer Treat Res Commun*. 2022 Feb;31:100534. **Coauthor or Collaborator**.
127. Majeed S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, Rahman F, Song L, Weiss J, Barayan R, Sugumar V, Barghout SH, Pearson JD, Bremner R, Schimmer AD, Tsao MS, **Liu G**, Lok BH. Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer. *Clin Cancer Res*. 2022 Feb;28(9):1966-1978. **Coauthor or Collaborator**.
128. Ren J, Pang W, Hueniken K, Haddad G, Hope A, Huang SH, Spreafico A, Hansen AR, Perez-Ordóñez B, Goldstein DP, Bratman SV, Zhang W, Zhao Y, Xu W, de Almeida JR, **Liu G**. Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. *Cancer*. 2022 Feb;128(3):497-508. **Senior Responsible Author**.
129. Stinchcombe TE, Wang X, Doebele RC, Drusbosky LM, Gerber DE, Horn L, Bertino EM, **Liu G**, Villaruz LC, Ross Camidge D. Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA. *Lung Cancer*. 2022 Jan;165:43-48. **Coauthor or Collaborator**.
130. Gormley M, Dudding T, Kachuri L, Burrows K, Chong AHW, Martin RM, Thomas SJ, Tyrrell J, Ness AR, Brennan P, Munafò MR, Pring M, Boccia S, Olshan AF, Diergaarde B, Hung RJ, **Liu G**, Tajara EH, Severino P, Toporcov TN, Lacko M, Waterboer T, Brenner N, Smith GD, Vincent EE, Richmond RC. Investigating the effect of sexual behaviour on oropharyngeal cancer risk: a methodological assessment of Mendelian randomization. *BMC Med*. 2022 Jan;20(1):40. **Coauthor or Collaborator**.
131. Rosenberger A, Muttray N, Hung RJ, Christiani DC, Caporaso NE, **Liu G**, Bojesen SE, Le Marchand L, Albanes D, Aldrich MC, Tardon A, Fernández-Tardón G, Rennert G, Field JK, Davies MPA, Liloglou T, Kiemeny LA, Lazarus P, Wendel B, Haugen A, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Duell EJ, Arnold SM, Goodman GE, Chen C, Doherty JA, Taylor F, Cox A, Woll PJ, Risch A, Muley TR, Johansson M, Brennan P, Landi MT, Shete SS, Amos CI, Bickeböller H; INTEGRAL-ILCCO Consortium. Gene-gene interaction of AhR with and within the Wnt cascade affects susceptibility to lung cancer. *Eur J Med Res*. 2022 Jan;27(1):14. **Coauthor or Collaborator**.
132. Schmid S, Zhan L, Dietrich K, Khan K, Chowdhury M, Herman M, Patel D, Zaeimi F, Leighl NB, Sacher A, Feld R, Shepherd FA, Donahoe L, de Perrot M, Cho BCJ, **Liu G**, Bradbury PA. Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. e43-e53. 2022 Jan;23(1):Clin Lung Cancer. **Co-Senior Responsible Author funding Dr. Schmid, Ms. Zhan, Dr. Herman, Ms. Patel and methodological approach (Dr. Bradbury was content SRA)**.
133. Sung MR, Tomasini P, Le LW, Kamel-Reid S, Tsao MS, **Liu G**, Bradbury PA, Shepherd FA, Li JJN, Feld R, Leighl NB. Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. *JTO Clin Res Rep*. 2021 Dec;3(2):100259. **Coauthor or Collaborator**.
134. Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, **Liu G**, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Shaw AT. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. *Future Oncol*. 2021 Dec;17(34):4649-4656. Review Article. **Coauthor or Collaborator**.
135. Popat S, **Liu G**, Lu S, Song G, Ma X, Yang JC. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). *Future Oncol*. 2021 Nov;17(32):4237-4247. Review Article. **Coauthor or Collaborator**.
136. Lau SCM, Ryan M, Weiss J, Fares AF, Garcia M, Schmid S, Kuang S, Kelly D, Tsao MS, Bradbury PA, Cho BCJ, Sun A, Raman S, Hope A, Giuliani M, Lok BH, Bezjak A, **Liu G**, Leighl NB, Shepherd FA, Sacher AG. Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy. *JTO Clin Res Rep*. 2021 Nov;2(12):100251. **Coauthor or Collaborator**.

137. Zazuli Z, de Jong C, Xu W, Vijverberg SJH, Masereeuw R, Patel D, Mirshams M, Khan K, Cheng D, Ordonez-Perez B, Huang S, Spreafico A, Hansen AR, Goldstein DP, de Almeida JR, Bratman SV, Hope A, Knox JJ, Wong RKS, Darling GE, Kitchlu A, van Haarlem SWA, van der Meer F, van Lindert ASR, Ten Heuvel A, Brouwer J, Ross CJD, Carleton BC, Egberts TCG, Herder GJM, Deneer VHM, Maitland-van der Zee AH, **Liu G**. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. *J Pers Med*. 2021 Nov;11(11):1233. **Senior Responsible Author**.
138. Jain A, Huang R, Lee J, Jawa N, Lim YJ, Guron M, Abish S, Boutros PC, Brudno M, Carleton B, Cuvelier GDE, Gunaratnam L, Ho C, Adeli K, Kuruvilla S, Lajoie G, **Liu G**, Nathan PC, Rod Rassekh S, Rieder M, Waikar SS, Welch SA, Weir MA, Winquist E, Wishart DS, Zorzi AP, Blydt-Hansen T, Zappitelli M, Urquhart B. A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. *Can J Kidney Health Dis*. 2021 Nov;8:2054358121105770. Review Article. **Coauthor or Collaborator**.
139. Melosky B, Cheema P, Juergens RA, Leighl NB, **Liu G**, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. *Ther Adv Med Oncol*. 2021 Nov;13:17588359211056306. Review Article. **Coauthor or Collaborator**.
140. Ortmann J, Rampášek L, Tai E, Mer AS, Shi R, Stewart EL, Mascaux C, Fares A, Pham NA, Beri G, Eeles C, Tkachuk D, Ho C, Sakashita S, Weiss J, Jiang X, **Liu G**, Cescon DW, O'Brien CA, Guo S, Tsao MS, Haibe-Kains B, Goldenberg A. Assessing therapy response in patient-derived xenografts. *Sci Transl Med*. 2021 Nov;13(620):eabf4969. **Coauthor or Collaborator**.
141. Xu Y, Yang W, Song Y, Cheng D, Cao M, Huang J, Ren J, Lee JW, Hueniken K, Chen Y, Brown C, Zhang Y, Qiu K, Xu W, Zhao Y, **Liu G**. Association of gastro-oesophageal reflux disease and quality of life in patients with chronic rhinosinusitis. *Acta Otorhinolaryngol Ital*. 2021 Oct;41(5):450-460. **Senior Responsible Author. Supervised YX**.
142. Ren J, Pang W, Luo Y, Cheng D, Qiu K, Rao Y, Zheng Y, Dong Y, Peng J, Hu Y, Ying Z, Yu H, Zeng X, Zong Z, **Liu G**, Wang D, Wang G, Zhang W, Xu W, Zhao Y. Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality. *J Allergy Clin Immunol Pract*. 2021 Oct;S2213-2198(21):01202-2. **Coauthor or Collaborator**.
143. Ferreiro-Iglesias A, McKay JD, Brenner N, Virani S, Lesseur C, Gaborieau V, Ness AR, Hung RJ, **Liu G**, Diergaarde B, Olshan AF, Hayes N, Weissler MC, Schroeder L, Bender N, Pawlita M, Thomas S, Pring M, Dudding T, Kanterewicz B, Ferris R, Thomas S, Brhane Y, Díez-Obrero V, Milojevic M, Smith-Byrne K, Mariosa D, Johansson MJ, Herrero R, Boccia S, Cadoni G, Lacko M, Holcátová I, Ahrens W, Lagiou P, Lagiou A, Polesel J, Simonato L, Merletti F, Healy CM, Hansen BT, Nygård M, Conway DI, Wright S, Macfarlane TV, Robinson M, Alemany L, Agudo A, Znaor A, Amos CI, Waterboer T, Brennan P. Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. *Nature Communications*. 2021 Oct;12(1):5945. **Coauthor or Collaborator**.
144. Eggen AC, Richard NM, Bosma I, Jalving M, Leighl NB, **Liu G**, Mah K, Higazy R, Shultz DB, Reyners AKL, Rodin G, Edelstein K. Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. *Neurooncol Pract*. 2021 Sep;9(1):50-58. **Coauthor or Collaborator**.
145. Kuehne N, Hueniken K, Xu M, Shakik S, Vedadi A, Pinto D, Brown MC, Bradbury PA, Shepherd FA, Sacher AG, Leighl NB, Xu W, Lok BH, **Liu G**, O'Kane GM. Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. *Clin Lung Cancer*. 2021 Sep;S1525-7304(21):00247-3. **Senior Responsible Author. Supervised NK, KH, MX, SS, AV, DP, MCB, and GO'K**.
146. Aggarwal R, Lam AC, Huang J, Hueniken K, Nguyen D, Khan K, Shaikh T, Shepherd FA, Tsao MS, Xu W, Kavanagh J, **Liu G**. Stratification and management of patients ineligible for lung cancer screening. *Respir Med*. 2021 Sep;188:106610. **Senior Responsible Author. Supervised RA, ACL, KH**.
147. Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, **Liu G**, Owzar K, Lin D, Innocenti F. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. *Int J Cancer*. 2021 Sep;150(2):279-289. **Coauthor or Collaborator**.

148. Sheilla de Oliveira Faria, Gillian Hurwitz, Jaemin Kim, Jacqueline Liberty, Kimberly Orchard, **Geoffrey Liu**, Lisa Barbera, Doris Howell. Identifying Patient-Reported Outcome Measures (PROMs) for Routine Surveillance of Physical and Emotional Symptoms in Head and Neck Cancer Populations: A Systematic Review. *J Clin Med*. 2021 Sep;10(18):4162. Review Article. **Coauthor or Collaborator**.
149. Bender JL, Hueniken K, Eng L, Brown MC, Kassirian S, Geist I, Balaratnam K, Liang M, Paulo CB, Geist A, Rao P, Magony A, Smith EC, Xu W, **Liu G**, Gupta AA. Internet and social media use in cancer patients: association with distress and perceived benefits and limitations. *Support Care Cancer*. 2021 Sep;29(9):5273-5281. **Co-Senior Responsible Author. Supervised KH, LE, MCB, SK, IG, KB, ML, CBP, AG, PR, AM, ECS**.
150. Burgener JM, Zou J, Zhao Z, Zheng Y, Shen SY, Huang SH, Keshavarzi S, Xu W, Liu FF, **Liu G**, Waldron JN, Weinreb I, Spreafico A, Siu LL, de Almeida JR, Goldstein DP, Hoffman MM, De Carvalho DD, Bratman SV. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res*. 2021 Aug 1;27(15):4230-4244. **Coauthor or Collaborator**.
151. Issa AM, Carleton B, Gerhard T, Filipinski KK, Freedman AN, Kimmel S, **Liu G**, Longo C, Maitland-van der Zee AH, Sansbury L, Zhou W, Bartlett G. Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. *Pharmacoepidemiol Drug Saf*. 2021 Aug;30(8):985-992. Review Article. **Coauthor or Collaborator**.
152. Mikubo M, Inoue Y, **Liu G**, Tsao MS. Mechanism of drug tolerant persister cancer cells: The landscape and clinical implication for therapy. *J Thorac Oncol*. 2021 Aug;S1556-0864(21):02332-7. **Coauthor or Collaborator**.
153. Koshkin V, De Oliveira MB, Peng C, Ailles LE, **Liu G**, Covens A, Krylov SN. Multi-drug-resistance efflux in cisplatin-naïve and cisplatin-exposed A2780 ovarian cancer cells responds differently to cell culture dimensionality. *Mol Clin Oncol*. 2021 Aug;15(2):161. **Coauthor or Collaborator**.
154. Yan M, Toh TS, Lindsay PE, Weiss J, Hueniken K, Yeung C, Sugumar V, Pinto D, Tadic T, Sun A, Bezjak A, Cho J, Raman S, Giuliani M, Moraes FY, **Liu G**, Hope AJ, Lok BH. Limited-stage small cell lung cancer: Outcomes associated with prophylactic cranial irradiation over a 20-year period at the Princess Margaret Cancer Centre. *Clin Transl Radiat Oncol*. 2021 Jul;30:43-49. **Coauthor or Collaborator**.
155. Herman M, Liu Z, Shepherd FA, Leighl N, **Liu G**, Bradbury PA. The effect of prior cancer on non-small cell lung cancer trial eligibility. *Cancer Med*. 2021 Jul;10(14):4814-4822. **Coauthor or Collaborator**.
156. Issa AM, Aboushawareb SA, Eisenstat DD, Guilcher GM, **Liu G**, Rassekh SR, Strahlendorf C, Tallen G, Tanoshima R, Carleton B. Deliberations about clinical pharmacogenetic testing in pediatric oncology. *Per Med*. 2021 Jul;18(4):399-405. **Coauthor or Collaborator**.
157. Gudi S, O'Sullivan B, Hosni A, Su J, Hope A, Ringash J, Hueniken K, **Liu G**, Tong L, Goldstein D, de Almeida J, Hansen AR, Bratman SV, Cho J, Giuliani M, Hahn E, Kim J, Xu W, Waldron J, Huang SH. Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-) radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. *Oral Oncology*. 2021 Jun 24;120:105419. **Coauthor or Collaborator**.
158. Yan M, Sigurdson S, Greifer N, Kennedy TAC, Toh TS, Lindsay PE, Weiss J, Hueniken K, Yeung C, Sugumar V, Sun A, Bezjak A, Cho BCJ, Raman S, Hope AJ, Giuliani ME, Stuart EA, Owen T, Ashworth A, Robinson A, de Moraes FY, **Liu G**, Lok BH. A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis. *Cancers (Basel)*. 2021 Jun 9;13(12):2895. **Coauthor or Collaborator**.
159. Rao YF, Wang J, Cheng DN, Xu Y, Ren X, Yang W, **Liu G**, Xu W, Yan XH, Song Y, Zheng YB, An P, Zhong DL, He ZP, Ren JJ, Zhao Y. The Controversy of Pepsinogen A/Pepsin A in Detecting Extra-Gastroesophageal Reflux. *J Voice*. 2021 Jun 2;S0892-1997(21):00145-4. **Coauthor or Collaborator**.
160. Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, **Liu G**, Card PB, Chu Q. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. *Lung Cancer*. 2021 Jun;S0169-5002(21):00429-3. Review Article. **Coauthor or Collaborator**.

161. Jabbour SK, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, **Liu G**, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed M. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. *J Natl Cancer Inst.* 2021 Jun;113(6):665-679. Review Article. **Coauthor or Collaborator.**
162. Sipeng Shen, Yongyue Wei, Yi Li, Weiwei Duan, Xuesi Dong, Lijuan Lin, Dongfang You, Adonina Tardon, Chu Chen, John K. Field, Rayjean J. Hung, **Geoffrey Liu**, Dakai Zhu, Christopher I. Amos, Li Su, Yang Zhao, Zhibin Hu, Hongbing Shen, Ruyang Zhang, Feng Chen, David C. Christiani. A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. *NPJ Precision Oncology.* 2021 May 17;5(1):39. Impact Factor 7.71. **Coauthor or Collaborator.**
163. Sayani A, Vahabi M, O'Brien MA, **Liu G**, Hwang S, Selby P, Nicholson E, Giuliani M, Eng L, Lofters A. Advancing health equity in cancer care: The lived experiences of poverty and access to lung cancer screening. *PLoS One.* 2021 May 6;16(5):e0251264. **Coauthor or Collaborator.**
164. Gormley M, Yarmolinsky J, Dudding T, Burrows K, Martin RM, Thomas S, Tyrrell J, Brennan P, Pring M, Boccia S, Olshan AF, Diergaarde B, Hung RJ, **Liu G**, Legge D, Tajara EH, Severino P, Lacko M, Ness AR, Davey Smith G, Vincent EE, Richmond RC. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. *PLoS Genet.* 2021 Apr 22;17(4):e1009525. **Coauthor or Collaborator.**
165. Lau SCM, Poletes C, Le LW, Mackay KM, Fares AF, Bradbury PA, Shepherd FA, Tsao MS, Leighl NB, **Liu G**, Shultz D, Sacher AG. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. *Lung Cancer.* 2021 Apr 8;156:76-81. **Coauthor or Collaborator.**
166. Haase KR, Avery J, Bryant-Lukosius D, Kryzanowska M, Kukretti V, **Liu G**, Mayo SJ, Jones J, Howell D. Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): exposing patients "hard work" of managing acute cancer. *Support Care Cancer.* 2021 Apr;29(4):1989-1998. **Coauthor or Collaborator.**
167. Dighe SG, Chen J, Yan L, He Q, Gharahkhani P, Onstad L, Levine DM, Palles C, Ye W, Gammon MD, Iyer PG, Anderson LA, **Liu G**, Wu AH, Dai JY, Chow WH, Risch HA, Lagergren J, Shaheen NJ, Bernstein L, Corley DA, Prenen H, deCaestecker J, MacDonald D, Moayyedi P, Barr H, Love SB, Chegwidan L, Attwood S, Watson P, Harrison R, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weismüller J, Gockel I, Vashist Y, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Ambrosone CB, Moysich KB, MacGregor S, Tomlinson I, Whitman DC, Jankowski J, Schumacher J, Vaughan TL, Madeleine MM, Hardie LJ, Buas MF. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. *Carcinogenesis.* 2021 Apr;42(3):369-377. **Coauthor or Collaborator.**
168. Lesseur C, Ferreira-Iglesias A, McKay JD, Bossé Y, Johansson M, Gaborieau V, Landi MT, Christiani DC, Caporaso NC, Bojesen SE, Amos CI, Shete S, **Liu G**, Rennert G, Albanes D, Aldrich MC, Tardon A, Chen C, Triantafyllou L, Field JK, Teare MD, Kiemeny LA, Diergaarde B, Ferris RL, Zienolddiny S, Lam S, Olshan AF, Weissler MC, Lacko M, Risch A, Bickeboller H, Ness AR, Thomas S, Le Marchand L, Schabath MB, Wünsch-Filho V, Tajara EH, Andrew AS, Clifford GM, Lazarus P, Grankvist K, Johansson M, Arnold S, Melander O, Brunnström H, Boccia S, Cadoni G, Timens W, Obeidat M, Xiao X, Houlston RS, Hung RJ, Brennan P. Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. *PLoS Genet.* 2021 Mar 5;17(3):e1009254. **Coauthor or Collaborator.**
169. Turner J, Pond GR, Tremblay A, Johnston M, Goss G, Nicholas G, Martel S, Bhatia R, **Liu G**, Schmidt H, Tammemagi MC, Puksa S, Atkar-Khattra S, Tsao MS, Lam S, Goffin JR. Risk Perception Among a Lung Cancer Screening Population. *Chest.* 2021 Mar 2;S0012-3692(21):00450-5. **Coauthor or Collaborator.**
170. Zhou W, **Liu G**, Hung RJ, Haycock PC, Aldrich MC, Andrew AS, Arnold SM, Bickeboller H, Bojesen SE, Brennan P, Brunnström H, Melander O, Caporaso NE, Landi MT, Chen C, Goodman GE, Christiani DC, Cox A, Field JK, Johansson M, Kiemeny LA, Lam S, Lazarus P, Le Marchand L, Rennert G, Risch A, Schabath MB, Shete SS, Tardón A, Zienolddiny S, Shen H, Amos CI. Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. *Int J Cancer.* 2021 Mar;148(5):1077-1086. **Coauthor or Collaborator.**

171. Hung RJ, Warkentin MT, Brhane Y, Chatterjee N, Christiani DC, Landi MT, Caporaso NE, **Liu G**, Johansson M, Albanes D, Le Marchand L, Tardon A, Rennert G, Bojesen SE, Chen C, Field JK, Kiemeny LA, Lazarus P, Zienolddiny S, Lam S, Andrew AS, Arnold SM, Aldrich MC, Bickeböll H, Risch A, Schabath MB, McKay JD, Brennan P, Amos CI. Assessing Lung Cancer Absolute Risk Trajectory based on a Polygenic Risk Model. *Cancer Res.* 2021 Mar;81(6):1607-1615. **Coauthor or Collaborator.**
172. Liu Y, Xia J, McKay J, Tsavachidis S, Xiao X, Spitz MR, Cheng C, Byun J, Hong W, Li Y, Zhu D, Song Z, Rosenberg SM, Scheurer ME, Kheradmand F, Pikielny CW, Lusk CM, Schwartz AG, Wistuba II, Cho MH, Silverman EK, Bailey-Wilson J, Pinney SM, Anderson M, Kupert E, Gaba C, Mandal D, You M, de Andrade M, Yang P, Liloglou T, Davies MPA, Lissowska J, Swiatkowska B, Zaridze D, Mukeria A, Janout V, Holcatova I, Mates D, Stojic J, Scelo G, Brennan P, **Liu G**, Field JK, Hung RJ, Christiani DC, Amos CI. Rare deleterious germline variants and risk of lung cancer. *NPJ Precis Oncol.* 2021 Feb;5(1):12. **Coauthor or Collaborator.**
173. Jiang M, Fares AF, Shepshelovich D, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz AG, Tardon A, Shete S, Schabath MB, Teare MD, Le Marchand L, Zhang ZF, Field JK, Brenner H, Diao N, Xie J, Kohno T, Harris CC, Wenzlaff AS, Fernandez-Tardon G, Ye Y, Taylor F, Wilkens LR, Davies M, Liu Y, Barnett MJ, Goodman GE, Morgenstern H, Holleczeck B, Thomas S, Brown MC, Hung RJ, Xu W, **Liu G**. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. *Lung Cancer.* 2021 Feb;152:58-65. **Senior Responsible Author. Supervised MJ, AFF, DS.**
174. Sun R, Xu M, Li X, Gaynor S, Zhou H, Li Z, Bossé Y, Lam S, Tsao MS, Tardon A, Chen C, Doherty J, Goodman G, Bojesen SE, Landi MT, Johansson M, Field JK, Bickeböll H, Wichmann HE, Risch A, Rennert G, Arnold S, Wu X, Melander O, Brunnström H, Le Marchand L, **Liu G**, Andrew A, Duell E, Kiemeny LA, Shen H, Haugen A, Johansson M, Grankvist K, Caporaso N, Woll P, Dawn Teare M, Scelo G, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Albanes D, Mak R, Barbie D, Brennan P, Hung RJ, Amos CI, Christiani DC, Lin X. Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. *Genet Epidemiol.* 2021 Feb;45(1):99-114. **Coauthor or Collaborator.**
175. Vedadi A, Shakik S, Brown MC, Lok BH, Shepherd FA, Leighl NB, Sacher A, Bradbury PA, Xu W, **Liu G**, O'Kane GM. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. *Qual Life Res.* 2021 Feb;30(2):445-454. **Co-Senior Responsible Author. Supervising AV, SS, MCB.**
176. Chan SWS, Smith E, Aggarwal R, Balaratnam K, Chen R, Hueniken K, Fazelzad R, Weiss J, Jiang S, Shepherd FA, Bradbury PA, Sacher AG, Leighl NB, Xu W, Brown MC, Eng L, **Liu G**. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. *Clin Lung Cancer.* 2021 Jan;S1525-7304(21):00005-X. **Senior Responsible Author. Supervised SWSC, ES, RA, KB, RC, KH, RF.**
177. Lau SCM, Fares AF, Le LW, Mackay KM, Soberano S, Chan SW, Smith E, Ryan M, Tsao MS, Bradbury PA, Pal P, Shepherd FA, **Liu G**, Leighl NB, Sacher AG. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. *Clin Lung Cancer.* 2021 Jan;S1525-7304(21):00003-6. **Coauthor or Collaborator.**
178. Sayani A, Vahabi M, O'Brien MA, **Liu G**, Hwang SW, Selby P, Nicholson E, Lofters A. Perspectives of family physicians towards access to lung cancer screening for individuals living with low income - a qualitative study. *BMC Fam Pract.* 2021 Jan;22(1):10. **Coauthor or Collaborator.**
179. Desilets A, Blanc-Durand F, Lau S, Hakoziaki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, Agulnik J, Cohen V, Charbonneau C, Marcoux N, Blais N, Leighl NB, Bradbury PA, **Liu G**, Shepherd FA, Bahig H, Routy B, Sacher A, Elkrief A. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer.* 2021 Jan;142:83-91. **Coauthor or Collaborator.**

180. Jiang DM, Sim HW, Espin-Garcia O, Chan BA, Natori A, Lim CH, Moignard S, Chen EX, **Liu G**, Darling G, Swallow CJ, Brar S, Brierley J, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Knox JJ, Jang RW, Elimova E. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. *Oncology*. 2021;99(1):49-56. **Coauthor or Collaborator**.
181. Dong J, Maj C, Tsavachidis S, Ostrom QT, Gharahkhani P, Anderson LA, Wu AH, Ye W, Bernstein L, Borisov O, Schröder J, Chow WH, Gammon MD, **Liu G**, Caldas C, Pharoah PD, Risch HA, May A, Gerges C, Anders M, Venerito M, Schmidt T, Izbicki JR, Hölscher AH, Schumacher B, Vashist Y, Neuhaus H, Rösch T, Knapp M, Krawitz P, Böhmer A, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Corley DA, Gockel I, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Cook MB, Whiteman DC, Vaughan TL, Schumacher J, Thrift AP. Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterology*. 2020 Dec;159(6):2065-2076. **Coauthor or Collaborator**.
182. Tse BC, Said BI, Fan ZJ, Hueniken K, Patel D, Gill G, Liang M, Razooqi M, Brown MC, Sacher AG, Bradbury PA, Shepherd FA, Leigh NB, Xu W, Howell D, **Liu G**, O'Kane G. Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. *Curr Oncol*. 2020 Dec;27(6):e552-e559. Epub 2020 Dec 1. **Co-Senior Responsible Author. Supervising BCT, BIS, ZJF, KH, DP, GG, ML, MR, MCB**.
183. Melosky B, Cheema PK, Brade A, McLeod D, **Liu G**, Price PW, Jao K, Schellenberg DD, Juergens R, Leigh N, Chu Q. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. *Oncologist*. 2020 Nov;25(11):981-992. Review Article. **Coauthor or Collaborator**.
184. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, **Liu G**, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. *N Engl J Med*. 2020 Nov;383(21):2018-2029. **Coauthor or Collaborator**.
185. Goffin JR, Pond GR, Puksa S, Tremblay A, Johnston M, Goss G, Nicholas G, Martel S, Bhatia R, **Liu G**, Schmidt H, Atkar-Khattra S, McWilliams A, Tsao MS, Tammemagi MC, Lam S. Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. *BMC Pulm Med*. 2020 Nov;20(1):300. **Coauthor or Collaborator**.
186. Gormley M, Dudding T, Sanderson E, Martin RM, Thomas S, Tyrrell J, Ness AR, Brennan P, Munafò M, Pring M, Boccia S, Olshan AF, Diergaarde B, Hung RJ, **Liu G**, Davey Smith G, Richmond RC. : A multivariable Mendelian randomization analysis investigating smoking and alcohol consumption in oral and oropharyngeal cancer. *Nature Communications*. 2020 Nov;11(1):6071. **Coauthor or Collaborator**.
187. Haddad G, Schouwenburg S, Altesha A, Xu W, **Liu G**. Using breath analysis as a screening tool to detect gastric cancer: A systematic review. *J Breath Res*. 2020 Oct 26;15(1). **Senior Responsible Author. Supervised GH, SS, AA**.
188. Grant RC, Rotstein C, **Liu G**, Forbes L, Vu K, Lee R, Ng P, Krzyzanowska M, Warr D, Knox J. Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada. *Support Care Cancer*. 2020 Oct;28(10):5031-5036. Review Article. **Coauthor or Collaborator**.
189. Aggarwal R, Hueniken K, Eng L, Kassirian S, Geist I, Balaratnam K, Liang M, Paulo CB, Geist A, Rao P, Mitchell L, Magony A, Jones JM, Grover SC, Brown MC, Bender J, Xu W, **Liu G**, Gupta AA. Health-Related Social Media Use and Preferences of Adolescent and Young Adult Cancer Patients for Virtual Programming. *Supportive Care in Cancer*. 2020 Oct;28(10):4789-4801. **Senior Responsible Author; Supervised RA, KA, LE, SK, IG, KB, ML**.
190. Giuliani M, Brual J, Eng L, **Liu G**, Papadakis T, Giannopoulos E, Papadakis J. Investigating the Smoking Cessation Informational Needs of Cancer Patients and Informal Caregivers. *J Cancer Educ*. 2020 Oct;35(5):954-964. **Coauthor or Collaborator**.
191. Hueniken K, Douglas CM, Jethwa AR, Mirshams M, Eng L, Hope A, Chepeha DB, Goldstein DP, Ringash J, Hansen A, Martino R, Li M, **Liu G**, Xu W, de Almeida JR. Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. *Cancer*. 2020 Sep;126(17):4042-4050. **Coauthor or Collaborator**.



192. Sridhar SS, Blais N, Tran B, Reaume MN, North SA, Stockler MR, Chi KN, Fleshner NE, **Liu G**, Robinson JW, Mukherjee SD, Rahim Y, Winkquist E, Booth CM, Nguyen NT, Beardsley EK, Alimohamed NS, McDonald GT, Ding K, Parulekar WR. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. *JAMA Oncol*. 2020 Sep;6(11):1-8. **Coauthor or Collaborator**.
193. Bleker de Oliveira M, Koshkin V, **Liu G**, Krylov SN. Analytical Challenges in Development of Chemoresistance Predictors for Precision Oncology. *Anal Chem*. 2020 Sep;92(18):12101-12110. **Coauthor or Collaborator**.
194. Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, **Liu G**. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. *Lung Cancer*. 2020 Aug;146:78-85. Impact Factor 5.3. **Co-Senior Responsible Author. Supervising RS, SNMF, AF**.
195. Fares AF, Lok BH, Zhang T, Cabanero M, Lau SCM, Stockley T, Patel D, Bradbury PA, Sacher A, Yasufuku K, Morash BA, Sabatini PJB, Nguyen LN, Leighl NB, Tsao MS, Shepherd FA, **Liu G**, Martins-Filho SN, Pal P. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. *Lung Cancer*. 2020 Aug;146:350-354. **Coauthor or Collaborator**.
196. Lam ACL, Aggarwal R, Cheung S, Stewart EL, Darling G, Lam S, Xu W, **Liu G**, Kavanagh J. Predictors of participant nonadherence in lung cancer screening programs. *Lung Cancer*. 2020 Aug;146:134-144. **Senior Responsible Author. Supervised and funded ACLL RA ELS**.
197. Thomas S, Carroll JC, Brown MC, Chen Z, Mirshams M, Patel D, Boyd K, Pierre A, Goldstein DP, Giuliani ME, Xu W, Eng L, Moez E, **Liu G**, Hung RJ. Nicotine dependence as a risk factor for upper aerodigestive tract (UADT) cancers: A mediation analysis. *PLOS ONE*. 2020 Aug;15(8):e0237723. **Co-Senior Responsible Author. Supervised CB, MM, DP, KB, LE**.
198. Lam AC, Aggarwal R, Huang J, Varadi R, Davis L, Tsao MS, Shepherd FA, Lam S, Kavanagh J, **Liu G**. Point-Of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening. *Am J Respir Crit Care Med*. 2020 Jul 16;202(10):1473-1477. Impact Factor 30.528. **Senior Responsible Author. Supervised ACL, RA**.
199. Koshkin V, Bleker de Oliveira M, Peng C, Ailles LE, **Liu G**, Covens A, Krylov SN. Spheroid-Based Approach to Assess the Tissue Relevance of Analysis of Dispersed-Settled Tissue Cells by Cytometry of the Reaction Rate Constant. *Anal Chem*. 2020 Jul 7;92(13):9348-9355. **Coauthor or Collaborator**.
200. Wang Y, Gorlova OY, Gorlov IP, Zhu M, Dai J, Albanes D, Lam S, Tardon A, Chen C, Goodman GE, Bojesen SE, Landi MT, Johansson M, Risch A, Wichmann HE, Bickeboller H, Christiani DC, Rennert G, Arnold SM, Brennan P, Field JK, Shete S, Le Marchand L, Melander O, Brunnstrom H, **Liu G**, Hung RJ, Andrew AS, Kiemeny LA, Zienoldiny S, Grankvist K, Johansson M, Caporaso NE, Woll PJ, Lazarus P, Schabath MB, Aldrich MC, Stevens VL, Ma H, Jin G, Hu Z, Amos CI, Shen H. Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls. *Cancer Epidemiol Biomarkers Prev*. 2020 Jul;29(7):1423-1429. **Coauthor or Collaborator**.
201. Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, Leighl NB, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, **Liu G**. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. *Lung Cancer*. 2020 Jul;145:144-151. Impact Factor 5.3. **Co-Senior Responsible Author. Supervising SNMF, AF, ELS, DP**.
202. Young K, Jiang H, Marquez M, Yeung J, Shepherd FA, Renner E, Keshavjee S, Kim J, Ross H, Aliev T, **Liu G**, Leighl NB, Feld R, Bradbury P. Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients. *Lung Cancer*. 2020 Jul;147:214-220. **Coauthor or Collaborator**.
203. Reis PP, Drigo SA, Carvalho RF, Lopez Lapa RM, Felix TF, Patel D, Cheng D, Pintilie M, **Liu G**, Tsao MS. Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways. *Cancers (Basel)*. 2020 Jul;12(8):2071. **Co-Senior Responsible Author. Supervising PPR, DP, DC**.

204. Brhane Y, Yang P, Christiani DC, **Liu G**, McLaughlin JR, Brennan P, Shete S, Field JK, Tardón A, Kohno T, Shiraishi K, Matsuo K, Bossé Y, Amos CI, Hung RJ. Genetic Determinants of Lung Cancer Prognosis in Never Smokers: A Pooled Analysis in the International Lung Cancer Consortium. *Cancer Epidemiol Biomarkers Prev*. 2020 Jul;29(10):1983-1992. **Coauthor or Collaborator**.
205. Eng L, Alton D, Song Y, Su J, Zhang Q, Che J, Farzanfar D, Mohan R, Kryz O, Mattina K, Harper C, Liu S, Yoannidis T, Milne R, Abdelmutti N, Brown MC, Vennettilli A, Hope AJ, Howell D, Jones JM, Selby P, Evans WK, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Awareness of the Harms of Continued Smoking Among Cancer Survivors. *Support Care Cancer*. 2020 Jul;28(7):3409-3419. **Senior Responsible Author**.
206. Sung JH, Brown MC, Perez-Cosio A, Pratt L, Houad J, Liang M, Gill G, Moradian S, **Liu G**, Howell D. Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study. *Lung Cancer*. 2020 Jun 24;147:1-11. **Coauthor or Collaborator**.
207. Moradian S, Krzyzanowska M, Maguire R, Kukreti V, Amir E, Morita PP, **Liu G**, Howell D. Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol. *BMJ Open*. 2020 Jun;10(6):e035648. **Coauthor or Collaborator**.
208. Giuliani M, Brual J, Cameron E, Chaiton M, Eng L, Haque M, **Liu G**, Mittmann N, Papadakis J, Saunders D, Truscott R, Evans WK. Smoking Cessation in Cancer Care: Myths, Presumptions and Implications for Practice. *Clin Oncol (R Coll Radiol)*. 2020 Jun;32(6):400-406. **Coauthor or Collaborator**.
209. Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, Gorlov I, Xiao X, Han Y, Gorlova O, Hung RJ, Brhane Y, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, **Liu G**, Bojesen SE, Le Marchand L, Albanes D, Bickeboller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Byun J, Dragnev KH, Field JK, Kiemeny LF, Lazarus P, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Diao N, Su L, Song L, Zhang R, Leighl N, Johansen JS, Møller H, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, Heijden EHFV, Kim JH, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulos A, Tumino R, Goodman GE, Cox A, Taylor F, Woll P, Wichmann E, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Butler LM, Offit K, Sriniv. Protein-altering germline mutations implicate novel genes related to lung cancer development. *Nat Commun*. 2020 May 11;11(1):2220. **Coauthor or Collaborator**.
210. Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, **Liu G**, Leighl NB. Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. *J Thorac Dis*. 2020 May;12(5):2706-2712. **Coauthor or Collaborator**.
211. Jiang DM, Suzuki C, Espin-Garcia O, Lim CH, Ma LX, Sun P, Sim HW, Natori A, Chan BA, Moignard S, Chen EX, **Liu G**, Swallow CJ, Darling GE, Wong R, Jang RW, Elimova E. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. *Cancer Med*. 2020 May;9(9):3023-3032. **Coauthor or Collaborator**.
212. Xu Y, Zheng Y, Cao M, Yang W, Ren J, Song Y, Cheng D, Wang J, Huang L, Xu W, Zhao Y, **Liu G**. Association of Single-Nucleotide Polymorphisms With Chronic Rhinosinusitis in a Southwestern Han Chinese Population: A Replication Study. *Am J Rhinol Allergy*. 2020 May;34(3):352-360. **Senior Responsible Author**.
213. Ren J, Xu W, Su J, Ren X, Cheng D, Chen Z, Bender N, Mirshams M, Habbous S, de Almeida JR, Perez-Ordóñez B, Goldstein DP, Wang JR, Bratman SV, Huang SH, Jang R, Zhao Y, Waterboer T, Hung RJ, **Liu G**. Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. *Int J Cancer*. 2020 Apr 15;146(8):2166-2174. Impact Factor 7.316. **Senior Responsible Author. Supervising JR, DC, ZC, MM, SH**.
214. Schmid S, Stewart EL, Martins-Filho SN, Cabanero M, Wang A, Bao H, Wu X, Patel D, Chen Z, Law JH, Bradbury PA, Shepherd FA, Leighl N, Tsao MS, Pugh T, Bratman SV, Sacher A, **Liu G**. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. *Clin Lung Cancer*. 2020 Apr 9;S1525-7304(20):30088-7. **Senior Responsible Author. Supervised SS, ELS, SNSF**.

215. Eng L, Bender J, Hueniken K, Kassirian S, Mitchell L, Aggarwal R, Paulo C, Smith EC, Geist I, Balaratnam K, Magony A, Liang M, Yang D, Jones JM, Brown MC, Xu W, Grover SC, Alibhai SMH, **Liu G**, Gupta AA. Age differences in patterns and confidence of using internet and social media for cancer-care among cancer survivors. *J Geriatr Oncol*. 2020 Mar 10;S1879-4068(19):30462-X. **Senior Responsible Author. Supervised LE, KH, RA, CP, ECS, IG, KB, AM, M L, Co-Senior with AAG.**
216. Eggen AC, Reyners AKL, Shen G, Bosma I, Jalving M, Leighl NB, **Liu G**, Richard NM, Mah K, Shultz DB, Edelstein K, Rodin G. Death anxiety in patients with metastatic non-small cell lung cancer with and without brain metastases. *J Pain Symptom Manage*. 2020 Mar 4;S0885-3924(4):30126-3. **Coauthor or Collaborator.**
217. Ren J, Jing X, Wang J, Ren X, Xu Y, Yang Q, Ma L, Sun Y, Xu W, Yang N, Zou J, Zheng Y, Chen M, Gan W, Xiang T, An J, Liu R, Lv C, Lin K, Zheng X, Lou F, Rao Y, Yang H, Liu K, **Liu G**, Lu T, Zheng X, Zhao Y. Automatic Recognition of Laryngoscopic Images Using a Deep-Learning Technique. *Laryngoscope*. 2020 Feb 18;130(11):E686-E693. **Coauthor or Collaborator.**
218. Lee MJ, Hueniken K, Kuehne N, Lu L, Jiang SX, Id Said B, McCartney A, Gao Y, Liang M, Obuobi T, Sorotsky H, Eng L, Brown MC, Xu W, **Liu G**. Cancer Patient-Reported Preferences and Knowledge for Liquid Biopsies and Blood Biomarkers at a Comprehensive Cancer Center. *Cancer Manag Res*. 2020 Feb 13;12:1163-1173. **Senior Responsible Author. Supervised MJL, KH, NK, LL, SXJ, BIS, AM YG, ML, TO, HS, LE.**
219. Kachuri L, Johansson M, Rashkin SR, Graff RE, Bossé Y, Manem V, Caporaso NE, Landi MT, Christiani DC, Vineis P, **Liu G**, Scelo G, Zaridze D, Shete SS, Albanes D, Aldrich MC, Tardón A, Rennert G, Chen C, Goodman GE, Doherty JA, Bickeböller H, Field JK, Davies MP, Dawn Teare M, Kiemeny LA, Bojesen SE, Haugen A, Zienolddiny S, Lam S, Le Marchand L, Cheng I, Schabath MB, Duell EJ, Andrew AS, Manjer J, Lazarus P, Arnold S, McKay JD, Emami NC, Warkentin MT, Brhane Y, Obeidat M, Martin RM, Relton C, Davey Smith G, Haycock PC, Amos CI, Brennan P, Witte JS, Hung RJ. Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. *Nat Commun*. 2020 Jan 7;11(1):27. **Coauthor or Collaborator.**
220. Rudkowski JL, Pond GR, Tremblay A, Johnston M, Goss G, Nicholas G, Martel S, Bhatia R, **Liu G**, Schmidt H, Tammemagi MC, Atkar-Khattra S, Tsao MS, Lam S, Goffin JR. Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. *Clin Trials*. 2020 Jan 2;17(2):202-211. **Coauthor or Collaborator.**
221. Moskovitz M, Jao K, Su J, Brown MC, Naik H, Eng L, Wang T, Kuo J, Leung Y, Xu W, Mittmann N, Moody L, Barbera L, Devins G, Li M, Howell D, **Liu G**. Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites. *Current Oncology*. 2019 Dec 1;26(6):E733-e741. **Senior Responsible Author.**
222. N. Abdelmutti MSc, Brual PhD., Papadakos MEd PhD, S. Fathima, J. Jones, D. Goldstein, L. Eng MD, T. Papadakos, G. Liu MD MSc, and M. Giuliani MBBS. Implementation of a comprehensive smoking cessation program in cancer care. *Current Oncology*. 2019 Dec;26(6):361-368. **Coauthor or Collaborator.**
223. Jiang SX, Walton RN, Hueniken K, Baek J, McCartney A, Labbé C, Smith E, Chan SWS, Chen R, Brown C, Patel D, Liang M, Eng L, Sacher A, Bradbury P, Leighl NB, Shepherd FA, Xu W, **Liu G**, Hurry M, O’Kane GM. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. *Cancer Med*. 2019 Dec;8(18):7542-7555. **Senior Responsible Author.**
224. Petrick JL, Li N, Anderson LA, Bernstein L, Corley DA, El Serag HB, Hardikar S, Liao LM, **Liu G**, Murray LJ, Rubenstein JH, Schneider JL, Shaheen NJ, Thrift AP, van den Brandt PA, Vaughan TL, Whiteman DC, Wu AH, Zhao WK, Gammon MD, Cook MB. Diabetes in relation to Barrett’s esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett’s and Esophageal Adenocarcinoma Consortium. *Cancer*. 2019 Dec;125(23):4210-4223. **Coauthor or Collaborator.**
225. Ramotar M, Barnes S, Moraes F, Dasgupta A, Laperriere N, Millar BA, Berlin A, Conrad T, van Prooijen M, Damyranovich A, Heaton R, Cho YB, Coolens C, **Liu G**, Shepherd FA, Bradbury P, Leighl N, Bernstein M, Zadeh G, Kongkham P, Doherty M, Shultz DB. Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. *Adv Radiat Oncol*. 2019 Nov 26;5(3):350-357. **Coauthor or Collaborator.**

- 226.Xie SH, Fang R, Huang M, Dai J, Thrift AP, Anderson LA, Chow WH, Bernstein L, Gammon MD, Risch HA, Shaheen NJ, Reid BJ, Wu AH, Iyer PG, **Liu G**, Corley DA, Whiteman DC, Caldas C, Pharoah PD, Hardie LJ, Fitzgerald RC, Shen H, Vaughan TL, Lagergren J. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2019 Nov 19;S1542-3565(19):31317-5. **Coauthor or Collaborator**.
- 227.Bossé Y, Li Z, Xia J, Manem V, Carreras-Torres R, Gabriel A, Gaudreault N, Albanes D, Aldrich MC, Andrew A, Arnold S, Bickeböllner H, Bojesen SE, Brennan P, Brunnstrom H, Caporaso N, Chen C, Christiani DC, Field JK, Goodman G, Grankvist K, Houlston R, Johansson M, Johansson M, Kiemeny LA, Lam S, Landi MT, Lazarus P, Le Marchand L, **Liu G**, Melander O, Rennert G, Risch A, Rosenberg SM, Schabath MB, Shete S, Song Z, Stevens VL, Tardon A, Wichmann HE, Woll P, Zienolddiny S, Obeidat M, Timens W, Hung RJ, Joubert P, Amos CI, McKay JD. Transcriptome-wide association study reveals candidate causal genes for lung cancer. Int J Cancer. 2019 Nov 6;146(7):1862-1878. **Coauthor or Collaborator**.
- 228.Shi R, Radulovich N, Ng C, Liu N, Notsuda H, Cabanero M, N Martins-Filho S, Raghavan V, Li Q, Mer AS, Rosen JC, Li M, Wang YH, Tamblyn L, Pham NA, Haibe-Kains B, **Liu G**, Moghal N, Tsao MS. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res. 2019 Nov 6;26(5):1162-1174. **Coauthor or Collaborator**.
- 229.Lee MJ, Kuehne N, Hueniken K, Liang S, Rai S, Sorotsky H, Herman M, Shepshelovich D, Bruce J, Liang M, Patel D, Cheng D, Chen Z, Eng L, Brown MC, Cho J, Leighl NB, de Perrot M, Reisman D, Xu W, Bradbury PA, **Liu G**. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. Mol Carcinog. 2019 Nov;58(11):1960-1973. **Senior Responsible Author**.
- 230.Albaba H, Barnes TA, Veitch Z, Brown MC, Shakik S, Su S, Naik H, Wang T, Liang M, Perez-Cosio A, Eng L, Mittmann N, Xu W, Howell D, **Liu G**. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience. Oncologist. 2019 Nov;24(11):e1219-e1227. **Senior Responsible Author**.
- 231.Teichman J, Dodbiba L, Thai H, Fleet A, Morey T, Liu L, McGregor M, Cheng D, Chen Z, Darling G, Brhane Y, Song Y, Espin-Garcia O, Xu W, Girgis H, Schwock J, MacKay H, Bristow R, Ailles L, **Liu G**. Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. PLoS One. 2019 Oct 30;14(10):e0224827. eCollection 2018. Impact Factor 2.766 (Trainee publication, Jennifer Teichman). **Senior Responsible Author**.
- 232.Shirley Xue Jiang, Ryan N. Walton, Katrina Hueniken, Justine Baek, Alexandra McCartney, Catherine Labbé, Elliot Smith, Sze Wah Samuel Chan, RuiQi Chen, Catherine Brown, Devalben Patel, Mindy Liang, Lawson Eng, Adrian Sacher, Penelope Bradbury, Natasha B. Leighl, Frances A. Shepherd, Wei Xu, **Geoffrey Liu**, Manjusha Hurry, Grainne M. O'Kane. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. Cancer Med. 2019 Oct 24;8(18):7542–7555. **Coauthor or Collaborator**.
- 233.Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, **Liu G**, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Shao-Weng Tan D. Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC. J Thorac Oncol. 2019 Oct 18;S1556-0864(19):33564-6. **Coauthor or Collaborator**.
- 234.Dai J, Huang M, Amos CI, Hung RJ, Tardon A, Andrew A, Chen C, Christiani DC, Albanes D, Rennert G, Fan J, Goodman G, **Liu G**, Field JK, Grankvist K, Kiemeny LA, Le Marchand L, Schabath MB, Johansson M, Aldrich MC, Johansson M, Caporaso N, Lazarus P, Lam S, Bojesen SE, Arnold S, Landi MT, Risch A, Wichmann HE, Bickeboller H, Brennan P, Shete S, Melander O, Brunnstrom H, Zienolddiny S, Woll P, Stevens V, Hu Z, Shen H. Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk. Int J Cancer. 2019 Oct 2;146(10):2855-2864. **Coauthor or Collaborator**.
- 235.Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, **Liu G**, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 Oct;14(10):1704-1717. Review Article. **Coauthor or Collaborator**.

236. Dong J, Gharahkhani P, Chow WH, Gammon MD, **Liu G**, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study Consortium, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbickei JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP. No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clin Gastroenterol Hepatol. 2019 Oct;17(11):2227-2235. **Coauthor or Collaborator**.
237. Jiang X, Finucane H, Schumacher F, Schmidt S, Tyrer J, Han Y, Michailidou K, Lesseur C, Kuchenbarcker K Dennis J, Conti D, Casey G, Gaudet M, Huyghe J, Albanes D, Aldrich M, Andrew A, Andrulis IL, Anton-Culver H, Antoniou A, Antonenkova N, Arnold S, Aronson K, **Liu G**, Et Al. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Sep 23;10(1):4386. Impact Factor 12.353. **Coauthor or Collaborator**.
238. Ren J, Yang W, Su J, Ren X, Fazelzad R, Albert T, Habbous S, Goldstein DP, de Almeida JR, Hansen A, Jang R, Bratman SV, Hope A, Chen R, Wang J, Xu Y, Cheng D, Zhao Y, Xu W, **Liu G**. Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. Int J Cancer. 2019 Sep 15;145(6):1465-1474. Impact Factor 7.316. **Senior Responsible Author. Supervising JR, WY, RF, SH, DC**.
239. Shepshelovich D, Xu W, Lu L, Fares A, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz AG, Tardon A, Schabath MB, Teare MD, Le Marchand L, Zhang ZF, Field JK, Brenner H, Diao N, Xie J, Kohno T, Harris CC, Wenzlaff AS, Fernandez-Tardon G, Ye Y, Taylor F, Wilkens LR, Davies M, Liu Y, Barnett MJ, Goodman GE, Morgenstern H, Holleczeck B, Brown MC, **Liu G**, Hung RJ. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. J Thorac Oncol. 2019 Sep;14(9):1594-1607. Impact Factor 20.4. **Co-Senior Responsible Author. Supervising DS, LL, AF, MCB**.
240. Hung RJ, Spitz MR, Houlston RS, Schwartz AG, Field JK, Ying J, Li Y, Han Y, Ji X, Chen W, Wu X, Gorlov IP, Na J, de Andrade M, **Liu G**, Brhane Y, Diao N, Wenzlaff A, Davies MPA, Liloglou T, Timofeeva M, Muley T, Rennert H, Saliba W, Ryan BM, Bowman E, Barros-Dios JM, Pérez-Ríos M, Morgenstern H, Zienolddiny S, Skaug V, Ugolini D, Bonassi S, van der Heijden EHFM, Tardon A, Bojesen SE, Landi MT, Johansson M, Bickeböller H, Arnold S, Le Marchand L, Melander O, Andrew A, Grankvist K, Caporaso N, Teare MD, Schabath MB, Aldrich MC, Kiemeny LA, Wichmann HE, Lazarus P, Mayordomo J, Neri M, Haugen A, Zhang ZF, Ruano-Raviña A, Brenner H, Harris CC, Orlov I, Rennert G, Risch A, Brennan P, Christiani DC, Amos CI, Yang P, Gorlova OY. Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1LI Region. J Thorac Oncol. 2019 Aug;14(8):1360-1369. **Coauthor or Collaborator**.
241. Lee DJ, McMullen CP, Foreman A, Huang SH, Lu L, Xu W, de Almeida JR, **Liu G**, Bratman SV, Goldstein DP. Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study. J Otolaryngol Head Neck Surg. 2019 Jul 25;48(1):34. **Coauthor or Collaborator**.
242. Wang D, Pham NA, Freeman TM, Raghavan V, Navab R, Chang J, Zhu CQ, Ly D, Tong J, Wouters BG, Pintilie M, Moran MF, **Liu G**, Shepherd FA, Tsao MS. Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. Cancers (Basel). 2019 Jul 19;11(7):E1009. **Coauthor or Collaborator**.
243. O'Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, Leighl NB, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, **Liu G**. The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist. 2019 Jul;24(7):e501-e509. **Senior Responsible Author**.
244. Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, **Liu G**, Sacher A, Shepherd FA, Leighl NB. Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. Clin Lung Cancer. 2019 Jul;20(4):231-236. Impact Factor 4.204. **Coauthor or Collaborator**.

245. Kachuri L, Helby J, Bojesen SE, Christiani DC, Su L, Wu X, Tardón A, Fernández-Tardón G, Field JK, Davies MP, Chen C, Goodman GE, Shepherd FA, Leighl NB, Tsao MS, Brhane Y, Brown MC, Boyd K, Shepshelovich D, Sun L, Amos CI, **Liu G**, Hung RJ. Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. *Cancer Epidemiol Biomarkers Prev.* 2019 Jul;28(7):1228-1237. **Coauthor or Collaborator.**
246. Aggarwal R, Lam ACL, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, **Liu G**, Kavanagh J. Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts. *J Thorac Oncol.* 2019 Jun;14(6):1003-1011. Epub 2019 Feb 13. Impact Factor 20.4. **Co-Senior Responsible Author. Supervising RA, ACLL, KH, HT.**
247. Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, **Liu G**, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. *Clin Lung Cancer.* 2019 May;20(3):e338-e345. Impact Factor 4.204. **Coauthor or Collaborator.**
248. Zulfan Zazuli, Leila S. Otten, Britt I. Drögemöller, Mara Medeiros, Jose G. Monzon, Galen E. B. Wright, Christian K. Kollmannsberger, Philippe L. Bedard, Zhuo Chen, Karen A. Gelmon, Nicole McGoldrick, Abhijat Kitchlu, Susanne J.H. Vijverberg, Rosalinde Masereeuw, Colin J.D. Ross, **Geoffrey Liu**, Bruce C. Carleton, Anke H. Maitland-van der Zee. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. *Genes.* 2019 May;10(5):364. Impact Factor 3.191. **Coauthor or Collaborator.**
249. Zhu Y, Wei Y, Zhang R, Dong X, Shen S, Zhao Y, Bai J, Albanes D, Caporaso NE, Landi MT, Zhu B, Chanock SJ, Gu F, Lam S, Tsao MS, Shepherd FA, Tardon A, Fernández-Somoano A, Fernandez-Tardon G, Chen C, Barnett MJ, Doherty J, Bojesen SE, Johansson M, Brennan P, McKay JD, Carreras-Torres R, Muley T, Risch A, Wichmann HE, Bickeboeller H, Rosenberger A, Rennert G, Saliba W, Arnold SM, Field JK, Davies MPA, Marcus MW, Wu X, Ye Y, Le Marchand L, Wilkens LR, Melander O, Manjer J, Brunnström H, Hung RJ, **Liu G**, Brhane Y, Kachuri L, Andrew AS, Duell EJ, Kiemeny LA, van der Heijden EH, Haugen A, Zienoldiny S, Skaug V, Grankvist K, Johansson M, Woll PJ, Cox A, Taylor F, Teare DM, Lazarus P, Schabath MB, Aldrich MC, Houlston RS, McLaughlin J, Stevens VL, Shen H, Hu Z, Dai J, Amos CI, Han Y, Zhu D, Goodman GE, Chen F, Christiani DC. Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. *Cancer Epidemiol Biomarkers Prev.* 2019 May;28(5):935-942. Impact Factor 5.057. **Coauthor or Collaborator.**
250. Liu SY, Lu L, Pringle D, Mahler M, Niu C, Charow R, Tiessen K, Lam C, Halytskyy O, Naik H, Hon H, Irwin M, Pat V, Gonos C, Chan CWT, Villeneuve J, Shani RM, Chaudhry M, Brown MC, Selby P, Howell D, Xu W, Alibhai SMH, Jones JM, **Liu G\***, Eng L\*. Impact of immigration status on health behaviors and perceptions in cancer survivors. *Cancer Med.* 2019 May;8(5):2623-2635. Impact Factor 3.202. **Co-Senior Responsible Author.**
251. Giuliani ME, **Liu G**, Xu W, Dirlea M, Selby P, Papadakos J, Abdelmutti N, Yang D, Eng L, Goldstein DP, Jones JM. Implementation of a Novel Electronic Patient-Directed Smoking Cessation Platform for Cancer Patients: Interrupted Time Series Analysis. *J Med Internet Res.* 2019 Apr;21(4):e11735. Impact Factor 4.671. **Coauthor or Collaborator.**
252. Jiang DM, Chan KKW, Jang RW, Booth C, **Liu G**, Amir E, Mason R, Everest L, Elimova E. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. *Cancer Med.* 2019 Apr;8(4):1584-1593. Impact Factor 3.202. **Coauthor or Collaborator.**
253. Vasista A, Stockler M, Martin A, Pavlakis N, Sjoquist K, Goldstein D, Gill S, Jain V, **Liu G**, Kannourakis G, Kim YH, Nott L, Snow S, Burge M, Harris D, Jonker D, Chua YJ, Epstein R, Bonaventura A, Kiely B. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. *Oncologist.* 2019 Apr;24(11):e1102-e1107. Impact Factor 5.306. **Coauthor or Collaborator.**
254. Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, Simes J, **Liu G**, Price TJ, Tebbutt NC, O'Callaghan CJ. Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. *Clin Colorectal Cancer.* 2019 Mar;18(1):e140-e149. Impact Factor 3.861. **Coauthor or Collaborator.**

255. Koshkin V, Kochmann S, Sorupanathan A, Peng C, Ailles LE, **Liu G**, Krylov SN. Cytometry of Reaction Rate Constant: Measuring Reaction Rate Constant in Individual Cells To Facilitate Robust and Accurate Analysis of Cell-Population Heterogeneity. *Anal Chem*. 2019 Mar;91(6):4186-4194. Impact Factor 6.042. **Coauthor or Collaborator**.
256. Li Y, Xiao X, Bossé Y, Gorlova O, Gorlov I, Han Y, Byun J, Leighl N, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Han J, Siminovitch K, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, **Liu G**, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickebøller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. *Oncotarget*. 2019 Mar;10(9):1760-1774. Impact Factor 5.168. **Coauthor or Collaborator**.
257. O'Kane GM, **Liu G**, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, Leighl NB. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. *Lung Cancer*. 2019 Mar;131:86-89. **Coauthor or Collaborator**.
258. Soldera SV, Shakik S, Naik H, Moskovitz M, Chen J, Mittmann N, Xu W, Hope A, Bezjak A, Parajian A, Keshavjee S, **Liu G**. Favourable health-related quality of life reported in survivors of thymic malignancies. *Eur J Cardiothorac Surg*. 2019 Feb 1;55(2):292-299. Impact Factor 3.504 (Trainee publication, Soldera SV, Shakik S, Naik H, Moskovitch M). **Senior Responsible Author**.
259. Melosky B, Cheema P, **Liu G**. Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib. *Curr Oncol*. 2019 Feb;26(1):e119-e120. Review Article. Impact Factor 1.967. **Coauthor or Collaborator**.
260. Taghizadeh N, Tremblay A, Cressman S, Peacock S, McWilliams AM, MacEachern P, Johnston MR, Goffin J, Goss G, Nicholas G, Martel S, Laberge F, Bhatia R, **Liu G**, Schmidt H, Atkar-Khattra S, Tsao MS, Tammemagi MC, Lam SC. Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. *BMJ Open*. 2019 Jan 17;9(1):e024719. **Coauthor or Collaborator**.
261. Taghizadeh N, Tremblay A, Cressman S, Peacock S, McWilliams AM, MacEachern P, Johnston MR, Goffin J, Goss G, Nicholas G, Martel S, Laberge F, Bhatia R, **Liu G**, Schmidt H, Atkar-Khattra S, Tsao MS, Tammemagi MC, Lam SC. Pan-Canadian Early Lung Cancer Study Group. Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. *BMJ Open*. 2019 Jan;9(1). Manuscript ID bmjopen-2018-024719.R1. Impact Factor 2.413. **Coauthor or Collaborator**.
262. Eng L, Pringle D, Su J, Espin-Garcia O, Niu C, Mahler M, Halytskyy O, Charow R, Lam C, Shani RM, Villeneuve J, Tiessen K, Dobriyal A, Zarrin A, Vennettilli A, Brown MC, Alibhai SMH, Howell D, Jones JM, Selby P, Xu W, **Liu G**. Patterns, perceptions and their association with changes in alcohol consumption in cancer survivors. *Eur J cancer Care (Engl)*. 2019 Jan;28(1):e12933. Impact Factor 2.409. **Senior Responsible Author**.
263. Krajcinovic M, Brukner I, Iqbal O, Bender R, Joshi VA, John T, Tsao MS, **Liu G**. Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. *Personalized Medicine*. 2019;5(4):325-329. **Coauthor or Collaborator**.
264. Saeed Moradian, BSN, PhD (nursing), MA; Monika Krzyzanowska, MD FRCPC, MD, MPH; Roma Maguire, MSc, PhD, BN; Plinio Morita, MAsC, PEng, PhD; Vishal Kukreti, MD FRCPC; Jonathan Avery, Ph.D in progress; **Geoffrey Liu**, MSc, MD; Joseph Cafazzo, BAsC, MHSc, PhD, PEng; Doris Howell, BS, RN, PhD. Usability Evaluation of a Mobile Phone- Based System for Remote Monitoring and Management of Chemotherapy-Related Side Effects in Canadian Cancer Patient. *JMIR Cancer*. 2018 Dec 21;4(2):e10932. **Coauthor or Collaborator**.

265. Shen SY, Singhanian R, Fehrer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, **Liu G**, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. *Nature*. 2018 Nov;563(7732):579-583. Epub 2018 Nov 14. **Coauthor or Collaborator**.
266. Rosenberger A, Hung RJ, Christiani DC, Caporaso NE, **Liu G**, Bojesen SE, Le Marchand L, Haiman CA, Albanes D, Aldrich MC, Tardon A, Fernández-Tardón G, Rennert G, Field JK, Kiemenev B, Lazarus P, Haugen A, Zienoldiny S, Lam S, Schabath MB, Andrew AS, Brunnsstöm H, Goodman GE, Doherty JA, Chen C, Teare MD, Wichmann HE, Manz J, Risch A, Muley TR, Johansson M, Brennan P, Landi MT, Amos CI, Pesch B, Johnen G, Brüning T, Bickeböller H, Gomolka M. Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. *Int Arch Occup Environ Health*. 2018 Nov;91(8):937-950. Epub 2018 Jul 3. Impact Factor 2.148. **Coauthor or Collaborator**.
267. Eng L, Pringle D, Su J, Shen X, Mahler M, Niu C, Charow R, Tiessen K, Lam C, Halytskyy O, Naik H, Hon H, Irwin M, Pat V, Gonos C, Chan C, Villeneuve J, Harland L, Shani RM, Brown MC, Selby P, Howell D, Xu W, **Liu G\***, Alibhai SMH\*, Jones JM\*. Patterns, perceptions, and perceived barriers to physical activity in adult cancer survivors. *Supportive Care in Cancer*. 2018 Nov;26(11):3755-3763. Epub 2018 May 29. Impact Factor 2.676. **Co-Senior Author**.
268. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, **Liu G**, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *J Thorac Oncol*. 2018 Nov;13(11):1655-1667. Epub 2018 Sep 25. Review Article. Impact Factor 10.34. **Coauthor or Collaborator**.
269. Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, **Liu G**. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. *Cancer Med*. 2018 Oct 14;7(11):5478-5487. Impact Factor 3.202 (Trainee publication, Daniel Sheshelovitch). **Senior Responsible Author**.
270. Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriy A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, **Liu G**, Hung RJ; COPDGene Investigators, Christiani DC, Schwartz AG, Amos CI, Spitz MR. Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer. *J Thorac Oncol*. 2018 Oct;13(10):1483-1495. Epub 2018 Jul 4. Impact Factor 10.34. **Coauthor or Collaborator**.
271. Kavanagh J, **Liu G**, Menezes R, O'Kane GM, McGregor M, Tsao M, Shepherd FA, Schmidt H. Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening. *Radiology*. 2018 Oct;289(1):218-224. Epub 2018 Jul 10. Impact Factor 29.146. **Co-Principal Author supervising GMO'K and MG**.
272. Zazuli Z, Vijverberg S, Slob E, **Liu G**, Carleton B, Veltman J, Baas P, Masereeuw R, Maitland-van der Zee AH. Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. *Front Pharmacol*. 2018 Sep 27. eCollection 2018. Review Article. Impact Factor 3.831. **Coauthor or Collaborator**.



273. Ferreiro-Iglesias A, Lesseur C, McKay J, Hung RJ, Han Y, Zong X, Christiani D, Johansson M, Xiao X, Li Y, Qian DC, Ji X, **Liu G**, Caporaso N, Scelo G, Zaridze D, Mukeriy A, Kontic M, Ognjanovic S, Lissowska J, Szołkowska M, Swiatkowska B, Janout V, Holcatova I, Bolca C, Savic M, Ognjanovic M, Bojesen SE, Wu X, Albanes D, Aldrich MC, Tardon A, Fernandez-Somoano A, Fernandez-Tardon G, Le Marchand L, Rennert G, Chen C, Doherty J, Goodman G, Bickeböll H, Wichmann HE, Risch A, Rosenberger A, Shen H, Dai J, Field JK, Davies M, Woll P, Teare MD, Kiemeny LA, van der Heijden EHFM, Yuan JM, Hong YC, Haugen A, Zienoldiny S, Lam S, Tsao MS, Johansson M, Grankvist K, Schabath MB, Andrew A, Duell E, Melander O, Brunnström H, Lazarus P, Arnold S, Slone S, Byun J, Kamal A, Zhu D, Landi MT, Amos CI, Brennan P. Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. *Nat Commun*. 2018 Sep 25;9(1):3927. Impact Factor 12.353. **Coauthor or Collaborator**.
274. Johnson-Obaseki S, Caulley L, Corsten M, **Liu G**, Dimitroulakos J, Goldstein D, Irish J, Rider J. C-reactive Protein in HPV-Positive and HPV-Negative Oropharyngeal Cancer. *Otolaryngol Head Neck Surg*. 2018 Sep 18. [Epub ahead of print]. Impact Factor 2.31. **Coauthor or Collaborator**.
275. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Feld R, **Liu G**, Iazzi M, Zawisza D, Nouriany N, Leighl NB. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2018 Sep;19(5):426-434. Epub 2018 May 8. Impact Factor 4.204. **Coauthor or Collaborator**.
276. Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, **Liu G**, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. *Lung Cancer*. 2018 Sep;123:22-29. Epub 2018 Jun 19. Impact Factor 4.599. **Coauthor or Collaborator**.
277. Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, **Liu G**, Bojesen SE, Le Marchand L, Albanes D, Bickeböll H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemegaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. *Nat Commun*. 2018 Aug 13;9(1):3221. Impact Factor 12.353. **Coauthor or Collaborator**.
278. Kachuri L, Saarela O, Bojesen SE, Davey Smith G, **Liu G**, Landi MT, Caporaso NE, Christiani DC, Johansson M, Panico S, Overvad K, Trichopoulou A, Vineis P, Scelo G, Zaridze D, Wu X, Albanes D, Diergaarde B, Lagiou P, Macfarlane GJ, Aldrich MC, Tardón A, Rennert G, Olshan AF, Weissler MC, Chen C, Goodman GE, Doherty JA, Ness AR, Bickeböll H, Wichmann HE, Risch A, Field JK, Teare MD, Kiemeny LA, van der Heijden EHFM, Carroll JC, Haugen A, Zienoldiny S, Skaug V, Wünsch-Filho V, Tajara EH, Ayoub Moysés R, Daumas Nunes F, Lam S, Eluf-Neto J, Lacko M, Peters WHM, Le Marchand L, Duell EJ, Andrew AS, Franceschi S, Schabath MB, Manjer J, Arnold S, Lazarus P, Mukeriy A, Swiatkowska B, Janout V, Holcatova I, Stojic J, Mates D, Lissowska J, Boccia S, Lesseur C, Zong X, McKay JD, Brennan P, Amos CI, Hung RJ. Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers. *Int J Epidemiol*. 2018 Jul 28. [Epub ahead of print]. Impact Factor 8.36. **Coauthor or Collaborator**.
279. Hall E, Tam E, Liang M, Zhang Q, Liu L, Wong L, Sarabia S, Yeung S, Gill G, Eng L, Perez-Cosio A, Brown MC, Xu W, Li M, Mittmann N, Jones J, Howell D, **Liu G**. Development and prospective evaluation of CAPLET, a cancer ambulatory patient physical function longitudinal evaluation tool for routine clinical practice. *Support Care Cancer*. 2018 Jul. [Epub ahead of print]. Impact Factor 2.676 (Trainee publication, Elizabeth Hall). **Senior Responsible Author**.
280. Avram R, Marquis-Gravel G, Simard F, Pacheco C, Couture É, Tremblay-Gravel M, Desplante O, Malhamé I, Bibas L, Mansour S, Parent MC, Farand P, Harvey L, Lessard MG, Ly H, **Liu G**, Hay AE, Marc Jolicoeur E. Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials. *Int J Cardiol*. 2018 Jul;262:110-116. Impact Factor 4.034. **Coauthor or Collaborator**.

281. Doherty MK, Leung Y, Su J, Naik H, Patel D, Eng L, Kong QQ, Mohsin F, Brown MC, Espin-Garcia O, Vennettilli A, Renouf DJ, Faluyi OO, Knox JJ, MacKay H, Wong R, Howell D, Mittmann N, Darling GE, Cella D, Xu W, **Liu G**. Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study. *Dis Esophagus*. 2018 Jun. [Epub ahead of print]. Impact Factor 2.323 (Trainee publication, M.K. Doherty). **Senior Responsible Author**.
282. Yu Y, Cheng D, Parfrey P, **Liu G**, Savas S. Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer. *PLoS One*. 2018 Jun;13(6):e0198873. eCollection 2018. Impact Factor 2.766. **Coauthor or Collaborator**.
283. Wang Z, Wei Y, Zhang R, Su L, Gogarten SM, **Liu G**, Brennan P, Field JK, McKay JD, Lissowska J, Swiatkowska B, Janout V, Bolca C, Kontic M, Scelo G, Zaridze D, Laurie CC, Doheny KF, Pugh EK, Marosy BA, Hetrick KN, Xiao X, Pikielny C, Hung RJ, Amos CI, Lin X, Christiani DC. Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. *EBioMedicine*. 2018 Jun;32:93-101. Epub 2018 May 31. Impact Factor 6.183. **Coauthor or Collaborator**.
284. Borean M, Shani K, Brown MC, Chen J, Liang M, Karkada J, Kooner S, Doherty MK, O'Kane GM, Jang R, Elimova E, Wong RK, Darling GE, Xu W, Howell D, **Liu G**. Development and Evaluation of Screening Dysphagia Tools for Observational Studies and Routine Care in Cancer Patients. *Health Sci Rep*. 2018 May;1(7):e48 (Trainee publication, Borean M, Shani K, Brown MC, Chen J, Liang M, Karkada J, Kooner S, Doherty MK, O'Kane GM, Jang R, El). **Senior Responsible Author**.
285. Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, **Liu G**, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. *Gastric Cancer*. 2018 May;21(3):473-480. Epub 2017 Aug 16. **Coauthor or Collaborator**.
286. Herman M, Warkentin MT, Shepshelovich D, Latifovic L, Hung R, **Liu G**. Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All. *J Thorac Oncol*. 2018 May;13(5):601-602. Impact Factor 10.34. **Senior Responsible Author**.
287. Alton D, Eng L, Lu L, Song Y, Su J, Farzanfar D, Mohan R, Krysz O, Mattina K, Harper C, Liu S, Yoannidis T, Milne R, Brown MC, Vennettilli A, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, **Liu G\***, Giuliani ME\*. Perceptions of Continued Smoking and Smoking Cessation Among Patients With Cancer. *J Oncol Pract*. 2018 Apr;14(5):e269-e279. Epub 2018 Apr 20. Impact Factor 2.509 (Trainee publication, Lawson Eng). **Senior Responsible Author**.
288. Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, **Liu G**, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. *Gastroenterology*. 2018 Apr;154(5):1273-1281. Epub 2017 Dec 13. **Coauthor or Collaborator**.
289. Drögemöller BI, Brooks B, Monzon JG, Wright GE, **Liu G**, Renouf DJ, Kollmannsberger C, Bedard PL, Hayden MR, Gelmon KA, Carleton B, Ross CJ. Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. *Clin Cancer Res*. 2018 Apr;24(8):1866-1871. Epub 2018 Jan 22. Impact Factor 10.199. **Coauthor or Collaborator**.
290. Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, **Liu G**, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA. Lung cancer in never smokers from the Princess Margaret Cancer Centre. *Oncotarget*. 2018 Apr;9(32):22559-22570. eCollection 2018 Apr 27. Impact Factor 5.168. **Coauthor or Collaborator**.
291. Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Corley DA, Shaheen NJ, Lagergren J, Hardie LJ, Reid BJ, Iyer PG, Risch HA, Caldas C, Caldas I, Pharoah PD, **Liu G**, Gammon MD, Chow WH, Bernstein L, Bird NC, Ye W, Wu AH, Anderson LA, MacGregor S, Whiteman DC, Vaughan TL, Thrift AP. Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. *Clin Gastroenterol Hepatol*. 2018 Mar 15. S1542-3565(18)30262-3.[Epub ahead of print]. Impact Factor 7.683. **Coauthor or Collaborator**.

292. Li Y, Xiao X, Han Y, Gorlova O, Qian D, Leighl N, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, **Liu G**, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickebøller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. *Carcinogenesis*. 2018 Mar 8;39(3):336-346. Impact Factor 5.072. **Coauthor or Collaborator**.
293. Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, **Liu G**, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. *Clin Colorectal Cancer*. 2018 Mar;17(1):73-79. pii: S1533-0028(17)30150-0. [Epub 2017 Oct 23]. Impact Factor 3.46. **Coauthor or Collaborator**.
294. Pasic I, Wong KM, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown C, Bucur R, Reisman D, Knox JJ, Xu W, Hung RJ, **Liu G\***, Cleary SP\*. Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. *Mol Carcinog*. 2018 Jan;57(1):106-113. Epub 2017 Oct 9. **Co-Senior Author**.
295. Lohavanichbutr P, Sakoda LC, Amos CI, Arnold SM, Christiani DC, Davies MPA, Field JK, Haura EB, Hung RJ, Kohno T, Landi MT, **Liu G**, Liu Y, Marcus MW, O'Kane GM, Schabath MB, Shiraishi K, Slone SA, Tardón A, Yang P, Yoshida K, Zhang R, Zong X, Goodman GE, Weiss NS, Chen C. Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium. *Clin Cancer Res*. 2017 Dec;23(24):7550-7557. Epub 2017 Oct 3. **Coauthor or Collaborator**.
296. Tammemagi MC, Schmidt H, Martel S, McWilliams A, Goffin JR, Johnston MR, Nicholas G, Tremblay A, Bhatia R, **Liu G**, Soghrati K, Yasufuku K, Hwang DM, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Nasute Fauerbach PV, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart L, Tsai S, Haider E, Boylan C, Cutz JC, Manos D, Xu Z, Goss GD, Seely JM, Amjadi K, Sekhon HS, Burrowes P, MacEachern P, Urbanski S, Sin DD, Tan WC, Leighl NB, Shepherd FA, Evans WK, Tsao MS, Lam S; PanCan Study Team. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. *Lancet Oncol*. 2017 Nov;18(11):1523-1531. Epub 2017 Oct 18. **Coauthor or Collaborator**.
297. Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, **Liu G**, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. *JAMA Oncol*. 2017 Nov;3(11):1558-1562. **Coauthor or Collaborator**.
298. Foreman A, Lee DJ, McMullen C, de Almeida J, Muhanna N, Gama RR, Giuliani M, **Liu G**, Bratman SV, Huang SH, O'Sullivan B, Song Y, Xu W, Goldstein DP. Impact of Type 2 Diabetes Mellitus on Survival in Head and Neck Squamous Cell Carcinoma. *Otolaryngol Head Neck Surg*. 2017 Oct;157(4):657-663. Epub 2017 Aug 29. **Coauthor or Collaborator**.
299. Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, **Liu G**, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. *Gut*. 2017 Oct;66(10):1739-1747. pii: gutjnl-2016-311622. [Epub 2016 Aug 2]. **Coauthor or Collaborator**.
300. Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, **Liu G**, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). *Lung Cancer*. 2017 Sep;111:23-29. Epub 2017 Jun 24. **Coauthor or Collaborator**.

301. Wang T, Moon JY, Wu Y, Amos CI, Hung RJ, Tardon A, Andrew A, Chen C, Christiani DC, Albanes D, Heijden EHFV, Duell E, Rennert G, Goodman G, **Liu G**, McKay JD, Yuan JM, Field JK, Manjer J, Grankvist K, Kiemeny LA, Marchand LL, Teare MD, Schabath MB, Johansson M, Aldrich MC, Davies M, Johansson M, Tsao MS, Caporaso N, Lazarus P, Lam S, Bojesen SE, Arnold S, Wu X, Zong X, Hong YC, Ho GYF. Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium. PLoS One. 2017 Sep;12(9):e0185660. eCollection 2017. **Coauthor or Collaborator**.
302. Cressman S, Peacock SJ, Tammemagi MC, Evans WK, Leighl NB, Goffin JR, Tremblay A, **Liu G**, Manos D, MacEachern P, Bhatia R, Puksa S, Nicholas G, McWilliams A, Mayo JR, Yee J, English JC, Pataky R, McPherson E, Atkar-Khattra S, Johnston MR, Schmidt H, Shepherd FA, Soghrati K, Amjadi K, Burrows P, Couture C, Sekhon HS, Yasufuku K, Goss G, Ionescu DN, Hwang DM, Martel S, Sin DD, Tan WC, Urbanski S, Xu Z, Tsao MS, Lam S. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. J Thorac Oncol. 2017 Aug;12(8):1210-1222. Epub 2017 May 10. **Coauthor or Collaborator**.
303. Habbous S, Chu KP, Lau H, Schorr M, Belayneh M, Ha MN, Murray S, O'Sullivan B, Huang SH, Snow S, Parliament M, Hao D, Cheung WY, Xu W, **Liu G**. Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. CMAJ. 2017 Aug;189(32):E1030-E1040. Impact Factor 7.7 (Trainee publication, GL supervised SH, KPC). **Senior Responsible Author**.
304. O'Kane GM, Bradbury PA, Feld R, Leighl NB, **Liu G**, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017 Jul;109:137-144. Epub 2017 Apr 27. **Coauthor or Collaborator**.
305. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, Byun J, Dunning A, Pooley KA, Qian DC, Ji X, **Liu G**, Timofeeva MN, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeboller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemegaard A, Saliba W, Haiman CA, Wilkens LR, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden HFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty JA, Barnett MP, Chen C, Goodman GE, Cox A, Taylor F, Woll P, Bröske I, Wichmann HE, Manz J, Muley TR, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd FA, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Et Al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017 Jul;49(7):1126-1132. Epub 2017 Jun 12. **Coauthor or Collaborator**.
306. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, **Liu G**, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Filip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):874-866. Epub 2017 Jun 9. **Coauthor or Collaborator**.
307. Leighl NB, Tsao MS, **Liu G**, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA. A phase I study of foretinib plus erlotinib in patients previously treated advanced non-small cell lung cancer: Canadian Cancer Trials Group IND.196. Oncotarget. 2017 Jun 28;8(41):69651-69662. eCollection. **Coauthor or Collaborator**.
308. Carreras-Torres R, Johansson M, Haycock PC, Wade KH, Relton CL, Martin RM, Davey Smith G, Albanes D, Aldrich MC, Andrew A, Arnold SM, Bickeboller H, Bojesen SE, Brunnström H, Manjer J, Bröske I, Caporaso NE, Chen C, Christiani DC, Christian WJ, Doherty JA, Duell EJ, Field JK, Davies MPA, Marcus MW, Goodman GE, Grankvist K, Haugen A, Hong YC, Kiemeny LA, van der Heijden EHFV, Kraft P, Johansson MB, Lam S, Landi MT, Lazarus P, Le Marchand L, **Liu G**, Melander O, Park SL, Rennert G, Risch A, Haura EB, Scelo G, Zaridze D, Mukeriya A, Savić M, Lissowska J, Swiatkowska B, Janout V, Holcatova I, Mates D, Schabath MB, Shen H, Tardon A, Teare MD, Woll P, Tsao MS, Wu X, Yuan JM, Hung RJ, Amos CI, McKay J, Brennan P. Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PLoS One. 2017 Jun 8;12(6):e0177875. eCollection 2017. **Coauthor or Collaborator**.

309. Gama RR, Song Y, Zhang Q, Brown MC, Wang J, Habbous S, Tong L, Huang SH, O'Sullivan B, Waldron J, Xu W, Goldstein D, **Liu G**. Body mass index and prognosis in patients with head and neck cancer. *Head Neck*. 2017 Jun;39(6):1226-1233. Epub 2017 Mar 21. **Senior Responsible Author**.
310. **Liu G**, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcborg JR, Karapetis CS, Dobrovic A. Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. *Clin Cancer Res*. 2017 May 15;22(10):2435-44. **Principal Author**.
311. Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, **Liu G**, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. *Radiother Oncol*. 2017 May;123(2):195-202. Epub 2017 Mar 28. **Coauthor or Collaborator**.
312. Korpanty GJ, Eng L, Qiu X, Olusesan Faluyi O, Renouf DJ, Cheng D, Patel D, Chen Z, Tse BC, Knox JJ, Dodbiba L, Teichman J, Azad AK, Wong R, Darling G, Reisman D, Cuffe S, **Liu G**, Xu W. Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome. *Oncotarget*. 2017 Apr;8(17):28093-28100. doi: 10.18632/oncotarget.15890. **Senior Responsible Author**.
313. Spreafico A, Coate L, Zhai R, Xu W, Chen ZF, Chen Z, Patel D, Tse B, Brown MC, Heist RS, Dodbiba L, Teichman J, Kulke M, Su L, Eng L, Knox J, Wong R, Darling GE, Christiani DC, **Liu G**. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. *Cancer Epidemiol*. 2017 Apr(47):28-34. [Epub 2017 Jan 12]. **Senior Responsible Author**.
314. Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, Lloyd A, Delahaye-Sourdeix M, Chubb D, Gaborieau V, Wheeler W, Chatterjee N, Thorleifsson G, Sulem P, **Liu G**, Kaaks R, Henrion M, Kinnersley B, Vallée M, Le Calvez-Kelm F, Stevens VL, Gapstur SM, Chen WV, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Krokan HE, Gabrielsen ME, Skorpen F, Vatten L, Njølstad I, Chen C, Goodman G, Benhamou S, Vooder T, Välik K, Nelis M, Metspalu A, Lener M, Lubiński J, Johansson M, Vineis P, Agudo A, Clavel-Chapelon F, Bueno-de-Mesquita HB, Trichopoulos D, Khaw KT, Johansson M, Weiderpass E, Tjønneland A, Riboli E, Lathrop M, Scelo G, Albanes D, Caporaso NE, Ye Y, Gu J, Wu X, Spitz MR, Dienemann H, Rosenberger A, Su L, Matakidou A, Eisen T, Stefansson K, Risch A, Chanock SJ, Christiani DC, Hung RJ, Brennan P, Landi MT, Houlston RS, Amos CI. Corrigendum: Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nat Genet*. 2017 Mar;49(4):651. **Coauthor or Collaborator**.
315. Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, Leighl NB, **Liu G**, Feld R, Burkes R, Wollner M, Tsao MS, Shepherd FA. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. *Clin Lung Cancer*. 2017 Mar;18(2):156-161. [Epub 2016 Oct 26]. **Coauthor or Collaborator**.
316. Wu L, Allo G, John T, Li M, Tagawa T, Opitz I, Anraku M, Yun Z, Pintilie M, **Liu G**, Pitcher B, Feld R, Johnston MR, de Perrot M, Tsao MS. Patient-derived xenograft establishment from human malignant pleural mesothelioma. *Clin Cancer Res*. 2017 Feb 15;23(4):1060-1067. pii: clincanres.0844.2016. [Epub 2016 Sep 28]. **Coauthor or Collaborator**.
317. Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, **Liu G**, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. *Int J Cancer*. 2017 Feb;140(3):662-673. **Coauthor or Collaborator**.
318. Naik H, Howell D, Su J, Qiu X, Brown MC, Vennettilli A, Irwin M, Pat V, Solomon H, Wang T, Hon H, Eng L, Mahler M, Thai H, Ho V, Xu W, Seung SJ, Mittmann N, **Liu G**. EQ-5D health utility scores: data from a comprehensive Canadian cancer centre. *Patient*. 2017 Feb;10(1):105-115. **Senior Responsible Author**.

319. Lam C, Liu WF, Bel RD, Chan K, Miller L, Brown MC, Chen Z, Cheng D, Patel D, Xu W, Darling GE, **Liu G**. Polymorphisms of the FOXF1 and MHC locus genes in individuals undergoing esophageal acid reflux assessments. *Dis Esophagus*. 2017 Feb;30(2):1-7. (Supervising CL, WFL, RDB, KC, LM, MCB, ZC, DC, DP) (Trainee publication). **Senior Responsible Author**.
320. Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, **Liu G**. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. *Cancer Med*. 2017 Feb;6(2):361-373. [Epub 2017 Jan11]. **Senior Responsible Author**.
321. Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leigh N, Maione P, Morabito A, **Liu G**, Tsao MS, Perrone F, Gridelli C. Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. *Oncotarget*. 2017 Feb;8:57528-57536. eCollection 2017. **Coauthor or Collaborator**.
322. Koshkin V, Ailles LE, **Liu G**, Krylov SN. Preservation of the 3D Phenotype Upon Dispersal of Cultured Cell Spheroids into Monolayer Cultures. *J Cell Biochem*. 2017 Jan;118(1):154-162. Epub 2016 Jun 21. **Coauthor or Collaborator**.
323. Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O'Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, Leigh NB, Bradbury PA, Shepherd FA, Xu W, **Liu G**, Howell D. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. *Clin Lung Cancer*. 2016 Dec 28;16:30391-6. pii: S1525-7304(16)30391-6. [Epub ahead of print]. **Senior Responsible Author**.
324. Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, **Liu G**, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of Standard Radiotherapy with Cisplatin vs Accelerated Radiotherapy with Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. *JAMA Oncol*. 2016 Dec 8. [Epub ahead of print]. **Coauthor or Collaborator**.
325. Goody R, Mackay H, Gill B, Oza A, Siu L, Kim J, Wong R, Chen E, Swallow C, Knox J, Kassam Z, Cummings B, Feld R, Hedley D, **Liu G**, Kryzanowska M, Diniwell R, Brade A, Dawson L, Pullie M, Ringash J. Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. *Int J Radiat Oncol Biol Phys*. 2016 Dec 1;96(5):994-1002. **Coauthor or Collaborator**.
326. Kachuri L, Latifovic L, **Liu G**, Hung RJ. Systematic review of genetic variation in chromosome 5p15.33 and telomere length as predictive and prognostic biomarkers for lung cancer. *Cancer Epidemiol Biomarkers Prev*. 2016 Dec;25(12):1537-1549. pii: cebp.0200.2016. [Epub ahead of print]. **Coauthor or Collaborator**.
327. Segedi M, Anderson LN, Espin-Garcia O, Borgida A, Bianco T, Cheng D, Chen Z, Patel D, Brown MC, Xu W, Reisman D, Gallinger S, Cotterchio M, Hung R, **Liu G**, Cleary SP. BRM polymorphisms, pancreatic cancer risk and survival. *Int J Cancer*. 2016 Dec;139(11):2474-81. Epub 2016 Aug 18. **Senior Responsible Author**.
328. Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, **Liu G**, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsagué X, Conway DI, Holcátová I, Mates D, Vilensky M, Healy CM, Szeszenia-Dąbrowska N, Fabiánová E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. *Nat Genet*. 2016 Dec;48(12):1544-1550. doi: 10.1038/ng.3685. **Coauthor or Collaborator**.
329. Naik H, Qiu X, Brown MC, Eng L, Pringle D, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Charow R, Pat V, Irwin M, Herzog L, Ho A, Xu W, Jones J, Howell D, **Liu G**. Socioeconomic Status and Lifestyle Behaviours in Cancer Survivors: Smoking and Physical Activity. *Curr Oncol*. 2016 Dec;23(6):e546-e555 (Trainee publication). **Senior Responsible Author**.

330. **Liu G**, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J. Association between time to progression and subsequent survival in ceritinib-treated patients with advanced ALK-positive non-small cell lung cancer. *Curr Med Res Opin*. 2016 Nov;32(11):1911-1918. **Senior Responsible Author**.
331. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RG, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, **Liu G**, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WH, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. *Lancet Oncol*. 2016 Oct;17(10):1363-1373. [Epub ahead of print]. **Coauthor or Collaborator**.
332. Naik H, Qiu X, Brown MC, Mahler M, Hon H, Tiesen K, Thai H, Ho V, Gonos C, Charow R, Pat V, Irwin M, Herzog L, Eng L, Pringle D, Ho A, Xu W, Howell D, eung S, **Liu G**, Mittmann N. Cancer Patients? Willingness to Routinely Complete the EQ-5D Instrument at Clinic Visits. *J Popul Ther Clin Pharmacol*. 2016 Sep 13;23(3):e196-e204. **Senior Responsible Author**.
333. Chen LS, Baker T, Hung RJ, Horton A, Culverhouse R, Hartz S, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Rosenberg A, Aben KK, Andrew AS, Cheng SC, Saum KU, Dienemann H, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Sjaug V, van der Heijden EH, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeboller H, Brenner H, Duell EJ, Haugen A, Bruske I, Kiemeny LA, Lazarus P, Marchand LL, **Liu G**, Mayordomo J, Risch A, Schwartz AG, Teare MD, Wu X, Wiencke JK, Yang P, Zhang ZF, Spitz MR, Amos CI, Bierut LJ. Genetic risk can be decreased: Quitting smoking decreases and delays lung cancer for smokers with high and low CHR5 risk genotypes - A Meta-analysis. *EBioMedicine*. 2016 Sep;11:219-226. **Coauthor or Collaborator**.
334. Tan DS, Araújo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, **Liu G**. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced or Metastatic NSCLC: An Adjusted Comparison with External Controls. *J Thorac Oncol*. 2016 Sep;11(9):1550-7. [Epub 2016 Jun 8]. **Senior Responsible Author**.
335. Leung YW, Brown C, Cosio AP, Dobriyal A, Malik N, Pat V, Irwin M, Tomasini P, **Liu G**, Howell D. Feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care. *Cancer*. 2016 Sep;122(18):2906-17. **Co-Principal Author**.
336. Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, **Liu G**, Tsao MS. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. *Clin Lung Cancer*. 2016 Sep;17(5):375-383. pii: S1525-7304(16)00005-X. [Epub ahead of print]. **Coauthor or Collaborator**.
337. Lee JW, Pussegoda K, Rassekh RS, Monzon JG, **Liu G**, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC; CPNDS clinical recommendations group. Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. *Ther Drug Monit*. 2016 Aug;38(4):423-31. [Epub ahead of print]. **Coauthor or Collaborator**.
338. Carreras-Torres R, Haycock PC, Relton CL, Martin RM, Smith GD, Kraft P, Gao C, Twohoger S, Le Marchand L, Wilkens LR, Park SL, Haiman C, Field JK, Davies M, Marcus M, **Liu G**, Caporaso NE, Christiani DC, Wei Y, Chen C, Doherty JA, Severi G, Goodman GE, Hung RJ, Amos CI, McKay J, Johansson M, Brennan P. The causal relevance of body mass index in different histological types of lung cancer: A Mendelian randomization study. *Sci Rep*. 2016 Aug. 6:31121. doi: 10.1038/srep31121. **Coauthor or Collaborator**.
339. Azad AK, Bairati I, Qiu X, Girgis H, Cheng L, Waggott D, Cheng D, Mirshams M, Ho J, Fortin A, Vigneault E, Huang SH, O'Sullivan B, Waldron J, Boutros PC, Goldstein D, Meyer F, Xu W, **Liu G**. A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. *Cancer Epidemiol*. 2016 Jun(42):173-180. **Senior Responsible Author**.

340. Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, **Liu G**, Morzycki W, Tsao MS, Xu Z, Hirsh V. Canadian Consensus: Inhibition of Anaplastic Lymphoma Kinase (ALK) Positive Tumours in Advanced Non-Small Cell Lung Cancer (NSCLC). *Current Oncol*. 2016 Jun;23(3):196-200. Epub 2016 Jun 9. **Coauthor or Collaborator**.
341. Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S, Wozniak A, Chachoua A, Leighl N, Tsao MS, de Perrot M, Xu W, **Liu G**. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2016 Jun;11(6):900-9. (Supervising ZC, DP, OE-G). (Trainee publication). **Senior Responsible Author**.
342. **Liu G**, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd L, Jonker D, O'Callaghan C, Zalberg JR, Karapetis CS, Dobrovic A. Fc-γ-Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer Survival. *Clin Cancer Res*. 2016 May;22(10):2435-44. AACR Press Release. Impact Factor 10.2 (Trainee publication, GL supervised ZC, EM, and DC.). **Senior Responsible Author**.
343. Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, De Perrot M, Shepherd FA, **Liu G**, Tsao M, Leighl NB. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. *Oncotarget*. 2016 May;7(18):25632-9. *oncotarget*.8350. [Epub ahead of print]. **Coauthor or Collaborator**.
344. Sampson L, Papadakos J, Milne V, Le LW, **Liu G**, Abdelmutti N, Milne R, Goldstein DP, Eng L, Giuliani M. Preferences for the Provision of Smoking Cessation Education Among Cancer Patients. *J Cancer Educ*. 2016 Apr 13. [Epub ahead of print]. **Coauthor or Collaborator**.
345. Kim DW, Mehra R, Tan DS, Filip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, **Liu G**, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol*. 2016 Apr;17(4):452-63. [Epub 2016 Mar 11]. **Coauthor or Collaborator**.
346. Martin P, Brown MC, Espin-Garcia O, Cuffe S, Pringle D, Mahler M, Villeneuve J, Niu C, Charow R, Lam C, Shani RM, Hon H, Otsuka M, Xu W, Alibhai S, Jenkinson J, **Liu G**. Patient preference: a comparison of electronic patient-completed questionnaires with paper among cancer patients. *Eur J Cancer Care*. 2016 Mar;25(2):334-41 (Trainee publication). **Senior Responsible Author**.
347. Gharahkhani P, Tung J, Hinds D, Mishra A; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), Vaughan TL, Whiteman DC, MacGregor S; BEACON study investigators. Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus. *Hum Mol Genet*. 2016 Feb;25(4):828-35. 2015 Dec 23. pii: ddv512. [Epub ahead of print]. **Coauthor or Collaborator**.
348. Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, **Liu G**. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. *Cancer Epidemiol*. 2016 Jan;24(41):50-56 (Trainee publication, Cuffe S, Azad AK, Qiu X, Chen Z, Cheng D). **Senior Responsible Author**.
349. Kachuri L, Amos CI, McKay JD, Johansson M, Vineis P, Bueno-de-Mesquita HB, Boutron-Ruault MC, Johansson M, Quirós JR, Sieri S, Travis RC, Weiderpass E, Le Marchand L, Henderson BE, Wilkens L, Goodman G, Chen C, Doherty JA, Christiani DC, Wei Y, Su L, Tworoger S, Zhang X, Kraft P, Zaridze D, Field JK, Marcus MW, Davies MP, Hyde R, Caporaso NE, Landi MT, Severi G, Giles GG, **Liu G**, McLaughlin JR, Li Y, Xiao X, Fehringer G, Zong X, Denroche RE, Zuzarte PC, McPherson JD, Brennan P, Hung RJ. Fine-mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci. *Carcinogenesis*. 2016 Jan;37(1):96-105. *carcin/bgv165*. Epub 2015 Nov 20. **Coauthor or Collaborator**.
350. Lim C, Sung M, Shepherd FA, Nouriany N, Sawczak M, Paul T, Perera-Low N, Foster A, Zawisza D, Feld R, **Liu G**, Leighl NB. Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? *J Thorac Oncol*. 2016 Jan;11(1):79-84. doi: 10.1016/j.jtho.2015.09.006 Co-Senior Responsible Author. **Coauthor or Collaborator**.



351. Koshkin V, Ailles LE, **Liu G**, Krylov SN. Metabolic suppression of a drug resistant subpopulation in cancer spheroid cells. *J Cell Biochem*. 2016 Jan;117(1):59-65. doi: 10.1002/jcb.25247. **Coauthor or Collaborator**.
352. Morgen EK, Lenz H-J, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, **Liu G**. Germline polymorphisms as biomarkers of tumour response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. *the Pharmacogenomics Journal*. 2016:1-7. **Senior Responsible Author**.
353. Chu KP, Habbous S, Kuang Q, Boyd K, Mirshams M, Liu FF, Espin-Garcia O, Xu W, Goldstein D, Waldron J, O'Sullivan B, Huang SH, **Liu G**. Socioeconomic status, human papillomavirus, and overall survival in head and neck squamous cell carcinomas in Toronto, Canada. *Cancer Epidemiol*. 2015 Dec 17(40):102-12. (Supervising KPC, SH, QK, KB, MM, OE-G). **Senior Responsible Author**.
354. Horgan AM, Darling G, Wong R, Guindi M, **Liu G**, Jonker DJ, Lister J, Xu W, MacKay HM, Dinniwell R, Kim J, Pierre A, Shargall Y, Asmis TR, Agboola O, Seely AJ, Ringash J, Wells J, Marginean EC, Haider M, Knox JJ. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial. *Dis Esophagus*. 2015 Dec 10. doi: 10.1111/dote.12444. [Epub ahead of print]. **Coauthor or Collaborator**.
355. Huang R, Wei Y, Hung RJ, **Liu G**, Su L, Zhang R, Zong X, Zhang ZF, Morgenstern H, Bröske I, Heinrich J, Hong YC, Kim JH, Cote M, Wenzlaff A, Schwartz AG, Stucker I, McLaughlin J, Marcus MW, Davies MP, Liloglou T, Field JK, Matsuo K, Barnett M, Thornquist M, Goodman G, Wang Y, Chen S, Yang P, Duell EJ, Andrew AS, Lazarus P, Muscat J, Woll P, Horsman J, Dawn Teare M, Flugelman A, Rennert G, Zhang Y, Brenner H, Stegmaier C, van der Heijden EH, Aben K, Kiemeny L, Barros-Dios J, Pérez-Ríos M, Ruano-Ravina A, Caporaso NE, Bertazzi PA, Landi MT, Dai J, Shen H, Fernandez-Tardon G, Rodriguez-Suarez M, Tardon A, Christiani DC. Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. *EBioMedicine*. 2015 Nov;2(11):1677-1685. eCollection 2015. **Coauthor or Collaborator**.
356. Ek WE, Lagergren K, Cook M, Wu AH, Abnet C, Levine D, Chow WH, Bernstein L, Risch HA, Shaheen NJ, Bird NC, Corley DA, Hardie LJ, Fitzgerald RC, Gammon S, Romero Y, **Liu G**, Ye W, Vaughan TL, MacGregor S, Whitman DC, Westberg L, Lagergren J. Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. *Int J Cancer*. 2015 Oct 5;138(5):1146-52. doi: 10.1002/ijc.29863. Epub 2015 Oct 5. **Coauthor or Collaborator**.
357. Ahmadizar F, Onland-Moret NC, de Boer A, **Liu G**, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One*. 2015 Oct;10(10):e0141704. doi: 10.1371/journal.pone.0141704. eCollection 2015. **Coauthor or Collaborator**.
358. Brenner DR, Amos CI, Brhane Y, Timofeeva MN, Caporaso N, Wang Y, Christiani DC, Bickeböller H, Yang P, Albanes D, Stevens VL, Gapstur S, McKay J, Boffetta P, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Krokan HE, Skorpén F, Gabrielsen ME, Vatten L, Njølstad I, Chen C, Goodman G, Lathrop M, Vooder T, Vålk K, Nelis M, Metspalu A, Broderick P, Eisen T, Wu X, Zhang D, Chen W, Spitz MR, Wei Y, Su L, Xie D, She J, Matsuo K, Matsuda F, Ito H, Risch A, Heinrich J, Rosenberger A, Muley T, Dienemann H, Field JK, Raji O, Chen Y, Gosney J, Liloglou T, Davies MP, Marcus M, McLaughlin J, Orlov I, Han Y, Li Y, Zong X, Johansson M; EPIC Investigators, **Liu G**, Tworoger SS, Le Marchand L, Henderson BE, Wilkens LR, Dai J, Shen H, Houlston RS, Landi MT, Brennan P, Hung RJ. Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. *Carcinogenesis*. 2015 Sep 10;36(11):1314-26. doi: 10.1093/carcin/bgv128. Epub 2015 Sep 10. **Coauthor or Collaborator**.
359. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, **Liu G**, Tsao MS. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. *J Clin Oncol*. 2015 Aug 1;33(22):2472-80. (Co-Supervising ELS with MST). **Coauthor or Collaborator**.

360. Niu C, Eng L, Qiu X, Shen X, Espin-Garcia O, Song Y, Pringle D, Mahler M, Halytskyy O, Charow R, Lam C, Shani RM, Villeneuve J, Tiessen K, Brown MC, Selby P, Howell D, Jones JM, Xu W, **Liu G**, Alibhai SM. Lifestyle Behaviors in Elderly Cancer Survivors: A Comparison With Middle-Age Cancer Survivors. *J Oncol Pract*. 2015 Jul;11(4):e450-9. **Senior Responsible Author**.
361. Niu C, Eng L, Qiu X, Shen X, Espin-Garcia O, Song Y, Pringle D, Mahler M, Halytskyy O, Charow R, Lam C, Shani RM, Villeneuve J, Tiessen K, Brown MC, Selby P, Howell D, Jones JM, Xu W, **Liu G**, Alibhai SM. Lifestyle behaviours in elderly cancer survivors: a comparison with middle-age cancer survivors. *J Oncol Pract*. 2015 Jun 9;11(4):e450-9. (Supervising CN, LE, XQ, XS, OEG, DP, MM, OH, RC, CL, RMS, JV, MCB). **Senior Responsible Author**.
362. Buas MF, Onstad L, Levine DM, Risch HA, Chow WH, **Liu G**, Fitzgerald RC, Bernstein L, Ye W, Bird NC, Romero Y, Casson AG, Corley DA, Shaheen NJ, Wu AH, Gammon MD, Reid BJ, Hardie LJ, Peters U, Whiteman DC, Vaughan TL. MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. *PLoS One*. 2015 Jun 3;10(6). doi: 10.1371/journal.pone.0128617. eCollection 2015. **Coauthor or Collaborator**.
363. Eng L, Azad AK, Qiu X, Kong QQ, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, **Liu G**, Faluyi OO. Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome. *Carcinogenesis*. 2015 May 25;36(9):956-62. (Supervising LE, AKA, DC, LD, DJR, OOF). (Trainee publication). **Senior Responsible Author**.
364. Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Lutz S, Rosenberger A, Aben KK, Andrew AS, Breslau N, Chang SC, Dieffenbach AK, Dienemann H, Frederiksen B, Han J, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Skaug V, van der Heijden HF, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeboller H, Brenner H, Duell EJ, Haugen A, Heinrich J, Hokanson JE, Hunter DJ, Kiemeny LA, Lazarus P, Le Marchand L, **Liu G**, Mayordomo J, Risch A, Schwartz AG, Teare D, Wu X, Wiencke JK, Yang P, Zhang ZF, Sptiz MR, Kraft P, Amos CI, Bierut LJ. CHRNA5 Risk Variant Predicts Delayed Smoking Cessation and Earlier Lung Cancer Diagnosis-A Meta-Analysis. *J Natl Cancer Inst*. 2015 May;107(5). jnci/djv100. Print 2015 May. **Coauthor or Collaborator**.
365. Lim C, Tsao MS, Le LW, Shepherd FA, Feld R, Burkes RL, **Liu G**, Kamel-Reid S, Hwang D, Tanguay J, da Cunha Santos G, Leighl NB. Biomarker testing and time to treatment decision in patients with advanced non-small cell lung cancer. *Ann Oncol*. 2015 Apr 28;26(7):1415-21. doi: 10.1093/annonc/mdv208. Epub 2015 Apr 28. **Coauthor or Collaborator**.
366. Winn DM, Lee YC, Hashibe M, Boffetta P, INHANCE consortium. The INHANCE consortium: toward a better understanding of the causes and mechanisms of head and neck cancer. *Oral Dis*. 2015 Apr 24;21(6):685-93. doi: 10.1111/odi.12342. Epub 2015 Apr 24. **Coauthor or Collaborator**.
367. Eng L, Qiu X, Su J, Pringle D, Niu C, Mahler M, Charow R, Villeneuve J, Halytskyy O, Lam C, Tiessen K, Brown MC, Howell D, Giuliani ME, Jones JM, Alibhai SM, Goldstein DP, Xu W, Selby P, **Liu G**. The role of second-hand smoke exposure on smoking cessation in non-tobacco-related cancers. *Cancer*. 2015 Apr 15;121(15):2655-63. (Supervising LE, XQ, JS, DP, CN, MM, RC, JV, OH, CL, KT, MCB). (Trainee publication). **Senior Responsible Author**.
368. Graham DM, Isaranuwachai W, Habbous S, de Oliveira C, **Liu G**, Siu LL, Hoch JS. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. *Cancer*. 2015 Apr 13;121(11):1785-92. doi: 10.1002/cncr.29111. Epub 2015 Apr 13. **Coauthor or Collaborator**.
369. Leung JM, Mayo J, Tan W, Tammemagi CM, **Liu G**, Peacock S, Shepherd FA, Goffin J, Goss G, Nicholas G, Tremblay A, Johnston M, Martel S, Laberge F, Bhatia R, Roberts H, Burrowes P, Manos D, Stewart L, Gingras M, Pasian S, Tsao MS, Lam S, Sin DD; Pan-Canadian Early Lung Cancer Study Group. Plasma pro-surfactant protein B and lung function decline in smokers. *Eur Respir J*. 2015 Apr;45(4):1037-45. Epub 2015 Jan 22. **Coauthor or Collaborator**.
370. Wei Y, Vellanki RN, Coyaud E, Ignatchenko V, Li L, Krieger JR, Taylor P, Tong J, Pham NA, **Liu G**, Raught B, Wouters BG, Kislinger T, Tsao MS, Moran MF. CHCHD2 is co-amplified with EGFR in NSCLC and regulates mitochondrial function and cell migration. *Mol Cancer Res*. 2015 Mar 17;13(7):1119-29. doi: 10.1158/1541-7786.MCR-14-0165-T. Epub 2015 Mar 17. **Coauthor or Collaborator**.

371. Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch S, Mackay HJ, Biagi J, Reedijk M, Weberpals JI, Fleming GF, Wang L, **Liu G**, Chen Z, Blattler C, Ivy SP, Oza AM. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Cancer Centre, Chicago and California phase II consortia. *Gynecol Oncol*. 2015 Mar 11;137(2):216-22. doi: 10.1016/j.ygyno.2015.03.005. Epub 2015 Mar 11. **Coauthor or Collaborator**.
372. Doddiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, Chen Z, Girgis H, Eng L, Espin-Garcia O, Shen X, Bandarchi B, Schwock J, Tsao MS, El-Zimaity H, Der SD, Xu W, Bristow RG, Darling GE, Boutros PC, Ailles LE, **Liu G**. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. *PLoS One*. 2015 Mar;10(3):e0121872. eCollection 2015 (Supervising LD, JT, AF, HT, ZC, HG, LE, OEG, XS) (Trainee publication). **Senior Responsible Author**.
373. Cuffe S, Hon H, Tobros K, Espin-Garcia O, Brhane Y, Harland L, Fadhel E, Eng L, LaDelfa A, Waldron J, Siu LL, Chen BE, Xu W, Simmons C, Kassam Z, Montenegro A, Parulekar WR, **Liu G**. Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial. *Clin Trials*. 2015 Jan 29;12(3):237-45. (Supervising SC, HH, KT, OE-G, YB, LH, EF, LE, AL). (Trainee publication). **Senior Responsible Author**.
374. Poirier JG, Brennan P, McKay JD, Spitz MR, Bickeböller H, Risch A, **Liu G**, Le Marchand L, Tworoger S, McLaughlin J, Rosenberger A, Heinrich J, Brüske I, Muley T, Henderson BE, Wilkens LR, Zong X, Li Y, Hao K, Timens W, Bossé Y, Sin DD, Obeidat M, Amos CI, Hung RJ. Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer. *Genet Epidemiol*. 2015 Jan 19;39(3):197-206. doi: 10.1002/gepi.21882. Epub 2015 Jan 19. **Coauthor or Collaborator**.
375. Derouet MF, **Liu G**, Darling GE. MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance. *PLoS One*. 2014 Dec 31;9(12):e115589. **Co-Principal Author**.
376. Wang JR, Habbous S, Espin-Garcia O, Chen D, Huang S, Simpson C, Xu W, Liu FF, Brown DH, Gilbert RW, Gullane PJ, Irish JC, Goldstein DP, **Liu G**. Comorbidity and performance status are independent prognostic factors in head and neck squamous cell carcinoma patients. *Head & Neck*. 2014 Dec 18. (Supervising JRW, SH, OEG, DC). (Trainee publication). **Senior Responsible Author**.
377. Zhai R, Wei Y, Su L, **Liu G**, Kulke MH, Wain JC, Christiani DC. Whole-miRNome profiling identifies prognostic serum miRNAs in esophageal adenocarcinoma: the influence of Helicobacter pylori infection status. *Carcinogenesis*. 2014 Nov 8;36(1):87-93. doi: 10.1093/carcin/bgu228. Epub 2014 Nov 8. **Coauthor or Collaborator**.
378. Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, Bolbocean C, Shepherd FA, Tsao MS, Manos D, **Liu G**, Atkar-Khattra S, Cromwell I, Johnston MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhorn HS, Yee J, Amjadi K, Cutz JC, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, Peacock SJ, Pan-Canadian Early Detection of Lung Cancer Study Team. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. *J Thorac Oncol*. 2014 Oct 9;9(10):1449-58. doi: 10.1097/JTO.0000000000000283. **Coauthor or Collaborator**.
379. Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, **Liu G**, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. *Carcinogenesis*. 2014 Oct 3;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3. **Coauthor or Collaborator**.
380. Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, **Liu G**. Managing skin toxicities related to panitumumab. *J Am Acad Dermatol*. 2014 Oct;71(4):754-9. Epub 2014 Jul 29 (Supervising HB, TW, RDB). (Trainee publication). **Senior Responsible Author**.
381. Habbous S, Pang V, Xu W, Amir E, **Liu G**. Human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis. *J Clin Virol*. 2014 Oct;61(2):220-9. (Supervising SH, VP). (Trainee publication). **Senior Responsible Author**.

382. Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, Risch HA, **Liu G**, Bird NC, Wu AH, Corley DA, Romero Y, Chanock SJ, Chow WH, Casson AG, Levine DM, Zhang R, Ek WE, MacGregor S, Ye W, Hardie LJ, Vaughan TL, Whitman DC. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a mendelian randomization study. *J Natl Cancer Inst.* 2014 Sep 30;106(11). doi: 10.1093/jnci/dju252. Print 2014 Nov. **Coauthor or Collaborator.**
383. Voncken FE, Jiang H, Kim J, Guindi M, Brierley J, Knox J, **Liu G**, Horgan AM, Lister J, Darling G, Metser U, Wong RK. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer. *Dis Esophagus.* 2014 Aug;27(6):552-9. Epub 2012 Nov 2. **Coauthor or Collaborator.**
384. Safieddine N, **Liu G**, Cuningham K, Ming T, Hwang D, Brade A, Bezjak A, Fischer S, Xu W, Azad S, Cypel M, Darling G, Yasufuku K, Pierre A, de Perrot M, Waddell T, Keshavjee S. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. *J Thorac Oncol.* 2014 Jul;9(7):1018-22. doi:10.1097/JTO.0000000000000215. **Coauthor or Collaborator.**
385. Cuffe S, Hon H, Qiu X, Tobros K, Wong CK, De Souza B, McFarlane G, Masroor S, Azad AK, Hasani E, Rozanec N, Leighl N, Alibhai S, Xu W, Issa AM, **Liu G**. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomics testing. *Pharmacogenet Genomics.* 2014 Jul;24(7):348-55. (Supervising SC, HH, XQ, KT, CKW, AKA). (Trainee publication). **Senior Responsible Author.**
386. Fehringier G, Gallinger S, Borgida A, Zhang LR, Adams L, **Liu G**, Hung RJ. The association of family history of cancer and medical history with pancreatic cancer risk. *Pancreas.* 2014 Jul;43(5):812-4. doi: 10.1097/MPA.0000000000000126. (Co-Supervisor of GF) (Trainee publication). **Coauthor or Collaborator.**
387. Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, Lloyd A, Delahaye-Sourdeix M, Chubb D, Gaborieau V, Wheeler W, Chatterjee N, Thorleifsson G, Sulem P, **Liu G**, Kaaks R, Henrion M, Kinnersley B, Vallee M, LeCalvez-Kelm F, Stevens VL, Gapstur SM, Chen WV, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Krokan HE, Gabrielsen ME, Skorpen F, Vatten L, Njolstad I, Chen C, Goodman G, Benhamou S, Vooder T, Valk K, Nelis M, Metspalu A, Lener M, Lubinski J, Johansson M, Vineis P, Agudo A, Clavel-Chapelon F, Bueno-de-Mesquita HB, Trichopoulos D, Khaw KT, Johansson M, Weiderpass E, Tjonneland A, Riboli E, Lathrop M, Scelo G, Albanes D, Caporaso NE, Ye Y, Gu J, Wu X, Spitz MR, Dienemann H, Rosenberger A, Su L, Matakidou A, Eisen T, Stefansson K, Risch A, Chanock SJ, Christiani DC, Hung RJ, Brennan , Landi MT, Houlston RS, Amos CI. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nat Genet.* 2014 Jul;46(7):736-41. Doi: 10.1038/ng.3002. Epub 2014 Jun 1. **Coauthor or Collaborator.**
388. Shen X, Espin-Garcia O, Qiu X, Brhane Y, **Liu G**, Xu W. Haplotype approach for association analysis on Hypertension. *BMC Proc.* 2014 Jun 17(8):Suppl 1. (Supervising XS, OE-G, XQ, YB, WX is affiliate scientist in Liu Lab). **Co-Principal Author.**
389. Espin-Garcia O, Shen X, Qiu X, Brhane Y, **Liu G**, Xu W. Genetic association analysis for common variants in the Genetic Analysis Workshop 18 data: a Dirichlet regression approach. *BMC Proc.* 2014 Jun 17(8):Suppl 1. (Supervising OE-G, XS, XQ, YB, WX is affiliate scientist in Liu Lab). **Co-Principal Author.**
390. Qiu X, Shen X, Espin-Garcia O, Azad AK, **Liu G**, Xu W. Genetic association analysis using weighted false discovery rate approach on Genetic Analysis Workshop 18 data. *BMC Proc.* 2014 Jun 17(8):Suppl 1. (Supervising XQ, XS, OE-G, AKA, WX is affiliate scientist in Liu Lab). **Co-Principal Author.**
391. Azad AK, Qiu X, Boyd K, Kuang Q, Emami M, Perera N, Palepu P, Patel D, Chen Z, Cheng D, Feld R, Leighl NB, Shepherd FA, Tsao MS, Xu W, **Liu G**, Cuffe S. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). *Lung Cancer.* 2014 Jun;84(3):289-94. (Supervising AKA, XQ, KB, QK, ME, NP, PP, DP, ZC, DC, SC was a clinical fellow in Liu Lab). (Trainee publication). **Senior Responsible Author.**

392. Wong KM, Qiu X, Cheng D, Azad AK, Habbous S, Palepu P, Mirshams M, Patel D, Chen Z, Roberts H, Knox J, Marquez S, Wong R, Darling G., Waldron J, Goldstein D, Leighl N, Shepherd FA, Tsao M, Der S, Reisman D, **Liu G**. Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers. *Cancer Med*. 2014 Apr;3(2):426-33. (Supervising KMW, XQ, DC, AKA, SH, PP, MM, DP, ZC). (Trainee publication). **Senior Responsible Author**.
393. Liu X, Cheng D, Kuang Q, **Liu G**, Xu W. Association of UGT1A1\*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. *Pharmacogenomics J*. 2014 Apr;14(2):120-9. Epub 2013 Mar 26. **Senior Responsible Author**.
394. Shaw AT, Kim D-W, Mehra R, Tan DSW, Felip E, Chow L, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Eiely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, **Liu G**, Santoro A, Law YY, Goldwasser M, Boral AL, and Engelman JA. Ceritinib in ALK-Rearranged non-small-cell lung cancer. *New England Journal of medicine*. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107. **Coauthor or Collaborator**.
395. Korst RJ, Bezjak A, Blackmon S, Choi N, Fidias P, **Liu G**, Marx A, Wright C, Mock S, Rutledge JR, Keshavjee S. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: A phase II, multi-institutional clinical trial. *J Thorac Cardiovasc Surg*. 2014 Jan;147(1):36-44. doi: 10.1016/j.jtcvs.2013.08.061. **Coauthor or Collaborator**.
396. Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, **Liu G**, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG.; Australasian Lung Cancer Trials Group.; NCI Naples Clinical Trials Unit. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. *Lancet Oncol*. 2014;15:1379-88. **Coauthor or Collaborator**.
397. Wang Q, Cui K, Espin-Garcia O, Cheng D, Qiu X, Chen Z, Moore M, Bristow RG, Xu W, Der S, **Liu G**. Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of g2/m arrest and apoptosis. *PLoS One*. 2013 Dec 4;8(12):e82363. (Supervising QW, KC, OE-G, DC, XQ, ZC). (Trainee publication). **Senior Responsible Author**.
398. Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, Lao-Sirieix P, Gammon MD, corley DA, Shaheen NJ, Bird NC, Hardie LJ, Murray LJ, Reid BJ, Chow WH, Rish HA, Nyren O, Ye W, **Liu G**, Romero Y, Bernstein L, Wu AH, Casson AG, Chanock SJ, Harrington P, Caldas I, Debram-Beecham I, Caldas C, Hayward NK, Pharoah PD, Fitzgerald RC, Macgregor S, Whiteman DC, Vaughan TL. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. *Nat Genet*. 2013 Dec;5(12):1487-93. Epub 2013 Oct 13. **Coauthor or Collaborator**.
399. Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PKE, Bresso F, Onstad LE, Schmidt PT, Tornblom H, Nordenstedt H, Romero Y, Chow W-H, Murray LJ, Gammon MD, **Liu G**, Bernstein L, Casson AG, Risch HA, Shaheen NJ, Bird NC, Reid BJ, Corley DA, Hardie LJ, Ye W, Wu AH, Zucchelli M, Spector TD, Hysi P, Vaughan TL, Whiteman DC, MacGregor S. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus and gastroesophageal reflux. *J Natl Cancer Inst*. 2013 Nov 20;105(22):1711-8. doi: 10.1093/jnci/djt303. Epub 2013 Oct 29. **Coauthor or Collaborator**.
400. Habbous S, Chu KP, Qiu X, La Delfa A, Harland LT, Fadhel E, Hui A, Perez-Ordóñez B, Weinreb I, Liu FF, Waldron J, O'Sullivan B, Goldstein D, Xu W, **Liu G**. The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. *Cancer Epidemiol*. 2013 Nov 1;37(6):820-9. (Supervising SH, KPC, XQ, ALD, LTGH, EF). (Trainee publication). **Senior Responsible Author**.
401. McWilliams A, Tammermagi MC, Mayo JR, Roberts H, **Liu G**, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras M, Atkar-Khattra S, Berg CD, Evans K, Finley R, Yee J, English J, Nasute P, Goffin J, Puksa S, Stewart L, Tsai S, Johnston MR, Manos D, Nicholas G, Goss GD, Seely J:M, Amjadi K, Tremblay A, Burrowes P, MacEachern P, Bhatia R, Tsao MS, Lam S. Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med*. 2013 Sep;369(10):910-19. doi: 10.1056/NEJMoa1214726. **Coauthor or Collaborator**.

402. Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, **Liu G**, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). *Br J Cancer*. 2013 Aug 20;109(4):943-9. Epub 2013 Jul 18. **Coauthor or Collaborator**.
403. Kashigar A, Habbous S, Eng L, Irish B, Bissada E, Irish J, Brown D, Gilbert R, Gullane P, Xu W, Huang SH, Witterick I, Freeman J, O'Sullivan B, Waldron J, **Liu G**, Goldstein D. Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. *Cancer*. 2013 Aug 1;119(15):2701-9. (Supervising AK, SH, LE) (Trainee publication). **Senior Responsible Author**.
404. Renouf D, Zhai R, Sun B, Xu W, Cheung WY, Heist RS, Kulke MH, Cescon D, Asomaning K, Marshall AL, Li S, Christiani DC, **Liu G**. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. *J Gastroenterol Hepatol*. 2013 Jun;28(9):1482-8. (Supervising DR, BS, WYC, DC, ALM). (Trainee publication). **Senior Responsible Author**.
405. Jang JH, Cotterchio M, Borgida A, **Liu G**, Gallinger S, Cleary SP. Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk. *Mol Carcinog*. 2013 Jun;52(Suppl 1):e103-9. doi: 10.1002/mc.22037. Epub 2013 Jun 12. **Coauthor or Collaborator**.
406. Azad AK, Bairati I, Qiu X, Huang H, Cheng D, **Liu G**, Adjei A, Meyer F, Xu W. Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. *Int J Cancer*. (Supervised AKA, XQ, HH, DC. WX is an affiliate scientist in the Liu Lab). **Senior Responsible Author**.
407. Wang JR, Gramling JB, Goldstein DP, Cheng D, Chen D, Azad AK, Tse A, Hon H, Chen Z, Mirshams M, Simpson C, Huang SH, Marquez S, O'Sullivan B, Liu FF, Roberts H, Xu W, Brown DH, Gilbert RW, Gullane PJ, Irish JC, Reisman DN, and **Liu G**. Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. *Carcinogenesis*. 2013 May;34(5):1012-7. (Supervising JRW, DC, AKA, AT, HH, ZC, MM). (Trainee publication). **Senior Responsible Author**.
408. Habbous S, Chu KP, Harland LTG, La Delfa A, Fadhel E, Sun B, Xu W, Wong A, Howell D, Ringash J, Waldron J, O'Sullivan B, Goldstein D, Huang S-H, **Liu G**. Validation of a one-page patient-reported charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. *Oral Oncol*. 2013 May;49(5):407-12. (Supervising SH, KPC, LTGH, LAD, EF, BS). (Trainee publication). **Senior Responsible Author**.
409. Habbous S, Harland LT, La Delfa A, Fadhel E, Xu W, Liu FF, Goldstein D, Waldron J, Huang SH, O'Sullivan B, **Liu G**. Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status. *Head and Neck*. 2013 Apr;36(6):802-10. Epub 2013 Jul 30. (Supervising SH, LTH, ALD, EF). (Trainee publication). **Senior Responsible Author**.
410. Dodbiba L, Teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi OO, Renouf DJ, Girgis H, Bandarchi B, Schwock J, Xu W, Bristow RG, Tsao MS, Darling GE, Ailles LE, El-Zimairy H, **Liu G**. Primary esophageal and gastroesophageal junction cancer xenograft models: clinicopathological features and engraftment. *Lab Invest*. 2013 Apr;93(4):397-407. (Supervising LD, JT, AF, HT, BS, DP, AT, ZC, OOF, DJR, HG). (Trainee publication). **Senior Responsible Author**.
411. Liu X, Cheng D, Kuang Q, **Liu G**, Xu W. Association between UGT1A1\*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in caucasians. *PLoS One*. 2013 Mar;8(3):e58489. doi:10.1371/journal.pone.0058489. Epub 2013 Mar 14 (Supervising XL, DC, QK). **Senior Responsible Author**.
412. Sulpher JA, Owen SP, Hon H, Tobros K, Shepherd FA, Sabri E, Gomes M, Sekhon H, **Liu G**, Canil CM, Wheatley-Price P. Factors influencing a specific pathologic diagnosis of non-small-cell-lung carcinoma. *Clin. Lung Cancer*. 2013 Jan 4;14(3):238-44. doi: 10.1016/j.clcc.2012.11.004. Epub 2013 Jan 4. **Coauthor or Collaborator**.
413. Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, Asomaning K, Ma C, Xu W, Wang Z, Hooshmand S, Su L, Christiani DC, **Liu G**. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. *Int J Cancer*. 2012 Dec;131(11):2478-86. (Supervising WYC, PB, JH, CM). (Trainee publication). **Senior Responsible Author**.

414. Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaoli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. *J Thorac Oncol*. 2012 Dec;7(12):1830-44. **Coauthor or Collaborator**.
415. Brenner DR, Boffetta P, Duell EJ, Bickeboller H, Rosenberger A, McCormack V, Muscat JE, Yang P, Wichmann HE, Brueske-Hohlfeld I, Schwartz AG, Cote ML, Tjønneland A, Friis S, Le Marchand L, Zhang ZF, Morgenstern H, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Foretova L, Janout V, Bencko V, Schejbalova M, Brennan P, Mates IN, Lazarus P, Field JK, Raji O, McLaughlin JR, **Liu G**, Wiencke J, Neri M, Ugolini D, Andrew AS, Lan Q, Hu W, Orlow I, Park BJ, Hung RJ. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. *Am J Epidemiol*. 2012 Oct 1;176(7):573-85. Epub 2012 Sep 17. **Coauthor or Collaborator**.
416. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, **Liu G**, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 As a blood and effusion biomarker for pleural mesothelioma. *N Engl J Med*. doi: 10.1056/NEJMoa1115050. **Coauthor or Collaborator**.
417. Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, Lescai F, Langford C, Nanji M, Edkins S, van der Winkel A, Levine D, Sasieni P, Bellenguez C, Howarth K, Freeman C, Trudgill N, Tucker AT, Pirinen M, Peppelenbosch MP, van der Laan LJ, Kuipers EJ, Drenth JP, Peters WH, Reynolds JV, Kelleher DP, McManus R, Grabsch H, Prenen H, Bisschops R, Krishnadath K, Siersema PD, van Baal JW, Middleton M, Petty R, Gillies R, Burch N, Bhandari P, Paterson S, Edwards C, Penman I, Vaidya K, Ang Y, Murray I, Patel P, Ye W, Mullins P, Wu AH, Bird NC, Dallal H, Shaheen NJ, Murray LJ, Koss K, Bernstein L, Romero Y, Hardie LJ, Zhang R, Winter H, Corley DA, Panter S, Risch HA, Reid BJ, Sargeant I, Gammon MD, Smart H, Dhar A, McMurtry H, Ali H, **Liu G**, Casson AG, Chow WH, Rutter M, Tawil A, Morris D, Nwokolo C, Isaacs P, Rodgers C, Ragunath K, MacDonald C, Haigh C, Monk D, Davies G, Wajed S, Johnston D, Gibbons M, Cullen S, Church N, Langley R, Griffin M, Alderson D, Deloukas P, Hunt SE, Gray E, Dronov S. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. *Nat Genet*. doi: 10.1038/ng.2408. Epub 2012 Sep 9. **Coauthor or Collaborator**.
418. Eng L, Azad AK, Habbous S, Vincent P, Maitland-van der Zee A-H, Savas S, MacKay H, Amir E, **Liu G**. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A systematic review and meta-analysis. *Clin Cancer Res*. 2012 Sep 1;18(17):4526-37. Epub 2012 Jun 25. (Supervising LE, AKA, SH, PV). (Trainee publication). **Senior Responsible Author**.
419. Horgan AM, Leighl NB, Coate L, **Liu G**, Palepu P, Knox JJ, Perera N, Emami M, Alibhai SM. Impact and feasibility of a comprehensive geriatric assessment. *AM J Clin Oncol*. 2012 Aug;35(4):322-8. doi:10.1097 [Epub ahead of print] (Supervising PP, NP, ME). **Coauthor or Collaborator**.
420. Fehringer G, **Liu G**, Pintilie M, Sykes J, Cheng D, Liu N, Chen Z, Seymour L, Der SD, Shepherd FA, Tsao MS, Hung RJ. Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. *Cancer Epidemiol Biomarkers Prev*. doi: 10.1158/1055-9965.EPI-11-1123-T. Epub 2012 Apr 26. (Co-supervised G. F). **Coauthor or Collaborator**.
421. Renouf D, Welch S, Moore M, Krzyzanowska M, Knox J, Feld R, **Liu G**, MacKay H, Petronis J, Wang L, Chen E. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Cancer Chemotherapy and Pharmacology*. doi: 10.1007/s00280-012-1843-9. Epub 2012 Feb 15. (Supervising DR). **Coauthor or Collaborator**.
422. Meyer F, Fortin A, Wang CS, **Liu G**, Bairati I. Predictors of severe acute and late toxicities in patients with localized head and neck cancer treated with radiation therapy. *Int J Radiat Oncol Biol Phys*. doi: 10.1016/j.ijrobp.2011.04.022. Epub 2011. **Coauthor or Collaborator**.
423. Azad AK, Bairati I, Samson E, Cheng D, Cheng L, Mirshams M, Savas S, Waldron J, Wang C, Goldstein D, Xu W, Meyer F, **Liu G**. Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. *Cancer*. 2012 Mar;118:1554-65. (Supervising AKA, DC, MM, SS, WX). (Trainee publication). **Senior Responsible Author**.

424. Zhai R, Zhao Y, **Liu G**, Ter-Minassian M, Wu IC, Wang Z, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case only study. *Cancer*. 2012 Feb 1;118(3):804-11. doi: 10.1002/cncr.26325. Epub 2011 Jul 12. **Coauthor or Collaborator**.
425. **Liu G**, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd FA, Tsao MS. Pharmacogenetic analysis of BR21, a placebo-controlled randomized Phase III clinical trial of erlotinib in advanced non-small cell lung cancer. *J Thoracic Oncol*. 2012 Feb;7(2):316-22. (Supervising DC, DP, ZC). **Senior Responsible Author**.
426. Diaz-Padilla I, Amir E, Marsh S, **Liu G**, MacKay H. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review. *Gynecol Oncol*. 2012 Feb;124(2):354-65. **Co-Principal Author**.
427. Fehrer G, **Liu G**, Briollais L, Brennan P, Amos CI, Spitz MR, Bickeboller H, Wichmann HE, Risch A, Hung RJ. Comparison of pathway analysis approaches using lung cancer GWAS data sets. *PLoS One*. 2012 Feb;7(2):e31816. doi: 10.1371/journal.pone.0031816. Epub 2012 Feb 21 (Co-supervising GF). **Coauthor or Collaborator**.
428. Zhai R, Zhao Y, Su L, Cassidy L, **Liu G**, Christiani DC. Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and barrett esophagus. *Neoplasia*. 2012 Jan;14(1):29-33. **Coauthor or Collaborator**.
429. Geraci J, **Liu G**, Jurisica I. Algorithms for systematic identification of small subgraphs. *Methods Mol Biol*. 2012;804:219-44. **Senior Responsible Author**.
430. Howell D, **Liu G**. Can routine collection of patient reported outcome data actually improve patient-centred health? *Healthcare Papers*. 2011;11:42-7. discussion 55-8. Dr. Liu wrote the CCO grant that served as the basis of this conceptual manuscript. **Senior Responsible Author**.
431. Cheng L, Hu P, Sykes J, Pintilie M, Liui G, Xu W. A pathway-based association analysis model using common and rare variants. *BMC Proc*. 2011;5(Suppl):9:S85. (Supervising LC). **Coauthor or Collaborator**.
432. Sykes J, Cheng L, Xu W, Tsao MS, **Liu G**, Pintilie M. Addition of multiple rare SNPs to known common variants improves the association between disease and gene in the Genetic Analysis Workshop 17 data. *BMC Proc*. 2011;5(Suppl):9:S97. (Supervising LC). **Coauthor or Collaborator**.
433. Meyer F, **Liu G**, Douville P, Samson E, Xu W, Adjei A, Barirati I. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. *Int. J Cancer*. 2011;128:1741-6. **Coauthor or Collaborator**.
434. Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, **Liu G**, Bradbury PA, Zhai R, Su L, Fraumeni CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. Genetic associations with sporadic neuroendocrine tumor risk. *Carcinogenesis*. doi: 10.1093/carcin/bgr095. Epub 2011 May 23. (Supervising PAB). **Coauthor or Collaborator**.
435. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, **Liu G**, Melosky B, Reiman T, Remeo P, Shepherd FA, Tsao MS, Leighl NB. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. *J Thorac Oncol*. 2011;6(8):1379-91. **Coauthor or Collaborator**.
436. Coate LE, Masey C, Hope A, Sacher a, Barrett K, Pierre A, Leighl N, Brade A, de Perrot M, Waddell T, **Liu G**, Feld R, Burkes R, Cho BC, Darling G, Sun A, Keshavjee S, Bezjak A, Shepherd FA. Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. *J Thorac Oncol*. 2011;6:537-44. **Coauthor or Collaborator**.
437. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, Wheatley-Price P, Hung RJ, Shepherd FA, **Liu G**. Pharmacogenetic and germline prognostic markers of lung cancer. *J Thorac Oncol*. 2011;6(2):296-304. (Supervising AMH, BY, AKA, DWC, PWP) (Trainee publication). **Senior Responsible Author**.
438. Wu IC, Zhao Y, Zhai R, **Liu G**, Ter-Minassian M, Asomaning K, Su L, Liu CY, Chen F, Kulke MH, Heist RS, Christiani DC. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. *Neoplasia*. 2011;13:386-92. **Coauthor or Collaborator**.



439. Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, Asomaning K, Su L, Heist RS, Kulke MH, **Liu G**, Christiani DC. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. *Carcinogenesis*. 2011;32:502-6. **Coauthor or Collaborator**.
440. Wei Y, Tong J, Taylor P, Strumpf D, Ignatchenko V, Pham NA, Yanagawa N, **Liu G**, Jurisica I, Shepherd FA, Tsao MS, Kislinger T, Moran MF. Primary tumor xenografts of human lung adenocarcinoma and squamous cell carcinoma express distinct proteomic signatures. *J. Proteome Res*. 2011;10:161-74. **Coauthor or Collaborator**.
441. Gramling S, Rogers C, **Liu G**, Reisman D. Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. *Oncogene*. 2011;30:3289-94. **Coauthor or Collaborator**.
442. Lin X, Cai T, Wu MC, Zhou Q, **Liu G**, Christiani DC, Lin X. Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies. *Genet Epidemiol*. 2011;35:620-31. **Coauthor or Collaborator**.
443. Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, **Liu G**, Dolan ME, Meltzer SJ, Wu X, Diasio RB, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. *BMC Cancer*. 2011;11:176. (Supervising XW). **Coauthor or Collaborator**.
444. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, **Liu G**, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. *Cancer Chemother Pharmacol*. 2011;68:863-70. **Coauthor or Collaborator**.
445. Horgan AM, Knox JJ, **Liu G**, Sahi C, Bradbury PA, Leighl NB. Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis. *Curr Oncol*. 2011;18:e64-70. **Coauthor or Collaborator**.
446. Truong T, Hung RJ, Amos CI, Wu X, Bickeboller H, Rosenberger A, Sauter W, Illig T, Wichmann HE, Risch A, Dienemann H, Kaaks R, Yang P, Jiang R, Wiencke JK, Wrensch M, Hansen H, Kelsey KT, Matsuo K, Tajima K, Schwartz AG, Wenzlaff A, Seow A, Ying C, Staratschek-Jox A, Nürnberg P, Stoelben E, Wolf J, Lazarus P, Muscat JE, Gallagher CJ, Zienoldiny S, Haugen A, van der Heijden HF, Kiemeny LA, Isla D, Mayordomo JI, Rafnar T, Stefansson K, Zhang ZF, Chang SC, Kim JH, Hong YC, Duell EJ, Andrew AS, Lejbkiewicz F, Rennert G, Müller H, Brenner H, Le Marchand L, Benhamou S, Bouchardy C, Teare MD, Xue X, McLaughlin J, **Liu G**, McKay JD, Brennan P, Spitz MR. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: A pooled analysis from the international lung cancer consortium. *J Natl Cancer Inst*. 2010 Jul;102(13):959-71. doi: 10.1093/jnci/djq178. Epub 2010 Jun 14. (Data analyses and interpretation). **Coauthor or Collaborator**.
447. Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, Wang Z, Su L, Heist RS, Kulke MH, Lin X, **Liu G**, Christiani DC. A large scale genetic association study of esophageal adenocarcinoma risk. *Carcinogenesis*. 2010 Jul;31(7):1259-63. doi: 10.1093/carcin/bgq092. Epub 2010 May 7. (Data analyses and interpretation). **Coauthor or Collaborator**.
448. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, **Liu G**. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. *J Clin Oncol*. 2010 Jul;28(20):3316-22. doi: 10.1200/JCO.2009.26.9944. Epub 2010 May 24. (Supervised PW-P, BY, DP). **Senior Responsible Author**.
449. Wong K, Huang SH, O'Sullivan B, Lockwood G, Dale D, Michaelson T, Waldron J, Bayley A, Cummings B, Dawson LA, Kim J, **Liu G**, Ringash J. Point-of-Care Outcome Assessment in the Cancer Clinic: Audit of Data Quality. *Radiotherapy and Oncology*. 2010 Jun;95(3):339-43. doi: 10.1016/j.radonc.2010.03.015. Epub 2010 Mar 31. (Study Design and Inception, Data Interpretation). **Coauthor or Collaborator**.
450. Zhai R, Chen F, **Liu G**, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Lynch TJ, Wain JC, Christiani DC. Interactions among BMI, smoking, and genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. *J Clin Oncol*. 2010 May 10;28(14):2445-51. Epub 2010 May 7. (Data analysis and interpretation). **Coauthor or Collaborator**.

451. Wang Q, Wang AH, Tan HS, Feng NN, Ye YJ, Feng XQ, **Liu G**, Zheng YX, Xia ZL. Genetic polymorphisms of DNA repair genes and chromosomal damage in workers exposed to 1,3-butadiene. *Carcinogenesis*. 2010 May;31(5):858-63. doi: 10.1093/carcin/bgq049. Epub 2010 Mar 11. **Coauthor or Collaborator**.
452. Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P, Hashibe M, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Field JK, Liloglou T, Xinarianos G, McLaughlin J, **Liu G**, Skorpén F, Elvestad MB, Hveem K, Vatten L, Study E, Benhamou S, Lagiou P, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Lowry R, Conway DI, Znaor A, Healy C, Curado MP, Koifman S, Eluf-Neto J, Matos E, Menezes A, Fernandez L, Metspalu A, Heath S, Lathrop M, Brennan P. Association between a 15q25 gene variant, smoking quantity, and tobacco related cancers among 17,000 individuals. *Int J Epidemiol*. 2010 Apr;39(2):563-77. doi: 10.1093/ije/dyp288. Epub 2009 Sep 23. **Coauthor or Collaborator**.
453. Chan K, **Liu G**, Miller L, Ma C, Xu W, Schlachta CM, Darling G. Lack of correlation between self-administered subjective GERD questionnaire and pathologic GERD diagnosed by 24 hour esophageal pH monitoring. *J Gastrointest Surg*. 2010 Mar;14(3):427-36. Conception, data collection, statistical analysis, interpretation, manuscript preparation: co-supervised K Chan (member of G. Liu Laboratory). **Co-Principal Author**.
454. Meyer F, Samson E, Douville P, Duchesne P, **Liu G**, Bairati I. Serum Prognostic Markers in Head and Neck Cancer. *Clin Cancer Res*. 2010 Feb;16(3):1008-15. doi: 10.1158/1078-0432.CCR-09-2014. Epub 2010 Jan 26. (Data analysis and Interpretation). **Coauthor or Collaborator**.
455. **Liu G**, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC. P53 Codon Arg72Pro, MDM2 T309G and CCND1 G870A Polymorphisms are not Associated with Susceptibility to Esophageal Adenocarcinoma. *Diseases of the Esophagus*. 2010 Jan;23(1):36-9. doi: 10.1111/j.1442-2050.2009.00960.x. Epub 2009 Mar 17. **Principal Author**.
456. Humberto Lara-Guerra, Thomas K Waddell, Maria A. Salvarrey, Anthony M Joshua, Catherine T Chung, Narinder Paul, Scott Boerner, Akira Sakurada, Olga Ludkovski, Clement Ma, Jeremy Squire, **Geoffrey Liu**, Frances A. Shepherd, Ming-Sound Tsao, and Natasha B Leighl. Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small Cell Lung Cancer. *J Clin Oncol* 2009 Dec 20; 27(36): 6229-36. (Sample Analysis and Interpretation). **Co-investigator**.
457. Savas S, Geraci J, Jurisica I, **Liu G**. A comprehensive catalogue of functional genetic variations from the EGFR pathway: protein-protein interaction analysis reveals novel genes and polymorphisms important for cancer research. *Int J Cancer* 2009 Sep 15; 125(6): 1257-65. (Supervised S. Savas). **Senior Responsible Author**.
458. Bradbury PA, Kulke MH, Heist RS, Pintilie M, Zhou W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, **Liu G**. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. *Pharmacogenet Genomics*. 2009 Aug; 19(8): 613-25. (Supervised PA Bradbury). **Senior Responsible Author**.
459. Cheung WY, Zhai R, Kulke M, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Lanuti M, Tanabe KK, Christiani DC, **Liu G**. Epidermal Growth Factor (EGF) A61G Gene Polymorphism, Gastroesophageal Reflux Disease (GERD), and Esophageal Adenocarcinoma (EAC) Risk. *Carcinogenesis*. 2009 Aug; 30(8): 1363-7. Epub 2009 Jun 11. (Supervised WY Cheung). **Senior Responsible Author**.
460. Bradbury P, Zhai R, Ma C, Xu W, Hopkins J, Kulke MH, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani DC, **Liu G**. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. *Clin Cancer Res*. 2009 Jul 15; 15(14): 4680-5. Epub 2009 Jul 7. (Supervised P. Bradbury). **Senior Responsible Author**.
461. Cescon DW, Bradbury PA, Asomaning K, Zhai R, Hopkins J, Kulke MH, Su L, Heist RS, Wain JC, Lynch TJ, Christiani DC, **Liu G**. p53, MDM2, and CCND1 polymorphisms in esophageal cancer prognosis. *Clin Cancer Res*. 2009 May 1; 15(9): 3103-9. (Supervised D. Cescon). (Trainee publication). **Senior Responsible Author**.
462. Bradbury P, Hopkins J, Singh S, Tse D, Kulke MH, Heist RS, Asomaning K, Marshall AL, Su L, Nishioka NS, Lynch TJ, Wain JC, Christiani DC, **Liu G**. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. *Carcinogenesis*. 2009 May; 30(5): 793-8. (Supervised P Bradbury, J Hopkins, D Tse). **Senior Responsible Author**.

463. Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, **Liu G**, Heist RS, Lynch TJ, Wain JC, Lin X, Devivo I, Christiani DC. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. *Carcinogenesis* 2008 Nov; 29(11): 2147-52. Epub 2008 Aug 29. (Samples, genotyping and interpretation). **Co-investigator**.
464. Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, **Liu G**. MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis. *Clin Cancer Res*. 2008 Jun 15; 14(12): 4010-5. (Supervised K. Asomaning). **Senior Responsible Author**.
465. Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, **Liu G**. Myeloperoxidase and Superoxide Dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. *Cancer* 2008 Mar 1; 112(5): 1037-42. (Supervised P. Wheatley-Price). **Senior Responsible Author**.
466. Heist RS, Zhai R, **Liu G**, Zhou W, Lin X, Su L, Asomaning K, Lynch TJ, Wain JC, Christiani DC. VEGF Polymorphisms and Survival in Early Stage Non-Small Cell Lung Cancer. *J Clin Oncol*. 2008; Feb; 26(6): 856-862. (Analysis and interpretation). **Co-investigator**.
467. Asomaning K, Miller DP, **Liu G**, Wain JC, Lynch TJ, Su L, Christiani DC. Second hand smoke, age of exposure and lung cancer risk. *Lung Cancer*. 2008 Jan 7; e-pub ahead of print. (Samples, genotyping and interpretation). **Co-investigator**.
468. **Liu G**, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist RS, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small cell lung cancer patients treated with gefitinib. *J Pharmacogenetics* 2008; 8(2): 129-38. **Principal Author**.
469. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, **Liu G**. A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies. *Cancer Epidemiol Biomarkers Prev.*, 2008; 17(1): 204-11. (Supervised P. Bradbury). **Senior Responsible Author**.
470. **Liu G**, Wheatley-Price P, Zhou W, Park S, Heist RS, Asomaning K, Wain JC, Lynch TJ, Su L, Christiani DC. Genetic polymorphisms of MDM2, cumulative cigarette smoking, and nonsmall cell lung cancer risk. *Int J Cancer* 2008; 122(4): 915-8. (Trainee publication, Wheatley-Price, P). **Principal Author**.
471. Zhai R, **Liu G**, Zhou W, Su L, Heist RS, Lynch TJ, Wain JC, Asomaning K, Lin X, Christiani DC. VEGF genotypes, haplotypes, gender and risk of non-small cell lung cancer. *Clin Cancer Res*. 2008; 14(2): 612-7 (analysis and interpretation). **Co-investigator**.
472. Tse D; Zhai R; Zhou W; Heist RS; Asomaning K; Su L; Lynch TJ; Wain JC; Christiani DC; **Liu G**. Polymorphisms of the NER Pathway Genes, ERCC1 and XPD Are Associated With Esophageal Adenocarcinoma Risk. *Cancer Causes Control* 2008; 19(10): 1077-83. (Supervised D. Tse). **Senior Responsible Author**.
473. Fruh M, Zhou W, Zhai R, Su L, Heist RS, Wain JC, Nishioka NS, Lynch TJ, Shepherd FA, Christiani DC, **Liu G**. Polymorphisms of Inflammatory and Metalloproteinase genes, Helicobacter pylori infection and the Risk of Esophageal Adenocarcinoma. *Br J Cancer* 2008; 98(4): 689-92. (Supervised M. Fruh). **Senior Responsible Author**.
474. Lanuti M, **Liu G**, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, Su L, Nishioka NS, Tanabe KK, Christiani DC. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels and esophageal adenocarcinoma risk and outcome. *Clin Cancer Res*. 2008; 14(10): 3216-22. (Polymorphism genotyping, analysis and interpretation). Co-First Author, performed data collection, data analysis and interpretation and manuscript writing. Original idea came from Dr Lanuti. **Co-Principal Author**.

475. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field J, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, **Liu G**, Narod SA, Krokan HE, Shorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Navarro C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature*. 2008; 452(7187): 633-7. (Samples, genotyping and interpretation). **Co-investigator**.
476. Heist RS, Zhou W, Wang Z, **Liu G**, Neuberg D, Su L, Asomaning K, Hollis BW, Lynch TJ, Wain JC, Giovannucci E, Christiani DC. Circulating 25-Hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. *J Clin Oncol*. 2008; 26: 5596-602. (Samples, genotyping and interpretation). **Co-investigator**.
477. Zhai R, **Liu G**, Asomaning K, Su L, Kulke MH, Heist RS, Nishioka NS, Lynch TJ, Wain JC, Lin X, Christiani DC. Genetic polymorphisms of vascular endothelial growth factor, interactions with cigarette smoking exposure, and esophageal adenocarcinoma risk. *Carcinogenesis*, 2008; 29: 2330-4. (Samples, genotyping and interpretation). **Co-investigator**.
478. **Liu G**, Zhou W, Yeap BY, Su L, Wain JC, Ponderos JM, Nishioka NS, Lynch TJ, Christiani DC. XRCC1 and XPD Polymorphisms and Esophageal Adenocarcinoma Risk. *Carcinogenesis*, 2007; 28(6): 1254-8. **Principal Author**.
479. Zhou W, Heist RS, **Liu G**, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC. Circulating 25-hydroxyvitamin d levels predict survival in early-stage non-small-cell lung cancer patients. *J Clin Oncol*. 2007; 25: 479-85. (Analysis and interpretation). **Co-investigator**.
480. Heist RS, Zhou W, Chirieac LR, Cogan-Drew T, **Liu G**, Su L, Neuberg D, Lynch TJ, Wain JC, Christiani DC. MDM2 polymorphism survival, and histology in early-stage non-small-cell lung cancer. *J. Clin Oncol*. 2007; 25(16); 2243-7. (Analysis and interpretation). **Co-investigator**.
481. Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, **Liu G**, Christiani DC. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. *Carcinogenesis*. 2006; 27: 1024-9. (Analysis and interpretation). **Co-investigator**.
482. Zhou W, Heist RS, **Liu G**, Park S, Neuberg DS, Asomaning K, Wain JC, Lynch TJ, Christiani DC. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. *Lung Cancer*. 2006; 53: 375-80. (Analysis and interpretation). **Co-investigator**.
483. Miller DP, Asomaning K, **Liu G**, Wain JC, Lynch TJ, Neuberg D, Su L, Christiani DC. An association between glutathione S-transferase P1 gene polymorphism and younger age at onset of lung carcinoma. *Cancer*. 2006; 107: 1570-7. (Analysis and interpretation). **Co-investigator**.
484. Heist RS, Marshall AL, **Liu G**, Zhou W, Su L, Neuberg D, Lynch TJ, Wain J, Christiani DC. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. *Clin Cancer Res*. 2006; 12: 5448-53. (Analysis and interpretation). **Co-investigator**.
485. Zhou W, Heist RS, **Liu G**, Asomaning K, Miller DP, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. *Clin Cancer Res*. 2006; 12: 7187-93. (Analysis and interpretation). **Co-investigator**.
486. Zhou W, Heist RS, **Liu G**, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Polymorphisms of vitamin d receptor and survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev*. 2006; 15: 2239-45. (Analysis and interpretation). **Co-investigator**.
487. Zhou W, **Liu G**, Park S, Wang Z, Wain JC, Lynch TJ, Su L, Christiani DC. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. *Cancer Epidemiol Biomarkers Prev*. 2005; 14: 491-6. Developed idea, collected and interpreted data. **Co-Principal Author**.

488. Su L, Zhou W, Park S, Wain JC, Lynch TJ, **Liu G**, Christiani DC. Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2005; 14: 567-70. (Analysis and interpretation). **Co-investigator**.
489. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, **Liu G**, Christiani DC. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. *Clin Cancer Res*. 2005; 11: 1534-8. (Analysis and interpretation). **Co-investigator**.
490. Thurston SW, **Liu G**, Miller DP, Christiani DC. Modeling lung cancer risk in case-control studies using a new dose metric of smoking. *Cancer Epidemiol Biomarkers Prev*. 2005; 14: 2296-302. (Patient population, clinical interpretation). **Co-investigator**.
491. Zhou W, Suk R, **Liu G**, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Vitamin D is associated with improved survival in early stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev*. 2005; 14: 2303-9. (Analysis and interpretation). **Co-investigator**.
492. Zhou W, Park S, **Liu G**, Miller DP, Wang LI, Pothier L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Dietary iron, zinc, and calcium and the risk of lung cancer. *Epidemiology*. 2005; 16: 772-9. (Analysis and interpretation). **Co-investigator**.
493. Gurubhagavatula S, **Liu G**, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. *J Clin Oncol*. 2004; 22: 2594-601. (Study design and inception, analysis and interpretation). Dr. Gurubhagavatula wrote manuscript. **Co-Principal Author**.
494. Zhou W, Gurubhagavatula S, **Liu G**, Park S, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. *Clin Cancer Res* 2004 10: 4939-4943. (Analysis and interpretation). **Co-investigator**.
495. **Liu G**, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. MPO and SOD2 polymorphisms, gender, and the risk of non-small lung cancer. *Cancer Lett*. 2004; 214: 69-79. **Principal Author**.
496. **Liu G**, Zhou W, Park S, Wang LI, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. The SOD2 Val/Val genotype enhances the risk of non-small cell lung carcinoma by p53 and XRCC1 polymorphisms. *Cancer*. 2004; 101: 2802-8. **Principal Author**.
497. Su L, **Liu G**, Zhou W, Xu LL, Miller DP, Park S, Lynch TJ, Wain JC, Christiani DC. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. *Cancer Epidemiol Biomarkers Prev* 2003; 12: 174-5. (Analysis and interpretation). **Co-investigator**.
498. Zhou W, **Liu G**, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Polymorphisms in DNA repair genes XRCC1 and ERCC2, smoking and lung cancer risk. *Cancer Epidemiol Biomarkers Prev* 2003; 12: 359-65. (Analysis and interpretation). **Co-investigator**.
499. Su L, Sai Y, Fan R, Thurston SW, Miller DP, Zhou W, Wain JC, Lynch TJ, **Liu G**, Christiani DC. p53 (codon 72) and p21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. *Lung Cancer* 2003; 40: 259-66. (Analysis and interpretation). **Co-investigator**.
500. Ghadirian P, **Liu G**, Gallinger S, Schmocker B, Paradis AJ, Lal G, Brunet JS, Foulkes WD, Narod SA. Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. *Int J Cancer*. 2002 Feb 20; 97(6): 807-10. (Analysis and interpretation). **Co-investigator**.
501. Xu LL, **Liu G**, Miller DP, Zhou W, Lynch TJ, Wain JC, Su L, Christiani DC. Counterpoint: the myeloperoxidase -463G-->A polymorphism does not decrease lung cancer susceptibility in Caucasians. *Cancer Epidemiology, Biomarkers, Prevention*, 2002 11: 1555-9. (Analysis and interpretation). **Co-Principal Author**.
502. Zhou W, **Liu G**, Thurston SW, Xu LL, Miller DP, Wain JC, Lynch TJ, Wain JC, Su L, Christiani DC. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. *Cancer Epidemiol Biomarkers Prev* 2002; 11: 15-21. (Analysis and interpretation). **Co-investigator**.

503. Zhai R, **Liu G**, Ge X, Yang C, Huang C, Wu C, Christiani DC. Genetic polymorphisms of MnSOD, GSTM1, GSTT1 and OGG1 in Coal Workers' Pneumoconiosis. *J Occup Environ Med*, 2002; 44: 372-7. (Analysis and interpretation). **Co-investigator**.
504. Miller DP, **Liu G**, DeVivo I, Lynch TJ, Wain JC, Su L, Christiani DC. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. *Cancer Research*, 2002; 62: 2819-23. (Analysis and interpretation). **Co-investigator**.
505. Zhou W, **Liu G**, Miller DP, Thurston SW, Wain JC, Lynch TJ, Su L, Christiani DC. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. *Cancer Research* 2002; 62: 1377-81. (Analysis and interpretation). **Co-investigator**.
506. Zhai R, **Liu G**, Ge X, Bao W, Wu C, Yang C, Liang D. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and their soluble receptors in coal workers' pneumoconiosis. *Respir Med* 2002; 96: 829-34. (Analysis and interpretation). **Co-investigator**.
507. Zhou W, Thurston SW, **Liu G**, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 461-6 (Analysis and interpretation). **Co-investigator**.
508. Zhai R, **Liu G**, Yang C, Huang C, Wu C, Christiani DC. The G to C polymorphism at -174 of the interleukin-6 gene is rare in a Southern Chinese Han population. *Pharmacogenetics* 2001; 11: 699-701. (Analysis and interpretation). **Co-investigator**.
509. **Liu G**, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on the risk of different histological subtypes of non-small cell lung cancer. *Cancer Res.* 2001 Dec 15; 61: 8718-22. **Principal Author**.
510. Wang LI, Miller DP, Sai Y, **Liu G**, Su L, Wain JC, Lynch TJ, Christiani DC. Manganese superoxide dismutase alanine-9-to-valine polymorphism at codon 16 and lung cancer risk. *J Natl Cancer Inst* 2001; 93: 1818-1821. (Analysis and interpretation). **Co-investigator**.
511. Lal G, **Liu G**, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M, Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1 and BRCA2 mutations. *Cancer Res* 2000; 60: 409-416 (study design and analysis). **Co-investigator**.
512. **Liu G**, Ghadirian P, Vesprini D, Hamel N, Paradis AJ, Lal G, Gallinger S, Narod SA, Foulkes W. Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. *Br J Cancer* 2000; 82: 1646-1649. **Principal Author**.
513. **Liu G**, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. *J Clin Oncol* 1997; 15: 110-115. **Principal Author**.
514. **Liu G**, Crump M, Goss PE, Dancey J, Shepherd FA. A prospective comparison of the sclerosing agents doxycycline versus bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. *J Clin Oncol* 1996; 14: 3141-3147. **Principal Author**.
515. **Liu G**, Shupak R, Chiu B. Aortic dissection in giant cell arteritis. *Semin Arthritis Rheum* 1995; 25: 160-171. **Principal Author**.
516. **Liu G**, Butany J, Wanless I, Cameron R, Levy G, Greig P. The vascular pathology of human hepatic allografts. *Human Path* 1993; 24: 182-188. **Principal Author**.
517. **Liu G**, Butany J. Morphology of graft arteriosclerosis in cardiac transplant recipients. *Human Path* 1992; 23: 768-773. **Principal Author**.

## Editorials

1. Matthew T Warkentin, Hamad Al-Sawaihey, Stephen Lam, **Geoffrey Liu**, Brenda Diergaarde, Jian-Min Yuan, David O Wilson, Sukhinder Atkar-Khattra, Benjamin Grant, Yonathan Brhane, Elham Khodayari-Moez, Kiera R, Murison Martin, C Tammemagi, Kieran R Campbell, Rayjean J Hung. Decoding pulmonary nodules: can machine learning enhance malignancy risk stratification? *Thorax*. 2024 Mar;79(4):293-294. **Coauthor or Collaborator**.
2. García-Pardo M, **Liu G**. Re: Response to Letter to the Editor "Respiratory and Cardiometabolic Comorbidities and Stage I-III Non-Small Cell Lung Cancer (NSCLC) Survival: A Pooled Analysis From the International Lung Cancer Consortium". *J Thorac Oncol*. 2023 Sep;18(9):e96-e97. **Co-Principal Author**.
3. **Liu G**, Brenner H, Chen C, Christiani D, Field JK, Hung R, Jie Z, Le Marchand L, Ryan B, Schabath MB, Schwartz AG, Shete S, Shiraishi K, Tardon A, Teare MD, Yang P, Zhang ZF, Xu W. A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?". *Lung Cancer*. 2021 Apr;154:225-226. **Senior Responsible Author**.
4. Herman M, Warkentin MT, Shepshelovich D, Latifovic L, Hung R, **Liu G**. Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All. *J Thorac Oncol*. 2018 May;13(5):601-602 (Trainee publication, Herman M, Sheshelovitch D, Latifovic L). **Senior Responsible Author**.

## Abstract

1. Sebastiao N. Martins-Filho, Jessica Weiss, Nhu-An Pham, Michael Cabanero, Aline Fusco Fares, Erin L. Stewart, Devalben Patel, Judy McConnell, Penelope Ann Bradbury, Adrian G. Sacher, Natasha B. Leighl, Alexandria Grindlay, Frances Allison, Ming Li, Kazuhiro Yasufuku, Frances A. Shepherd, Nadeem Moghal, Ming Sound Tsao, **Geoffrey Liu**. Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma (LUAD). *Journal of Clinical Oncology*. 2020 Jun 3. (suppl; abstr 3110). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_264481.html](http://abstracts.asco.org/239/AbstView_239_264481.html). **Senior Responsible Author supervising SNMF, AFF, ELS, DP**.
2. Natasha Leighl, Kirstin Perdrizet, Tracy Stockley, Jennifer H Law, Muqdas Shabir, Tong Zhang, Lisa Le, Anthea Lau, Ming Sound Tsao, Suzanne Kamel-Reid, Prodipto Pal, Michael Cabanero, Joerg Schwock, Hyangmi Ko, **Geoffrey Liu**, Penelope A Bradbury, Adrian G Sacher, Frances Shepherd. Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model. *Proc World Conf Lung Cancer*. 2019 Sep;P1(01-30). **Coauthor or Collaborator**.
3. Sally CM Lau, Lisa Le, Sze Wah Samuel Chan, Elliot Smith, Malcolm Ryan, M Catherine Brown, Katrina Hueniken, Lawson Eng, Devalben Patel, Rui Qi Chen, Mike Sung, Alona Zer, Penelope A Bradbury, Pamela S Ohashi, Frances Shepherd, Ming Sound Tsao, Natasha B Leighl, **Geoffrey Liu**, Adrian G Sacher. Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy. *Proc World Conf Lung Cancer*. 2019 Sep;P1(01-70). **Coauthor or Collaborator**.
4. Simranjit Kooner, **Geoffrey Liu**, Katrina Hueniken, Suheon Lee, Jennifer Harris, Catherine De Guia, Edith Anokye-Yeboah, Pansy Chow, Priya Bapat, Wei Xu, Doris Howell, Iryna Tymoshyk, Anne Embleton. Screening for Long Term Ototoxicity in Lung and Upper Aerodigestive Cancer Survivors Treated with Platinum Chemotherapy. *Proc World Conf Lung Cancer*. 2019 Sep;P1(07-15). **Co-Principal Author supervising SK, KH, PC, PB**.
5. **Geoffrey Liu**, Lawson Eng, Jie Su, Katrina Hueniken, M Catherine Brown, Andrew Hope, Andrea Bezjak, Adrian G Sacher, Penelope A Bradbury, Frances Shepherd, Natasha B Leighl, Andrew F Pierre, Peter Selby, David P Goldstein, Wei Xu, Meredith E Giuliani, William K. Evans, Michael Chaiton. Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. *Proc World Conf Lung Cancer*. 2019 Sep;P1(10-05). **Senior Responsible Author supervising LE, JS, KH**.
6. Erin L Stewart, Ao Wang, Ju Huang, Hua Bao, Xue Wu, Devalben Patel, Zhuo Chen, Jennifer H Law, Penelope A Bradbury, Frances Shepherd, Adrian G Sacher, Ming Sound Tsao, Scott V Bratman, Natasha B Leighl, Trevor Pugh, **Geoffrey Liu**. Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance. *Proc World Conf Lung Cancer*. 2019 Sep;P1(14-07). **Senior Responsible Author supervising ELS, DP, ZC**.

7. Ming Sound Tsao, Roushi Shi, Nikolina Radulovich, Christine Ng, Hirotsugu Notsuda, Michael Cabanero, Sebastiao N Martins-Filho, Vibha Raghavan, Quan Li, Arvind Singh Mer, Ni Liu, Nhu-An Pham, Benjamin Haibe-Kains, **Geoffrey Liu**, Nadeem Moghal. Organoid Cultures as Novel Preclinical Models of Non-Small Cell Lung Cancer. Proc World Conf Lung Cancer. 2019 Sep. **Coauthor or Collaborator**.
8. Yanhong Liu, James McKay, Xiangjun Xiao, John Kirkpatrick Field, Michael Davies, Paul Brennan, **Geoffrey Liu**, Rayjean J. Hung On Behalf Of The International Lung Cancer Consortium, David C. Christiani, Christopher Ian. Amos Pathogenic Germline Rare Variants and Risk of Lung Cancer. Proc World Conf Lung Cancer. 2019. 2019 Sep:P2.03-18. **Coauthor or Collaborator**.
9. Aline Fusco Fares, Sebastiao N Martins-Filho, Vibha Raghavan, Erin L Stewart, deepthi Ravi, jessica Weiss, Katrina Hueniken, Devalben Patel, Nhu-An Pham, Adrian G Sacher, Penelope A Bradbury, Natasha B Leighl, Frances Shepherd, Ming Sound Tsao, **Geoffrey Liu**. Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition. Proc World Conf Lung Cancer 2019. 2019 Sep:P2.03-37. **Senior Responsible Author supervising AFF, SNMF, ELS, DR, JW, KH, DP**.
10. Erin L Stewart, Roya Navab, Sebastiao N Martins-Filho, Nhu-An Pham, **Geoffrey Liu**, Ming Sound Tsao. Tumor-Stromal Microenvironment Interactions in a PDX Model of EGFR TKI Drug Tolerance. Proc World Conf Lung Cancer. 2019. 2019 Sep:P2.14-40. **Coauthor or Collaborator**.
11. Prodipto Pal, Aline Fusco Fares, Devalben Patel, Erin L Stewart, Nicole Perera-Low, Alexandria Grindley, Frances Allison, Nhu-An Pham, Rioshi Shi, Natasha B Leighl, Frances Shepherd, Penelope A Bradbury, Adrian G Sacher, Patrik Rogalla, Kazuhiro Yasufuku, Michael Cabanero, Ming Sound Tsao, **Geoffrey Liu**, Sebastiao N Martins-Filho, Lananh Nguyen. Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors. Proc World Conf Lung Cancer. 2019. 2019 Sep:MA18.07. **Coauthor or Collaborator**.
12. Andrew CL Lam, Reenika Aggarwal, Erin L. Stewart, Katrina Hueniken, Maureen McGregor, Wei Xu, Heidi Schmidt, John Kavanagh, **Geoffrey Liu**. Quality improvement of lung cancer patient selection using clinic-based spirometry. J Clin Oncol 37, 2019. 2019 Sep. (suppl 27; abstr 282). **Senior Responsible Author supervising ACLL, RA, ELS, KH**.
13. Lorin Dodbiba, Katrina Hueniken, Shirley Xue Jiang, Sze Wah Samuel Chan, Elliot Charles Smith, Lawson Eng, Devalben Patel, Maryam Razooqi, M. Catherine Brown, Frances A. Shepherd, Natasha B. Leighl, Penelope Ann Bradbury, Wei Xu, Adrian G. Sacher, **Geoffrey Liu**. Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations. J Clin Oncol 37, 2019. 2019 Sep. (suppl 27; abstr 102). **Senior Responsible Author supervising LD, KH, SXJ, SWSC, ECS, LE, DP, MR**.
14. Priya Bapat, Pansy Chow, Katrina Hueniken, Mary Mahler, M. Catherine Brown, Carolyn Falls, Andrew J. Hope, Aaron Richard Hansen, David Paul Goldstein, John Rutka, Doris Howell, Wei Xu, **Geoffrey Liu**. Barriers and facilitators to the implementation of routine ototoxicity screening for head and neck cancer patients. J Clin Oncol 37, 2019. 2019 Sep. (suppl 27; abstr 127). **Senior Responsible Author supervising PB, PC, KH, MM**.
15. Lucy Xiaolu Ma, Osvaldo Espin-Garcia, Charles Henry Lim, Peiran Sun, Di Maria Jiang, Hao-Wen Sim, Akina Natori, Bryan Anthony Chan, Daniel Yokom, Stephanie Moignard, Chihiro Suzuki, Eric Xueyu Chen, **Geoffrey Liu**, Carol Jane Swallow, Gail Elizabeth Darling, Rebecca Wong, Sara Hafezi-Bakhtiari, James Conner, Elena Elimova, Raymond Woo-Jun Jang. Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer. Journal of Clinical Oncology. 2019 Jun 3. (suppl; abstr 4069). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_271223.html](http://abstracts.asco.org/239/AbstView_239_271223.html). **Co-Principal Author**.
16. Lawson Eng, Jie Su, Steven Habbous, Katrina Hueniken, M. Catherine Brown, Deborah Saunders, John R. de Almeida, Andrew Hope, Andrea Bezjak, Frances A. Shepherd, Natasha B. Leighl, Andrew Pierre, Peter Selby, David Paul Goldstein, Wei Xu, Meredith Elana Giuliani, William K. Evans, **Geoffrey Liu**, Michael Chaiton. Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. Journal of Clinical Oncology. 2019 Jun 2. (suppl; abstr 11559). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_263335.html](http://abstracts.asco.org/239/AbstView_239_263335.html). **Senior Responsible Author supervising LE, JS, SH, KH**.



17. Kirstin Perdrizet, Tracy Stockley, Jennifer H. Law, Muqdas Shabir, Tong Zhang, Lisa W Le, Anthea Lau, Ming Sound Tsao, Prodipto Pal, Michael Cabanero, Hyangmi Ko, Joerg Schwock, Suzanne Kamel-Reid, **Geoffrey Liu**, Adrian G. Sacher, Penelope Ann Bradbury, Frances A. Shepherd, Natasha B. Leighl. Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model. *Journal of Clinical Oncology*. 2019 Jun. (suppl; abstr 2620). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_249803.html](http://abstracts.asco.org/239/AbstView_239_249803.html). **Coauthor or Collaborator**.
18. Lawson Eng, Katrina Hueniken, M. Catherine Brown, Andrew Hope, Meredith Elana Giuliani, Peter Selby, Kelvin K. Chan, Nicole Mittmann, Wei Xu, David Paul Goldstein, **Geoffrey Liu**, John R. de Almeida. Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors. *Journal of Clinical Oncology*. 2019 Jun. (suppl; abstr 11561). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_267815.html](http://abstracts.asco.org/239/AbstView_239_267815.html). **Senior Responsible Author supervising LE, KH**.
19. Aline Fusco Fares, Daniel Shepshelovich, Lin Lu, M. Catherine Brown, Ping Yang, Jie Zhang, Brid M Ryan, David C. Christiani, Ann Schwartz, Chu Chen, Garcia Adonina, Matthew B. Schabath, Kouya Shiraishi, Teare Down, Loic Le Marchand, Zhang Zuo-Feng, Hermann Brenner, Wei Xu, Rayjean J Hung, **Geoffrey Liu**. Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts). *Journal of Clinical Oncology*. 2019 Jun. (suppl; abstr 1562). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_266853.html](http://abstracts.asco.org/239/AbstView_239_266853.html). **Senior Responsible Author supervising AFF, DS, LL**.
20. Kirsty Taylor, Osvaldo Espin-Garcia, Tina Romagnuolo, Frances Allison, Lucy Xiaolu Ma, Micheal McInnis, Aline Fusco Fares, **Geoffrey Liu**, Gail Elizabeth Darling, Rebecca Wong, Eric Xueyu Chen, Patrick Veit-Haibach, Raymond Woo-Jun Jang, Dmitry Rozenberg, Elena Elimova. Prognostic significance of sarcopenia in metastatic esophageal squamous cell carcinoma. *Journal of Clinical Oncology*. 2019 Jun. (suppl; abstr 4068). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_269485.html](http://abstracts.asco.org/239/AbstView_239_269485.html). **Coauthor or Collaborator**.
21. Jaspreet K Bajwa, Aline Fusco Fares, George Dong, Daniel Vilarim Araujo, Katrina Hueniken, Devalben Patel, Kirsty Taylor, Gail Elizabeth Darling, Rebecca Wong, Eric Xueyu Chen, Jennifer J. Knox, Raymond Woo-Jun Jang, Elena Elimova, Wei Xu, **Geoffrey Liu**, Dmitry Rozenberg, Micheal McInnis. Muscle wasting, visceral and subcutaneous adiposity, inflammation, nutritional deficiencies, and metastatic esophageal cancer (MEC) prognosis. *Journal of Clinical Oncology*. 2019 May. *J Clin Oncol* 37, 2019 (suppl; abstr e14595). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_252795.html](http://abstracts.asco.org/239/AbstView_239_252795.html). **Principal Co-Author supervised AFF, GD, KH, DP. Project PI/REB PI/Funding complete project/PI of underlying project/Collaboration initiator**.
22. Sally CM Lau, Lisa W Le, Sze Wah Samuel Chan, Elliot Charles Smith, Malcolm Ryan, M. Catherine Brown, Katrina Hueniken, Lawson Eng, Devalben Patel, RuiQi Chen, Alona Zer, Mike Ru Sung, Penelope Ann Bradbury, Pamela S Ohashi, Frances A. Shepherd, Ming Sound Tsao, Natasha B. Leighl, **Geoffrey Liu**, Adrian G. Sacher. Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors. *Journal of Clinical Oncology*. 2019 May. *J Clin Oncol* 37, 2019 (suppl; abstr e20594). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_259493.html](http://abstracts.asco.org/239/AbstView_239_259493.html). **Coauthor or Collaborator**.
23. Hadas Sorotsky, Mansi Aparanthi, Daniel Zongjie Wang, Francesca McFadden, Sandra N Popescu, Reza M Mohamadi, Mark Pereira, Jessica Weiss, Devalben Patel, Safa Majeed, Michael Cabanero, Adrian G. Sacher, Penelope Ann Bradbury, Natasha B. Leighl, Frances A. Shepherd, Ming Sound Tsao, **Geoffrey Liu**, Shana O Kelley, Benjamin H. Lok. Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients. *Journal of Clinical Oncology*. 2019 May. *J Clin Oncol* 37, 2019 (suppl; abstr e20091). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_261729.html](http://abstracts.asco.org/239/AbstView_239_261729.html). **Coauthor or Collaborator**.
24. John R. de Almeida, Katrina Hueniken, Lawson Eng, Meredith Giuliani, Jolie Ringash, Aaron Richard Hansen, **Geoffrey Liu**, Wei Xu, Madeline Li, David Paul Goldstein. Predictors of financial toxicity among head and neck cancer patients: A prospective cohort study. *Journal of Clinical Oncology*. 2019 May. *J Clin Oncol* 37, 2019 (suppl; abstr e18361). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_266665.html](http://abstracts.asco.org/239/AbstView_239_266665.html). **Coauthor or Collaborator**.

25. Sally CM Lau, Lisa W Le, Elliot Charles Smith, Sze Wah Samuel Chan, Malcolm Ryan, M. Catherine Brown, Katrina Hueniken, Lawson Eng, Devalben Patel, RuiQi Chen, Mike Ru Sung, Alona Zer, Penelope Ann Bradbury, Pamela S Ohashi, Frances A. Shepherd, Ming Sound Tsao, **Geoffrey Liu**, Natasha B. Leighl, Adrian G. Sacher. Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI). Journal of Clinical Oncology. 2019 May. J Clin Oncol 37, 2019 (suppl; abstr e20667). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_266257.html](http://abstracts.asco.org/239/AbstView_239_266257.html). **Coauthor or Collaborator**.
26. RuiQui Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Katrina Hueniken, M. Catherine Brown, Habeeb Majeed, Kendra Ross, Diana Gray, Wei Xu, David Hogg, Srikala S. Sridhar, Adrian G. Sacher, Natasha B. Leighl, Monika K. Krzyzanowska, Marcus O. Butler, **Geoffrey Liu**, Lawson Eng. Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy. Journal of Clinical Oncology. 2019 Feb. J Clin Oncol 37, 2019 (suppl 8; abstr 85). Available from: <https://meetinglibrary.asco.org/record/170464/abstract>. **Senior Responsible Author supervising RQC, ECS, SWSC, KH, LE. Project funding, PI Project and REB; Project initiation.**
27. Shirley Xue Jiang, Shubhangi Shah, Elliot Charles Smith, Justine Baek, Mindy Liang, M. Catherine Brown, Allyson Mayo, **Geoffrey Liu**, Jonathan Yeung, Rebecca Wong, Elena Elimova, Gail Elizabeth Darling. The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool. Journal of Clinical Oncology. 2019 Jan. J Clin Oncol 37, 2019 (suppl 4; abstr 37). Available from: <https://meetinglibrary.asco.org/record/168472/abstract>. **Coauthor or Collaborator**.
28. Di Maria Jiang, Chihiro Suzuki, Osvaldo Espin-Garcia, Charles Henry Lim, Lucy Xiaolu Ma, Peiran Sun, Hao-Wen Sim, Akina Natori, Bryan Anthony Chan, Daniel Yokom, Stephanie Moignard, Eric Xueyu Chen, **Geoffrey Liu**, Carol Jane Swallow, Gail Elizabeth Darling, Rebecca Wong, Raymond Woo-Jun Jang, Elena Elimova. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC). Journal of Clinical Oncology. 2019 Jan. J Clin Oncol 37, 2019 (suppl; abstr e15579). Available from: [http://abstracts.asco.org/239/AbstView\\_239\\_269133.html](http://abstracts.asco.org/239/AbstView_239_269133.html). **Coauthor or Collaborator**.
29. A. Bang, D. Pinto, K. Hueniken, C. Brown, W. Xu, **G. Liu**, B. Lok. Outcomes of IMRT/VMAT vs 2D/3D-conformal thoracic radiation in limited stage small-cell lung cancer. Radiotherapy and Oncology. 2019;133. Radiotherapy and Oncology 2019; 133 (supp 1) abstr PO-0774. **Coauthor or Collaborator**.
30. Alexander Magony, Katrina Hueniken, Shayan Kassirian, Ilana Geist, Chelsea Paulo, Lawson Eng, Elliot Charles Smith, Arielle Geist, Pryangka Rao, M. Catherine Brown, Mindy Liang, Dongyang Yang, Wei Xu, Jackie Bender, Abha A. Gupta, **Geoffrey Liu**. Comparison of health care-related social media and Internet usage between patients treated with curative and palliative intent. Journal of Clinical Oncology. 2018 Nov. J Clin Oncol 36, 2018 (suppl 34; abstr 173). Available from: <https://meetinglibrary.asco.org/record/167245/abstract>. **Coauthor or Collaborator**.
31. Srikala S. Sridhar, Normand Blais, Ben Tran, M. Neil Reaume, Scott A. North, Martin R. Stockler, Kim N. Chi, Neil Eric Fleshner, **Geoffrey Liu**, John W Robinson, Som Mukherjee, Yasmin Rahim, Eric Winquist, Christopher M. Booth, Nghia Trung Nguyen, Emma Kate Beardsley, Nimira S. Alimohamed, Gail T McDonald, Keyue Ding, Wendy R. Parulekar. Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993). Journal of Clinical Oncology. 2018 Jun. J Clin Oncol 36, 2018 (suppl; abstr 4505). Available from: <https://meetinglibrary.asco.org/record/161516/abstract>. **Coauthor or Collaborator**.
32. Lawson Eng, RuiQui Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Katrina Hueniken, M. Catherine Brown, Habeeb Majeed, Kendra Ross, Diana Gray, Wei Xu, David Hogg, Srikala S. Sridhar, Adrian G. Sacher, Natasha B. Leighl, Monika K. Krzyzanowska, **Geoffrey Liu**, Marcus O. Butler. Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs). J Clin Oncol 37, 2019. (suppl 8; abstr 82). **Senior Responsible Author supervising RQC, ECS, SWSC, KH, LE. Project funding, PI Project and REB; Project initiation.**

## Manuscript

1. Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price, Waldron J, Goldstein D, Meyer F, Bairati I, **Liu G**. Development and application of Critical Appraisal Tool in Molecular Epidemiologic Cancer Prognostic Studies. (supervised J Hopkins, D Cescon, D Tse, P Bradbury, P. Wheatley-Price). **Senior Responsible Author**.

## Manuscripts

1. Asomaning K, Zhai R, Bradbury P, Heist RS, Wain JC, Lynch TJ, Su L, Lin X, Christiani DC, **Liu G**. Polymorphisms of Signal transduction Pathway and Esophageal Cancer Prognosis. (supervised K. Asomaning). **Senior Responsible Author**.

## 3. NON-PEER-REVIEWED PUBLICATIONS

### Journal Articles

1. **Liu G**, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon D, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leigh NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN. BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 trial. Clin Cancer Res. 2017 May;23(10):2460-2470. Epub 2016 Nov 8. (Trainee publication, GL supervised SC, SL, AKA, LC, YB, XQ, ZC, DC, DP, BCT). Available from: S Cuffe, S Liang, AK Azad, L Cheng, Y Brhane, X Qiu, D Cescon, D Patel, BC Tse. Impact Factor 10.2 (Trainee publication). **Senior Responsible Author**.
2. Stewart EL, Tan ZS, **Liu G**, Tsao MS. Current Mechanisms of Resistance of EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Translational Lung Cancer Research. 2015 Feb;4(1):67-81. doi: 10.3978/j.issn.2218-6751.2014.11.06 (co-supervisor of ELS with MST) (Trainee publication). **Coauthor or Collaborator**.
3. Eng L, **Liu G**. Polymorphisms in vascular endothelial growth factor and associated receptors as prognostic and pharmacogenetic factors in cancer: A 2013 Update. Pharmacogenomics. 2013 Oct;14(13):1659-1667. 2013 Oct 31. pii:S1877-7821(13)00153-7. (trainee publication; Supervising LE). **Senior Responsible Author**.
4. Savas S, **Liu G**, Xu W. Special considerations in prognostic research in cancer involving genetic polymorphisms. BCM Med. 2013 Jun 17. **Senior Responsible Author**.
5. Savas S, and **Liu G**. Genetic variations as cancer prognostic markers: review and update. Hum Mutat. 2009 Oct; 30(10): 1369-77. (Trainee publication). **Senior Responsible Author**.
6. Savas, S, and **Liu G**. Studying genetic variations in cancer prognosis (And Risk): A primer for clinicians. Oncologist. 2009 Jul; 14(7): 657-66. (Trainee publication). **Senior Responsible Author**.
7. S. Marsh, and **G Liu**. Pharmacokinetics and Pharmacogenomics in Breast Cancer Chemotherapy. Advanced Drug Delivery Reviews (2009), May 20; 61(5): 381-7. Epub 2008 Dec 3 Review. PMID: 19100797 [PubMed – indexed for MEDLINE]. **Co-Principal Author**.
8. Cheung WY and **Liu G**. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am. 2009 Mar; 38(1): 75-91, viii. (Trainee publication). **Senior Responsible Author**.
9. Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price, Waldron J, Goldstein D, Meyer F, Bairati I, **Liu G**. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev, 2008; 17(3): 490-9. (Supervised J. Hopkins). **Senior Responsible Author**.
10. **Liu G**, Zhou W, Christiani DC. Molecular Epidemiology of Lung Cancer. Sem in Resp Crit Care Med 2005; 26: 265-72. **Principal Author**.
11. **Liu G**, Mayer R.J. Adjuvant therapy of colon cancer. Advances in Oncology 2001; 4: 2-16. **Principal Author**.

12. Wang JR, Habbous S, Espin-Garcia O, Chen D, Huang s, Simpson C, Xu W, Liu FF, Brown DH, Gilbert RW, Gullane PJ, Irish JC, Goldstein DP, **Liu G**. Comorbidity and performance status are independent prognostic factors in head and neck squamous cell carcinoma patients. Head & Neck. In Press. **Senior Responsible Author**.

## Books

1. Ming T, **Liu G**, and John T. Overview of Molecular Testing in Non–Small Cell Lung Cancer: Mutational Analysis, Gene Copy Number, Protein Expression, and Other Biomarkers of EGFR for the Prediction of Response to Tyrosine Kinase Inhibitors. Macmillan Publishers Limited (trading as Nature Publishing Group), Oncogene 2009. **Co-Principal Author**.

## Book Chapters

1. Cescon DW, Hopkins J, Bradbury P, Tse D, **Liu G**. Epidemiology of Esophageal Cancer-Molecular. In: Jobe BA, Thomas CR, Hunter JG (Eds) . Esophageal Tumors – Principles and Practice. Demos Medical, NY, 2009. (Trainee publication). **Senior Responsible Author**.
2. **Liu G**. Esophageal Cancer. In: Chabner B, Lynch TJ, Longo D (eds). Harrison's Handbook of Oncology. McGraw-Hill 2008; p387-394. **Principal Author**.
3. **Liu G**, Zhou W, Wang Z, McLeod HL. Incorporating molecular oncology in prognosis. In: Gospodarowicz MK, O'Sullivan B, Sobin, L (Eds). Prognostic Factors in Cancer. 3rd edition. Wiley and Sons 2006; p79-94. **Principal Author**.
4. **Liu G**. Epidemiology of cancer – you are not alone. In: Stern TA, Sekeres MA (Eds). Facing cancer – a complete guide for people with cancer, their families and caregivers. McGraw-Hill 2004; p79-88. **Principal Author**.
5. **Liu G**. Pharmacogenomics: Predicting responders and nonresponders to chemotherapy and targeted agents. In: Lynch TJ (ed). Progress in non-small cell lung cancer: Molecular mechanisms of novel agents. InforMedical Communications CME Educational Activity 2004 (monograph); p16-18. **Principal Author**.

## Editorials

1. Mittal A, Moore S, Navani V, Jiang DM, Stewart DJ, **Liu G**, Wheatley-Price P. What Is Ailing Oncology Clinical Trials? Can We Fix Them? Curr Oncol. 2024 Jun;31(7):3738-3751. 10.3390/curroncol31070275. **Co-Principal Author**.
2. Marrone M, Schilsky RL, **Liu G**, Khoury MJ, Freedman AN. Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):484-9. doi: 10.1158/1055-9965.EPI-14-1086. **Coauthor or Collaborator**.
3. Heist RS, **Liu G**, Zhou W. Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer? Nat Clin Pract Oncol. 2007 Oct; 4(10): 564-5.
4. Tsao, MS, **Liu, G**, Shepherd FA. Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap? J Natl. Cancer Inst. 2007; 99(11): 826-7.
5. **Liu G**, Darling ML, Chan J, Jaklitsch MT, Skarin AT. Gynecomastia in a patient with lung cancer. J Clin Oncol 1999; 17: 1956-1957.

## Thesis

1. **Liu G**. The association of GSTM1 and GSTT1 polymorphisms with smoking in pancreatic cancer. [MSc. Dissertation]. Toronto; Univ. of Toronto; 2002.

## F. Presentations and Special Lectures

### 1. INTERNATIONAL

#### Invited Lectures and Presentations

- 2024 Mar 5 **Keynote Speaker.** Development of the Sub-saharan Africa Lung CancerAtlas, SALCA. Pan African Cancer Research Institute's second annual international Conference. Pretoria, South Africa. 25 minutes.
- 2024 Jan 31 **Invited Speaker.** ALK NSCLC: from Early to Late Stage. Roche National Conference. Switzerland. 20 individuals, 60 minutes.
- 2023 Nov **Invited Plenary Talk.** Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC). Multidisciplinary Thoracic Cancers Symposium 2023. New Orleans, Louisiana, United States.
- 2023 Oct **Invited Speaker.** Smoking Metrics and Lung Cancer Survival. International Lung Cancer Consortium Annual Meeting, International Agency for Research in Cancer (IARC). Lyons, France. Audience (hybrid): 95 individuals – multilevel trainees, scientists.
- 2023 Oct **Invited Speaker.** ALK+ NSCLC: Maximising the potential for patients throughout their treatment journey. European Society of Medical Oncology (ESMO) Congress. Madrid, Spain. Chair/Speaker.
- 2023 Jul 1 **Invited Speaker.** Managing Metastatic Non-Small Cell Lung Cancer Patients with ALK and ROS1 fusions in North America (Virtual Presentation). The Shandong Doctors' Association. Qufu, Shandong, China.
- 2023 Mar **Chair and presenter..** Raising the bar for patients with ALK+ NSCLC on their treatment journey: Symposium. European Lung Cancer Conference. Copenhagen, Denmark. 150 physicians, nurses, scientists advocates.
- 2022 Nov 4 **Invited Speaker.** Management of non-targetable NSCLC. Shaukat Khanum Cancer Symposium 2022 (Virtual). Islamabad, Pakistan. Audience: 75 individuals - multilevel trainees.
- 2022 Oct 25 **Invited Speaker.** 1. Update on Clinical Outcome Studies of ILCCO; 2. Genomics of Immunotherapy. International Lung Cancer Consortium Annual Meeting. Los Angeles, California, United States. Audience: multilevel trainees, n = 70
- Presentation 1: Update on Clinical Outcome Studies of ILCCO (15 min)
- Presentation 2: Genomics of Immunotherapy, Young Scientist Session, Commentary (15 min).
- 2022 Oct 25 **Invited Speaker.** Immunotherapy toxicities and genome wide analyses. University of California (ULCA). Los Angeles, California, United States. Audience (hybrid): 54 individuals – multi-level trainees.
- 2022 Oct 24 **Invited Speaker.** ILCCO Clinical Outcomes Updates. University of California (ULCA). Los Angeles, California, United States. Audience (hybrid): 95 individuals – multilevel trainees.
- 2021 Sep 18 **Invited Speaker.** Third generation EGFR inhibitor osimertinib in adjuvant setting. First Chinese University of Shanghai (Virtual). China. Audience: China. Virtual Presentation.
- 2020 Oct 23 **Invited Speaker.** COS-ILCCO Update. International Lung Cancer Consortium Annual (Virtual Meeting). United States. Audience: Multilevel; 85 individuals; 30 minutes preparation.
- 2020 May 19 **Invited Speaker.** Smoking cessation and NSCLC survival. ASCO Annual Conference Press Conference. United States. Audience: Reporters;

15 minutes.

- 2019 May 22 **Invited Speaker.** Clinical Outcome Analyses of Head and Neck Cancer Genomics; Head and Neck Cancer Smoking Outcomes Study; HPV-associated Oropharyngeal Cancer. VOYAGER CONSORTIUM MEETING. Memphis, Tennessee, United States. 30 individuals; 240 minute preparation.
- 2019 Apr 11 **Invited Speaker.** Head and Neck Translational Program At Princess Margaret Cancer Centre. INHANCE Consortium meeting. New York, United States. 25 individuals; 180 minutes preparation.
- 2018 Oct 29 **Keynote Speaker.** Pharmacogenomics study design and methods. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China.
- 2018 Oct 27 **Invited Speaker.** Non database descriptive pharmacoepidemiology. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China.
- 2018 Oct 17 **Invited Lecturer.** ALK positive cancers and real world evidence. European Society for Medical Oncology (ESMO) European Cancer Conference. Munich, Germany.
- 2018 Aug 24 **Invited Speaker.** Pharmacoepidemiology and Personalized Medicine. International Conference in Pharmacoepidemiology. Prague, Czech Republic.
- 2018 Jun 29 **Invited Speaker.** Comorbidity and Outcomes in Head and Neck Cancer Patients. INHANCE Consortium Meeting. Milan, Italy.
- 2018 Mar 5 **Invited Speaker.** Germline Predictors of Cisplatin Toxicity. Queensland Genomics Centre. Brisbane, Australia.
- 2018 Jan 29 **Keynote Speaker.** Pharmacogenomic Epidemiology: A New Generation. Queensland College of Pharmacy. Brisbane, Queensland, Australia.
- 2017 Dec 1 **Invited Speaker.** Osimertinib in T790M positive lung cancer. Lung Cancer Meeting. Indore, India.
- 2017 Nov 28 **Invited Speaker.** Laboratory analysis of T790M mutations and Osimertinib in lung cancer. Lung Cancer Meeting, November 27-30. Chennai, Delhi, Mumbai, India.
- 2017 Oct 30 **Invited Speaker.** Introduction to non-database Epidemiology. International Society for Pharmacoepidemiology (ISPE). Brisbane, Australia. 10th Asian Conference on Pharmacoepidemiology.
- 2017 Oct 24 **Invited Speaker.** The Toronto Head and Neck Molecular Epidemiology Study. International Agency for Research on Cancer. Lyon, France. ENHANCE Meeting.
- 2017 Oct 15 **Invited Speaker.** Epidemiology of Lung Cancer. International Association for the Study of Lung Cancer (IASLC). Yokohama, Japan. World Conference on Lung Cancer.
- 2017 Sep 18 **Invited Speaker.** BMI and lung cancer prognosis. International Lung and Cancer Consortium (ILCCO). New York, New York, United States. Transdisciplinary Research in Cancer of the Lung (TRICL).
- 2017 Aug 14 **Invited Speaker.** Laboratory analysis of T790M mutations and Osimertinib in lung cancer. Lung Cancer Meeting, August 8-14. Bangalore, Delhi, Mumbai, Chennai, India.
- 2017 Apr 3 **Invited Speaker.** Pharmacogenomics for the naive epidemiologist. International Society for Pharmacoepidemiology (ISPE). London, City of, United Kingdom.
- 2017 Mar 27 **Invited Speaker.** Mesothelioma primary derived xenograft models and their use in translational science. International Association for the Study of Lung Cancer (IASLC). Bethesda, Maryland, United States.
- 2016 Apr 20 **Invited Speaker.** Update on ICON7 and CO.20 Pharmacogenomic Analyses. PGRN-RIKEN. San Francisco, California, United States.

- 2016 Mar 9 **Invited Speaker.** MLN1117-1501 US Investigator Meeting. Takeda Pharmaceuticals International. Chicago, Illinois, United States.
- 2015 Sep 9 **Invited Speaker.** Time to Progression and Post-Progression Survival in ALK+Ceritinib-Treated NSCLC. International Association for the Study Lung Cancer (IASLC). Denver, Colorado, United States.
- 2015 Sep 9 **Invited Speaker.** EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer. International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States.
- 2015 Jun 3 **Invited Speaker.** How do we make ILCCO relevant to the clinic? International Association for the Study of Lung Cancer. New York, New York, United States.
- 2015 Apr 13 **Invited Speaker.** Update on Pharmacogenomics. International Society for Pharmacoepidemiology (ISPE). Bordeaux, France.
- 2015 Feb 25 **Invited Speaker.** ICON7 Survival Analysis. PGRN-RIKEN. San Francisco, California, United States.
- 2014 Jun 23 **Invited Speaker.** PHICON7: Pharmacogenetic Results from the ICON7 trial. RIKEN-PGRN Meeting Podium Presentation. Tôkyô [Tokyo], Japan. 40 Scientists, Clinicians.
- 2014 Apr 7 **Invited Speaker.** Biomarker Epidemiology for the Masses Grand Rounds. Department of Epidemiology, Utrecht University. Utrecht, Netherlands. 40 Scientists, PIs, Trainees.
- 2014 Apr 5 **Invited Speaker.** Genome Wide Association Pharmacogenetic Studies. International Conference for Pharmacoepidemiology, Mid-Year Meeting. Netherlands. 90 Epidemiologist, Statisticians, Pharmacists, Trainees.
- 2014 Mar 29 **Invited Speaker.** Molecular Tumor Databanks and Annotation Science. Shanghai Renji Hospital/Jiao Tong University School of Medicine, International Forum. Shanghai, China. 130 PIs, Scientists, Clinicians, Directors, Trainees.
- 2013 Jun 21 **Invited Speaker.** CO20 Pharmacogenetic Analyses. RIKEN CGM meeting. Tôkyô [Tokyo], Japan. Researchers (35).
- 2012 Mar 17 **Invited Speaker.** BEAGESS Survival Analysis. NIH BEACON meeting. Rockville, Maryland, United States. Researchers (20).
- 2012 Mar 1 **Invited Speaker.** PHICON7: A Pharmacogenetic Analysis. RIKEN-CGM-PGRN meeting. Tôkyô [Tokyo], Japan. Researchers (50).
- 2011 Sep 24 **Invited Lecturer.** Molecular Genomics and Individualized Pharmacotherapy. 1st International Conference on Developmental, Translational, & Clinical Pharmacogenomics. Tampa, Florida, United States. Attendees: 50 MDs, PhDs, PharmDs, Researchers, Pharmacy Students.
- 2011 Aug 18 **Invited Speaker.** Introduction to Pharmacogenetic Epidemiology Course. Educational Session: 26th International Conference on Pharmacoepidemiology. Chicago, United States. Scientists, Epidemiologists, Clinicians (N=55).
- 2010 Dec 11 **Panelist.** Chicago Multidisciplinary Symposium in Thoracic Oncologist Biomarkers Panel Discussion/Case Presentation. Chicago, United States.
- 2010 Oct 28 **Invited Speaker.** Cancer Pharmacogenomics: Integrating Discoveries in Basic, Clinical and Population Sciences to Advance Predictive Cancer Care Recommendations for the future of pharmacogenomic research. Bethesda, Maryland, United States.
- 2010 Oct 6 **Invited Speaker.** Cancer Pharmacogenetics: Lessons Learned & New Strategies. Bronx, New York, United States. MDs, PhDs, Residents, Graduate Students, and Post-Doctoral Fellows (N=60).
- 2010 Aug 21 **Chair.** Pharmacogenomics, Predictors, Prognosis, and Personalized Medicine. Educational Session: 26th International Conference on Pharmacoepidemiology. Brighton, United Kingdom. Scientists,

Epidemiologists, Clinicians (n=50). (Continuing Education).

- 2010 Aug 17 **Invited Speaker and Organizer.** Introduction to Pharmacogenetic Epidemiology course. Educational Session: 26th International Conference on Pharmacoepidemiology. Brighton, United Kingdom. Scientist, Epidemiologists, and Clinicians (n=50). (Continuing Education).
- 2009 Oct 16 **Invited Speaker and Co-Chair.** Current Challenges in the Design and Conduct of Pharmacogenetic and Pharmacogenomic Studies. Pharmacogenetics and Pharmacogenomics Session: 3th EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer". Brussels, Belgium. Scientists and Clinicians (n=104). (Continuing Education).
- 2009 Aug 15 **Invited Speaker and Course Organizer.** Biospecimens (and where to get them) for Pharmacoepidemiologists. "Introduction to Pharmacogenetic Epidemiology" course, Educational Session. 25th International Conference on Pharmacoepidemiology. Providence, Rhode Island. Scientists, Epidemiologists, Clinicians (n=78). (Continuing Education).
- 2008 Aug 19 **Invited Speaker.** Linking Pharmacoepidemiology and Pharmacogenomics: Opportunities to Incorporate Genomics into Pharmacoepidemiology Studies. Internal Society of Pharmacoepidemiology. Copenhagen, Denmark. Post-graduate and undergraduate, whole class (n=50), PhD/MD. (Continuing Education).
- 2008 Jun 11 **Invited Speaker.** Pharmacogenetic Epidemiology. University of Buffalo, Department of Social and Preventive Medicine Seminar Series. Graduate, whole class (n=60), MSc. Epidemiology.
- 2008 Apr 1 **Invited Lecturer.** NCIC-CTG studies, MA.31 and MA.30. Breast Cancer Intergroup-Pharmacogenetics Research Network Summit. Bethesda, Maryland. Post-graduate, whole class (n=60), PhD/MD. (Continuing Education).
- 2008 Jan 30 **Invited Lecturer.** Pharmacogenetics of Aerodigestive Cancers: Quality Control Matters. Roswell Park Cancer Institute Rounds. Buffalo, New York. Post-graduate and graduate, whole class (n=30) MD/PhD. (Continuing Education).
- 2007 Dec 1 **Invited Lecturer.** Pharmacogenomics to Guide Lung Cancer Therapy (Early and Advanced Disease). 4th Annual Symposium on the Future of Lung Cancer. Washington, District of Columbia. 50 attendees: post-graduate PhD/MD clinicians, scientists. (Continuing Education).
- 2007 May 18 **Invited Lecturer.** Harvard-Toronto Esophageal Adenocarcinoma Case-control and Case Outcomes Study). 3rd BEACON (Barrett's Esophagus and Adenocarcinoma CONSortium) Annual workshop. Rockville, Maryland. Whole class (40) attendees: post-graduate Clinicians, scientists, government agencies. (Continuing Education).
- 2006 Jan 24 **Invited Lecturer.** Observational studies and SNP selection issues in solid tumors using lung cancer as example: Rapid Case Outcomes Ascertainment Systems help. American Association of Cancer Research Symposium on Molecular and Clinical Prognostic Factors in Cancer Research. Charleston, South Carolina. 150 attendees, scientists. (Continuing Education).
- 2005 Aug 23 **Invited Lecturer.** Observational Studies in Cancer Pharmacogenetics. University of Pittsburgh Medical Center Comprehensive Cancer Center. Pittsburgh, Pennsylvania. 30 attendees, scientists and physicians. (Continuing Education).
- 2005 Jul 7 **Invited Lecturer.** Pharmacogenetics of Cancer Outcomes: The Good, The Bad, and the Ugly. iteman Comprehensive Cancer Center. St. Louis, Missouri. 35 attendees, Scientists and physicians. (Continuing Education).
- 2005 Jun 21 **Invited Lecturer.** Observational Studies of Lung Cancer Outcomes Bad Data In and Bad Data Out. MD Anderson Cancer Center. Houston, Texas. 30 attendees, scientists and epidemiologists. (Continuing Education).
- 2005 Jun 9 **Invited Lecturer.** Pharmacogenetics of Lung Cancer. Duke Comprehensive Cancer Center. Durham, North Carolina. 20 attendees, scientists and physician staff. (Continuing Education).



- 2005 Mar 23 **Invited Lecturer.** Molecular Epidemiology of Lung Cancer. Moores Cancer Center University of California at San Diego. San Diego, California. 30 attendees, physician staff. (Continuing Education).
- 2004 Jul 21 **Invited Lecturer.** The Role of SNPs and Polymorphisms in Lung Cancer. Society of Chinese Bioscientists of America. Beijing, China. 50 attendees, graduate students and scientists (including Principal Investigators). (Continuing Education).
- 2004 Apr 9 **Invited Lecturer.** Esophageal Cancer. 2004 Diana Haney Memorial Cancer Conference. Augusta, Maine. 30 attendees, nursing and physician staff. (Continuing Education).
- 2001 Aug 17 Multi-Modality Therapy for Esophageal Cancer. Multidisciplinary Thoracic Oncology Rounds, Massachusetts General Hospital. Boston, Massachusetts, United States. (Continuing Education).
- 2001 Mar 12 Review of AACR in Thoracic Oncology. Multidisciplinary Thoracic Oncology Rounds, Massachusetts General Hospital. Boston, Massachusetts, United States. (Continuing Education).
- 2000 Sep 15 Molecular Risk Factors for Barrett's Esophagus. Molecular Epidemiology Rounds, Occupational Health Department, Harvard School of Public Health. Boston, Massachusetts, United States. (Continuing Education).

### Presented and Published Abstracts

- 2023 Nov Change in Smoking Demographics Over Time in Older Adults with Lung Cancer. International Society of Geriatric Oncology (SIOG). Valencia, Spain.
- Publication Details:*  
Elizabeth Faour, Martha Pienkowski, M. Catherine Brown, Wei Xu, Shabbir Alibhai, **Geoffrey Liu**. Change in Smoking Demographics Over Time in Older Adults with Lung Cancer. **Senior Responsible Author.**
- 2023 Nov Overall survival in older adults with non-small cell lung cancer by smoking status from 1990 to 2020. International Society of Geriatric Oncology (SIOG). Valencia, Spain.
- Publication Details:*  
Elizabeth Faour, Martha Pienkowski, M. Catherine Brown, Wei Xu, Shabbir Alibhai, **Geoffrey Liu**. Overall survival in older adults with non-small cell lung cancer by smoking status from 1990 to 2020. **Senior Responsible Author.**
- 2023 Nov **Invited Plenary Talk.** Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC). Multidisciplinary Thoracic Cancers Symposium 2023. New Orleans, Louisiana, United States. Invited Plenary Talk.
- Publication Details:*  
**Geoffrey Liu**, Jing Zhang, Yarong Wang, Justin Burgener, Owen Hall, Shu Yi Shen, Martha Pienkowski, Shao Hui Huang, Eduardo Sosa, Angelica Polio, Sarah Goldberg, Peter Mazzone, Scott Bratman, Abel Licon, Krystal Brown, Brian Allen, Anne-Renee Hartman, Daniel D. De Carvalho, Ben Ho Park. Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology, Biology, Physics. 2024 Jan;118(1):e3-e4. **Coauthor or Collaborator.**
- 2023 Oct Updated patient-reported outcomes from the CROWN study: analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs). European Society of Medical Oncology (ESMO) Congress. Madrid, Spain.
- Publication Details:*  
Mazieres J, Toffalorio F, Thomaidou D, Reisman A, Le H, Solomon B, Houqing G, **Liu G**. Updated patient-reported outcomes from the CROWN study: analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs). **Senior Responsible Author.**

- 2023 Oct Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Head and Neck Cancer. European Society of Medical Oncology (ESMO) Congress. Madrid, Spain.
- Publication Details:*  
**Liu G**, Zhang J, Hall O, Burgener J, Wang Y, Brown B, Min J, Shen SY, Pienkowski M, Huang SH, Ailles L, Sosa E, Polio A, Bratman S, Allen B, Brown K, Licon A, Hartman AR, De Carvalho DD, Park BH. Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Head and Neck Cancer. **Coauthor or Collaborator.**
- 2023 Oct Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer (NSCLC): Interim Analysis of Global TRUST-II Study. European Society of Medical Oncology (ESMO) Congress. Madrid, Spain.
- Publication Details:*  
Perol M, Yang N, Choi CM, Ohe Y, Sugawara S, Yanagitani N, **Liu G**, De Braud F, Nieva J, Nagasaka M, Bazhenova L, Zhou C, Felip E, Zhang X, Li Shaunglian, Pennell NA. Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer (NSCLC): Interim Analysis of Global TRUST-II Study. **Coauthor or Collaborator.**
- 2023 Oct Evaluation of a Genome-Wide Methylome Enrichment Platform for Circulating Tumor DNA Quantification and Prognostic Performance in Renal Cell Carcinoma (RCC). European Society of Medical Oncology (ESMO) Congress. Madrid, Spain.
- Publication Details:*  
Rini B, Zhang J, Hall O, Burgener J, Wang Y, Brown B, Min J, Shan SY, Fleshner N, **Liu G**, Polio A, Sosa E, Bratman S, Allen B, Brown K, Licon A, Hartman R, De Carvalho DD, Park BH. Evaluation of a Genome-Wide Methylome Enrichment Platform for Circulating Tumor DNA Quantification and Prognostic Performance in Renal Cell Carcinoma (RCC). **Coauthor or Collaborator.**
- 2023 Oct Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real world setting. European Society of Medical Oncology (ESMO) Congress. Madrid, Spain.
- Publication Details:*  
Mittal A, Everest L, Patel D, Zhan LJ, Brown MC, Zaeimi F, Schmid S, Khan K, Dietrich K, Balaratnam K, Garcia M, Eng L, Sacher AG, Shepherd FA, Leighl NB, Cho JCB, de Perrot M, **Liu G**, Bradbury P. Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real world setting. **Senior Responsible Author.**
- 2023 Oct Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsy. European Society of Medical Oncology (ESMO) Congress. Madrid, Spain.
- Publication Details:*  
Schmid S, Ul-Haq S, Zhan L, Brown MC, Patel D, Shepherd FA, Leighl N, Sacher AG, de Perrot M, Cho JCB, Zaeimi F, Lok BH, Bratman SV, Tsao MS, Fruh M, Bradbury P, **Liu G**. Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsy. **Senior Responsible Author.**
- 2023 Oct **Invited Speaker.** Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors. American Association for Cancer Research (AACR). Boston, Massachusetts, United States. J.J. Lin, M.L Johnson, E. Felip, S.H.I Ou, B. Besse, C.S. Baik, J. Mazieres, Y.Y. Elamin, J.E. Reuss, A. Minchom, A. Swaldutz, N. Pavlakakis, **G. Liu**, S.M. Gadgeel, D.R. Camidge, J. Green, J. Shen, J. Soglia, Y. Sun, V.W. Zhu, A. Drilon.
- Publication Details:*  
Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors.
- 2023 Oct Multi-task machine learning of the electronic medical record to predict future symptoms among patients

with cancer. American Society of Clinical Oncology (ASCO) Quality Care Symposium. Boston, United States.

*Publication Details:*

Baijiang Yuan, Muammar Kabir, Kevin He, Benjamin Grant, Sharon Narine, Rami Ajaj, Luna Zhan, Aly Fawzy, Janine Xu, Yuhua Zhang, Vivien Yu, Conor French, Wei Xu, Rahul Krishnan, Steven Gallinger, Monika Krzyzanowska, Tran Truong, **Geoffrey Liu**, Robert Grant. Multi-task machine learning of the electronic medical record to predict future symptoms among patients with cancer. **Senior Responsible Author**.

2023 Sep Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study. IASLC 2023 World Conference on Lung Cancer. Suntec, Singapore.

*Publication Details:*

M. Garcia Pardo, K. Czarnecka, J.H. Law, Z.J. Fan, T.K. Waddell, K. Yasufuku, **G. Liu**, L.L. Donahoe, A. Pierre, L.W. Le, T. Gunasegaran, N. Ghumman, P.A. Bradbury, F. Shepherd, A. Sacher, L. Corke, J. Feng, T. Stockley, P. Pal, P. Rogalla, C. Pipinikas, K.D. Howarth, M. Tsao, N.B. Leighl. Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study. **Coauthor or Collaborator**.

2023 Sep Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC). IASLC 2023 World Conference on Lung Cancer. Suntec, Singapore.

*Publication Details:*

J. Feng, K. Hueniken, Z.J. Fan, L. Corke, N.B. Leighl, **G. Liu**, P.A. Bradbury, A. Sacher, L. Eng, T. Stockley, M.S. Tsao, F. Shepherd. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC). **Coauthor or Collaborator**.

2023 Sep Transcriptomic Features as Determinant of Therapy Response in Neuroendocrine-Transformed Adenocarcinomas Following TKI. IASLC 2023 World Conference on Lung Cancer. Suntec, Singapore.

*Publication Details:*

S. Nunes Martins Filho, M. Mikubo, Q. Li, E.L. Stewart, N-A. Pham, M. Li, J. Weiss, J. Rosen, P. Pal, F. Shepherd, B. Lok, N. Moghal, **G. Liu**, M.S. Tsao. Transcriptomic Features as Determinant of Therapy Response in Neuroendocrine-Transformed Adenocarcinomas Following TKI.

2023 Sep Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy. IASLC 2023 World Conference on Lung Cancer. Suntec, Singapore.

*Publication Details:*

A. Sun, B. Abdulkarim, N. Blais, J. Greenland, A. Louie, B. Melosky, D. Schellenberg, S. Snow, **G. Liu**. Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy. **Senior Responsible Author**.

2023 Sep Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). IASLC 2023 World Conference on Lung Cancer. Suntec, Singapore.

*Publication Details:*

L.J. Zhan, S. Barghout, S. Raptis, F. Al-Agha, A. Popovacki, N. Esfahanian, G. Kasymjanova, F. Proulx-Rocray, S. Chan, M. Richardson, M.C. Brown, D. Patel, M.L. Dean, V. Navani, E. Moore, L. Carvery, E. Yan, J. Cleary-Gosine, A.J. Gibson, L. Hubley, K. Balaratnam, T. Ngo, A. Gill, M. Black, A. Sacher, P.A. Bradbury, F. Shepherd, N. Leighl, P. Cheema, S. Kuruvilla, J. Agulnik, S. Banerji, R. Juergens, N. Blais, W. Cheung, P. Wheatley-Price, **G. Liu**, S. Snow. Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). **Co-Principal Author**.

2023 Sep CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study. IASLC 2023 World Conference on Lung Cancer. Suntec, Singapore.

*Publication Details:*

F. Al Agha, S. Raptis, L.J. Zhan, S.H. Barghout, D. Patel, M.C. Brown, W. Xu, C. Ho, W. Cheung, D. Dawe, S. Banerji, S. Kuruvilla, P. Cheema, I. Menjak, R. Burkes, K. Jao, A. Fung, N. Blais, J. Agulnik, N. Bouchard, L. Galvis, R.A. Juergens, P. Wheatley-Price, S. Moore, S. Snow, **G. Liu**. CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study. **Senior Responsible Author**.

2023 Sep Profiling data at time of Osimertinib early resistance in first or second line (CARMA-BROS). IASLC, 2023 World Conference on Lung Cancer (WCLC). Singapore. Presenter(s): Abdulrahman Alghabban.

*Publication Details:*

Abdulrahman Alghabban MD\*, Abhenil Mittal MD\*, Devalben Patel BSc, Luna Jia Zhan MPH, Catherine Brown MSc, Jamie Feng MD, Vicky Mai MD, Jae Lee, Khaleeq Khan BSc, Karmugi Balaratnam MD, Lawson Eng MD, Adrian G. Sacher MD, Frances A. Shepherd MD, Natasha B. Leighl MD, Penelope A. Bradbury MD BCh, Samir Baghout PhD, Geoffrey Liu MD. Profiling data at time of Osimertinib early resistance in first or second line (CARMA-BROS).

2023 Sep Prevalence, Treatment Patterns and Survival Outcomes of Uncommon NSCLC EGFR Mutations: Real World Data from a CARMA-BROS site. IASLC, 2023 World Conference on Lung Cancer (WCLC). Singapore. Presenter(s): Elizabeth Faour.

*Publication Details:*

Elizabeth Faour, Luuk van Esveld, Abhenil Mittal, Luna Jia Zhan, Devalben Patel, Mary Catherine Brown, Khaleeq Khan, Karmugi Balaratnam, Jamie Feng, Penelope Bradbury, Lawson Eng, Natasha Leighl, Adrian Sacher, Frances A. Shepherd, **Geoffrey Liu**. Prevalence, Treatment Patterns and Survival Outcomes of Uncommon NSCLC EGFR Mutations: Real World Data from a CARMA-BROS site. **Senior Responsible Author**.

2023 Sep CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study. IASLC, 2023 World Conference on Lung Cancer (WCLC). Singapore. Presenter(s): Faisal Al Agha. Mini oral.

*Publication Details:*

F. Al Agha, S. Raptis, L.J. Zhan, S.H. Barghout, D. Patel, M.C. Brown, W. Xu, C. Ho, W. Cheung, D. Dawe, S. Banerji, S. Kuruvilla, P. Cheema, I. Menja, R. Burkes, K. Jao, A. Fung, N. Blais, J. Agulnik, N. Bouchard, L. Galvis, R.A. Juergens, P. Wheatley-Price, S. Moore, S. Snow, **G. Liu**. CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study. **Senior Responsible Author**.

2023 Sep Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). IASLC, 2023 World Conference on Lung Cancer (WCLC). Singapore. Presenter(s): Luna Zhan, L.J. Zhan, S. Barghout, S. Raptis, F. Al-Agha, A. Popovacki, N. Esfahanian, G. Kasymjanova, F. Proulx-Rocray, S. Chan, M. Richardson, M.C. Brown, D. Patel, M.L. Dean, V. Navani, E. Moore, L. Carvery, E. Yan, J. Cleary-Gosine, A.J. Gibson, L. Hubley, K. Balaratnam, T. Ngo, A. Gill, M. Black, A. Sacher, P.A. Bradbury, F. Shepherd, N. Leighl, P. Cheema, S. Kuruvilla, J. Agulnik, S. Banerji, R. Juergens, N. Blais, W. Cheung, P. Wheatley-Price, **G. Liu**, S. Snow.

*Publication Details:*

Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). **Senior Responsible Author**.

2023 Jun Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial. American Society of Clinical Oncology Annual Meeting. Chicago, United States.

*Publication Details:*

Todd Michael Bauer, Enriqueta Felip, Tony S. K. Mok, Yi-Long Wu, **Geoffrey Liu**, Yasushi Goto, Dong-

Wan Kim, Jolanda Paolini, Anna Polli, Benjamin J. Solomon. Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial. *Journal of Clinical Oncology*. 2023 Jun;41(16):9063-9063. **Coauthor or Collaborator**.

2023 Jun Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques. American Society of Clinical Oncology Annual Meeting. Chicago, United States.

*Publication Details:*

Zhen (Jason) Fan, Roxana Tudor, Lisa W Le, Jennifer H. Law, Andrea S. Fung, Shelley Kuang, Nicholas Meti, Kirstin Perdrizet, Laura Ranich, Cuihong Wei, Peter Sabatini, Prodipto Pal, Ming Sound Tsao, **Geoffrey Liu**, Frances A. Shepherd, Penelope Ann Bradbury, Adrian G. Sacher, Lawson Eng, Michael Cabanero, Natasha B. Leighl. Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques. *Journal of Clinical Oncology*. 2023 Jun;41(16):9085-9085. **Coauthor or Collaborator**.

2023 Jun Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT). American Society of Clinical Oncology Annual Meeting. Chicago, United States.

*Publication Details:*

Daniel Adam Breadner, Mark David Vincent, **Geoffrey Liu**, Jeffrey Rothenstein, Ines B. Menjak, Parneet Kaur Cheema, Rosalyn A. Juergens, Hamid Mithoowani, Puneet Bains, Ying Wang, Paul Wheatley-Price. Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT). *Journal of Clinical Oncology*. 2023 Jun;41(16):TPS9160-TPS9160. **Coauthor or Collaborator**.

2023 Jun The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study. American Society of Clinical Oncology Annual Meeting. Chicago, United States.

*Publication Details:*

Elizabeth Faour, Rinku Sutradhar, Yosuf Kaliwal, Yue Niu, Ning Liu, Melanie Lynn Powis, **Geoffrey Liu**, Jeffrey M. Peppercorn, Monika K. Krzyzanowska, Shabbir M.H. Alibhai, Lawson Eng. The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study. *Journal of Clinical Oncology*. 2023 Jun;41(16):12053-12053. **Coauthor or Collaborator**.

2023 Jun Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC). American Society of Clinical Oncology Annual Meeting. Chicago, United States.

*Publication Details:*

Melina Elpi Marmarelis, Connor B. Grady, Caroline McCoach, Fangdi Sun, **Geoffrey Liu**, Devalben Patel, Jorge J. Nieva, Kristen A. Marrone, Vamsidhar Velcheti, Stephen V. Liu, Tejas Patil, Jared Weiss, William Schwartzman, Liza C Villaruz, Amanda Cass, Dara L. Aisner, Wei-Ting Hwang, Charu Aggarwal, D. Ross Camidge, Lova Sun. Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC). **Coauthor or Collaborator**.

2023 Jun An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE. American Society of Clinical Oncology Annual Meeting. United States.

*Publication Details:*

Robert C. Grant, Muammar Kabir, Baijiang Yuan, Benjamin Grant, Sharon Narine, Kevin He, Rami Ajaj, Luna Jia Zhan, Aly Fawzy, Janine Xu, Yuhua Zhang, Vivien Yu, Conor French, Wei Xu, Rahul G. Krishnan, Steven Gallinger, Monika K. Krzyzanowska, Tran Truong, **Geoffrey Liu**. An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE. *Journal of Clinical Oncology*. 2023 Jun;41(16):1557-1557. **Senior Responsible Author**.

2023 Jun A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint

therapy due to immune related toxicity (CCTG IND.238A). American Society of Clinical Oncology Annual Meeting. Chicago, United States.

*Publication Details:*

Peter Michael Ellis, Sara Kristina Taylor, Penelope Ann Bradbury, John R. Goffin, Rosalyn A. Juergens, Scott A. Laurie, **Geoffrey Liu**, Jennifer L. Spratlin, Nicole Grace Chau, Danielle Charpentier, Courtney Coschi, Joana Sederias, Siwei Zhang, Dongsheng Tu, Lesley Seymour, Pierre-Olivier Gaudreau. A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A). Journal of Clinical Oncology. 2023 Jun;41(16):TPS2673-TPS2673. **Coauthor or Collaborator**.

2022 Sep Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO). European Society for Medical Oncology ESMO Congress 2022. Paris, France. Presenter(s): Miguel Garcia.

*Publication Details:*

Miguel Garcia, Amy Chang, Sabine Schmid, Mei Dong, Catherine Brown, David Christiani, Hilary Aurora Tindleel, Paul Brennan, Chu Chen, Jie Zhang, Brid M Ryan, David Zaridze, Matthew B Schabath, Rui Manuel Reis, Adonina Tardon, Sanjay S Shete, Angeline Andrew, Hermann Brenner, Wei Xu, Rayjean Hung, **Geoffrey Liu**. Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO). Annals of Oncology. 2022 Sep;33(7):S979. **Senior Responsible Author**.

2022 Sep Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of Stage 4 diagnosis, by presence versus absence of EGFR/ALK mutations. European Society for Medical Oncology ESMO Congress 2022. Paris, France. Presenter(s): Sabine Schmid.

*Publication Details:*

S. Schmid, L. Zhan, M. Garcia, S. Cheng, K. Khan, M. Chowdhury, A. Sabouhanian, J. Herman, P. Walia, E. Storm, M. C. Brown, D. Patel, W. Xu, F.A. Shepherd, S.G. Sacher, N. B. Leighl, P.A. Bradbury, D. Shultz, **G Liu**. Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of Stage 4 diagnosis, by presence versus absence of EGFR/ALK mutations. Annals of Oncology. 2022 Sep;33(7):S1073. **Senior Responsible Author**.

2022 Aug Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience. IASLC, 2022 World Conference on Lung Cancer (WCLC) (Virtual). Vienna, Austria. Presenter(s): Abhenil Mittal.

*Publication Details:*

Abhenil Mittal, Katrina Hueniken, Sierra Cheng, Luna Zhan, M. Catherine Brown, Vicky Mai, Jae Lee, Olanisun Olufemi Adewole, Josh Herman, Amir Sabouhanian, Evan Storm, Maisha Tasnim Chowdhury, Alison Moore, Preet Walia, Tedi Hoxha, Jennifer Parker, Devalben Patel, Karmugi Balanatram, Khaleeq Khan, Miguel Garcia, Sabine Schmid, Adrian G. Sacher, Penelope A. Bradbury, Frances A. Shepherd, Natasha B. Leighl, **Geoffrey Liu**. Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience. Journal of Thoracic Oncology. 2022 Sep;17(9):S245. **Senior Responsible Author**.

2022 Aug Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations. IASLC, 2022 World Conference on Lung Cancer (WCLC) (Virtual). Vienna, Austria. Presenter(s): Alison Moore.

*Publication Details:*

Alison Moore, Emilie Pianarosa, Khaleeq Khan, Karmugi Balaratnam, Maisha Tasnim Chowdhury, Preet Walia, Amir Sabouhanian, Josh Herman, Evan Strom, Lucy Corke, Vicky Mai, Luna Jia Zhan, M Catherine Brown, Sierra Cheng, Katrina Hueniken, Natasha Leighl, Frances A Shepherd, Penelope Bradbury, Adrian Sacher, **Geoffrey Liu**, Miguel Garcia. Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations. Journal of Thoracic Oncology. 2022 Sep;17(9):S237. **Senior Responsible Author**.

- 2022 Aug Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study. IASLC, 2022 World Conference on Lung Cancer (WCLC) (Virtual). Austria. Presenter(s): Jae Lee.
- Publication Details:*  
Jae Yun Lee, Vicky Mai, Miguel Garcia, Sierra Cheng, Khaleeq Khan, Karmugi Balaratnam, Abhinav Thakral, M. Catherine Brown, Luna Zhan, Lucy Corke, Natasha Leighl, Frances A. Shepherd, Penelope Bradbury, Adrian Sacher, **Geoffrey Liu**. Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study. Journal of Thoracic Oncology. 2022 Sep;17(9):S440. **Senior Responsible Author**.
- 2022 Aug Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports. IASLC, 2022 World Conference on Lung Cancer (WCLC) (Virtual). Vienna, Austria. Presenter(s): Jessica Petricca.
- Publication Details:*  
Jessica Petricca, Conor French, Rami Ajaj, Arash Zelifan, Benjamin Grant, Luna Zhan, Yucheng Zhang, Abhinav Thakral, Danielle Nicholls, Ying-Han R. Hsu, Prodipto Pal, Michael Cabanero, Ming S. Tsao, **Geoffrey Liu**. Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports. Journal of Thoracic Oncology. 2022 Sep;17(9):S515. **Senior Responsible Author**.
- 2022 Aug Longitudinal symptom burden and health utility scores in patients receiving PD-1 inhibitors for metastatic NSCLC. IASLC, 2022 World Conference on Lung Cancer (WCLC) (Virtual). Vienna, Austria. Presenter(s): Sally Lau.
- Publication Details:*  
Christopher Poletes, Sierra CL Cheng, Luna Jia Zhan, Juehea Lee, Devalban Patel, Penelope A Bradbury, Frances A Shepherd, Natasha B Leighl, Adrian G Sacher, **Geoffrey Liu**, Sally CM Lau. Longitudinal symptom burden and health utility scores in patients receiving PD-1 inhibitors for metastatic NSCLC. Journal of Thoracic Oncology. 2022 Sep;17(9):S95-S96. **Coauthor or Collaborator**.
- 2022 Aug Real World Survival Outcome Analysis of Adjuvant Therapies in non-EGFR, non-ALK Early-stage Resected NSCLC. IASLC, 2022 World Conference on Lung Cancer (WCLC) (Virtual). Vienna, Austria. Presenter(s): Tedi Hoxha.
- Publication Details:*  
Tedi Hoxha, Martha Pienkowski, Khaleeq Khan, Alison Moore, Karmugi Balaratnam, Maisha Tasnim Chowdhury, Preet Walia, Amir Sabouhanian, Josh Herman, Evan Strom, Katrina Hueniken, Lucy Corke, Natasha Leighl, Frances A. Shepherd, Penelope Bradbury, Adrian Sacher, Sierra Cheng, M Catherine Brown, Vicky Mai, Miguel Garcia, Luna Jia Zhan, Wei Xu, **Geoffrey Liu**. Real World Survival Outcome Analysis of Adjuvant Therapies in non-EGFR, non-ALK Early-stage Resected NSCLC. Journal of Thoracic Oncology. 2022 Sep;17(9):S236. **Senior Responsible Author**.
- 2022 Feb Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada. International Conference for Healthcare and Medical Students (ICAMs). Ireland. Presenter(s): Simren Chotai. Best Overall Oral Presentation.
- Publication Details:*  
Simren Chotai, Sabine Schmid, Sierra Cheng, Luna Zhan, Karmugi Balaratnam, Khaleeq Khan, Devalben Patel, Wei Xu, Patrick Moriarty, Oksana Kaidanovich-Beilin, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Penelope Bradbury, **Geoffrey Liu**. Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada. **Senior Responsible Author**.
- 2022 Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer(NSCLC) that progressed on crizotinib (CRZ). European Society for Medical Oncology (ESMO) Congress. Switzerland.

*Publication Details:*

J.C. Yang, **G. Liu**, S. Lu, J. He, M. Burotto, S. Vincent, J. Yin, X. Ma, S. Popat. Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer(NSCLC) that progressed on crizotinib (CRZ). *Annals of Oncology*. 2022;33(9):S1560-S1597. **Coauthor or Collaborator**.

2021 Oct Association of Genetics of Tobacco and Alcohol Use Behaviors with Head and Neck Cancer. American Society of Human Genetics (ASHG) (Virtual). United States. Presenter(s): Abhinav Thrakal.

*Publication Details:*

Thakral A, Lee JW, Virani S, Olshan A, Ness A, Hayes, Waterboer T, Diergaarde, Brennan P, Hung R, **Liu G**, Xu W, Espin-Gracia. Association of Genetics of Tobacco and Alcohol Use Behaviors with Head and Neck Cancer. **Coauthor or Collaborator**.

2021 Sep Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Presenter(s): Miguel Garcia.

*Publication Details:*

Miguel Garcia, Sabine Schmid, Katrina Hueniken, Luna Zhan, Karmugi Balaratnam, Khaleeq Khan, Aline F. Fares, Sze WS Chan, Elliot C. Smith, Reenika Aggarwal, M. Catherine Brown, Devalben Patel, Adrian G. Sacher, Penelope A. Bradbury, Frances A. Shepherd, Natasha B. Leighl, **Geoffrey Liu**. Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? *Journal of Thoracic Oncology*. 2021 Oct;16(10):S1107-S1108. **Senior Responsible Author**.

2021 Sep Prevalence, treatment patterns and long-term clinical outcomes of patients with EGFR positive resected stage IB-IIIA NSCLC. IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Presenter(s): Sabine Schmid.

*Publication Details:*

Sabine Schmid, Miguel Garcia, Katrina Hueniken, Karmugi Balaratnam, Devalben Patel, Luna Zhan, M. Catherine Brown, Adrian G. Sacher, Penelope Bradbury, Natasha B. Leighl, Frances A. Shepherd, **Geoffrey Liu**. Prevalence, treatment patterns and long-term clinical outcomes of patients with EGFR positive resected stage IB-IIIA NSCLC. **Senior Responsible Author**.

2021 Sep Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort. IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Presenter(s): Sabine Schmid.

*Publication Details:*

S. Schmid, S. Chotai, S. Cheng, L. Zhan, K. Balaratnam, K. Khan, D. Patel, M.C. Brown, W. Xu, P.M. Moriarty2, O. Kaidanovich-Beilin2, F.A. Shepherd, A.G. Sacher, N. Leighl, P. Bradbury, **G. Liu**. Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort. *Journal of Thoracic Oncology*. 2021 Oct;16(10):S908-S909. **Senior Responsible Author**.

2021 Sep Real-world clinically-relevant toxicities of ALK TKIs in a cohort of patients with advanced/metastatic ALK+ NSCLC. IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Presenter(s): Sabine Schmid.

*Publication Details:*

S. Schmid, S. Chotai, S. Cheng, L. Zhan, K. Balaratnam, K. Khan, D. Patel, M.C. Brown, W. Xu, P.M. Moriarty3, O. Kaidanovich-Beilin3, F.A. Shepherd, A.G. Sacher, N. Leighl, P. Bradbury, **G. Liu**. Real-world clinically-relevant toxicities of ALK TKIs in a cohort of patients with advanced/metastatic ALK+ NSCLC. *Journal of Thoracic Oncology*. 2021 Oct;16(10):S1088. **Senior Responsible Author**.

2021 Sep IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients. Presenter(s): Josh Herman.



*Publication Details:*

J. Herman, S. Schmid, L. Zhan, M. Garcia, C. Brown, K. Khan, M. Chowdhury, A. Sabouhanian, P. Walia, E. Strom, A.G. Sacher, P. Bradbury, F.A. Shepherd, N. Leighl, S. Cheng, D. Patel, D. Shultz, **G. Liu**. IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Journal of Thoracic Oncology. 2021 Oct;16(10):S967-S968. **Senior Responsible Author**.

2021 Sep EGFR mutation status, liver metastasis, and overall survival in advanced lung adenocarcinoma patients. IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Presenter(s): Preet Walia.

*Publication Details:*

Preet Walia, Luna Zhan, Sabine Schmid, Catherine Brown, Khaleeq Khan, Maisha T. Chowdhury, Amir Sabouhanian, Joshua E. Herman, Evan Strom, Miguel Garcia, Sierra Cheng, Devalben Patel, Penelope Bradbury, Natasha B. Leighl, Adrian G. Sacher, Frances A. Shepherd, David Shultz, **Geoffrey Liu**. EGFR mutation status, liver metastasis, and overall survival in advanced lung adenocarcinoma patients. Journal of Thoracic Oncology. 2021 Oct;16(10):S1154-S1155. **Senior Responsible Author**.

2021 Sep Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada. IASLC, 2021 World Conference on Lung Cancer (WCLC) (Virtual). Presenter(s): Simren Chotai.

*Publication Details:*

Simren Chotai, Sabine Schmid, Sierra Cheng, Luna Zhan, Karmugi Balaratnam, Khaleeq Khan, Devalben Patel, Wei Xu, Patrick Moriarty, Oksana Kaidanovich-Beilin, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Penelope Bradbury, **Geoffrey Liu**. Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada. Journal of Thoracic Oncology. 2021 Oct;16(10):S1089. **Senior Responsible Author**.

2021 Sep Characteristics, treatment patterns and outcome of Non-Small Cell Lung Cancer (NSCLC) patients presenting with brain-only metastatic disease. European Society for Medical Oncology ESMO Congress 2021 (Virtual). France. Presenter(s): Amir Sabouhanian.

*Publication Details:*

Amir Sabouhanian, Sabine Schmid, Miguel Garcia, Luna Zhan, Sierra Cheng, Khaleeq Khan, Maisha Chowdhury, Joshua Herman, Preet Walia, Evan Strom, M. Catherine Brown, Devalben Patel, Wei Xu, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Penelope A. Bradbury, **Geoffrey Liu** David Shultz. Characteristics, treatment patterns and outcome of Non-Small Cell Lung Cancer (NSCLC) patients presenting with brain-only metastatic disease. Annals of Oncology. 2021 Sep;32(5):S1027. **Senior Responsible Author**.

2021 Sep Cumulative Incidence and Metastatic Patterns of Relapsed vs. De Novo Stage IV Non-Small Cell Lung Cancer (NSCLC) Characterized by Histology and EGFR Status. European Society for Medical Oncology ESMO Congress 2021 (Virtual). France. Presenter(s): Evan Strom.

*Publication Details:*

Evan Strom, Sabine Schmid, Miguel Garcia, Sierra Cheng, Luna Zhan, M. Catherine Brown, Khaleeq Khan, Preet Walia, Amir Sabouhanian, Maisha T. Chowdhury, Joshua Herman, Devalben Patel, Natasha Leighl, Penelope Bradbury, Frances A. Shepherd, Adrian Sacher, Wei Xu, David Shultz, **Geoffrey Liu**. Cumulative Incidence and Metastatic Patterns of Relapsed vs. De Novo Stage IV Non-Small Cell Lung Cancer (NSCLC) Characterized by Histology and EGFR Status. Annals of Oncology. 2021 Sep;32(5):S979-S980. **Senior Responsible Author**.

2021 Sep Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive Non-Small Cell Lung Cancer (NSCLC). European Society for Medical Oncology ESMO Congress 2021 (Virtual). France. Presenter(s): Maisha T. Chowdhury.

*Publication Details:*

Maisha T. Chowdhury, Miguel Garcia, Sabine Schmid, Sierra Cheng, Luna Zhan, Catherine M. Brown, Khaleeq Khan, Preet Walia, Amir-Arsalan Sabouhanian, Evan Strom, Joshua Herman, Natasha Leighl, Penelope Bradbury, Frances A. Shepherd, Adrian Sacher, Wei Xu, **Geoffrey Liu**, David Shultz.

Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 2021 Sep;32(5):S1028-S1029. **Senior Responsible Author.**

2021 Mar 11 Polygenic Risk Scores, Head and Neck Cancer, HPV Status. Voyager-Headspace Annual Meeting (Virtual). Lyons, France.

*Publication Details:*

Lee J, Espin-Garcia O, Thakral A, Xu W, **Liu G**. Polygenic Risk Scores, Head and Neck Cancer, HPV Status. Proc VH Annual Meeting. 2021. **Senior Responsible Author. Supervising JL, OEG, AT.**

2021 Jan Using breath analysis as a screening tool to detect gastric cancer: A Systematic review. American Society of Clinical Oncology (ASCO) GI Symposium Conference. Washington, United States. Presenter(s): Ghazal Haddad.

*Publication Details:*

Haddad G, Schouwenburg S, Altesha A, Xu W, **Liu G**. Using breath analysis as a screening tool to detect gastric cancer: A Systematic review. J Clin Oncol. 2021;39(3):abstr 175. **Senior Responsible Author. Supervising GH, SS, and AA.**

2021 Jan EGFR status, risk factors for brain metastases and overall survival in advanced non-small cell lung cancer (NSCLC) patients. IASLC, 2020 World Conference on Lung Cancer (WCLC). Singapore. Presenter(s): Maisha Chowdhury.

*Publication Details:*

Maisha Chowdhury, Katrina Hueniken, Sabine Schmid, Catherine Brown, Khaleeq Khan, Preet Walia, Amir Sabouhanian, Evan Strom, Joshua Herman, Wei Xu, Dr. Natasha B. Leighl, Dr. Adrian G. Sacher, Dr. Penelope A. Bradbury, Dr. Frances A. Shepherd, Dr. Geoffrey Liu, Dr. David Shultz. EGFR status, risk factors for brain metastases and overall survival in advanced non-small cell lung cancer (NSCLC) patients. Journal of Thoracic Oncology. 2021 Mar;16(3):S625-S626. **Coauthor or Collaborator.**

2020 Nov Genome-wide Pathway Analysis Identifies Biological Pathways Related To Treatment Response In Metastatic Colorectal Cancer Patients Given Cetuximab: A Secondary Analysis Of Clinical Trials Data. ISPE Annual Meeting 2020 (Virtual). United States. Presenter(s): Lidija Latifovic. All Access Conference Scholarship.

*Publication Details:*

Lidija Latifovic, Wei Xu, Rayejan Hung, **Geoffrey Liu**. Genome-wide Pathway Analysis Identifies Biological Pathways Related To Treatment Response In Metastatic Colorectal Cancer Patients Given Cetuximab: A Secondary Analysis Of Clinical Trials Data. 2020. **Senior Responsible Author.**

2020 Oct 10 Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts). ASCO Quality of Care Symposium. United States. (Trainee Presentation)

*Publication Details:*

Spencer Soberano, Khaleeq Khan, Katrina Hueniken, Elyon Diekoloreoluwa Famoriyo, Joelle Soriano, Sarfraz Gill, Luna Jia Zhan, Frances A. Shepherd, Adrian G. Sacher, Penelope Ann Bradbury, Natasha B. Leighl, Philippe L. Bedard, Aaron Richard Hansen, Anna Spreafico, Wei Xu, Catherine Brown, **Geoffrey Liu**. Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts). J Clin Oncol. 2020;38:223. Poster. **Senior Responsible Author.**

2020 Oct 10 Comparing cancer survivors' perceptions on lifestyle behaviors between adolescent-young adult (AYA) and middle-aged patients (pts). American Society of Clinical Oncology (ASCO) Quality Care Symposium. Chicago, United States.

*Publication Details:*

Spencer Soberano, Lawson Eng, RuiQi Chen, Ashraf Altesha, Subiksha Nagaratnam, Sarah Rudolph-Naiberg, Simren Chotai, Wanning Wang, Lin Lu, Wei Xu, Katrina Hueniken, Catherine Brown, **Geoffrey Liu**. Comparing cancer survivors' perceptions on lifestyle behaviors between adolescent-young adult (AYA) and middle-aged patients (pts). J Clin Oncol. 2020;38(29):207. **Senior Responsible Author**.

2020 Oct 10 Machine learning to classify clinically meaningful patient groups by ESAS symptom clusters in oropharyngeal cancer patients undergoing initial treatment. American Society of Clinical Oncology ASCO Quality Care Symposium. Chicago, United States. Presenter(s): Ghazal Haddad.

*Publication Details:*

Ghazal Haddad, Katrina Hueniken, Scott Victor Bratman, John R de Almeida, David Paul Goldstein, Shao Hui Huang, Aaron Richard Hansen, Andrew J. Hope, Anna Spreafico, Wei Xu, **Geoffrey Liu**. Machine learning to classify clinically meaningful patient groups by ESAS symptom clusters in oropharyngeal cancer patients undergoing initial treatment. J Clin Oncol. 2020;38(29):171. **Senior Responsible Author**.

2020 Oct 10 Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM). American Society of Clinical Oncology (ASCO) Quality Care Symposium. Chicago, United States.

*Publication Details:*

Lawson Eng, Amol A Verma, Saeha Shin, Afsaneh Raissi, Alejandro Berlin, Christine Brezden, Kelvin K. Chan, Katherine Enright, Genevieve Bouchard-Fortier, Lauren Linett, Melanie Lynn Powis, Haider Samawi, **Geoffrey Liu**, Monika K. Krzyzanowska, Fahad Razak. Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM). J Clin Oncol. 2020;38(29):21. **Coauthor or Collaborator**.

2020 Oct Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts). ASCO Quality Care Symposium. Chicago, United States. Presenter(s): Spencer Soberano.

*Publication Details:*

Spencer Soberano, Khaleeq Khan, Katrina Hueniken, Elyon Diekoloreoluwa Famoriyo, Joelle Soriano, Sarfraz Gill, Luna Jia Zhan, Frances A. Shepherd, Adrian G. Sacher, Penelope Ann Bradbury, Natasha B. Leighl, Philippe L. Bedard, Aaron Richard Hansen, Anna Spreafico, Wei Xu, Catherine Brown, **Geoffrey Liu**. Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts). Journal of Clinical Oncology. 2020;38(29):223. **Senior Responsible Author**.

2020 Sep Clinical Characterization of Cisplatin-based Chemoradiation Ototoxicity in Head and Neck Squamous Cell Carcinoma. AAO-HNSF 2020 Annual Meeting & OTO Experience (Virtual). Boston, Massachusetts, United States.

*Publication Details:*

John JW Lee, Mary Mahler, Astrid Billfalk-Kelly, Andrew Hope, **Geoffrey Liu**, David Goldstein. Clinical Characterization of Cisplatin-based Chemoradiation Ototoxicity in Head and Neck Squamous Cell Carcinoma. 2020. **Coauthor or Collaborator**.

2020 Jun 4 The impact of tobacco retail density on overall survival (OS) in lung cancer survivors. American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual). Chicago, United States. Presenter(s): Lawson Eng.

*Publication Details:*

Lawson Eng, Katrina Hueniken, Todd A Norwood, Gerald J Romme, M. Catherine Brown, Andrew J. Hope, Andrea Bezjak, Adrian G. Sacher, Penelope Ann Bradbury, Frances A. Shepherd, Natasha B. Leighl, Andrew Pierre, Peter Selby, David Paul Goldstein, Wei Xu, Meredith Elana Giuliani, William K. Evans, Michael Chaiton, **Geoffrey Liu**. The impact of tobacco retail density on overall survival (OS) in lung cancer survivors. J Clin Oncol. 2020;38(15):12058. **Senior Responsible Author**.

2020 Jun 4 Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. Virtual

ASCO Annual Meeting. United States.

*Publication Details:*

D. Ross Camidge, Huifeng Niu, Hye Ryun Kim, James Chih-Hsin Yang, Myung-Ju Ahn, Jacky Yu-Chung Li, Maximilian Hochmair, Angelo Delmonte, Alexander I. Spira, Rosario Garcia Campelo, Fabrice Barlesi, **Geoffrey Liu**, Marcello Tiseo, Cong Li, Miguel Williams, Hyunjin Shin, Pingkuan Zhang, Sanjay Popat. Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. J Clin Oncol. 2020;38(15):9517. **Coauthor or Collaborator**.

2020 Jun 4 Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer. American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual). Chicago, United States.

*Publication Details:*

Joelle Soriano, Katrina Hueniken, Jaspreet K. Bajwa, George Dong, Wanning Wang, Tyler Soberano, Kirsty Taylor, M. Catherine Brown, Eric Xueyu Chen, Jennifer J. Knox, Raymond Woo-Jun Jang, Rebecca Wong, Gail Elizabeth Darling, Wei Xu, Elena Elimova, **Geoffrey Liu**, Dmitry Rozenberg, Micheal McInnis, Aline Fusco Fares. Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer. J Clin Oncol. 2020;38(15):4544. **Coauthor or Collaborator**.

2020 Jun Smoking cessation (SC) and lung cancer (LC) outcomes: A survival benefit for recent-quitters? A pooled analysis of 34,649 International Lung Cancer Consortium (ILCCO) patients. Virtual ASCO Annual Meeting. Chicago, United States. Merit Award Selected for ASCO's Official Press Program.

*Publication Details:*

Aline Fusco Fares, Mei Jiang, Ping Yang, David C. Christiani, Chu Chen, Paul Brennan, Jie Zhang, Ann G. Schwartz, Maria Teresa Landi, Kouya Shiraishi, Brid M Ryan, Hongbing Shen, Matthew B. Schabath, Garcia Adonina, Sanjay Shete, Loic Le Marchand, Angela Cox, Rayjean Hung, Wei Xu, **Geoffrey Liu**. Smoking cessation (SC) and lung cancer (LC) outcomes: A survival benefit for recent-quitters? A pooled analysis of 34,649 International Lung Cancer Consortium (ILCCO) patients. J Clin Oncol. 2020;38(15):1512. **Senior Responsible Author**.

2020 Jun Patterns and Perceptions of Cannabis Use by Cancer Survivors. American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual). Chicago, United States. Presenter(s): Lawson Eng.

*Publication Details:*

Lawson Eng, Subiksha Nagaratanam, RuiQi Chen, Spencer Soberano, Sarah Rudolph-Naiberg, Simren Chotai, Karmugi Balaratanam, M Catherine Brown, Wei Xu, Michael Chaiton, Camilla Zimmermann, Deborah P Saunders, William K Evans, Peter Selby, Meredith E Giuliani, **Geoffrey Liu**, David Hammond. Patterns and Perceptions of Cannabis Use by Cancer Survivors. 2020. **Coauthor or Collaborator**.

2020 Jun Association of germline WFS1 rs62283056 single nucleotide polymorphism (SNP) with cisplatin-associated ototoxicity and survival outcomes in chemoradiation-treated head and neck squamous cell carcinoma (HNSCC) patients. American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual). Chicago, United States. Presenter(s): Mary Mahler.

*Publication Details:*

Mary Mahler, Daniel Breadner, Katrina Hueniken, Jong Lee, Yiwen Zhang, Wendy Teft, M. Catherine Brown, Maryam Mirshams, Dangxiao Cheng, Yun-Hei Hee ChoiChoi, Bayardo Perez-Ordenez, Shao Hui Huang, David Goldstein, Andrew Hope, Anna Spreafico, Ute I. Schwarz, Richard B. Kim, Wei Xu, **Geoffrey Liu**, Eric Winquist. Association of germline WFS1 rs62283056 single nucleotide polymorphism (SNP) with cisplatin-associated ototoxicity and survival outcomes in chemoradiation-treated head and neck squamous cell carcinoma (HNSCC) patients. 2020. **Coauthor or Collaborator**.

2020 May 29 Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC. ASCO 2020 Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

Sally CM Lau, Stephanie WY Wong, Ben X Wang, Devalben Patel, Aline Fusco Fares, Ming-Sound Tsao, Penelope Ann Bradbury, **Geoffrey Liu**, Natasha B. Leighl, Frances A. Shepherd, Pamela S Ohashi, Adrian G. Sacher. Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC. J Clin Oncol. 2020;38:3084. Poster. **Coauthor or Collaborator**.

- 2020 May 29 TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab. ASCO 2020 Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

Sally CM Lau, Shirin Soleimani, Stephanie WY Wong, Stephanie Pedersen, Ben X Wang, Arielle Elkrif, Devalben Patel, Aline Fusco Fares, Kevin Jao, Nathalie Daaboul, Taiki Hakozaki, Penelope Ann Bradbury, **Geoffrey Liu**, Natasha B. Leighl, Ming-Sound Tsao, Pamela S Ohashi, Trevor John Pugh, Bertrand Routy, Frances A. Shepherd, Adrian G. Sacher. TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab. J Clin Oncol. 2020;38:3050. Poster. **Coauthor or Collaborator**.

- 2020 May 29 Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers. ASCO 2020 Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

Aline Fusco Fares, Sebastiao N. Martins-Filho, Quan Li, Andrew Seto, Erin L. Stewart, Tong Zhang, Sally CM Lau, Deepti Ravi, Jessica Weiss, Devalben Patel, Nhu-An Pham, Adrian G. Sacher, Penelope Ann Bradbury, Tracy Stockley, Natasha B. Leighl, Frances A. Shepherd, Ming Sound Tsao, **Geoffrey Liu**. Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers. J Clin Oncol. 2020;38:3571. Poster. **Senior Responsible Author**.

- 2020 May 29 CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI). ASCO 2020 Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

David Benjamin Shultz, Sally CM Lau, Christopher Poletes, Lisa W Le, Kate MacKay, Frances A. Shepherd, Penelope Ann Bradbury, Natasha B. Leighl, **Geoffrey Liu**, Adrian G. Sacher. CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI). J Clin Oncol. 2020;38:e14505. Poster. **Coauthor or Collaborator**.

- 2020 May 29 Predictors of and longitudinal assessment of health utility scores in patients with small cell lung cancer using real-world data. American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual). Chicago, Illinois, United States.

*Publication Details:*

Nathan Kuehne, Katrina Hueniken, Wei Xu, Sharara Shakik, Ali Vedadi, Dixon Pinto, Catherine Brown, Penelope Ann Bradbury, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Benjamin H. Lok, **Geoffrey Liu**, Grainne M. O'Kane. Predictors of and longitudinal assessment of health utility scores in patients with small cell lung cancer using real-world data. J Clin Oncol. 2020;38(15):e19306. **Co-Senior Responsible Author. Supervising NK, KH, SS, AV, DP, CB**.

- 2020 May Longitudinal Health Utilities, Symptoms and Toxicities in Anaplastic Lymphoma Kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients: A real world assessment. American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual). Chicago, United States. Presenter(s): Brandon Tse.

*Publication Details:*

B.C. Tse, B.I. Said, Z.J. Fan, K. Hueniken, D. Patel, G. Gill, M. Liang, M. Razooqi, M.C. Brown, A.G. Sacher, P.A. Bradbury, F.A. Shepherd, N.B. Leighl, W. Xu, D. Howell, **G. Liu**, G. O'Kane. Longitudinal Health Utilities, Symptoms and Toxicities in Anaplastic Lymphoma Kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients: A real world assessment. Curr Oncol. 2020 Dec;27(6):e552-e559. **Co-Senior Responsible Author. Supervising BCT, BIS, ZJF, KH, DP, GG, ML, MR, MCB**.

- 2020 Apr 24      Assessment of statistical power in one mouse per treatment design for preclinical anticancer agent PDX large scale drug screens. Proc AACR Annual Meeting. United States.
- Publication Details:*  
Jessica Weiss, Nhu-An Pham, Melania Pintilie, Ming Li, Ming Tsao, **Geoffrey Liu**, Wei Xu. Assessment of statistical power in one mouse per treatment design for preclinical anticancer agent PDX large scale drug screens. AACR. 2020;80(16):1680. **Coauthor or Collaborator.**
- 2020 Feb 6      Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. 2020 ASCO-SITC Clinical Immuno-Oncology Symposium. Orlando, Florida, United States.
- Publication Details:*  
Dimas Yusuf, Jenny J. Ko, Hyekeun Cho, Corey Sheremeto, Ying Wang, Rosalyn A. Juergens, Peter Michael Ellis, Alkarim Billawala, Amin Kay, Swati Kulkarni, Tarek A. Elfiki, Rasna Gupta, Krista Naccarato, Alex Pennetti, Devalben Patel, Elliot Charles Smith, Ryan Walton, Manjusha Hurry, **Geoffrey Liu**, Winson Y. Cheung. Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. J Clin Oncol. 2020;38(5):54. **Coauthor or Collaborator.**
- 2020 Jan 23      Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers. 2020 Gastrointestinal Cancers Symposium. San Francisco, California, United States.
- Publication Details:*  
Lauren Amanda Beck, Lucy Xiaolu Ma, Osvaldo Espin-Garcia, Chihiro Suzuki, Di Maria Jiang, **Geoffrey Liu**, Eric Xueyu Chen, Jennifer J. Knox, Rebecca Wong, Savtaj Singh Brar, Carol Jane Swallow, Jonathan Yeung, Gail Elizabeth Darling, James Conner, Elena Elimova, Raymond Woo-Jun Jang. Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers. J Clin Oncol. 2020;38(4):325. **Coauthor or Collaborator.**
- 2020 Jan 23      Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field. 2020 Gastrointestinal Cancers Symposium. San Francisco, California, United States.
- Publication Details:*  
Lucy Xiaolu Ma, Peiran Sun, Osvaldo Espin-Garcia, Chihiro Suzuki, Di Maria Jiang, Charles Henry Lim, Kirsty Taylor, Bryan Anthony Chan, Hao-Wen Sim, Akina Natori, Eric Xueyu Chen, **Geoffrey Liu**, Jennifer J. Knox, Jonathan Yeung, Gail Elizabeth Darling, John Kim, Sangeetha Kalimuthu, Elena Elimova, Raymond Woo-Jun Jang. Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field. J Clin Oncol. 2020;38(4):328. **Coauthor or Collaborator.**
- 2020 Jan 23      Pre-operative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC). 2020 Gastrointestinal Cancers Symposium. San Francisco, California, United States.
- Publication Details:*  
Sophie Feng, Hao-Wen Sim, Roxana Bucur, Reenika Aggarwal, Phillipe Abreu, Monali Ray, Michael Herman, Dangxiao Cheng, Zhuo Chen, Wenjiang Zhang, Paul David Greig, Alice Chia-chi Wei, Carol-Anne Moulton, Ian M. McGilvray, Sean P. Cleary, Steven Gallinger, Gonzalo Sapisochin, Jennifer J. Knox, **Geoffrey Liu**, Eric Xueyu Chen. Pre-operative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC). J Clin Oncol. 2020;38(4):571. **Coauthor or Collaborator.**
- 2020 Jan      Blood-based-inflammation-markers, body mass index, and survival of nonmetastatic esophageal cancer. American Society of Clinical Oncology GI Symposium. San Francisco, California, United States. Presenter(s): Wanning Wang.
- Publication Details:*  
Wanning Wang, Joelle Soriano, Tyler Soberano, Katrina Hueniken, M. Catherine Brown, Kirsty Taylor, Jaspreet K. Bajwa, George Dong, Eric Xueyu Chen, Jennifer J. Knox, Raymond Woo-Jun Jang, Rebecca

Wong, Gail Elizabeth Darling, Wei Xu, Micheal McInnis, **Geoffrey Liu**, Dmitry Rozenberg, Elena Elimova, Aline Fusco Fares. Blood-based-inflammation-markers, body mass index, and survival of nonmetastatic esophageal cancer. J Clin Oncol. 2020;38(4):324. **Coauthor or Collaborator**.

- 2019 Oct 25 Routine Edmonton Symptom Assessment System (ESAS) Scores in epithelioid malignant pleural mesothelioma (eMPM) patients undergoing palliative systemic therapy. ASCO Supportive Care in Oncology Symposium. San Francisco, California, United States.

*Publication Details:*

Kristen Dietrich, Luna J. Zhan, Michael Herman, Subiksha Nagaratnam, Kathryn S. Corbett, Devalben Patel, Katrina Hueniken, Wei Xu, M. Catherine Brown, Marc de Perrot, John Cho, Natasha B. Leighl, Penelope Bradbury, **Geoffrey Liu**. Routine Edmonton Symptom Assessment System (ESAS) Scores in epithelioid malignant pleural mesothelioma (eMPM) patients undergoing palliative systemic therapy. Journal of Clinical Oncology. 2019;37(31):abstr 96. **Senior Responsible Author**.

- 2019 Oct 25 Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors. ASCO Supportive Care in Oncology Symposium. San Francisco, California, United States.

*Publication Details:*

Kathryn Corbett, Jingyue Huang, Sophia Liu, Elliot Charles Smith, Delaram Farzanfar, Karmugi Balaratnam, Dixon Pinto, Alexandra McCartney, RuiQi Chen, Amedra Basgaran, Devon Alton, M. Catherine Brown, Doris Howell, Madeline Li, Wei Xu, **Geoffrey Liu**, Lawson Eng. Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors. Journal of Clinical Oncology. 2019;37(31):abstr 141. **Senior Responsible Author**.

- 2019 Oct Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors. European Society for Medical Oncology (ESMO) Congress. Spain.

*Publication Details:*

L. Eng, J.Su, K. Hueniken, M.C. Brown, D.P. Saunders, J.R. de Almeida, A. Hope, P. Selby, A. Spreafico, A.R. Hansen, D.P. Goldstein, W.Xu, M.E. Giulian, W.K. Evans, **G. Liu**, M. Chaiton. Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors. Ann Oncol. 2019 Oct;30(5):V742. **Coauthor or Collaborator**.

- 2019 Sep 27 Sex, smoking status, body-mass index (BMI) at the time of non-small cell lung cancer diagnosis, and overall survival (OS):. A pooled analysis of 14,396 International Lung Cancer Consortium (ILCCO) patients. European Society for Medical Oncology (ESMO). European Cancer Conference (ECC) 2019. Barcelona, Spain.

*Publication Details:*

Aline Fares, Daniel Shepshelovich, Lin Lu, M. Catherine Brown, Ping Yang, Jie Zhang, Brííd M Ryan, David Christiani, Ann G Schwartz, Chu Chen, Adonina Tardon, Matthew B. Schabath, Kouya Shiraishi, M. Dawn Teare, Loic Le Marchand, Zuo-Feng Zhang, Hermann Brenner, Wei Xu, Rayjean Hung, **Geoffrey Liu**. Sex, smoking status, body-mass index (BMI) at the time of non-small cell lung cancer diagnosis, and overall survival (OS):. A pooled analysis of 14,396 International Lung Cancer Consortium (ILCCO) patients. 2019. **Senior Responsible Author**.

- 2019 Sep 27 Tobacco Retail Availability and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors. European Society for Medical Oncology (ESMO). European Cancer Conference (ECC). Barcelona, Spain.

*Publication Details:*

Lawson Eng, Jie Su, Katrina Hueniken, M. Catherine Brown, Deborah P Saunders, John R De Almeida, Andrew Hope, Peter Selby, Anna Spreafico, Aaron Hansen, David Paul Goldstein, Wei Xu, Meredith Elana Giuliani, William K. Evans, **Geoffrey Liu**, Michael Chaiton. Tobacco Retail Availability and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors. Journal of Clinical Oncology. 2019;37(15):abstr 11559. **Coauthor or Collaborator**.

- 2019 Sep 27 Pre-operative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection

for hepatocellular carcinoma (HCC). European Society for Medical Oncology (ESMO). European Cancer Conference (ECC). Barcelona, Spain.

*Publication Details:*

Feng S, Sim H, Bucur R, Aggarwal R, Abreu P, Ray M, Herman M, Cheng D, Chen Z, Zhang W, Greig P, Wei AC, Moulton C, McGilvray I, Cleary S, Gallinger S, Sapisochin G, Knox J, **Liu G**, Chen E. Pre-operative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2019;38(4):abstr 571. **Coauthor or Collaborator.**

- 2019 Sep 7 Tumor-Stromal Microenvironment Interactions in a PDX Model of EGFR TKI Drug Tolerance. IASLC, 20th World Conference on Lung Cancer (WCLC). Barcelona, Spain.

*Publication Details:*

E. Stewart, R. Navab, S. Martins-Filho, N.-A. Pham, **G. Liu**, M. Tsao. Tumor-Stromal Microenvironment Interactions in a PDX Model of EGFR TKI Drug Tolerance. Journal of Clinical Oncology. 2019;14(10):S845. **Coauthor or Collaborator.**

- 2019 Sep 7 A predominance of myeloid cells in peripheral blood associates with rapid progression and poor survival in advanced non-small cell lung cancer (NSCLC) patients who received first line treatment with PD-1/PD-L1 monotherapy. IASLC, 20th World Conference on Lung Cancer (WCLC). Barcelona, Spain.

*Publication Details:*

Sally CM Lau (MD), Lisa W. Le (MSc), Sze Wah Samuel Chan (BSc), Elliot Smith, Malcolm Ryan, Catherine Brown (MSc), Katrina Hueniken (MPH), Lawson Eng (MD), Devalben Patel, RuiQi Chen (PhD), Mike Sung, Alona Zer (MD), Penelope A. Bradbury (MB, BCh, FRACP, MD), Pamela S. Ohashi (PhD), Frances A. Shepherd (MD, FRCPC), Ming-Sound Tsao (MD, FRCPC) Natasha B. Leighl (MD, MMSc, FRCPC), **Geoffrey Liu** (MD, MSc, FRCPC), Adrian G. Sacher (MD, MSc, FRCPC). A predominance of myeloid cells in peripheral blood associates with rapid progression and poor survival in advanced non-small cell lung cancer (NSCLC) patients who received first line treatment with PD-1/PD-L1 monotherapy. 2019. **Coauthor or Collaborator.**

- 2019 Sep 7 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. IASLC, 20th World Conference on Lung Cancer (WCLC). Barcelona, Spain.

*Publication Details:*

Lawson Eng, Jie Su, Katrina Hueniken, M. Catherine Brown, Andrew Hope, Andrea Bezjak, Adrian G. Sacher, Penelope A Bradbury, Frances A. Shepherd, Natasha B. Leighl, Andrew Pierre, Peter Selby, David Paul Goldstein, Wei Xu, Meredith Elana Giuliani, William K. Evans, **Geoffrey Liu**, Michael Chaiton. Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. Journal of Clinical Oncology. 2019;14(10):S512. **Coauthor or Collaborator.**

- 2019 Sep 7 Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance. IASLC, 20th World Conference on Lung Cancer (WCLC). Barcelona, Spain.

*Publication Details:*

E. Stewart, A. Wang, J. Huang, H. Bao, X. Wu, D. Patel, Z. Chen, J. Law, P. Bradbury, F. Shepherd, A. Sacher, M. Tsao, S. Bratman, N. Leighl, T. Pugh, **G. Liu**. Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance. Journal of Clinical Oncology. 2019;14(10):S554-S555. **Senior Responsible Author. Supervising ELS, DP, ZC.**

- 2019 Sep 6 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA. IASLC, 20th World Conference on Lung Cancer (WCLC). Barcelona, Spain.

*Publication Details:*

E. Stewart, S. Martins-Filho, M. Cabanero, A. Wang, J. Huang, H. Bao, X. Wu, D. Patel, Z. Chen2, J. Law, P. Bradbury, F. Shepherd, N. Leighl, M. Tsao, T. Pugh, S. Bratman, **G. Liu**, A. Sacher. Early, Subclinical



SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA. Journal of Clinical Oncology. 2019;14(10):S855-S856. **Coauthor or Collaborator.**

2019 Sep 6 Performance of the patient reported CAPLET2.0 physical functioning assessment tool. ASCO Quality Care Symposium. San Diego, California, United States.

*Publication Details:*

Alexandra McCartney, Julia Singer, Reenika Aggarwal, Katrina Hueniken, Raiza Commiting, Shubhangi Shah, Susan Tang, Priya Bapat, Pansy Chow, Kristen Dietrich, Elizabeth Hall, M. Catherine Brown, Wei Xu, **Geoffrey Liu**. Performance of the patient reported CAPLET2.0 physical functioning assessment tool. Journal of Clinical Oncology. 2019;37(27):abstr 194. **Senior Responsible Author. Supervising AM, JS, RA, KH, RC, SS, ST, PB,PC, KD, EH.**

2019 Sep 6 Barriers and Facilitators to the Implementation of Routine Ototoxicity Screening for Head and Neck Cancer Patients. ASCO Quality Care Symposium. San Diego, California, United States.

*Publication Details:*

Priya Bapat, Pansy Chow, Katrina Hueniken, Mary Mahler, M. Catherine Brown, Carolyn Falls, Andrew J. Hope, Aaron Richard Hansen, David Paul Goldstein, John Rutka, Doris Howell, Wei Xu, **Geoffrey Liu**. Barriers and Facilitators to the Implementation of Routine Ototoxicity Screening for Head and Neck Cancer Patients. Journal of Clinical Oncology. 2019;37(27):abstr 127. **Senior Responsible Author. Supervising PB, PC, KH, MM.**

2019 Sep 6 Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations. ASCO Quality Care Symposium. San Diego, California, United States.

*Publication Details:*

Lorin Dodbiba, MD, Katrina Hueniken, MSc, Shirley Xue Jiang, BSc, Sze Wah Samuel Chan, Elliot Charles Smith, Lawson Eng, MD, Devalben Patel, Maryam Razooqi, M. Catherine Brown, MSc, Frances A. Shepherd, MD, FASCO, BA, Natasha B. Leighl, MD, FASCO, Penelope Ann Bradbury, MBChB, Wei Xu, PhD, Adrian G. Sacher, MD, MedSc, **Geoffrey Liu**, MD. Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations. Journal of Clinical Oncology. 2019;37(27):abstr 102. **Senior Responsible Author. Supervising LD,KH, SXJ, SWSC, ECS, LE, DP, MR.**

2019 Sep 6 Quality improvement of lung cancer patient selection using clinic-based spirometry. ASCO Quality Care Symposium. San Diego, California, United States.

*Publication Details:*

Andrew CL Lam, Reenika Aggarwal, Erin L. Stewart, Katrina Hueniken, Maureen McGregor, Wei Xu, Heidi Schmidt, John Kavanagh, **Geoffrey Liu**. Quality improvement of lung cancer patient selection using clinic-based spirometry. Journal of Clinical Oncology. 2019;37(27):abstr 282. **Senior Responsible Author. Supervising ACLK, RA, ELS, KH.**

2019 Sep 4 Determinants of Lung Cancer Prognosis. ILCCO Annual Meeting. Lyons, France.

*Publication Details:*

Aline Fares, CM. Catherine Brown, Wei Xu, **Geoffrey Liu**. Determinants of Lung Cancer Prognosis. 2019. **Senior Responsible Author.**

2019 Sep Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype(EGFR/ALK-Wildtype) Lung Adenocarcinomas. Proc World Conf Lung Cancer. Barcelona, Spain.

*Publication Details:*

Sebastiao N Martins-Filho, Aline Fusco Fares, Vibha Raghavan, Erin L Stewart, Deepti Ravi, Kirstin Perdrizet, Jessica Weiss, Katrina Hueniken, Devalben Patel, Nhu-An Pham, Adrian G Sacher, Penelope

A Bradbury, Natasha B Leighl, Frances Shepherd, Ming Sound Tsao, **Geoffrey Liu**. Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype(EGFR/ALK-Wildtype) Lung Adenocarcinomas. JTO. 2019 Oct;14(10):S686-S687. **Senior Responsible Author supervising SNMF, AFF, ELS, DR, KP, JW, KH.**

- 2019 Aug 24 Toxicity latent classes in chemotherapy-refractory, metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibody: latent class analysis of clinical trials data. International Conference on Pharmacoepidemiology (ISPE/ICPE).Annual Meeting. Philadelphia, Pennsylvania, United States.

*Publication Details:*

Lidija Latifovic, Wei Xu, Rayjean Hung, Dongsheng Tu, Michiaki Kubo, Taisei Mushiroda, Eric Chen, Amanda Townsend, Timothy Price, Chris O'Callaghan, Derek Jonker, Mark Ratain and **Geoffrey Liu**. Toxicity latent classes in chemotherapy-refractory, metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibody: latent class analysis of clinical trials data. 2019. **Senior Responsible Author.**

- 2019 Jun 21 A Remote-Symptom Reporting (RSR) Mobile Application for Lung Cancer and Sarcoma Patients in an Outpatient Clinic: Environmental Scan and Readiness Assessment. Multinational Association of Supportive Care in Cancer (MASCC/ISOO). San Francisco, California, United States.

*Publication Details:*

Jason Fan, Subiksha Nagaratnam, Suheon Lee, Jennifer Harris, Catherine De Guia, M. Catherine Brown, Simranjit Kooner, **Geoffrey Liu**. A Remote-Symptom Reporting (RSR) Mobile Application for Lung Cancer and Sarcoma Patients in an Outpatient Clinic: Environmental Scan and Readiness Assessment. 2019. **Senior Responsible Author.**

- 2019 Jun 21 Predictors Of Adherence To A Remote Web-based Symptom Monitoring Intervention. Multinational Association of Supportive Care in Cancer (MASCC/ISOO). San Francisco, California, United States.

*Publication Details:*

D. Davies, S. Moradian, R. Maguire, M. Krzyzanowska, V. Kukreti, J. Cafazzo A., P. Morita, J. Bender, L. Le W., M. Puts Martin, A. Husain, E. Amir3, G. Liu3, D. Howell. Predictors Of Adherence To A Remote Web-based Symptom Monitoring Intervention. 2019. **Senior Responsible Author.**

- 2019 May 31 Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illinois, United States. NOYCIA Award.

*Publication Details:*

Lawson Eng, Jie Su, Steven Habbous, Katrina Hueniken, M. Catherine Brown, Deborah Saunders, John R. de Almeida, Andrew Hope, Andrea Bezjak, Frances A. Shepherd, Natasha B. Leighl, Andrew Pierre, Peter Selby, David Paul Goldstein, Wei Xu, Meredith Elana Giuliani, William K. Evans, **Geoffrey Liu**, Michael Chaiton. Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. Journal of Clinical Oncology. 2019;37(5):abstr 11559. **Coauthor or Collaborator.**

- 2019 May 31 Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in Non-Small-Cell-Lung-Cancer (NSCLC)? A pooled analysis of 17326 International Lung Cancer Consortium (ILCCO) patients (pts). American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

Aline Fares, Daniel Shepshelovich, Lin Lu, M. Catherine Brown, Ping Yang, Jie Zhang, Brid M Ryan, David C. Christiani, Ann G Schwartz, Chu Chen, Adonina Tardon, Matthew B Schabath, Kouya Shiraishi, M. Dawn Teare, Loic Le Marchand, Zuo-Feng Zhang, Hermann Brenner, Wei Xu, Hermann Brenner, Rayjean Hung, **Geoffrey Liu**. Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in Non-Small-Cell-Lung-Cancer (NSCLC)? A pooled analysis of 17326 International Lung Cancer Consortium (ILCCO) patients (pts). Journal of Clinical Oncology. 2019;37(15):abstr 1562. **Senior Responsible Author. Supervising AFF, DS, LL.**

- 2019 May 31 Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

Lawson Eng, Katrina Hueniken, M. Catherine Brown, Andrew Hope, Meredith Elana Giuliani, Peter Selby, Kelvin K. Chan, Nicole Mittmann, Wei Xu, David Paul Goldstein, **Geoffrey Liu**, John R. de Almeida. Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors. Journal of Clinical Oncology. 2019;37(15):abstr 11561. **Senior Responsible Author supervising LE, KH; funding project; REB/Project PI.**

- 2019 Apr 26 Outcomes of IMRT/VMAT vs 2D/3D-conformal thoracic radiation in limited stage small-cell lung cancer. Milan, Italy.

*Publication Details:*

Tzen Szen Toh, Andrew Bang, Dixon Pinto, Katrina Hueniken, Catherine Brown, Wei Xu, **Geoffrey Liu**, Benjamin Lok. Outcomes of IMRT/VMAT vs 2D/3D-conformal thoracic radiation in limited stage small-cell lung cancer. Radiotherapy and Oncology. 2019. **Coauthor or Collaborator.**

- 2019 Mar 29 Targeting an ubiquitin-activating enzyme in small-cell lung cancer (SCLC). Annual Meeting of the American Association for Cancer Research (AACR). Atlanta, Georgia, United States. UoT, School of Graduate Studies, Conference Travel Grant.

*Publication Details:*

Safa Majeed, Mansi K. Aparnathi, Lifang Song, Aaron D. Schimmer, Ming S. Tsao, **Geoffrey Liu**, Benjamin H. Lok. Targeting an ubiquitin-activating enzyme in small-cell lung cancer (SCLC). Cancer Res. 2019;79(13):abstr 2699. **Coauthor or Collaborator.**

- 2019 Mar 10 Utility of Spirometry in Lung Cancer Screening Participant Selection. American Society of Preventive Oncology (ASPO). Tampa, Florida, United States. Presenter(s): Reenika Aggarwal.

*Publication Details:*

Aggarwal R, Lam ACL, Stewart E, Heuniken K, McGregor M, Xu W, Schmidt H, **Liu G**, Kavanagh J. Utility of Spirometry in Lung Cancer Screening Participant Selection. 2019. **Senior Responsible Author.**

- 2019 Mar 10 Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts. American Society of Preventive Oncology (ASPO). Tampa, Florida, United States.

*Publication Details:*

Lam ACL, Aggarwal R, Tsao MS, Shepherd FA, McGregor M, Menezes R, Tateishi H, Xu W, McInnis M, O'Kane GM, Hueniken K, Schmidt H, Kavanagh J, **Liu G**. Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts. J Thorac Oncol. 2019;14(6):1003-1011. **Senior Responsible Author.**

- 2019 Feb 28 Real-World Characterization of Cancer Patients Admitted with Immune Related Adverse Events (irAEs). ASCO-SITC (Clinical Immuno-Oncology Symposium). San Francisco, California, United States. Presenter(s): Lawson Eng.

*Publication Details:*

Lawson Eng, RuiQi Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Katrina Hueniken, M Catherine Brown, Habeeb Majeed, Kendra Ross, Diana Gray, Wei Xu, David Hogg, Srikala S. Sridhar, Adrian G. Sacher, Natasha B. Leighl, Monika K. Krzyzanowska, **Geoffrey Liu**, Marcus O. Butler. Real-World Characterization of Cancer Patients Admitted with Immune Related Adverse Events (irAEs). Journal of Clinical Oncology. 2019;37(8):abstr 82. **Coauthor or Collaborator.**

- 2019 Feb Comparison of Care Patterns for Hospitalized Immune Related Adverse Events (irAEs) Between Melanoma Patients on Combination Immune Checkpoint Inhibitor (ICI) Therapy vs ICI Monotherapy. ASCO-SITC (Clinical Immuno-Oncology Symposium). San Francisco, California, United States.

Presenter(s): Richard Chen.

*Publication Details:*

RuiQi Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Katrina Hueniken, M Catherine Brown, Habeeb Majeed, Kendra Ross, Diana Gray, Wei Xu, David Hogg, Srikala S. Sridhar, Adrian G. Sacher, Natasha B. Leighl, Monika K. Krzyzanowska, Marcus O. Butler, **Geoffrey Liu**, Lawson Eng. Comparison of Care Patterns for Hospitalized Immune Related Adverse Events (irAEs) Between Melanoma Patients on Combination Immune Checkpoint Inhibitor (ICI) Therapy vs ICI Monotherapy. Journal of Clinical Oncology. 2019;37(8):abstr 85. **Coauthor or Collaborator**.

- 2019 Jan 17 The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool. American Society of Clinical Oncology: Cancers of the Esophagus and Stomach. San Francisco, California, United States. Presenter(s): Shirley Jiang.

*Publication Details:*

Shirley Xue Jiang, Shubhangi Shah, Elliot Charles Smith, Justine Baek, Mindy Liang, M. Catherine Brown, Allyson Mayo, **Geoffrey Liu**, Jonathan Yeung, Rebecca Wong, Elena Elimova, Gail Elizabeth Darling. The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool. Journal of Clinical Oncology. 2019;37(4):37. **Coauthor or Collaborator**.

- 2018 Nov Comparison of Healthcare-Related Social Media and Internet Usage Between Patients Treated With Curative and Palliative Intent. American Society for Clinical Oncology (ASCO) Palliative and Supportive Care Symposium. San Diego, California, United States. Presenter(s): Alexander Magony. (Trainee Presentation)

*Publication Details:*

Magony A, Paulo C, Hueniken K, Eng L, Kassirian S, Smith EC, Geist A, Rao P, Brown MC, Liang M, Yang D, Xu W, **Liu G**, Bender J, Gupta AA. Comparison of Healthcare-Related Social Media and Internet Usage Between Patients Treated With Curative and Palliative Intent. **Coauthor or Collaborator**.

- 2018 Oct Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer. European Society for Medical Oncology (ESMO) European Cancer Conference. Munich, Germany. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Bender J, Hueniken K, Kassirian S, Yang D, Mitchell L, Paulo CB, Magony A, Smith EC, Liang M, Brown MC, Xu W, Alibhai SMH, **Liu G**, Gupta A. Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer. **Coauthor or Collaborator**.

- 2018 Oct What Information and Features do Young and Older Adults with Cancer Want in their Hospital-based Social Media Cancer Resource? European Society for Medical Oncology (ESMO) European Cancer Conference. Munich, Germany. Presenter(s): Chelsea Paulo. (Trainee Presentation)

*Publication Details:*

Paulo C, Eng L, Mitchell L, Geisst I, Kassirian S, Magony A, Smith EC, Brown MC, Liang M, Hueniken K, Yang, D, Xu W, **Liu G**, Gupta AA, Bender J. What Information and Features do Young and Older Adults with Cancer Want in their Hospital-based Social Media Cancer Resource? **Coauthor or Collaborator**.

- 2018 Oct Acceptability in Cancer Outpatients of Completing Routine Assessments of Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) versus Other Patient Reported Symptom Outcome Tools. European Society for Medical Oncology (ESMO). European Cancer Conference. Munich, Germany. Presenter(s): Hamzeh Albaba. (Trainee Presentation)

*Publication Details:*

Lababa H, Brown MC, Shakik S, Su S, Naik H, Wiang T, Liang M, Perez-Cosio A, Eng L, Mittman N, Xu

W, **Liu G**, Howell D, Barnes TA. Acceptability in Cancer Outpatients of Completing Routine Assessments of Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) versus Other Patient Reported Symptom Outcome Tools. **Coauthor or Collaborator**.

2018 Oct The Association of FCGR2A and FCGR3A Polymorphisms with Clinical Outcomes in Cetuximab-treated Patients with Metastatic Colorectal Cancer. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Daniel Shepshelovich. (Trainee Presentation)

*Publication Details:*

Shepshelovich D, Townsend A, Espin-Garcia O, Latifovic L, O'Callaghan C, Jonker D, Tu D, Chen E, Morgen E, Price T, Shapiro J, Siu L, Kubo M, Dobrovic A, Ratain M, Xu W, Mushiroda T, **Liu G**. The Association of FCGR2A and FCGR3A Polymorphisms with Clinical Outcomes in Cetuximab-treated Patients with Metastatic Colorectal Cancer. Poster. **Senior Responsible Author**.

2018 Oct Association of two BRM promoter polymorphisms and tobacco exposure with malignant pleural mesothelioma (MPM) risk and survival. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Min Joon Lee. (Trainee Presentation)

*Publication Details:*

Lee MJ, Kuehne N, Hueniken K, Sorotsky H, Liang M, Patel D, Cheng D, Chen Z, Eng L, Brown MC, Cho J, Leighl NB, De Perrot M, Reisman D, Xu W, Bradbury PA, **Liu G**. Association of two BRM promoter polymorphisms and tobacco exposure with malignant pleural mesothelioma (MPM) risk and survival. Poster. **Senior Responsible Author**.

2018 Oct Two BRM promoter polymorphisms do not predict susceptibility or prognosis of thymoma. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Min Joon Lee. (Trainee Presentation)

*Publication Details:*

Lee MJ, Kuehne N, Hueniken K, Shepshelovich D, Soldera SV, Shakik S, Patel D, Cheng D, Chen Z, Eng L, Brown MC, Bezjak A, Keshavjee S, Reisman D, Xu W, **Liu G**. Two BRM promoter polymorphisms do not predict susceptibility or prognosis of thymoma. Poster. **Senior Responsible Author**.

2018 Oct Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Nathan Kuehne. (Trainee Presentation)

*Publication Details:*

Hueniken K, Zhang Y, Falls C, Brown MC, Mirshams M, Rahimi M, Spreafico A, Jang R, Hansen A, Siu L, Waldron J, Bayley A, Giuliani ME, Goldstein D, Wang J, Hope A, Xu W, Bratman S, **Liu G**, Mahler M. Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation. Poster. **Senior Responsible Author**.

2018 Oct Head and Neck Cancer Patients Treated with Cisplatin-Based. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Mary Mahler. (Trainee Presentation)

*Publication Details:*

Mahler M, Zhang Y, Hueniken K, Brown MC, Waldron J, Goldstein D, Bratman S, Siu L, Xu W, Hope A, **Liu G**. Head and Neck Cancer Patients Treated with Cisplatin-Based. Poster. **Senior Responsible Author**.

2018 Oct The effect of WFS1 and ABCC2 heritable variants on cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Mary Mahler. (Trainee Presentation)

*Publication Details:*

Mahler M, Zhang Y, Hueniken K, Brown MC, Chen Z, Mirshams M, Wang J, Siu L, Spreafico A, Breadner D, Teft W, Kim R, Winquist E, Falls C, Liu F, Goldstein D, Bratman S, Xu W, Hope A, **Liu G**. The effect of WFS1 and ABCC2 heritable variants on cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients. Poster. **Senior Responsible Author**.

- 2018 Oct Fc- $\gamma$  receptor polymorphisms and overall survival in colorectal cancer patients treated with cetuximab: an assessment of mediation by cetuximab pharmacokinetics. International Society for Pharmacoepidemiology (ISPE) Asian Conference on Pharmacoepidemiology. Xi'an, China. Presenter(s): Lidija Latifovic. (Trainee Presentation)

*Publication Details:*

Latifovic L, Hung RJ, Xu W, Shepshelovic D, Townsend AR, Espin-Garcia O, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro JD, Siu LL, Owzar K, Ratain MJ, Kubo M, Dobrovic A, Mushiroda T, **Liu G**. Fc- $\gamma$  receptor polymorphisms and overall survival in colorectal cancer patients treated with cetuximab: an assessment of mediation by cetuximab pharmacokinetics. Poster. **Senior Responsible Author**.

- 2018 Sep 29 Assessment of Language Needs and Resource Use among Canadian Immigrant Patients with Cancer. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Sophia Liu. (Trainee Presentation)

*Publication Details:*

Liu S, Smith EC, McCartney A, Basgaran A, Balaratnam K, Brown MC, Howell D, Jones JM, Giuliani ME, Xu W, **Liu G**, Eng L. Assessment of Language Needs and Resource Use among Canadian Immigrant Patients with Cancer. 2018 Sep 29. Poster J Clin Oncol 36, 2018 (suppl 30; abstr 77). **Senior Responsible Author**.

- 2018 Sep 29 Cancer patient (pt) attitudes and preferences towards smoking status assessment. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Liu S, Zhang Q, Farzanfar D, Milne R, Yeung S, Brown MC, Howell D, Xu W, Goldstein DP, Jones JM, Selby P, Evans WK, Giuliani ME, **Liu G**. Cancer patient (pt) attitudes and preferences towards smoking status assessment. Poster J Clin Oncol 36, 2018 (suppl 30; abstr 177). **Senior Responsible Author**.

- 2018 Sep 29 The influence of patient reported adverse events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) patients. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Sharara Shakik. (Trainee Presentation)

*Publication Details:*

Shakik S, Vedadi A, Brown MC, Xu W, O'Kane GM, **Liu G**, Shepherd FA, Leighl NB, Bradbury PA, Lok BH, Sacher AG. The influence of patient reported adverse events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) patients. J Clin Oncol 36, 2018 (suppl 30; abstr 185). **Coauthor or Collaborator**.

- 2018 Sep 29 Routine Collection of EQ-5D-5L Derived Utility Scores in a Brain Metastases Clinic: Correlation with Health-Related Quality of Life (FACT-Br). American Society for Clinical Oncology (ASCO) Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Judy Chen. (Trainee Presentation)

*Publication Details:*

Chen J, Gao Y, Baek J, Chaudhry M, Hueniken K, Liang M, Brown MC, O'Kane GM, Eng L, Xu W, Howell D, Shultz DB, **Liu G**. Routine Collection of EQ-5D-5L Derived Utility Scores in a Brain Metastases Clinic: Correlation with Health-Related Quality of Life (FACT-Br). Poster J Clin Oncol 36, 2018 (suppl 30; abstr

200). **Senior Responsible Author.**

2018 Sep 29 Comparison of health utility values from EQ-5D-3L and EQ-5D-5L in breast cancer patients in different health states. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Tffany Tse. (Trainee Presentation)

*Publication Details:*

Tse Tiffany, Yang D, Baek J, Liang M, Skitch A, Brezden-Masley, C, Brown MC, Torres S, Xu W, **Liu G**. Comparison of health utility values from EQ-5D-3L and EQ-5D-5L in breast cancer patients in different health states. Poster J Clin Oncol 36, 2018 (suppl 30; abstr 197). **Senior Responsible Author.**

2018 Sep 29 Financial toxicity among patients with lung cancer in a publicly funded health care system. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Doreen Anuli Ezeife. (Trainee Presentation)

*Publication Details:*

Ezeife DA, Morganstein J, Lau SC, Le L, Cella D, Bradbury PA, **Liu G**, Sacher AG, Shepherd FA, Leighl NB. Financial toxicity among patients with lung cancer in a publicly funded health care system. Poster J Clin Oncol 36, 2018 (suppl 30; abstr 192). **Coauthor or Collaborator.**

2018 Jun 28 Cancer Care-Related Social Media (SM) and Internet Usage Differences Between Age Groups Among Patients With Cancer. Multinational Association of Supportive Care in Cancer (MASCC/ISOO). Vienna, Austria. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Bender J, Hueniken K, Kassirian S, Yang Y, Mitchell L, Paulo C, Magony A, Smith EC, Liang M, Brown MC, Xu W, **Liu G**, Gupta AA. Cancer Care-Related Social Media (SM) and Internet Usage Differences Between Age Groups Among Patients With Cancer. Oral, Young Investigators Award. **Senior Responsible Author.**

2018 Jun Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Liu S, Farzanfar D, Smith EC, McCartney A, Basgaran A, Balaratnam K, Yeung S, Brown MC, Howell D, Jones JM, Xu W, Goldstein DP, Evans WK, Selby P, Giuliani ME, **Liu G**. Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors. J Clin Oncol. 2018 Jun. **Senior Responsible Author.**

2018 Jun Smoking cessation and elimination of second hand smoke (SHS) exposure among patients with non-tobacco related cancers (non-TRC). American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Liu S, Farzanfar D, Alron D, Krys O, Mohan R, Mattina K, Harper C, Yeung S, Brown MC, Xu W, Howell D, Evans WK, Jones JM, Goldstein DP, Giuliani ME, **Liu G**. Smoking cessation and elimination of second hand smoke (SHS) exposure among patients with non-tobacco related cancers (non-TRC). J Clin Oncol. 2018 Jun. **Senior Responsible Author.**

2018 Jun Cancer Patient Perceptions and Attitudes Towards Routine Assessment and Counselling of Health Behaviors. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): Sophia Liu. (Trainee Presentation)

*Publication Details:*

Liu S, Lu L, Smith EC, Balaratnam K, McCartney A, Basgaran A, Brown MC, Howell D, Jones JM, Giuliani ME, Xu W, Selby P, **Liu G**, Eng L. Cancer Patient Perceptions and Attitudes Towards Routine Assessment and Counselling of Health Behaviors. J Clin Oncol. 2018 Jun. **Senior Responsible Author.**

- 2018 Jun Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): Min Joon Lee. (Trainee Presentation)
- Publication Details:*  
Lee MJ, Jiang SX, Gao Y, Hueniken K, Lu L, Eng L, McCartney A, Obuobi T, Kuehne N, Said BI, Liang M, Sorotsky H, Brown MC, Xu W, **Liu G**. Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre. J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 6587). **Senior Responsible Author**.
- 2018 Jun Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Jiang DM, Jang RWJ, Chan KK, **Liu G**, Amir E, Elimova E. Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations. J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 6619) Poster. **Coauthor or Collaborator**.
- 2018 Jun Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Natori A, Sim HW, Chan BA, Sun P, Moignard S, Yokom D, Lim CH, Jiang DM, Ma LX, Chen EX, **Liu G**, Knox JJ, Darling GE, Yeung JCW, Wong R, Hafezi-Bakhtiari S, Conner J, Rogalla P, Jang RWJ, Elimova E. Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre. J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 4066) Poster. **Coauthor or Collaborator**.
- 2018 Jun The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC). American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Sorotsky H, Moskovitz M, Weiss J, Pintilie M, Leighl NB, Bradbury PA, Liu G, Kia A, Cabanero M, Pugh TJ, Torti D, Tsao MS, Torchia J, Shepherd FA. The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC). J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 8533) Poster. **Coauthor or Collaborator**.
- 2018 Jun Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants. American Society For Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): Mary Mahler.
- Publication Details:*  
Mahler M, Zhang Y, Hueniken K, Brown MC, Chen Z, Mirshams M, Wang J, Siu LL, Spreafico A, Breadner DA, Teft WA, Kim RB, Winquist E, Falls C, Liu FF, Goldstein DP, Bratman SV, Xu W, Hope A, **Liu G**. Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants. J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 6048) Poster. **Senior Responsible Author**.
- 2018 Jun Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993). American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Sridhar SS, Blais N, Tran B, Reaume MN, North SA, Stockler MR, Chi KN, Fleshner NE, **Liu G**, Robinson JW, Mukherjee S, Rahim Y, Winquist E, Booth CM, Nguyen NT, Beardsley EK, Alimohamed NS, McDonald GT, Ding K, Parulekar WR. Cctg BL12: Randomized phase II trial comparing nab-paclitaxel



(Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993). J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 4505) Oral. **Coauthor or Collaborator**.

2018 Jun Upfront next generation sequencing in NSCLC: A publicly funded perspective. American Society for Clinical Oncology. Chicago, Illinois, United States.

*Publication Details:*

Perdrizet K, Stockley T, Tsao MS, Morganstein J, Kamel-Reid S, Ranich L, Shepherd FA, **Liu G**, Bradbury PA, Hwang D, Pal P, Schwock J, Boerner SL, Law JH, Leighl NB. Upfront next generation sequencing in NSCLC: A publicly funded perspective. J Clin Oncol. J Clin Oncol 36, 2018 (suppl; abstr 12062) Poster. **Coauthor or Collaborator**.

2018 Jun Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation. ASCO Annual Meeting. Chicago, United States. Presenter(s): Mary Mahler.

*Publication Details:*

Mary Mahler, Yiwen Zhang, Katrina Hueniken, Carolyn Falls, M. Catherine Brown, Maryam Mirshams, Manada Rahimi, Anna Spreafico, Raymond Woo-Jun Jang, Aaron Richard Hansen, Lillian L. Siu, John Waldron, Andrew Bayley, Meredith Elana Giuliani, David Paul Goldstein, Jennifer Wang, Andrew Hope, Wei Xu, Scott Victor Bratman, **Geoffrey Liu**. Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation. **Senior Responsible Author**.

2018 Jun Acceptability of Routine Evaluations using Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) and Other Patient Reported Symptom Outcome Tools in Cancer Outpatients. ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Hamzeh Albaba.

*Publication Details:*

Hamzeh Albaba, M. Catherine Brown, Sharara Shakik, Jie Su, Hiten Naik, Tian Qi Wang, Mindy Liang, Andrea Perez-Cosio, Lawson Eng, Nicole Mittmann, Wei Xu, **Geoffrey Liu**, Doris Howell, Tristan Alexandra Barnes. Acceptability of Routine Evaluations using Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) and Other Patient Reported Symptom Outcome Tools in Cancer Outpatients. **Coauthor or Collaborator**.

2018 Jun Cancer care-related social media (SM) and Internet usage differences between age groups among patients with cancer. ASCO Annual Meeting. Chicago, United States. Presenter(s): Abha A. Gupta.

*Publication Details:*

Abha A. Gupta, Lawson Eng, Katrina Hueniken, Shayan Kassirian, Dongyang Yang, Laura Mitchell, Chelsea Paulo, Alexander Magony, Elliot Charles Smith, Mindy Liang, M Catherine Brown, Wei Xu, Jackie Bender, **Geoffrey Liu**. Cancer care-related social media (SM) and Internet usage differences between age groups among patients with cancer. **Senior Responsible Author**.

2018 Jun Polymorphisms of cisplatin function and locoregional and distant control of locally advanced head and neck squamous cell carcinomas (LA-HNSCC) treated with chemoradiation. ASCO Annual Meeting. Chicago, United States. Presenter(s): Katrina Hueniken.

*Publication Details:*

Katrina Hueniken, Yiwen Zhang, M. Catherine Brown, Dangxiao Cheng, Zhuo Chen, Maryam Mirshams, Jennifer Wang, Raymond Woo-Jun Jang, Aaron Richard Hansen, Daniel Adam Breadner, Wendy A. Teft, Richard B. Kim, Eric Winkquist, John Waldron, David Paul Goldstein, Scott Victor Bratman, Wei Xu, Andrew Hope, **Geoffrey Liu**, Mary Mahler. Polymorphisms of cisplatin function and locoregional and distant control of locally advanced head and neck squamous cell carcinomas (LA-HNSCC) treated with chemoradiation. **Senior Responsible Author**.

2018 Apr 14 The influence of comorbidity on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in

Small Cell Lung Cancer (SCLC) compared to Non-Small Cell Lung Cancer (NSCLC). European Lung Cancer Congress (ELCC). Geneva, Switzerland. Presenter(s): Ali Vedadi. (Trainee Presentation)

*Publication Details:*

Vedadi A, Shakik S, Brown MC, O'Kane G, **Liu G**. The influence of comorbidity on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) compared to Non-Small Cell Lung Cancer (NSCLC). J Thor Oncol. Poster. **Senior Responsible Author**.

2018 Feb Feasibility pilot implementation of a low-dose CT screening program. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Joo Hyung Yoon. (Trainee Presentation)

*Publication Details:*

Yoon JH, Lofters A, **Liu G**. Feasibility pilot implementation of a low-dose CT screening program. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 109) (poster). **Senior Responsible Author**.

2018 Feb Facilitating patient communication through understanding their social media use: A comparison by age groups. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Shayan Kassirian. (Trainee Presentation)

*Publication Details:*

Kassirian S, Eng L, Paulo C, Geist I, Magony A, Smith EC, Liang M, Yang D, Jones JM, Alibhai SMH, Bender J, Brown MC, Xu W, Gupta AA, **Liu G**. Facilitating patient communication through understanding their social media use: A comparison by age groups. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 71) (poster). **Senior Responsible Author**.

2018 Feb Cancer patient interest and perceptions of health behavior change programs. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Lawson Eng, Sophia Yijia Liu, Qihuang Zhang, Delaram Farzanfar, Sabrina Yeung, M Catherine Brown, Wei Xu, Doris Howell, David Paul Goldstein, Jennifer M. Jones, Peter Selby, Meredith Elana Giuliani, **Geoffrey Liu**. Cancer patient interest and perceptions of health behavior change programs. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 98) (poster). **Senior Responsible Author**.

2018 Feb Barriers of EQ5D-5L implementation into routine clinical practice: A multisite evaluation. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Justine Baek. (Trainee Presentation)

*Publication Details:*

Baek J, Tse T, Brown MC, Skitch A, Chen J, Liang M, Naik H, Eng L, Howell D, Xu W, Shultz D, Brezden CB, **Liu G**. Barriers of EQ5D-5L implementation into routine clinical practice: A multisite evaluation. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 11) (poster). **Senior Responsible Author**.

2018 Feb Impact of immigration status on health behaviors and perceptions in cancer survivors. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Sophia Yijia Liu. (Trainee Presentation)

*Publication Details:*

Liu SY, Lu L, Balaratnam K, Pringle D, Mahler M, Niu C, Naik H, Tiessen K, Hon H, Brown MC, Selby P, Howell D, Xu W, Alibhai SMH, Jones JM, **Liu G**, Eng L. Impact of immigration status on health behaviors and perceptions in cancer survivors. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 27) (poster). **Senior Responsible Author**.

2018 Feb Cancer patient attitudes and preferences towards smoking status assessment. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Liu SY, Zhang Q, Farzanfar D, Milne R, Yeung S, Brown MC, Howell D, Xu W, Goldstein DP, Jones JM, Selby P, Evans WK, Giuliani ME, **Liu G**. Cancer patient attitudes and preferences towards smoking status assessment. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 110) (poster). **Senior Responsible Author**.

2018 Feb Body mass index (BMI), health behaviors, and perceptions in cancer survivors. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Lawson Eng. (Trainee Presentation)

*Publication Details:*

Eng L, Liu SY, Su J, Pringle D, Mahler M, Niu C, Naik H, Mohan R, Tiessen K, Hon H, Brown MC, Jones JM, Howell D, Selby P, Alibhai SMH, Xu W, **Liu G**. Body mass index (BMI), health behaviors, and perceptions in cancer survivors. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 97) (poster). **Senior Responsible Author**.

2018 Feb Implementation of an electronic referral smoking cessation tool into clinical practice across cancer clinics of different disease sites and institutions. ASCO - Cancer Survivorship Symposium: Advancing Care & Research. Orlando, Florida, United States. Presenter(s): Tamoor Afzaal. (Trainee Presentation)

*Publication Details:*

Afzaal T, Chen L, Baek J, Tse T, Chan KK, Brown MC, Howell D, Selby P, Giuliani ME, Jones JM, Skitch A, Brezden CB, Eng L, Eisen A, **Liu G**. Implementation of an electronic referral smoking cessation tool into clinical practice across cancer clinics of different disease sites and institutions. J Clin Oncol. 2018 Feb. 36, 2018 (suppl 7S; abstr 112) (poster). **Senior Responsible Author**.

2018 Jan Screening for cancer-associated dysphagia: The development of two rapid tools for use in observational studies and routine care. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States. Presenter(s): Michael Borean. (Trainee Presentation)

*Publication Details:*

Borean M, Shani K, Brown MC, Chen J, Liang M, Karkada J, Kooner S, Doherty MK, O'Kane GM, Jang RWJ, Elimova E, Wong R, Darling GE, Xu W, Howell D, **Liu G**. Screening for cancer-associated dysphagia: The development of two rapid tools for use in observational studies and routine care. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 164) (poster). **Senior Responsible Author**.

2018 Jan Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC). ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Jiang DM, Lim CH, Ma LX, Sun P, Sim HW, Natori A, Chan BA, Yokom D, SMOignard, Chen EX, **Liu G**, Knox JJ, Swallow CJ, Darling GE, Brar SS, Hafezi-Bakhtiari S, Conner J, Jang RWJ, Elimova E. Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC). J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 147) (poster). **Coauthor or Collaborator**.

2018 Jan Management of metastatic gastric and esophageal cancer in older adults. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Yokom D, Natori A, Sim HW, Chan BA, Moignard S, Sun P, Lim CH, Jiang DM, Ma LX, Darling GE, Swallow CJ, Brierley JD, Wong R, **Liu G**, Chen EX, Knox JJ, Alibhai SMH, Jang RWJ, Elimova E. Management of metastatic gastric and esophageal cancer in older adults. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 163) (poster). **Coauthor or Collaborator**.

2018 Jan Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ)

adenocarcinoma. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Chan BA, Sim HW, Natori A, Moignard S, Yokom D, Lim CH, Jiang DM, Chen EX, Knox JJ, **Liu G**, Darling GE, Swallow CJ, Brar SS, Brierley JD, Ringash J, Wong R, Kim J, Hafezi-Bakhtiari S, Elimova E, Jang RWJ. Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 148) (poster). **Coauthor or Collaborator.**

2018 Jan Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Natori A, Sim HW, Chan BA, Sun P, Moignard S, Yokom D, Lim CH, Jiang M, Ma LX, Chen EX, **Liu G**, Knox JJ, Darling GE, Yeung JCW, Wong R, Hafezi-Bakhtiari S, Conner J, Rogalla P, Jang RWJ, Elimova E. Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 122) (poster). **Coauthor or Collaborator.**

2018 Jan Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Lim CH, Yokom D, Jiang DM, Ma LX, Sun P, Sim HW, Natori A, Chan BA, Moignard S, Knox JJ, Chen EX, **Liu G**, Swallow CJ, Darling GE, Brar SS, Hafezi-Bakhtiari S, Conner J, Elimova E, Jang RWJ. Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 131) (poster). **Coauthor or Collaborator.**

2018 Jan Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Ma LX, Lim CH, Sun P, Jiang M, Sim HW, Natori A, Chan BA, Yokom D, Moignard S, Le LW, Chen EX, **Liu G**, Swallow CJ, Darling GE, Kongkham PN, Shultz D, Hafezi-Bakhtiari S, Conner J, Elimova E, Jang RWJ. Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 145) (poster). **Coauthor or Collaborator.**

2018 Jan The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis. ASCO - Gastrointestinal Cancers Symposium. San Francisco, California, United States. Presenter(s): Daniel Sheshelovich. (Trainee Presentation)

*Publication Details:*

Sheshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro JD, Siu LL, Owzar K, Ratain MJ, Kubo M, Dobrovic A, Xu W, Mushiroda T, **Liu G**. The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 4S; abstr 633) (poster). **Senior Responsible Author.**

2018 Jan Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost. ASCO-SITC. San Francisco, California, United States.

*Publication Details:*

Moskovitz MT, Matthews PM, Pavel AM, Xu W, Bradbury PA, **Liu G**, Shepherd FA, Leighl NB. Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost. J Clin Oncol. 2018 Jan. 36, 2018 (suppl 5S; abstr 174). **Coauthor or Collaborator**.

2017 Oct Informational Needs on Smoking Cessation of Cancer. International Association for the Study of Lung Cancer (IASLC), World Conference on Lung Cancer. Yokohama, Japan.

*Publication Details:*

Giuliani M, Eng L, Papadakos T, Quartey NK, Abdelmutti N, **Liu G**, Papadakos T. Informational Needs on Smoking Cessation of Cancer. J Thoracic Oncol. 2017;12(11):S2295. **Coauthor or Collaborator**.

2017 Oct Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population. International Association for the Study of Lung Cancer (IASLC), World Conference on Lung Cancer. Yokohama, Japan.

*Publication Details:*

Goffin J, Pond G, Tremblay A, Johnston M, Goss G, Nicholas G, Martel S, Bhatia R, **Liu G**, Roberts H, Tammemagi M, Atkhar-Khattra S, Tsao M, Lam S, Puksa S. Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population. J Thoracic Oncol. 2017 Nov;12(11):S1890. **Coauthor or Collaborator**.

2017 Oct Health Utility Scores in Patients with Thymic Malignancies Treated with Multimodality Therapy. International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. Yokohama, Japan.

*Publication Details:*

Soldera S, Naik H, Shakik S, Moskovitz M, Parajian A, Mittman N, Xu W, Hope A, Bezjak A, Keshavjee S, **Liu G**. Health Utility Scores in Patients with Thymic Malignancies Treated with Multimodality Therapy. J Thoracic Oncol. 2017 Nov;12(11):S1868. **Senior Responsible Author**.

2017 Oct The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumour DNA T790M Testing. International Association for the Study of Lung Cancer (IASLC), World Conference on Lung Cancer. Yokohama, Japan.

*Publication Details:*

Barnes T, Laskin J, Cheema P, **Liu G**, Iqbal M, Rothenstein J, Burkes R, Owen S, Laurence D, Carvalhana I, Markin L, Wong L, Perera-Low N, Sawczak M, Tsao M, Leighl N. The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumour DNA T790M Testing. J Thoracic Oncol. 2017 Nov;12(11):S2225. **Coauthor or Collaborator**.

2017 Oct Canadian Multicenter Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing. International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. Yokohama, Japan.

*Publication Details:*

Tsao M, Zhang T, Cheema P, Laskin J, Karsan A, Barnes T, **Liu G**, Owen S, Rothenstein J, Burkes R, Iqbal M, Spatz A, Izevbaye I, Kempen L, Kamel-Reid S, Leighl N. Canadian Multicenter Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing. J Thoracic Oncol. 2017 Nov;12(11):S2207. **Coauthor or Collaborator**.

2017 Oct Lung Cancer Screening: Participant Selection by Risk Model - The Pan-Canadian Study. International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. Yokohama, Japan.

*Publication Details:*

Tammemagi M, Schmidt H, Martel S, McWilliams A, Goffin J, Johnston M, Goss G, Tremblay A, Bhatia R, **Liu G**, Soghrati K, Yasufuku K, Hwang D, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Nasute Fauerbach PV, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart L, Tsai S, Haider E, Boylan C, Cutz J, Manos D, Xu Z, Nicholas G, Seely JM, Amjadi K, Sekhon HS, Burrowes P, Maceachern P, Urbanski S, Sin D, Tan WC, Leighl N, Shepherd F, Evans W,

Tsao M, Lam S. Lung Cancer Screening: Participant Selection by Risk Model - The Pan-Canadian Study. J Thoracic Oncol. 2017 Nov;12(11):S1784-S1785. **Coauthor or Collaborator**.

2017 Oct Perceptions on the effect of physical activity on quality of life, overall survival, and fatigue in palliative cancer patients. American Society for Clinical Oncology (ASCO) Palliative and Supportive Care in Oncology Symposium. San Diego, California, United States.

*Publication Details:*

Balaratnam K, McFarlane G, Selby P, Alibhai S, Brown MC, Jones JM, Howell D, Pringle D, Xu W, **Liu G**, Eng L. Perceptions on the effect of physical activity on quality of life, overall survival, and fatigue in palliative cancer patients. J Clin Oncol. 2017;35(31):abstract 198. **Senior Responsible Author**.

2017 Oct Palliative versus nonpalliative patients' perceptions of the effect of alcohol consumption on clinical outcomes. American Society for Clinical Oncology (ASCO) Palliative and Supportive Care in Oncology Symposium. San Diego, California, United States.

*Publication Details:*

McFarlane G, Balaratnam K, Selby S, Alibhai S, Brown MC, Jones JM, Howell D, Pringle D, Xu W, **Liu G**, Eng L. Palliative versus nonpalliative patients' perceptions of the effect of alcohol consumption on clinical outcomes. JCO. 2017;35(31). **Senior Responsible Author**.

2017 Sep EGFR Copy Number Aberrations Detected in cfDNA from Advanced NSCLC Patients. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

O'Kane G, Li T, Tsao M, **Liu G**, Pugh T, Leighl N. EGFR Copy Number Aberrations Detected in cfDNA from Advanced NSCLC Patients. Annals of Oncology. 2017 Sep;28(5):V35. **Coauthor or Collaborator**.

2017 Sep Real world comparison of common patient reported symptoms with health utility scores in cancer outpatients. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Moskovits M, Jao K, Brown C, Su S, Naik H, Eng L, Wang T, Leung Y, Xu W, **Liu G**, Li M, Devins G, Howell D. Real world comparison of common patient reported symptoms with health utility scores in cancer outpatients. Annals of Oncology. 2017 Sep;28(5):V35. **Coauthor or Collaborator**.

2017 Sep Costs of Dacomitinib Versus Placebo in Pretreated Unselected Patients (Pts) with Advanced NSCLC: CCTG BR.26. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Karim S, Ding K, Bradbury P, Ellis P, Mittman N, Xiaoqun Sun X, Millward M, **Liu G**, Sun S, Stockler M, Cohen V, Blais N, Sangha R, Boyer M, Sasidharan R, Lee C, Shepherd F, Goss G, Seymour L, Leighl N. Costs of Dacomitinib Versus Placebo in Pretreated Unselected Patients (Pts) with Advanced NSCLC: CCTG BR.26. Ann Oncol. 2017 Sep;28(5):V398. **Coauthor or Collaborator**.

2017 Sep Intracranial Efficacy of Brigatinib (BRG) in Patients (Pts) with Crizotinib (CRZ)-Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) and Baseline CNS Metastases. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Ou S, Tiseo M, Camidge R, Ahn M, Huber R, Hochmair M, Kim S, West H, Reckamp K, Molina J, **Liu G**, Delmonte A, Viteri S, Bearz A, Summers Y, Reichmann W, Kerstein D, Gettinger S, Kim D. Intracranial Efficacy of Brigatinib (BRG) in Patients (Pts) with Crizotinib (CRZ)-Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) and Baseline CNS Metastases. Ann Oncol. 2017 Sep;28(5):V480-V481. **Coauthor or Collaborator**.

2017 Sep Treatment Beyond Disease Progression: ALK Inhibitors in ALK-Rearranged Advanced NSCLC. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Leighl N, Kuo J, Pavel A, Prescilla M, Shepherd F, **Liu G**, Bradbury P, Moskovits M. Treatment Beyond Disease Progression: ALK Inhibitors in ALK-Rearranged Advanced NSCLC. Ann Oncol. 2017 Sep;28(5):V481-V482. **Coauthor or Collaborator**.

2017 Sep Body Mass Index (BMI), Lifestyle Behaviors, and Perceptions in Cancer Survivors. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Eng L, Su S, Pringle D, Mahler M, Niu C, Naik H, Mohan R, Tiessen K, Hon H, Brown C, Jones J, Howell D, Selby P, Alibhai S, Xu W, **Liu G**. Body Mass Index (BMI), Lifestyle Behaviors, and Perceptions in Cancer Survivors. Ann Oncol. 2017 Sep;28(5):V555-V556. **Senior Responsible Author**.

2017 Sep Cancer Patient Interest and Perceptions of Lifestyle Behavior Programs. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Eng L, Liu S, Zhang Q, Farzanfar D, Yeung S, Brown C, Xu W, Howell D, Goldstein D, Jones J, Selby P, Giuliani M, **Liu G**. Cancer Patient Interest and Perceptions of Lifestyle Behavior Programs. Annals of Oncology. 2017 Sep;28(5):V558-V559. **Senior Responsible Author**.

2017 Sep Cancer Patient Attitudes and Preferences Towards Smoking Status Assessment. European Society for Medical Oncology (ESMO) Congress. Madrid, Spain.

*Publication Details:*

Eng L, Liu S, Zjang Q, Farzanfar D, Milne R, Yeung S, Brown C, Howell D, Xu W, Goldstein D, Jones J, Selby P, Giuliani M, **Liu G**. Cancer Patient Attitudes and Preferences Towards Smoking Status Assessment. Ann Oncol. 2017 Sep;28(5):V562. **Senior Responsible Author**.

2017 Jun CEASE: A novel patient directed electronic smoking cessation platform for cancer patients. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Jones JM, **Liu G**, Selby P, Eng L, Goldstein DP, Giuliani ME. CEASE: A novel patient directed electronic smoking cessation platform for cancer patients. J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 6584) (Poster). **Coauthor or Collaborator**.

2017 Jun Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer (CRC): An analysis of NCIC CTG CO.17 and CO.20. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Wells C, Siu LL, Shapiro JD, Tu D, Jonker DJ, Karapetis CS, Simes J, **Liu G**, Price TJ, Tebbutt NC, O'Callaghan CJ. Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer (CRC): An analysis of NCIC CTG CO.17 and CO.20. J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 3555) (Poster). **Coauthor or Collaborator**.

2017 Jun Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Jiang DM, Sim HW, Siu LL, Shapiro JD, **Liu G**, Price TJ, Jonker DJ, Karapetis CS, Strickland A, Zhang W, Jeffery M, Tu D, Ng S, Sabesan SS, Shannon J, Townsend AR, Morgen E, Xu W, O'Callaghan CJ, Chen EX. Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 3600) (Poster). **Coauthor or Collaborator**.

2017 Jun Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Natori A, Chan BA, Sim HW, Ma LX, Yokom D, Chen EX, **Liu G**, Darling GE, Swallow CJ, Brar SS, Brierley JD, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox JJ, Elimova E, Jang RWJ. Outcomes for patients  $\geq 75$  years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre. J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 10037) (Poster). **Coauthor or Collaborator**.

2017 Jun Use of a marketing plan for recruitment to a lung cancer screening study. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Goffin JR, Pond GR, Tremblay A, Johnston MR, Goss GD, Nicholas GA, Martel S, Bhatia R, **Liu G**, Roberts H, Tammemagi M, Atkar-Khattra S, Tsao MS, Lam SC, Rudkowski J, Pan-Canadian Early Detection of Lung Cancer Study Research Team. Use of a marketing plan for recruitment to a lung cancer screening study. J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 1548) (Poster). **Coauthor or Collaborator**.

2017 Jun Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC). American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Felip E, De Braud FG, Maur M, Loong HHF, Tsang Shaw A, Vansteenkiste JF, John T, **Liu G**, Lolkema MP, Scott JW, Yu R, Selvaggi G, Mishra K, Lau YYY, Tan DSW. Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 2502) (Oral). **Coauthor or Collaborator**.

2017 Jun Neurocognitive function testing and health related quality of life in stage IV lung cancer patients with and without brain metastases. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

O'Kane GM, Tse BC, Tam V, Brown MC, Lu L, Borean M, Tse T, Labbe C, Naik H, Mittman N, Tam E, Doherty M, Leighl NB, Bradbury PA, Shepherd FA, Howell D, **Liu G**. Neurocognitive function testing and health related quality of life in stage IV lung cancer patients with and without brain metastases. J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 2073) (Poster). **Senior Responsible Author**.

2017 Jun Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Sim HW, Chan BA, Natori A, Lim CH, Jiang DM, Moignard S, Chen EX, **Liu G**, Darling GE, Swallow CJ, Brar SS, Brierley JD, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Knox JJ, Jang RWJ, Elimova E. Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer. J Clin Oncol. 2017. J Clin Oncol 35, 2017 (suppl; abstr 4053) (Poster). **Coauthor or Collaborator**.

2017 Mar Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Orlando, Florida, United States.

*Publication Details:*

Li Y, Brown MC, Estey K, Gill G, Liang M, Cosio Perez A, Borean M, Shani K, Bradbury PA, Shepherd FA, Leighl NB, Howell D, **Liu G**. Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. J Clin Oncol. 2017;35(8):abstract167. **Senior Responsible**



**Author.**

- 2017 Mar The role of annual personal health visits (APHV) on patients' with cancer knowledge and perceptions of the harms of continued smoking. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Orlando, Florida, United States.
- Publication Details:*  
Farzanfar D, Lu L, Su J, Alton D, Mohan R, Liu S, Krysz O, Yoannidis T, Brown MC, Vennetilli A, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**, Eng L. The role of annual personal health visits (APHV) on patients' with cancer knowledge and perceptions of the harms of continued smoking. J Clin Oncol. 2017;35(8):abstract 152. **Senior Responsible Author.**
- 2017 Mar Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM). American Society for Clinical Oncology (ASCO) Quality Care Symposium. Orlando, Florida, United States.
- Publication Details:*  
Tam V, Tse BC, Tse T, Lu L, Tam E, Borean M, Labbé C, Doherty M, Bradbury PA, Leighl NB, Brown MC, Xu W, Howell D, **Liu G**, O'Kane G. Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM). J Clin Oncol. 2017;35(suppl 8):abstract 24. **Senior Responsible Author.**
- 2017 Mar Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs. the 32-combined item HAQ-DI + WHODAS (HW) survey: A quality improvement controlled trial. American Society for Clinical Oncology (ASCO) Quality Care Symposium. Orlando, Florida, United States.
- Publication Details:*  
Tam E, Chen J, Zhang Q, Zheng D, Tam V, Li Y, Tse T, Brown MC, Xu W, Howell D, **Liu G**, Hall E. Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs. the 32-combined item HAQ-DI + WHODAS (HW) survey: A quality improvement controlled trial. J Clin Oncol. 2017;35(suppl 8S; abstract 136). **Senior Responsible Author.**
- 2017 Jan Reducing the burden of patient reporting of physical function in the chronic care of cancer survivors through a branching logic electronic symptom survey (BLESS). American Society for Clinical Oncology (ASCO) Survivorship Symposium. San Diego, California, United States.
- Publication Details:*  
Hall E, Liang M, Tam E, Chen J, Tian C, Campbell MA, Bucci K, Lu L, Tse BC, Zheng D, Wong L, Sarabia S, Yeung S, Gill G, Perez-Cosio A, Brown MC, Xu W, **Liu G**, Howell D. Reducing the burden of patient reporting of physical function in the chronic care of cancer survivors through a branching logic electronic symptom survey (BLESS). J Clin Oncol. 2017;35(5):abstr 5. **Senior Responsible Author.**
- 2017 Jan The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM). American Society for Clinical Oncology (ASCO) Survivorship Symposium. San Diego, California, United States.
- Publication Details:*  
Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Doherty MK, Bradbury PA, Leighl NB, Brown MC, Xu W, Howell D, **Liu G**, O'Kane G. The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM). J Clin Oncol. 2017;35(5):abstr 225. **Senior Responsible Author.**
- 2017 Jan Awareness among patients with cancer of the harms of continued smoking. American Society for Clinical Oncology (ASCO) Survivorship Symposium. San Diego, California, United States.
- Publication Details:*  
Eng L, Alton D, Che J, Song Y, Su J, Farzanfar D, Mohan R, Krysz O, Yoannidis T, Milne R, Brown MC, Vennetilli A, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Awareness

among patients with cancer of the harms of continued smoking. J Clin Oncol. 2017;35(5):abstr 179.  
**Senior Responsible Author.**

2017 Jan Quality of life (QOL) in esophageal cancer patients treated with tri-modality therapy: Is the CROSS protocol better? American Society for Clinical Oncology, Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Woo R, Chan E, Vanderwater C, Cho C, Wong J, Xu W, Zhang Q, **Liu G**, Zhang B, Cheung A, Lee A, Chacko PP, Fadhel E, Kassam Z. Quality of life (QOL) in esophageal cancer patients treated with tri-modality therapy: Is the CROSS protocol better? J Clin Oncol. 2017. (suppl 4S; abstract 132). **Coauthor or Collaborator.**

2017 Jan Recurrence patterns in esophageal cancer patients undergoing curative trimodality therapy. American Society for Clinical Oncology, Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Chan E, Vanderwater C, Woo R, Cho C, Wong J, Xu W, Zhang Q, **Liu G**, Zhang B, Cheung A, Lee A, Chacko PP, Fadhel E, Kassam Z. Recurrence patterns in esophageal cancer patients undergoing curative trimodality therapy. J Clin Oncol. 2017. (suppl 4S; abstract 195). **Coauthor or Collaborator.**

2017 Jan Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care. American Society for Clinical Oncology, Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Shani K, Borean M, Chen J, Li Y, Brown MC, Vennettilli A, Lau A, Zheng D, Kuang Q, Boyd K, Leung Y, Cella D, Mackay H, Darling GE, Wong R, Patel D, Xu W, **Liu G**, Howell D. Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care. J Clin Oncol. 2017. (suppl 4S; abstract 155). **Senior Responsible Author.**

2017 Jan Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre. American Society for Clinical Oncology, Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Sim HW, Chan B, Natori A, Lim CH, Jiang DM, Chen EX, **Liu G**, Darling GE, Swallow CJ, Brar SS, Brierley JD, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox JJ, Jang RWJ, Elimova E. Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre. J Clin Oncol. 2017. (suppl 4S; abstract 126). **Coauthor or Collaborator.**

2017 Jan Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre. American Society for Clinical Oncology, Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Natori A, Chan B, Sim HW, Chen EX, **Liu G**, Darling GE, Swallow CJ, Brar SS, Brierley JD, Ringash J, Wong R, Kim JHJ, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox JJ, Elimova E, Jang RWJ. Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre. J Clin Oncol. 2017. (suppl 4S; abstract 189). **Coauthor or Collaborator.**

2017 Jan Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). American Society for Clinical Oncology, Gastrointestinal Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Jiang DM, Sim HW, Siu LL, Shapiro JD, **Liu G**, Price TJ, Jonker DJ, Karapetis CS, Strickland A, Zhang W, Jeffery M, Tu D, Ng S, Sabesan SS, Shannon J, Townsend AR, Morgen E, Xu W, O'Callaghan CJ, Chen EX. Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017. (suppl 4S; abstract 699). **Coauthor or Collaborator**.

- 2016 Sep 9 Differences in perceptions of smoking and second-hand smoke (SHS) in palliative and nonpalliative patients with cancer. American Society for Clinical Oncology. San Francisco, California, United States.

*Publication Details:*

Mohan R, Alton D, Su J, Song Y, Farzanfar D, Kryz O, Yoannidis T, Milne R, Brown CM, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**, Eng L. Differences in perceptions of smoking and second-hand smoke (SHS) in palliative and nonpalliative patients with cancer. J Clin Oncol. 2016. (suppl 26S; abstr 251).

- 2016 Sep Long term health related quality of life in patients with thymic malignancies. International Thymic Malignancy Interest Group. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Naik H, Song Y, Brown MC, Gill G, Liang M, Rett A, Yeung S, Silva Lemes JG, Leung Y, Labbe C, Mittmann N, Bezjak A, Keshavjee S, Xu W, Howell D, **Liu G**. Long term health related quality of life in patients with thymic malignancies. Oral presentation. **Senior Responsible Author**.

- 2016 Jun 3 Cancer patient awareness of the harms of continued smoking. American Society for Clinical Oncology. Chicago, Illinois, United States.

*Publication Details:*

**Liu G**, Alton D, Che J, Song Y, Su J, Farzanfar D, Mohan R, Kryz O, Yoannidis T, Milne R, Brown MC, Vennettilli A, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, Eng L. Cancer patient awareness of the harms of continued smoking. J Clin Oncol. 2016. (suppl; abstr 10086).

- 2016 Jun 3 A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC. American Society for Clinical Oncology. Chicago, Illinois, United States.

*Publication Details:*

Karim S, Feld R, Leighl NB, Shepherd FA, Bradbury PA, **Liu G**, Graham DM. A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC. J Clin Oncol. 2016. (suppl; abstr TPS2609).

- 2016 Jun 3 Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). American Society for Clinical Oncology. Chicago, Illinois, United States.

*Publication Details:*

Labbe C, Korpanty G, Tomasini P, Doherty M, Mascaux C, Jao K, Pitcher B, Pintilie M, Leighl NB, Feld R, **Liu G**, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA. Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). J Clin Oncol. 2016. (suppl; abstr 11585).

- 2016 Jun 3 Cancer patients' interest and preferences for an inpatient smoking cessation program (SCP). American Society for Clinical Oncology. Chicago, Illinois, United States.

*Publication Details:*

Eng L, Alton D, Song Y, Su J, Farzanfar D, Mohan R, Kryz O, Yoannidis T, Milne R, Brown MC, Vennettilli A, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Cancer patients' interest and preferences for an inpatient smoking cessation program (SCP). J Clin Oncol. 2016. (suppl; abstr 10090).

- 2016 Jun 3 Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and

response to therapy. American Society for Clinical Oncology, Annual Meeting. Chicago, Illinois, United States.

*Publication Details:*

Labbe C, Stewart EL, Brown MC, Perez Cosio A, Vennettilli A, Patel D, Cheng NY, Liang M, Gill G, Rett A, Leung Y, Naik H, Eng L, Mittmann N, Leigh NB, Feld R, Bradbury PA, Shepherd FA, Howell D, **Liu G**. Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy. J Clin Oncol. 2016. (suppl; abstr 6567).

- 2016 Feb 26 Does physical function impact the acceptability of routine patient-reported outcome surveys in cancer patients? American Society for Clinical Oncology, Quality Care Symposium. Phoenix, Arizona, United States.

*Publication Details:*

Wong L, Brown MC, Perez-Cosio A, Leung Y, Liang M, Gill G, Sarabia S, Yeung S, Liu A, Howell D, **Liu G**. Does physical function impact the acceptability of routine patient-reported outcome surveys in cancer patients? J Clin Oncol. 2016. (suppl 7S; abstr 67).

- 2016 Feb 26 Identifying tools for capturing the overall experience of dyspnea in a lung cancer population: The patient's perspective. American Society for Clinical Oncology, Quality Care Symposium. Phoenix, Arizona, United States.

*Publication Details:*

Gill G, Liu A, Chan B, Tsui B, Hall E, Wong L, Liang M, Sarabia S, Yeung S, Perez-Cosio A, Brown MC, Leung Y, Howell D, **Liu G**. Identifying tools for capturing the overall experience of dyspnea in a lung cancer population: The patient's perspective. J Clin Oncol. 2016. (suppl 7S; abstr 73).

- 2016 Feb 26 Implementation of a new patient health questionnaire into standard practice in outpatient cancer clinics to improve patient care and quality of treatment. American Society for Clinical Oncology, Quality Care Symposium. Phoenix, Arizona, United States.

*Publication Details:*

Estey K, Brown MC, Perez-Cosio A, Gill G, Liang M, **Liu G**. Implementation of a new patient health questionnaire into standard practice in outpatient cancer clinics to improve patient care and quality of treatment. J Clin Oncol. 2016. (suppl 7S; abstr 214).

- 2016 Jan 15 Patient preferences for research access to administrative data in Ontario. Cancer Survivorship Symposium: Advancing Care and Research. San Francisco, California, United States. Patient preferences for research access to administrative data in Ontario.

*Publication Details:*

Tian C, Brown C, Perez Cosio A, Leung Y, Lagrotteria A, Liang M, Gill G, Wong L, Sinnesael K, Noronha C, Willing S, Bell EN, Vennettilli A, Edwards J, Pater JL, Howell D, Kassam Z, **Liu G**, Hay AE. Patient preferences for research access to administrative data in Ontario. J Clin Oncol. 2016. (suppl 3S; abstr 144).

- 2016 Jan 15 Elimination of second-hand smoke (SHS) exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient smoking cessation. Cancer Survivorship Symposium: Advancing Care and Research. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Alton D, Song Y, Farzanfar D, Kryz O, Yoannidis T, Milne RA, Habbous S, Brown MC, Vennettilli A, Shepherd FA, Leigh NB, Hope AJ, Howell DS, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Elimination of second-hand smoke (SHS) exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient smoking cessation. 2016 Jan. (suppl 3S; abstr 183).

- 2015 Nov 9 Economic Burden of Patients with Alk+ Mutation non-Small Cell Lung Cancer After Treatment with Crizotinib: a Canadian Retrospective Observational Study. International Society for Pharmacoeconomics

and Outcomes Research (ISPOR). Milan, Italy.

*Publication Details:*

Kayaniyil S, Wilson J, Hurry M, Koch C, Zhang J, **Liu G**. Economic Burden of Patients with Alk+ Mutation non-Small Cell Lung Cancer After Treatment with Crizotinib: a Canadian Retrospective Observational Study. Value Health. 2015 Nov 9;18(7):A452. 2015 Nov;18(7):A452. doi: 10.1016/j.jval.2015.09.1142. Epub 2015 Oct 20. Poster presentation. **Senior Responsible Author**.

2015 Nov The Willingness of Cancer Outpatients to Complete Patient-Reported Outcome Measures Outside of the Clinic. International Society of Pharmacoeconomics. Milan, Italy. (Trainee Presentation)

*Publication Details:*

Ho V, Song Y, Brown MC, Vennettilli A, Eng L, Zarrin A, Dobriyal A, Chen L, Mirshams M, Patel D, Hon H, Pat V, Ho A, Solomon H, Tiessen K, Thai H, Irwin M, Mahler M, Xu W, **Liu G**, Howell D. The Willingness of Cancer Outpatients to Complete Patient-Reported Outcome Measures Outside of the Clinic. Value Health. 2015 Nov. 2015 Nov;18(7):A470-1. doi: 10.1016/j.jval.2015.09.1246. Epub 2015 Oct 20. International Society of Pharmacoeconomics and Outcomes Research 18th Annual European Congress (Poster). **Senior Responsible Author**.

2015 Sep 9 EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer. International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States. (Trainee Presentation)

*Publication Details:*

Labbe C, Stewart EL, Brown C, Perez Cosio A, Vennettilli A, Patel D, Cheng N, Liang M, Gill G, Leung Y, Naik H, Mittmann N, Leighl N, Feld R, Bradbury P, Shepherd F, Howell D, **Liu G**. EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer. 2015 Sep. (abstr: 1613), World Lung Cancer Conference, 2015, Colorado, USA (Poster). **Senior Responsible Author**.

2015 Sep 9 Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC. International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States.

*Publication Details:*

**Liu G**, Zhang J, Zhou Z, Li J, Signorovitch J, Cai X. Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC. WCLC 2015 - 16th World Conference on Lung Cancer, September 9, 2015; Abstr 945 (Oral). **Principal Author**.

2015 Sep 9 Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States.

*Publication Details:*

Lim C, Sung M, Nouriany N, Sawczak M, Paul T, Perera-Low N, Foster A, Zawisza D, Feld R, **Liu G**, Shepherd FA, Leighl N. Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? WCLC 2015 - 16th World Conference on Lung Cancer, September 9, 2015; Abstr 663 (Oral). **Co-Investigator**.

2015 Sep 8 Genomic Profiling of Patient-Derived Xenografts Identify Passenger Aberrations Associated with Better Prognosis in Non-Small Cell Lung Cancer. International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States.

*Publication Details:*

Wang D, Pham N, Sakashita S, Allo G, Kim L, Yanagawa N, Zhu C, Li M, Kaufman E, Moghal N, **Liu G**, Pintilie M, Jurisica I, McPherson JD, Shepherd FA, Tsao MS. Genomic Profiling of Patient-Derived Xenografts Identify Passenger Aberrations Associated with Better Prognosis in Non-Small Cell Lung Cancer. WCLC 2015 - 16th World Conference on Lung Cancer, September 8, 2015; Abstr 1735 (Oral). **Co-Investigator**.

2015 Sep 7      Where Are We with Defining Potential Biomarkers. International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States.

*Publication Details:*

**Liu G.** Where Are We with Defining Potential Biomarkers. WCLC 2015 - 16th World Conference on Lung Cancer, September 7, 2015; Abstr 1858 (Oral). **Principal Author.**

2015 Sep 7      Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer (NSCLC) Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on Outcome. International Association for the Study of Lung Cancer (IASLC). Denver, Colorado, United States.

*Publication Details:*

Doherty MK, Korpany G, Tomasini P, Alizadeh M, Jao K, Labbe C, Mascaux C, Martin P, Kamel-Reid S, Pintilie M, **Liu G**, Bradbury P, Feld R, Leigh N, Chung C, Shepherd FA. Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer (NSCLC) Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on Outcome. WCLC 2015 - 16th World Conference on Lung Cancer, September 7, 2015; Abstr 1251 (Oral). **Co-Investigator.**

2015 Sep      Barriers to Using Computer-assisted Technology (CAT) in Patient Reported Outcome Symptom Surveys for Routine Supportive Care. European Cancer Organisation. Vienna, Austria. (Trainee Presentation)

*Publication Details:*

Merali Z, Brown C, Su S, Vennettilli A, Perez Cosio A, Xu W, **Liu G.** Barriers to Using Computer-assisted Technology (CAT) in Patient Reported Outcome Symptom Surveys for Routine Supportive Care. 2015 Sep. European Cancer Congress 2015; 2015 Sep 27th-30th, Vienna, Austria. Abstract number: 1620. **Senior Responsible Author.**

2015 Aug      Active surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): A feasibility study. International Society for Pharmacoepidemiology. Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Wang TQ, Bergman H, Brown MC, Vennettilli A, Patel D, Seki JT, Perez-Cosio A, Howell D, **Liu G.** Active surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): A feasibility study. 2015 Aug. ICPE and Therapeutic Risk Management, August 2015, Boston, USA. (Poster). **Senior Responsible Author.**

2015 Aug      Pharmacovigilance data from systematic patient reported outcome (PRO) tools versus usual clinician interactions: Are cancer patients. International Society for Pharmacoepidemiology. Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Samuel JN, Wang TQ, Perez-Cosio A, Brown MC, Vennettilli A, Cheng N, Gill G, Liang M, Howell D, Xu W, Seki J, **Liu G.** Pharmacovigilance data from systematic patient reported outcome (PRO) tools versus usual clinician interactions: Are cancer patients. 2015 Aug. ICPE and Therapeutic Risk Management, August 2015, Boston, USA. (Poster). **Senior Responsible Author.**

2015 Aug      Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations by drug therapy. International Society for Pharmacoepidemiology. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Stewart EL, Labbe C, Brown MC, Perez-Cosio A, Vennettilli A, Patel D, Cheng N, Liang M, Gill G, Leung Y, Mittmann N, Naik H, **Liu G.** Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations by drug therapy. 2015 Aug. (abstr 750994) 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management, 2015, Boston, USA. (Poster). **Senior Responsible Author.**

- 2015 Aug Access to Drug Benefit Plans Among Canadian Cancer Survivors. Pharmacoeconomics and Therapeutic Risk Management. Boston, Massachusetts, United States. (Trainee Presentation)
- Publication Details:*  
Eng L, Alton D, Yoannidis T, Milne RA, Sarabia S, Merali Z, Murphy L, Brown MC, Xu W, Giuliani ME, **Liu G**. Access to Drug Benefit Plans Among Canadian Cancer Survivors. 2015 Aug. 31st International Conference on Pharmacoeconomics and Therapeutic Risk Management. Boston, MA (Poster). **Senior Responsible Author**.
- 2015 Jun Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Lim CH, Sung M, Nouriany NZ, Sawczak M, Paul T, Perera-Low N, Feld R, **Liu G**, Shepherd FA, Leighl NB. Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Co-Investigator**.
- 2015 Jun A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Sridhar SS, Blais N, North SA, Tran B, Chi KN, Robinson JW, Reaume MN, **Liu G**, McDonald GT, Ding K, Parulekar WR. A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993). 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Co-Investigator**.
- 2015 Jun EGFR mutations in NSCLC: Does ethnicity influence outcomes? American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Tomasini P, Sung M, Kamel-Reid S, Tsao MS, **Liu G**, Bradbury PA, Shepherd FA, Feld R, Leighl NB. EGFR mutations in NSCLC: Does ethnicity influence outcomes? 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Abstract). **Co-Investigator**.
- 2015 Jun Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Korpanty G, Kamel-Reid S, Tsao MS, Hwang DM, Zer A, **Liu G**, Leighl NB, Feld R, Gill B, Pintilie M, Shepherd FA. Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Abstract). **Co-Investigator**.
- 2015 Jun Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Jao K, Tomasini P, Kamel-Reid S, Tsao MS, Korpanty GJ, Mascaux C, **Liu G**, Leighl NB, Feld R, Bradbury PA, Ennis M, Shepherd FA. Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Co-Investigator**.
- 2015 Jun Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma

kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Tan DSW, Araujo A, Zhang J, Signorovitch JE, Zhou ZY, Cai X, **Liu G**. Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison. 2015 Jun. ASCO Annual Meeting, May 29- June2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author**.

2015 Jun Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Tomasini P, Jao K, Kamel-Reid S, Stockley T, Tsao MS, **Liu G**, Leighl NB, Feld R, Bradbury PA, Pintilie M, Mascaux C, Shepherd FA. Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). 2015 Jun. ASCO Annual Meeting, May 29- June2, 2015, Chicago, IL, USA (Poster). **Co-Investigator**.

2015 Jun The relationship between health utility, quality of life, and symptom scores in Canadian patients with esophageal cancer. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Doherty M, Naik H, Eng L, Patel D, Kong QQ, Xu W, Brown MC, Espin-Garcia O, Vennettilli A, Renouf DJ, Faluyi OO, Knox JJ, Mackay H, Wong R, Howell D, Mittmann N, Darling GE, Cella D, **Liu G**. The relationship between health utility, quality of life, and symptom scores in Canadian patients with esophageal cancer. 2015 Jun. ASCO Annual Meeting, May 29- June2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author**.

2015 Jun Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Doherty M, Leung Y, Naik H, Patel D, Eng L, Kong QQ, Brown MC, Espin-Garcia O, Vennettilli A, Renouf DJ, Faluyi OO, Knox JJ, Mackay H, Wong R, Cella D, Darling GE, Howell D, Mittmann N, Xu W, **Liu G**. Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients. 2015 Jun. ASCO Annual Meeting, May 29- June2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author**.

2015 Jun Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, **Liu G**, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. 2015 Jun. ASCO Annual Meeting, May 29- June2, 2015, Chicago, IL, USA (Oral). **Co-Investigator**.

2015 Jun Stage specific health utility index scores of Canadian cancer patients. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Naik H, Howell D, Su S, Qiu X, Brown MC, Vennettilli A, Irwin M, Pat V, Solomon H, Wang T, Hon H, Eng L, Mahler M, Thai H, Ho V, Ho A, Xu W, Seung SJ, Mittmann N, **Liu G**. Stage specific health utility index



scores of Canadian cancer patients. 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author.**

2015 Jun Cancer patients' attitudes, knowledge, and preferences for smoking cessation (SC). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Alton D, Yoannidis T, Kong QQ, Milne R, Sarabia S, Merali Z, Murphy L, Brown MC, Waldron J, Pierre A, Bezjak A, Hope A, Howell D, Jones J, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Cancer patients' attitudes, knowledge, and preferences for smoking cessation (SC). 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author.**

2015 Jun Change in second-hand smoke exposure after a lung and head and neck diagnosis and subsequent patient smoking cessation. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Alton D, Yoannidis T, Song Y, Milne R, Sarabia S, Merali Z, Habbous S, Brown MC, Vennettilli A, Shepherd FA, Leighl NB, Hope A, Howell D, Jones J, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Change in second-hand smoke exposure after a lung and head and neck diagnosis and subsequent patient smoking cessation. 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author.**

2015 Jun Prediction models of smoking cessation in lung and head and neck cancer patients: Role of second-hand smoke (SHS) exposure. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

**Liu G**, Song Y, Alton D, Yoannidis T, Milne R, Sarabia S, Merali Z, Habbous S, Brown MC, Vennettilli A, Hope A, Howell D, Jones JJ, Selby P, Goldstein DP, Giuliani ME, Xu W, Eng L. Prediction models of smoking cessation in lung and head and neck cancer patients: Role of second-hand smoke (SHS) exposure. 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Principal Author.**

2015 Jun Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Doherty M, Leung Y, Naik H, Patel D, Eng L, Brown MC, Espin-Garcia O, Vennettilli A, Renouf D, Faluyi O, Knox J, Mackay H, Wong R, Cella D, Darling G, Howell D, Mittmann N, **Liu G**. Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients. 2015 Jun. ASCO Annual Meeting, May 29-June 2, 2015, Chicago, IL, USA (Poster). **Senior Responsible Author.**

2015 Apr Development of resistance models to tyrosine kinase inhibitors (TKIs) in patient-derived xenograft models (PDXs) of lung adenocarcinoma with epidermal growth factor receptor (EGFR). International Association for the Study of Lung Cancer. Geneva, Switzerland. (Trainee Presentation)

*Publication Details:*

Stewart EL, Sakashita S, Wang T, Pham NA, Li M, **Liu G**, Tsao MS. Development of resistance models to tyrosine kinase inhibitors (TKIs) in patient-derived xenograft models (PDXs) of lung adenocarcinoma with epidermal growth factor receptor (EGFR). 2015 Apr. Annual European Lung Cancer Conference, 2015, Geneva, Switzerland. Abstr 472 (Poster). **Co-Investigator.**

2015 Jan The Relationship between Health Utility, Quality of Life, and Symptom Scores in Canadian Patients with Esophageal Cancer. American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Doherty MK, Naik H, Kong Q, Devalben P, Eng L, Brown MC, Espin-Garcia O, Vennettilli A, Renouf D,

Faluyi O, Knox J, Mackay H, Wong R, Cella D, Darling G, Howell D, Xu W, Mittmann N, **Liu G**. The Relationship between Health Utility, Quality of Life, and Symptom Scores in Canadian Patients with Esophageal Cancer. 2015 Jan. ASCO GI Cancers Symposium, January 15-17, 2015, San Francisco, CA, USA (Poster). **Senior Responsible Author**.

2015 Jan      Quality of life in esophageal cancer patients treated with radiation in the radical setting. American Society of Clinical Oncology (ASCO) GI Cancer Symposium. San Francisco, California, United States.

*Publication Details:*

Choudhary A, **Liu G**, Chacko PP, Fadhel E, Cho C, Woo R, Chrung A, Vanderwater C, Xin C, Xu W, Wong J, Lee A, Kassam Z. Quality of life in esophageal cancer patients treated with radiation in the radical setting. 2015 Jan. ASCO GI Cancers Symposium, January 15-17, 2015, San Francisco, CA, USA (Poster). **Co-Investigator**.

2014 Oct      Involving clinic patients in systematic symptom reporting to improve cancer care: Exploring prevalence of sleep disturbances (SD) and fatigue (FAT). American Society for Clinical Oncology. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Irwin M, Brown MC, Vennettilli A, Eng L, Zarrin A, Dobriyal A, Chen L, Mirshams M, Patel D, Hon H, Pat V, Ho A, Solomon H, Tiessen K, Thai H, Ho V, Mahler M, Xu W, **Liu G**, Howell D. Involving clinic patients in systematic symptom reporting to improve cancer care: Exploring prevalence of sleep disturbances (SD) and fatigue (FAT). Journal of Clinical Oncology. 2014 Oct. J Clin Onc; (abstr 137246) (Poster). **Senior Responsible Author**.

2014 Oct      Involving patients to improve their care through real-time patient reported outcome (PRO)-CTCAE chemotoxicity surveys in an outpatient chemodaycare (DC) setting: Evaluating patient acceptability. American Society of Clinical Oncology. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Solomon H, Brown C, Vennettilli A, Zarrin A, Dobriyal A, Chen L, Pat V, Ho A, Xin C, Irwin M, Wang TQ, Gonos C, Merali Z, Wong L, Xu W, Howell D, **Liu G**. Involving patients to improve their care through real-time patient reported outcome (PRO)-CTCAE chemotoxicity surveys in an outpatient chemodaycare (DC) setting: Evaluating patient acceptability. Journal of Clinical Oncology. 2014 Oct. J Clin Onc; Abstract #137081 (Poster). **Senior Responsible Author**.

2014 Oct      Canadian cancer site-specific health utility values: Creating the basis for measuring value and costs of therapy. American Society of Clinical Oncology. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Naik H, Howell D, Qiu X, Brown C, Vennettilli A, Irwin M, Pat V, Solomon H, Wang T, Hon H, Eng L, Mahler M, Tiessen K, Thai H, Ho V, Pringle D, Xu W, Seung SJ, Mittmann N, **Liu G**. Canadian cancer site-specific health utility values: Creating the basis for measuring value and costs of therapy. Journal of Clinical Oncology. 2014 Oct. J Clin Onc Abstract #137351 (Oral presentation & Poster). **Senior Responsible Author**.

2014 Oct      Assessing the utility of a patient-reported screener question to detect fatigue symptoms: Improving the quality of systematic symptom measurement in clinical practice. American Society of Clinical Oncology. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Tomasini P, Brown C, Vennettilli A, Zarrin A, Dobriyal A, Chen L, Mirshams M, Patel D, Irwin M, Ho V, Ho A, Pat V, Solomon H, Thai H, Mahler M, Xu W, Howell D, **Liu G**. Assessing the utility of a patient-reported screener question to detect fatigue symptoms: Improving the quality of systematic symptom measurement in clinical practice. Journal of Clinical Oncology. 2014 Oct. J Clin Onc Abstract #137482 (Poster). **Senior Responsible Author**.

- 2014 Oct Perceptions of physical activity (PA) in cancer survivors affect PA behaviors: Helping healthcare providers improve patient communication. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Naik H, **Liu G**, Qiu X, Pringle D, Brown MC, Eng L, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Charow R, Pat V, Irwin M, Herzog L, Ho A, Jones J, Xu W, Howell D. Perceptions of physical activity (PA) in cancer survivors affect PA behaviors: Helping healthcare providers improve patient communication. Journal of Clinical Oncology. 2014 Oct. J Clin Onc; Abstract #137363 (Poster). **Co-Principal Author**.

- 2014 Oct Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice. American Society of Clinical Oncology (ASCO). Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Brown MC, Vennettilli A, Patel D, Zeman KZ, Lau A, Qin K, Boyd K, Leung Y, Cella D, MacKay H, Darling GE, Wong R, Xu W, **Liu G**, Howell D. Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice. Journal of Clinical Oncology. 2014 Oct. J Clin Onc; Abstract #137566 (Poster). **Senior Responsible Author**.

- 2014 Oct Improving quality of care by obtaining patient reported outcomes (PRO)-CTAE chemotoxicities using tablet technology in daycare (DC) waiting rooms. American Society of Clinical Oncology (ASCO). Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Wang TQ, Brown MC, Vennettilli A, Wong L, Zarrin A, Dobriyal A, Chen L, Pat V, Ho A, Xin C, Solomon H, Irwin M, Gonos C, Merali Z, Mitchell S, Xu W, Howell D, **Liu G**. Improving quality of care by obtaining patient reported outcomes (PRO)-CTAE chemotoxicities using tablet technology in daycare (DC) waiting rooms. Journal of Clinical Oncology. 2014 Oct. J Clin Onc; Abstract #137355 (Poster). **Senior Responsible Author**.

- 2014 Oct Quality care and patient involvement in their care: Preferences for transitioning cancer follow-up care to the community. American Society of Clinical Oncology (ASCO) Quality Care Symposium. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Herzog LS, Howell D, Moura S, Qiu X, Brown MC, Vennettilli A, Eng L, Chen L, Malik N, Zvetkova S, Zarrin A, Dobriya A, Patel D, Xu W, Townsley C, **Liu G**. Quality care and patient involvement in their care: Preferences for transitioning cancer follow-up care to the community. Journal of Clinical Oncology. 2014 Oct. J Clin Onc; Abstract #137548 (Poster). **Senior Responsible Author**.

- 2014 Oct Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment. American Society of Clinical Oncology (ASCO) Quality Care Symposium. Boston, Massachusetts, United States. (Trainee Presentation)

*Publication Details:*

Pat V, Brown MC, Vennettilli A, Zarrin A, Dobriyal Z, Chen L, Mirshams M, Patel D, Hon H, Irwin M, Ho A, Solomon H, Tiessen K, Mahler M, Ho V, Thai H, Eng L, Xu W, Howell D, **Liu G**. Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment. J Clin Oncol. 2014 Oct. J Clin Oncol (abstr 137069) (Poster). **Senior Responsible Author**.

- 2014 Oct Second-Hand Smoke (SHS) and Smoking Cessation in Non-Tobacco Related Cancers. American Association of Cancer Research (AACR). New Orleans, Louisiana, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Qiu X, Su J, Brown MC, Irwin M, Pringle D, Niu C, Mahler M, Naik H, Hon H, Tiessen K, Charow R, Thai H, Ho V, Pat V, Herzog L, Ho A, Jones JM, Howell DS, Goldstein DP, Giuliani ME, Xu W, Selby P, **Liu G**. Second-Hand Smoke (SHS) and Smoking Cessation in Non-Tobacco Related Cancers. 2014 Oct.

American Association of Cancer Research: 13th Annual AACR International Conference on Frontiers in Cancer Prevention Research. New Orleans, LA. October 2014. (Poster). **Senior Responsible Author.**

2014 Sep Genetic polymorphisms associated with toxicity are associated with overall survival following curative radiation for non-small cell lung cancer. American Society of Radiation Oncology (ASTRO). San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Barrett K, **Liu G**. Genetic polymorphisms associated with toxicity are associated with overall survival following curative radiation for non-small cell lung cancer. 2014 Sep. (ASTRO) Annual Meeting, Sept. 14-17, 2014, San Francisco, CA, USA (Poster). **Senior Responsible Author.**

2014 Jul Two BRM promoter polymorphisms predict survival outcomes in patients with head and neck squamous cell carcinoma. International Federation of Head and Neck Oncologic Societies (IFHNOS) and American Head and Neck Society (AHNS). New York, New York, United States. (Trainee Presentation)

*Publication Details:*

Wang JR, **Liu G**. Two BRM promoter polymorphisms predict survival outcomes in patients with head and neck squamous cell carcinoma. 2014 Jul. IFHNOS 5th World Congress/American Head & Neck Society 2014 Annual Meeting, July 2014 (accepted for oral presentation). **Senior Responsible Author.**

2014 Jun Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Tan DSW, Shaw AT, Mehra R, Felip E, Chow LQM, Camidge DR, Vansteenkiste JF, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, **Liu G**, Santoro A, Geraldles M, Boral A, Yovine AJ, Kim DW. Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. J Clin Oncol. 2014. J Clin Oncol 32:5s, June 2014 (suppl; abstr 8078) (Oral). **Co-Investigator.**

2014 Jun Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Lim CH, Le L, Shepherd FA, Feld R, Burkes RL, **Liu G**, Kamel-Reid S, Tsao MS, Leighl NB. Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer. J Clin Oncol. 2014 Jun. J Clin Oncol 32:5s, June 2014 (suppl; abstr 6595) (Poster). **Co-Investigator.**

2014 Jun Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Chiu JWY, Roehrl MHA, Serra S, Krzyzanowska MK, Knox JJ, Mackay H, David H, Moore M, **Liu G**, Dhani NC, Kamel-Reid S, Torlakovic E, Wang T, Chadwick D, Zhang T, Sakashita S, Bedard PL, Chen EX, Tsao MS, Yu C. Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience. J Clin Oncol. 2014 Jun. J Clin Oncol 32:5s, June 2014 (suppl; abstr 3572) (Poster). **Co-Investigator.**

2014 Jun Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste JF, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, **Liu G**, Santoro A, Geraldles M, Boral A, Yovine AJ, Shaw AT. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell

lung cancer (NSCLC): Results of the ASCEND-1 trial. J Clin Oncol. 2014 Jun. J Clin Oncol 32:5s, June 2014 (suppl; abstr 8003^a) (Poster). **Co-Investigator**.

2014 Jun Lung cancer in never-smokers from Princess Margaret Cancer Centre. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Korpanty G, Kamel-Reid S, Tsao MS, Zer A, **Liu G**, Leighl NB, Feld R, Pintilie M, Shepherd FA. Lung cancer in never-smokers from Princess Margaret Cancer Centre. J Clin Oncol. 2014 Jun. J Clin Oncol 32:5s, 2014 June (suppl; abstr 8099) (Poster). **Co-Investigator**.

2014 Jun NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Ellis PM, **Liu G**, Millward M, Perrone F, Shepherd FA, Sun S, Cho BC, Morabito A, Stockler MR, Wierbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Wilson CF, O'Connell J, Ding K, Goss GD, Bradbury PA. NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. J Clin Oncol. 2014 Jun. J Clin Oncol 32:5s, June 2014 (suppl; abstr 8036^a) (Poster discussion). **Co-Investigator**.

2014 Jun Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): CH Lim. (Trainee Presentation)

*Publication Details:*

Lim CH, Le L, Shepherd FA, Feld R, Burkes RL, **Liu G**, Kamel-Reid S, Tsao MS, Leighl NB. Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer. J Clin Oncol. 2014 Jun;32(5). J Clin Oncol 32:5s, June 2014 (suppl; abstr 6595) (Poster). **Co-Investigator**.

2014 Jun Early intervention of skin toxicities by panitumumab and clinical outcomes in the clinical setting. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Bergman H, Walton T, Del Bel R, Seki TJ, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, **Liu G**. Early intervention of skin toxicities by panitumumab and clinical outcomes in the clinical setting. J Clin Oncol. 2014 Jun;32. (Poster) J Clin Oncol 32, June 2014 (suppl; abstr e20673). **Senior Responsible Author**.

2014 Jun Socioeconomic status and lifestyle behaviors in cancer survivors. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Naik H, Eng L, Brown C, Qiu X, Pringle D, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Charow R, Pat V, Irwin M, Herzog L, Ho A, Xu W, Jones JM, Howell D, **Liu G**. Socioeconomic status and lifestyle behaviors in cancer survivors. J Clin Oncol. 2014 Jun;32(5s). J Clin Oncol 32:5s, June 2014 (suppl; abstr 6568) (Poster). **Senior Responsible Author**.

2014 Jun Social and perceptual influences on alcohol consumption in cancer survivors. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Su J, Qiu X, Brown MC, Naik H, Pringle D, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Pat V, Irwin M, Herzog L, Ho a, Xu W, Jones JM, Howell D, **Liu G**. Social and perceptual influences on alcohol consumption in cancer survivors. J Clin Oncol. 2014 Jun;32(5s). J Clin Oncol 32:5s, June 2014

(suppl; abstr 9575) (Poster). **Senior Responsible Author.**

2014 Jun Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and sub analysis of the NCIC clinical trials group HN.6 clinical trial. American Society for Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Cuffe S, Hon H, Tobros K, Espin-Garcia O, Brhane Y, Harland L, Fadhel E, Eng L, LaDelfa A, Waldron JN, Chen BE, Xu W, Simmons CE, Kassam Z, Siu LL, Montenegro A, Parulekar WR, **Liu G**. Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and sub analysis of the NCIC clinical trials group HN.6 clinical trial. J Clin Oncol. 2014 Jun;32(5s). J Clin Oncol 32:5s, June 2014 (suppl; abstr 1586) (Poster). **Senior Responsible Author.**

2014 Apr Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patent-derived xenografts (PDX) of on-small cell lung cancer (NSCLC). American Association of Cancer Research. San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Stewart EL, Mascaux C, Panchal D, Kim L, Shakashita S, Wang D, Li M, Pham NA, Leighl N, **Liu G**, Shepherd F, Tsao M-S. Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patent-derived xenografts (PDX) of on-small cell lung cancer (NSCLC). 2014 Apr. AACR Annual Meeting April 5-9, 2014, (abstr 1184) San Diego, California, USA (Poster). **Coauthor or Collaborator.**

2014 Mar Functional BRM promoter polymorphisms, pancreatic adenocarcinoma survival. Society of Surgical Oncology (SSO) Cancer Symposium. Pheonix, Arizona, United States. (Trainee Presentation)

*Publication Details:*

Segedi M, Anderson LN, Espin-Garcia O, Borgida A, Bianco T, Cheng D, Chen Z, Patel D, Brown MC, Hung RJ, Cotterchio M, Gallinger S, Xu W, Reisman D, **Liu G**, Cleary SP. Functional BRM promoter polymorphisms, pancreatic adenocarcinoma survival. J Clin Oncol. J Clin Oncol 32, March 2014 (Poster). **Co-Investigator.**

2014 Jan BRM promoter insertion/deletion polymorphisms in hepatocellular carcinoma risk and survival. American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States.

*Publication Details:*

Wong KM, **Liu G**, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown MC, Wong A, Reisman D, Xu W, Knox JJ, Cleary SP, Hung RJ. BRM promoter insertion/deletion polymorphisms in hepatocellular carcinoma risk and survival. J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 225). **Co-Investigator.**

2014 Jan Functional BRM promoter polymorphisms, pancreatic adenocarcinoma risk. American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Segedi M, Anderson LN, Espin-Garcia O, Borgida A, Bianco T, Cheng D, Chen Z, Patel D, Brown MC, Hung RJ, Cotterchio M, Gallinger S, Xu W, Reisman D, **Liu G**, Cleary SP. Functional BRM promoter polymorphisms, pancreatic adenocarcinoma risk. J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 222). **Co-Investigator.**

2014 Jan Association between polymorphisms of the FOXF1 and MHC locus genes and gastroesophageal reflux disease (GERD). American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Liu WF, Lam C, Del Bel R, Chan K, Miller L, Brown MC, Chen Z, Cheng D, Patel D, Xu W, Darling GE,

**Liu G.** Association between polymorphisms of the FOXF1 and MHC locus genes and gastroesophageal reflux disease (GERD). J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 15). **Senior Responsible Author.**

2014 Jan Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians. American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Wong KM, Lee JJ, Wong A, **Liu G**, Sherman M, Cleary SP, Knox JJ. Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians. J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 289). **Co-Investigator.**

2014 Jan Genomic determinants of prognosis in esophageal adenocarcinoma: Using computational methods to account for gene-gene interactions. American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Morgen E, Shen X, Vaughan TL, Whiteman D, Wu AH, Gammon MD, Chow WH, Stram DO, Romero Y, Xu W, **Liu G**. Genomic determinants of prognosis in esophageal adenocarcinoma: Using computational methods to account for gene-gene interactions. J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 42). **Senior Responsible Author.**

2014 Jan Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Chiu JW, Bedard PL, Roehrl MH, Serra s, Kryzanowska MK, Knox JJ, Mackay H, Hedley DW, Moore MJ, **Liu G**, Dhani NC, Kamel-Reid S, Torlakovic E, Wang T, Tsao MS, Chadwick D, Zhang T, Yu C, Chen EX, Sakashita S. Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience. J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 459). **Co-Investigator.**

2014 Jan Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. American Society of Clinical Oncology (ASCO) GI Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Spreafico A, Coate LE, Shen X, Zhai R, Xu W, Chen Z-F, Chen Z, Patel D, Brown MC, Kuang Q, Boyd K, Kulke M, Su L, Mackay H, Knox JJ, Wong R, Darling GE, Christiani DC, **Liu G**. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. J Clin Oncol. 2014 Jan;32. J Clin Oncol 32, 2014 (suppl 3; abstr 10). **Senior Responsible Author.**

2013 Nov PMCC behaviours in cancer survival group. Dietary habits and changes in dietary behaviors in adult cancer survivors in Toronto, Canada. American Association for Cancer Research. Bethesda, Maryland, United States. (Trainee Presentation)

*Publication Details:*

Herzog LS, Shen X, Brown MC, Eng L, Xu W, **Liu G**. PMCC behaviours in cancer survival group. Dietary habits and changes in dietary behaviors in adult cancer survivors in Toronto, Canada. 2013 Nov. Proc Am Inst Cancer Res Annual Meeting (November, 2013) (Poster), Bethesda, MA, USA. (Senior author supervising LSH, XS, MCB, LE). **Senior Responsible Author.**

2013 Nov PMCC behaviours in cancer survival group. Comparison of recent and remote cancer survivor-reported body size (Body Mass Index) with body-image Stunkard Figure Rating Scale SFRS). American Association for Cancer Research. Bethesda, Maryland, United States. (Trainee Presentation)

*Publication Details:*

Brown MC, Mahler M, Shen X, Eng L, Xu W, **Liu G**. PMCC behaviours in cancer survival group. Comparison of recent and remote cancer survivor-reported body size (Body Mass Index) with body-image Stunkard Figure Rating Scale SFRS). 2013 Nov. Proc Am Inst Cancer Res Annual Meeting (November, 2013) (Poster), Bethesda, MA, USA. (Senior author supervising MCM, MM, XS, LE). **Senior Responsible Author**.

2013 Nov PMCC behaviours in cancer survival group. Obesity, body image, and cancer survivorship behaviours. American Association of Cancer Research. Bethesda, Maryland, United States. (Trainee Presentation)

*Publication Details:*

Mahler M, Shen X, Brown MC, Pringle D, Xu W, **Liu G**. PMCC behaviours in cancer survival group. Obesity, body image, and cancer survivorship behaviours. 2013 Nov. Proc Am Inst Cancer Res Annual Meeting, (November, 2013) (Poster), Bethesda, MA, USA. (Senior author supervising MM, XS, DP, MCB). **Senior Responsible Author**.

2013 Nov PMCC behaviours in cancer survival group. Physical activity in cancer survivors: perceived benefits and perceived barriers. American Association of Cancer Research. Bethesda, Maryland, United States. (Trainee Presentation)

*Publication Details:*

Harland L, Brown C, Shen X, Xu W, **Liu G**, Pringle D. PMCC behaviours in cancer survival group. Physical activity in cancer survivors: perceived benefits and perceived barriers. 2013 Nov. Proc Am Inst Cancer Res Annual Meeting (November, 2013) (Poster, Bethesda, MA, USA). **Co-Investigator**.

2013 Nov Complementary and alternative medicine and other health behaviours. American Society of Clinical Oncology (ASCO). San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Graham DM, Espin-Garcia O, Brown C, Halytsky O, Mahler M, Pringle D, Eng L, Niu C, Lam C, Charow R, Villeneuve J, Shani RM, Tiessen K, Howell D, Jones JM, Alibhai SMH, Xu W, **Liu G**. Complementary and alternative medicine and other health behaviours. 2013 Nov. ASCO Quality Care Symposium. San Diego, CA. November 2013 (Poster). **Senior Responsible Author**.

2013 Oct Pan-Canadian early lung cancer study group. Factors associated with smoking cessation in participants of the Pan-Canadian Early Lung Cancer Study. World Conference on Lung Cancer. Sydney, Australia. (Trainee Presentation)

*Publication Details:*

Korpanty G, **Liu G**, Tammemagi, Lam S, Eng L, Selby P, Su S, Xu W. Pan-Canadian early lung cancer study group. Factors associated with smoking cessation in participants of the Pan-Canadian Early Lung Cancer Study. 2013 Oct. Lung Cancer (WCLC suppl): abstr (Oral) Sydney Australia, October, 2013. (Senior author supervising GK). **Co-Investigator**.

2013 Oct BRM promoter variants and survival outcomes of advanced non-small cell lung cancer (NSCLC) patients: A validation study in the NCIC Clinical Trials Group (NCIC-CTG) BR24 Clinical Trial. World Conference on Lung Cancer. Sydney, Australia. (Trainee Presentation)

*Publication Details:*

Cuffe S, Cheng L, Azad AK, Brhane Y, Cheng D, Chen Z, Qiu X, Boyd K, Leighl N, Xu W, Chen BE, Bradbury P, Shepherd FA, Seymour L, Tsao MS, Reisman DN, **Liu G**. BRM promoter variants and survival outcomes of advanced non-small cell lung cancer (NSCLC) patients: A validation study in the NCIC Clinical Trials Group (NCIC-CTG) BR24 Clinical Trial. 2013 Oct. Lung Cancer (WCLC suppl): abstr 1999 (Oral) Sydney, Australia (Senior author supervising SC). **Senior Responsible Author**.

2013 Oct The effect of two BRM promoter polymorphisms on the risk of advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in smokers' lung cancer (WCLC suppl). World Conference on Lung Cancer. Sydney, Australia. (Trainee Presentation)



*Publication Details:*

Cuffe S, Qiu X, Patel D, Azad AK, Cheng D, Chen Z, Boyd K, Leighl N, Xu W, Shepherd FA, Tsao MS, Reisman D, **Liu G**. The effect of two BRM promoter polymorphisms on the risk of advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in smokers' lung cancer (WCLC suppl). 2013 Oct. abstr 1987 (Oral) Sydney, Australia. (Senior author supervising SC). **Senior Responsible Author**.

2013 Oct The impact of body mass index on survival in stage 3 and 4 lung cancer. World Conference on Lung Cancer. Sydney, Australia. (Trainee Presentation)

*Publication Details:*

Wong KM, Cuffe S, Coate L, Espin-Garcia O, Boyd K, Feld R, Leighl N, Shepherd FA, Xu W, **Liu G**. The impact of body mass index on survival in stage 3 and 4 lung cancer. 2013 Oct. Lung Cancer (WCLC suppl): abstr 663 (Oral) Sydney, Australia, October, 2013. (Senior author supervising KMW). **Senior Responsible Author**.

2013 Oct Genetic polymorphisms of inflammatory and DNA repair pathways, radiation-related esophagitis and pneumonitis in definitive chemoradiation treated non-small cell lung cancer patients. World Conference on Lung Cancer. Sydney, Australia. (Trainee Presentation)

*Publication Details:*

Barrett K, Xu J, Woon KS, Boyd K, Cheng D, Chen Z, Bezjak A, Sun A, Cho J, Saibishkumar EP, Leighl N, Shepherd FA, Xu W, Hope A, **Liu G**. Genetic polymorphisms of inflammatory and DNA repair pathways, radiation-related esophagitis and pneumonitis in definitive chemoradiation treated non-small cell lung cancer patients. 2013 Oct. Lung Cancer (WCLC suppl): abstr 2997 (Oral) Sydney, Australia, October 2013. (Senior author supervising KB). **Senior Responsible Author**.

2013 Oct Assessment of the accuracy and reliability of health related behavioural data obtained from patient-reported surveys (PRS) compared with electronic patient records (EPR) in lung cancer patient population. World Conference on Lung Cancer. Sydney, Australia. (Trainee Presentation)

*Publication Details:*

Palepu PR, Brown C, Espin-Garcia O, Joshi G, Eng L, Ramanna J, Cuffe S, Keshavjee S, Waddell T, Darling GE, Pierre A, Yasufuku K, De Perrot M, Cypel M, Xu W, **Liu G**. Assessment of the accuracy and reliability of health related behavioural data obtained from patient-reported surveys (PRS) compared with electronic patient records (EPR) in lung cancer patient population. 2013 Oct. Lung Cancer (WCLC suppl): abstr 2948 (Poster) Sydney, Australia, October 2013. (Senior Author supervising PRP). **Senior Responsible Author**.

2013 Oct Patient-derived primary non-small cell lung cancerinoma xenograft models for mechanistic studies of resistance to EGFR tyrosine kinase inhibitor therapy. World Conference on Lung Cancer. Sydney, Australia.

*Publication Details:*

Mascaux C, Martin P, Stewart E, Panchal D, Kim L, Sakasita S, Wang D, Pham NA, Leighl N, **Liu G**, Shepherd FA, Tsao MS. Patient-derived primary non-small cell lung cancerinoma xenograft models for mechanistic studies of resistance to EGFR tyrosine kinase inhibitor therapy. 2013 Oct. Lung Cancer (WCLC suppl): abstr (Oral) Sydney, Australia, October 2013. **Co-investigator**.

2013 Jun Perceptions of benefits and harms of alcohol consumption as predictors of alcohol cessation in adult cancer survivors. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

**Liu G**, Pringle D, Espin-Garcia O, Niu C, Halytskyy O, Mahler M, Villeneuve J, Charow R, Lam C, Shani RM, Tiessen K, Brown MC, Howell D, Alibhai SMH, Xu W, Selby P, Eng L. Perceptions of benefits and harms of alcohol consumption as predictors of alcohol cessation in adult cancer survivors. 2013 Jun. American Society of Clinical Oncology Annual Meeting 2013. Chicago, IL. June 2013 (Poster). **Principal Author**.

2013 Jun Comparing elderly and non-elderly adult cancer survivors: differences in modifiable behaviours of smoking and alcohol cessation and physical activity. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Niu C, Eng L, Qiu X, Shen X, Espin-Garcia O, Pringle D, Mahler M, Halytskyy O, Charow R, Lam C, Shani RM, Villeneuve J, Tiessen K, Brown MC, Selby P, Howell D, Jones JM, Xu W, Alibhai SMH, **Liu G**. Comparing elderly and non-elderly adult cancer survivors: differences in modifiable behaviours of smoking and alcohol cessation and physical activity. 2013 Jun. ASCO Annual Meeting 2013. Chicago, IL. June 2013 (Poster). **Senior Responsible Author**.

2013 Jun Promoter polymorphisms of the SWI/SNF chromatin remodeling complex molecule, BRM, and esophageal adenocarcinoma outcome. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Korpanty G, Qiu X, Eng L, Faluyi OO, Cheng D, Renouf DJ, Knox JJ, Wong R, Darling G, Xu W, Dodbiba L, Azad AK, Reisman D, Cuffe S, **Liu G**. Promoter polymorphisms of the SWI/SNF chromatin remodeling complex molecule, BRM, and esophageal adenocarcinoma outcome. 2013 Jun. American Society of Clinical Oncology Annual Meeting 2013. Chicago, IL. June 2013 (Poster). **Senior Responsible Author**.

2013 Jun The role of social exposure to smoking on smoking cessation in adult cancer survivors. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Pringle D, Qiu X, Shen X, Niu C, Halytskyy O, Mahler M, Villeneuve J, Charow R, Lam C, Shani RM, Tiessen K, Brown MC, Howell D, Alibhai SMH, Xu W, Selby P, **Liu G**. The role of social exposure to smoking on smoking cessation in adult cancer survivors. 2013 Jun. ASCO Annual Meeting. **Senior Responsible Author**.

2013 Apr Polymorphisms in the microRNA biogenesis pathway as prognostic markers of survival in esophageal cancer patients. American Association of Cancer Research (AACR). Washington, District of Columbia, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Faluyi OO, Qiu X, Cheng D, Renouf DJ, Dodbiba L, Marsh S, Savas S, Knox JJ, Darling GE, Wong RKS, Xu W, **Liu G**, Azad AK. Polymorphisms in the microRNA biogenesis pathway as prognostic markers of survival in esophageal cancer patients. 2013 Apr. American Association of Cancer Research Annual Meeting 2013. Washington, DC. April 2013. **Senior Responsible Author**.

2013 Jan MicroRNA polymorphisms and esophageal cancer outcome. American society of Clinical Oncology: Gastrointestinal Cancers Symposium. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Faluyi OO, Eng L, Qiu X, Cheng D, Renouf DJ, Marsh S, Savas S, Knox JJ, Darling GE, Wong R, Xu W, Azad AK, **Liu G**. MicroRNA polymorphisms and esophageal cancer outcome. 2013 Jan. (January 2013), American society of Clinical Oncology: Gastrointestinal Cancers Symposium, San Francisco, CA, January 2013. **Senior Responsible Author**.

2012 Nov Use of online internet resources by patients with cancer: The Canadian experience. American Association of Clinical Oncology. San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Eng L, Pringle D, Brown MC, Shen X, Mahler M, Niu C, Villeneuve J, Charow R, Lam C, Shani RM, Alibhai SMH, Jones JM, Xu W, **Liu G**, Grover SC. Use of online internet resources by patients with cancer: The Canadian experience. 2012 Nov. American Society of Clinical Oncology: Quality Care Symposium, San Diego, CA (Senior Author supervising LE, DP, MCB, XS, MM, CN, JV, RC, CL, RMS). **Senior Responsible Author**.

- 2012 Nov      Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments. American Society of Clinical Oncology (ASCO). California, United States.
- Publication Details:*  
Eng L, Su J, Qiu X, Palepu PR, Hon H, Fadhel E, Harland L, La Delfa A, Habbous S, Kashigar A, Cuffe S, Leigh NB, Pierre A, Selby P, Goldstein DP, **Liu G**, Xu W. Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments. 2012 Nov. American Society of Clinical Oncology: Quality Care Symposium, San Diego, CA, 2012. **Senior Responsible Author.**
- 2012 Aug      Completing epidemiology questionnaires incorporated into cancer clinical trials: A patient preference analysis. International Society for Pharmacoepidemiology. Barcelona, Spain. (Trainee Presentation)
- Publication Details:*  
Hon H, Fadhel E, Ebrahim J, Eng L, La Delfa A, Harland L, Tobros K, Han D, Simmons C, Kassam Z, Xu W, **Liu G**, Cuffe S. Completing epidemiology questionnaires incorporated into cancer clinical trials: A patient preference analysis. 2012 Aug. 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012. **Senior Responsible Author.**
- 2012 Aug      Vascular endothelial growth factor (VEGF) pathway polymorphisms and esophageal cancer outcome. International Society for Pharmacoepidemiology. Barcelona, Spain. (Trainee Presentation)
- Publication Details:*  
Eng L, Azad AK, Qui X, Cheng D, Tse A, Faluyi O, Renouf DJ, Marsh S, Savas S, Knox JJ, Darling GE, Wong RKS, Xu W, **Liu G**. Vascular endothelial growth factor (VEGF) pathway polymorphisms and esophageal cancer outcome. 2012 Aug. 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain. (Oral presentation) (Senior Author supervising LE, AKA, XQ, DC, OF, DJR). **Senior Responsible Author.**
- 2012 Jun      Social environment as a predictor of smoking cessation and recidivism in lung cancer patients. American Society of Clinical Oncology. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Eng L, Su J, Palepu PR, Hon H, Fadhel E, Harland L, La Delfa A, Habbous S, Kashigar A, Cuffe S, Leigh NB, Pierre A, Goldstein DP, **Liu G**, Xu W. Social environment as a predictor of smoking cessation and recidivism in lung cancer patients. Journal of Clinical Oncology. 2012 Jun. (June 2012) American Society of Clinical Oncology Annual Meeting 2012, Chicago, IL, (Poster Discussion Session). **Senior Responsible Author.**
- 2012 Jun      Association of p53 Arg72Pro polymorphism and HPV status in the initiation, progression, and development of cervical cancer (CC): A Meta-Analysis. American Society of Clinical Oncology. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Habbous S, Pang V, Eng L, MacKay H, Amir E, **Liu G**. Association of p53 Arg72Pro polymorphism and HPV status in the initiation, progression, and development of cervical cancer (CC): A Meta-Analysis. 2012 Jun. American Society of Clinical Oncology Conference, Chicago, June 2012; (Abstr 1597) (Senior Author supervising SH, VP, LE). **Senior Responsible Author.**
- 2012 Apr      Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Hon H, Qiu X, Tobros K, Wong C-K A, De Souza B, McFarlane G, Masroor S, Azad AK, Hasani E, Issa AM, **Liu G**, Cuffe S. Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). Journal of Clinical Oncology. 2012 Apr. 2012, v30(n15)(supl) (abstr 6005) (oral presentation) (Co-Investigator supervising HH, XQ, KT, SC). **Co-Investigator.**

- 2012 Apr The effect of comorbidity, smoking and alcohol on survival of head and neck cancer anatomic subsites: A retrospective analysis of 4689 patients. American Association of Cancer Research. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Habbous S, Chu KP, Waldron J, Harland I, La Delfa A, Su S, Xu W, Hui A, Liu F-F, Goldstein D, O'Sullivan B, Huang S-H, **Liu G**. The effect of comorbidity, smoking and alcohol on survival of head and neck cancer anatomic subsites: A retrospective analysis of 4689 patients. Proc Am Assoc Cancer Res. 2012 Apr. American Association for Cancer Research, Conference, Chicago, April 2012; (abstr 666) (Senior Author supervising SH, KPC, LH, ALD). **Senior Responsible Author**.
- 2012 Apr Polymorphisms in vascular endothelial growth factor (VEGF) and associated receptors as prognostic and predictive factors in advanced solid tumors. American Association for Cancer Research. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Eng L, Amir E, Azad AK, Habbous S, Pang V, Maitland-van der Zee A-H, Savas S, MacKay H, **Liu G**. Polymorphisms in vascular endothelial growth factor (VEGF) and associated receptors as prognostic and predictive factors in advanced solid tumors. Proc Am Assoc Cancer Res. 2012 Apr. American Association for Cancer Research Conference, Chicago, April, 2012; (abstr 4505) (Poster) (Senior Author supervising LE, AKA, SH). **Senior Responsible Author**.
- 2012 Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage IV non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Azad AK, Qiu X, Cuffe S, Qiu X, Boyd K, Kuang Q, Emami M, Perera N, Palepu PR, Patel D, Chen Z, Cheng D, Feld R, Leighl NB, Shepherd FA, Tsao MS, Xu W, **Liu G**. Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2012. 2012, v30(n15)(supl), (abstr 1535) (poster discussion) (Senior Author supervising AKA, SC, KB, ME, NP, PRP, DP, XC, DC). **Senior Responsible Author**.
- 2012 Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Cuffe S, Qiu X, Azad AK, Qiu X, Boyd K, Kuang Q, marsh S, Savas S, Shepherd FA, Tsao MS, Xu W, **Liu G**. Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 2012. 2012, v30(n15)(supl), (abstr 7586) (Senior Author supervising SC, AKA, KB, SS). **Senior Responsible Author**.
- 2012 The effect of two-BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Wong KM, Qiu X, Cheng D, Azad AK, Der S, Reisman D, **Liu G**. The effect of two-BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. Journal of Clinical Oncology. 2012. 2012, v30(n15)(supl) (abstr 10522) (poster discussion) (Senior Author supervising KMW, DC, AKA). **Senior Responsible Author**.
- 2011 Aug The rise of Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer (OPC) in Toronto, Canada: A Case for Vaccinating Males. International Society for Pharmacoepidemiology. Barcelona, Spain. (Trainee Presentation)
- Publication Details:*

Habbous S, Chu KP, La Delfa A, Harland L, Qiu X, Xu W, Goldstein D, Waldron J, O'Sullivan B, Huang S-H, **Liu G**. The rise of Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer (OPC) in Toronto, Canada: A Case for Vaccinating Males. 2011 Aug. International Society for Pharmacoepidemiology, Conference, Barcelona, Spain, August 2011 (abstract #902, oral presentation #14). **Senior Responsible Author**.

- 2011 Patterns of Practice and its Effects on Outcomes for Patients with Localized Esophageal (E) and Gastroesophageal (GEJ) Cancer - a decade of practice. American Society for Radiation Oncology. Miami, Florida, United States.

*Publication Details:*

Kang S, Atenafu E, Kim J, Brierley J, Dinniwell R, Dawaon L, Cummings B, Kox J, **Liu G**, Keshavjee S, Darling G, Wong KSR. Patterns of Practice and its Effects on Outcomes for Patients with Localized Esophageal (E) and Gastroesophageal (GEJ) Cancer - a decade of practice. Cancer. ASTRO meeting, 2011; Poster. **Co-investigator**.

- 2011 Gene-environment Interactions in Esophageal Adenocarcinoma Risk: A case-only analysis. American Association of Cancer Research. Orlando, Florida, United States.

*Publication Details:*

Zhai R, Zhao Y, **Liu G**, Ter-Minassian M, Wang Z, Wu I-C, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Gene-environment Interactions in Esophageal Adenocarcinoma Risk: A case-only analysis. Proc am Assoc Cancer Res. 2011. 2011, Abstract 3742, Orlando; Poster. **Co-investigator**.

- 2011 Nicotinic Acetylcholine Receptor SNPs are Associated with Smoking Cessation. Orlando, Florida, United States. (Trainee Presentation)

*Publication Details:*

Asomaning K, Heist R, Zhai R, Sheu C-C, Chen F, **Liu G**, Su L, Lin X, De Vivo I, Christiani DC. Nicotinic Acetylcholine Receptor SNPs are Associated with Smoking Cessation. Proc Am Assoc Cancer Res. 2011. 2011, Abstract 2760, Orlando; Poster (Co-Investigator supervising KA). **Co-investigator**.

- 2011 Association of the MDM2 T309G Polymorphism and Gastroesophageal Reflux Disease (GERD) with Overall Survival (OS) in Esophageal Adenocarcinoma (EAC). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Renouf DJ, Sun B, Zhai R, Xu W, Heist RS, Kulke MH, Su L, Christiani DC, **Liu G**. Association of the MDM2 T309G Polymorphism and Gastroesophageal Reflux Disease (GERD) with Overall Survival (OS) in Esophageal Adenocarcinoma (EAC). J Clin Oncol. 2011. 29; 2011; (suppl; abstract 10595), Chicago; Poster (Senior Author supervising DJR). **Senior Responsible Author**.

- 2011 Factors Influencing a Specific Histologic Diagnosis of Non-Small Cell Lung Cancer. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Sulpher JA, Owen SP, Hon H, Tobros K, Shepherd FA, Sabri E, **Liu G**, Canil CM, Wheatley-Price P. Factors Influencing a Specific Histologic Diagnosis of Non-Small Cell Lung Cancer. J Clin Oncol. 2011. 29; 2011 (suppl; abstract 7541), Chicago; Poster. **Co-investigator**.

- 2011 Early Adulthood Obesity, Cumulative Smoking, and Esophageal Cancer Survival. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Coate LE, Zhai R, Xu W, Chen Z, Asomanic K, Kulke M, Heist RS, Christiani D, **Liu G**. Early Adulthood Obesity, Cumulative Smoking, and Esophageal Cancer Survival. J Clin Oncol. 2011. 29; 2011, (suppl; abstract 1546); Chicago; Poster (Senior Author supervising LEC). **Senior Responsible Author**.

- 2011 Adjuvant Sunitinib (Su) for Locally Advanced Esophageal Cancer (LAEC): Results of a Phase II Trial. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Knox JJ, Wong R, Darling GE, Lister J, Gjuindi M, **Liu G**, Xu W, Kim JJ, Jonker DJ, Wells J, Kendal W, MacKay H, Visbal A, Dinniwell RE, Pierre A, Feld R, Sundaresan S, Bayley A, Shargall Y, Horgan AM. Adjuvant Sunitinib (Su) for Locally Advanced Esophageal Cancer (LAEC): Results of a Phase II Trial. J Clin Oncol. 2011. 29: 2011; (suppl; abstract 4091); Chicago; Poster. **Co-investigator**.
- 2011 Genetic Sequence Variants (GSV) in Relation to Acute and Late Toxicities in Head and Neck Cancer (HNC) Patients Treated with Radiation Therapy (RT). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.
- Publication Details:*  
Meyer F, Bairati I, Xu W, Azad AK, **Liu G**. Genetic Sequence Variants (GSV) in Relation to Acute and Late Toxicities in Head and Neck Cancer (HNC) Patients Treated with Radiation Therapy (RT). J Clin Oncol. 2011. 29: 2011; (suppl; abstract 5507); Chicago; Poster. **Senior Responsible Author**.
- 2011 Systemic Therapy Usage and outcomes for Patients Diagnosed with malignant Pleural Mesothelioma (MPM) Between 2005 and 2010 in Ontario, Canada. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Hasani A, Sun B, **Liu G**, Xu W, Feld R, Leighl NB. Systemic Therapy Usage and outcomes for Patients Diagnosed with malignant Pleural Mesothelioma (MPM) Between 2005 and 2010 in Ontario, Canada. J Clin Oncol. 2011; (suppl; abstract 7085); Chicago; Poster (Co-Investigator supervising AH). **Co-investigator**.
- 2011 Comparing Epidemiologic Survey Data to Abstracted Data From A Head and Neck Cancer (HNC) Radiation Oncology Administrative Database. Miami, Florida, United States.
- Publication Details:*  
Habbous S, Chu KP, Hui HS, Xu W, Cheng L, Tse A, Goldstein DP, Waldron J, O'Sullivan B, **Liu G**. Comparing Epidemiologic Survey Data to Abstracted Data From A Head and Neck Cancer (HNC) Radiation Oncology Administrative Database. International Journal of Radiation Oncology Biology Physics. 2011. 81:2: 2011; (supplement, pages S501-S502); Miami; Poster (Senior Author supervising SH). **Senior Responsible Author**.
- 2011 Degree of Tumor Shrinkage Following Neoadjuvant Chemoradiotherapy- a Potential Predictor for Complete Pathological Response in Esophageal Cancer? Miami, Florida, United States.
- Publication Details:*  
Voncken F, Xu W, Kim J, Guindi M, Brierley J, Cummings B, Knox J, **Liu G**, Darling G, Wong RKS. Degree of Tumor Shrinkage Following Neoadjuvant Chemoradiotherapy- a Potential Predictor for Complete Pathological Response in Esophageal Cancer? International Journal of Radiation Oncology Biology Physics. 81:2: 2011; (supplement, pages S314-S315); Miami; Poster. **Co-investigator**.
- 2011 Epidemiological Changes of Oropharyngeal Cancer and other Head and Neck Squamous Cell Carcinomas Treated from 2003-2010. Miami, Florida, United States. (Trainee Presentation)
- Publication Details:*  
Chu KP, Habbous S, Huang S, Cheng L, Xu W, **Liu G**, Hope A, Liu F, Waldron J, O'Sullivan B. Epidemiological Changes of Oropharyngeal Cancer and other Head and Neck Squamous Cell Carcinomas Treated from 2003-2010. International Journal of Radiation Oncology Biology Physics. 2011. 81:2: 2011; (supplement, page S18); Miami; Oral (Co-Investigator supervising KPC, SH). **Co-investigator**.
- 2011 Evaluation of Smoking Status in Development of Radiation Pneumonitis (RP) in Non Small Cell Lung

Cancer (NSCLC) Patients Treated with Radical Radiotherapy. Miami, Florida, United States.

*Publication Details:*

Kim S, Cheng L, Lindsay PE, Azad A, Xu W, **Liu G**, Hope A. Evaluation of Smoking Status in Development of Radiation Pneumonitis (RP) in Non Small Cell Lung Cancer (NSCLC) Patients Treated with Radical Radiotherapy. International Journal of Radiation Biology Physics. 2011. 81:2: 2011; (supplement,pages S608-S609); Miami; Poster (Co-Investigator supervising AA). **Co-investigator**.

2011 Impact of Socioeconomic Status (SES) on Head and Neck Cancer (HNC) Survival in an Equal Access Health Care System. Miami, Florida, United States. (Trainee Presentation)

*Publication Details:*

Chu KP, Habbous S, Huang S, Cheng L, Hope A, Xu W, O'Sullivan B, Waldron J, Chang ET, **Liu G**. Impact of Socioeconomic Status (SES) on Head and Neck Cancer (HNC) Survival in an Equal Access Health Care System. International Journal of Radiation Oncology Biology Physics. 81:2: 2011; (supplement, pages S107-S108); Miami; Oral (Senior Author supervising KPC, SH, LC). **Senior Responsible Author**.

2011 Patient Attitudes Toward Receiving Chemotherapy and Pharmacogenetic Testing in Curative and Palliative Cancer Patients. Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Cuffe S, Hon H, Tobros K, Wong CKA, De Souza B, McFarlane G, Masroor S, Hasani E, Sun B, Di Tommaso N, Xu W, Leighl N, Alibhai S, Issa A, **Liu G**. Patient Attitudes Toward Receiving Chemotherapy and Pharmacogenetic Testing in Curative and Palliative Cancer Patients. 2011. Proc International Conference Pharmacoept 2011; (abstract 754); Chicago; Poster (Senior Author supervising SC, HH, KT). **Senior Responsible Author**.

2010 May 14 EGFR and ABCG2 Polymorphisms as Prognostic and Predictive Markers in the NCIC CTG BR.21 Trial of Single-Agent Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC). American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

**Liu G**, Cheng D, Le Maitre A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao MS. EGFR and ABCG2 Polymorphisms as Prognostic and Predictive Markers in the NCIC CTG BR.21 Trial of Single-Agent Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC). 2010 May. AACR 101st Annual Meeting, J Clin Oncol 28:15s, 2010 (suppl; abstract 7538). **Principal Author**.

2010 Apr Two Novel Insertion Polymorphisms of the BRM Gene are Associated with Loss of BRM Expression and Lung Cancer Risk. American Association of Cancer Research. Washington, District of Columbia, United States.

*Publication Details:*

Rogers C, **Liu G**, Munoz D, Cheng D, Kalam AK, Mirshams M, Chen Z, Xu W, Roberts H, Shepherd FA, Tsao MS, Reisman D. Two Novel Insertion Polymorphisms of the BRM Gene are Associated with Loss of BRM Expression and Lung Cancer Risk. 2010 Apr. AACR 101st Annual Meeting, 2010: 198 (Abstr) Poster. **Co-Investigator**.

2010 Apr Nicotinic Acetylcholine Receptor Polymorphisms, Secondhand Smoke and Lung Cancer Risk. American Association of Cancer Research. Washington, District of Columbia, United States.

*Publication Details:*

Asomaning K, Zhai R, Sheu C-C, Heist R, Chen F, **Liu G**, Su L, Lin X, Christiani DC. Nicotinic Acetylcholine Receptor Polymorphisms, Secondhand Smoke and Lung Cancer Risk. 2010 Apr. AACR 101st Annual Meeting, 2010: 937 (Abstr), Washington, DC. **Co-Investigator**.

2010 Single Nucleotide Polymorphisms (SNPs) in the Matrix Metalloproteinase (MMP) Gene Family, Gastroesophageal Reflux Disease (GERD), and Risk of Esophageal Adenocarcinoma (EAC). Brighton,

United Kingdom. (Trainee Presentation)

*Publication Details:*

Cheung WY, Zhai R, Kulke M, Heist R, Asomaning K, Ma C, Wang Z, Su L, **Liu G**, Christiani D. Single Nucleotide Polymorphisms (SNPs) in the Matrix Metalloproteinase (MMP) Gene Family, Gastroesophageal Reflux Disease (GERD), and Risk of Esophageal Adenocarcinoma (EAC). 2010. Pharmacoepidemiol Drug Safety 2010; 19: Abstract 261, Brighton, UK (Co-Investigator supervising WYC). **Co-Investigator**.

- 2010 Genetic Polymorphisms and the Development of Secondary Primary Cancers (SPC) in Patients with Head and Neck Cancer (HNC). Brighton, United Kingdom. (Trainee Presentation)

*Publication Details:*

Azad AK, Cheng D, Xu W, Samson E, Mirshams M, Savas S, Chen Z, Waldron J, **Liu G**, Meyer F, Bairati I. Genetic Polymorphisms and the Development of Secondary Primary Cancers (SPC) in Patients with Head and Neck Cancer (HNC). 2010. Pharmacoepidemiol Drug Safety 2010; 19: Abstract 297, Brighton, UK (Co-Investigator supervising AKA). **Co-Investigator**.

- 2010 Early-Adulthood Obesity [EOB] Modifies the Cisplatin [C]-DNA Repair Gene Polymorphism XPD ASP312ASN [X] Relationship in Esophageal Cancer (EC) Survival: A Combined Pharmacogenetic-Molecular Epidemiologic Analysis. Brighton, United Kingdom. (Trainee Presentation)

*Publication Details:*

Renouf D, Coate L, Zhai R, Kulke M, Heist RS, Bradbury P, Xu W, Chen Z, Asomaning K, Wain J, Su L, **Liu G**, Christiani DC. Early-Adulthood Obesity [EOB] Modifies the Cisplatin [C]-DNA Repair Gene Polymorphism XPD ASP312ASN [X] Relationship in Esophageal Cancer (EC) Survival: A Combined Pharmacogenetic-Molecular Epidemiologic Analysis. 2010. Pharmacoepidemiol Drug Safety 2010; 19: Abstract 485. Brighton, UK (Co-Investigator supervising DR). **Co-Investigator**.

- 2010 Prognostic Role of Genetic Polymorphisms in Head and Neck Cancer (HNC) Survival. Brighton, United Kingdom. (Trainee Presentation)

*Publication Details:*

Azad AK, **Liu G**, Xu W, Cheng D, Samson E, Mirshams M, Chen Z, Savas S, Waldron J, Bairati I, Meyer F. Prognostic Role of Genetic Polymorphisms in Head and Neck Cancer (HNC) Survival. 2010. Pharmacoepidemiol Drug Safety 2010; 19: Abstract 487. Brighton, UK (Co-Investigator supervising AKA). **Co-Investigator**.

- 2010 Genetic Polymorphisms as Prognostic/Predictive Biomarkers of Single-Agent Erlotinib Therapy in NCIC-CTG BR.21 Non-Small Cell Lung Cancer (NSCLC) Trial. Brighton, United Kingdom.

*Publication Details:*

**Liu G**, Cheng D, Le Maitre A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao MS. Genetic Polymorphisms as Prognostic/Predictive Biomarkers of Single-Agent Erlotinib Therapy in NCIC-CTG BR.21 Non-Small Cell Lung Cancer (NSCLC) Trial. 2010. Pharmacoepidemiol Drug Safety 2010; 19: Abstract 489. **Principal Author**.

- 2010 The Interaction Between Smoking Status and Disease Stage on Non-small Cell Lung Cancer (NSCLC) Survival. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States.

*Publication Details:*

Horgan AM, Wang YV, Shepherd FA, Brenner D, Knox JJ, McLaughlin J, **Liu G**, Hung RJ. The Interaction Between Smoking Status and Disease Stage on Non-small Cell Lung Cancer (NSCLC) Survival. J Clin Oncol 28, 2010 (suppl; abstr e18021). **Co-Investigator**.

- 2010 Comprehensive Geriatric Assessment (CGA) in Treatment Decisions in Elderly Patients (pts) with Gastrointestinal (GI) Cancer. American Society of Clinical Oncology. Orlando, Florida, United States. Presenter(s): AM Horgan. (Trainee Presentation)



*Publication Details:*

Horgan AM, Knox JJ, Palepu P, **Liu G**, Leighl NB, Alibhai SM. Comprehensive Geriatric Assessment (CGA) in Treatment Decisions in Elderly Patients (pts) with Gastrointestinal (GI) Cancer. 2010. Proc Am Soc Clin Oncol, Gastrointestinal Cancers Symposium 2010; 120 (abstr) (Co-Investigator supervising AMH). **Co-Investigator**.

- 2010 Single Nucleotide Polymorphisms (SNPs) in the Matrix Metalloproteinase (MMP) Gene Family, Gastroesophageal Reflux disease (GERD), and Risk of Esophageal Adenocarcinoma (EAC). Orlando, Florida, United States. (Trainee Presentation)

*Publication Details:*

Cheung WY, Zhai R, Kulke M, Heist RS, Asomaning K, Ma C, Wang Z, Su L, **Liu G**, Christiani DC. Single Nucleotide Polymorphisms (SNPs) in the Matrix Metalloproteinase (MMP) Gene Family, Gastroesophageal Reflux disease (GERD), and Risk of Esophageal Adenocarcinoma (EAC). 2010. Proc Am Soc Clin Oncol, Gastrointestinal Cancers Symposium 2010; 8 (abstr) (Co-Investigator supervising WYC, KA). **Co-Investigator**.

- 2010 Adjuvant Sunitinib Following Trimodality Therapy for Locally Advanced Esophageal Cancer (LAEC). Orlando, Florida, United States.

*Publication Details:*

Horgan AM, Hornby J, Wong R, Darling GE, **Liu G**, Jonker DJ, Visbal A, Guindi M, Hendler A, Knox JJ. Adjuvant Sunitinib Following Trimodality Therapy for Locally Advanced Esophageal Cancer (LAEC). Proc Am Soc Clin Oncol, Gastrointestinal Cancers Symposium 2010: 105 (Abstr). **Co-Investigator**.

- 2010 Interactions Between Variants of Angiogenesis Pathway Genes and Reflux Symptom, BMI, and Smoking in Esophageal Adenocarcinoma Susceptibility. American Association of Cancer Research. Washington, District of Columbia, United States.

*Publication Details:*

Zhai R, Chen F, Liu G, Ter-Minassian M, Su L, Asomaning K, Wang Z, Kulke MH, Lin X, Heist RS, Sheu C-C, Wain JC, Hooshmand SH, Nishioka NS, Christiani DC. Interactions Between Variants of Angiogenesis Pathway Genes and Reflux Symptom, BMI, and Smoking in Esophageal Adenocarcinoma Susceptibility. 2010. AACR 101st Annual Meeting, Proc Am Assoc Cancer Res, 2010: 51 (Abstr) 4739. **Co-Investigator**.

- 2010 Assessing the Relationship between Radiotherapy Dosimetric Characteristics and Post-operative Pulmonary Complications in Trimodality Esophageal Cancer Therapy. San Diego, California, United States.

*Publication Details:*

Shorthouse AA, Kim KH, Brierley J, Ringash J, Knox JJ, **Liu G**, Darling GE, Cummings BJ, Xu W, Wong RKS. Assessing the Relationship between Radiotherapy Dosimetric Characteristics and Post-operative Pulmonary Complications in Trimodality Esophageal Cancer Therapy. International Journal of Radiation Oncology Biology Physics. 78:3 (Supplement, Pages S296-S297) 2010; San Diego Poster. **Co-investigator**.

- 2009 EGF gene polymorphisms, gastroesophageal reflux disease and risk of esophageal adenocarcinoma. San Francisco, California, United States. (Trainee Presentation)

*Publication Details:*

Cheung WY, Zhai R, Kulke M, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Christiani DC, **Liu G**. EGF gene polymorphisms, gastroesophageal reflux disease and risk of esophageal adenocarcinoma. Proc Am Soc Clin Oncol GI Cancers Symposium; 2 (abstr). 2009. San Francisco (Oral). Won American Society of Clinical Oncology (ASCO) merit award for first author. (Senior Author supervising WYC). **Senior Responsible Author**.

- 2009 Nicotinic acetylcholine receptor polymorphisms, smoking and lung cancer risk. Denver, Colorado, United States. (Trainee Presentation)
- Publication Details:*  
Asomaning K, Zhai R, Heist RS, **Liu G**, Wain JC, Lynch TJ, Su L, Lin X, Christiani DC. Nicotinic acetylcholine receptor polymorphisms, smoking and lung cancer risk. Proc Am Assoc Clin Res 2009; 50: 105 (abstr). Denver (Poster). (Co-Investigator supervising KA). **Co-investigator**.
- 2009 Outcome prediction based on genetic polymorphisms (GPs) in epidermal growth factor (EGF) pathway in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). Denver, Colorado, United States.
- Publication Details:*  
Yoon HH, Powell M, Gibson MK, Montgomery EA, Hafez MJ, Catalano P, **Liu G**, Skaar TC, Dolan ME, Wu X, Diasio RB, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Outcome prediction based on genetic polymorphisms (GPs) in epidermal growth factor (EGF) pathway in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). Proc Am Assoc Clin Res 2009; 50: 1621 (abstr). Denver (Poster). **Co-investigator**.
- 2009 Genetic susceptibility to esophageal adenocarcinoma. Denver, Colorado, United States.
- Publication Details:*  
Ter-Minassian M, Wang Z, Asomaning K, Wu M, Liu CY, Su L, Lin X, **Liu G**, Christiani DC. Genetic susceptibility to esophageal adenocarcinoma. Proc Am Assoc Clin Res 2009; 50: 2106 (abstr). Denver (Poster). **Co-investigator**.
- 2009 Interactions among BMI, smoking, and genetic variants of apoptosis pathway genes in esophageal adenocarcinoma risk. Denver, Colorado, United States.
- Publication Details:*  
Zhai R, Chen F, **Liu G**, Su L, Asomaning K, Lynch TJ, Wain JC, Christiani DC. Interactions among BMI, smoking, and genetic variants of apoptosis pathway genes in esophageal adenocarcinoma risk. Proc Am Assoc Clin Res 2009; 50: 2107 (abstr). Denver (Poster). **Co-investigator**.
- 2009 Nicotinic acetylcholine receptor polymorphisms and survival in early stage non-small cell lung cancer. Denver, Colorado, United States.
- Publication Details:*  
Heist RS, Zhai R, Asomaning K, Wang Z, **Liu G**, Su L, Neuberg D, Lynch TJ, Wain JC, Christiani DC. Nicotinic acetylcholine receptor polymorphisms and survival in early stage non-small cell lung cancer. Proc Am Assoc Clin Res 2009; 50: 4841 (abstr). Denver (Poster). **Co-investigator**.
- 2009 Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk. Miami, Florida, United States. (Trainee Presentation)
- Publication Details:*  
Cheung WY, Zhai R, Kulke M, Heist R, Asomaning K, Ma C, Wang Z, Su L, Christiani DC, **Liu G**. Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk. J Clin Oncol 27: 15s, 2009 (suppl; abstr 11029). Miami (Oral). (Senior Author supervising WYC). **Senior Responsible Author**.
- 2009 Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). Miami, Florida, United States.

*Publication Details:*

H.H. Yoon, M. Powell, K. Murphy, E. A. Montgomery, M. J. Hafez, **G. Liu**, A. A. Forastiere, A. B. Benson, L. R. Kleinberg, M. K. Gibson. Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 27: 15s, 2009 (suppl; abstr 4530). Miami (Oral). **Co-investigator**.

- 2009 Mesothelin as a marker of response in malignant pleural mesothelioma. Orlando, Florida, United States. (Trainee Presentation)

*Publication Details:*

Wheatley-Price P, Yang B, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho B, De Perrot M, **Liu G**. Mesothelin as a marker of response in malignant pleural mesothelioma. 2009. J Clin Oncol 27: 15s, 2009 (suppl; abstr 7581). Orlando (Poster). (Senior Author Supervising PWP). **Senior Responsible Author**.

- 2009 Chemoradiation in older patients with stage III non-small cell lung cancer. San Francisco, California, United States.

*Publication Details:*

Ng, A. Sun, L. Coate, C. Ma, A. Bezjak, A. Brade, R.L. Burkes, J. Cho, R. Feld, **G Liu**, F. Shepherd, N.B. Leighl. Chemoradiation in older patients with stage III non-small cell lung cancer. Proc Int Assoc Study Lung Cancer; 2009: Abstr P3.026. San Francisco (Poster). **Co-investigator**.

- 2009 The Pan-Canadian Early Detection Of Lung Cancer Study. San Francisco, California, United States.

*Publication Details:*

S. Lam, M.S. Tsao, M. Tammemagi, J. Mayo, H. Roberts, A. McWilliams, A. Tremblay, S. Puksa, S. Martel, M. Johnston, G. Nicholas, S. Peacock, D. Sin, **G. Liu**, J. Goffin, B. Evans, P. Burrowes, L. Stewart, K. Yasufuku, K. Soghrati, J. Seely, D. Manos, M. Gingras, K. Amjadi, N. Leighl, A. Gazdar, F. Shepherd. The Pan-Canadian Early Detection Of Lung Cancer Study. Proc Int Assoc Study Lung Cancer, 2009: Abstr D1.1. San Francisco (Oral). **Co-investigator**.

- 2008 p53, MDM2, and CCND1 polymorphisms in esophageal cancer prognosis. Chicago, Illinois, United States. (Trainee Presentation)

*Publication Details:*

Cescon DW, Bradbury PA, Asomaning K, Zhai R, Hopkins J, Kulke MH, Su L, Heist RS, Wain JC, Lynch TJ, Christiani DC, **Liu G**. p53, MDM2, and CCND1 polymorphisms in esophageal cancer prognosis. Proc Am Soc Clin Oncol, 2008; 11033 (abstr). Chicago (Poster Discussion). Won American Society of Clinical Oncology (ASCO) merit award for first author. Won Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.) award for first author. (Senior Author supervising DWC). **Senior Responsible Author**.

- 2008 P53 Codon Arg72Pro, MDM2 T309G and CCND1 G870A Polymorphisms are not Associated with Susceptibility to Esophageal Adenocarcinoma. San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Cescon DW, **Liu G**, Zhai R, Zhou W, Pintilie M, Su L, Asomaning K, Wain JC, Lynch TJ, Christiani DC. P53 Codon Arg72Pro, MDM2 T309G and CCND1 G870A Polymorphisms are not Associated with Susceptibility to Esophageal Adenocarcinoma. Proc Am Assoc Cancer Res 2008; 49: 3915 (abstr). San Diego (Poster). Won American Association of Cancer Research (AACR) Clinical Scholars Award for first author. (Co-Principal Author supervising DWC). **Co-Principal Author**.

- 2008 Polymorphisms of the NER Pathway Genes, ERCC1 and XPD Are Associated With Esophageal Adenocarcinoma Risk. San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Tse D; **Liu G**; Zhai R; Zhou W; Heist RS; Asomaning K; Su L; Lynch TJ; Wain JC; Christiani DC. Polymorphisms of the NER Pathway Genes, ERCC1 and XPD Are Associated With Esophageal Adenocarcinoma Risk. Proc Am Assoc Cancer Res, 2008; 49: 1878 (abstr). San Diego (Poster). (Co-Investigator supervising DT). **Co-investigator**.

2008 MECPAT: A critical appraisal tool for assessing molecular epidemiologic studies of cancer prognosis. San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price, Waldron J, Goldstein D, Meyer F, Bairati I, **Liu G**. MECPAT: A critical appraisal tool for assessing molecular epidemiologic studies of cancer prognosis. Proc Am Assoc Cancer Res, 2008; 49: 3866 (abstr). San Diego (Poster). (Senior Author supervising JH). **Senior Responsible Author**.

2008 A functional EGF polymorphism, EGF serum levels and esophageal adenocarcinoma risk and outcome. San Diego, California, United States.

*Publication Details:*

Lanuti M, **Liu G**, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, Su L, Nishioka NS, Tanabe KK, Christiani DC. A functional EGF polymorphism, EGF serum levels and esophageal adenocarcinoma risk and outcome. Proc Am Assoc Cancer Res 2008; 49: 3911 (abstr). San Diego (Poster). **Co-Investigator**.

2008 Polymorphisms of signal transduction pathway and esophageal cancer prognosis. San Diego, California, United States. (Trainee Presentation)

*Publication Details:*

Asomaning K, Zhai R, Bradbury P, Heist RS, Wain JC, Lynch TJ, Su L, Lin X, Christiani DC, **Liu G**. Polymorphisms of signal transduction pathway and esophageal cancer prognosis. Proc Am Assoc Cancer Res 2008; 49: 3872 (abstr). San Diego (Poster). (Senior Author supervising KA). **Senior Responsible Author**.

2008 Polymorphism in TP53-binding protein 1 (TP53BP1) and survival in early stage lung cancer. San Diego, California, United States.

*Publication Details:*

Heist RS, Asomaning K, Zhai R, Zhou W, **Liu G**, Su L, Lin X, Wain JC, Lynch TJ, Christiani DC. Polymorphism in TP53-binding protein 1 (TP53BP1) and survival in early stage lung cancer. Proc Am Assoc Cancer Res 2008; 49: 3873 (abstr). San Diego (Poster). **Co-investigator**.

2008 Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure in esophageal adenocarcinoma. San Diego, California, United States.

*Publication Details:*

Zhai R, **Liu G**, Su L, Lynch TJ, Wain JC, Asomaning K, Lin X, Christiani DC. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure in esophageal adenocarcinoma. Proc Am Assoc Cancer Res 2008; 49: 5818 (abstr) San Diego (Poster). **Co-investigator**.

2008 Serum prognostic markers in head and neck cancers. Chicago, Illinois, United States.

*Publication Details:*

Meyer F, Samson E, Douville P, Duchesne T, **Liu G**, Bairati I. Serum prognostic markers in head and neck cancers. Proc Am Soc Clin Oncol, 2008; 27 (abstr). Chicago (Poster). **Co-investigator**.

2007 DNA repair polymorphisms and overall survival in early stage NSCLC. Los Angeles, California, United States.

*Publication Details:*

Heist RS, Zhou W, **Liu G**, Asomaning K, Su L, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. DNA repair polymorphisms and overall survival in early stage NSCLC. Proc Am Assoc Cancer Res 2007; 48:

142 (abstr). Los Angeles (Poster). **Co-investigator**.

2007 MDM2 Promoter Polymorphism and Pancreatic Cancer Prognosis. Los Angeles, California, United States. (Trainee Presentation)

*Publication Details:*

Asomaning K, Reid AE, Zhou W, Heist RS, Su L, Kwak EL, Zhu AX, Ryan DP, Christiani DC, **Liu G**. MDM2 Promoter Polymorphism and Pancreatic Cancer Prognosis. Proc Am Assoc Cancer Res 2007; 48: 3406 (abstr). Los Angeles (Poster). (Senior Author Supervising KA). **Senior Responsible Author**.

2007 Comparison of Internet tools for SNP selection applied to a molecular epidemiological study of non-small cell lung cancer. Los Angeles, California, United States.

*Publication Details:*

Ter-Minassian M, Zhou W, **Liu G**, Bradbury P, Wang Z, Kulke MH, Christiani DC. Comparison of Internet tools for SNP selection applied to a molecular epidemiological study of non-small cell lung cancer. Proc Am Assoc Cancer Res 2007; 48: 44 (abstr). Los Angeles (Poster). **Co-investigator**.

2007 Second hand smoke, age of exposure and lung cancer risk. Los Angeles, California, United States. (Trainee Presentation)

*Publication Details:*

Asomaning K, Miller DP, **Liu G**, Wain JC, Lynch TJ, Su L, Christiani DC. Second hand smoke, age of exposure and lung cancer risk. Proc Am Assoc Cancer Res 2007; 48: 67 (abstr). Los Angeles (Poster). (Supervising KA). **Co-investigator**.

2007 Serum 25(OH)D levels and vitamin D receptor polymorphism in NSCLC survival. Los Angeles, California, United States.

*Publication Details:*

Zhou W, Heist RS, **Liu G**, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Su L, Giovannucci E, Christiani DC. Serum 25(OH)D levels and vitamin D receptor polymorphism in NSCLC survival. Proc Am Assoc Cancer Res 2007; 48: 3403 (abstr). Los Angeles (Poster). **Co-investigator**.

2007 VEGF haplotypes, Gender, and the Risk of Lung Cancer. Los Angeles, California, United States.

*Publication Details:*

Zhai R, **Liu G**, Zhou W, Su L, Lin X, Asomaning K, Wain JC, Lynch TJ, Christiani DC. VEGF haplotypes, Gender, and the Risk of Lung Cancer. Proc Am Assoc Cancer Res 2007; 48: LB-129 (abstr) Los Angeles (Poster). **Co-investigator**.

2007 MMP polymorphisms and progression-free survival in locally advanced and metastatic pancreatic cancer patients. Los Angeles, California, United States.

*Publication Details:*

Asomaning K, Reid AE, Zhou W, Heist RS, Su, L, Blaszkowsky LS, Zhu AX, Ryan DP, Christiani DC, **Liu G**. MMP polymorphisms and progression-free survival in locally advanced and metastatic pancreatic cancer patients. Proc Am Assoc Cancer Res 2007; 48: 137 (abstr). Los Angeles (Poster). **Senior Responsible Author**.

2007 Matrix metalloproteinase 2 (MMP2) polymorphism, Helicobacter pylori (HP) infection and esophageal adenocarcinoma (EA) risk. Chicago, Illinois, United States.

*Publication Details:*

Zhou W, Fruh M, Zhai R, Su L, Heist RS, Wain JC, Lynch TJ, Shepherd FA, Christiani DC, **Liu G**. Matrix metalloproteinase 2 (MMP2) polymorphism, Helicobacter pylori (HP) infection and esophageal adenocarcinoma (EA) risk. Proc Am Soc Clin Oncol 2007; 25: 10553 (abstr). Chicago (Poster). **Senior Responsible Author**.

- 2007 Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Bradbury PA, Marshall AL, Kulke MH, Zhou W, Heist RS, Su L, Lynch TJ, Shepherd FA, Christiani DC, **Liu G**. Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer. Proc Am Soc Clin Oncol 2007; 25: 2511 (abstr). Chicago (Poster Discussion). Won American Society of Clinical Oncology (ASCO) merit award for first author. Won Novartis Oncology Young Canadian Investigator Award (N.O.Y.C.I.A.) award for first author. (Senior Author supervising PAB). **Senior Responsible Author**.
- 2007 MMP1 1G/2G promoter polymorphism and risk of esophageal adenocarcinoma. Chicago, Illinois, United States. (Trainee Presentation)
- Publication Details:*  
Singh S, Asomaning K, Kulke MH, Zhou W, Zhai R, Su L, Heist RS, Lynch TJ, Christiani DC, **Liu G**. MMP1 1G/2G promoter polymorphism and risk of esophageal adenocarcinoma. 2007. Proc Am Soc Clin Oncol 2007; 25: 10555 (abstr). Chicago (Poster). (Senior Author supervising SS). **Senior Responsible Author**.
- 2007 Stage and histology influence the relationship between the MDM2 promoter polymorphism and esophageal cancer overall survival (OS). Chicago, Illinois, United States.
- Publication Details:*  
Mackay H, Bradbury P, Asomaning K, Zhou W, Kulke MH, Su L, Heist RS, Lynch TJ, Christiani DC, **Liu G**. Stage and histology influence the relationship between the MDM2 promoter polymorphism and esophageal cancer overall survival (OS). Proc Am Soc Clin Oncol 2007; 25: 21047 (abstr) Chicago. **Senior Responsible Author**.
- 2007 The Anthology of Outcomes: Audit of Outcomes Data Quality in a Prospective Point-of-care Database for Head and Neck Cancer Patients. Phoenix, Arizona, United States.
- Publication Details:*  
Ringash J, Huang S, Lockwood G, Bayley AJ, Cummings B, Dawson LA, Kim J, Waldron J, **Liu G**, O'Sullivan B. The Anthology of Outcomes: Audit of Outcomes Data Quality in a Prospective Point-of-care Database for Head and Neck Cancer Patients. Proc ASTRO-ASCO Multidiscip Head Neck Cancer Symposium 2007; 109 (abstr). Phoenix (Poster). **Co-investigator**.
- 2006 Treatment outcomes of Advanced Esophageal Cancer Patients and Polymorphisms of Nucleotide and Base Excision Repair Pathway Genes. Washington, District of Columbia, United States.
- Publication Details:*  
**Liu G**, Marshall A, Zhou W, Wain JC, Lynch TJ, Suk R, Asomaning K, Su L, Christiani DC. Treatment outcomes of Advanced Esophageal Cancer Patients and Polymorphisms of Nucleotide and Base Excision Repair Pathway Genes. Proc Am Assoc Cancer Res 2006; 47: 5665 (abstr). Washington DC (Poster). **Principal Author**.
- 2006 MTHFR polymorphisms and the risk of lung cancer. Washington, District of Columbia, United States.
- Publication Details:*  
Ter-Minassian M, Zhou W, Asomaning K, Su L, Wain JC, Lynch TJ, **Liu G**, Lin X, Christiani DC. MTHFR polymorphisms and the risk of lung cancer. Proc Am Assoc Cancer Res 2006; 47: 443 (abstr). Washington DC (Poster). **Co-investigator**.
- 2006 Polymorphisms of vitamin D receptor and survival in early stage non-small cell lung cancer patients. Washington, District of Columbia, United States.
- Publication Details:*

Zhou W, Suk R, **Liu G**, Neuberger D, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Polymorphisms of vitamin D receptor and survival in early stage non-small cell lung cancer patients. Proc Am Assoc Cancer Res 2006; 46: 1191 (abstr). Washington DC (Poster). **Co-investigator**.

2006 Second hand smoke exposure and survival in early stage non-small cell lung cancer patients. Washington, District of Columbia, United States.

*Publication Details:*

Zhou W, Heist R, **Liu G**, Miller DP, Neuberger DS, Asomaning K, Wain JC, Lyunch TJ, Christiani DC. Second hand smoke exposure and survival in early stage non-small cell lung cancer patients. Proc Am Assoc Cancer Res 2006; 46: LB345 (abstr). Washington DC (Poster). **Co-investigator**.

2006 MMP-1, -3, and -12 polymorphisms and haplotypes and survival outcomes in Stage I adenocarcinoma of the lung. Washington, District of Columbia, United States.

*Publication Details:*

Heist R, Marshall A, **Liu G**, Chiu D, Zhou W, Neuberger D, Su L, Lynch TJ, Wain JC, Christiani DC. MMP-1, -3, and -12 polymorphisms and haplotypes and survival outcomes in Stage I adenocarcinoma of the lung. Proc Am Assoc Cancer Res 2006; 46: 4529 (abstr). Washington DC (Poster). **Co-investigator**.

2006 MDM2 polymorphism and recurrence-free and overall survival in early stage non-small cell lung cancer (NSCLC). Atlanta, Georgia, United States.

*Publication Details:*

Heist RS, Zhou W, Cogan-Drew T, **Liu G**, Su L, Neuberger D, Lynch TJ, Wain JC, Christiani DC. MDM2 polymorphism and recurrence-free and overall survival in early stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006; 24: 7221 (abstr). Atlanta (Poster). **Co-investigator**.

2005 Smoking cessation and survival in early stage non-small cell lung cancer patients. Washington, District of Columbia, United States.

*Publication Details:*

Christiani DC, Suk R, **Liu G**, Park S, Neuberger D, Wain JC, Lynch TJ, Zhou W. Smoking cessation and survival in early stage non-small cell lung cancer patients. Proc Am Assoc Cancer Res 2006; 46: 1193 (abstr). Washington DC (Poster). **Co-investigator**.

2005 A new metric for second hand smoke and its association with lung cancer risk. Anaheim, California, United States.

*Publication Details:*

Park S, Miller DP, Gitin E, Zhou W, **Liu G**, Wain JC, Lynch TJ, Christiani DC. A new metric for second hand smoke and its association with lung cancer risk. Proc Am Assoc Cancer Res 2005; 46: 2222 (abstr). Anaheim (Poster). **Co-investigator**.

2005 p53 and overall survival in early stage non-small cell lung cancer. Anaheim, California, United States.

*Publication Details:*

Suk R, Park S, **Liu G**, Cogan-Drew T, Zhou W, Su L, Wain J, Lynch T, Christiani D. p53 and overall survival in early stage non-small cell lung cancer. Proc Am Assoc Cancer Res 2005; 46: 2625 (abstr). Anaheim (Poster). **Co-investigator**.

2005 MMP-1 polymorphism predicts time-to-progression in bronchioloalveolar carcinoma. Anaheim, California, United States.

*Publication Details:*

**Liu G**, Marshall A, Zhou W, Park S, Suk R, Lynch TJ, Wain JC, Su L, Neuberger D, Christiani DC. MMP-1 polymorphism predicts time-to-progression in bronchioloalveolar carcinoma. Proc Am Assoc Cancer Res 2005; 46: 2626 (abstr). Anaheim (Poster). **Principal Author**.

- 2005 Polymorphisms of DNA repair genes XRCC1, hOGG1, APE1 and the risk of lung cancer. Anaheim, California, United States.
- Publication Details:*  
Su L, Zhou W, Park S, Wain JC, Lynch TJ, **Liu G**, Christiani DC. Polymorphisms of DNA repair genes XRCC1, hOGG1, APE1 and the risk of lung cancer. Proc Am Assoc Cancer Res 2005; 46: 4080 (abstr). Anaheim (Poster). **Co-investigator**.
- 2005 Epidermal growth factor receptor intron 1 polymorphism and disease progression in gefitinib-treated lung cancer patients. Anaheim, California, United States.
- Publication Details:*  
**Liu G**, Gurubhagavatula S, Zhou W, Wang Z, Suk R, Park S, Lynch TJ, Neuberg DS, Christiani DC. Epidermal growth factor receptor intron 1 polymorphism and disease progression in gefitinib-treated lung cancer patients. Proc Am Assoc Cancer Res 2005; 46: LB-240 (abstr). Anaheim (Poster). **Principal Author**.
- 2005 Dietary iron, zinc, calcium and the risk of lung cancer, a case-control study. Anaheim, California, United States.
- Publication Details:*  
Zhou W, Park S, **Liu G**, Miller DP, Wang LI, Pothier L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Dietary iron, zinc, calcium and the risk of lung cancer, a case-control study. Proc Am Assoc Cancer Res 2005; 46: 5801(abstr). Anaheim (Poster). **Co-investigator**.
- 2005 MMP-1 polymorphism predicts time-to-progression in bronchioloalveolar carcinoma. Anaheim, California, United States.
- Publication Details:*  
**Liu G**, Marshall A, Zhou W, Park S, Suk R, Lynch TJ, Wain JC, Su L, Neuberg D, Christiani DC. MMP-1 polymorphism predicts time-to-progression in bronchioloalveolar carcinoma. Proc Am Assoc Cancer Res 2005; 46: 4504 (abstr). **Principal Author**.
- 2005 Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC). Orlando, Florida, United States.
- Publication Details:*  
Suk R, Park S, **Liu G**, Cogan-Drew T, Zhou W, Su L, Wain J, Lynch T, Christiani D. Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005; 24: 9524(abstr). Orlando (Poster Discussion). **Co-investigator**.
- 2004 MMP-1 1G/2G polymorphism is not a predictor for overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy regimens. Orlando, Florida, United States.
- Publication Details:*  
Gurubhagavatula S, Zhou W, Su Li, **Liu G**, Park S, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. MMP-1 1G/2G polymorphism is not a predictor for overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy regimens. Proc Am Assoc Cancer Res 2004; 45: 1920 (abstr). Orlando (Poster). **Co-investigator**.
- 2004 ERCC2 Asp312Asn polymorphism modifies the association between second hand smoke and lung cancer risk. Orlando, Florida, United States.
- Publication Details:*  
Miller DP, Park S, Gitin E, Zhou W, **Liu G**, Wang Z, Wain JC, Lynch TJ, Su L, Christiani DC. ERCC2 Asp312Asn polymorphism modifies the association between second hand smoke and lung cancer risk. Proc Am Assoc Cancer Res 2004; 45: 2904 (abstr). Orlando (Poster). **Co-investigator**.
- 2004 Modeling cancer risk in case-control studies using a new dose metric of smoking based on a DNA-adduct



model of carcinogenesis. Orlando, Florida, United States.

*Publication Details:*

Thurston SW, **Liu G**, Miller DP, Christiani DC. Modeling cancer risk in case-control studies using a new dose metric of smoking based on a DNA-adduct model of carcinogenesis. Proc Am Assoc Cancer Res 2004; 45: 3969 (abstr). Orlando (Poster). **Co-investigator**.

- 2004 Gene-environment interaction for the ERCC1 polymorphism and cumulative cigarette smoking exposure in lung cancer. Orlando, Florida, United States.

*Publication Details:*

Zhou W, **Liu G**, Park S, Wang Z, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. Gene-environment interaction for the ERCC1 polymorphism and cumulative cigarette smoking exposure in lung cancer. Proc Am Assoc Cancer Res 2004; 45: 3973 (abstr). Orlando (Poster). **Co-investigator**.

- 2004 Polymorphisms of DNA repair and glutathione s-transferase genes and progression-free survival (PFS) in treated advanced esophageal cancer (EC) patients. New Orleans, Louisiana, United States.

*Publication Details:*

**Liu G**, Zhou W, Park S, Gurubhavagatula S, Yeap B, Nishioka NS, Su L, Wain JC, Lynch TJ, Christiani DC. Polymorphisms of DNA repair and glutathione s-transferase genes and progression-free survival (PFS) in treated advanced esophageal cancer (EC) patients. Proc Am Soc Clin Oncol 2004; 23: 9564 (abstr). New Orleans (Poster). **Principal Author**.

- 2004 The combination of MnSOD Ala16Val and MMP-1 1G/2G polymorphisms and lung cancer risk. Orlando, Florida, United States.

*Publication Details:*

**Liu G**, Zhou W, Su L, Wang LI, Park S, Wang Z, Miller DP, Wain JC, Lynch TJ, Christiani D. The combination of MnSOD Ala16Val and MMP-1 1G/2G polymorphisms and lung cancer risk. Proc Am Assoc Cancer Res 2004; 45: 5294 (abstr) Orlando (Poster). **Principal Author**.

- 2004 Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Orlando, Florida, United States.

*Publication Details:*

Su L, Zhou W, **Liu G**, Park S, Wang Z, Miller DP, Wain JC, Lynch TJ, Christiani DC. Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Proc Am Assoc Cancer Res 2004; 45: 5299 (abstr). Orlando (Poster). **Co-investigator**.

- 2004 Nucleotide excision repair (NER) gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis. New Orleans, Louisiana, United States.

*Publication Details:*

Gurubhagavatula S, Zhou W, Park S, Neuberg DS, Lynch TJ, Wain JC, Su L, **Liu G**, Christiani DC. Nucleotide excision repair (NER) gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis. Proc Am Soc Clin Oncol 2004; 23: 3040 (abstr). New Orleans (Oral). **Co-investigator**.

- 2004 The ERCC1 C8092A polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. New Orleans, Louisiana, United States.

*Publication Details:*

Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg DS, **Liu G**, Christiani DC. The ERCC1 C8092A polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. Proc Am Soc Clin Oncol 2004; 23: 2014 (abstr). New Orleans (Poster Discussion). **Co-investigator**.

- 2004 Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. New Orleans, Louisiana, United States.

*Publication Details:*

Johnson BE, Lucca J, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, **Liu G**, Janne PA. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2004; 23: 7080 (abstr). New Orleans (Poster Discussion). **Co-investigator**.

- 2003 MPO and MnSOD polymorphisms, gender, and the risk of lung cancer. Washington, District of Columbia, United States.

*Publication Details:*

Su L, Zhou W, **Liu G**, Wang LI, Miller DP, Xu LL, Park S, Wain JC, Lynch TJ, Christiani DC. MPO and MnSOD polymorphisms, gender, and the risk of lung cancer. Proc Am Assoc Cancer Res 2003; 44: 4534 (abstr). Washington DC (Poster). **Co-investigator**.

- 2003 The MnSOD Val/Val genotype enhances lung cancer risk by p53 and XRCC1 polymorphisms. Washington, District of Columbia, United States.

*Publication Details:*

**Liu G**, Zhou W, Wang LI, Xu LL, Miller DP, Park S, Wain JC, Lynch TJ, Su L, Christiani DC. The MnSOD Val/Val genotype enhances lung cancer risk by p53 and XRCC1 polymorphisms. Proc Am Assoc Cancer Res 2003; 44: 4541 (abstr). Washington DC (Poster). **Principal Author**.

- 2003 Gender-specific interactions between the polymorphisms of ERCC2 and GSTM1 in lung cancer risk. Washington, District of Columbia, United States.

*Publication Details:*

Zhou W, **Liu G**, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Gender-specific interactions between the polymorphisms of ERCC2 and GSTM1 in lung cancer risk. Proc Am Assoc Cancer Res 2003; 44: 4542 (abstr). Washington DC (Poster). **Co-investigator**.

- 2003 MPO and p53 polymorphisms, gender, and the risk of lung cancer. Washington, District of Columbia, United States.

*Publication Details:*

Christiani DC, Zhou W, Xu LL, Miller DP, Park S, Wain JC, Lynch TJ, Su L, **Liu G**. MPO and p53 polymorphisms, gender, and the risk of lung cancer. Proc Am Assoc Cancer Res 2003; 44: 4543 (abstr). Washington DC (Poster). **Senior Responsible Author**.

- 2003 NAT2 and NQO1 genetic polymorphisms predict overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). Washington, District of Columbia, United States.

*Publication Details:*

Gurubhagavatula S, **Liu G**, Park S, Zhou W, Xu LL, Su L, Wain JC, Lynch TJ, Christiani DC. NAT2 and NQO1 genetic polymorphisms predict overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 2003; 44: LB-91 (abstr). Washington DC (Poster). **Co-investigator**.

- 2002 Gene-environment interaction for the XRCC1 and ERCC2 polymorphisms and cumulative smoking exposure. San Francisco, California, United States.

*Publication Details:*

Zhou W, **Liu G**, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Gene-environment interaction for the XRCC1 and ERCC2 polymorphisms and cumulative smoking exposure. Proc Am Assoc Cancer Res 2002; 43: 2004 (abstr). San Francisco (Oral). **Co-investigator**.

- 2002 The Arg399Gln XRCC1 and GSTT1-deletion polymorphisms and the risk of esophageal adenocarcinoma and Barrett's esophagus. San Francisco, California, United States.

*Publication Details:*

**Liu G**, Zhou W, Miller DP, Poneris JM, Xu LL, Su L, Puricelli W, Wain JC, Nishioka NS, Lynch TJ, Christiani DC. The Arg399Gln XRCC1 and GSTT1-deletion polymorphisms and the risk of esophageal adenocarcinoma and Barrett's esophagus. Proc Am Assoc Cancer Res 2002; 43: 2826 (abstr). San Francisco (Poster). **Principal Author**.

- 2002 mEH polymorphisms and risk of different histological types of esophageal cancer and their precursor lesions. San Francisco, California, United States.

*Publication Details:*

**Liu G**, Zhou W, Poneris JM, Miller DP, Xu LL, Puricelli W, Su L, Lynch TJ, Wain JC, Nishioka NS, Christiani DC. mEH polymorphisms and risk of different histological types of esophageal cancer and their precursor lesions. Proc Am Assoc Cancer Res 2002; 43: 2827 (abstr). San Francisco (Poster). **Principal Author**.

- 2002 p21 (codon 31) Ser-Arg polymorphisms is associated with different risks of lung cancer in non-smokers and smokers. San Francisco, California, United States.

*Publication Details:*

Su L, Xu LL, Zhou W, Miller DP, Lynch TJ, Wain JC, **Liu G**, Christiani DC. p21 (codon 31) Ser-Arg polymorphisms is associated with different risks of lung cancer in non-smokers and smokers. Proc Am Assoc Cancer Res 2002; 43: 4224 (abstr). San Francisco (Poster). **Co-Investigator**.

- 2002 p53 (codon 72) and p21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. San Francisco, California, United States.

*Publication Details:*

Su L, Sai Y, Fan R, Thurston SW, Miller DP, Xu LL, Wain JC, Lynch TJ, **Liu G**, Christiani DC. p53 (codon 72) and p21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Proc Am Assoc Cancer Res 2002; 43: 5053 (abstr). San Francisco (Poster). **Co-investigator**.

- 2001 Differential Effects of the codon 72 p53 polymorphism on the risk of adenocarcinoma versus squamous cell carcinoma of the lung. New Orleans, Louisiana, United States.

*Publication Details:*

Fan R, Miller DP, **Liu G**, Thurston SW, Xu LL, Su L, Lynch TJ, Wain JC, Christiani DC. Differential Effects of the codon 72 p53 polymorphism on the risk of adenocarcinoma versus squamous cell carcinoma of the lung. Proc Am Assoc Cancer Res, 2001; 42: 194 (abstr). New Orleans (Oral Presentation). **Co-investigator**.

- 2001 The variant –G463A polymorphism of the myeloperoxidase (MPO) gene does not decrease lung cancer susceptibility in a Caucasian population. New Orleans, Louisiana, United States.

*Publication Details:*

Xu LL, Miller DP, **Liu G**, Thurston SW, Fan R, Lynch TJ, Wain JC, Su L, Christiani DC. The variant –G463A polymorphism of the myeloperoxidase (MPO) gene does not decrease lung cancer susceptibility in a Caucasian population. Proc Am Assoc Cancer Res 2001; 42: 1536 (abstr). New Orleans (Poster Discussion). **Co-investigator**.

- 2001 The GSTT1-null genotype is associated with a decreased susceptibility for esophageal carcinoma in a Caucasian population. New Orleans, Louisiana, United States.

*Publication Details:*

**Liu G**, Xu LL, Miller DP, Fan R, Su L, Wain JC, Lynch TJ, Christiani DC. The GSTT1-null genotype is associated with a decreased susceptibility for esophageal carcinoma in a Caucasian population. Proc Am Assoc Cancer Res 2001; 42: 2669 (abstr). New Orleans (Poster). **Principal Author**.

## 2. NATIONAL

### Invited Lectures and Presentations

- 2024 Mar 13 **Co-Chair.** Mobile Lung Cancer Screening Community Engagement. Mobile LCS Community Engagement Program. Toronto, Ontario, Canada. Virtual. National. 10 individuals.
- 2024 Feb 26 **Co-chair.** Mobile Lung Cancer Screening Community Engagement. Mobile LCS Community Engagement Program. Toronto, Ontario, Canada. Virtual. National. 10 individuals.
- 2024 Feb 10 **Chair & Invited Speaker.** CARMA BROS Annual Meeting. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada. 30 individuals. 80 minutes.
- 2024 Feb 8 **Chair & Invited Speaker.** ALK positive Lung Cancer: Updates in management and toxicity management. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada. 25 individuals. 3.5 hours.
- 2024 Jan 19 **Co-Chair & Invited Speaker.** Designing Program for Mobile Lung Cancer Screening. Better Breathing Week. Toronto, Ontario, Canada. Virtual. National, but presented from Toronto. 25 individuals, 90 minutes.
- 2024 Jan 17 **Chair.** AZ's Annual Lung Oncology Review. AstraZeneca. Toronto, Ontario, Canada. Virtual Presentation. National, but presented from Toronto. 30 individuals, 90 minutes.
- 2023 Nov 28 **Invited Speaker.** Case Based Discussion, metastatic NSCLC post-chemo and immunotherapy. Amgen & AstraZeneca. Toronto, Ontario, Canada. Virtual. National. 30 individuals, 15 minutes.
- 2023 Oct 12 **Invited Speaker.** Precision Oncology studies: OPTIMAL (Organoids to guide Post-resistance Therapy In driver MutAled Lung cancers) and CARMA BROS (CANadian Rare Molecular Alteration Basket-umbrella Real-world Observational Studies. Precision Oncology and Experimental Therapeutics (POET) Conference, University of Calgary. Calgary, Alberta, Canada. 120 multi-level trainees, oncologists, scientists.
- 2023 Aug **Invited Speaker.** Real World Evidence Challenges in Cancer Pharmacoepidemiology. International Conference for Pharmacoepidemiology. Halifax, Nova Scotia, Canada. 80 Epidemiologists, regulators, clinicians, scientists.
- 2023 Feb **Invited Speaker.** Battle of the IOs: KN189 and KN407 trials. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada. 200 clinicians and scientists.
- 2022 Nov 9 **Invited Speaker.** CARMA BROS: CANadian Rare Molecular Alterations Basket-umbrella Real-world Observational Studies. Glans-Look Lung Cancer Research Day (Virtual). Calgary, Alberta, Canada. Audience: Canada. Virtual Presentation.
- 2022 Sep 29 **Chair and Invited Speaker.** 1. Precision Oncology Care: What have we learnt from NTRK gene fusions in Lung Cancer; 2. NTRK fusion pragmatic management: Case presentations. Bayer Educational Session. Ontario, Canada. Multilevel trainees and medical oncologists (30 attendees).
- 2022 Jun 16 **Chair and Invited Speaker.** Let's tALK: Pragmatic management of ALK TKI toxicities. National Educational Session from Takeda (Virtual). Toronto, Ontario, Canada. Attendees: 35 multilevel (20 minutes).
- 2022 May 17 **Chair and Invited Speaker.** CROWN trial: Updated Data. Pfizer Lorlatinib Lung Cancer National Advisory Board Meeting (Virtual). Toronto, Ontario, Canada. 15 Medical Oncologists across Canada 20 minutes.
- 2021 Nov 22 **Invited Speaker.** Inspire Bayer. Bayer (Virtual). Canada. Audience: Canada. Virtual Presentation.
- 2021 Aug 19 **Invited Speaker.** The Management of ALK-positive Nonsmall Cell Lung Cancer (NSCLC): Application of

- Real-world Evidence (RWE). Pfizer (Virtual). Canada. Audience: Canada.  
Virtual Presentation.
- 2021 Jun 3 **Invited Speaker.** Overview of Data in ALK+ Landscape. Takeda (Virtual). Canada. Audience: Canada.  
Virtual Presentation.
- 2021 Apr 28 **Invited Speaker.** PCODR presentation\_Lorlatinib. The current status of treating ALK-fusion in non-small cell lung cancer (NSCLC). pCODR (Virtual). Canada. Audience: Canada.  
Virtual Presentation.
- 2021 Feb 28 **Invited Speaker.** Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumour resection: ADAURA. Finally moving the needle for resectable early stage NSCLC. CCO Meeting (Virtual). Canada. Audience: Canada.  
Virtual Presentation.
- 2021 Feb 9 **Invited Speaker.** The Basket or Umbrella Real-world Observational Study (BUROS) Design for Molecular Cancer Subtypes. The Applied Health Research Centre (AHRC) (Virtual). Canada. Audience: Canada.  
Virtual Presentation.
- 2021 Jan 20 **Invited Speaker.** Lung Cancer Updates across all stages. The Rounds Primary Care Education (Virtual). Halifax, Nova Scotia, Canada. Audience: Primary Care Physicians;  
235 individuals;  
1 hour preparation.
- 2020 Nov 28 **Invited Speaker.** Update on ALK positive lung cancers. Vancouver (virtual). British Columbia, Canada. Audience: Multilevel;  
63 individuals;  
1 hour preparation.
- 2020 Nov 18 **Invited Speaker.** Overview of ALK+ NSCLC landscape. Saskatoon Cancer Centre (virtual). Saskatchewan, Canada. Audience: Multilevel;  
22 individuals;  
1 hour preparation.
- 2020 Nov 14 **Invited Speaker.** Lung Cancer: No more Nihilism. C.H.I.E.F. Rounds (virtual). British Columbia, Canada. Audience: Primary Care Practitioners;  
164 individuals;  
1 hour preparation.
- 2020 Jan 23 **Invited Speaker.** Targetable NSCLCs. McGill University. Quebec, Canada. Audience: Multilevel;  
10 individuals;  
1 hour preparation.
- 2020 Jan 22 **Invited Speaker.** Tyrosine kinase inhibitors and Lung Cancer. Centre hospitalier universitaire de Sherbrooke. Quebec, Canada. Audience: Multilevel;  
20 individuals  
1 hour preparation.
- 2020 Jan 22 **Invited Speaker.** CARMA study. Montreal Jewish Hospital. Quebec, Canada. Audience: Multilevel;  
20 individuals;  
1 hour preparation.
- 2020 Jan 22 **Invited Speaker.** Observational studies in ALK lung cancer. Centre hospitalier universitaire de Montreal. Quebec, Canada. Audience: Multilevel;  
20 individuals;  
1 hour preparation.
- 2020 Jan 21 **Invited Speaker.** ALK+ Lung Cancers. Quebec Heart and Lung Institute (IUCPQ). Quebec, Canada. Audience: Multilevel;  
30 individuals;

1 hour preparation.

- 2019 Feb 8 **Invited Speaker.** Debate: Alectinib is the first-line standard treatment for ALK positive lung cancer. Canadian Lung Cancer Conference (Vancouver). British Columbia, Canada. 200 individuals; Multilevel trainees to faculty; oncology  
240 minutes preparation.
- 2018 Mar 2 **Invited Speaker.** Lung Cancer, Molecular Targeting. Atlantic Regional Consultancy Meeting. Montreal, Quebec, Canada.
- 2018 Feb 8 **Invited Speaker.** ALK Positive Lung Cancer Review. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2017 Aug 24 **Invited Speaker.** Pharmacogenetics of Cancer. International Society for Pharmacoepidemiology (ISPE). Montreal, Quebec, Canada.
- 2017 Feb 9 **Invited Speaker.** Are we pushing efficacy at the expense of toxicity in Canada? A pharmacoepidemiologic perspective. Depth of Family Medicine and Community Health, University of Manitoba. Winnipeg, Manitoba, Canada. BOLD Meeting.
- 2015 Nov 7 **Invited Speaker.** ALK Trials ASCEND 2/3 Data Efficacy and Toxicity. National Lung Cancer Advisory Board Meeting (Novartis). Montreal, Quebec, Canada.
- 2015 Jan 15 **Invited Speaker.** Oncologic Trials for Pharmacogenetic Study. Canadian Pharmacogenomic Network for Drug and Safety (CPNDS). Vancouver, British Columbia, Canada.
- 2013 Aug 26 **Invited Speaker.** Geographic Diversity and Patterns of Disease Examples in Cancer. ICPE meeting. Montreal, Quebec, Canada. Researchers (50).
- 2012 May 29 **Invited Speaker.** The ON-PROST Collaboration. CC-ARCC Annual meeting. Montreal, Quebec, Canada. Researchers (30), trainees.
- 2008 Apr 7 **Guest Lecturer.** Pharmacogenetic Epidemiology of Upper Aerodigestive Tract Cancer Prognosis. Grand Rounds, Le Centre de Recherche de L'Hôtel-Dieu de Québec. Quebec City, Quebec. Post-graduate and graduate, whole class (n=30), PhD/MSc. (Continuing Education).
- 2007 Aug 21 **Invited lecturer and symposium co-chair.** Pharmacogenetics for epidemiologists: What we know and what we need to know. 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk. Quebec City, Quebec, Canada. 200 attendees: pharmacoepidemiologists PhD/MD, post-graduate, whole class molecular biologists, molecular epidemiologists. (Continuing Education).

## Presented and Published Abstracts

- 2023 Aug Influence of Cancer Stage at Diagnosis on Lung Cancer Prognosis of Targetable Molecular Patient Subgroups. International Conference for Pharmacoepidemiology. Halifax, Canada.
- Publication Details:*  
Niki Esfahanian, Luna Jia Zhan, Louis Everest  
Khaleeq Khan, Karmugi Balaratnam, Mary Brown, **Geoffrey Liu**. Influence of Cancer Stage at Diagnosis on Lung Cancer Prognosis of Targetable Molecular Patient Subgroups. **Senior Responsible Author.**
- 2023 Aug A Systematic Literature Review of Current Application of Machine Learning for Patient Phenotyping and Selection in Observational Studies [875]. International Conference for Pharmacoepidemiology. Halifax, Canada.
- Publication Details:*  
Fidelia Ida, Sabina Nduaguba, Dimitri Bennett  
Tham Le, Mehmet Burcu, **Geoffrey Liu**, Di Zhang, Dongmu Zhang, Jie Li. A Systematic Literature Review of Current Application of Machine Learning for Patient Phenotyping and Selection in Observational

Studies [875]. **Coauthor or Collaborator.**

2023 Aug CARMA-BROS: An efficient Basket/Umbrella Real-World Observational Study (BUROS) Design for Rare Cancer Subtypes [921]. International Conference for Pharmacoepidemiology. Halifax, Canada.

*Publication Details:*

Samir Barghout, Stavroula Raptis, Mary Brown, Faisal Al-Agha, Luna Jia Zhan, Devalben Patel, **Geoffrey Liu**. CARMA-BROS: An efficient Basket/Umbrella Real-World Observational Study (BUROS) Design for Rare Cancer Subtypes [921]. **Senior Responsible Author.**

2023 Aug Integration of Basket/Umbrella Real-world Observational Studies (BUROS) into International Epidemiological Consortia to Inform Cancer Clinical Course and Disease Epidemiology [929]. International Conference for Pharmacoepidemiology. Halifax, Canada.

*Publication Details:*

Samir Barghout, Luna Jia Zhan, Stavroula Raptis, Mary Brown, Faisal Al-Agha, Devalben Patel, Rayjean Hung, **Geoffrey Liu**. Integration of Basket/Umbrella Real-world Observational Studies (BUROS) into International Epidemiological Consortia to Inform Cancer Clinical Course and Disease Epidemiology [929]. **Senior Responsible Author.**

2018 May 27 Assessment of Language Needs and Resource Use among Canadian Immigrant Patients with Cancer. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Sophia Liu. (Trainee Presentation)

*Publication Details:*

Liu SY, Smith EC, McCartney A, Basgaran A, Balaratnam K, Leeman E, Brown MC, Howell D, Jones JM, Giuliani M, Xu W, **Liu G**, Eng L. Assessment of Language Needs and Resource Use among Canadian Immigrant Patients with Cancer. Poster. **Senior Responsible Author.**

2018 May 27 Perception of Prognosis by Non-oncologist for Cancer Patients with 7 Common Advanced Stage Malignancies. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Tamoor Afzaal. (Trainee Presentation)

*Publication Details:*

Afzaal T, Liang M, Shepshelovich D, **Liu G**. Perception of Prognosis by Non-oncologist for Cancer Patients with 7 Common Advanced Stage Malignancies. Poster. **Senior Responsible Author.**

2018 May 27 Implementation of an eReferral Smoking Cessation Tool Following CT Screening for Early Detection of Lung Cancer. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Lina Chen. (Trainee Presentation)

*Publication Details:*

Chen L, Afzaal T, Hueniken K, McGregor M, Schmidt H, Gao Y, Eisen A, Brezden-Masley C, Brown MC, Giuliani M, Jones J, Eng L, **Liu G**. Implementation of an eReferral Smoking Cessation Tool Following CT Screening for Early Detection of Lung Cancer. Poster. **Senior Responsible Author.**

2018 May 27 Influence of Patients' Knowledge of Cancer Biomarkers on Preference for Receiving a Hypothetical Liquid versus Tissue Biopsy for Treatment Decisions. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Katrina Huenikan. (Trainee Presentation)

*Publication Details:*

Hueniken K, Jiang SX, Lu L, Said B, Liang M, Brown MC, Xu W, **Liu G**, Eng L, Lee MJ. Influence of Patients' Knowledge of Cancer Biomarkers on Preference for Receiving a Hypothetical Liquid versus Tissue Biopsy for Treatment Decisions. Poster. **Senior Responsible Author.**

2018 May 27 Head and Neck Cancer Patients Treated with Cisplatin-Based Chemoradiation: Prevalence and Predictors of Hearing Loss. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Mary Mahler. (Trainee Presentation)

*Publication Details:*

Mahler M, Zhang Y, Kueniken K, Brown MC, Waldron J, Goldstein D, Bratman S, Siu L, Xu W, Hope A, **Liu G**. Head and Neck Cancer Patients Treated with Cisplatin-Based Chemoradiation: Prevalence and Predictors of Hearing Loss. Poster. **Senior Responsible Author**.

- 2018 May 27 "Comparison of health utility values from EQ-5D-3L and EQ-5D-5L in breast cancer patients in different health statuses. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Tiffany Tse. (Trainee Presentation)

*Publication Details:*

Tse T, Yang D, Baek J, Liang M, Skitch A, Brezden-Masley C, Brown MC, Torres S, Xu W, **Liu G**. "Comparison of health utility values from EQ-5D-3L and EQ-5D-5L in breast cancer patients in different health statuses. Poster. **Senior Responsible Author**.

- 2018 May 27 Patient Preferences and Depth of Preferences for Liquid vs. Tissue Biomarker for Oncology Drug Therapy Selection? Applied research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Min Joon Lee. (Trainee Presentation)

*Publication Details:*

Lee MJ, Jiang S, Hueniken K, Eng L, Lu L, Gao Y, McCartney A, Brown MC, **Liu G**. Patient Preferences and Depth of Preferences for Liquid vs. Tissue Biomarker for Oncology Drug Therapy Selection? Poster. **Senior Responsible Author**.

- 2018 May 27 Consistency of Patient Preferences for Liquid over Tissue Biopsy across Clinico-Demographic Variables. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Shirley Jiang. (Trainee Presentation)

*Publication Details:*

Jiang S, **Liu G**. Consistency of Patient Preferences for Liquid over Tissue Biopsy across Clinico-Demographic Variables. **Senior Responsible Author**.

- 2018 May Influence of Patients' Knowledge of Cancer Biomarkers on Preference for Receiving a Hypothetical Liquid versus Tissue Biopsy for Treatment Decisions. Applied Research in Cancer Control (ARCC). Montreal, Quebec, Canada. Presenter(s): Katrina Hueniken.

*Publication Details:*

Katrina Hueniken, Shirley Xue Jiang, Lin Lu, Badr Said, Mindy Liang, M. Catherine Brown, Wei Xu, **Geoffrey Liu**, Lawson Eng, Min Joon Lee. Influence of Patients' Knowledge of Cancer Biomarkers on Preference for Receiving a Hypothetical Liquid versus Tissue Biopsy for Treatment Decisions. **Coauthor or Collaborator**.

- 2016 Sep Outcomes of esophageal cancer patients treated with trimodality in a community centre. Canadian Association of Radiation Oncologists. Banff, Alberta, Canada.

*Publication Details:*

Vanderwater C, Chan E, Woo R, Cho C, Wong J, Ardern C, **Liu G**, Zhang B, Cheung A, Lee A, Chacko P, Fadhel E, Kassam Z. Outcomes of esophageal cancer patients treated with trimodality in a community centre. 2016 Sep.

- 2015 Nov Chronic epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of an EGFR-mutant lung adenocarcinoma patient-derived xenograft model (PDX) results in resistance and increased expression of EGFR-dimerization partners. Canadian Institutes of Health Research. Montreal, Quebec, Canada.

*Publication Details:*

Stewart EL, Sakashita S, Tao W, Pham NA, Li M, **Liu G**, Tsao MS. Chronic epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of an EGFR-mutant lung adenocarcinoma patient-derived xenograft model (PDX) results in resistance and increased expression of EGFR-



dimerization partners. 2015 Nov. Canadian Cancer Research Conference, 2015, Montreal, Canada (Poster) (Accepted but withdrawn). **Co-Investigator**.

2014 Aug Genetic polymorphisms associated with radiation-related esophagitis and pneumotitis following definitive treatment for non-small cell lung cancer (NSCLC). Canadian Society of Radiation Oncology (CARO). St John's, Newfoundland and Labrador, Canada. (Trainee Presentation)

*Publication Details:*

Barrett K, **Liu G**. Genetic polymorphisms associated with radiation-related esophagitis and pneumotitis following definitive treatment for non-small cell lung cancer (NSCLC). 2014 Aug. Poster. **Senior Responsible Author**.

2014 May Characterization of patient-derived primary NSCLC models as tools to study treatments of EGFR-mutant patients. Terry Fox Research Institute. Montreal, Quebec, Canada. (Trainee Presentation)

*Publication Details:*

Stewart EL, Mascaux C, Panchal D, Kim L, Shakashita S, Wang D, Li M, Pham NA, Leighl N, **Liu G**, Shepherd FA, Tsao M-S. Characterization of patient-derived primary NSCLC models as tools to study treatments of EGFR-mutant patients. 2014 May. Won the poster competition so was asked to give an oral presentation. Terry Fox Research Institute Trainee Travel Award \$180. **Coauthor or Collaborator**.

2014 Apr 29 Socio-demographic and clinical factors associated with dispositional optimism in adult cancer survivors. Canadian Association of Psychosocial Oncology (CAPO). Winnipeg, Manitoba, Canada. (Trainee Presentation)

*Publication Details:*

Naik H, To K-H, Brown MC, Hon H, Eng L, Mahler M, Tiessen K, Thai H, Ho V, Ho A, Irwin M, Pat V, Charow R, Herzog L, Xu W, **Liu G**. Socio-demographic and clinical factors associated with dispositional optimism in adult cancer survivors. 2014 Apr 29. Canadian Association of Psychosocial Oncology (CAPO) Conference, April 29-May 2, 2014, Winnipeg, MB, Canada (Poster). **Senior Responsible Author**.

2013 Aug Germline polymorphisms and response to cetuximab in colorectal cancer: A meta-analysis of published studies. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)

*Publication Details:*

Morgen EL, Jonker DJ, O'Callaghan CJ, **Liu G**. Germline polymorphisms and response to cetuximab in colorectal cancer: A meta-analysis of published studies. 2013 Aug. Abstr 43 (Oral presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author**.

2013 Aug Polymorphisms in microRNA (miRNA) pathways as predictors of survival and response to cisplatin in esophageal cancer (EC) patients. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)

*Publication Details:*

Eng L, Azad AK, Qiu X, Cheng D, Renouf DJ, Dodbiba L, Marsh S, Savas S, Knox JJ, Darling GE, Wong RKS, Xu W, Faluyi OO, **Liu G**. Polymorphisms in microRNA (miRNA) pathways as predictors of survival and response to cisplatin in esophageal cancer (EC) patients. 2013 Aug. Abstr 44 (Oral presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author**.

2013 Aug Drug response in diverse populations: Role of ethnicity. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada.

*Publication Details:*

Pulford DJ, **Liu G**, Gross AS, Carleton B. Drug response in diverse populations: Role of ethnicity. 2013 Aug. Abstr 75 (Oral presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Co-investigator**.

- 2013 Aug Interactions of human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)
- Publication Details:*  
Habbous S, Pang V, Eng L, Amir E, **Liu G**. Interactions of human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis. 2013 Aug. Abstr 646 (Poster presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author.**
- 2013 Aug Racial differences affect patients willingness in providing additional biospecimens for pharmacogenomic testing. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)
- Publication Details:*  
Loo TT, Cuffe S, Hon H, Martin P, Brown MC, Alibhai S, Qiu X, Xu W, **Liu G**. Racial differences affect patients willingness in providing additional biospecimens for pharmacogenomic testing. 2013 Aug. Abstr 202 (Poster presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author.**
- 2013 Aug Effect of BRM promoter polymorphisms on survival outcomes of platinum-treated advanced non-small cell lung cancer (NSCLC) patients. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)
- Publication Details:*  
Cuffe S, Cheng L, Azad AK, Brhane Y, Cheng D, Chen Z, Qui X, Boyd K, Xu W, Shepherd FA, Tsao MS, Reisman D, **Liu G**. Effect of BRM promoter polymorphisms on survival outcomes of platinum-treated advanced non-small cell lung cancer (NSCLC) patients. 2013 Aug. Abstr 203 (Poster presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author.**
- 2013 Aug Patient willingness to provide different types of biological samples for pharmacogenomic testing. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)
- Publication Details:*  
Loo TT, Cuffe S, Hon H, Martin P, Brown MC, Alibhai S, Qiu X, Xu W, **Liu G**. Patient willingness to provide different types of biological samples for pharmacogenomic testing. 2013 Aug. Abstr 263 (Poster presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author.**
- 2013 Aug Use of pharmaceutical and non-pharmaceutical complementary and alternative medicine in cancer patients. International Conference for Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)
- Publication Details:*  
Halytskyy O, Eng L, Espin-Garcia O, Lam C, Tiessen K, Villeneuve J, Charow R, Shani RM, Niu C, Pringle D, Mahler M, Alibhai SMH, Howell D, Jones JM, Brown CM, Xu W, **Liu G**. Use of pharmaceutical and non-pharmaceutical complementary and alternative medicine in cancer patients. 2013 Aug. Abstr 147 (Poster presentation at the International Conference for Pharmacoepidemiology, Montreal Canada). **Senior Responsible Author.**
- 2013 Aug Differences in use of pharmacologic smoking cessation aids between lung and other cancers patients. International Conference of Pharmacoepidemiology. Montreal, Quebec, Canada. (Trainee Presentation)
- Publication Details:*  
Eng L, Qiu X, Palepu PR, Hon H, Habbous S, Pringle D, Niu C, Harland L, Mahler M, Halytskyy O, Brown MC, Cuffe S, Jones JM, Alibhai SMH, Howell D, Selby P, Xu W, **Liu G**. Differences in use of pharmacologic smoking cessation aids between lung and other cancers patients. 2013 Aug. 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Montreal, QC.

August 2013. **Senior Responsible Author.**

2013 Jun Association of two BRM promoter polymorphisms with oropharyngeal squamous cell carcinoma (OSCC) survival. Canadian Society of Otolaryngology-Head and Neck Surgery (CSOHNS) Annual Meeting. Banff, Alberta, Canada. (Trainee Presentation)

*Publication Details:*

Wang J, **Liu G**. Association of two BRM promoter polymorphisms with oropharyngeal squamous cell carcinoma (OSCC) survival. 2013 Jun. Accepted at the Poliquin Resident Research Competition of the 67th CSOHNS Annual Meeting in Banff, Alberta for a podium presentation. **Senior Responsible Author.**

2013 May Perceived benefits and barriers as predictors of improved physical activity in cancer survivors. Canadian Physiotherapy Association Congress. Montreal, Quebec, Canada. (Trainee Presentation)

*Publication Details:*

Pringle D, Eng L, Brown C, Shen X, Halytskyy O, Mahler M, Niu C, Villeneuve J, Charow R, Lam C, Shani RM, Tiessen K, Howell D, Alibhai SMH, Xu W, Jones JM, **Liu G**. Perceived benefits and barriers as predictors of improved physical activity in cancer survivors. 2013 May. (May 2013) Canadian Physiotherapy Association Congress 2013, Montreal, QC. **Senior Responsible Author.**

2011 Genetic sequence variants and head and neck cancer outcome: a genome-wide association study. American Society of Human Genetics. Montreal, Quebec, Canada. (Trainee Presentation)

*Publication Details:*

Azad AK, Bairati I, Cheng L, Waggott D, Samson E, Cheng D, Mirshams M, Savas S, Waldron J, Wang C, Goldstein D, Boutros P, **Liu G**, Meyer F, Xu W. Genetic sequence variants and head and neck cancer outcome: a genome-wide association study. 2011. 61th Annual Meeting of The American Society of Human Genetics, Montreal, Canada 2011, (abstr 1182W, p245) (Co-Investigator supervising AKA, LC, DW, DC, MM. **Co-Investigator.**

2003 **Presenter.** MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. International Association for the Study of Lung Cancer (IASLC). Vancouver, British Columbia, Canada. Presenter(s): **Liu G**. Liu G, Zhou W, Wang LI, Miller DP, Xu LL, Park S, Wain JC, Lynch TJ, Su L, Christiani DC. Cancer Lett 2004; 41 (supp): O-84 (abstr).

*Publication Details:*

MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004 Oct 8;214(1):69-79. **Coauthor or Collaborator.**

2003 Polymorphisms of the xenobiotic genes, MPO and NQO1, and overall survival (OS) in advanced staged non-small cell lung cancer (NSCLC) patients. International Association for the Study of Lung Cancer (IASLC). Vancouver, British Columbia, Canada.

*Publication Details:*

Gurubhagavatula S, **Liu G**, Park S, Xu LL, Su L, Zhou W, Wain JC, Neuberg DS, Lynch TJ, Christiani DC. Polymorphisms of the xenobiotic genes, MPO and NQO1, and overall survival (OS) in advanced staged non-small cell lung cancer (NSCLC) patients. Lung Cancer 2003; 41(supp): O-337 (abstr). Presented at the International Association for the Study of Lung Cancer (IASLC). Vancouver (Oral). **Co-investigator.**

2003 Gender, MPO and MnSOD polymorphisms and non-small cell lung cancer risk. International Association for the Study of Lung Cancer (IASLC). Vancouver, British Columbia, Canada.

*Publication Details:*

**Liu G**, Zhou W, Wang LI, Miller DP, Xu LL, Park S, Wain JC, Lynch TJ, Su L, Christiani DC. Gender, MPO and MnSOD polymorphisms and non-small cell lung cancer risk. Lung Cancer 2003; 41 (supp): O-84 (abstr). **Principal Author.**

2003 Polymorphisms of DNA repair and xenobiotic metabolism genes affect overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with platinum agents. Vancouver, British Columbia,

Canada.

*Publication Details:*

Gurubhagavatula S, **Liu G**, Park S, Zhou W, Miller DP, Xu LL, Su L, Lynch TJ, Neuberg DS, Christiani DC. Polymorphisms of DNA repair and xenobiotic metabolism genes affect overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with platinum agents. Lung Cancer 2003; 41(supp): O-171 (abstr). Presented at the International Association for the Study of Lung Cancer (IASLC). Vancouver (Oral). **Co-investigator**.

2003 MnSOD, p53, XRCC1 polymorphisms and non-small cell lung cancer risk. International Association for the Study of Lung Cancer (IASLC). Vancouver, British Columbia, Canada.

*Publication Details:*

**Liu G**, Zhou W, Lynch TJ, Wang LI, Park S, Wain JC, Su L, Christiani DC. MnSOD, p53, XRCC1 polymorphisms and non-small cell lung cancer risk. Lung Cancer 2003; 41(supp): P-99 (abstr). Presented at the International Association for the Study of Lung Cancer (IASLC). Vancouver (Poster). **Principal Author**.

1995 **Presenter**. Patient preference for oral versus intravenous chemotherapy. International Conference for Chemotherapy. Montreal, Quebec, Canada. Presenter(s): **Liu G**. Liu G, Warner E, Franssen E. Fitch. Clin Invest Med 1995; 18(supp 4):604 (abstr). (Trainee Presentation)

*Publication Details:*

Patient preference for oral versus intravenous chemotherapy.

1995 **Presenter**. Patient preferences for oral versus intravenous chemotherapy. International Chemotherapy and Anti-Infectives Meeting. Montreal, Quebec, Canada. Presenter(s): **Liu G**. Liu G, Warner E, Franssen E, Fitch M. Can J Infect Dis 1995; 6(supp C):0273 (abstr).

*Publication Details:*

Patient preferences for oral versus intravenous chemotherapy. **Co-Principal Author**.

1995 Patient preference for oral versus intravenous chemotherapy. Montreal, Quebec, Canada.

*Publication Details:*

**Liu G**, Warner E, Franssen E. Fitch. Patient preference for oral versus intravenous chemotherapy. Clin Invest Med 1995; 18(supp 4): 604 (abstr). **Principal Author**.

1995 Patient preferences for oral versus intravenous chemotherapy. Montreal, Quebec, Canada.

*Publication Details:*

**Liu G**, Warner E, Franssen E, Fitch M. Patient preferences for oral versus intravenous chemotherapy. Can J Infect Dis 1995; 6(supp C):0273 (abstr). **Principal Author**.

1991 Arterial and Venous Changes in Hepatic Allografts. International Academy of Pathology. Montreal, Quebec, Canada.

*Publication Details:*

**Liu G**, Butany J, Cameron R, Greig P, Levy G. Arterial and Venous Changes in Hepatic Allografts. International Academy of Pathology Annual Meeting, March, 1991, Montreal (Poster). **Principal Author**.

### 3. PROVINCIAL / REGIONAL

#### Invited Lectures and Presentations

2023 Nov 21 **Panel Member and Discussant**. Lung Cancer Diagnostic Pathway: Current Status and Challenges. Provincial at Integration of the Diagnostic with the Molecular Roche Symposium. Mississauga, Ontario,

Canada. 120 minutes.

- 2021 Oct 28 **Invited Speaker.** Pragmatic and Rational Approaches to Drug Selection and Sequencing in Molecularly Targetable NSCLC in the GTA. Pfizer (Virtual). Ontario, Canada. Audience: Ontario, Canada. Virtual Presentation.
- 2020 Dec 10 **Invited Speaker.** Lung Cancer Progress. Queen's University. Ontario, Canada. Audience: Multilevel; 16 individuals; 1 hour preparation.
- 2020 Nov 26 **Invited Speaker.** Overview of ALK+ Lung Cancer. Grand River Regional Cancer Centre (virtual). Ontario, Canada. Audience: Multilevel; 27 individuals; 1 hour preparation.
- 2020 Nov 25 **Invited Speaker.** Lung cancer targetable with TKIs. St. Joseph's Health Centre, Toronto (virtual). Ontario, Canada. Audience: Multilevel; 16 individuals; 1 hour preparation.
- 2020 Nov 24 **Invited Speaker.** ALK+ NSCLC progress. Windsor Regional Cancer Centre (virtual). Ontario, Canada. Audience: Multilevel; 19 individuals; 1 hour preparation.
- 2017 Jul 18 **Invited Speaker.** ALK positive lung cancer. Health Canada. Ottawa, Ontario, Canada.
- 2014 Apr 3 **Invited Speaker.** Incorporation of Epidemiological Methods into Clinical Trials Grand Rounds. Queen's University, NCIC CTG. Kingston, Ontario, Canada. 30 PIs, Scientists, Centre Staff, Trainees.
- 2008 Sep 5 **Invited Speaker.** Pharmacogenetics and variations in response and toxicity in lung cancer. Roswell Park Center Institute, Lung Cancer symposium. Niagara on the Lake, Ontario. Post-graduate, continuing education (n=50), MD. (Continuing Education).
- 2007 Mar 3 **Invited Lecturer.** The future of radiation treatment in the 21st Century. Cancer Care Ontario; Radiation Treatment Program Symposium. Hamilton. 70 attendees - academic and community oncologists, cancer researchers, Post-graduate, continuing education. (Continuing Education).

### Presented and Published Abstracts

- 2019 Nov 5 Systemic Inflammatory Markers of Survival in Epidermal Growth Factor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC). Canadian Cancer Research Conference (by the CCRA: Canadian Cancer Research Alliance). Ottawa, Ontario, Canada.

#### *Publication Details:*

Sze Wah Samuel Chan, Elliot Smith, Reenika Aggarwal, Karmugi Balaratnam, RuiQi Chen, Katrina Hueniken, Frances A. Shepherd, Penelope A. Bradbury, Adrian G. Sacher, Natasha B. Leighl, Catherine Brown, Lawson Eng, **Geoffrey Liu**. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 2021;S1525-7304(21):00005-X. **Senior Responsible Author.**

- 2019 Nov 3 Factors Influencing Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors using Real World Data. Canadian Cancer Research Conference (by the CCRA: Canadian Cancer Research Alliance). Ottawa, Ontario, Canada.

#### *Publication Details:*

Sze Wah Samuel Chan, Sally Lau, Elliot Smith, Lisa W. Le, Katrina Hueniken, Catherine Brown, Lawson Eng, RuiQi Chen, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, **Geoffrey Liu**, Adrian Sacher. Factors Influencing Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with

Immune Checkpoint Inhibitors using Real World Data. 2019. **Coauthor or Collaborator**.

2019 Nov 3 Sites of Metastases and Lung Cancer Outcomes After Treatment with Immune Checkpoint Inhibitors. Canadian Cancer Research Conference (by the CCRA: Canadian Cancer Research Alliance). Ottawa, Ontario, Canada.

*Publication Details:*

Sze Wah Samuel Chan, Elliot Smith, Sally Lau, Lisa W. Le, Katrina Hueniken, Catherine Brown, Lawson Eng, RuiQi Chen, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, **Geoffrey Liu**, Adrian Sacher. Sites of Metastases and Lung Cancer Outcomes After Treatment with Immune Checkpoint Inhibitors. 2019. **Coauthor or Collaborator**.

2019 Nov 3 Clinical Predictors of Hyperprogression in advanced NSCLC following PD-1/PD-L1 inhibitor initiation. Canadian Cancer Research Conference (by the CCRA: Canadian Cancer Research Alliance). Ottawa, Ontario, Canada.

*Publication Details:*

Elliot Smith, Sally Lau, Sze Wah Samuel Chan, Lisa W. Le, Katrina Hueniken, M. Catherine Brown, Natasha B. Leighl, Penelope A. Bradbury, Frances A. Shepherd, Lawson Eng, RuiQi Chen, **Geoffrey Liu**, Adrian Sacher. Clinical Predictors of Hyperprogression in advanced NSCLC following PD-1/PD-L1 inhibitor initiation. 2019. **Coauthor or Collaborator**.

2019 May 13 Identifying a high risk subpopulation within a lung cancer screening program via long term interval screening. Canadian Society of Epidemiology and Biostatistics (CSEB). Ottawa, Ontario, Canada.

*Publication Details:*

Aggarwal R, Lam AC L, Tsao MS, Shepherd FA, McGregor M, Menezes R, Tateishi H, Xu W, McInnis M, O'Kane GM, Hueniken K, Schmidt H, Kavanagh, **Liu G**. Identifying a high risk subpopulation within a lung cancer screening program via long term interval screening. 2019. **Senior Responsible Author**.

2019 May 13 Improving participant selection for lung cancer screening with the addition of spirometry: an interim analysis. Canadian Society of Epidemiology and Biostatistics (CSEB). Ottawa, Ontario, Canada.

*Publication Details:*

Lam ACL, Aggarwal R, Stewart E, Hueniken K, McGregor M, Xu W, Schmidt H, **Liu G**, Kavanagh J. Improving participant selection for lung cancer screening with the addition of spirometry: an interim analysis. 2019. **Senior Responsible Author**.

2012 Nov Identification of predictive characteristics of alcohol reduction and relapse among lung cancer survivors. American Society of Clinical Oncology (ASCO). Kingston, Ontario, Canada.

*Publication Details:*

Dong J, Fadhel E, Espin-Garcia O, Palepu PR, Joshi G, Hon H, Harland L, La Delfa A, Habbous S, Cuffe S, Pierre A, Brade A, Leighl NB, Shepherd FA, Xu W, Eng L, **Liu G**. Identification of predictive characteristics of alcohol reduction and relapse among lung cancer survivors. 2012 Nov. Canadian Undergraduate Conference on Healthcare, Kingston, Ontario, 2012. **Senior Responsible Author**.

2009 The Associations between Asbestos-Exposure, Pulmonary Function and Computed Tomography Found Pulmonary Fibrosis. Ottawa, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Stegne M, Tammemagi M, **Liu G**, Roberts H. The Associations between Asbestos-Exposure, Pulmonary Function and Computed Tomography Found Pulmonary Fibrosis. Proc Can Soc Epidemiol Biostat 2009; abstr 56. Ottawa (Poster). (Co-Investigator supervising MS). **Co-investigator**.

#### 4. LOCAL

##### Invited Lectures and Presentations

- 2023 Mar **Invited Speaker.** Update on role of immunotherapy in metastatic. NSCLC. Toronto, Ontario, Canada. 25 nurses.
- 2021 Nov 4 **Invited Speaker.** Pembrolizumab as the backbone treatment of nontargetable metastatic NSCLC. Merck (Virtual). Toronto, Ontario, Canada. Virtual Presentation.
- 2021 Nov 1 **Invited Lecturer.** Cancer Outcome and Survivorship. University of Toronto (Virtual). Toronto, Ontario, Canada. DLSPH course lecture. Virtual Presentation.
- 2021 May 26 **Invited Speaker.** Natural Language Processing for the Identification of Pre-Invasive Precursor Lesions in Pathology: NLP4. A combined PM Cancer Prevention pilot and 2BLAST/Biobank Use Case. UHN Prevention Group (Virtual). Toronto, Ontario, Canada. Virtual Presentation.
- 2021 Apr 15 **Invited Lecturer.** Grant writing “or How to write scientifically” A small string of pearls. University of Toronto (Virtual). Toronto, Ontario, Canada. Medical Oncology Fellow lecture. Virtual Presentation.
- 2021 Apr 14 **Invited Lecturer.** Non-Small Cell Lung Cancer: Progress, Promises and Pitfalls. University of Toronto (Virtual). Toronto, Ontario, Canada. Pharmacy Talk. Virtual Presentation.
- 2021 Mar 21 **Invited Lecturer.** Molecular Pharmacology and Epidemiology. University of Toronto (Virtual). Toronto, Ontario, Canada. MBP course lecture. Virtual Presentation.
- 2019 May 19 **Invited Speaker.** Lung-CALIBRE Program. Princess Margaret Cancer Research Retreat. Toronto, Ontario, Canada. 60 individuals; 180 minute preparation.
- 2019 Feb 22 **Invited Speaker.** Breathomics for diagnosis of esophageal cancer. Esophageal Cancer Research meeting, University Health network. Toronto, Ontario, Canada. 30 individuals; multilevel trainees to faculty; oncology 180 minutes preparation.
- 2018 Apr 24 **Invited Speaker.** Scenario 4: Phenotyping issues of toxicity in the cancer setting. International Society for Pharmacoepidemiology (ISPE) Mid Year Meeting. Toronto, Ontario, Canada.
- 2018 Mar **Invited Speaker.** ALK positive Lung Cancer. Medical Oncology City Wide Grand Rounds. Canada.
- 2017 Nov 17 **Invited Speaker.** It's ALK Crazy: The rapidly changing therapeutic face of ALK positive lung cancer. University of Toronto. Toronto, Ontario, Canada. Oncology CE Rounds.
- 2017 Apr 20 **Invited Speaker.** A clinician scientist and serendipity. University of Toronto. Toronto, Ontario, Canada. Phillipson Scholars Celebration.
- 2016 Nov 4 **Invited Speaker.** Pharmacogenetics. Ontario Institute for Cancer Research. Toronto, Ontario, Canada. 30 scientists and trainees, OICR, Toronto, Ontario.
- 2016 Oct 6 **Invited Speaker.** Smoking Cessation and Lung Cancer Screening. TEACH Oncology. Toronto, Ontario, Canada.
- 2015 Oct 20 **Invited Speaker.** Big Data and the Biomarker Pipeline. University of Toronto, Medical Biophysics Department. Orillia, Ontario, Canada.
- 2013 Jun 27 **Invited Speaker.** Molecular Epidemiology in the Brave new World of Personalized Medicine. Toronto,

Ontario, Canada. Clinicians and Researchers.

- 2011 Dec 2 **Invited Speaker.** ON-PROST Background. Toronto, Ontario, Canada. Presenter(s): Patient Reported Outcomes Workshop. Researchers, Clinicians, and Health Care Policy Leaders at Provincial Level.
- 2011 Nov 29 **Invited Lecturer.** BRM Polymorphisms in Lung Cancer Risk Stratification: A New Clinical Paradigm. Canadian Cancer Research Conference. Toronto, Ontario, Canada. Attendees: 250 researchers and students.
- 2011 Nov 27 **Invited Lecturer.** Challenges and Opportunities: ON-PROST perspective. ON-PROST-Ontario Cancer Study Joint Meeting. Toronto, Ontario, Canada. Researchers at all levels.
- 2010 Apr 8 CCO Annual Research Day Pharmacogenetic Epidemiology. University Health Network, MaRS Building. Toronto, Ontario, Canada. Researchers at all levels. (Continuing Education).
- 2010 Mar 5 Body Mass Index in Early Adulthood and Esophageal Cancer Prognosis. Cancer Epidemiology Group, University of Toronto. Toronto. Seminar 15 attendees, Graduate students and Research Epidemiologists. (Continuing Education).
- 2009 Jun 29 **Invited Lecturer.** Biospecimen Resources and Clinical Annotation. Ontario Institute of Cancer Research First Biomarkers Workshop. Toronto, Ontario, Canada. Seminar 50 attendees, Scientists and Clinicians. (Continuing Education).
- 2009 Mar 10 Cancer Case Control Studies and Case Outcomes Analyses. Lunenfeld Genetic Biostatistics Group. Toronto. Seminar 15 attendees, PhD graduate and Post-graduate. (Continuing Education).
- 2009 Jan 7 Pharmacogenetics of Upper Aerodigestive Tract Cancers. Applied Molecular Oncology Seminar. Toronto. Seminar 40 attendees, PhD/MD graduate and post-graduate. (Continuing Education).
- 2008 Dec 19 **Invited Lecturer.** Pharmacogenetic Epidemiology of Upper Aerodigestive Tract Cancers. City-wide Oncology Rounds, PMH (broadcast province wide). Toronto, Ontario, Canada. 30 attendees, Oncologists (medical/radiation/surgical) MD, continuing education. (Continuing Education).
- 2007 Nov 17 **Invited Lecturer.** Pharmacogenomics of lung cancer: Methods and Results. Joint Meeting of the 4th ISC International Conference on Cancer Therapeutics and the 7th Princess Margaret Hospital Conference: New Developments in Cancer Management. Toronto, Ontario, Canada. 130 attendees: clinicians, scientists; post-graduate, whole class; MDs. (Continuing Education).
- 2007 Oct 15 **Invited Lecturer.** Predictive Biomarkers for Response to EGFR Therapy: Clinical Perspective. 2nd Annual Innovations in Clinical Trials: Implementation of Biomarkers (Cambridge Healthtech Institute/Ontario Genomics Institute). Toronto, Ontario. 45 attendees: post-graduate, MD clinicians, PhD scientists, policy-makers. (Continuing Education).
- 2007 Sep 17 Molecular epidemiology of esophageal cancer prognosis. Sunnybrook GI Oncology Multidisciplinary Rounds, Toronto Sunnybrook Regional Cancer Centre. Toronto, Ontario. 10 attendees, seminar, oncologists (medical/radiation/surgical) Continuing Education, post-graduate. (Continuing Education).
- 2007 Jun 8 Molecular epidemiology of upper aerodigestive cancer outcomes. Elia Wharton Head and Neck Cancer Research Day, Princess Margaret Hospital. Toronto, Ontario. 35 attendees, whole class, post-graduate physicians and scientists, radiation therapists, MD, continuing education. (Continuing Education).
- 2007 May 2 Pharmacogenetics of Aerodigestive Cancers. University Health Network Medicine Grand Rounds, Princess Margaret Hospital. Toronto, Ontario. Invited lecture, 80 attendees, physicians MD, continuing education, post-graduate. (Continuing Education).
- 2002 Jul 18 **Invited Lecturer.** Lung Cancer and Genetic Polymorphisms. Princess Margaret Hospital Seminar Series. Toronto, Ontario, Canada. 40 attendees, Physician staff and scientists (including Principal Investigators). (Continuing Education).
- 1998 Feb 13 GSTM1 and pancreatic cancer. Institute of Clinical Evaluative Sciences Rounds. Toronto. (Continuing Education).



Geoffrey LIU

- 1998 Jan 15 The Genetics of Pancreatic Cancer. Interdisciplinary Preventive Oncology Rounds, Ontario Cancer Institute. Toronto. (Continuing Education).
- 1996 Mar 12 Patient Preferences for Oral versus Intravenous Chemotherapy. Toronto Sunnybrook Regional Cancer Centre, Nursing Rounds. Toronto. (Continuing Education).

### Presented Abstracts

- 1990 May The measurement of cellular proliferation in breast tissues can be performed on fine needle aspirates. Annual Assembly of General Surgeons and Residents, University of Toronto. Toronto, Ontario, Canada. Presenter(s): **Liu G.** Liu G, McCready D, Trudeau M, Lickley L, Boyd N, Buick R.

### Presented and Published Abstracts

- 2023 Sep Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Canadian Society of Otolaryngology - Head & Neck Surgery - 2023 Annual Meeting. Toronto, Ontario, Canada. Presenter(s): Salahaldin Alamleh. 1st place overall poster.

#### *Publication Details:*

S Alamleh, J Lee, L Zhan, K Hueniken, M Mahler, A Billfalk-Kelly, J Davies, C Brown, S Huang, A Hope, W Xu, D Goldstein, **G Liu.** Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. **Senior Responsible Author.**

- 2023 Feb Outcomes of patients with KRASG12C mutant Non-Small Cell Lung Cancer (NSCLC) with stage IV disease at diagnosis (De Novo) versus at recurrence. Medical Student Research Day, University of Toronto. Toronto, Ontario, Canada. Presenter(s): Niki Esfahanian. Best CREMS poster in MSRD.

#### *Publication Details:*

N. Esfahanian, L.J. Zhan, M.C. Brown, K. Khan, J. Lee, K. Balaratnam, T. Hoxha, J. Parker, **G. Liu.** Outcomes of patients with KRASG12C mutant Non-Small Cell Lung Cancer (NSCLC) with stage IV disease at diagnosis (De Novo) versus at recurrence. **Senior Responsible Author.**

- 2023 Feb Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Medical Student Research Day, University of Toronto. Toronto, Ontario, Canada. Presenter(s): Salahaldin Alamleh. Best Clinical Medicine poster.

#### *Publication Details:*

S Alamleh, J Lee, L Zhan, K Hueniken, M Mahler, A Billfalk-Kelly, J Davies, C Brown, S Huang, A Hope, W Xu, D Goldstein, **G Liu.** Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. **Senior Responsible Author.**

- 2022 Jun Developing a standardized framework for curating oncology datasets generated by manual abstraction and artificial intelligence. Department of Medical Oncology Research Day, Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Presenter(s): Rami Ajaj.

#### *Publication Details:*

Rami Ajaj, Benjamin M. M. Grant, Luna Zhan, Aein Zarrin, Lina Darwish, Khaleeq Khan, Devalben Patel, Kaitlyn Chiasson, Karmugi Balaratnam, Maisha T. Chowdhury, Amir-Arsalan Sabouhanian, Joshua Herman, Preet Walia, Evan Strom, M. Catherine Brown, Miguel Garcia-Pardo, Sabine Schmid, Christopher Pettengell, Erin L. Stewart, **Geoffrey Liu.** Developing a standardized framework for curating oncology datasets generated by manual abstraction and artificial intelligence. Cancer Research. 2022 Jun;82(12):4087. **Senior Responsible Author.**

- 2022 Jun Cumulative incidence and Metastatic Patterns of Advanced Non-Small Cell Lung Cancer (NSCLC) Characterized by EGFR status and Histology. Department of Medical Oncology Research Day, Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Presenter(s): Evan Strom.

#### *Publication Details:*

Evan Strom, Sabine Schmid, Miguel Garcia, Sierra Cheng, Luna Zhan, M. Catherine Brown, Khaleeq Khan, Preet Walia, Amir Sabouhanian, Maisha T. Chowdhury, Joshua Herman, Devalben Patel, Natasha Leighl, Penelope Bradbury, Frances A. Shepherd, Adrian Sacher, Wei Xu, David Shultz, **Geoffrey Liu**. Cumulative incidence and Metastatic Patterns of Advanced Non-Small Cell Lung Cancer (NSCLC) Characterized by EGFR status and Histology. **Senior Responsible Author**.

2022 Feb Treatment patterns and outcomes of Osimertinib-treated EGFR mutation-positive NSCLC patients: A real-world study. Medical Student Research Day, University of Toronto. Toronto, Ontario, Canada. Presenter(s): Jae Lee.

*Publication Details:*

Jae Yun Lee, Vicky Mai, Miguel Garcia, Sierra Chang, Khaleeq Khan, Karmugi Balaratnam, Abhinav Thakral, Catherine Brown, Luna Zhan, **Geoffrey Liu**. Treatment patterns and outcomes of Osimertinib-treated EGFR mutation-positive NSCLC patients: A real-world study. **Senior Responsible Author**.

2019 Jun 14 Performance of the patient reported CAPLET2.0 physical functioning assessment tool. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Alexandra McCartney, Julia Singer, Reenika Aggarwal, Katrina Hueniken, Raiza Committing, Shubhangi Shah, Susan Tang, Priya Bapat, Pansy Chow, Kristen Dietrich, Elizabeth Hall, M. Catherine Brown, Wei Xu, **Geoffrey Liu**. Performance of the patient reported CAPLET2.0 physical functioning assessment tool. Journal of Clinical Oncology. 2019;37(27):abstr 194. **Senior Responsible Author**.

2019 Jun 14 Improving participant selection for lung cancer screening with the addition of spirometry: an interim analysis. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Lam ACL, Aggarwal R, Stewart E, Hueniken K, McGregor M, Xu W, Schmidt H, **Liu G**, Kavanagh J. Improving participant selection for lung cancer screening with the addition of spirometry: an interim analysis. 2019. **Senior Responsible Author**.

2019 Jun 14 Predictors of adherence to remote web-based symptom monitoring intervention. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada. Best Poster Award.

*Publication Details:*

D. Davies, S. Moradian, R. Maguire, M. Krzyzanowska, V. Kukreti, J. Cafazzo A., P. Morita, J. Bender, L. Le W., M. Puts Martin, A. Husain, E. Amir, **G. Liu**, D. Howell. Predictors of adherence to remote web-based symptom monitoring intervention. 2019. **Senior Responsible Author**.

2019 Jun 14 Clinical Predictors of Hyperprogression in Advanced NSCLC Following PD-1/PD-L1 Inhibitor Initiation. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Elliot Smith, Sally Lau, Sze Wah Samuel Chan, Lisa W. Le, Katrina Hueniken, M. Catherine Brown, Natasha B. Leighl, Penelope A. Bradbury, Lawson Eng, RuiQi Chen, **Geoffrey Liu**, Adrian Sacher. Clinical Predictors of Hyperprogression in Advanced NSCLC Following PD-1/PD-L1 Inhibitor Initiation. 2019. **Coauthor or Collaborator**.

2019 Jun 14 A Remote-Symptom Reporting Mobile Application for Lung Cancer and Sarcoma Patients in an Outpatient Clinic: Environmental Scan and Readiness Assessment. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Fan J, Nagaratnam S, Lee S, Harris J, De Guia C, Brown MC, Kooner S, **Liu G**. A Remote-Symptom Reporting Mobile Application for Lung Cancer and Sarcoma Patients in an Outpatient Clinic: Environmental Scan and Readiness Assessment. 2019. **Senior Responsible Author**.

- 2019 Jun 14 Ototoxicity in Cisplatin based chemotherapy in Head and Neck Cancer patients Prevalence Estimates and potential Risk factors. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Sachumsky T, Zhan LJ, Hueniken K, Lee J, Aggarwal R, **Liu G**. Ototoxicity in Cisplatin based chemotherapy in Head and Neck Cancer patients Prevalence Estimates and potential Risk factors. 2019. **Senior Responsible Author**.

- 2019 Jun 14 Implementing Routine Ototoxicity Screening for Head and Neck Cancer Patients within the HN Translational Study. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

P Chow, P Bapat, K Hueniken, M Mahler, MC Brown, C Falls, A Hope, A Hansen, DP Goldstein, J Rutka, D Howell, W Xu, **G Liu**. Implementing Routine Ototoxicity Screening for Head and Neck Cancer Patients within the HN Translational Study. 2019. **Senior Responsible Author**.

- 2019 Jun 14 Barriers and Facilitators to the Implementation of Routine Ototoxicity Screening for Head and Neck Cancer Patients. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Priya Bapat, Pansy Chow, Katrina Hueniken, Mary Mahler, M. Catherine Brown, Carolyn Falls, Andrew J. Hope, Aaron Richard Hansen, David Paul Goldstein, John Rutka, Doris Howell, Wei Xu, **Geoffrey Liu**. Barriers and Facilitators to the Implementation of Routine Ototoxicity Screening for Head and Neck Cancer Patients. 2019. **Senior Responsible Author**.

- 2019 Jun 14 Identifying a high risk subpopulation within a lung cancer screening program via long term interval screening. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Aggarwal R, Lam AC L, Tsao MS, Shepherd FA, McGregor M, Menezes R, Tateishi H, Xu W, McInnis M, O'Kane GM, Hueniken K, Schmidt H, Kavanagh J, **Liu G**. Identifying a high risk subpopulation within a lung cancer screening program via long term interval screening. 2019. **Senior Responsible Author**.

- 2019 Jun 14 Real-World Characterization of Cancer Patients Admitted with Immune-Related Adverse Events (irAEs). UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

R. Chen, E .C. Smith, S.W.S. Chan, K. Hueniken, M.C. Brown, H. Majeed, K. Ross, D. Gray, W. Xu, D. Hogg, S.S. Sridhar, A.G. Sacher, N.B. Leighl, M.K. Krzyzanowska, M .O. Butler, **G. Liu**, L. Eng. Real-World Characterization of Cancer Patients Admitted with Immune-Related Adverse Events (irAEs). 2019. **Senior Responsible Author**.

- 2019 Jun 14 Real-world Health Utility Scores and Toxicities to Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Advanced Non-small Cell Lung. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Jiang, Shirley Xue, Walton, Ryan N., Hueniken, Katrina, Baek, Justine, McCartney, Alexandra, Labbé, Catherine, Smith, Elliot, Chan, Sze Wah Samuel, Chen, RuiQi, Brown, Catherine, Patel, Devalben, Liang, Mindy, Eng, Lawson, Sacher, Adrian, Bradbury, Penelope, Leighl, Natasha B., Shepherd, Frances A., Xu, Wei, **Liu, Geoffrey**, Hurry, Manjusha, O'Kane, Grainne M. Real-world Health Utility Scores and Toxicities to Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Advanced Non-small Cell Lung. Cancer Med. 2019;8(18):7542-7555. **Coauthor or Collaborator**.

- 2019 Jun 14 Longitudinal Real-world Health Utility Scores and Toxicities to Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Advanced Non-small Cell Lung Cancer. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Jiang, Shirley Xue, Walton, Ryan N., Hueniken, Katrina, Baek, Justine, McCartney, Alexandra, Labbé, Catherine, Smith, Elliot, Chan, Sze Wah Samuel, Chen, RuiQi, Brown, Catherine, Patel, Devalben, Liang, Mindy, Eng, Lawson, Sacher, Adrian, Bradbury, Penelope, Leighl, Natasha B., Shepherd, Frances A., Xu, Wei, **Liu, Geoffrey**, Hurry, Manjusha, O'Kane, Grainne M. Longitudinal Real-world Health Utility Scores and Toxicities to Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Advanced Non-small Cell Lung Cancer. 2019. **Coauthor or Collaborator**.

- 2019 Jun 14 A Feasibility and Implementation Study of Remote Symptom Reporting in Thoracic. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Simranjit Kooner, **Geoffrey Liu**, Suheon Lee, Jennifer Harris, Catherine De Guia, Subiksha Nagaratnam. A Feasibility and Implementation Study of Remote Symptom Reporting in Thoracic. 2019. **Senior Responsible Author**.

- 2019 Jun 14 The Esophageal-Online Patient Reported Outcome Questionnaire (EsO-PRO): Formal Implementation Assessment of a Combined Clinical and Research Data Collection Tool. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Shirley Xue Jiang, Shubhangi Shah, Elliot Smith Justine Baek, Mindy Liang, M. Catherine Brown, Allyson Mayo, **Geoffrey Liu**, Jonathan Yeung, Rebecca Wong, Elena Elimova, Gail Darling. The Esophageal-Online Patient Reported Outcome Questionnaire (EsO-PRO): Formal Implementation Assessment of a Combined Clinical and Research Data Collection Tool. Journal of Clinical Oncology. 2019;37(4):abstr 37. **Coauthor or Collaborator**.

- 2019 Jun 14 Lung Cancer Outcomes After Treatment with Immune Checkpoint Inhibitors. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Sze Wah Samuel Chan, Sally Lau, Elliot Smith, Lisa W. Le, Katrina Hueniken, Catherine Brown, Lawson Eng, RuiQi Chen, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, **Geoffrey Liu**, Adrian Sacher. Lung Cancer Outcomes After Treatment with Immune Checkpoint Inhibitors. 2019. **Coauthor or Collaborator**.

- 2019 Jun 14 Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. UHN-DMOH-Annual Divisional Research Day. Toronto, Ontario, Canada.

*Publication Details:*

Lawson Eng, Jie Su, Steven Habbous, Katrina Hueniken, M. Catherine Brown, Deborah Saunders, John R. de Almeida, Andrew Hope, Andrea Bezjak, Frances A. Shepherd, Natasha B. Leighl, Andrew Pierre, Peter Selby, David Paul Goldstein, Wei Xu, Meredith Elana Giuliani, William K. Evans, **Geoffrey Liu**, Michael Chaiton. Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. Journal of Clinical Oncology. 2019;37(15):abstr 11559. **Coauthor or Collaborator**.

- 2018 Oct 22 Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation. Canadian Association for Population Therapeutics (CAPT) 2018 Annual Conference. Toronto, Ontario, Canada. Presenter(s): Katrina Hueniken. (Trainee Presentation)

*Publication Details:*

Hueniken K, Zhang Y, Falls C, Brown MC, Mirshams M, Rahimi M, Spreafico A, Jang R, Hansen A, Siu L, Waldron J, Bayley A, Giuliani ME, Goldstein DP, Wang J, Hope A, Xu W, Bratman S, **Liu G**, Mahler M. Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation. Poster. **Senior Responsible Author**.

- 2018 Sep 26 Establishment of PDX from Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Sebastiao Martins-Filho. (Trainee Presentation)

*Publication Details:*

S. Martins-Filho, M. Cabanero, N. Pham, E. Stewart, D. Ravi, D. Patel, J. McConnell, A. Grindlay, F. Allison, M. Li, F. Shepherd, M. Tsao, K. Yasufuku, **G. Liu**. Establishment of PDX from Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids. Mini-oral Presentation MA27.01. **Senior Responsible Author**.

- 2018 Sep 26 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutate NSCLC Primary-Derived Xenograft. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Erin Stewart. (Trainee Presentation)

*Publication Details:*

E. Stewart, M. Cabanero, V. Raghavan, J. Bruce, P. Guilhamon, R. Singhanian, N. Pham, S.Y. Shen, T. Li, M. Li, N. Leighl, F. Shepherd, T. Pugh, D. De Carvalho, M. Lupien, **G. Liu**, M. Tsao. Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutate NSCLC Primary-Derived Xenograft. Mini-oral Presentation MA27.03. **Senior Responsible Author**.

- 2018 Sep 25 Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Michael Herman. (Trainee Presentation)

*Publication Details:*

M. Herman, N. Leighl, F. Shepherd **G. Liu**, P. Bradbury. Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility. Poster P2.01-46. **Coauthor or Collaborator**.

- 2018 Sep 25 Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Min Joon Lee. (Trainee Presentation)

*Publication Details:*

M.J. Lee, N. Kuehne, K. Hueniken, H. Sorotsky, M. Liang, D. Patel, D. Cheng, Z. Chen, L. Eng, M.C. Brown, J. Cho, N. Leighl, M. De Perrot, D. Reisman, W. Xu, P. Bradbury, **G. Liu**. Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival. Poster P2-06-23. **Senior Responsible Author**.

- 2018 Sep 25 Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Badr Id Said. (Trainee Presentation)

*Publication Details:*

B. Id Said, K. Hueniken, M.C. Brown, D. Patel, M. Liang, C. Labbe, L. Eng, H. Nail, P. Bradbury, F. Shepherd, N. Leighl, **G. Liu**, G. O'Kane. Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer. Poster P2.15-10. **Senior Responsible Author**.

- 2018 Sep 25 The Impact of Clinical and Molecular Profile of resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Mor Moskovitz. (Trainee Presentation)

*Publication Details:*

M. Moskovitz, M. Cabanero, J. Torchia, H. Sorotsky, J. Weiss, M. Pintilie, N. Leighl, P. Bradbury, **G. Liu**, G. Zadeh, M. Doherty, A. Kia, D. Torti, M. Tsao, T. Pugh, F. Shepherd. The Impact of Clinical and Molecular Profile of resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases. Poster P3.16-07. **Coauthor or Collaborator**.

- 2018 Sep 25 Two BRM promoter polymorphisms do not predict susceptibility or prognosis of thymoma. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Nathan Kuehne. Oral presentation OA11.06. (Trainee Presentation)
- Publication Details:*  
M.J. Lee, N. Kuehne, K. Hueniken, D. Shepshelovich, S. Soldera, S. Shakik, D. Patel, D. Cheng, Z. Chen, L. Eng, M.C. Brown, A. Bezjak, S. Keshavjee, D. Reisman, W. Xu, **G. Liu**. Two BRM promoter polymorphisms do not predict susceptibility or prognosis of thymoma. 2018 Sep 25. **Senior Responsible Author**.
- 2018 Sep 25 Predictors of Financial Toxicity, an Underrecognized Patient-Reported Outcome. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Doreen Ezeife. Mini-oral presentation MA14.06. (Trainee Presentation)
- Publication Details:*  
D. Ezeife, J. Morganstein, S. Lau, J. Law, L. Le, P. Bradbury, **G. Liu**, F. Shepherd, N. Leighl. Predictors of Financial Toxicity, an Underrecognized Patient-Reported Outcome. 2018 Sep 25. **Coauthor or Collaborator**.
- 2018 Sep 25 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Lawson Eng. Mini-oral presentation MA18.07. (Trainee Presentation)
- Publication Details:*  
L. Eng, S. Liu, D. Farzanfar, D. Alton, E. Smith, A. McCartney, S. Yeung, A. Basgaran, K. Balaratnam, K. Mattina, C. Harper, R. Mohan, M.C. Brown, A. Hope, P. Bradbury, A. Sacher, N. Leighl, F. Shepherd, A. Bezjak, D. Howell, J. Jones, W. Xu, D. Goldstein, W. Evans, P. Selby, M. Giuliani, **G. Liu**. Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors. 2018 Sep 25. **Senior Responsible Author**.
- 2018 Sep 25 Remote System Reporting for Tele-nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Simranjit Kooner. (Trainee Presentation)
- Publication Details:*  
S. Kooner, J. Harris, S. Lee, C. De Guia, D. Howell, **G. Liu**. Remote System Reporting for Tele-nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement. Mini-oral presentation MA17.09. **Senior Responsible Author**.
- 2018 Sep 25 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Shirley Xue Jiang. (Trainee Presentation)
- Publication Details:*  
S. Jiang, M. Hurry, K. Hueniken, M.C. Brown, M. Liang, D. Patel, C. Labbe, L. Eng, H. Naik, P. Bradbury, N. Leighl, F. Shepherd, W. Xu, **G. Liu**, R. Walton, G. O'Kane. Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. Mini-oral Presentation MA19.09. **Coauthor or Collaborator**.
- 2018 Sep 24 Real-World Evaluation of Tolerability in Older Adult Patients ( $\geq 75$  Years Old) with EGFR-Mutated NSCLC. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Shirley Xue Jiang. (Trainee Presentation)
- Publication Details:*  
S. Jiang, M. Hurry, K. Hueniken, C. Labbe, M.C. Brown, L. Eng, H. Naik, M. Liang, D. Patel, P. Bradbury, N. Leighl, F. Shepherd, W. Xu, **G. Liu**, R. Walton, G. O'Kane. Real-World Evaluation of Tolerability in Older Adult Patients ( $\geq 75$  Years Old) with EGFR-Mutated NSCLC. Poster P1.01-42. **Coauthor or Collaborator**.

- 2018 Sep 24 Pro-CTCAE Toxicities in advanced NSCLC Patients with RGFR Mutations: a Real World Assessment. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Katrina Hueniken. (Trainee Presentation)
- Publication Details:*  
K. Hueniken, M. Hurry, S. Jiang, C. Labbe3, M.C. Brown, L. Eng, H. Naik, M. Liang, D. Patel, P. Bradbury, N. Leighl, F. Shepherd, W. Xu, G. O'Kane, R. Walton, **G. Liu**. Pro-CTCAE Toxicities in advanced NSCLC Patients with RGFR Mutations: a Real World Assessment. Poster P1.13-11. **Senior Responsible Author.**
- 2018 Sep 24 Detection of EGFR Mutations in CFDNA and Development of Resistance. International Association for the Study of Lung Cancer (IASLC). Toronto, Ontario, Canada. Presenter(s): Grainne O'Kane. (Trainee Presentation)
- Publication Details:*  
G. O'Kane, **G. Liu**, T. Stockley, M. Shabir, T. Zhang, L. Le, F. Shepherd, P. Bradbury, N. Leighl. Detection of EGFR Mutations in CFDNA and Development of Resistance. Poster P1.13-15. **Co-Principal Author.**
- 2018 Sep Awareness of Harms of Continued Smoking Among Lung Cancer (LC) Survivors. IASLC, 19th World Conference on Lung Cancer (WCLC). Toronto, Ontario, Canada. Presenter(s): Lawson Eng.
- Publication Details:*  
Lawson Eng, Sophia Liu, Delaram Farzanfar, Devon Alton, Elliot Charles Smith, Alexandra McCartney, Sabrina Yeung, Amedra Basagaran, Karmugi Balaratnam, Katie Mattina, Christopher Harper, Rahul Mohan, M Catherine Brown, Andrew Hope, Penelope A Bradbury, Adrian G Sacher, Natasha B Leighl, Frances A Shepherd, Andrea Bezjak, Doris Howell, Jennifer M Jones, Wei Xu, David P Goldstein, William K Evans, Peter Selby, Meredith Giuliani, **Geoffrey Liu**. Awareness of Harms of Continued Smoking Among Lung Cancer (LC) Survivors. **Senior Responsible Author.**
- 2018 Sep Association of two BRM promoter polymorphisms and tobacco exposure with malignant pleural mesothelioma (MPM) risk and survival. IASLC, 19th World Conference on Lung Cancer (WCLC). Toronto, Canada. Presenter(s): Min Joon Lee.
- Publication Details:*  
Min Joon Lee, Nathan Kuehne, Katrina Hueniken, Hadas Sorotsky, Mindy Liang, Devalben Patel, Dangxiao Cheng, Zhuo Chen, Lawson Eng, M. Catherine Brown, John Cho, Natasha B. Leighl, Marc De Perrot, David Reisman, Wei Xu, Penny Bradbury, **Geoffrey Liu**. Association of two BRM promoter polymorphisms and tobacco exposure with malignant pleural mesothelioma (MPM) risk and survival. **Senior Responsible Author.**
- 2018 Sep Remote Symptom Reporting for Tele-Nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement. IASLC, 19th World Conference on Lung Cancer (WCLC). Toronto, Canada. Presenter(s): Simranjit Kooner.
- Publication Details:*  
Simranjit Kooner RN, Jennifer Harris RN, Suheon Lee RN, Catherine De Guia RN, Doris Howell RN PhD, **Geoffrey Liu**, MD. Remote Symptom Reporting for Tele-Nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement. **Senior Responsible Author.**
- 2018 Jun 14 A Feasibility and Implementation Study of Remote Symptom Reporting in Thoracic and Sarcoma Oncology Patients. Collaborative Academic Practice Research and Innovation Day 2018 (UHN). Toronto, Ontario, Canada.
- Publication Details:*  
Kooner S, **Liu G**, Lee S, Harris J, De Guia C, Nagaratnam S. A Feasibility and Implementation Study of Remote Symptom Reporting in Thoracic and Sarcoma Oncology Patients. **Coauthor or Collaborator.**
- 2018 May 30 Health-Related Social Media Use among Adult Cancer Patients: Association with Anxiety/Depression,

Health Score and Perceived Benefits. Canadian Association of Psychosocial Oncology conference (CAPO). Toronto, Ontario, Canada.

*Publication Details:*

Bender J, Hueniken K, Eng L, Mitchell L, Yang D, Kassirian S, Geist I, Paulo C, Magony A, Smith EC, Brown MC, Liang M, Xu W, **Liu G**, Gupta AA. Health-Related Social Media Use among Adult Cancer Patients: Association with Anxiety/Depression, Health Score and Perceived Benefits. Poster. **Coauthor or Collaborator**.

2018 May 30 Cancer-Related Social Media Use among Adolescent and Young Adults (AYA) with Cancer and Preferences for AYA Virtual Programming. Canadian Association of Psychosocial Oncology conference (CAPO). Toronto, Ontario, Canada. Presenter(s): Ilana Geist. (Trainee Presentation)

*Publication Details:*

Geist I, Eng L, Mitchell L, Hueniken K, Yang D, Kassirian S, Paulo C, Brown MC, Xu W, **Liu G**, Gupta AA, Bender J. Cancer-Related Social Media Use among Adolescent and Young Adults (AYA) with Cancer and Preferences for AYA Virtual Programming. Poster. **Coauthor or Collaborator**.

2018 May Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre. Canadian Association of Psychosocial Oncology conference (CAPO). Toronto, Ontario, Canada. Presenter(s): Min Joon Lee.

*Publication Details:*

Min Joon Lee, Shirley Jiang, Yizhuo Gao, Katrina Hueniken, Lin Lu, Lawson Eng, Alexandra McCartney, Tamara Obuobi, Nathan Kuehn, Badr Id Said, Mindy Liang, Hadas Sorotsky, M. Catherine Brown, Wei Xu and **Geoffrey Liu**. Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre. **Senior Responsible Author**.

2018 Apr 12 Feasibility for the Pilot Implementation of a Low Dose CT Lung Cncer Screening Program. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. Presenter(s): Joo Yoon. (Trainee Presentation)

*Publication Details:*

Yoon JH, Lofters A, **Liu G**. Feasibility for the Pilot Implementation of a Low Dose CT Lung Cncer Screening Program. 2018 Apr 12. Poster. **Senior Responsible Author**.

2018 Apr 12 Integrating EQ5D-5L into Oncology Practice. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. Presenter(s): Justine Baek. (Trainee Presentation)

*Publication Details:*

Baek J, Tse T, Brown MC, Skitch A, Chen J, Liang M, Naik H, Eng L, Howell D, Xu W, Shultz D, Brezden-Masley C, **Liu G**. Integrating EQ5D-5L into Oncology Practice. **Senior Responsible Author**.

2018 Apr 12 Implementtion of an eReferral Smoking Cessation Tool Following CT Screening for Early Detection of Lung Cancer. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. Presenter(s): Lina Chen. (Trainee Presentation)

*Publication Details:*

Chen L, Afzaal T, Hueniken K, McGregor M, Schmidt H, Gao Y, Eisen A, Brezden-Masley C, Brown MC, Giuliani M, Jones J, Eng L, **Liu G**. Implementtion of an eReferral Smoking Cessation Tool Following CT Screening for Early Detection of Lung Cancer. Poster. **Senior Responsible Author**.

2018 Apr 12 Comparison of Health Utility Values from EQ-5D-3L and EQ-5D-5L in Breast Cancer Patients in Different Health States. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. Presenter(s): Tiffany Tse. (Trainee Presentation)

*Publication Details:*

Tse T, Yang D, Baek J, Liang M, Skitch A, Brezden-Maskey C, Trudeau M, Brown MC, Torres S, Xu W, **Liu G**. Comparison of Health Utility Values from EQ-5D-3L and EQ-5D-5L in Breast Cancer Patients in



Different Health States. Poster. **Senior Responsible Author.**

2018 Apr Acceptability of Routine Evaluations using Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) and Other Patient Reported Symptom Outcome Tools in Cancer Outpatients. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. Presenter(s): Hamzeh Albaba.

*Publication Details:*

H.Albaba, M.C. Brown, S. Shakik, S. Su, H. Naik, T. Wang, M. Liang, A. Perez-Cosio, L. Eng, N. Mittmann, W. Xu, **G. Liu**, D. Howell, T.A. Barnes. Acceptability of Routine Evaluations using Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) and Other Patient Reported Symptom Outcome Tools in Cancer Outpatients. Annals of Oncology. 2018 Oct;29(8):VIII605. **Co-Principal Author.**

2018 Mar 1 Impact of immigration status on lifestyle behaviours and perceptions in cancer survivors. Toronto Global Cancer Control Conference. Toronto, Ontario, Canada. Presenter(s): Sophia Liu. (Trainee Presentation)

*Publication Details:*

SY. Liu, L. Lu, K. Balarathnam, W. Xu, D. Pringle, M.C. Brown, J. Jones, **G. Liu**, L. Eng. Impact of immigration status on lifestyle behaviours and perceptions in cancer survivors. Rapid Fire Presentation. MACK Foundation Bursary. **Senior Responsible Author.**

2017 Apr The impact of neurocognitive function (NCF) on health utility scores (HUS) in Stage 4 lung cancer (S4LC) patients (pts) with and without brain metastases (BrM). Cancer Care Ontario (CCO), Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Doherty MK, Bradbury PA, Leighl NB, Brown MC, Xu W, Howell D, **Liu G**, O'Kane G. The impact of neurocognitive function (NCF) on health utility scores (HUS) in Stage 4 lung cancer (S4LC) patients (pts) with and without brain metastases (BrM). Poster. **Senior Responsible Author.**

2017 Apr Reducing the burden of patient reporting of physical function in the chronic care of cancer survivors through a branching logic electronic symptom survey (BLESS). Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Hall E, Liang M, Tam E, Chen J, Tian C, Bucci K, Liu L, Tse B, Zheng D, Wong L, Sarabia S, Yeung S, Gill G, Perez-Cosio A, Brown MC, Xu W, **Liu G**, Howell D. Reducing the burden of patient reporting of physical function in the chronic care of cancer survivors through a branching logic electronic symptom survey (BLESS). 2017. Poster. **Senior Responsible Author.**

2017 Apr Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs the 32-combined item HAQ-DI/WHODAS (HW) survey: a quality improvement controlled trial. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Tam E, Chen J, Zhang Q, Zheng D, Tam V, Li Y, Tse T, Brown MC, Xu W, Howell D, **Liu G**, Hall E. Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs the 32-combined item HAQ-DI/WHODAS (HW) survey: a quality improvement controlled trial. 2017. Poster. **Senior Responsible Author.**

2017 Apr The Impact of Brain Metastases and their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

O'Kane GM, Labbe C, Su S, Tse B, Tam V, Tse T, Doherty MK, Stewart EL, Brown MC, Perez Cosio A,

Patel D, Liang M, Gill G, Rett A, Leung Y, Naik H, Eng L, Mittmann N, Leighl NB, Feld R, Bradbury PA, Shepherd FA, Xu W, Howell D, **Liu G**. The Impact of Brain Metastases and their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients. Poster. **Senior Responsible Author**.

2017 Apr Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Shani K, Borean M, Chen J, Li Y, Brown MC, Vennettilli A, Lau A, Zheng D, Kuang Q, Boyd K, Leung Y, Cella D, Mackay H, Darling GE, Wong R, Patel D, Xu W, **Liu G**, Howell D. Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care. Poster. **Senior Responsible Author**.

2017 Apr The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM). Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Tam V, Tse BC, Tse T, Lu L, Borean M, Tam E, Labbé C, Doherty MK, Bradbury PA, Leighl NB, Brown MC, Xu W, Howell D, **Liu G**, O'Kane G. The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM). Poster. **Senior Responsible Author**.

2017 Apr Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. Cancer Care Ontario (CCO) Research Day. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Li Y, Brown MC, Estey K, Gill G, Liang M, Cosio Perez A, Borean M, Shani K, Bradbury PA, Shepherd FA, Leighl NB, Howell D, **Liu G**. Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. Poster. **Senior Responsible Author**.

2017 Feb Reducing patient burden in physical function reporting in cancer survivors through a branching logic electronic symptom survey (BLESS). University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Hall E, Liang M, Tam E, Chen J, Tian C, Bucci K, Liu L, Tse B, Zheng D, Wong L, Sarabia S, Yeung S, Gill G, Perez-Cosio A, Brown MC, Xu W, **Liu G**, Howell D. Reducing patient burden in physical function reporting in cancer survivors through a branching logic electronic symptom survey (BLESS). Poster presentation. **Senior Responsible Author**.

2017 Feb Feasibility and acceptability of patient-reported outcomes for routine capture of dyspnea experience in lung cancer patients and patient's perceptions of self-management support. University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada.

*Publication Details:*

Howell D, Pratt L, Gill G, Brown MC, Perez-Cosio A, Patel D, Yvonne Leung, Naik H, Eng, L Liu G. Feasibility and acceptability of patient-reported outcomes for routine capture of dyspnea experience in lung cancer patients and patient's perceptions of self-management support. Poster. **Senior Responsible Author**.

2017 Feb Characterizing residual erlotinib-tolerant population using EGFR-mutated NSCLC Primary Derived Xenografts: The last holdouts. University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Stewart EL, Cabanero M, Pham NA, Shen SY, Li T, Bruce JP, Li M, Leighl NB, Shepherd FA, Pugh TJ, De Carvalho D, Lupien M, **Liu G**, Tsao MS. Characterizing residual erlotinib-tolerant population using EGFR-mutated NSCLC Primary Derived Xenografts: The last holdouts. Poster. **Senior Responsible Author**.

2017 Feb Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Stewart EL, Labbé C, Brown MC, Perez-Cosio A, Vennetilli S, Patel D, Cheng N, Liang M, Gill G, Leung Y, Mitchell S, Mittmann N, **Liu G**. Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Oral and poster. **Senior Responsible Author**.

2017 Feb Patient-reported symptoms and Canadian Health Utility Scores in Esophageal Cancer Patients. University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada.

*Publication Details:*

Doherty M, Leung Y, Naik H, Patel D, Eng L, Brown MC, Espin-Garcia O, Vennetilli A, Renouf D, Faluyi, Knox J, Mackay H, Wong R, Cella D, Darling G, Howell D, Mittmann N, **Liu G**. Patient-reported symptoms and Canadian Health Utility Scores in Esophageal Cancer Patients. 2017. Poster. **Senior Responsible Author**.

2017 Feb Active surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): A feasibility study. University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Wang TQ, Bergman H, Brown MC, Vennetilli A, Patel D, Seki JT, Perez-Cosio A, Howell D, **Liu G**. Active surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): A feasibility study. Poster. **Senior Responsible Author**.

2017 Feb Feasibility of Collecting Routine Information for Clinical and Research Purposes via Electronic Format Questionnaire. University Health Network, Personalizing Cancer Medicine Conference. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Li Y, Brown MC, Estey K, Gill G, Liang M, Perez Cosio A, Borean M, Shani K, Bradbury P, Shepherd FA, Leighl NB, Dowell D, **Liu G**. Feasibility of Collecting Routine Information for Clinical and Research Purposes via Electronic Format Questionnaire. Poster. **Senior Responsible Author**.

2016 Apr 18 Evaluating patient preferences for research access to Ontario administrative data for long term clinical trial follow up. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Hay AE, Leung YW, Willing S, Perez Cosio A, Bell E, Venetilli A, Edwards J, Howell D, Pater JL, Tian C, Noronha C, Sinnesael K, Kassan Z, **Liu G**. Evaluating patient preferences for research access to Ontario administrative data for long term clinical trial follow up. 2016.

2016 Apr 18 Real World EQ5D Health Utility Values for Metastatic Cancer Patients by Molecular Alteration and Response to Therapy. Cancer Cancer Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Labbé C, Stewart E, Brown C, Perez Cosio A, Vennetilli A, Patel D, Cheng N, Liang M, Gill G, Leung Y, Naik H, Eng L, Mittmann N, Leighl NB, Feld R, Bradbury PA, Shepherd FA, Howell D, **Liu G**. Real World EQ5D Health Utility Values for Metastatic Cancer Patients by Molecular Alteration and Response to

Therapy. 2016.

- 2016 Apr 18      Assessment of a single screening questions for dysphagia for routine clinical use in a tertiary care practice. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Brown C, Vennettilli A, Patel D, Zeman KZ, Lau A, Kuang Q, Boyd K, Cella D, Mackay H, Darling GE, Wong R, Xu W, **Liu G**, Howell D. Assessment of a single screening questions for dysphagia for routine clinical use in a tertiary care practice. J Clin Oncol. 2016.

- 2016 Apr 18      Bench to Bedside Pipeline for Testing Utility of Patient-Reported Outcomes in Routine Cancer Practice: The Ontario Patient Reported Outcomes of Symptoms and Toxicity Applied Clinical Research Unit. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Howell D, Leighl N, Brundage M, Barbera P, Bradbury P, Ringash J, Hope A, Wong R, Rodin G, Li M, Hung R, Kim R, Beddard P, Eng L, Naik H, Mittman N, Amir E, Krzyzanowska M, Brown MC, Perez-Cosio A, Dancey J, Earle C, **Liu G**. Bench to Bedside Pipeline for Testing Utility of Patient-Reported Outcomes in Routine Cancer Practice: The Ontario Patient Reported Outcomes of Symptoms and Toxicity Applied Clinical Research Unit. 2016.

- 2016 Apr 18      Feasibility and acceptability of patient-reported outcomes for routine capture of dyspnea experience in lung cancer patients and patient's perceptions of self-management support. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Howell D, Pratt L, Gill G, Brown C, Perez-Cosio A, Patel D, Naik H, Eng L, **Liu G**. Feasibility and acceptability of patient-reported outcomes for routine capture of dyspnea experience in lung cancer patients and patient's perceptions of self-management support. 2016.

- 2016 Apr 18      Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations by drug therapy. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Stewart E, Labbe C, Brown MC, Perez-Cosio A, Vennettilli A, Patel D, Cheng N, Liang M, Gill G, Leung Y, Mittmann N, Naik H, **Liu G**. Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations by drug therapy. 2016.

- 2016 Apr 18      FRAPPER: The Flexible, Rapid Assessment of Patient Preferences and Experiences Resource: Analysis of impact. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

**Liu G**, Brown MC, Patel D, Howell D. FRAPPER: The Flexible, Rapid Assessment of Patient Preferences and Experiences Resource: Analysis of impact. 2016.

- 2016 Apr 18      Implementation of a New Patient Health Questionnaire into standard practice in outpatient cancer clinics to improve patient care and quality of treatment. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Estey K, Brown MC, Perez-Cosio A, Gill G, Liang M, **Liu G**. Implementation of a New Patient Health Questionnaire into standard practice in outpatient cancer clinics to improve patient care and quality of treatment. 2016.

- 2016 Apr 18      Change in Second-Hand Smoke Exposure After A Lung and Head and Neck Cancer Diagnosis and Subsequent Patient Smoking Cessation. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Eng L, Alton D, Yoannidis T, Song Y, Milne R, Sarabia S, Merali Z, Habbous S, Brown MC, Vennettilli A, Shepherd FA, Leighl NB, Hope A, Howell D, Jones JJ, Selby P, Xu W, Goldstein DP, Giuliani ME, **Liu G**. Change in Second-Hand Smoke Exposure After A Lung and Head and Neck Cancer Diagnosis and Subsequent Patient Smoking Cessation. 2016.

- 2016 Apr 18 Patient-reported symptoms and Canadian Health Utility Scores in Esophageal Cancer Patients. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Doherty M, Leung Y, Naik H, Patel D, Eng L, Brown MC, Espin-Garcia O, Vennettilli A, Renouf D, Faluyi OO, Knox J, Mackay H, Wong R, Cella D, Darling GE, Howell D, Mittmann N, **Liu G**. Patient-reported symptoms and Canadian Health Utility Scores in Esophageal Cancer Patients. 2016.

- 2016 Apr 18 Usability and Feasibility Study of the Advanced Symptom Management System (ASyMS) for Chemotherapy Toxicities in Canadian Cancer Patients: ASyMS-Canada. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Moradian S, Howell D, Maguire R, Kearney N, Krzynakowski M, Morita P, Stinson J, Husain A, Cafazzo J, Barbera, Kukreti LV, Nowell A, Bender J, Lerasts T, **Liu G**. Usability and Feasibility Study of the Advanced Symptom Management System (ASyMS) for Chemotherapy Toxicities in Canadian Cancer Patients: ASyMS-Canada. 2016.

- 2016 Apr 18 Effectiveness of Internet-based interventions in managing chemotherapy-related symptoms in patients with cancer: A systematic review. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Moradian S, Voelker N, **Liu G**, Brown MC, Howell D. Effectiveness of Internet-based interventions in managing chemotherapy-related symptoms in patients with cancer: A systematic review. 2016.

- 2016 Apr 18 Active surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): A feasibility study. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Wang, TQ, Bergman, H, Brown, MC, Vennettilli, A, Patel, D, Seki, JT, Perez-Cosio, A, Howell, D, **Liu, G**. Active surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): A feasibility study. 2016.

- 2016 Apr 18 Comparison of Prevalence of Pain Symptoms and Completion Rates using a Patient-Reported Outcomes (PRO) Tool of Pain in Palliative and Curative Patients. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Leung Y, Yeung S, Brown MC, Perez-Cosio A, Liang M, Gill G, Sarabia S, Liu A, Wong L, Howell D, **Liu G**. Comparison of Prevalence of Pain Symptoms and Completion Rates using a Patient-Reported Outcomes (PRO) Tool of Pain in Palliative and Curative Patients. 2016.

- 2016 Apr 18 Feasibility and Diagnostic Accuracy of the Patient Reported Outcome Information System (PROMIS®) Item Banks for Routine Surveillance of Sleep and Fatigue Problems in Ambulatory Cancer Care. Cancer Care Ontario, Research Day 2016. Toronto, Ontario, Canada.

*Publication Details:*

Leung YW, Brown MC, Perez Cosio A, Dobriyal A, Zarrin A, Malik N, Pat V, Irwin M, Tomasini P, **Liu G**, Howell D. Feasibility and Diagnostic Accuracy of the Patient Reported Outcome Information System (PROMIS®) Item Banks for Routine Surveillance of Sleep and Fatigue Problems in Ambulatory Cancer Care. 2016.

- 2016 Apr Stage Specific Health Utility Index Scores of Canadian Cancer Patients. Cancer Care Ontario. Toronto, Ontario, Canada. (Trainee Presentation)
- Publication Details:*  
Naik H, Howell D, Su S, Qiu X, Brown MC, Vennettilli A, Irwin M, Pat V, Solomon H, Wang T, Hon H, Eng L, Mahler, Thai H, Ho V, Xu W, Seung SJ, Mittmann N, **Liu G**. Stage Specific Health Utility Index Scores of Canadian Cancer Patients. Poster presentation. **Senior Responsible Author**.
- 2015 Jun The application of Canadian patient-reported health utility scores (HUS) derived from the EQ5D-3L questionnaire for metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. The Canadian Society for Epidemiology and Biostatistics. Mississauga, Ontario, Canada. (Trainee Presentation)
- Publication Details:*  
Stewart EL, Labbe C, Brown MC, Perez-Cosio A, Vennettilli A, Patel D, Cheng N, Liang M, Gill G, Leung Y, Mittmann N, Naik H, **Liu G**. The application of Canadian patient-reported health utility scores (HUS) derived from the EQ5D-3L questionnaire for metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. 2015 Jun. The Canadian Society for Epidemiology and Biostatistics Annual conference, 2015, Mississauga, Canada. (abstr 866) (Poster). **Senior Responsible Author**.
- 2014 Nov Characterizing health utility values of Canadian cancer patients. Canadian Association for Population Therapeutics (CAPT). Toronto, Ontario, Canada. (Trainee Presentation)
- Publication Details:*  
Naik H, Qiu X, Brown MC, Eng L, Pringle D, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Pat V, Irwin M, Charow R, Herzog L, Ho A, Xu W, Howell D, Seung SJ, Mittmann N, **Liu G**. Characterizing health utility values of Canadian cancer patients. 2014 Nov. (CAPT) 2014 Annual Conference, November 2, 2014, Toronto, ON, Canada (Oral Presentation). **Senior Responsible Author**.
- 2014 Nov Characterizing health utility values of Canadian cancer patients. Canadian Centre for Applied Research in Cancer Control (ARCC). Toronto, Ontario, Canada.
- Publication Details:*  
Naik H, Qiu X, Brown MC, Pringle D, Eng L, Mahler M, Hon H, Tiessen K, Ho V, Thai H, Gonos C, Pat V, Irwin M, Charow R, Herzog L, Ho A, Xu W, Howell D, Seung SJ, Mittmann N, **Liu G**. Characterizing health utility values of Canadian cancer patients. 2014 Nov. **Senior Responsible Author**.
- 2014 Nov Feasibility of routinely administering the EQ-5D health utility instrument to cancer patients. Canadian Association for Population Therapeutics (CAPT). Toronto, Ontario, Canada. (Trainee Presentation)
- Publication Details:*  
Naik H, Qiu X, Brown MC, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Charow R, Gonos C, Irwin M, Pat V, Herzog L, Eng L, Pringle D, Ho A, Xu W, Howell D, Seung SJ, **Liu G**, Mittmann N. Feasibility of routinely administering the EQ-5D health utility instrument to cancer patients. 2014 Nov. (CAPT) 2014 Annual Conference, November 2, 2014, Toronto, ON, Canada (Poster). **Senior Responsible Author**.
- 2014 Aug Complementary & alternative medicine use following cancer diagnosis. Canadian Association of Radiation Oncologist Annual Scientific Meeting. Markham, Ontario, Canada.
- Publication Details:*  
Chacko PP, Le K, Fadhel E, Lliu G, Cho C, Fenkell L, Taremi M, Allibhai Z, Wong J, Wells W, Kassam Z. Complementary & alternative medicine use following cancer diagnosis. 2014 Aug. Poster discussion at the Canadian Association of Radiation Oncologist Annual Scientific Meeting in August 2014. **Co-Investigator**.
- 2014 May The willingness of cancer patients to regularly complete the EQ-5D health utility questionnaire. Canadian Centre for Applied Research in Cancer Control (ARCC) Annual Conference. Toronto, Ontario, Canada.

(Trainee Presentation)

*Publication Details:*

Naik H, Qiu X, Brown MC, Eng L, Pringle D, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Pat V, Irwin M, Charow R, Herzog L, Ho A, Xu W, Howell D, Seung SJ, Mittmann N, Lili G. The willingness of cancer patients to regularly complete the EQ-5D health utility questionnaire. 2014 May. (ARCC) Annual Conference, May 11-12, 2014, Toronto, Ontario Canada (Poster). **Senior Responsible Author.**

2014 May Comorbidity and performance status are independent prognostic factors in head and neck squamous cell carcinoma patients. University of Toronto, otolaryngology Head & Neck Surgery. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Wang J, **Liu G.** Comorbidity and performance status are independent prognostic factors in head and neck squamous cell carcinoma patients. 2014 May. Poster. **Senior Responsible Author.**

2014 May Genetic polymorphisms associated with radiation-related esophagitis and pneumonitis following definitive treatment for non-small cell lung cancer (NSCLC). University of Toronto Department of Radiation Oncology. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Barrett K, **Liu G.** Genetic polymorphisms associated with radiation-related esophagitis and pneumonitis following definitive treatment for non-small cell lung cancer (NSCLC). 2014 May. Poster. **Senior Responsible Author.**

2013 Apr Modifiable behaviours in elderly cancer survivors: a survey of smoking, alcohol cessation, and physical activity. Canadian Geriatric Society. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Niu C, Eng L, Qiu X, Shen X, Espin-Garcia O, Pringle D, Mahler M, Halytskyy O, Charow R, Lam C, Shani RM, Villeneuve J, Tiessen K, Brown MC, Selby P, Howell D, Jones JM, Xu W, **Liu G**, Alibhai SMH. Modifiable behaviours in elderly cancer survivors: a survey of smoking, alcohol cessation, and physical activity. 2013 Apr. 33rd Annual Scientific Meeting of the Canadian Geriatric Society. **Senior Responsible Author.**

2012 Jun Socio-demographic factors influencing the rates of alcohol cessation and relapse in lung cancer survivors. Primary Health Care Research Day - Trillium 2012. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Fadhel E, Brhane Y, Palepu PR, Joshi G, Hon H, Harland L, La Delfa A, Habbous S, Cuffe S, Dong J, Pierre A, Brade A, Leighl NB, Shepherd FA, Xu W, **Liu G**, Eng L. Socio-demographic factors influencing the rates of alcohol cessation and relapse in lung cancer survivors. 2012 Jun. (June 2012) Primary Health Care Research Day - Trillium 2012, Toronto, ON. **Senior Responsible Author.**

2012 Feb The role of vascular endothelial growth factor (VEFG) and associated receptor polymorphisms as prognostic and predictive markers in cancer: A systematic review and meta-analysis. University of Toronto. Toronto, Ontario, Canada. (Trainee Presentation)

*Publication Details:*

Eng L, Amir E, Habbous S, Pang V, Savas S, **Liu G.** The role of vascular endothelial growth factor (VEFG) and associated receptor polymorphisms as prognostic and predictive markers in cancer: A systematic review and meta-analysis. 2012 Feb. (February 2012) Medical Student Research Day 2012. University of Toronto, February 2012. **Senior Responsible Author.**

2011 Nov On-PROST: Ontario Patient Reported Outcomes of Symptoms and Toxicity. Canadian Cancer Research Alliance (CCRA). Toronto, Ontario, Canada.

*Publication Details:*

Howell D, **Liu G**. On-PROST: Ontario Patient Reported Outcomes of Symptoms and Toxicity. 2011 Nov. 2011; Canadian Cancer Research Conference, November 27-30, 2011; Toronto, Canada. **Senior Responsible Author**.

2011 Nov      Improving Health by Measurement: the Ontario Patient Reported Outcomes of Symptoms and Toxicity (On-PROST) Research Unit. Canadian Cancer Research Alliance. Toronto, Ontario, Canada.

*Publication Details:*

Howell D, Perez Cosio A, Brundage M, Hope A, Rodin G, **Liu G**. Improving Health by Measurement: the Ontario Patient Reported Outcomes of Symptoms and Toxicity (On-PROST) Research Unit. 2011 Nov. Canadian Cancer Research Alliance (CCRA), 2011; Canadian Cancer Research Conference, November 27-30; Poster. **Senior Responsible Author**.

2011      Improving Health by Measurement: the Ontario Patient Reported Outcomes of Symptoms and Toxicity (On-PROST) Research Unit. Toronto Cancer Conference. Toronto, Ontario, Canada.

*Publication Details:*

Howell D, Perez-Cosio A, Brundage M, Hope A, Rodin G, **Liu G**. Improving Health by Measurement: the Ontario Patient Reported Outcomes of Symptoms and Toxicity (On-PROST) Research Unit. 2011. Toronto Cancer Conference, October 24-25, 2011, Toronto, Canada; Poster. **Senior Responsible Author**.

2008      Preliminary cost-consequence analysis of epirubicin/cisplatin/5FU (ECF) compared to epirubicin/cisplatin/capecitabine (ECX) in patients with advanced oesophagogastric cancer. Toronto, Ontario, Canada.

*Publication Details:*

Horgan AM, Knox J, **Liu G**, Bradbury PA, Sahi C, Leighl NB. Preliminary cost-consequence analysis of epirubicin/cisplatin/5FU (ECF) compared to epirubicin/cisplatin/capecitabine (ECX) in patients with advanced oesophagogastric cancer. International Society For Pharmacoeconomics and Outcomes Research 13th International Conference. Toronto (Poster). **Co-Investigator**.

2007      Expert Opinion in Treatment Approaches for Illustrative Cases of Thymoma. Toronto, Ontario, Canada.

*Publication Details:*

Myrehaug S, **Liu G**, Keshavjee S, Bezjak A. Expert Opinion in Treatment Approaches for Illustrative Cases of Thymoma. Proc Canadian Assoc Rad Oncol – Assoc Canadian Rad Oncol; 2007: 17: 454 (abstr). Toronto (Poster). **Co-Investigator**.

## 5. OTHER

### Presented and Published Abstracts

Real-world evidence on treatment patterns and survival among ALK+ NSCLC patients in Canada who discontinue crizotinib treatment. American Society for Clinical Oncology. Chicago, Illinois, United States.

*Publication Details:*

Kayaniyil S, Hurry M, Wilson J, Wheatley-Price P, Melosky BL, Rothenstein J, Cohen V, Koch C, Zhang J, Osenenko K, **Liu G**. Real-world evidence on treatment patterns and survival among ALK+ NSCLC patients in Canada who discontinue crizotinib treatment. J Clin Oncol. 2016. (suppl; abstr e20610).

## G. Teaching and Design

(A) 2 011- pres.



COMBIEL Cancer Outcomes, Medicine, Biostatistics, Bioinformatics, Epidemiology, and Laboratory Medicine. Research Training Program, Multilevel Education, Faculty of Medicine, Department of Medicine, Oncology (Medical), University of Toronto

(B) 2009-pres.

Introduction to Pharmacogenetics/Advanced Topics in Pharmacogenetics, Continuing Education, International Conference for Pharmacoepidemiology (ICPE), Medicine/Pharmaceutical Sciences, International Society for Pharmacoepidemiology (ISPE).

(C) 2017 - present

Oncology for Pharmacoepidemiologists. Continuing Education, International Conference for Pharmacoepidemiology (ISPE), Medicine/Pharmaceutical Sciences, International Society for Pharmacoepidemiology (ISPE).

(D) 2017 - present

Non-Database Pharmacoepidemiology: Learning through examples from Resource-Limited and Resource-Rich Countries. Continuing Education, Asian Conference for Pharmacoepidemiology (ACPE), Medicine/Pharmaceutical Sciences, International Society for Pharmacoepidemiology (ISPE).

## 1. INNOVATIONS AND DEVELOPMENT IN TEACHING AND EDUCATION

2015 Sep - present

Introduction to Pharmacoepidemiology (JRH0001), Graduate Education, Dalla Lana School of Public Health, Dept. of Medicine, Faculty of Medicine, Epidemiology/Pharmacy School Joint Course, University of Toronto

*This new course was co-created by Dr. Liu and is the first course in pharmacoepidemiology at the University of Toronto. It is also the first joint course offering between the Dalla Lana School of Public Health and the Faculty of Pharmacy. A mix of seminar/workshops and didactic lectures, the goal is to eventually have this course be the foundation for a Pharmacoepidemiology stream within both Epidemiology (MPH/PhD) and Pharmacy (DPharm).*

*Impact: First course on this subject in any Toronto-based University.*

2013 Jul - present

R4 Research Course, Postgraduate MD, Faculty of Medicine, Dept of Medicine, Oncology (Medical), University of Toronto

*Co-created a research course to teach Medical Oncology R4 residents how to develop a research proposal, using the PICO method and a Socratic approach. Residents develop this protocol during their research month-long block, and present their proposals to a core committee.*

*Impact: Increase in interest and understanding of research in medical oncology.*

2011 Jul - present

COMBIEL Didactic and Workshop Series, Multilevel Education, Faculty of Medicine, Dept of Medicine, Oncology (Medical), University of Toronto

*Developed innovative lecture series, seminars, and workshops for all levels from undergraduate/high school graduate through to visiting scientists focused on research methodological concepts. See [www.uhncombiel.com](http://www.uhncombiel.com) for additional details. This innovative multidisciplinary training program is designed to train team scientists who can communicate and collaborate across disciplines of Cancer (health) outcomes, medicine, biostatistics, informatics, epidemiology and laboratory research. The lecture series runs twice weekly from May through August, and monthly sessions run the rest of the year. Trainees from different disciplines (epidemiology, medicine, biostatistics, informatics, laboratory, etc.) work on the same research projects to foster better inter-disciplinary understanding and communication. A major criterion of success is the number of abstracts/publications with different trainees of various disciplines. Another criterion is the number of individuals who remain in translational academics.*

*Impact: Increased multidisciplinary translational oncology training, interest in translational oncology research. Over 15 publication and 50 presentations/abstracts followed the multidisciplinary trainee exposure model. At least two dozen past-trainees have continued to stay in academics/research fields.*

2009 Jul - present	<p><i>Awarded the Innovation in Education Award, Princess Margaret Cancer Centre, 2020.</i></p> <p>Introduction to Pharmacogenetics/Advanced Topics in Pharmacogenetics, Continuing Education, International Society for Pharmacoepidemiology (ISPE), Medicine/Pharmaceutical Sciences, ISPE</p> <p><i>Since 2009, this has been an annual pre-conference course for the International Conference for Pharmacoepidemiology. Innovative aspects: (i) first pre-conference course to have round-table sessions, 2009; (ii) first pre-conference course to be full day (double session), 2009; (iii) first pre-conference course to have basic and advanced topic streams (2012); (iv) first pre-conference course to collect formal feedback from attendees (2009).</i></p> <p><i>Impact: Increased awareness and interest in pharmacogenetics by pharmacoepidemiologists.</i></p>
2013 - 2017	Molecular Oncology of Basic Science, Faculty of Medicine, Dept of Medicine, Oncology (Medical), University of Toronto

## H. Research Supervision

### 1. PRIMARY OR CO-SUPERVISION

#### Undergraduate Education

2025 Jan - 2025 Aug	<b>Primary Supervisor.</b> Anmol Jassal. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC, CARMA-PFS, ACORN.</i>
2024 Nov - 2025 Apr	<b>Primary Supervisor.</b> Varun Sekar. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Western Ontario. <i>ALK/ROS1 mutated lung cancers.</i>
2024 Sep - 2024 Nov	<b>Primary Supervisor.</b> Alexandria Freeman-Idemilili. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC, CARMA-PFS, ACORN.</i>
2024 Jul - 2024 Aug	<b>Primary Supervisor.</b> Talia Rahif. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Limerick. <i>Lung cancer real world evidence.</i>
2024 May - 2024 Aug	<b>Primary Supervisor.</b> Abdulwadud Nafees. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC (new pt updates), Breathomics, CARMA-PFS.</i>
2024 May - 2024 Jul	<b>Primary Supervisor.</b> Ethan Tsang. Supervisee Position: Undergraduate Student, Supervisee Institution: Western University. <i>HNC long-term toxicity survey. SCLC data abstraction.</i>
2024 May - 2024 Jul	<b>Primary Supervisor.</b> Michael Wang. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Guelph. <i>Helping recruit.</i>
2024 Jan - 2024 Aug	<b>Primary Supervisor.</b> Naomi Skye Clarkson. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC (new pt updates), Breathomics, CARMA-PFS.</i>
2023 Sep - 2024 Aug	<b>Primary Supervisor.</b> Abdullah Butt. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC.</i> Awards: BioTalent Canada - Student Work Placement Program (SWPP) - \$7,000 CAD.
2023 Sep - 2023 Dec	<b>Primary Supervisor.</b> Rianna Khaki. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC.</i> Awards: BioTalent Canada - Student Work Placement Program (SWPP) - \$7,000 CAD.
2023 Sep - 2023 Dec	<b>Primary Supervisor.</b> Vivien Yu. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>AIM2REDUCE, ML analyses. Using large language models to automate the classification of clinical lung cancer reports.</i> Awards: BioTalent Canada - Student Work Placement Program (SWPP) - \$7,000 CAD.

2023 Jun - 2023 Aug	<b>Primary Supervisor.</b> Maria Xu. Supervisee Position: Undergraduate Student, Supervisee Institution: Harvard University. <i>Machine Learning Models of early longitudinal toxicity trajectories predict cetuximab concentrations and efficacy for refractory metastatic colorectal cancer patients (CCTG/AGITC CO.17/CO.20 trials).</i>
2023 May - 2023 Dec	<b>Primary Supervisor.</b> Naihe (Howard) Xiao. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Toronto at Scarborough. <i>Machine Learning projects related to lung cancer research.</i> Awards: University of Toronto ASIP Wage Subsidy Program: \$5,000 CAD.
2023 May - 2023 Aug	<b>Primary Supervisor.</b> Chloe Yu. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Toronto. <i>Lung cancer data harmonization.</i> Awards: University of Toronto ASIP Wage Subsidy Program: \$5,000 CAD.
2023 May - 2023 Aug	<b>Primary Supervisor.</b> Michael Wang. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Guelph. <i>HNC long-term toxicity survey, SCLC data abstraction.</i>
2023 May - 2023 Aug	<b>Primary Supervisor.</b> Ethan Tsang. Supervisee Position: Undergraduate Student, Supervisee Institution: Western University. <i>HNC long-term toxicity survey. SCLC data abstraction.</i>
2023 May - 2023 Jul	<b>Primary Supervisor.</b> Michelle Wong. Supervisee Position: Undergraduate Student, Supervisee Institution: Western University. <i>HNC long-term toxicity survey, SCLC data abstraction.</i>
2023 Feb - 2023 Sep	<b>Primary Supervisor.</b> Charlotte MacKay. Supervisee Position: Undergraduate Student, Supervisee Institution: McGill University. <i>CARMA-BROS &amp; TH recruitment.</i>
2023 Jan - 2023 Aug	<b>Primary Supervisor.</b> Christina Mac. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC (new pt updates), Breathomics, CARMA-PFS and Single Organ Mets Projects Abstractions.</i>
2023 Jan - 2023 Aug	<b>Primary Supervisor.</b> Zhaoyang (Joy) Zeng. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC (new pt updates), Breathomics, CARMA-PFS and Single Organ Mets Projects Abstractions.</i>
2023 Jan - 2023 Apr	<b>Primary Supervisor.</b> William Bai. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>Data Harmonization Assistant, Lung cancer databases.</i>
2023 Jan - 2023 Apr	<b>Primary Supervisor.</b> Vivien Yu. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>AIM2REDUCE, ML analyses.</i>
2022 Sep - 2022 Dec	<b>Primary Supervisor.</b> Rori Schaefer. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC, PRS-ML, Breathomics.</i>
2022 Sep - 2022 Dec	<b>Primary Supervisor.</b> Vivien Ji Hui Hoang. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Waterloo. <i>EPIC, PRS-ML, Breathomics.</i>
2022 Jun - 2022 Sep	<b>Primary Supervisor.</b> Sarah Rudolph-Naiberg. Supervisee Position: Undergraduate Student, Supervisee Institution: Cornell University. <i>EPiC.</i>
2022 May - 2022 Sep	<b>Primary Supervisor.</b> Shreya Gramolini. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Toronto. <i>EPiC.</i>
2022 May - 2022 Sep	<b>Primary Supervisor.</b> Varun Sekar. Supervisee Position: Undergraduate Student, Supervisee Institution: Western University. <i>EPiC.</i>
2022 May - 2022 Sep	<b>Primary Supervisor.</b> Dhairya Bhatt. Supervisee Position: Undergraduate Student, Supervisee Institution: McMaster University. <i>EPiC.</i>
2022 May - 2022 Sep	<b>Primary Supervisor.</b> Michelle Wong. Supervisee Position: Undergraduate Student, Supervisee Institution: Western University. <i>EPiC.</i>
2022 May - 2022 Sep	<b>Primary Supervisor.</b> Natalia Diamond. Supervisee Position: Undergraduate Student, Supervisee Institution: University of Guelph. <i>EPiC.</i>
2021 May - 2022 Sep	<b>Primary Supervisor.</b> Arash Zelifan. Supervisee Position: Undergraduate computer science student, Supervisee Institution: University Of Western Ontario. <i>NLP. Rules-based/ontology of NLP coding.</i>
2021 May - 2022 Sep	<b>Primary Supervisor.</b> Conor French. Supervisee Position: Undergraduate computer science

	student, Supervisee Institution: Dalhousie University. <i>NLP. Utilizes and adapts NLP packages to evaluate the more free-text based variables.</i>
2020 Jul - 2020 Aug	<b>Primary Supervisor.</b> Julia Singer. Supervisee Position: Summer Student, Supervisee Institution: McMaster University. <i>CARMA.</i>
2019 Jun - 2021 Mar	<b>Primary Supervisor.</b> Christy Yeung. Supervisee Position: Research Student, Supervisee Institution: Queen's University. <i>Breathomics - implementation of clinico-epi and PRO data collection on LC patients undergoing bronchoscopy or pleural fluid thoracentesis.</i>
2019 May - 2020 May	<b>Primary Supervisor.</b> Spencer Soberano. Supervisee Position: Research Student, Supervisee Institution: Western University. <i>IO database (IASLC).</i>
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Wanning Wan. Supervisee Position: Summer Student, Supervisee Institution: McMaster University. <i>Lung Cancer/ Esophageal Ca and Sarcopenia.</i>
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Tyler Soberano. Supervisee Position: Summer Student, Supervisee Institution: Western University. <i>AYA - Distress and AYA extension.</i>
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Julia Singer. Supervisee Position: Summer Student, Supervisee Institution: McMaster University. <i>CFI/LCC/CARMA.</i>
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Shubhangi Shah. Supervisee Position: Summer Student, Supervisee Institution: Western University. <i>LC Screening.</i>
2019 May - 2019 Jul	<b>Primary Supervisor.</b> Jonathan Fortini. Supervisee Position: Summer Student, Supervisee Institution: Western University. <i>AYA - Primary care access. Transition from pediatrician to Fam MD.</i>
2019 May - 2019 Jul	<b>Primary Supervisor.</b> Subiksha Nagaratnam. Supervisee Position: Summer Student, Supervisee Institution: McMaster University. <i>PRS in HN patients (Nicotine dependence, SC).</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Pansy Chow. Supervisee Position: Undergraduate. <i>Assessing Hearing Loss Routinely in the Head and Neck Multidisciplinary Cancer Clinic.</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Julia Singer. Supervisee Position: Undergraduate. <i>CAPLET follow-up with EQ5D-5L.</i>
2018 Jun - 2018 Jul	<b>Primary Supervisor.</b> Toh Tzen Szen. Supervisee Position: Undergraduate. <i>Developing a Small Cell Lung Cancer Clinical Database: SCLC-DATA (Dr. Benjamin Lok).</i>
2018 Jun - 2018 Jul	<b>Primary Supervisor.</b> Dixon Pinto. Supervisee Position: Undergraduate. <i>The Princess Margaret Behaviour and Lifestyle in Cancer Survivors Project: BLICS.</i>
2018 May - 2018 Aug	<b>Co-Supervisor.</b> Ali Vedadi. Supervisee Position: Undergraduate. <i>Validation of the PROMIS-57 Profile in Patients with Chronic Kidney Disease.</i> Supervisor(s): Istvan Mucsi.
2018 May - 2018 Aug	<b>Primary Supervisor.</b> Alexandra McCatney. Supervisee Position: Undergraduate. <i>CAPLET follow-up with EQ5D-SL.</i>
2018 May - 2018 Aug	<b>Primary Supervisor.</b> Elliot Smith. Supervisee Position: Undergraduate. <i>Managing Cancer Patients In Hospital On Immunotherapy Who Develop Immune-Related Adverse or Toxic Events. The IRATE Real-World Evidence Project.</i>
2018 May - 2018 Aug	<b>Primary Supervisor.</b> Susan Tang. Supervisee Position: Undergraduate. <i>Screening of Lung Cancer in Underserved Populations: SLiC UP.</i>
2018 May - 2018 Jul	<b>Primary Supervisor.</b> Subiksha Nagaratnam. Supervisee Position: Undergraduate. <i>Feasibility Testing of the LifeguardRx Mobile App to Report Real-Time Symptoms and Toxicities of Cancer Patients Undergoing Systemic and Chemotherapy: Knowledge Translation Research.</i>
2018 May - 2018 Jul	<b>Primary Supervisor.</b> Shubhangi Shah. Supervisee Position: Undergraduate. <i>Esophageal cancer questionnaire iPad implementation project.</i>
2017 Jun - 2017 Aug	<b>Primary Supervisor.</b> Alexandra McCartney. Supervisee Position: Undergraduate. <i>Cancer Personalized Medicine and the Patient: Patient-Reported Knowledge, Preferences, and Behaviours.</i>
2017 May - 2017 Aug	<b>Primary Supervisor.</b> Judy Chen. Supervisee Position: Undergraduate. <i>EQ5D-Brain mets.</i> Awards: Lung Cancer Canada Summer Studentship Award \$5,000.
2017 May - 2017 Aug	<b>Primary Supervisor.</b> Tiffany Tse. Supervisee Position: Undergraduate. <i>Breast Cancer Data</i>

	<i>from EQ5D Toronto PMH.</i>
2017 May - 2017 Aug	<b>Primary Supervisor.</b> Elliott Smith. Supervisee Position: Undergraduate. <i>Lifestyle Behaviours In Canadian Cancer Survivors.</i>
2017 May - 2017 Jul	<b>Primary Supervisor.</b> Michael Borean. Supervisee Position: Undergraduate. <i>Screening for Cancer-Associated Dysphagia: The Development of Two Rapid Tools for use in Observational Studies and Routine Care.</i>
2017 May - 2017 Jul	<b>Primary Supervisor.</b> Nathan Kuehne. Supervisee Position: Undergraduate. <i>BRM genotyping and mesothelioma and thymoma.</i>
2016 Jun - 2016 Aug	<b>Primary Supervisor.</b> Farzanfar Delaram. Supervisee Position: Undergraduate. <i>Patient preferences and attitudes for lifestyle behaviour change programs in cancer survivors.</i>
2016 Jun - 2016 Aug	<b>Primary Supervisor.</b> Sophia Liu. Supervisee Position: Undergraduate. <i>Patient preferences and attitudes for lifestyle behaviour change programs in cancer survivors.</i>
2016 Jun - 2016 Aug	<b>Primary Supervisor.</b> Judy Chen. Supervisee Position: Undergraduate. <i>Physical Function Study (Feasibility).</i>
2016 Jun - 2016 Aug	<b>Primary Supervisor.</b> Tiffany Tse. Supervisee Position: Undergraduate. <i>EQ5DL.</i>
2016 May - 2016 Aug	<b>Primary Supervisor.</b> Elizabeth Hall. Supervisee Position: Undergraduate. <i>Physical Function (branching logic).</i>
2016 May - 2016 Jul	<b>Primary Supervisor.</b> Vivian Tam. Supervisee Position: Undergraduate. <i>EQ5DL.</i>
2016 May - 2016 Jul	<b>Primary Supervisor.</b> Michael Borean. Supervisee Position: Undergraduate. <i>Dysphagia.</i>
2016 May - 2016 Jul	<b>Primary Supervisor.</b> Brandon Tse. Supervisee Position: Undergraduate. <i>EQ5DL.</i>
2016 May - 2016 Jul	<b>Primary Supervisor.</b> Emily Tam. Supervisee Position: Undergraduate. <i>Physical Function (branching Logic).</i>
2015 Sep - 2015 Dec	<b>Primary Supervisor.</b> Co-Op Student. Alexandra Rett. Supervisee Position: Co-Op Student, Supervisee Institution: University of Waterloo. <i>EQ5D Lung.</i>
2015 Sep - 2015 Dec	<b>Primary Supervisor.</b> Co-Op Student. Nathan Voelker. Supervisee Position: Co-Op Student, Supervisee Institution: University of Waterloo. <i>EQ5D Lung.</i>
2015 Sep - 2015 Dec	<b>Primary Supervisor.</b> Joshua Gottsman. Supervisee Position: Research Student. <i>ASyMS.</i>
2015 Jun - 2015 Sep	<b>Primary Supervisor.</b> Elizabeth Hall. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 Jun - 2015 Aug	<b>Primary Supervisor.</b> Chenchen Tian. Supervisee Position: Undergraduate. <i>Pain and Physical Function.</i>
2015 Jun - 2015 Aug	<b>Primary Supervisor.</b> Brandon Tse. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 Jun - 2015 Aug	<b>Primary Supervisor.</b> Aixin Liu. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 Jun - 2015 Aug	<b>Primary Supervisor.</b> Brandon Chan. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 Jun - 2015 Aug	<b>Primary Supervisor.</b> Kathryn Bucci. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 May - 2015 Aug	<b>Primary Supervisor.</b> Delaram Farzanfar. Supervisee Position: Undergraduate, Supervisee Institution: University of Toronto. <i>Cancer patient understanding of the harms of continued smoking.</i>
2015 May - 2015 Aug	<b>Primary Supervisor.</b> Olivia Krys. Supervisee Position: Undergraduate, Supervisee Institution: University of Toronto. <i>Comparing cancer patient perceptions of smoking and second-hand smoke.</i>
2015 May - 2015 Jul	<b>Primary Supervisor.</b> Samantha Sarabia. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 May - 2015 Jul	<b>Primary Supervisor.</b> Sabrina Yeung. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2015 Jan - 2015 Sep	<b>Primary Supervisor.</b> B. Sc. Gursharam Gill. Supervisee Position: Co-Op Student,

Supervisee Institution: University of Waterloo. *Pain and Physical Function; Dyspnea; EQ5D Lung.*

2015 Jan - 2015 Sep	<b>Primary Supervisor.</b> Co-op Student. Mindy Liang. Supervisee Position: Co-Op Student, Supervisee Institution: University of Waterloo. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2014 Jul - 2014 Aug	<b>Primary Supervisor.</b> Alborz Kia. Supervisee Position: Undergraduate. <i>Improving quality of care by obtaining patient reported outcomes (PRO) - CTCAE chemotoxicities using tablet technology in daycare (C) waiting rooms.</i>
2014 Jul - 2014 Aug	<b>Primary Supervisor.</b> Dena Kia. Supervisee Position: Undergraduate. <i>Assessing the utility of a patient-reported screener question to detect fatigue symptoms: Improving the quality of systematic symptom measurement in clinical practice.</i>
2014 Jun - 2014 Aug	<b>Primary Supervisor.</b> Alisa Lagrotteria. Supervisee Position: Undergraduate. <i>Involving patients to improve their care through real-time patient reported outcome (PRO) - CTCAE chemotoxicity surveys in an outpatient chemodayscare (DC) setting: Evaluating patient acceptability.</i>
2014 Jun - 2014 Aug	<b>Primary Supervisor.</b> Chenchen Tian. Supervisee Position: Undergraduate. <i>Patient willingness to use various platforms of computer-assisted technology to complete patient reported outcome measure (self-report) surveys for use in clinical practice.</i>
2014 Jun - 2014 Aug	<b>Primary Supervisor.</b> Emma Small. Supervisee Position: Undergraduate. <i>Patient willingness to use various platforms of computer-assisted technology to complete patient reported outcome measure (self-report) surveys for use in clinical practice.</i>
2014 Jun - 2014 Aug	<b>Primary Supervisor.</b> Samantha Sarabia. Supervisee Position: Undergraduate. <i>Assessing the utility of a patient-reported screener question to detect fatigue symptoms: Improving the quality of systematic symptom measurement in clinical practice.</i>
2014 May - 2014 Aug	<b>Primary Supervisor.</b> Tian Wang. Supervisee Position: Undergraduate. <i>Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment.</i>
2014 May - 2014 Jul	<b>Primary Supervisor.</b> Linda Chen. Supervisee Position: Undergraduate. <i>Involving patients to improve their care through real-time patient reported outcome (PRO) - CTCAE chemotoxicity surveys in an outpatient chemodayscare (DC) setting: Evaluating patient acceptability.</i>
2014 May - 2014 Jul	<b>Primary Supervisor.</b> Hanna Solomon. Supervisee Position: Undergraduate. <i>Improving quality of care by obtaining patient reported outcomes (PRO) - CTCAE chemotoxicities using tablet technology in daycare (DC) waiting rooms.</i>
2013 Jun - 2013 Aug	<b>Primary Supervisor.</b> Rebecca Charow. Supervisee Position: Undergraduate, Supervisee Institution: UCSF. <i>Modifiable behaviours and cancer.</i>
2013 Jun - 2013 Aug	<b>Primary Supervisor.</b> Anthea Ho. Supervisee Position: Undergraduate, Supervisee Institution: Western University. <i>Cancer survivorship.</i>
2013 May - 2014 Jun	<b>Primary Supervisor.</b> Kyoko Tiessen. Supervisee Position: Undergraduate, Supervisee Institution: University of Toronto. <i>Social support and exercise in cancer.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Catherine Chan. Supervisee Position: Undergraduate, Supervisee Institution: McGill University. <i>Cancer surveys.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Vivien Pat. Supervisee Position: Undergraduate - Medicine, Supervisee Institution: St. Bonaventure U Georgetown U. <i>Exercise and cancer.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Margaret Irwin. Supervisee Position: Undergraduate, Supervisee Institution: Harvard University. <i>Smoking cessation and cancer survivors.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Christine Gonos. Supervisee Position: Undergraduate - Kinesiology, Supervisee Institution: Western University. <i>Exercise in cancer survivors.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Wei Fan(Lucy) Liu. Supervisee Position: Undergraduate, Supervisee Institution: University of Toronto. <i>Hedgehog inhibition in esophageal cancer.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Trevor Morey. Supervisee Position: Undergraduate - Medicine, Supervisee Institution: Western University. <i>Hedgehog inhibition in esophageal cancer.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Valerie Ho. Supervisee Position: Undergraduate, Supervisee

	Institution: Limerick University.
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Madison McGregor. Supervisee Position: Undergraduate, Supervisee Institution: University of Western Ontario - Animal Biology. <i>Radiation xenograft models.</i>
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Co-op student. Henry Thai. Supervisee Position: Undergraduate Coop Student, Supervisee Institution: University of Waterloo. <i>Pharmacologic Therapy.</i>
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Luke Harland. Supervisee Position: Undergraduate, Supervisee Institution: Western University. <i>Radiation and Hedgehog Signaling in Esophageal Xenografts.</i> Awards: *Received Medical Biophysics Summer Scholarship. Completed 2012.
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Jiayin (Jenn) Dong. Supervisee Position: Undergraduate, Supervisee Institution: Queens University. <i>Role of alcohol in lung cancer outcome.</i> Completed 2012.
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Madison McGregor. Supervisee Position: Summer student, Supervisee Institution: Western University. <i>Development of Radiation Models.</i> Completed 2012.
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Dan Pringle. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Physical Activity and Cancer Outcome.</i> Completed 2012.
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Rebecca Charow. Supervisee Position: Summer Student, Supervisee Institution: UCSF. <i>Modifiable Behaviours and Cancer.</i>
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Ravi Majoj Shani. Supervisee Position: Undergraduate Student, Supervisee Institution: Western University. <i>Patient Preference for Pharmacogenomics.</i> Completed 2012.
2011 Aug - 2012 Jan	<b>Primary Supervisor.</b> Co-op Student. Andrew Fleet. Supervisee Position: Undergraduate Co-op Student, Supervisee Institution: University of Toronto. <i>Esophageal Cancer Xenografting.</i>
2011 May - 2011 Aug	<b>Primary Supervisor.</b> Valerie Ho. Supervisee Position: Summer Student, Supervisee Institution: Western University. <i>Cell Line Development from Xenografts.</i> Completed 2011.
2011 May - 2011 Aug	<b>Primary Supervisor.</b> Ravi Manoj Shani. Supervisee Position: Summer Student, Supervisee Institution: Western University. <i>Technical Comparisons of DNA &amp; RNA Extraction Protocols in our Xenograft Specimens.</i>
2011 May - 2011 Aug	<b>Primary Supervisor.</b> Daria Taiakina. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Esophageal Cancer Xenografting Program.</i> Completed 2011.
2011 May - 2011 Aug	<b>Primary Supervisor.</b> Luke Harland. Supervisee Position: Summer Student, Supervisee Institution: Western University. <i>Patient Perception of 'Epidemiologic Surveys.</i> Completed 2011.
2011 May - 2011 Aug	<b>Primary Supervisor.</b> Alexander Yiu. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Survey of Funding of Supplemental and oral Therapies.</i> Completed 2011.
2011 May - 2011 Aug	<b>Primary Supervisor.</b> Lily Tong. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Esophageal Cancer Xenograft Characterization.</i> Completed 2011.
2010 May - 2013 Mar	<b>Primary Supervisor.</b> B. Sc. Kangping Cui. Supervisee Position: BSc. candidate, Supervisee Institution: University of Toronto. <i>Bleomycin Pharmacogenetics.</i> Awards: *Won 2nd prize, AACR-Gary J. Miller under-graduate student Prize.
2010 May - 2010 Aug	<b>Primary Supervisor.</b> B.Sc. Anatomy and Cell Biology Honours. Yumeng (Marina) Li. Supervisee Position: Summer Research Student, Supervisee Institution: McGill University. <i>The response of primary esophageal xenografts and tumor initiating fractions to Paclitaxel chemotherapy.</i>
2010 May - 2010 Aug	<b>Primary Supervisor.</b> BSch - Major Health and Kinesiology Minor (Psychology). Tammy Popper. Supervisee Position: Summer Student, Supervisee Institution: York University. <i>Mesothelioma.</i>
2010 May - 2010 Aug	<b>Primary Supervisor.</b> Aliya Ramjaun. Supervisee Position: Summer Research Student, Supervisee Institution: McMaster University. <i>The response of primary esophageal xenografts and tumour initiating factors to cisplatin chemotherapy.</i>
2009 May - 2009 Aug	<b>Primary Supervisor.</b> Henrique Hon. Supervisee Institution: University of Toronto. <i>Bleomycin</i>

*Pharmacogenetics (Cell Lines and Human Specimens).*

- 2008 - 2009 **Primary Supervisor.** Jennifer Teichman. Supervisee Position: McGill Undergraduate. *Esophageal Cancer Xenograft and Tumour Initiating Cells.*
- 2007 - 2009 **Primary Supervisor.** Boming Yang. Supervisee Position: York University Undergraduate. *Mesothelioma and Esophageal Cancer.*

## Graduate Education

- 2022 Sep - present **Primary Supervisor.** Baijiang Yuan. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Machine Learning for real-time early detection of undesired cancer event.* Awards: 2023-24 Institute of Medical Science Open Fellowship Award: \$5,000 CAD.
- 2021 Sep - present **Primary Supervisor.** Rami Ajaj, Institute of Medical Science (IMS). Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Head and Neck Cancer.*
- 2025 Feb - 2025 Jun **Primary Supervisor.** Ilja Timmermans. Supervisee Position: Graduate Student, Supervisee Institution: University of Utrecht. *Real-world experience of immunotherapy for neoadjuvant treated stage II/III NSCLC: a retrospective cohort study on data from the Princess Margaret Cancer Center, Toronto, Canada.*
- 2024 May - 2024 Aug **Primary Supervisor.** Vipuja Sivayogarajah. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *Lung analyses. CARMA-Bros.*
- 2024 May - 2024 Aug **Primary Supervisor.** Michela Marcellino. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *Lung analyses. CARMA-Bros.*
- 2024 Jan **Primary Supervisor.** Matthew Djan. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Lineage plasticity of non-neuroendocrine and neuroendocrine lung cancer organoids and xenografts.* Awards: Mitacs-Accelerate Award: \$15,000 (Sept 2023 - Aug 2024). Supervisor(s): Co-Supervisor: Ming Tsao.
- 2023 Jul - 2026 May **Primary Supervisor.** Tianzhichao Hou. Supervisee Position: Graduate Student, Supervisee Institution: Shanghai Jiao Tong University School of Medicine. *VOYAGER MR Smoking Risk. ILCCO proposal of Mendelian Randomization.* Awards: 2024 National Scholarship for PhDs in China. Ministry of Education of China. 30000 CNY.
- 2023 May - 2024 Sep **Primary Supervisor.** Jeniszka Gill. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *SCLC.*
- 2023 May - 2023 Aug **Primary Supervisor.** Khalil Kain. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *Lung analyses.*
- 2023 Jan - 2023 Apr **Primary Supervisor.** Pardis Noormohammadpour. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *HN cancer analyses + long term toxicity protocol development.*
- 2023 Jan - 2023 Apr **Primary Supervisor.** Janine Xu. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *AIM2REDUCE, ML analyses.*
- 2023 Jan - 2023 Apr **Primary Supervisor.** Louis Everest. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *CARMA BROS analyses, some data cleaning, survival analysis. Health economic and outcomes research (AMGEN, AZ, CASCADE, etc.).*
- 2022 May - 2022 Sep **Primary Supervisor.** Baijiang Yuan. Supervisee Position: Graduate Student, Supervisee Institution: University College London.
- 2022 May - 2022 Aug **Primary Supervisor.** Sabrina Chiodo. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *Genetic, Behavioural, and Clinical Predictors for Lung Cancer Outcomes in Real-World Cohorts.*
- 2022 May - 2022 Aug **Primary Supervisor.** Shruti Parshad. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. *Genetic, Behavioural, and Clinical Predictors for Lung Cancer Outcomes in Real-World Cohorts.*
- 2022 Jan - 2022 Dec **Primary Supervisor.** Danni Cheng. Supervisee Position: International Visiting Graduate Student, Supervisee Institution: Sichuan University. *The role of genetics in ototoxicity among*



*head and neck cancer patients treated with cisplatin.*

2022 Jan - 2022 Apr	<b>Primary Supervisor.</b> Emilie Pianarosa. Supervisee Position: MPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Genetic, Behavioural, and Clinical Predictors for Lung Cancer Outcomes in Real-World Cohorts.</i>
2022 Jan - 2022 Apr	<b>Primary Supervisor.</b> Martha Pienkowski. Supervisee Position: MPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Genetic, Behavioural, and Clinical Predictors for Head and Neck Cancer Outcomes in Real-World Cohorts.</i>
2022 Jan - 2022 Feb	<b>Primary Supervisor.</b> Jurrian Van der Valk. Supervisee Position: International Visiting Graduate Student, Supervisee Institution: Leiden University. <i>Assessing the feasibility of transferring the sequencing of hydroxymethylation patterns of cell-free DNA from blood-based liquid biopsies into the academic laboratory setting.</i>
2021 May - 2021 Aug	<b>Primary Supervisor.</b> Kaitlyn Chiasson. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Patterns of Systemic Treatment Deferral in a Palliative Mesothelioma Population.</i>
2021 May - 2021 Aug	<b>Primary Supervisor.</b> Mary Wahba. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Genetic, Behavioural, and Clinical Predictors for Lung Cancer Outcomes in Real-World Cohorts.</i>
2021 Jan - 2021 Apr	<b>Primary Supervisor.</b> Vijay Kunaratnam. Supervisee Position: MPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Behavioural and Clinical Predictors for Head and Neck Cancers in Real-World Cohorts.</i>
2021 Jan - 2021 Apr	<b>Primary Supervisor.</b> Sierra Cheng. Supervisee Position: MPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Behavioural and Clinical Predictors for Lung Cancer in Real-World Cohorts.</i>
2021 Jan - 2021 Apr	<b>Primary Supervisor.</b> Abhinav Thakral. Supervisee Position: MPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Genetic Predictors for Head and Neck Cancer Outcomes.</i>
2021 Jan - 2021 Apr	<b>Primary Supervisor.</b> Amy Chang. Supervisee Position: MPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Associations between comorbidity and lung cancer survival: Effect of Ethnicity, and Modifying Effect of Smoking and other Environmental Exposures.</i>
2020 Jan - 2020 Apr	<b>Primary Supervisor.</b> Luna Jia Zhan. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health.
2019 Sep - 2020 Dec	<b>Primary Supervisor.</b> Yang Xu. Supervisee Position: International Visiting Graduate Student, Supervisee Institution: Sichuan University. <i>HANG-OUT.</i>
2019 Sep - 2020 Feb	<b>Primary Supervisor.</b> Stef Schouwenbug. Supervisee Position: International Visiting Graduate Student, Supervisee Institution: Leiden University. <i>Breathomics.</i>
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Luna Jia Zhan. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health.
2019 Jan - 2019 Apr	<b>Primary Supervisor.</b> Reenika Aggarwal. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Early Detection and Screening Program in Lung Cancer.</i>
2018 May - 2018 Aug	<b>Primary Supervisor.</b> Master of Public Health. Reenika Aggarwal. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Early Detection and Screening Program in Lung Cancer (I-ELCAP).</i>
2018 May - 2018 Aug	<b>Primary Supervisor.</b> Maha Chaudhry. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Analysis of PROMs data. Multiple projects, datasets and analyses.</i>
2018 Jan - 2018 Apr	<b>Primary Supervisor.</b> Master of Public Health. Katrina Hueniken. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Review multiple cancer survey studies and biomarker studies on analysis.</i>
2018 - 2022	<b>Primary Supervisor.</b> Michael Herman, Medical Science. Supervisee Position: Graduate Student, Supervisee Institution: USC. <i>Hepatocellular Cancer Biomarkers.</i>

2018 - 2020	<b>Primary Supervisor.</b> Safa Majeed, Medical Biophysics. Supervisee Position: MSc Graduate Student. <i>Small Cell Lung Cancer Translational Studies</i> .
2017 Oct - 2018 Oct	<b>Primary Supervisor.</b> Visiting Graduate Student. Jianjun Ren. Supervisee Institution: Sichuan University, Peoples Republic of China.
2017 Jan - 2017 Apr	<b>Primary Supervisor.</b> Sharara Shakik. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Lung, small cell (ESAS-EQ5D Outcome analysis)</i> .
2016 Sep - 2022 Dec	<b>Primary Supervisor.</b> Lidija Latifovic, Public Health Sciences. DLSPH (Epidemiology). Supervisee Position: PhD Candidate. <i>Pathway analysis of GWAS data to investigate the role of genetic variation on clinical outcomes in metastatic colorectal cancer patients enrolled in the CO.20 phase III clinical trial of cetuximab</i> . Awards: Ontario Graduate Scholarship - \$15,000; CIHR Banting and Best graduate scholarship - \$105,000.
2015 May - 2015 Aug	<b>Primary Supervisor.</b> Master of Public Health. Kathryn Estey. Supervisee Position: DLSPH Practicum Student, Supervisee Institution: Dalla Lana School of Public Health. <i>Feasibility of collecting data on a routine basis for clinical and research purposes, Non-thesis Project</i> .
2015 May - 2015 Aug	<b>Primary Supervisor.</b> PharmD. Tian Wang, Pharmaceutical Sciences. Supervisee Position: PharmD summer student. <i>Chemotoxicity; Skin Toxicity, Non-thesis Project</i> .
2015 May - 2015 Aug	<b>Primary Supervisor.</b> PharmD. Tian Wang. Supervisee Position: Summer Student PharmD. <i>Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment</i> .
2014 Sep - 2018 Apr	<b>Co-Supervisor.</b> PhD. Erin Stewart. Supervisee Position: PhD candidate, Medical Biophysics, Supervisee Institution: University of Toronto. <i>Modeling mechanisms of resistance and predictive biomarker discovery against targeted therapy using human primary non-small cell lung cancer xenografts</i> . Awards: 2015-CIHR Scholarship Doctoral Award-\$30,000/year + \$5,000 research allowance/year up to 3 years. 2014-CIHR-Terry Fox Foundation Excellence in Radiation Research of the 21st Century (EIRR21) Scholar Liaison stipend \$1, 500. 2014-CIHR-Terry Fox Foundation EIRR21 Alum Award \$2, 500. Supervisor(s): Ming-Sound Tsao.
2013 Jan - 2014 Mar	<b>Co-Supervisor.</b> MSc. Ryan del Bal. Supervisee Position: Biostatistics Intern Masters, Supervisee Institution: University of Waterloo. <i>Genetic analysis of clinical cancer outcomes</i> . Awards: OICR funding.
2012 Sep - 2014 Sep	<b>Primary Supervisor.</b> MSc. Osvaldo Espin-Garcia, Public Health Sciences. Supervisee Position: Biostatistics Intern - Masters, Supervisee Institution: University of Waterloo. <i>Genetic Analysis on Clinical Cancer Outcomes, Non-thesis Project</i> . Awards: *Won Toronto McLaughlin Centre Training and GWW18 Travel awards.
2012 Sep - 2014 Aug	<b>Primary Supervisor.</b> MSc. Erin Stewart. Supervisee Position: MSc. candidate/PhD candidate, Medical Biophysics, Supervisee Institution: University of Toronto. <i>Determining the potential of primary human non-small cell lung cancer xenograft models to investigate multiple targeted therapy</i> . Awards: Won the Terry Fox Foundation Strategic Training Initiative for Excellence in Radiation Research for the 21st Century (EIRR21) Scholarship at CIHR.
2012 Sep - 2013 Jun	<b>Co-Supervisor.</b> MSc. Xiaowei Shen. Supervisee Position: Biostatistics Intern Masters, Supervisee Institution: University of Waterloo. <i>Genetic Analysis on Clinical Cancer Outcomes</i> . Awards: *Won Toronto McLaughlin Centre Training and GAW18 Travel awards.
2012 - 2014	<b>Primary Supervisor.</b> Master of Public Health. Eric Morgen, Public Health Sciences. Supervisee Position: MPH Candidate. Awards: ASCO GI Meeting, Merit Award.
2012 - 2013	<b>Primary Supervisor.</b> Master of Public Health. Eric Morgen. Supervisee Position: Pathology Resident - MPH candidate, Supervisee Institution: University of Toronto. <i>Pharmacogenetics of GI cancers, Non-thesis Project</i> . Awards: 2014* Won ASCO GI Meeting, Merit Award; *Won CIHR Banting and Best Fellowship (MSc. level)(2012); and International Society for Pharmacoepidemiology, Student Travel Award (2013).
2011 Sep - 2012	<b>Co-Supervisor.</b> MSc. Memori Otsuka. Supervisee Position: MSc. Supervisee Institution: University of Toronto. <i>Designing a Visual Scenario-based Instrument that Measures Patient's Understanding of Hypothetical Risk</i> . Completed 2012.
2011 Aug - 2012 Aug	<b>Co-Supervisor.</b> MSc. Yonathan Brhane. Supervisee Position: Biostatistics Masters Intern.

	<i>Biostatistical and Bioinformatics GWAS analysis of BR.24.</i> Completed 2012.
2011 - 2013	<b>Co-Supervisor.</b> MSc. Xin Qiu. Supervisee Position: Biosatistics Intern Masters, Supervisee Institution: University of Waterloo. <i>Lung cancer polymorphism outcome analyses.</i>
2010 Nov - 2012 Oct	<b>Primary Supervisor.</b> MSc. Jennifer Teichman. Supervisee Position: MSc. Graduate student, Medical Biophysics, Supervisee Institution: University of Toronto. <i>Radiation treatment of esophageal cancer.</i> Completed 2012.
2010 Jul - 2013	<b>Co-Supervisor.</b> MSc. Lu Cheng. Supervisee Position: Biostatistics Intern, Supervisee Institution: University of Waterloo. <i>Esophageal cancer outcome analyses.</i>
2010 Jul - 2012 Dec	<b>Primary Supervisor.</b> PhD. Bin Sun. Supervisee Position: PhD graduate student, Supervisee Institution: York University. <i>Biostatistics of Cancer Survival, Biostatistics.</i> Completed 2012.
2009 - 2013	<b>Primary Supervisor.</b> MSc. Lorin Dodbiba. Supervisee Position: Masters Medical Biophysics. <i>Pharmacogenomics and Stem Cell.</i> Completed 2013.

## Undergraduate MD

2025 Jan - 2025 Dec	<b>Primary Supervisor.</b> Anushka Pradhan. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto, Temerity Faculty of Medicine. <i>Ototoxicity in Patients with HNC cancer within the Head and Neck Translational Study.</i>
2024 Nov - 2025 Aug	<b>Primary Supervisor.</b> Ealia Khosh Kish. Supervisee Position: Undergraduate MD, Supervisee Institution: University of Toronto, Temerty Medicine. <i>What are patterns of care, choice of drug, outcomes, predictors of patients with "Bad ALK" lung cancers? What are patterns of care and outcomes in early stage EGFR+ lung cancers?.</i>
2024 Jul - 2025 Jun	<b>Primary Supervisor.</b> Jimmy Tseng. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto. <i>Breathomics.</i>
2024 Jan - 2024 Apr	<b>Primary Supervisor.</b> Jason Guo. Supervisee Position: Undergraduate MD Student, Supervisee Institution: McMaster University. <i>NLP processes involved in extracting biomarker and pathology information from pathology, clinical and radiology reports, including model selection, testing and validation.</i>
2022 Jun - 2024 Sep	<b>Primary Supervisor.</b> Salahaldin Alamleh. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto. <i>MR analysis of BMI and Vit D in lung cancer survival, a GWAS in early stage lung cancer survival.</i> Awards: 1st place overall poster for "Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma" at the Canadian Society of Otolaryngology - Head & Neck Surgery - 2023 Annual Meeting.
2022 Jun - 2024 Apr	<b>Primary Supervisor.</b> Niki Esfahanian. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto. <i>CARMA-BROS.</i>
2022 Jun - 2022 Aug	<b>Primary Supervisor.</b> Jimmy Tseng. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto. <i>Breathomics.</i>
2022 May - 2023 Apr	<b>Primary Supervisor.</b> Jinny Kim. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto. <i>Improved Coordination of Lung Cancer Screening through Innovative Technology.</i>
2022 May - 2023 Apr	<b>Primary Supervisor.</b> Aly Fawzy. Supervisee Position: Undergraduate MD Student, Supervisee Institution: University of Toronto. <i>AIM2REDUCE project and its associated data curation pipeline 2BLAST.</i>
2021 May - 2022 Aug	<b>Primary Supervisor.</b> Jae Yun Lee. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>CARMA-BUROS.</i> Awards: CREMS Stipend: \$2,750 (May - Aug 2021).
2021 May - 2022 Apr	<b>Primary Supervisor.</b> Alison Moore. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>CARMA (BRAF, ROS1, RET, KRAS)/ PALEOS (pilot of IO-treated stage IV NSCLC pts).</i>
2021 May - 2022 Apr	<b>Primary Supervisor.</b> Jessica Petricca. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>MOHCCN gold cohorts/ NLP-Prevention/Precancerous-Pathology Pilot study.</i>

2021 May - 2022 Apr	<b>Primary Supervisor.</b> Tedi Hoxha. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>DFS and OS correlation in KRAS + NSCLC patients.</i>
2021 May - 2021 Dec	<b>Primary Supervisor.</b> Yucheng (Lance) Zhang. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>MBLAST. Use of rules-based and long/short term memory neural networks to identify presence, size and location of lung nodules on CT scan reports.</i>
2021 May - 2021 Dec	<b>Primary Supervisor.</b> Danielle Lilly Nicholls. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>MBLAST/ CO.17, CO.20.</i> Awards: T-CAIREM Award: \$2,992.50 (May - Aug 2021).
2021 May - 2021 Dec	<b>Primary Supervisor.</b> Jianrui (Peter) Liu. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>I-ELCAP.</i> Awards: CREMS Stipend: \$2,750.
2021 May - 2021 Dec	<b>Primary Supervisor.</b> Jennifer Parker. Supervisee Position: Medical student, Supervisee Institution: University of Toronto. <i>Early Stage Resected NSCLC annotation project.</i>
2020 Jul - 2020 Aug	<b>Primary Supervisor.</b> Joelle Soriano. Supervisee Position: Summer Student, Supervisee Institution: University of Ottawa. <i>Lung cancer in never smokers.</i>
2020 Jul - 2020 Aug	<b>Primary Supervisor.</b> Simren Chotai. Supervisee Position: Summer Student, Supervisee Institution: Royal College of Surgeons in Ireland. <i>ALK+/ CARMA-BROS.</i>
2020 Jun - 2021 Apr	<b>Primary Supervisor.</b> Yucheng (Lance) Zhang. Supervisee Position: Research Student, Supervisee Institution: University of Toronto. <i>Miracle and 2Blast.</i>
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Christina (Joo Hyun) Kim. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Shoebox.</i>
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Evan Strom. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>CARMA-BROS.</i>
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Joshua Herman. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>CARMA-BROS.</i>
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Lanujan Kaneswaran. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>MBLAST.</i>
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Lucia (Juehea) Lee. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>CARMA-BROS.</i>
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Preet Walia. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>CARMA-BROS.</i> Awards: CREMS Stipend: \$2,750.
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Danielle Lilly Nicholls. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>MBLAST.</i> Awards: CREMS Stipend: \$2,750.
2020 Jun - 2020 Aug	<b>Primary Supervisor.</b> Supervisee Position: Amir Sabouhanian, Supervisee Institution: University of Toronto. <i>SHOEBOX CREMS.</i> Awards: CREMS Stipend: \$2,750.
2020 Jan - 2021 Aug	<b>Primary Supervisor.</b> Aein Zarrin, Medical Biophysics. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Lung CALIBRE-NLP.</i>
2019 Jul - 2019 Aug	<b>Primary Supervisor.</b> Year 3. Dasith Jayatilake. Supervisee Position: Summer Student, Supervisee Institution: Royal College of Surgeons in Ireland. <i>EGFR/ALK (CARMA/CARMAC/IASLC).</i>
2019 Jul - 2019 Aug	<b>Primary Supervisor.</b> Year 2. Kate McKay. Supervisee Position: Summer Student, Supervisee Institution: University of Cambridge. <i>Real World Observational Outcomes Study of Brain Metastases in Lung Cancer in the new era of Selective Neurosurgery, Stereotactic Radiation, and Targeted Agents.</i>
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Year 2. Amy-Rose Wheeler. Supervisee Position: Summer Student, Supervisee Institution: University of Dublin - Trinity College. <i>AYA, primary care access, switch from ped to Fam MD.</i>
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Year 2. Richard Chen. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>IRATE + PRO toxicity screening tool in LC.</i>
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Maisha Chowdhury. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Real World Observational Outcomes Study of Brain Metastases in Lung Cancer in the new era of Selective Neurosurgery, Stereotactic</i>

	<i>Radiation, and Targeted Agents.</i> Awards: CREMS Stipend: \$2,750.
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Sarfraz Gill. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Pharmacogenomics of Platinum Toxicities in Cancer Patients: Combined Translational and Knowledge Implementation Study.</i> Awards: CREMS Stipend: \$2,750.
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Ashraf Altesha. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Phase 2 Trial of Breathomics for Diagnosis of Pulmonary Disease and Pulmonary Treatment Complications.</i> Awards: CREMS Stipend: \$2,750.
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Year 1. Arsalan Khan. Supervisee Position: Summer Student, Supervisee Institution: Royal College of Surgeons in Ireland. <i>HN Shoebox/HN long term toxicity.</i>
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Year 1. Joelle Soriano. Supervisee Position: Summer Student, Supervisee Institution: University of Ottawa. <i>HN Otoxicity Shoebox and pharmacogenomics.</i> Awards: SURP award Stipend: \$2,000 IMS. WINNER OF IMS SUMMER STUDENT RESEARCH DAY PRESENTATION, 2019.
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Year 1. Xin Ge Chen (Cindy). Supervisee Position: Summer Student, Supervisee Institution: University of Alberta. <i>Breathomics - implementation of clinico-epi and PRO data collection on LC patients undergoing bronchoscopy or pleural fluid thoracentesis.</i>
2019 May - 2019 Aug	<b>Primary Supervisor.</b> Year 2. Simren Chotai. Supervisee Position: Summer Student, Supervisee Institution: Royal College of Surgeons in Ireland. <i>Breathomics: Phase 2 Trial of Breathomics for Diagnosis of Pulmonary Disease and Pulmonary Treatment Complications.</i>
2019 Jan - 2020 Aug	<b>Primary Supervisor.</b> Ghazal Haddad. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. <i>Breathomics: Phase 2 Trial of Breathomics for Diagnosis of Pulmonary Disease and Pulmonary Treatment Complications.</i> Awards: CREMS Stipend: \$7,500.
2018 Jun - 2018 Aug	<b>Co-Supervisor.</b> Year 1. Daniel Davies. Supervisee Position: Undergraduate MD. ASyMS. Supervisor(s): Doris Howell.
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Year 1. Hannah Tateishi. Supervisee Position: Undergraduate MD. <i>Screening of Lung Cancer in Underserved Populations: SLiC UP.</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Year 2. Shirley Jiang. Supervisee Position: Undergraduate MD. <i>Esophageal cancer questionnaire iPad implementation project.</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Year 1. Kathryn Corbett. Supervisee Position: Undergraduate MD. <i>The Princess Margaret Behaviour and Lifestyle in Cancer Survivors Project: BLICS.</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Year 2. Priya Bapat. Supervisee Position: Undergraduate MD. <i>Assessing Hearing Loss Routinely in the Head and Neck Multidisciplinary Cancer Clinic.</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Year 1. Zhen (Jason) Fan. Supervisee Position: Undergraduate MD. <i>Feasibility Testing of the LifeguardRx Mobile App to Report Real-Time Symptoms and Toxicities of Cancer Patients Undergoing Systemic and Chemotherapy: Knowledge Translation Research.</i>
2018 Jun - 2018 Aug	<b>Primary Supervisor.</b> Year 1. RuiQi (Richard) Chen. Supervisee Position: Undergraduate MD. <i>Managing Cancer Patients In Hospital On Immunotherapy Who Develop Immune-Related Adverse or Toxic Events. The IRATE Real-World Evidence Project.</i>
2018 Jan - 2019 Aug	<b>Primary Supervisor.</b> Year 1. Andrew Lam. Supervisee Position: Undergraduate MD. <i>Early Detection and Screening Program in Lung Cancer (I-ELCAP).</i>
2017 Jul - 2017 Aug	<b>Primary Supervisor.</b> Year 5, Cambridge. Amedra Basgaran. Supervisee Position: Undergraduate MD. <i>Cancer Personalized Medicine and the Patient: Patient-Reported Knowledge, Preferences, and Behaviours.</i>
2017 Jun - 2017 Aug	<b>Co-Supervisor.</b> Year 2. Tamoor Afzaal. Supervisee Position: Undergraduate MD. <i>Knowledge Translation Research: Implementation of an Electronic Smoking Cessation Tool.</i> Supervisor(s): Andrea Eisen.
2017 Jun - 2017 Aug	<b>Co-Supervisor.</b> Year 1. Justine Baek. Supervisee Position: Undergraduate MD. <i>Barriers of EQ5D-5L implementation into routine clinical practice: A Multisite Evaluation.</i> Supervisor(s):

Christine Brezden-Masley.

2017 Jun - 2017 Aug	<b>Primary Supervisor.</b> Year 2. Sophia Liu. Supervisee Position: Undergraduate MD. <i>Disparities in Lifestyle Behaviours Between Immigrant and non Immigrant Cancer Survivors.</i>
2017 Jun - 2017 Aug	<b>Primary Supervisor.</b> Year 2. Joo Yoon. Supervisee Position: Undergraduate MD. <i>Feasibility of Screening for Lung Cancer using Low Dose CT scans in Marginalized Populations?.</i>
2017 Jun - 2017 Aug	<b>Primary Supervisor.</b> Year 1. Shirley Jiang. Supervisee Position: Undergraduate MD. <i>(Quality of) Life After Failure – How Treatment Beyond Progression Affects the Health Status of EGFR Lung Cancer Patients.</i>
2017 Jun - 2017 Aug	<b>Primary Supervisor.</b> Year 2. Shayan Kassirian. Supervisee Position: Undergraduate MD. <i>Social media and internet use for cancer education by adult and AYA patients.</i>
2017 Jun - 2017 Aug	<b>Primary Supervisor.</b> Year 2. Badr Id Said. Supervisee Position: Undergraduate MD. <i>Lung, ALK (ESAS-EQ5D Outcome analysis).</i>
2017 May - 2017 Aug	<b>Primary Supervisor.</b> Year 1. Ali Vedadi. Supervisee Position: Undergraduate MD. <i>Lung, small cell (ESAS-EQ5D Outcome analysis).</i>
2017 May - 2017 Jul	<b>Primary Supervisor.</b> Year 2. Lina Chen. Supervisee Position: Undergraduate MD. <i>Knowledge Translational Research: Implementation of an Electronic Smoking Cessation Tool.</i>
2017 Jan - 2018 Aug	<b>Primary Supervisor.</b> Year 1. Min Joon Lee. Supervisee Position: Undergraduate MD. <i>Have Cancer Patients Caught up to Precision Oncology 2.0? Patient's Knowledge, Attitudes and Preferences of Cancer Biomarkers.</i>
2016 Jun - 2016 Aug	<b>Primary Supervisor.</b> Year 2. Yuchen Li. Supervisee Position: Undergraduate MD. <i>New Patient Questionnaire (Lung).</i>
2016 Jun - 2016 Aug	<b>Primary Supervisor.</b> Year 2. Kishan Shani. Supervisee Position: Undergraduate MD. <i>Dysphagia.</i>
2015 Nov - 2016 May	<b>Primary Supervisor.</b> Year 4. João Gabriel Silva Lemes. Supervisee Position: Visiting student- Research Internship, Supervisee Institution: School of Medicine of the Federal University of Paraná (UFPR), Brazil.
2015 Jul - 2016 Jun	<b>Primary Supervisor.</b> Year 2. Sze Wah (Samuel) Chan. Supervisee Position: Undergraduate MD. <i>Development of a prognostic database of NSCLC pts treated with Immunotherapies.</i>
2015 Jul - 2016 Jun	<b>Primary Supervisor.</b> Year 1. Kristen Dietrich. Supervisee Position: Undergraduate MD. <i>Developing a Mesothelioma Clinical Database: MESO-DATA.</i>
2015 Jul - 2016 Jun	<b>Primary Supervisor.</b> Amir-Arsalan Sabouhanian. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>SHOEBOX (CARMA-BROS).</i> Awards: CREMS Stipend: \$2,750.
2015 Jun - 2015 Jul	<b>Primary Supervisor.</b> Year 2. Lauren Wong. Supervisee Position: Undergraduate. <i>Pain and Physical Function; Dyspnea; EQ5D Lung.</i>
2014 Jul - 2014 Aug	<b>Primary Supervisor.</b> Year 1. Wyanne Law. Supervisee Position: Undergraduate, Summer Student. <i>Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment.</i>
2014 Jun - 2014 Aug	<b>Primary Supervisor.</b> Zahara Meralli. Supervisee Position: Undergraduate, Summer Student. <i>Involving patients to improve their care through real-time patient reported outcome (PRO) - CTCAE chemotoxicity surveys in an outpatients chemodacare (DC) setting: Evaluating patient acceptability.</i>
2014 Jun - 2014 Aug	<b>Primary Supervisor.</b> Lauren Wong. Supervisee Position: Undergraduate MD, Summer Student. <i>Involving clinic patients in systematic symptom reporting to improve cancer care: Exploring prevalence of sleep disturbances (SD) and fatigue (FAT).</i>
2013 May - 2015 Jan	<b>Primary Supervisor.</b> Hiten Naik. Supervisee Position: Undergraduate MD, Supervisee Institution: University of Toronto. <i>20 month Research Scholar Program (CREMS).</i> Awards: (2015) - Won ASCO Merit Award (2014/10) - Won ASCO Merit Award (2014/11) - Won Best Student Poster Presentation Award, Canadian Association for Population Therapeutics (CAPT) 2014 Annual Conference

2013 May - 2013 Sep	<b>Primary Supervisor.</b> Year 2. Lindsay Herzog. Supervisee Position: Undergraduate MD, Supervisee Institution: University of Toronto. <i>Summer Research Program (CREMS) - Patient Preference for Transitioning Oncologic Care.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Christine Lam. Supervisee Position: Undergraduate - Medicine, Supervisee Institution: U of Nottingham. <i>Modifiable behaviours and cancer polymorphisms and GERD risk.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Henry Thai. Supervisee Position: Undergraduate - Medicine, Supervisee Institution: University of Toronto. <i>Modifiable behaviours in cancer survivors.</i>
2013 May - 2013 Aug	<b>Primary Supervisor.</b> Mary Mahler. Supervisee Position: Undergraduate, Supervisee Institution: University College, Dublin Medicine. <i>Modifiable behaviours and cancer.</i>
2012 Nov - 2013 Jun	<b>Primary Supervisor.</b> Tenneille Loo. Supervisee Position: Medical Student (DOCH II), Supervisee Institution: University of Toronto. <i>Cancer patient willingness to provide new biopsies and blood samples for pharmacogenomic testing.</i>
2012 Jun - 2013 Sep	<b>Primary Supervisor.</b> Chongya Niu. Supervisee Position: Medical Student, Supervisee Institution: University of Toronto. <i>Elderly cancer survivors and modifiable behaviours (CREMS).</i>
2012 May - 2014 Jun	<b>Primary Supervisor.</b> Lawson Eng. Supervisee Position: Medical Student, Supervisee Institution: University of Toronto. <i>Multiple projects (CREMS).</i> Awards: (2013) - *Won ICPE travel award (2012), ASCO Merit Award International twice.
2012 May - 2012 Sep	<b>Primary Supervisor.</b> Anthony La Delfa. Supervisee Position: Medical Student, Supervisee Institution: University of Toronto. <i>Social support in cancer survivors (CREMS).</i>
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Mary Mahler. Supervisee Position: Medical Student, Supervisee Institution: University College, Dublin. <i>Modifiable Behaviours and Cancer.</i> Completed 2012.
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Jodie Villeneuve. Supervisee Position: Medical Student, Supervisee Institution: Galloway Medicine. <i>Patient Preference for Pharmacogenomic Testing.</i> Completed 2012.
2012 May - 2012 Aug	<b>Primary Supervisor.</b> Year 1. Christine Lam. Supervisee Position: Medical Student, Supervisee Institution: Nottingham Medicine. <i>Modifiable Behaviours and Cancer, Non-thesis Project.</i> Completed 2012.
2010 May - 2010 Aug	<b>Primary Supervisor.</b> Graham McFarlane. Supervisee Position: Summer Research Student, Supervisee Institution: University of College Dublin. <i>Patient physician preferences for pharmacogenetic and pharmacogenomic testing in cancer patients in a Canadian population.</i>
2010 May - 2010 Aug	<b>Primary Supervisor.</b> Chung-Kwun Wong. Supervisee Position: Summer Student, Supervisee Institution: Queen's University. <i>Patient and Physician preferences for Pharmacogenetic Pharmacogenomic testing in Cancer patients in a Canadian population.</i>
2010 May - 2010 Aug	<b>Primary Supervisor.</b> Bradley De Souza. Supervisee Position: Summer Research Student, Supervisee Institution: University College Dublin. <i>Patient physician preferences for pharmacogenetic and pharmacogenomic testing in cancer patients in a Canadian population.</i>

## Postgraduate MD

2023 Jul - present	<b>Co-Supervisor.</b> Beatriz Jimenez Munarriz. Supervisee Position: Clinical Fellow, Princess Margaret Cancer Centre, Supervisee Institution: University of Toronto. <i>1. ALK TKI dosing and weight/BSA; 2. Lurbinectedin and Transformed Neuroendocrine Cancer.</i>
2023 Jul - present	<b>Co-Supervisor.</b> Zachary Coyne. Supervisee Position: Clinical Fellow, Princess Margaret Cancer Centre, Supervisee Institution: University of Toronto. <i>1. Stage-specific predictors of NSCLC risk and prognosis: ILCCO analysis.</i>
2023 Jul - present	<b>Co-Supervisor.</b> Abdulrahman Alghabban. Supervisee Position: Clinical Fellow, Princess Margaret Cancer Centre, Supervisee Institution: University of Toronto. <i>ROS1-positive NSCLC – CARMA BROS analysis.</i>
2023 Jul - present	<b>Co-Supervisor.</b> Sameena Khan. Supervisee Position: Clinical Fellow, Princess Margaret Cancer Centre, Supervisee Institution: University of Toronto. <i>1. ALK VTE and genetic analyses; 2. Small cell lung cancer outcomes in ILCCO.</i>

2023 Jul - present	<b>Primary Supervisor.</b> Yuchen Li. Supervisee Position: Clinical Fellow, Princess Margaret Cancer Centre, Supervisee Institution: University of Toronto. <i>1. HNSCC and NLR related outcomes; 2. Stage III NSCLC and NLR related outcomes. 3. Machine Learning predictors of adverse outcomes in solid tumour patients.</i>
2024 Jul - 2024 Dec	<b>Primary Supervisor.</b> Shirley Tam. Supervisee Position: Postgraduate Md, Supervisee Institution: McGill University. <i>ALK-Alectinib project.</i>
2023 May - 2023 Aug	<b>Co-Supervisor.</b> Yehuda Rosenberg. Supervisee Position: Yehuda Rosenberg, Supervisee Institution: Touro College of Osteopathic Medicine - Harlem Campus. <i>ALK patient clinical information and to gather VTE (thrombosis) data.</i> Supervisor(s): Dr. Frances Shepherd.
2021 Dec - 2023 Jun	<b>Primary Supervisor.</b> Nicholas Holzapfel. Supervisee Position: Intern and Resident, Supervisee Institution: University of Toronto.
2021 Mar - 2022 Jun	<b>Primary Supervisor.</b> Nicholas Meti. Supervisee Position: Medical Oncology Resident, Supervisee Institution: University of Toronto. <i>Pre-Cancer and Cancer Data Through Machine Learning (PCC DatMac).</i>
2021 Feb - 2022 Jun	<b>Primary Supervisor.</b> Alborz Kia. Supervisee Position: BSc Internship, Supervisee Institution: University of Toronto. <i>Early Stage Lung Cancer IASLC project.</i>
2017 Oct - 2018 Apr	<b>Primary Supervisor.</b> Visiting Resident. Mary Mahler. Supervisee Position: Resident. <i>Gather some ototoxicity data from our cisplatin-treated HNSCC patients.</i>
2017 Jun - 2021 Jun	<b>Primary Supervisor.</b> Karmugi Balaratnam. Supervisee Position: Research Trainee. <i>Lifestyle Behaviours In Canadian Cancer Survivors.</i>
2014 Jul - 2020 Dec	<b>Primary Supervisor.</b> Core Program. Dr. Lawson Eng. Supervisee Position: Intern and Resident - Research Blocks - Multiple, Supervisee Institution: University of Toronto. <i>Multiple projects.</i> Awards: 2014/2015 Won two additional separate ASCO Merit Awards; ISPE Travel Award.
2014 May - 2014 Aug	<b>Primary Supervisor.</b> Visiting Scientist. Dr. Ricardo Gama. Supervisee Position: Visiting Scientist, Supervisee Institution: Hospital Universitário Evangélico de Curitiba.
2014 Jan - 2014 Jun	<b>Primary Supervisor.</b> Dr. Nanjimo Yang. Supervisee Position: Visiting Scientist, Translational Epidemiology. Awards: National Science Foundation of China Award (Sept. 2014).
2014 - 2016	<b>Primary Supervisor.</b> Pathology Fellow. Dr. Eric Morgen. Supervisee Position: Pathology Fellow, Supervisee Institution: University of Toronto. <i>Pharmacogenetics of Ovarian Cancer.</i> Awards: (2014) ASCO GI Merit Award (ASCO Gastrointestinal Cancers Symposium), International (2013) International Society for Pharmacoepidemiology, Student Travel Scholarship (2012) CIHR Frederick Banting and Charles Best Graduate Scholarship Master's Award winner, Canada.
2013 Jul - 2014	<b>Primary Supervisor.</b> Radiation Oncology Resident. Katherine Barrett. Supervisee Position: Radiation Oncology Resident, Supervisee Institution: University of Toronto. <i>Polymorphism and lung radiation toxicities.</i> Awards: (2014/9) - Won ASTRO Annual Meeting Abstract Awards: 2nd Place trophy in the Resident Poster Viewing Award-Biology section.
2013 Mar - 2014	<b>Primary Supervisor.</b> Clinical Fellow. Donna Graham. Supervisee Position: Clinical Fellow, Supervisee Institution: PMH-OCI. <i>Complementary Medicine in cancer survivors.</i>
2013 Feb - 2014	<b>Primary Supervisor.</b> Clinical Fellow. Maja Segedi. Supervisee Position: Clinic Fellow, Supervisee Institution: PMH-UHN. <i>BRM and pancreatic cancer.</i> Awards: (2014/3) - One of the five finalists for the SSO 2014 Poster Contest in the Best Basic/Transitional Research Poster category.
2013 Feb - 2014	<b>Primary Supervisor.</b> Clinical Fellow. Anna Spreafico. Supervisee Position: Clinical Fellow, Supervisee Institution: PMH-OCI. <i>BMI and esophageal cancer outcomes.</i>
2012 Aug - 2013 Jul	<b>Primary Supervisor.</b> Dr. Oleksandr Halytskyy. Supervisee Position: Post-doctoral Fellow/Ontario Cancer Fellow, Supervisee Institution: Ontario Cancer Institute. <i>Supplement use and cancer patients.</i>
2012 May - 2013 Jun	<b>Primary Supervisor.</b> Dr. Petra Martin. Supervisee Position: OCI/PMH Fellow, Supervisee Institution: University of Toronto. <i>iPad Pharmacogenetics Preference.</i> Awards: *Won ASCO Merit award.



2012 Mar - 2012 Sep	<b>Primary Supervisor.</b> Visiting Scientist. Dr. Xiang Liu. Supervisee Position: Associate Professor, Supervisee Institution: Hunan First University. <i>Molecular Epidemiology</i> . Completed 2012.
2012 - 2018	<b>Primary Supervisor.</b> Dr. Jennifer Wang. Supervisee Position: Clinician Investigator Program Resident, Otolaryngology, Supervisee Institution: University of Toronto. <i>BRM and Head and Neck Cancer</i> . Awards: *Won Best Paper, Otolaryngology Resident, Research Day.
2012 - 2014	<b>Primary Supervisor.</b> OCI Clinical Fellow. Grzegorz Janusz Korpany. Supervisee Position: OCI Clinical Fellow, Supervisee Institution: University of Toronto. <i>BRM and Esophageal Outcomes</i> .
2012	<b>Primary Supervisor.</b> PDF, OCI-PMH Fellow. Olusola O. Faluyi. Supervisee Position: PDF, OCI-PMH Fellow. <i>MIRNA polymorphism and esophageal cancer outcomes</i> . Awards: *Won ASCO Merit Award.
2011 May - 2013 Jun	<b>Primary Supervisor.</b> Ehab Fadhel. Supervisee Position: Post Doctoral Fellow. <i>Patient Perception of Epidemiologic Surveys</i> . Completed 2013.
2010 May - 2010 Aug	<b>Primary Supervisor.</b> Masters of Bio Engineering (Chemical Engineering). Henrique Hon. Supervisee Position: Summer Student, Supervisee Institution: University of Toronto. <i>Patient and Physician preferences for pharmacogenetic and pharmacogenomic testing in cancer patients in a Canadian population</i> .
2010 - 2014	<b>Primary Supervisor.</b> Dr. Kitman Wong. Supervisee Position: Resident, Medicine, University of Toronto. <i>Multiple Projects</i> . Awards: *Won ASCO Merit and N.O.Y.C.I.A. awards (2012) and ASCO Merit award, International (2013).
2010	<b>Primary Supervisor.</b> Dr. Armin Hasani. Supervisee Position: Post-doctoral fellow, Ontario Cancer Institute. <i>Mesothelioma and Biomarkers</i> .
2009 - 2013	<b>Primary Supervisor.</b> Dr. Sinead Cuffe, post-graduate. Supervisee Position: Post Doctoral Fellow. <i>Health Services, Clinical Epidemiology Lung Cancer</i> . Awards: *Won N.O.Y.C.I.A. and ASCO Merit Awards (2012) and ASCO Merit Award, International (2013).
2009 - 2011	<b>Primary Supervisor.</b> Dr. Daniel Renouf, post-graduate. Supervisee Position: Post-doctoral fellow, Ontario Cancer Institute. <i>GI Cancer Pharmacogenetics</i> .
2009 - 2011	<b>Primary Supervisor.</b> Dr. Linda Coate. Supervisee Position: Post-doctoral fellow, Ontario Cancer Institute. <i>Lung Cancer, Pharmacogenetics</i> .
2009 - 2010	<b>Primary Supervisor.</b> Dr. Xiaoping Qiu, Visiting Scientist. Supervisee Position: Visiting Scientist from China. <i>Molecular Epidemiology, Bleomycin Pharmacogenetics</i> .
2008 - 2011	<b>Primary Supervisor.</b> Subspecialty. Dr. Anne Horgan, post-graduate. Supervisee Position: Post-doctoral Fellow, Princess Margaret Hospital. <i>Lung Cancer</i> .
2008 - 2009	<b>Primary Supervisor.</b> Dr. Joseph Geraci, post-graduate. Supervisee Position: Post-doctoral fellow, Ontario Cancer Institute. <i>Bioinformatics</i> .
2008 - 2009	<b>Primary Supervisor.</b> Dr. Winson Cheung, post-graduate. Supervisee Position: Assistant Professor, Medicine University of British Columbia. <i>Esophageal Cancer Risk/Prognosis</i> .
2007 - 2009	<b>Primary Supervisor.</b> Dr. Dangxiao Cheng, post-graduate. Supervisee Position: Research Technician, Ontario Cancer Institute. <i>Molecular Biology Methodology</i> .
2007 - 2009	<b>Primary Supervisor.</b> Dr. David Cescon, post-graduate. Supervisee Position: Medical Oncology resident, University of Toronto. <i>Esophageal Cancer Risk/Prognosis</i> .
2007 - 2008	<b>Primary Supervisor.</b> Dr. Sevtap Savas, post-graduate. Supervisee Position: Assistant Professor, Genetics, Memorial University of Newfoundland. <i>Genetic Epidemiology</i> .
2007 - 2008	<b>Primary Supervisor.</b> Paul Wheatley-Price, post-graduate. Supervisee Position: Assistant Professor, Medicine, University of Ottawa. <i>Mesothelioma and Esophageal Cancer</i> .
2007 - 2008	<b>Primary Supervisor.</b> Dr. Darren Tse, post-graduate. Supervisee Position: ENT Resident, Ottawa Hospital. <i>Head and Neck Cancer</i> .
2006 - 2008	<b>Primary Supervisor.</b> Dr. Penny Bradbury. Supervisee Position: NCIC Clinical Trials Physician Coordinator, Kingston; Assistant Professor, Queens University. <i>Esophageal Cancer Prognosis</i> .
2006 - 2007	<b>Primary Supervisor.</b> Dr. Martin Fruh. Supervisee Position: Attending Staff, Zurich,

Switzerland. *Esophageal Cancer Risk*.

## Postdoctoral Research Fellow (PhD)

2023 Nov - 2024 Oct	<b>Primary Supervisor.</b> Peng Song. Supervisee Position: Postdoctoral Fellow, Supervisee Institution: Shandong Provincial Hospital Affiliated to Shandong First Medical University. <i>Lung Cancer Clinic translational research</i> .
2023 Jan - 2025 Dec	<b>Primary Supervisor.</b> Samir Barghout. Supervisee Position: Postdoctoral Research Fellow, Supervisee Institution: University of Toronto. <i>Harnessing tissue-specific expression of E3 ligases for selective protein degradation in cancer</i> . Awards: Canadian Institutes of Health Research (CIHR) - \$135,000.
2018 Apr - 2018 Jun	<b>Primary Supervisor.</b> Erin Stewart. Supervisee Position: Post Doctorate Fellow. <i>Investigate mechanisms of resistance to EGFR targeted therapies</i> .
2014 Jul - 2014 Nov	<b>Primary Supervisor.</b> Dr. Carlos Pantoja. Supervisee Position: Visiting Scientist, Supervisee Institution: Institute of Ophthalmology, Mexico City.
2010 - 2013 Jul	<b>Primary Supervisor.</b> 1-3. Dr. Qi Wang, Medical Biophysics. Supervisee Position: Post-doctoral fellow, Ontario Cancer Institute. <i>Bleomycin Pharmacogenomics</i> .
2008 - 2013 Sep	<b>Primary Supervisor.</b> 1-3. Dr. Azad Kalam, Medical Biophysics. Supervisee Position: Post-doctoral fellow, Ontario Cancer Institute. <i>Head and Neck Molecular Epidemiology</i> . Awards: ISPE Travel Award 2012.

## Clinical Research Fellow (MD)

2021 - 2023	<b>Primary Supervisor.</b> Lucy Corke. Supervisee Institution: University of Toronto. <i>Single Organ metastases in lung cancer patients</i> .
2020 - 2022	<b>Primary Supervisor.</b> Miguel Garcia. <i>COS-ILCCO</i> .
2020 - 2022	<b>Primary Supervisor.</b> Ulf Keuge. <i>Esophageal and Hepatocellular Research</i> .
2019 - 2022	<b>Primary Supervisor.</b> Sabine Schmid. <i>Lung Cancer Breathomics</i> .
2018 - 2020	<b>Primary Supervisor.</b> Aline Fares. <i>Lung Cancer Markers</i> .
2016 Sep - 2019 Jun	<b>Primary Supervisor.</b> Daniel Shepshelovich. <i>Multiple Pharmacogenetic and Epidemiological Studies</i> . Awards: American Society of Clinical Oncology (ASCO) Merit Award.
2016 Jul - 2017 Jun	<b>Primary Supervisor.</b> Mor Moscovitch. <i>Mapping of EQ5D to ESAS in Cancer Patients</i> .
2016 Jul - 2017 Jun	<b>Primary Supervisor.</b> Sara Soldera. <i>Thymoma and Thymic Cancer and Health Utility Scores</i> .
2016 Jul - 2017 Jun	<b>Primary Supervisor.</b> Tristan Barnes. <i>Acceptability of EQ5D in Routine Cancer Outpatient Practice</i> .
2016 Jan - 2017 Dec	<b>Primary Supervisor.</b> Grainne O'Kane, Aerospace Studies. <i>Multiple Lung Cancer Projects</i> . Awards: Novartis Oncology Young Canadian Investigator Awards (NOYCIA).

## Other

2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Elise Wan. Supervisee Position: Summer Student. <i>AYA/ ESAS DART AYA (Distress, Mental Health)</i> .
2019 Jun - 2019 Aug	<b>Primary Supervisor.</b> Sarah Rudolph-Naiberg. Supervisee Position: Summer Student. <i>Lifestyle: Cannabis &amp; e-cig, Smoking hx and Sex history</i> .

## 2. OTHER SUPERVISION

### Graduate Education

#### Secondary Supervisor

2014 Jun - 2014 Aug	<b>MSc.</b> Cindy Xin. Supervisee Position: Biostatistical Intern/Masters Program. <i>Evaluating the benefit of electronic patient Reported symptom assessments for in-patient oncology patients</i> .
---------------------	--

Geoffrey LIU

2009 Oct - 2010 Jun **MSc.** Bin Sun. Supervisee Position: MSc Graduate Student, Biostatistics, Supervisee Institution: York University. *Biostatistics of Cancer Survival*.

2009 - 2010 **PhD.** Dr. ZhengFei Chen. Supervisee Position: PhD, Graduate Student, Biostatistics, Supervisee Institution: University of Toronto. *Biostatistics of Cancer Survival*.

2006 - 2009 Dr. Kofi Asomaning. Supervisee Position: ScD, Harvard School of Public Health. *Genetics of GI cancer Outcomes*.

2006 - 2009 Dr. Jianbao Wu, graduate. Supervisee Position: PhD, Biostatistician. *Biostatistics*.

#### Thesis Committee Member

2021 - present Daniele Sacdalan. Supervisee Position: PhD Candidate, Supervisee Institution: University of Toronto.

2019 - 2021 Sami Al Haq. Supervisee Position: MSc Candidate, Supervisee Institution: University of Toronto. *Small Cell Lung Cancer*.

2016 - 2021 **PhD.** Matthew Walkerton. Supervisee Position: PhD Candidate.

2016 - 2019 Rene Quevado, Medical Biophysics. Supervisee Position: PhD Candidate, Supervisee Institution: University of Toronto. *Copy Number Bioinformatics*.

2015 - 2019 **PhD.** Rene Quevado, Medical Biophysics. Supervisee Position: PhD Candidate, Supervisee Institution: University of Toronto. *Medical Biophysics*.

2015 - 2016 **PhD.** Haozhang Situ. Supervisee Position: PhD Candidate, Supervisee Institution: University of Toronto.

2014 - 2019 **PhD.** Linda Kachuri. Supervisee Position: PhD Candidate, Supervisee Institution: Dalla Lana School of Public Health. *Epidemiology*.

2014 - 2017 **PhD.** Javier Alfaro. Supervisee Position: PhD Candidate, Supervisee Institution: University of Toronto. *Medical Biophysics*.

2013 - 2016 **PhD.** Nardin Samuel, Medical Biophysics. Supervisee Position: PhD Candidate, Supervisee Institution: University of Toronto. *Medical Biophysics*.

2010 Sep - 2012 Jun **PhD.** Darren Brenner. Supervisee Position: PhD Candidate. *Epidemiology*. Completed 2012.

2008 - 2009 **MSc.** Melena Stegne, MSc candidate. Supervisee Position: Brock University. *Epidemiology of Asbestos Exposure*.

#### Co-Primary Supervisor

2022 Sep - present Yifan (Andy) Yu. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Organoid Resistance Models*. Supervisor(s): Ming Tsao.

2022 Sep - present Yoshimasa Kudo. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Mechanisms of cfDNA biology using lung cancer samples and models*. Supervisor(s): Scott Bratman.

2022 Sep - present Janice Li. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Hydroxymethylation in lung cancer*. Supervisor(s): Ben Lok.

2021 Sep - present Christie Lau. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Informatics for serial xenograft-based single cell analyses*. Supervisor(s): Gregory Schwartz.

2020 Sep - present Khadija Jafarova. Supervisee Position: Graduate Student, Supervisee Institution: University of Toronto. *Lung cancer organoids*. Supervisor(s): Ming Tsao.

#### Research course supervisor

2007 - 2008 **MSc.** Dr. Jessica Hopkins. Supervisee Position: Family/Community Health Clinician Investigator and Physician Epidemiologist, Supervisee Institution: University of Toronto. *Epidemiology of Cancer*.

Geoffrey LIU

## Postgraduate MD

### Secondary Supervisor

2010 - 2012	Dr. Ivan Padilla. Supervisee Position: OCI-PMH Fellow. <i>Pharmacogenetics of Gynecologic Cancers</i> .
2003 - 2006	Dr. Rebecca Suk (Heist). Supervisee Position: Asst Professor, Harvard, Boston. <i>Genetics of Lung Cancer Treatment Toxicity</i> .
2002 - 2004	Dr. Sarada Gurubhagavatula. Supervisee Position: Attending Physician, Baltimore. <i>Genetics of Lung Cancer Survivorship</i> .
2001 - 2003	Dr. Wei Zhou. Supervisee Position: Senior Epidemiologist, Merck. <i>Genetics of Cancer Outcome</i> .

### Other

Ricardo Gama. Supervisee Institution: Hospital Universitario.

**Date Submitted:** 2024-08-23 00:21:48

**Confirmation Number:** 1803142

**Template:** CIHR Biosketch

---

## **Dr. Megan Delisle**

Correspondence language: English

Sex: Female

Date of Birth: 8/16

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

## **Contact Information**

The primary information is denoted by (\*)

### **Address**

Primary Affiliation (\*)

GF432-820 Sherbrook  
Health Sciences Center  
Winnipeg Manitoba R3A 1R9  
Canada

### **Telephone**

Mobile (\*) 1-204-510-5351

### **Email**

Work (\*) megan.delisle@umanitoba.ca

### **Website**

Corporate <https://umanitoba.ca/medicine/faculty-staff/megan-delisle>



Protected when completed

## Dr. Megan Delisle

---

### Degrees

2021/7 - 2023/6	Doctorate, Complex General Surgical Oncology, University of Ottawa Degree Status: Completed
2014/7 - 2021/5	Doctorate, General Surgery, The University of Manitoba Degree Status: Completed
2017/7 - 2019/5	Master's Thesis, Masters of Science, The University of Manitoba Degree Status: Completed
2017/6 - 2019/5	Master's non-Thesis, Masters of Public Health, Harvard School of Public Health Degree Status: Completed
2009/8 - 2014/5	Doctorate, Doctor of Medicine, McGill University Degree Status: Completed
2007/9 - 2009/5	Bachelor's Equivalent, Quebec Diploma of College Studies, Dawson College Degree Status: Completed

### Credentials

2024/1	Complex General Surgical Oncology, American Board of Surgery
2023/9	Complex General Surgical Oncology, Royal College of Physicians and Surgeons of Canada
2021/10	General Surgery, American Board of Surgery
2021/7	General Surgery, Royal College of Physicians and Surgeons of Canada
2019/7	Clinician Investigator Program, Royal College of Physicians and Surgeons of Canada

### Recognitions

2023/2	Department of Surgery Resident and Fellow Recognition Award Nominee University of Ottawa
2022/6	Culture Changer Champion Canadian Federation of Medical Students
2019/6	Nancie J. Mauro Graduate Scholarship in Oncology Research The University of Manitoba
2018/6	Canadian Institute of Health Research Master's Award Canadian Institutes of Health Research
2018/6	Mindel and Tom Olenick Research Studentships in Medicine The University of Manitoba

## Employment

2023/7	Affiliate Scientist Health Services Research Lab, Paul Albrechtsen CancerCare Manitoba Research Institute, CancerCare Manitoba
2023/7	Assistant Professor Department of Surgery, Faculty of Health Sciences, The University of Manitoba
2023/7	Surgical Oncologist Shared Health
2021/7 - 2023/6	Fellow, Complex General Surgical Oncology Surgery, Faculty of Medicine, University of Ottawa
2021/7 - 2023/6	General Surgeon Locum The Ottawa Hospital
2014/7 - 2021/6	Resident, General Surgery Surgery, Faculty of Health Sciences, The University of Manitoba
2017/7 - 2019/6	Post-Doctoral Research Fellow Epidemiology, Ariadne Labs, Harvard School of Public Health

## Affiliations

The primary affiliation is denoted by (\*)

(\*) 2023/7 Assistant Professor, Surgery, The University of Manitoba

## Research Funding History

### Awarded [n=12]

2022/7 - 2027/7 Co-investigator	Canadian Cholangiocarcinoma Collaborative (C3)  <b>Funding Sources:</b> Canadian Cancer Society Breakthrough Team Grants Total Funding - 7,404,250 Funding Competitive?: Yes  Co-investigator : Arif Awan; Brad Nelson; Carmen G. Loiselle; Catherine Forse; Cynthia Walsh; Faiyaz Notta; Francine Aubin; Jad Abou-Khalil; Jennifer Knox; John Bell; Laszlo G. Radvanyi; Melinda Bachini; Michael Raphael; Natasha Kekre; Pablo Serrano; Paul Karanicolas; Peter Kim; Rachel Goodwin; Ralph Wong; Robert Holt; Sean Bennett; Sharlene Gill; Simon Turcotte; Steve Welch; Trevor Pugh; Trevor Pugh; Vallerie Gordon;  Co-knowledge User : Adam Auer; Ambuj Srivastava; Judit Zubovits; Neil Marr; Scott Stennett; Sylvie Breton;  Principal Investigator : Carolina Ilkow; Rebecca Auer
2024/5 - 2027/5 Co-investigator	Assess the effectiveness and implementation of the CTN program, using a navigator-assisted clinical trial enrollment platform  <b>Funding Sources:</b> Breast cancer Canada Breast Cancer Canada Annual research grant award 2024-2027 Total Funding - 75,000 Funding Competitive?: Yes

Co-investigator : Doris Howell; Kayla Touma; Lee McGrath; Mahmoud Hossami; Nasong Anthony Luginaah; Renee Nassar; Rhonda Abdel-Nabi;

Principal Investigator : Dr. Caroline Hamm, MD FRCPC

2024/7 - 2026/6

Principal Investigator

HDRN Pragmatic Clinical Trials

**Funding Sources:**

Canadian Institutes of Health Research (CIHR)

HDRN Canada Pragmatic Trials Training Program

Total Funding - 30,000

Funding Competitive?: Yes

2024/5 - 2026/5

Principal Investigator

Advancing Precision Oncology in the Real-World Environment (AsPIRE)

**Funding Sources:**

University of Manitoba

Department of surgery 2024 GFT Grant

Total Funding - 15,000

Funding Competitive?: Yes

Co-investigator : Dr. Kathleen Decker, Ms. Iresha Ratnayake

2024/1 - 2026/1

Principal Investigator

Improving patient outcomes by increasing equity in clinical trial enrollment with the Clinical Trial Navigation Program: A stakeholder-engaged process for refining trial design and a pilot study of of a prospective, pragmatic multi-centre, stepped we

**Funding Sources:**

Beigene Canada

Fund for Research and Innovation

Total Funding - 50,000

Funding Competitive?: Yes

Co-investigator : Caroline Hamm; Kathleen Decker; Nicole Laferriere

2024/1 - 2026/1

Principal Applicant

Enhancing the Patient Journey to Clinical Trial Enrolment with Navigation to Optimize Accrual: A Pilot and Feasibility Study of a prospective, pragmatic multi-centre, stepped wedge, cluster randomized controlled trial

**Funding Sources:**

Canadian Institutes of Health Research (CIHR)

Catalyst Grant : SPOR Innovative Clinical Trials (iCT)

Total Funding - 200,000

Funding Competitive?: Yes

Co-applicant : Gallagher, Jennifer; Pond, Greg; Tiano, Teresa;

Collaborator : Barnard, Kathleen; Butler, Marcus; Park, Jason; Porter, Lisa; Pugh, Trevor; Sundquist, Stephen; Wright, Jim;

Principal Applicant : Decker, Kathleen; Laferriere, Nicole; Marley, Diane; Perera, Sheron; Petrella, Teresa;

Principal Investigator : Hamm, Caroline

2023/7 - 2025/6

Principal Investigator

Improving Cancer Surgery through Continuous, Province-Wide Feedback for Surgeons

**Funding Sources:**

CancerCare Manitoba (CCMB)

CancerCare Manitoba Foundation Project Grant

Total Funding - 175,000

Funding Competitive?: Yes

Co-investigator : Lambert, Pascal; Pamela Hebbard; Park, Jason; Pitz, Marshall;



	<p>Collaborator : Brindle, Mary;</p> <p>Principal Investigator : Decker, Kathleen</p>
2024/3 - 2025/3 Co-investigator	<p>Personalized Approach to Extended Thromboembolism Prophylaxis Compared to Usual Care After Major Abdominal Surgery for Cancer (TPDA): A Pilot Pragmatic Randomized Trial</p> <p><b>Funding Sources:</b>  The Ottawa Hospital Academic Medical Organization  Innovation Fund Grant  Total Funding - 43,673  Funding Competitive?: Yes</p> <p>Co-investigator : Brittany Dingley; Guillaume Martel; Isabelle Raiche; Justin Presseau; Kimberly Bertens; Ramzi Helewa; Ranjeeta Mallick; Rebecca Auer; Sameer Apte; Scott Hurton;</p> <p>Principal Investigator : Marc Carrier; Victoria Ivankovic</p>
2024/1 - 2025/1 Principal Investigator	<p>CLEAN Wound Trial</p> <p><b>Funding Sources:</b>  University of Manitoba  University Research Grants Program  Total Funding - 10,000  Funding Competitive?: Yes</p> <p>Co-investigator : Jordan Nantais; Lev Bubis; Rae Spiwak; Sarvesh Logsetty;</p> <p>Principal Investigator : Paul Karanicolas</p>
2024/1 - 2025/1 Principal Applicant	<p>CAN-TAP-TALENT Early Career Researcher Award</p> <p><b>Funding Sources:</b>  CAN-TAP-TALENT CIHR and other provincial partners  Canadian Training Platform for Trials Leveraging Existing Networks, Clinical Trials Training Program  Total Funding - 20,000  Funding Competitive?: Yes</p>
2023/7 - 2024/7 Co-investigator	<p>2Expansion of the Clinical Trials Navigator (CTN) Program with Staged Introduction of the Navigator program to demonstrate benefit to availability of the CTN program</p> <p><b>Funding Sources:</b>  WE-SPARK Health Institute  Igniting Discovery Grants  Total Funding - 10,000  Funding Competitive?: Yes</p> <p>Principal Investigator : Caroline Hamm; Nicole Laferriere</p>
2022/7 - 2024/6 Co-investigator	<p>Feasibility of a new training model, VISION (VIdeo obServation wIthin grOups debriefiNg) simulation training to improve interprofessional teamwork</p> <p><b>Funding Sources:</b>  Institut de Recherche de l'Hôpital Montfort (IRHM)  Fonds Innovation  Total Funding - 96,847  Funding Competitive?: Yes</p> <p>Co-investigator : Denis-Leblanc, Manon; Dubois Desroches, Valérie; Hannenberg, Alexander;</p>

Principal Investigator : Boet, Sylvain; Truong, Steve

## Publications

### Journal Articles

1. Ivankovic V, Delisle M, Stacey D, Abou-Khalil J, Balaa F, Bertens K, Dingley B, Martel G, McAlpine K, Nessim C, Tadros S, Carrier M, Auer R. (2023). Beta-testing of a risk-stratified patient decision aid to facilitate shared decision-making for post-operative extended thromboprophylaxis in patients undergoing major abdominal surgery for cancer. *Can J Surg*. pending: pending.  
Accepted  
Refereed?: Yes, Open Access?: Yes
2. Delisle M, Wang Y, Fitch M, Nagaratnam K, Srikanthan A. (2023). Variations in Emergency Service Utilization among Cancer Survivors: Results from the Pan-Canadian Experiences of Cancer Patients in a Transition Study Survey. *J Oncol*.2023: 5056408.  
Published  
Refereed?: Yes, Open Access?: Yes
3. Nayak A, Pickett A, Delisle M, Dingley B, Mallick R, Hamilton T, Stuart H, Talbot M, McKinnon G, Jost E, Thiboutot E, Francescutti V, Samman S, Easson A, Schellenberg A, Merchant S, La J, Vanderbeck K, Wright F, Berger-Richardson D, Hebbard P, Hershorn O, Younan R, Patocskai E, Rodriguez-Qizilbash S, Meguerditichian A, Tchuenta V, Kazandjian S, Matheison A, Hossain F, Hetu J, Corsten M, Tohme A, Nessim C, Johnson-Obaseki S. (2023). Survival of Patients With Head and Neck Merkel Cell Cancer: Findings From the Pan-Canadian Merkel Cell Cancer Collaborative. *JAMA Open*. 6(11): e2344127.  
Published  
Refereed?: Yes, Open Access?: Yes
4. Delisle M, Kung V, Alves S, Mohamed F, Cecil T, Moran B. (2023). Excellent quality of life for two decades after cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin. *Eur J Surg Oncol*.pending: pending.  
Accepted  
Refereed?: Yes, Open Access?: No
5. Wang Y, Delisle M, Smith D, Alshamsan B, Srikanthan A. (2022). Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: A systematic review. *Int J Clin Oncol*.22: 1767-779.  
Published  
Refereed?: Yes, Open Access?: Yes
6. Wang Y, Delisle M, Smith D, Alshamsan B, Srikanthan A. (2022). Metastasectomy in Synovial Sarcoma: A Systematic Review & Meta-Analysis. *Eur J Surg Oncol*.48(9): 1901-10.  
Published  
Refereed?: Yes, Open Access?: No
7. Delisle M, Gyorki D, Bonvalot S, Nessim C. (2022). Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma. *Ann Surg Oncol*. 29(12): 7297-311.  
Published  
Refereed?: Yes, Open Access?: No
8. Mocanu V, Dang JT, Delisle M, Switzer NJ, Birch DW, Karmali S. (2022). 30-day Major Adverse Cardiac Events (MACE) After Elective Bariatric Surgery: The Development and Validation of the Bari-MACE Clinical Predictive Tool. *Surg Obes*. 18(3): 357-64.  
Published  
Refereed?: Yes, Open Access?: No

9. Delisle M, Alshamsan B, Nagaratnam K, Smith D, Wang Y, Srikanthan A. (2022). Metastasectomy in Leiomyosarcoma: A Systematic Review & Pooled Survival Analysis. *Cancers*.14(3): 3055.  
Published  
Refereed?: Yes, Open Access?: Yes
10. Pradarelli J, Delisle M, Briggs A, Smink D, Yule S. (2021). Identifying Naturalistic Coaching Behavior among Practicing Surgeons in the Operating Room. *Ann Surg*. 273(1): 181-86.  
Published  
Refereed?: Yes, Open Access?: No
11. Goodwin C, Velasquez E, Ross J, Kueffer A, Molefe A, Modali L, Bell G, Delisle M, Hannenberg A. (2021). Development of a Novel and Scalable Simulation-Based Teamwork Training Model Using Within-Group Debriefing of Observed Video Simulation. *Jt Comm J Qual Saf*. 47(6): 385-91.  
Published  
Refereed?: Yes, Open Access?: No
12. Panda N, Solsky I, Huang E, Lipsitz S, Pradarelli J, Delisle M, Cusack J, Gadd M, Lubitz C, Mullen J, Qadan M, Smith B, Specht M, Stephen A, Tanabe K, Gawande AA, Onnella JP, Haynes AB. (2020). Using Smartphones to Capture Novel Recovery Metrics after Cancer Surgery. *JAMA Surg*. 155(2): 123-29.  
Published  
Refereed?: Yes, Open Access?: No
13. Wang Y, Delisle M, Smith D, Srikanthan A. (2020). Survival by Histology among Patients with Bone and Soft Tissue Sarcoma who undergo Metastasectomy: Protocol for a Systematic Review and Meta-Analysis. *Syst Rev*. 9: 189.  
Published  
Refereed?: Yes, Open Access?: Yes
14. Delisle M, Singh S, Howard J, Panda N, Weppler AM, Wang Y. (2020). Refusal of Colorectal Cancer Surgery in the United States: Predictors and Associated Cancer-Specific Mortality in a SEER Cohort. *Surgery Open Science*.2(4): 12-18.  
Published  
Refereed?: Yes, Open Access?: Yes
15. Delisle M, Pradarelli JC, Panda N, Koritsanszky L, Sonnay Y, Lipsitz S, Pearse R, Harrison E, Biccadd B, Berry W, Weiser T, Haynes AB. (2020). Variation in the Global Uptake of the Safe Surgery Checklist. *Br J Surg*.107(2): e151-160.  
Published  
Refereed?: Yes, Open Access?: No
16. Delisle M, Hannenberg AA. (2020). Alternatives to High-Fidelity Simulation. *Anesthesia Clin*. 38(4): 761-73.  
Published  
Refereed?: Yes, Open Access?: No
17. Dang J, Tran C, Switzer N, Delisle M, Laffin M, Madsen K, Birch D, Karmali K. (2020). Predicting Surgical Site Infections Following Laparoscopic Bariatric Surgery: Development of the Bariwound Tool Using the MBSAQIP Database. *Surg Endo*.34: 1802-11.  
Published  
Refereed?: Yes, Open Access?: No
18. Delisle M, Pradarelli JC, Panda N, Haynes AB, Hannenberg AA. (2020). Methods for Scaling Simulation-Based Teamwork Training. *BMJ Qual Saf*.29: 98-102.  
Published  
Refereed?: Yes, Open Access?: No

19. Panda N, Koritsanszky L, Delisle M, Anyomih TTK, Desai EV, Sonnay Y, Molina G, Madani K, Vervoot D, Weiser TG, Benjamin EM, Haynes AB. (2020). Global Survey of Perceptions of the Surgical Safety Checklist Among Medical Students, Trainees and Early Career Providers. *World J Surg.* 44: 2857-68.  
Published  
Refereed?: Yes, Open Access?: No
20. Delisle M, Ward M, Helewa R, Park J, Hochman D, McKay A. (2019). Timing of Palliative Care in Colorectal Cancer Patients: Does it Matter?. *J Surg Res.* 241: 285-293.  
Published  
Refereed?: Yes, Open Access?: No
21. Gu J, Delisle M, Engler-Stringer R, Groot G. (2019). Mastectomy versus Breast Conservation Therapy: An Examination of how Individual, Clinico-pathological, and Physician Factors Influence Decision Making. *Curr Oncol.* 26(4): e522-34.  
Published  
Refereed?: Yes, Open Access?: Yes
22. Delisle M, Chernos C, Park J, Hardy K, Vergis A. (2019). Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the *BariClot* tool using the MBSAQIP database. *Surg Endosc.* 33(3): 821-31.  
Published  
Refereed?: Yes, Open Access?: No
23. Delisle M, Ward M, Pradarelli J, Panda N, Howard J, Hannenberg A. (2019). Comparing the Learning Effectiveness of Healthcare Simulation in the Observer versus Active Role: Systematic Review and Meta-Analysis. *Simul Healthc.* 14(5): 318-32.  
Published  
Refereed?: Yes, Open Access?: Yes
24. Delisle M, Helewa R, Ward M, Park J, Hochman D, McKay A. (2019). The Association Between Wait Times for Colorectal Cancer Treatment and Healthcare Costs: A Population-Based Study. *Dis Colon Rectum.* 63(2): 160-71.  
Published  
Refereed?: Yes, Open Access?: No
25. Ward M, Alenazi A, Delisle M, Logsetty S. (2019). The Impact of Frailty on Acute Care General Surgery Patients: A Systematic Review. *J Trauma Acute Care Surg.* 86(1): 148-54.  
Published  
Refereed?: Yes, Open Access?: No
26. Howard J, Ising M, Delisle M, Martin R. Hospital Readmission after Pancreaticoduodenectomy: A Systematic Review and Meta-Analysis. (2019). Hospital Readmission after Pancreaticoduodenectomy: A Systematic Review and Meta-Analysis. *Am J Surg.* 217(1): 156-61.  
Accepted  
Refereed?: Yes, Open Access?: No
27. Enani G, Bilgic E, Lebedeva E, Delisle M, Vergis A, Hardy K. (2019). The Incidence of Iron Deficiency Anemia Post-Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A Systematic Review. *Surg Endo.* 34: 3002-10.  
Published  
Refereed?: Yes, Open Access?: No
28. Delisle M, Wirtzfeld D. (2018). Gender Diversity in Academic Medical Leadership: Are we Moving the Needle?. *Canadian Journal of Physician Leaders.* 5(1): 39-47.  
Published  
Refereed?: Yes, Open Access?: Yes

- [29.](#) Dang J, Switzer N, Delisle M, Laffin M, Gill R, Birch D, Karmali S. (2018). Canadian General Surgery Residents' Need Formal Curricula and Objective Performance Assessments in Gastrointestinal Endoscopy Training: A Program Director Census. *Surg Endosc.* 32(12): 5012-20.  
Published  
Refereed?: Yes, Open Access?: No
- [30.](#) Delisle M, McCarthy B, Hebbard P, Rivard J, Wirtzfeld D. (2017). National Survey of Mentorship in Canadian General Surgery Residency Programs: Where are we and what do we need?. *Can Med Educ J.* 8(4): e42-53.  
Published  
Refereed?: Yes, Open Access?: Yes

## Clinical Care Guidelines

1. Reviewed and updated previous sections on surgical management of melanoma. Guideline for the Management and Surveillance of Stage I-III Melanoma. (2024).  
Contributors: Rittberg, R; Hurton, S; Hebbard, P; Wong, R.  
Description / Contribution Value: CancerCare Manitoba clinical practice guideline

## Presentations

1. (2024). Surgical Oncology Emergencies on Acute Care Surgery. Continuing Medical Education Dinner Event, Canada  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: Yes
2. Delisle M, Hamm C. (2023). The Clinical Trials Navigator Program. 3CTN Stakeholder Meeting, Canada  
Main Audience: Decision Maker  
Invited?: Yes, Keynote?: No
3. (2023). Radiology Perspectives on Non-Operative Management for Rectal Cancer. City Wide Radiology Rounds, Canada  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: Yes
4. Delisle M. (2023). Organ preservation for locally advanced rectal cancer: A shift towards precision surgery. University of Ottawa Division of General Surgery Grand Rounds, Canada  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: Yes
5. Delisle M. (2022). Differences in Experiences with Cancer Survivorship Follow-up Among Cancer Survivors in Canada Based on Physician Specialty. Society of Surgical Oncology Annual Meeting, United States of America  
Main Audience: Knowledge User  
Invited?: No, Keynote?: No

## Knowledge and Technology Translation

2023/9	<p>Lead, Community Engagement</p> <p>Activity Description: I am responsible for organizing and leading stakeholder engagement committee meetings every six weeks. Stakeholders include people with lived experience with cancer. Through these meetings, we discuss my research program and I obtain their input to ensure that the work I am doing is meaningful to people with lived experience. We also circulate a monthly newsletter through my personal blog to keep stakeholders updated of our progress: <a href="https://meganelizabeth.substack.com/?utm_source=discover_search">https://meganelizabeth.substack.com/?utm_source=discover_search</a></p>
2023/1	<p>Consultant, Consultation Service</p> <p>Activity Description: I provide surgical oncology expertise to RCM Health Inc. The goal of RCM Health Inc. is to achieve the best possible outcomes through advocacy and guided access to the most advanced diagnostics, innovative treatments and quality decision support from world-class experts. I provide expert advice for people with cancer who seek their assistance.</p>
2023/1	<p>Committee Member, Standards Development</p> <p>Activity Description: I am part of the CCTG Equity, Diversity, Inclusivity, Indigenization, and Accessibility (EDIIA) Working Groups. As part of the CCTG EDIIA Action Plan, the Working Groups strive to create an equitable, diverse, inclusive, accessible, and culturally safe community for our network and for patients.</p>

## Student/Postdoctoral Supervision

### Bachelor's [n=3]

2024/6 - 2024/8	Doris Goubran, University of Manitoba
Principal Supervisor	Thesis/Project Title: Improving Cancer Surgery in Manitoba Present Position: Medical Student
2024/5 - 2024/8	Nicole Alcasid, University of Manitoba
Principal Supervisor	Thesis/Project Title: Clinical Trials Navigator Program Present Position: Student
2024/1 - 2024/4	Celine Dainhi, University of Manitoba
Principal Supervisor	Thesis/Project Title: Clinical Trials Navigator Program Present Position: Student

**Date Submitted:** 2025-01-20 19:39:54

**Confirmation Number:** 1897397

**Template:** CIHR Academic

---

## **Dr. Caroline Hamm**

Correspondence language: English

Sex: Female

Date of Birth: 12/21

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

## **Dr. Caroline Marie Hamm**

Correspondence language: English

Sex: Female

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

## **Contact Information**

The primary information is denoted by (\*)

### **Address**

Primary Affiliation (\*)

Western University  
Schulich School of Medicine  
Windsor Campus  
Windsor Ontario N8W 2X3  
Canada

### **Telephone**

Fax	519-2558675
Mobile	1-519-8904382
Work (*)	519-2535253

### **Email**

Work (*)	caroline.hamm@wrh.on.ca
----------	-------------------------

### **Website**

Corporate	<a href="https://www.wesparkhealth.com/programs-1/cancer">https://www.wesparkhealth.com/programs-1/cancer</a>
-----------	---



Protected when completed

## Dr. Caroline Hamm

---

### Language Skills

Language	Read	Write	Speak	Understand
English	Yes	Yes	Yes	Yes

### User Profile

Disciplines Trained In: Oncology

Research Disciplines: Oncology

Areas of Research: Breast Cancer, Leukemia

Fields of Application: Biomedical Aspects of Human Health

Research Specialization Keywords: barriers to clinical trials accrual, clinical trials, immune modulation, leukemia, lymphoma, medical student education, Mentorship in Clinical Research, myeloma, survivorship issues, triple negative breast cancer

### Degrees

2017/10 - 2017/10	Certificate, Certificate of Achievement, Canadian Medical Association Degree Status: Completed
1998/9 - 1999/12	Doctorate, Fellowship in Hematology, Medicine - Hematology, Wayne State University Degree Status: Completed Transferred to PhD without completing Masters?: No Supervisors: Charles Schiffer
1998/7 - 1999/12	Doctorate, Doctor of Medicine, Stem Cell Transplantation, Wayne State University Degree Status: Completed Transferred to PhD without completing Masters?: No Supervisors: Dr. Bill Peters
1998/9 - 1998/12	Master's Thesis, Master's level course, Epidemiology (Systems Analysis and Meta-Analysis) Course, University of Ottawa Degree Status: Completed Supervisors: Department of Epidemiology
1996/9 - 1998/8	Doctorate, Royal College of Physicians and Surgeons of Canada Fellowship in Medical Oncology, Ottawa Regional Cancer Centre Degree Status: Completed



1996/9 - 1998/6	<p>Doctorate, Doctor of Medicine, Medical Oncology, University of Ottawa</p> <p>Degree Status: Completed</p> <p>Transferred to PhD without completing Masters?: No</p> <p>Supervisors: Department of Medicine - Christine Cripps</p>
1993/9 - 1996/6	<p>Doctorate, Fellowship Internal Medicine, Internal Medicine, University of Ottawa</p> <p>Degree Status: Completed</p> <p>Transferred to PhD without completing Masters?: No</p> <p>Supervisors: Department of Medicine - Ottawa - Craig Campbell</p>
1992/9 - 1993/6	<p>Doctorate, Doctor of Medicine, Medicine - Rotating Internship, Dalhousie University</p> <p>Degree Status: Completed</p> <p>Transferred to PhD without completing Masters?: No</p> <p>Supervisors: Department of Medicine</p>
1990/9 - 1992/6	<p>Bachelor's, Bachelor of Science, McGill University</p> <p>Degree Status: Completed</p>
1988/9 - 1992/6	<p>Doctorate, Doctor of Medicine, Dalhousie University</p> <p>Degree Status: Completed</p> <p>Transferred to PhD without completing Masters?: No</p>
1976/9 - 1977/6	<p>Bachelor's, B.Ed., University of Western Ontario</p> <p>Degree Status: Completed</p>
1973/9 - 1976/6	<p>Bachelor's, Bachelor of Arts, University of Western Ontario</p> <p>Degree Status: Completed</p>

## Credentials

2001/2	Physician, Michigan Board of Medicine
2001/2	Physician, Michigan Board of Medicine
1998/1	Medical Oncologist, Royal College of Physicians and Surgeons of Canada, Medical Oncology
1998/1	Medical Oncologist, Royal College of Physicians and Surgeons of Canada, Medical Oncology
1997/1	Physician, Royal College of Physicians and Surgeons of Canada
1997/1	Physician, Royal College of Physicians and Surgeons of Canada
1996/6	Medical Oncologist, College of Physicians and Surgeons of Ontario
1996/6	Medical Oncologist, College of Physicians and Surgeons of Ontario
1998/1 - 1998/11	Medical Oncology, American Board of Internal Medicine, Medical Oncology
1998/1 - 1998/11	Medical Oncology, American Board of Internal Medicine, Medical Oncology
1996/1 - 1996/6	Fellowship in Internal Medicine, American Board of Internal Medicine
1996/1 - 1996/6	Fellowship in Internal Medicine, American Board of Internal Medicine

## Recognitions

2025/1	<p>King Charles III Coronation Medal for Contributions to Canada (Canadian dollar)</p> <p>Senate of Canada</p> <p>Honor</p>
--------	---

2022/10	Honorary Doctorate of Laws (Canadian dollar) University of Windsor Distinction
2018/7	Human Touch Award (Canadian dollar) Cancer Care Ontario Distinction
2015/2	Glenn Sawyer Service Award Ontario Medical Association (OMA) Distinction
2013/11	HUMEC award for teaching Schulich School of Medicine Distinction
2013/7	Academic Excellence in the Department of Oncology Western Schulich School of Medicine and Dentistry Distinction
1997/3 - 1997/3	Peter Lawrence Fenn Award of Distinction - 0 University of Ottawa Distinction
1992/11 - 1992/11	Golden D Award - 0 Dalhousie University Distinction
1991/11 - 1991/11	First Prize, Medical Student-Resident Research Day - 3,000 Dalhousie University Prize / Award
1986/6 - 1986/6	Dean's Honour List - 0 The University of Manitoba Distinction

## Employment

2017/6	Associate Professor UWO Oncology, Schulich School of Medicine & Dentistry, University of Western Ontario
2012/11	Clinical Director Windsor Cancer Research Group
2012/11	Clinical Director Windsor Cancer Research Group
2007/9	Cancer Care Ontario Regional Systemic Lead Erie St. Clair Regional Cancer Program (CCO)
2007/9	Cancer Care Ontario Regional Systemic Lead Erie St. Clair Regional Cancer Program (CCO)
2006/9	Adjunct Professor University of Windsor
2006/9	Adjunct Professor University of Windsor
2002/9	Director of Research and Clinical Trials Windsor Regional Cancer Centre

2002/9	Medical Oncologist Windsor Regional Cancer Centre
2002/9	Medical Oncologist Windsor Regional Cancer Centre
2002/9	Director of Research and Clinical Trials Windsor Regional Cancer Centre
2002/9	Director of Research Windsor Regional Cancer Centre
2002/9	Director of Research Windsor Regional Cancer Centre
2010/7 - 2017/6	Assistant Professor UWO Oncology, Schulich School of Medicine & Dentistry, University of Western Ontario
2002/7 - 2009/6	Adjunct Professor UWO Oncology, Schulich School of Medicine & Dentistry, University of Western Ontario
1999/1 - 2002/9	Assistant Professor Wayne State University
1999/1 - 2002/9	Assistant Professor Wayne State University
1997/9 - 1998/6	Chief Resident University of Ottawa
1997/9 - 1998/6	Chief Resident University of Ottawa

## Affiliations

The primary affiliation is denoted by (\*)

(\*) 2002/7 Associate Professor, Western University, Windsor Regional Hospital

## Research Funding History

### Awarded [n=13]

2024/6 - 2028/6  
Principal Applicant Examining the Implementation of the Clinical Trials Navigator in an expansion study to Winnipeg and Thunder Bay on Patient Reported Outcomes and participation in breast cancer clinical trials

#### Funding Sources:

2024/6 - 2028/6 Breast Cancer Canada  
Annual Research Grant  
Total Funding - 75,000 (Canadian dollar)  
Funding Competitive?: Yes

2024/6 - 2025/6  
Co-investigator Investigating the Significance of Grade in Triple Negative Breast Cancer

**Funding Sources:**

2024/6 - 2025/6      University of Western Ontario  
 Summer Research Training Program  
 Total Funding - 5,000 (Canadian dollar)  
 Funding Competitive?: Yes

2024/2 - 2025/2      Enhancing the Patient Journey to Clinical Trial Enrolment with Navigation to Optimize  
 Principal Investigator      Accrual: A Pilot Study for a prospective, pragmatic multi-centre, stepped wedge, cluster  
 randomized controlled trial

**Funding Sources:**

2024/1 - 2024/12      Canadian Institutes of Health Research (CIHR)  
 Innovative Clinical Trials  
 Total Funding - 198,000 (Canadian dollar)  
 Funding Competitive?: Yes

2022/9 - 2024/9      Define fertility outcomes in cancer patient in a comprehensive cancer clinic  
 Principal Applicant

**Funding Sources:**

2022/7 - 2024/7      University of Western Ontario  
 SRTP  
 Total Funding - 1,000 (Canadian dollar)  
 Funding Competitive?: Yes

2022/9 - 2023/9      Curating Clinical Trials : Clinical Trials Navigator  
 Principal Applicant

**Funding Sources:**

2022/9 - 2023/6      Mathematics of Information Technology and Complex Systems  
 (MITACS)  
 Grant  
 Total Funding - 80,000 (Canadian dollar)  
 Funding Competitive?: Yes

2022/7 - 2023/9      The examination of the migrant worker experiencing life-threatening illness  
 Co-applicant

**Funding Sources:**

2022/3 - 2023/3      WeSpark Health Institute  
 Inciting Discovery Grant  
 Total Funding - 10,000 (Canadian dollar)  
 Funding Competitive?: Yes

2018/1 - 2023/6      Intestinal Tissue for Live Cell Culture: Circadian rhythms in live cell culture  
 Co-investigator

**Funding Sources:**

2018/1 - 2023/6      Canadian Institutes of Health Research (CIHR)  
 Canada foundation for Innovation Grant  
 Total Funding - 645,000 (Canadian dollar)  
 Funding Competitive?: Yes

2022/6 - 2023/6      CURating Clinical Trials. Investigating use of artificial intelligence to search for clinical  
 Principal Applicant      trials for cancer patients

**Funding Sources:**

2022/9 - 2023/6      Windsor & Essex County Cancer Foundation  
 TD Ready Commitment  
 Total Funding - 100,000 (Canadian dollar)  
 Funding Competitive?: No

2021/7 - 2022/9 Principal Applicant	Real World Experience –Stopping Study in Chronic Myeloid Leukemia - Defining a new paradigm for Ontario <b>Funding Sources:</b> 2021/7 - 2022/7      University of Windsor We Spark Total Funding - 15,000 (Canadian dollar) Funding Competitive?: Yes
2019/5 - 2022/7 Co-applicant	Does Integration of the Predict 2.1 algorithm into routine clinical practice improve the value of the multigene assays in early stage breast cancer? A prospective cohort study with a pre-versus post-comparison <b>Funding Sources:</b> 2019/5 - 2023/7      Ontario Institute for Cancer Research (OICR) Grant Total Funding - 260,000 (Canadian dollar) Funding Competitive?: Yes
2021/9 - 2021/12 Principal Applicant	International Research Platform for Windsor Regional Hospital <b>Funding Sources:</b> 2021/9 - 2021/12      BioTalent Canada Grant Total Funding - 15,000 (Canadian dollar) Funding Competitive?: Yes
2020/7 - 2021/7 Co-applicant	Investigating Barriers to Clinical Trials <b>Funding Sources:</b> 2020/7 - 2021/7      University of Windsor Care Grant Total Funding - 40,000 (Canadian dollar) Funding Competitive?: Yes
2015/7 - 2020/6 Co-investigator	Novel Cell Cycle Regulation in the Initiation and Therapeutic Intervention of Triple Negative Breast Cancer <b>Funding Sources:</b> 2015/7 - 2020/6      Canadian Institute of Health Research Canadian Institute of Health Research Total Funding - 765,200 (Canadian dollar) Funding Competitive?: Yes
<b>Declined [n=1]</b>	
2021/5 - 2024/7 Principal Applicant	Clinical Trials Navigator : Person Centred Approach <b>Funding Sources:</b> 2021/5 - 2024/7      Canadian Cancer Society Challenge Grant Total Funding - 465,000 (Canadian dollar) Funding Competitive?: Yes
<b>Under Review [n=1]</b>	
2024/1 - 2028/1 Co-applicant	Prospective Enrolment Working Group for Marathon Of Hope Cancer Centres Network

**Funding Sources:**

2025/7 - 2028/6      Terry Fox Research Institute (TFRI)  
 Total Funding - 3,000,000 (Canadian dollar)  
 Funding Competitive?: Yes

**Student/Postdoctoral Supervision****Bachelor's [n=4]**

Principal Supervisor    Pratham Gupta (In Progress) , Western University  
 Student Degree Start Date: 2022/9  
 Student Degree Expected Date: 2025/5  
 Project Description: Curating Clinical Trials: Patient Engagement Processes  
 Present Position: Undergraduate student

Principal Supervisor    Olla Hilal (In Progress) , Western University  
 Student Degree Start Date: 2022/9  
 Student Degree Expected Date: 2025/5  
 Present Position: Undergraduate student

Principal Supervisor    Amy Llancari (Completed) , University of Windsor  
 Student Degree Start Date: 2020/9  
 Student Degree Received Date: 2023/5  
 Project Description: Critical Illness in Migrant Workers  
 Present Position: Master's student

Principal Supervisor    Milica Paunic (All But Degree) , University of Windsor  
 Student Degree Start Date: 2020/9  
 Student Degree Expected Date: 2023/5  
 Project Description: Critical analysis of clinical trials search engines  
 Present Position: medical student

**Master's non-Thesis [n=7]**

Principal Supervisor    Mahmoud Housami (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Project Description: Curating Clinical Trials : building a better search process for clinical trials  
 Present Position: Master's student

Principal Supervisor    Siri Ravipati (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Present Position: Master's student

Principal Supervisor    Waffa Bakheet (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Present Position: Master's student

Principal Supervisor Rhonda El-Abed (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Project Description: Curating Clinical Trials : building a better search process for clinical trials  
 Present Position: Master's student

Principal Supervisor Kayla Touma (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Project Description: Curating Clinical Trials : building a better search process for clinical trials  
 Present Position: Master's student

Academic Advisor Ryan Palazzo (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Project Description: Critical Illness in Migrant Workers  
 Present Position: Research Associate

Principal Supervisor Genesis Flores (Completed) , University of Windsor  
 Student Degree Start Date: 2022/9  
 Student Degree Received Date: 2023/5  
 Present Position: Master's student

**Doctorate [n=15]**

Principal Supervisor Hammad Saif (In Progress) , Western University  
 Student Degree Start Date: 2021/9  
 Student Degree Expected Date: 2025/5  
 Project Description: Real world experience of measles, mumps rubella vaccination status post stem cell transplant

Principal Supervisor Haniya Farroq (In Progress) , Dublin  
 Student Degree Start Date: 2021/9  
 Student Degree Expected Date: 2025/5  
 Project Description: significance of grade in triple negative breast cancer

Principal Supervisor Daniel Read (In Progress) , Western University  
 Student Degree Start Date: 2021/9  
 Student Degree Expected Date: 2025/5  
 Project Description: Quality improvement focusing on grade 2 toxicities

Principal Supervisor Gopika Punchhi (In Progress) , Western University  
 Student Degree Start Date: 2021/9  
 Student Degree Expected Date: 2025/5  
 Project Description: Real world experience of measles, mumps, rubella vaccinations post stem cell transplant

Principal Supervisor Mah-noor Malik (In Progress) , Western University  
 Student Degree Start Date: 2021/9  
 Student Degree Expected Date: 2025/5

Principal Supervisor Tina Joseph (In Progress) , Western University  
 Student Degree Start Date: 2021/9  
 Student Degree Expected Date: 2025/5  
 Project Description: Quality improvement focusing on grade 2 toxicities

Principal Supervisor	Neya Ramanan (In Progress) , Western University Student Degree Start Date: 2021/9 Student Degree Expected Date: 2025/5 Project Description: Significance of Grade in TNBC
Principal Supervisor	Megan Miklas (In Progress) , Western University Student Degree Start Date: 2021/9 Student Degree Expected Date: 2025/8 Project Description: Identifying a new barrier to clinical trials accrual Present Position: Research Assistant
Principal Supervisor	Melissa Fenech (In Progress) , Western University Student Degree Start Date: 2021/9 Student Degree Expected Date: 2025/5 Project Description: Identifying a new barrier to clinical trials accrual Present Position: Research Assistant
Principal Supervisor	Sanghyuk (Claire) Rim (In Progress) , Western University Student Degree Start Date: 2021/9 Student Degree Expected Date: 2025/5 Project Description: Optimizing the cancer patient journey in the identification of meaningful clinical trial options Present Position: Research Assistant
Principal Supervisor	Gopika Punchhi (In Progress) , Western University Student Degree Start Date: 2020/9 Student Degree Expected Date: 2025/5 Present Position: Medical Student
Principal Supervisor	Geoff Rempel (In Progress) , Western University Student Degree Start Date: 2020/9 Student Degree Expected Date: 2025/5 Project Description: Outcomes of patients treated with carboplatin containing chemotherapy Present Position: Medical Student
Principal Supervisor	Kanza Mirza (In Progress) , Western University Student Degree Start Date: 2020/9 Student Degree Expected Date: 2025/5 Present Position: medical student
Principal Supervisor	Farwa Zaib (In Progress) , Western University Student Degree Start Date: 2020/9 Student Degree Expected Date: 2025/5 Present Position: Medical Student
Principal Supervisor	Sangyuk Rim (In Progress) , Western University Student Degree Start Date: 2020/9 Student Degree Expected Date: 2025/5 Present Position: Medical Student

**Post-doctorate [n=2]**

Co-Supervisor	John Lenehan (In Progress) , The University of Western Ontario Student Degree Start Date: 2016/5 Present Position: PGY 5 Oncology
---------------	---



Principal Supervisor Brindusa Mocanu (Completed) , Queen's University at Kingston  
 Student Degree Start Date: 2014/7  
 Project Description: Clinic supervision  
 Present Position: PGY 6 Medical Oncology

## Mentoring Activities

2021/12 Chair of mentorship committee, University of Western Ontario  
 Number of Mentorees: 18  
 Developed a mentorship program for Schulich School of Medicine at Windsor site to guide academic physicians through career; included mentoring 18 physicians

2020/5 - 2025/5 Mentor colleague, University of Western Ontario  
 Number of Mentorees: 5  
 Academic Mentor for Colleague

2021/9 - 2024/9 Chair of Mentorship Committee, Windsor Regional Hospital  
 Number of Mentorees: 20  
 Develop mentorship program for physicians in the academic pathway. Prepare Assistant professors for promotion to Associate Professor. Guide those clinicians who are trying to prepare for an academic appointment.

## Community and Volunteer Activities

2012/1 - 2023/12 Clinical Research Director, Windsor Cancer Research Group  
 Founded and continue to promote and develop the Windsor Cancer Research Group. This group is responsible for improving collaborative cancer research involving Windsor clinical and basic science researchers as well as those others in Ontario, as well as the United States.

2020/1 - 2022/12 Academic Lead Windsor Regional Hospital, University of Western Ontario  
 Develop and promote academic activities and advancement of the cancer clinicians in Windsor/ Essex/ Lambton county, Ontario.

2012/6 - 2022/12 Provincial Lead Peer Assessor for Hematology Oncology, College of Physicians and Surgeons of Ontario  
 In addition to peer assessment, I also perform registration assessments for physicians hoping to practice in Ontario. Also, I help to develop assessment platforms that aid in these initiatives.

## International Collaboration Activities

2021/9 - 2023/9 Mentor and Collaborator, Ethiopia  
 Mentoring a clinician researcher from Ethiopia in research: grant writing, research team building, manuscript writing

## Presentations

1. (2023). Update from 2023 American Society of Clinical Oncology: Breast Cancer. Windsor Update, Canada  
 Main Audience: Knowledge User  
 Invited?: Yes

2. (2022). Clinical Trials Navigator: Curating clinical trials searches for patients. SunnyBrook Grand Rounds, Canada  
Main Audience: Knowledge User  
Invited?: Yes
3. (2022). The Clinical Trials Navigator Program: Improving Clinical Trials Accrual. Windsor Regional Hospital Grand Rounds, Canada  
Main Audience: Knowledge User  
Invited?: Yes
4. (2021). Clinical Trials Navigator: Curating Clinical Trials Searches for patients and health care professionals. London Oncology Grand Rounds, Canada  
Main Audience: Knowledge User  
Invited?: Yes

## Publications

### Journal Articles

1. Rahman Ladak • Bre-Anne Fifield • Lisa Porter • Khalid Hirmiz • Caroline Hamm. (2024). Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects. Cureus. 10.7759/cureus.68576: 68576.  
Last Author  
Published  
Number of Contributors: 4
2. Mahmoud Hossami, Rhonda Abdel-Nabi, Farwa Zaib, Kayal Touma, Renee Nassar, Sanghyuk Rim, Milica Paunic, Olla Hilal, Pratham Gupta, Roaa Hirmiz, Michael Touma, Govana Sadik, Emmanuel Akingbade, Depen Sharma, Swati Kalia, Rija Fatima, Anthony Luginaah, Ibrahim Mohamed, Rong Luo, Megan Delisle, Caroline Hamm. (2024). Facilitation of Enrollment onto Cancer Clinical Trials Using a Novel Navigator-Assisted Program, Cross-sectional study. Current Oncology. 31(11)
3. Gopika Punchhi, Kayla Negus, Hammad Saif, Sharon Pritchard, Olivia Owen, Aman Sehmbi, Caroline Hamm. (2023). High Incidence of Ineligibility for Measles, Mumps and Rubella Vaccination Two Years after Autologous and Allogeneic Hematopoietic Stem Cell Transplant. Vaccine. 1(1): 1-2.  
Accepted
4. Milica Paunic, Claire Rim, Olla Hilal, Renee Nassar, Farwa Zaib, Kayla Touma, Mahmoud Hossami, Rhonda Abdel-Nabi, Roaa Hirmiz, and Caroline M. Hamm. (2023). Cross-sectional analysis of clinical trials search results for cancer patients using a navigator-assisted clinical trials search using five different search engines. PLOS One. 1(1): 1.  
Submitted
5. Alex Zhou, Abdelhady Osman, Genesis Flores, Dhuvvaraha Srikrishnaraj, Jayashree Mohanty, Retage Al-Bader, Amy Llancari, Aya El-Hashemi, Manahel Elias, Kanza Mirza, Maureen Muldoon, Ryan Palazzolo, Farwa Zaib, Indryas Woldie and Caroline Hamm. (2023). Critical Illness in Migrant Workers in the Windsor-Essex Region: A Descriptive Analysis. International Journal of Environmental and Public Health. 20: 1-5.  
Last Author  
Accepted
6. Melissa Fenech, Maegan Miklas, Youshaa El-Abed, Devinder Moudgil, Rhonda Abdel-Nabi, Kayla Touma, Mahmoud Hossami, Renee Nassar, Farwa Zaib, Sanghyuk Claire Rim, Roaa Hirmiz, Olla Hilal, Milica Paunic, Dora Cavallo-Medved and Caroline Hamm. (2023). Identifying and Addressing a New Barrier to Community-Based Patients Accessing Cancer Clinical Trials. Contemporary Clinical Trials Communications. 1(1): 1.  
Submitted  
Refereed?: No

7. Kathryn Shum, Abdulkadir Hussein, Caroline Hamm. (2022). Are we overtreating stage I triple negative breast cancer in Ontario? A retrospective population-based Analysis. *Medical Oncology*. 39(12): 228.  
Published
8. Caroline Hamm, MD, Dora Cavallo-Medved, Devinder Moudgil, Lee McGrath, John Huang, Yueyang Li, Tyler W Stratton, Tyler Robinson, Krista Naccarato, Steven Sundquist, Janet Dancey. (2022). Addressing the Barriers to Clinical Trials Accrual in Community Cancer Centres Using a National Clinical Trials Navigator: A Cross-Sectional Analysis. *Cancer Control*. 29: 1-7.  
Accepted
9. Na Li, Syed Mahamad, Sameer Parpia, Alfonso Lorio, Farid Foroutane, Nancy Heddle, Cyrus Hsia, Michelle Sholzberg, E Rimmer, Sudeep Shivakumar, S Usn, Mohammad Refaei, Caroline Hamm, Donald Arnold. (2022). Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia. *Journal of Thrombosis and Haemostasis*. Dec(12): 2988-2997.  
Published
10. Martin Crozier, Janice Tubman, Bre-Anne Fifield , Rosa-Maria Ferraiuolo , Jenna Ritchie , Katie Zuccato , Emily Mailloux , Indrajit Sinha, Caroline Hamm , Lisa A. Porter. (2022). Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells. *PLoS One*. 9(17): 1-15.
11. Hamm, Caroline £1-5, Fifield, Bre-Anne1,3, Kay, Amin1,2, Kulkarni, Swati 1,2,3,5, Gupta, Rasna1,2,3, Mathews, John1,2, Ferraiuolo, Rosa-Maria 3,4, Al-Wahsh, Huda6, Mailloux, Emily1,3, Hussein, Abdulkadir1, Porter, Lisa A. (2022). A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane based chemotherapy in triple negative breast cancer. *Medical Oncology*. 49(4): 49.  
Published
12. Katharine McLaughlan, Amanda Stojcevski, Abdulkadir Hussein, Indryas Woldie, Caroline Hamm. (2021). Patient vital signs in relation to ICU admission in treatment of acute leukemia: aretrospective chart review.*Hematology*. 26(1): 637-647.  
Last Author  
Published
13. Hillis CM, Jackson Chornenki NL, Bence-Bruckler , Busque L, Cote Y, Hamm C, Hasegawa W, Kamel-Reid S, Savoie L, Turner AR, Xenocostas A, Lipton JH, Leber B. (2020). The predictive value of intracellular imatinib levels in newly diagnosed chronicmyeloid leukemia. *Leukemia Research*. 88: 319.  
Co-Author  
Published
14. Upneja S, Hussein A, Moudgil D, Kulkarni S, Gupta R, Hamm C. (2020). A Retrospective Single Center Study Investigating the Clinical Significance ofGrade in Triple Negative Breast Cancer. *Cancer Studies and Therapeutics*. 6(3): 1-8.  
Last Author  
Published
15. Gupta V, Cerquozzi S, Foltz I, Hillis C, Devlin R, Elsayy M, Hamm C. (2020). Perspectives of the Canadian Myeloproliferative Neoplasm Group. *Journal of Oncology Practice*. 10(16): 7.  
Co-Author  
Published

## Conference Publications

1. Siri Ravipati, Waffa Bakheet, and Caroline M. Hamm. (2023). **Stopping study in chronic myeloid leukemia: Defining anew paradigm for Ontario CML1**.American Society of Clinical Oncology Abstract  
Last Author  
Published, Invited?: No

2. Milica Paunic, Claire Rim, Olla Hilal, Renee Nassar, Farwa Zaib, Kayla Tuma, Mahmoud Hossami, Rhonda Abdel-Nabi, Roaa Hirmiz, and Caroline M. Hamm. (2022). **Engine failures: A critical analysis of current clinicaltrial websites' search engines**.American Society of Clinical Oncology  
Abstract  
Last Author  
Published, Invited?: No
3. Rhonda Abdel-Nabi, Mahmoud Hossami, Kayla Tuma, Renee Nassar, Milica Paunic, Olla Hilal, Farwa Zaib, Claire Rim, Roaa Hirmiz, and Caroline M. Hamm. (2022). **Curating clinical trials: Helping patients find hope byexploring clinical trial opportunities**.American Society of Clinical Oncology  
Poster  
Last Author  
Accepted, Invited?: Yes
4. Claire Rim, Farwa Zaib, Kayla Tuma, Mahmoud Hossami, Rhonda Abdel-Nabi, Dora Cavallo-Medved, Olla Hilal, Zoe Driedger, Devinder Moudgil, Milica Paunic, Renee Nassar, Roaa Hirmiz, Lee McGrath, and Caroline M. Hamm. (2022). **Examination of current status of cross-provincial borderaccess for clinical trials for patients with cancer**.American Society of Clinical Oncology  
Abstract  
Last Author  
Published, Invited?: No
5. Upneja S, Hamm C. (2020). Significance of Grade in Triple negative Breast Cancer. Canadian Cancer Research Conference  
Poster  
Last Author  
Accepted, Invited?: Yes